Text,CUIS
,
characteristic,C1521970
placebo n $nmbr$,C0032042;C1696465;C1706408
gemfibrozil n $nmbr$,C0017245
age yr,C0001779;C0439234
$nmbr$ $nmbr$,
age $nmbr$ yr,C0001779;C0439234
$nmbr$,
race white,C0007457;C0043157;C0220938
black,C0005680;C0027567;C0085756;C0439541
other,
education $nmbr$ yr,C0013621;C0439234;C0013622;C0013658;C0039401
current smoker,C3173209;C3241966
alcohol consumption,C0001948
$nmbr$ $nmbr$ drinks dav,C0452428
$nmbr$ drinks dav,C0452428
hypertension,C0020538;C1963138
diabetes,C0011847;C0011849
prior myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
time since most recent myocardial,C0040223;C3541383
infarction yr history of congestive heart failure,C0455531
cabg or ptca,C0010055;C2936173
medication use aspirin,C0240320;C0004057
nitratesf,
calcium channel blockers,C0006684;C2757014
ace inhibitors,C0003015
beta blockers,C0001645
any antianginal drug,C0013227;C1254351
body mass index,C0005893;C0578022;C1305855
waist to hip ratio,C0205682
$nmbr$ $nmbr$ $nmbr$ $nmbr$,
blood pressure mm hg systolic,C0005823;C0039155;C1271104;C1272641
diastolic,C0012000
plasma lipids mg dl $nmbr$ total cholesterol mean,C0444504;C2347634;C2348143
interquartile range,C1711350
ldl cholesterol mean,C0444504;C2347634;C2348143
hdl cholesterol mean,C0444504;C2347634;C2348143
triglycerides mean,C0444504;C2347634;C2348143
plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$,C0042295;C1704970;C0010055;C0190211;C0920394;C0011847;C0011849;C0011198;C0017480;C3541240;C0205232;C0687757;C0745732;C3272378;C0040028;C0028125;C0332257;C1552866;C2700399;C1521827;C3812761;C0013227;C1254351;C0699857;C3848573;C0006684;C3536851;C4521885;C0001645;C0005893;C0578022;C1305855;C0005910;C0043100;C1305866;C1705104;C0332849;C0205120;C1552595;C0441074;C0008377;C0439190;C0475211;C1719797;C2911648;C0041004;C1532563
subgroupt,
placebo,C0032042;C1696465;C1706408
gemfibrozil,C0017245
risk reduction $nmbr$ cl,C1137094;C0596019
p value,C1709380
no with event total no,C0439175;C0439810
age,C0001779
$nmbr$ $nmbr$ $nmbr$,
$nmbr$ $nmbr$ to $nmbr$,
$nmbr$ yr,C0439234
race,C0034510;C1706779;C3853635
white,C0007457;C0043157;C0220938
nonwhite,
family history^,C0241889
yes,C1549445;C1705108;C1710701
no,
smoking,C0037369;C0453996;C1881674
current,C0521116;C1705970
former or never diabetes,C0205156;C0750523;C0011847;C0011849
$nmbr$ $nmbr$ $nmbr$ to $nmbr$,
aspirin use,C0042153;C0457083;C1947944
no beta blocker use,C0042153;C0457083;C1947944
hdl cholesterol,C0023822;C0392885
$nmbr$ $nmbr$ mg dl triglycerides^,C0439269;C0041004
$nmbr$ mg dl ldl cholesterol,C0023824;C0202117
$nmbr$ mg dl,C0439269
$nmbr$ $nmbr$ mg dl,C0439269
risk reduction $nmbr$ percent confidence interval ci and p value are derived from cox models for risk reductions negative numbers indicate an increase in risk diabetes and hypertension were defined by clinical history a family history was defined as having one or more first degree relatives with either myocardial infarction or sudden death before the age of $nmbr$ hdl cholesterol levels are shown according to the median value $nmbr$ $nmbr$ mg per deciliter [ $nmbr$ $nmbr$ mmol per liter] triglyceride levels are shown according to the median value $nmbr$ mg per deciliter [ $nmbr$ $nmbr$ mmol per liter] ldl cholesterol levels are shown according to the median value $nmbr$ mg per deciliter [ $nmbr$ $nmbr$ mmol per liter] and according to the values that divide the subjects into three equal groups $nmbr$ mg per deciliter [ $nmbr$ $nmbr$ mmol per liter],C0008107;C3259781;C1709380;C1441547;C3245521;C1137094;C2825415;C0442805;C1171304;C0020538;C1963138;C1704788;C3539106;C0241889;C0205447;C1518469;C1546180;C1547282;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0439241;C0439190;C0475211;C0428475;C0202117;C0850994;C0680240;C0042295;C0332849;C0681850;C1550501;C1706203;C2349001;C2697811
stent plus placebo,C0038257;C0032042;C1696465;C1706408
stent plus abciximab,C0038257;C0288672
p,C0369773;C2603361
balloon angioplasty plus abciximab,C0002996;C0002997
pt,C0032743;C0699718
diabetic patients,C0241863;C0030705
total,C0439175;C0439810
death,C0011065;C1306577;C4082313;C4552775
death large mi,C0011065;C3810814;C1306577;C4082313;C4552775
large mi,C0549177;C3810814
tvr,
non diabetic patients,C1829939;C0241863
nct $nmbr$,
characteristics,C1521970
chlorthalidone group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
doxazosin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
no of subjects,C0681850;C1550501;C1706203;C2349001;C2697811
age y,C0001779
women,C0043210
race ethnicity white non hispanic,C1533020;C1533021
black non hispanic,C1533017;C1533018
white hispanic,C1533020;C1533021
black hispanic,C1533017;C1533018
other race,C0034510;C1706779;C3853635
education y,C0013621;C0013622;C0013658;C0039401
blood pressure mm hg,C0005823;C0439475;C1271104;C1272641
treated for hypertension,C1522326;C0020538;C1963138
eligibility risk factors t ascvo,C0035648;C1553898
st t wave changes,C0392747;C0443172
type $nmbr$ diabetes,C1320657
cigarette smoking,C0239059;C0700219
hdl c,C3715113
lvh from electrocardiogram,C0149721;C0013798;C1547122;C1623258
lvh from echocardiogram,C0149721;C0013516;C2243117
serum biochemistry potassium mmol l,C0302353;C1532563;C0543465
fasting glucose mg dl,C0015663;C0439269
creatinine mg dl,C0010294;C0439269;C1561535
cholesterol mg dl,C0008377;C0439269
ldl c mg dl,C0439269
hdl c mg dl,C3715113;C0439269
fasting triglycerides mg dl,C0015663;C0041004;C0439269
tirofiban n $nmbr$,C0247025
abciximab n $nmbr$,C0288672
male sex,C0086582
weight kg,C0022718;C0439209;C4054209
smoker,C0337664
medical history,C0262926;C1704706
coronary artery bypass grafting,C0010055
percutaneous coronary revascularization,C1532338
myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
cerebrovascular accident,C0038454
primary target vessel,C0205225;C0449618;C0439612;C0439631
l eft anterior descending coronary artery,C0439394;C0226032;C1706495;C3642217
r ight coronar y artery,C0003842;C0226004
left circumflex artery,C0226037
bypass graft,C0185098
restenotic vessel,C0005847
variable,C0439828;C4553760
no of patients,C0030705
irofiban,
abciximab,C0288672
sex,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
male,C0086582;C1706180;C1706428;C1706429
female,C0043210;C0086287;C1705497;C1705498
clopidogrel given before procedure,C0070166;C0184661;C2700391;C3274430;C3539779
location of treatment center,C0450429;C1515974;C4284930;C4284931
united states,C0041703
indication for stent,C0392360;C3146298
acute coronary syndrome $nmbr$,C0948089
clinical characteristics,C0683325
hyperlipidemia,C0020473;C0428465;C4555212
history of hypertension,C0455527
histor y of myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
histor y of unstable angina,C0002965
histor y of stable angina,C0340288
histor y of heart failure,C0018801;C0018802;C4554158
congestive heart failure,C0018802
cardiogenic shock during first $nmbr$ hr after randomization,C0036980;C0205435;C1279901;C0034656
previous intervention,C0184661;C0886296;C1273869
percutaneous transluminal coronary angioplasty,C2936173
coronar y artery bypass grafting,C0332835;C1527362;C1961139
administration of study drug,C0150270;C0262754;C3469597
bolus,C1186706;C1511237;C1705509;C3812160
bolus and infusion,C1186706;C1511237;C1705509;C3812160;C0574032;C1827465
infarct territory,C1301808;C2983136
$nmbr$ $nmbr$ f,C0016327
anterior,C0205094
inferior,C0542339;C0678975
infarct related vessel,C0021308;C0005847
l eft anterior descending,C0439394;C0205094;C1706495;C3642217;C0205386;C1547177
r ight coronary,C0205090;C0018787;C0684010;C2603358
circumflex,C1880089
graft,C0181074;C0332835;C1961139
sr ii b $nmbr$ cjl $nmbr$,C0753208;C1709991;C3813610;C3890900;C3891546
age years,C1510829
body mass index kg m $nmbr$,C0022718;C0439209;C4054209
history of hypertension a c,C0455527
history of high cholesterol a $nmbr$,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
history of diabetes a,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
history of parental myocardial,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0027061;C1522564
infarction before age $nmbr$ a,C0021308;C0001779
smoking a,C0037369;C0453996;C1881674
never,C2003901
past,
alcohol intake a,C0001948
rarely,C0522498
monthly,C0332177
weekly,C0332174
daily,C0332173
exercise at least weekly a,C0015259;C0332174;C1522704
post menopausal a,C0232970
use of hormone replacement therapy a,C1524063;C0282402
randomized to active yitamin e,C0034656;C3815594
number reporting migraine on $nmbr$ month questionnaire,C0149931;C0034394
aspirin asa $nmbr$ $nmbr$,C0004057;C3853627
placebo n $nmbr$ $nmbr$,C0032042;C1696465;C1706408
odds ratio $nmbr$ ci,C0008107;C3259781
all randomized women,C0034656;C0043210;C3815594
hormonal status,C0458083;C0449438
$nmbr$ $nmbr$ to $nmbr$ $nmbr$,
pre menopausal without hormone replacement,C0332152;C0025320;C0740175;C2257086;C3669034
therapy asa $nmbr$ placebo $nmbr$,C0032042;C1696465;C1706408
pre menopausal with hormone replacement,C0332152;C0025320;C0740175;C2257086;C3669034
post menopausal without hormone replacement,C0019930
therapy asa $nmbr$ $nmbr$ placebo $nmbr$,C0032042;C1696465;C1706408
post menopausal with hormone replacement,C0019930
age yrs,C0001779
digoxin,C0012265
n,C0369718;C0441922
prior mi,C0332152;C3810814;C2826257
diabetes etiology,C0015127;C1314792;C1524003
ischemic,C0475224
nonischemic,
heart rate min_ $nmbr$ mean,C0444504;C2347634;C2348143
systolic bp mm hg mean nyha class,C0488053;C1882083
ttf fv,C1332112;C1705840;C4087167
ct ratio $nmbr$ $nmbr$,C0456603;C1547037
ejection fraction mean,C0444504;C2347634;C2348143
creatinine $nmbr$ $nmbr$ mg dl medications,C0013227;C0802604;C2598133;C4284232
diuretics,C0012798
stent group n $nmbr$,C0038257;C0441848
alteplase group n $nmbr$,C0032143;C0441848
demography,C0011298
median iqr age years,C0549183;C1510829;C0876920;C2347635;C2348144;C2939193
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ^ $nmbr$,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
m f,C0016327
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
receiving insulin therapy,C1514756;C0021641;C0039798;C0087111;C1363945;C1533581;C1579433;C3714501
median iqr cholesterol,C0549183;C0008377;C0876920;C2347635;C2348144;C2939193
mmol l,C1532563
previous myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
previous cabg,C0205156;C0010055;C1552607
infarct localisation,C0475264;C1744691
lateral,C0205093
killip class,C1881332
i,C0021966;C0221138
ii,
iii,C0439070;C1705160
iv,C0022326;C4265176
median iqr admission data,C1511726;C3245479;C3714741
systolic blood pressure,C0488055;C0871470;C1306620
mm hg,C0439475
diastolic blood pressure,C0428883;C1305849
heart rate beats min,C0439385
time to admission min,C3854258;C3854259
time to balloon needle min,C0040223;C3541383
losartan n $nmbr$,C0126174
atenolol n $nmbr$,C0004147
all with diabetes n $nmbr$,C0011847;C0011849
all without diabetes n $nmbr$,C0011847;C0011849
demographic and clinical characteristics,C0011298;C0683325
ethnic origin white,C0007457;C0043157;C0220938
hispanic,C0086409
asian,C0078988
heart rate bpm,C0018810
bmi kg m $nmbr$,C0022718;C0439209;C4054209
cornell voltage duration product mmxmsec,C0598352;C0449238;C2926735
sokolow lyon mm,C4330985;C4554674
framingham risk score,C0035647;C0449820;C4050231;C4552904
current smokers,C3173209;C3241966
any vascular diasease,C0005847;C1558950;C1801960
coronary heart disease,C0010054;C0010068;C1956346
cerebrovascular disease,C0007820
peripheral vascular disease,C0085096
atrial fibrillation,C0004238;C0344434;C1963067
isolated systolic hypertension^,C0745133
clopidogrel n $nmbr$,C0070166
ticlopidine n $nmbr$,C0040207
women n,C0043210
diabetes n,C0011847;C0011849
smoking habit n,C4505437
hypercholesterolemia n,C0020443;C1522133
systemic arterial hypertension n,C0020538
previous myocardial infarction n,C0027051;C0428953;C2926063;C3810814;C4552959
previous balloon angioplasty n,C0002996;C0002997
previous bypass surgery n,C0205156;C1536078;C1552607
unstable angina n,C0002965
platelet count x $nmbr$ mm $nmbr$,C4330985;C4554674
baseline demographics,C0011298;C1704791
simvastatin n $nmbr$,C0074554
women men [ ],C0043210;C0025266
disease duration yr,C0872146;C0439234
mmse points,C1552961;C2347617;C3714763
adas cog score,C0449820;C4050231
points,C1552961;C2347617;C3714763
serum ldl cholesterol,C0428474
mg dl,C0439269
csf a $nmbr$ pm,C3540512;C3889436;C0030266;C4049155
csf lathosterol jlg cll,C0064673;C0023434
csf cholesterol,C3540512;C0008377;C3889436
csf $nmbr$ s hydroxy,C3540512;C3889436;C0700307
cholesterol ng ml,C0008377;C0439275
mmse mini mental state examination adas cog alzhei,C0451306
mer s disease assessment,C1261322;C1516048
scale cognitive portion ldl low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
density lipoprotein csf,C3540512;C3889436
cerebrospinal fluid,C0007806;C0007807
mmse $nmbr$ $nmbr$,C0451306
simvastatin,C0074554
measures,C0079809;C1879489
n $nmbr$,C0369718;C0441922
serum,C0229671;C1546774;C1550100
aldl cholesterol,C0008377
$nmbr$ $nmbr$ $nmbr$ $nmbr$ b,
csf,C3540512;C3889436
a a $nmbr$,
aab $nmbr$,
alathosterol,
acholesterol,
a $nmbr$ s hydroxy,C0700307
cholesterol,C0008377
$nmbr$ $nmbr$ $nmbr$ $nmbr$ r mmse mini mental,C0205090;C0451306;C0684010;C2603358;C0445542;C0229992
ipeated measures state examinatioi,C0079809;C1301808;C1442792;C3148680;C1879489
analysis compared with the pretreatment condition baseline n ldl low density lipoprotein csf cerebrospinal fluid,C0002778;C0936012;C1524024;C1707455;C0023823
table $nmbr$ characteristics of patients treated with losartan and atenolol,C0039224;C0815172;C1706074;C0332293;C0126174;C0004147
women no,C0043210
ethnicity no,C0015031;C0243103
systolic,C0039155
cornell voltage duration product mm x ms,C2349943;C3539704;C3713294
framingham risk score arbitrary units,C0035647;C0439183;C4552904
current smoker no,C3173209;C3241966
medical history no,C0262926;C1704706
previously untreated isolated systolic hypertension,C0745133
diagnosed diabetes n $nmbr$,C0011847;C0011849
undiagnosed diabetes n $nmbr$,C0011847;C0011849
impaired fasting giucose levei n $nmbr$,C0221099;C0015663
normai fasting giucose levei n $nmbr$,C0015663
p vaiue,C0369773;C2603361
age mean sd y,C0001779;C0444504;C2347634;C2348143
race nonwhite,C0034510;C1706779;C3853635
smoking current,C0521116;C1705970
alcohol with $nmbr$ drink d,C0001948;C0556297
prior myocardial intarction,C0332152;C0027061;C1522564;C2826257
prior stroke,C0038454;C4554100
ptca cabg,C2936173;C0010055
ptca,C2936173
cabg,C0010055
medication use,C0240320
aspirin,C0004057
ace inhibitor,C0003015;C4541021
anyantianginal agent,C0450442;C1254351;C1521826
calcium channel blocker,C0006684;C3536851;C4521885
p blocker,C0369773;C2603361
bmi mean sd,C0444504;C2699239;C2347634;C2348143
waist circumference mean sd in,C0455829;C2699239
blood pressure mean sd mm hg,C0428886;C0439475
lipids mean sd mg dlf,C0023779;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
triglycerides,C0041004
ldl c,
total cholesterol,C0201950;C0543421
fpg mean sd mg dlf,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
fpi mean sd pu rnff,C0444504;C0018387;C2347634;C2348143
outcome,C1274040
hr,
subgroup_name_level,C0441889;C0456079;C1547707;C2946261
combined end poir,C0205195;C0444930;C2746065
it $nmbr$ $nmbr$,
p oo $nmbr$,C0369773;C2603361
no diabetes,C0011847;C0011849
p $nmbr$,C0369773;C2603361
nonfatal myocardiail infarction,C0021308
chd death,C0011065;C1306577;C4082313;C4552775
p o $nmbr$,C0369773;C2603361
stroke,C0038454;C4554100
subgroup_name,C0027365;C1547383;C4522128
subgroup_level fpi gu ml pmol l,C1635169
hazard ratio,C2985465
fasting plasma insulin,C0015663;C0857690
overall n $nmbr$,C0282416;C1561607
rate control group n $nmbr$,C0441848
rhythm control group n $nmbr$,C0441848
female sex no,C0086287
ethnic minority group no,C0015031;C1879937
predominant cardiac diagnosis no,C0011900;C1704338;C1704656
coronar y artery disease,C0852949
cardiomyopathy,C0878544
valvular disease,C3258293
no apparent heart disease,C0750489;C0018799
histor y of congestive heart failure no,C0018802
duration of qualifying atrial fibrillation $nmbr$ days no,C0449238;C2926735;C1514624;C0004238;C0439228;C0344434;C1963067
first episode of atrial fibrillation vs recurrent episode no f,C0332189;C0439615;C0443287;C0016327
any prerandomization failure of an antiarrhythmic drug no,C0231174;C0680095
size of left atrium normal no,C0225860;C0332506
left ventricular ejection fraction,C0428772;C0488728
normal left ventricular ejection fraction no j,C0428772;C0488728
no of participants,C0679646
$nmbr$ chlorthalidone n $nmbr$,C0008294
amlodipine n $nmbr$,C0051696
i lisinopril n $nmbr$,C0021966;C0065374;C0221138
age range y,C0001779;C1514721;C2348147;C3542016
a $nmbr$,
ethnicity,C0015031;C0243103
white non hispanic,C1533020;C1533021
education mean sd y,C0013621;C0013622;C0013658;C0039401
receiving antihypertensive,C1514756;C0003364
treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
treated at baseline,C1522326;C0168634;C1442488
untreated at baseline,C0332155;C0168634;C1442488
$nmbr$ $nmbr$ s $nmbr$ $nmbr$,
eligibility risk factors,C0035648;C1553898
cigarette smoker,C0337667
atherosclerotic cvdj,C0333482
history of ml or stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0038454;C4554100
history of coronary,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
revascularization,C0581603
other atherosclerotic cvd,C0333482;C0007222
major st depression or,C0041696;C1269683
t wave inversion,C0520888
lvh by electrocardiogram,C0149721;C0013798;C1547122;C1623258
lvh by echocardiogram,C0149721;C0013516;C2243117
history of chd at baseline,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0168634;C1442488
body mass index mean sd,C0005893;C2699239;C0578022;C1305855
current medication use,C0240320
estrogen supplementation,C0014939;C0242297;C2936882;C4542544
women only,C0043210
lioid trial participants,C1997894;C2242969
placebo group n $nmbr$,C0032042;C0441848;C1696465;C1706408
warfarin group n $nmbr$,C0043031;C0441848
median,C0549183;C0876920;C2347635;C2348144;C2939193
female sex,C0086287
race or ethnic group,C0034510;C1706779;C3853635;C0015031;C1879937
non hispanic white,C0007457;C0043157;C0220938
non hispanic black,C0005680;C0027567;C0085756;C0439541
history of diabetes,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
$nmbr$ previous venous thromboembolisms,C0205156;C1997614;C1552607
family history of venous thromboembolism,C0455533
factor v leiden,C0380964;C0584960;C1414509;C3542419
prothrombin mutation,C1610621
duration of full dose warfarin therapy before enrollment mo,C0444917;C0366686;C0026544;C0332177
time between cessation of full dose warfarin therapy and enrollment mo,C0682295;C0366686;C0026544;C0332177
placebo group,C0032042;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1696465;C1706408
warfarin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
hazard ratio $nmbr$ ci,C0008107;C3259781
p value for interaction^,C1709380;C1704675
no of events,C0441471;C3541888
no $nmbr$ person yr,C0027361;C0439234;C2347489
factor v leiden or prothrombin mutation,C0380964;C0584960;C1414509;C3542419;C1610621
present,C0150312;C0449450
absent,C0332197;C4285062
$nmbr$ $nmbr$ yr,C0439234
no of previous venous thromboembolic events,C1861172;C1997614;C3160733
time since randomization,C0040223;C3541383
time since cessation of full dose warfarin therapy,C0682295;C0366686
$nmbr$ mo,C0026544;C0332177
hba $nmbr$ c strata,C0019016;C1825777;C3538758
rsg $nmbr$ mg day,C0439422
patients n,C0030705
age years mean sd,C1510829;C2699239
gender male female,C0043210;C0086287;C1705497;C1705498
white black other,C0005680;C0027567;C0085756;C0439541
bmi kg m $nmbr$ mean sd,C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
hba $nmbr$ c,C0019016;C1825777;C3538758
baseline mean sd,C0168634;C2699239;C1442488
week $nmbr$ mean sd,C0332174;C2699239;C0439230
comparison with baseline,C1707455;C0168634;C1442488
mean change $nmbr$ ci,C0008107;C3259781
comparison with placebo,C1707455;C0032042;C1696465;C1706408
mean difference $nmbr$ ci,C0008107;C3259781
fpg mg dl,C0439269
baseline geometric mean cv,C3538987;C4048877;C4318503
week $nmbr$ geometric mean cv,C3538987;C4048877;C4318503
comparison with baseline mean,C1707455;C0168634;C1442488
change $nmbr$ ci,C0008107;C3259781
comparison with placebo mean,C1707455;C0032042;C1696465;C1706408
difference $nmbr$ ci,C0008107;C3259781
usual care n $nmbr$,C3538928;C1947933
intervention n $nmbr$,C0184661;C0886296;C1273869
demographics,C0011298;C1704791
sex female,C0086287
marital status married,C0024841;C0555047
education high school or higher,C0683862;C0205250
medical characteristics,C0199168;C1521970;C0205476
smoking history,C1519384
hypercholesterolemia,C0020443;C1522133
renal insufficiency,C0035078;C1565489
previous ml,C0439526;C1705224;C3887665
previous cabg surgery,C0038894;C0038895;C0543467;C1274039
previous ptca,C0205156;C2936173;C1552607
chf history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
comorbidity score mean sd t,C0009488;C0444504;C2347634;C2348143
systolic blood pressure mean sd mm hg,C0428886;C0439475
body mass index mean sd t,C0005893;C0578022;C1305855
characteristics of the index ml,C1521970;C0439526;C1705224;C3887665
infarct type,C0332307;C1547052
q wave,C0429089;C1305738
non q wave,C0429089;C1305738
indeterminate or unknown,C0205258;C0439673;C3541433;C4050014
infarct location,C0450429;C1515974;C4284930;C4284931
ejection fraction category,C0683312;C3889287
severe dysfunction,C3274777
moderate dysfunction,C3274776
mild dysfunction or normal,C3274775;C0205307;C0231683;C0439166;C2347086;C4553972
killip class lll iv,C2697847;C1261077
treatment of the index ml,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
thrombolytic therapy,C0040044
cabg surgery,C0038894;C0038895;C0543467;C1274039
cardiac catheterization,C0018795
current prescribed medications,C3166216;C3202967
anticoagulants,C0003280
p blockers,C0369773;C2603361
lipid lowering drugs,C0086440
psychosocial risk factors,C0033963
depressed only,C0344315;C0549249
low perceived social support only,C0037438;C0748877;C1540833;C3669642
depressed and low perceived social support,C0344315;C0549249;C0037438;C0748877;C1540833;C3669642
abbreviations ace angiotensin converting enzyme cabg coronary artery bypass graft chf congestive heart failure ml myocardial infarction ptca percutaneous transluminal coronary angioplasty data are presented as no unless otherwise indicated denominator may vary due to missing values tbased on charlson comorbidity index range in sample $nmbr$ $nmbr$ recalculated as weight in kilograms divided by the square of height in meters,C1511726;C3245479;C3714741;C0449450;C1444656;C2825218;C0678226;C0042295;C4546361;C2348147;C0005910;C0043100;C1305866;C1705104;C0332849;C0205120;C1552595;C0441074
patients treated with losartan n $nmbr$,C0030705;C0332293;C0126174
patients treated with atenoloi n $nmbr$,C0030705;C0332293
aii patients n $nmbr$,C1424250;C0030705;C2698414
age x,C0001779
ethnicity n,C0015031;C0243103
bmi kg m^,C0022718;C0439209;C4054209
cornell voltage x duration product mm x ms,C2349943;C3539704;C3713294
sokolow lyon voltage mm,C4330985;C4554674
current smokers n,C3173209;C3241966
atrial fibrillation n,C0004238;C0344434;C1963067
isolated systolic hypertension n,C0745133
patients with clinically evident vascular disease,C0683521
patients without clinically evident vascular disease,C0683521
treated with losartan n $nmbr$,C0332293;C0126174
treated with atenolol n $nmbr$,C0332293;C0004147
adjusted hazard ratio $nmbr$ cl,C2985465;C0596019
unadjusted hazard ratio $nmbr$ cl,C2985465;C0596019
unadjusted hazard ratio $nmbr$ ci,C0008107;C3259781
patients,C0030705
ratet,
primary composite end points,C0205199;C2349179;C1547335
$nmbr$ ^ $nmbr$,
cardiovascular mortality,C0026565;C0026566
\ $nmbr$ $nmbr$ $nmbr$,
total mortality,C0026565;C0026566
hospitalization,C0019993
angina pectoris,C0002962
heart failure,C0018801;C0018802;C4554158
new onset diabetes,C0011847;C0011849
analysis,C0002778;C0936012;C1524024
doubling of baseline serum creatinine or esrd rr ci,C0205173;C1705764;C0008107;C3259781
esrd only rr ci,C0022661;C0035078;C2316810;C0008107;C3259781
unadjusted,C1439367
adjusted for all baseline variables $nmbr$,C0456081;C0168634;C1442488
adjusted for all baseline variables and interaction between acei and baseline upb,C0456081;C0168634;C1442488;C1704675
adjusted for all baseline variables interaction between acei and baseline up and declines in sbp and up,C0456081;C0168634;C1442488;C0085805
relative risk of outcome in acei group iw control group bbaseline variables for models included logarithm of age reciprocal of serum creatinine sbp up excretion treatment assignment and terms for studies $nmbr$ $nmbr$ $nmbr$ and $nmbr$ see footnotes of table $nmbr$ other baseline variables considered for analysis p $nmbr$ $nmbr$ in univariate analysis included dp mean arterial pressure type of antihypertensive regimen in the control group planned duration of follow up whether or not the investigators were blinded whether or not dietary advice was given and the year of publication,C0242492;C1274040;C0439828;C0039798;C1516050;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0233324;C1515273;C1705313;C2826302;C2825232;C0039224;C1706074;C0168634;C1442488;C0750591;C0002778;C0936012;C1524024;C0332307;C1547052;C0009932;C4288391;C1518422;C0035173;C0150108;C0204932;C0439234;C0439508
$nmbr$ prolonged antithrombotic pretreatment n $nmbr$,C0439590;C1550147;C2709094;C3539075;C3539076
$nmbr$ early intervention n $nmbr$,C0242687;C1964029
age median iqr y,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
active smoker,C0205177;C0337664;C3853793;C3888249
serum cholesterol median iqr mg dl,C0587184;C0439269
arterial hypertension,C0020538
diabetes mellitus,C0011849
insulin dependent,C0021641;C0429964;C0429986;C0851827;C1701901;C3244310;C4321395;C1533581;C1579433;C3714501
previous balloon angioplasty,C0002996;C0002997
entry criteria,C1705654;C0243161
st segment depression,C0520887
cardiac troponin t level $nmbr$ $nmbr$ pg l,C3538889;C0439278
cardiac troponin t level median iqr pg l,C3538889;C0439278
no of coronary vessels with $nmbr$ diameter stenosis,C0010075;C0678234;C1261287;C2632116
none,
left ventricular ejection fraction median iqr,C0428772;C0488728
calcium antagonist strategy n $nmbr$ $nmbr$,C0006684;C0679199
non calcium antagonist strategy n $nmbr$ $nmbr$,C0006684;C0679199
demographic $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0011298
race ethnicity white,C0007457;C0043157;C0220938
other multiracial,C1881928
bmi mean sd kg m $nmbr$,C0022718;C0439209;C4054209
condition $nmbr$ $nmbr$ $nmbr$,C0012634;C0348080;C1705253;C3864998
abnormal angiogram,C0002978;C1548816;C3891555;C4255126
prior ml or abnormal angiogram,C0439526;C1705224;C3887665;C0002978;C1548816;C3891555;C4255126
concordant stress test abnormalities,C0000768;C0000769
cabg $nmbr$ month ago,C0332177;C0439231
pci $nmbr$ month ago,C0332177;C0439231
cabg or pci,C0010055;C4049621
left ventricular hypertrophy,C0149721;C3484363
unstable angina $nmbr$ mo ago,C0026544;C0332177
arrhythmia,C0003811
heart failure class l lll,C0018801;C1261077;C0018802;C4554158
smoking past,C0037369;C0453996;C1881674
within last $nmbr$ d,
diabetesf,
hypercholesterolemiat,
renal impairmentt,C0022646
cancer,C0006826;C0998265;C1306459
aspirin or other antiplatelet agent,C0004057;C0085826
medication $nmbr$ $nmbr$ $nmbr$,C0013227;C3244316;C4284232
other nsaids,C0003211
antidiabetic medication,C0935929
any lipid lowering agent,C0086440
nitrates,C0028125
potassium supplement,C0304475
hormone replacement,C0282402
abbreviations bmi body mass index cabg coronary artery bypass graft nsaids nonsteroidal anti inflammatory drugs pci percutaneous coronary interventions values expressed as number percentage unless otherwise indicated percentages may not equal $nmbr$ due to rounding fhistory of or currently taking antidiabetic or lipid lowering medications ^history of or currently have elevated serum creatinine level but less than $nmbr$ mg dl_,C1881192;C0237753;C0439165;C1549488;C1561533;C0449788;C0242503;C0332490;C0521116;C0935929;C0023779;C0441994;C2003888;C1553893;C0600061;C0700225;C0439269
baseline subgroup,C1079230;C1515021
calcium antagonist strategy cas events n,C0006684;C0441471;C3541888
non calcium antagonist strategy ncas events n,C0006684;C0441471;C3541888
rr $nmbr$ cl,C4554402;C0596019
race ethnicity,C0015031;C0243103
us resident,C4698406
candesartan group n $nmbr$,C0717550;C0441848
control group n $nmbr$,C0441848
mean age y,C0444504;C0001779;C2347634;C2348143
ejection fraction,C0489482;C2700378
history of,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
smoking status,C1519386
exsmoker,C0337671;C4555205
arterial hypertension no,C0020538
type $nmbr$ diabetes no,C1320657
hypercholesterolemia no,C0020443;C1522133
prior myocardial infarction no,C0027051;C0428953;C2926063;C3810814;C4552959
prior aortocoronary bypass surgery no,C0455610;C0010055
angina class iii or iv no,C0264677;C0022326;C4265176
multivessel disease no,C0012634
duration of clopidogrel pretreatment hr median,C0449238;C2926735
$nmbr$ th $nmbr$ th percentiles,C0039725;C1264641;C0039738;C1420718;C4282123;C4285344
drug therapy at admission no aspirin,C0013216;C0013217;C0004057
calcium channel antagonists,C0006684;C2757014
statins,C0360714
group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
abciximab no total,C0288672;C0439175;C0439810
placebo no total,C0032042;C1696465;C1706408;C0439175;C0439810
all patients,C0030705
angina class iii or iv prior myocardial infarction,C0264677;C0027051;C0428953;C2926063;C3810814;C4552959
intervention in complex lesions,C1292781;C0221198
type of lipid lowering regimen,C0332307;C1547052;C0441994;C2003888;C0040808;C2945654
i moderate $nmbr$ mg of pravastatin n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
i intensive $nmbr$ mg of atorvastatin n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mean sd $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0444504;C2699239;C2347634;C2348143
cholesterol mg dl total,C0201950;C0543421
low density lipoprotein,C0023823
high density lipoprotein,C0023821
triglycerides mg dl,C0041004;C0439269
apolipoprotein b $nmbr$ mg dl,C0003593;C0439269
c reactive protein mg l,C0006560;C0439268;C1413716;C4048285
men n $nmbr$,C0025266
no $nmbr$ $nmbr$,
white n $nmbr$,C0007457;C0043157;C0220938
smoking status current smoker n $nmbr$,C1519386;C3173209;C3241966
past or nonsmoker n $nmbr$,C0337672;C0425293;C4554605
history of hypertension n $nmbr$,C0455527
prior statin use n $nmbr$,C0332152;C0042153;C0457083;C1947944;C2826257
history of diabetes mellitus n $nmbr$,C0455488
metabolic syndrome n $nmbr$,C0524620
subgroup,C1079230;C1515021
test for interaction p value,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
gender,C0079399;C1522384
country,C0454664;C1511538
ethnic group,C0015031;C1879937
disease history,C0683519
mi,C3810814
ihd,C0151744
angina,C0002962
microalbuminuria,C0730345
ish,
alcohol intake,C0001948
exercise status,C0015259;C0449438;C1522704
bmi,C0578022
systolic bp,C0871470
diastolic bp,C0428883
ecg lvh cornell,C0232306
ecg lvh sokolow lyon,C0232306
a worldwide black and non black patients,C0005680;C0027567;C0085756;C0439541;C1829939
worldwide black patients,C0005680;C0030705;C0027567;C0085756;C0439541
crude rate,C0871208;C1521828
adjusted hazard ratio $nmbr$ ci,C0008107;C3259781
rate,C0871208;C1521828
composite,C0205199;C1547335
components of primary composite end point secondary end points,C1882460
mi fatal nonfatal,C1302234;C1705232
stroke fatal nonfatal,C0038454;C1302234;C1705232;C4554100
worldwide non black patients,C1829939;C0005680;C0027567;C0085756;C0439541
losartan n $nmbr$ $nmbr$,C0126174
atenolol n $nmbr$ $nmbr$,C0004147
b u s black and non black patients,C0005680;C0027567;C0085756;C0439541;C1829939
u s black patients,C0041703;C0030705
u s non black patients,C0041703;C1829939
monteiukast n $nmbr$,
sex no,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
race no,C0034510;C1706779;C3853635
patients receiving immunotherapy no,C0030705;C1514756;C0005525;C0021083
allergic rhinitis duration mean sd y,C1334103;C2607914;C4552864
baseline daytime nasal symptoms score mean sd,C0231918;C2699239
pollen exposure,C0274281;C0332157
patients included in analysis,C0030705;C0332257;C0002778;C0936012;C1524024
daytime nasal symptoms score change from baseline mean se,C0436315
ls mean difference $nmbr$ cl,C0023668;C0596019
monteiukast,
monteiukast vs placebo,C0032042;C1696465;C1706408
pollent $nmbr$,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$,
pollent s $nmbr$,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ t,C2603360
first recorded event no and of patients,C0441471;C4019010;C0030705
hemispheric tia n $nmbr$,C0205139;C0007787;C0917805;C1054154
hemispheric stroke n $nmbr$,C0205139;C0038454;C4554100
myocardial infarction or angina,C0027051;C0428953;C2926063;C3810814;C4552959;C0002962
smoking in the past year,C0037369;C0453996;C1881674
$nmbr$ degree of ica stenosis,C0201519;C4034225
irregular or ulcerated ica p laque [,C0205271;C0041582;C0201519;C3887532
infarct on brain imaging,C0021308;C0203860
intracranial disease of major artery,C0852949;C0752138
iduration of symptoms $nmbr$ min,C0683368;C0702093;C1524029;C3813700;C1457887
factor,C1521761;C2827422
no of strokes no of patients in category and,C0038454;C0030705;C0683312;C3889287
hazard ratio and $nmbr$ ci,C2985465;C0008107;C3259781
factor present,C0150312;C0449450
factor absent,C1521761;C2827422;C0332197;C4285062
crude,
adjusted,C0456081
ica stenosis $nmbr$ $nmbr$ f,C0201519;C0016327
irregular or ulcerated ica plaquef,C0205271;C0041582;C0201519;C3887532
infarct on brain imaging^,C0021308;C0203860
intracranial disease of major artery disease t,C0752138
duration of symptoms $nmbr$ min,C0436359;C0702093;C1524029;C3813700
none n $nmbr$,C0369718;C0441922
$nmbr$ $nmbr$ week n $nmbr$,C0332174;C0439230
$nmbr$ $nmbr$ week n $nmbr$ $nmbr$ $nmbr$ week n $nmbr$,C0332174;C0439230
$nmbr$ week n $nmbr$,C0332174;C0439230
age years s d,C1510829
x $nmbr$ n,
female n,C0043210;C0086287;C1705497;C1705498
white n,C0007457;C0043157;C0220938
black n,C0005680;C0027567;C0085756;C0439541
hispanic n,C0086409
asian n,C0078988
other race n,C0034510;C1706779;C3853635
cigarette smoking n,C0239059;C0700219
previous smokers,C0337671
$nmbr$ $nmbr$ day,C0332173;C0439228;C0439505
$nmbr$ day,C0332173;C0439228;C0439505
exercise n,C0015259;C1522704
p $nmbr$ min twice week,C0332174;C0439230
$nmbr$ min twice week,C0332174;C0439230
enoxaparin n $nmbr$,C0206460
unfractionated heparin n $nmbr$,C0019134;C2825026
female sex no total,C0086287;C0439175;C0439810
region no total,C0017446;C0205147;C0439175;C0439810
austral ia new zealand,C0027978;C0324547
europe,C0015176
north america,C0028405
south america,C0037713
race no total,C0034510;C1706779;C3853635;C0439175;C0439810
american indian,C0002460
pacific islander,C0242191
clinical variables median iqr,C0205210;C0439828
medical history and risk factors no total,C0262926;C1704706;C0035648;C1553898;C0439175;C0439810
killip class $nmbr$,C1881332
prior angina,C0332152;C0002962;C2826257
prior infarction,C0332152;C0021308;C2826257
prior oabg surgery,C0455610
prior pci,C0332152;C4049621;C2826257
g $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0439267
prior congestive heart failure,C0332152;C0018802;C2826257
history of peripheral vascular disease,C1881056
previous,C0205156;C1552607
family history of cad,C0241889;C1504769;C2239547;C3813548;C4284121
time from symptom onset to enrollment,C0449244;C1516879;C1696073;C3888021
median iqr h,C0033727;C0369286;C0441932;C0564385;C4528284
time from hospital admission to enrollment,C3854258;C3854259;C1516879;C1696073;C3888021
placebo $nmbr$ mg d of simvastatin n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0073187;C0074554;C0332173;C4484261
simvastatin $nmbr$ $nmbr$ mg d n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0369718;C0441922
age median $nmbr$ th $nmbr$ th percentiles y,C0001779;C0039725;C0039738;C1420718;C4282123;C4285344
men,C0025266
prior cardiovascular history,C0332152;C1880008;C2826257
percutaneous coronary intervention,C1532338
prior to index event,C0441471;C4019010
for treatment of index event,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
peripheral arterial disease,C0085096;C1704436
risk factors,C0035648;C1553898
current smoking,C0037369;C0453996;C1881674
premature cad among family members,C1504769;C2239547;C3813548;C4284121
qualifying event,C1514624;C0441471;C4019010
st segment elevation mi,C0520886;C3810814
non st segment elevation acs,C0520886;C0742343;C4318612
participation in phase a,C0679823;C0205390;C1710475
concomitant therapies at hospital discharge,C1707479;C0586003
primary end point kaplan meier rate,C0871208;C1521828
simvastatin $nmbr$ $nmbr$ mg d,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
placebo $nmbr$ mg d of simvastatin,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0073187;C0074554;C0332173;C4484261
risk reduction,C1137094
ldl cholesterol mg dl,C0023824;C0439269;C0202117
hdl cholesterol mg dl,C0023822;C0439269;C0392885
index diagnosis,C0011900;C1704338;C1704656
pci for index event,C4049621;C0441471;C4019010
strategy,C0679199
verapamil sr no $nmbr$,C1527129
atenolol no $nmbr$,C0004147
mean age sd years,C0444504;C1510829;C2347634;C2348143
age $nmbr$ years,C1510829
mean bmi sd kg m $nmbr$,C0022718;C0439209;C4054209
previous ml or abnormal angiogram,C0439526;C1705224;C3887665;C0002978;C1548816;C3891555;C4255126
cabg or angioplasty,C0010055;C0162577;C1548817
stroke tia,C0007787;C0917805;C1054154
lvh,C0149721
unstable angina,C0002965
pvd,C0085096;C4521226
renal impairmentf,C0022646
cancert,
heart rate sd bpm blood pressure mm hg,C0428876;C0439475
sbp sd,C0085805;C2699239
dbp sd,C0536221;C2699239;C3813197;C4281799
antihypertensive medication,C0003364
mean no agents sd other medications,C0444504;C2347634;C2348143;C0450442;C2699239;C1254351;C1521826;C0013227;C0802604;C2598133;C4284232
aspirin or other antiplatelet agents,C0004057;C0085826
antidiabetic medications,C0935929
insulin,C0021641;C1533581;C1579433;C3714501
oral hypoglycemics hormone replacement,C0359086;C0282402
percentage of females,C0439165;C1549488;C1561533
percentage unless otherwise noted cabg indicates coronary artery bypass graft lvh left ventricular hypertrophy nsaids nonsteroidal antiinflammatory drugs pvd peripheral vascular disease tia transient ischemic attack history of hypercholesterolemia or reporting use of lipid lowering medications at baseline thistory of or currently have elevated serum creatinine level,C0439165;C1549488;C1561533;C4288581;C0010055;C1553893;C0020443;C1522133;C1524063;C0023779;C0441994;C2003888;C0013227;C0802604;C2598133;C4284232;C0521116;C0600061;C0700225
$nmbr$ cl,C0596019
verapamil sr n $nmbr$,C1527129
primary outcome,C0205225;C1274040;C0439612;C0439631
death all cause,C0011065;C1306577;C4082313;C4552775;C0015127;C1524003
nonfatal ml,C0439526;C1705224;C3887665
nonfatal stroke,C0038454;C4554100
cardiovascular death,C0011065;C1306577;C4082313;C4552775
cardiovascular hospitalization,C0007226;C0019993;C3887460
per $nmbr$ participant years composite of first occurrence death all cause nonfatal ml or nonfatal stroke cardiovascular death excluding those classified as unable to determine,C0205199;C1547335;C0439526;C1705224;C3887665;C0011065;C1306577;C4082313;C4552775;C0566415;C1299582;C4048706;C4321405
planned conservative therapy subgroup,C1079230;C1515021
overall a phase population,C0282416;C1561607;C0032659;C1257890
male gender,C0086582;C1706180
us site of enrollment,C0815353;C2945843;C3889164
angina past $nmbr$ weeks,C0002962;C0439230
coronary revascularisation,C0877341
bypass surgery,C1536078
percutaneous intervention,C0522523;C0184661;C0886296;C1273869
congestive heart failure chf in past $nmbr$ weeks,C0018802;C0439230
left ventricular dysfunction,C0242698
prior medications,C0013227;C0802604;C2598133;C4284232
angiotensin converting enzyme inhibitor,C0003015;C2757044;C3536837;C4541021
b blocker,
nitrate,C0028125;C0699857;C3848573
diuretic,C0012798
long term aspirin,C0443252;C0004057
unfractionated heparin before randomisation,C0019134;C2825026
low molecular weight lmw heparin before randomisation,C0019139;C3536766
neither uh or lmw heparin,C0019134;C0770546
investigator determined myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
st change $nmbr$ mm,C4330985;C4554674
enoxaparin,C0206460
ufh,
k m n,C0369637;C0441923
k m,C0369637;C0441923
overall effect,C1280500;C1518681;C2348382
males,C0086582
females,C0086287
$nmbr$ yea s,
non diabetics,C1518422;C0241863
diabetics,C0241863
no prior aspirin,C0332152;C0004057;C2826257
prior aspirin,C0332152;C0004057;C2826257
normal troponin,C0205307;C0041199;C0231683;C0439166;C2347086;C4553972
elevated troponin,C0205250;C0041199;C3163633
no st depression or elevation,C0520887;C0439775;C0702240
st depression or elevation,C0520887;C0439775;C0702240
timi risk score $nmbr$ $nmbr$,C0035647;C0449820;C4050231;C4552904
niacin n $nmbr$,C0027996;C1142562
male gender n,C0086582;C1706180
age mean sd,C0001779;C2699239
type $nmbr$ diabetes mellitus n,C1320657
hypertension n,C0020538;C1963138
tobacco use n,C0040335;C0543414;C0841002;C3853727
family history ot chd n,C0241889;C0280604;C3542407
metabolic syndrome n,C0524620
history ot chd n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
ml,C0439526;C1705224;C3887665
angina with documented ischemia,C0002962;C0022116;C4321499
medications n,C0013227;C0802604;C2598133;C4284232
$nmbr$ blocker,
vitamin e,C0042874;C3714803
vitamin c,C0003968;C2349136;C3714687;C4522080
figure $nmbr$ change in imt across $nmbr$ months in patients treated with placebo and extended release niacin in presence or absence of metabolic syndrome or type $nmbr$ diabetes mellitus,C0392747;C0443172;C1705241;C4319952;C0439231;C0030705;C0332293;C0032042;C1696465;C1706408;C0027996;C1142562;C0332197;C1689985;C1320657
serum creatinine concentration and randomization to losartan,C0683149;C0034656;C0126174
or placebo treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
lowest tertile range $nmbr$ $nmbr$ $nmbr$ $nmbr$ mg dl mean sd $nmbr$ $nmbr$ $nmbr$ $nmbr$ mg dl,C3539687
middle tertile range $nmbr$ $nmbr$ $nmbr$ $nmbr$ mg dl mean sd $nmbr$ $nmbr$ $nmbr$ $nmbr$ mg dl,C3539687
highest tertile range $nmbr$ $nmbr$ $nmbr$ $nmbr$ mg dl mean sd $nmbr$ $nmbr$ $nmbr$ $nmbr$ mg dl,C3539687
losartan,C0126174
nkf stage,C0205390;C1300072;C1306673
gfr ml min per $nmbr$ $nmbr$ nr,C0017654;C0439445;C1424601
esrd on losartan,C0022661;C0035078;C2316810
esrd on placebo,C0022661;C0035078;C2316810
risk reduction $nmbr$ ci,C0008107;C3259781
p losartan versus placebo,C0369773;C0126174;C2603361;C0032042;C1696465;C1706408
chf on losartan,C0018802;C0126174
chf on placebo,C0018802;C0032042;C1696465;C1706408
patients ft,C1881534;C3890579
asian black white hispanic other clinical parameters,C1533017;C1533018;C0205210;C0449381
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
stage i gfr $nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$ and stage v gfr,C0441766;C0439445;C0205390;C1300072;C1306673;C0017654;C1424601
systolic bp mmhg,C0871470;C0439475
heart failure ci confidence interval,C0018801;C0009667;C0018802;C4554158
diastolic bp mmhg,C0428883;C0439475
mean bp mmhg,C0037623;C0439475;C1415692;C1708288;C4318478
oral antidiabetic drugs insulin,C0021641;C1533581;C1579433;C3714501
smoking laboratory parameters,C0022877;C0449381;C3244292;C4283904
hbalc,
total cholesterol mg dl,C0201950;C0439269;C0543421
potassium meq l,C0032821;C0439375;C0202194;C0304475;C0597277;C3714637
uric acid mg dl creatinine clearance ml min per $nmbr$ $nmbr$ m $nmbr$,C0151280
mean sd,C0444504;C2699239;C2347634;C2348143
range,C1514721;C2348147;C3542016
$nmbr$ $nmbr$ ^ $nmbr$ $nmbr$,
median albumin creatinine ratio g mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
beta carotene n $nmbr$ $nmbr$,C0053396;C0696105
mean age yrs,C0444504;C0001779;C2347634;C2348143
reported hypertension,C0020538;C1963138
reported high cholesterol,C0020443;C1522133
reported diabetes mellitus,C0684224;C0011849;C0700287;C4319718
mean body mass index kg m $nmbr$,C0022718;C0439209;C4054209
parental history of mii,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
health habits,C0018684;C0018464
past only,
alcohol use,C0001948
rarely never,C4035880
physical activity,C0015259;C0026606
multivitamin use current,C0521116;C1705970
rr,
$nmbr$ ci,C0008107;C3259781
beta carotene,C0053396;C0696105
p interaction,C0369773;C1704675;C2603361
cases,C0868928;C1533148
total cataract,C3665439
current non smoker,C0425311
total cataract extraction,C0007389
eze,
pooled simva,C1709595;C2349200;C4522255
pooled eze simva,C1709595;C2349200;C4522255
n ms,C2349943;C3539704;C3713294
ri $nmbr$,C0035487;C1826843
$nmbr$ $nmbr$ i $nmbr$ s,C0021966;C0221138
patients aged $nmbr$ y no ss,C0001779;C0001792;C1999167;C2699257;C3891295;C4551874
pace no $nmbr$,C0287990;C1552930;C4048252
b lack,C0332268
bmi mean sd kg rn $nmbr$,C2827110;C3540639;C4281819
baseline lipid lipoprotem values,C0023779;C0042295
ldl c mean sd mg dl,C0444504;C0439269;C2347634;C2348143
tg median sdy rng cjl,C0337445;C0549183;C0876920;C2347635;C2348144;C2939193
tc mean sd rrig dl,C0039411;C3642216;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
hdl c mean sd mg dl,C0444504;C0439269;C2347634;C2348143
non hdl c mean sd rng dl,C0444504;C3642216;C2347634;C2348143
ldl cihdl c mean sd,C0444504;C2699239;C2347634;C2348143
tchdl c mean sd,C0444504;C2699239;C2347634;C2348143
apo b mean sd mg dl,C0003593;C0439269;C3252643
apo a $nmbr$ mean sd mg dl,C0003592;C0439269;C0523508;C4553344;C4553379
crp median se rng l,C0549183;C0036919;C0876920;C2347635;C2348144;C2939193
plp c mean sd mg dl,C0034266;C0439269;C1175541;C1257874;C1705623
$nmbr$ $nmbr$ i,C0021966;C0221138
eze ezetimibe $nmbr$ mg pooled sinva simvastatin pooled across doses pooled eze sinva ezetimibe simvastatin tablet pooled across doses bni body mass index ldl c low density lipoprotein cholesterol t g triglycerides t c total cholesterol hdl c high density lipoprotein cholesterol apo apolipoprotein c rp c neactive protein rlp c remnant like particle cholesterol,C1532737;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0039225;C1705223;C4319774;C1709595;C2349200;C4522255;C2612459
figure $nmbr$ mean percent change $nmbr$ cis from baseline to end point in plasma concentration of low density lipoprotein cho lesterol ldl c for pooled ezetimibe simvastatin eze simva and pooled simvastatin simva presented by sub group numbers in parentheses indicate numbers for the pooled simva and pooled eze simva groups respec tively ht hypertension dm diabetes mellitus bmi body mass index ldl c low density lipoprotein cholesterol chd coronary heart disease tg triglycerides hdl c high density lipoprotein cholesterol,C1504308;C1742862;C2349179;C2826544;C1709595;C1532737;C2349200;C4522255;C0074554;C0449450;C2985777;C0237753;C0449788;C0552369
amiodarone n $nmbr$,C0002598
icd therapy n,C0021122;C0039798;C0087111;C1363945
nonwhite race no ejection fraction,C0034510;C1706779;C3853635;C0489482;C2700378
diabetes no,C0011847;C0011849
pulmonary disease no,C0024115
hypertension no,C0020538;C1963138
atrial fibrillation or flutter no,C0004238;C0344434;C1963067;C0016385;C2242390
nonsustained ventricular tachycardia no j,C0750194;C2919575
syncope no,C0039070;C3541349;C4554644
electrophysiological study no weight ibj,C0850293;C0005910;C0043100;C1305866;C1705104
systolic blood pressure mm hg,C0488055;C0439475;C0871470;C1306620
diastolic blood pressure mm hg,C0428883;C0439475;C1305849
serum sodium meq liter,C0523891;C0475211
serum creatinine mg dl,C0201976;C0439269;C0600061
medication use no ^,C0240320
ace inhibitor at enrollment,C0003015;C4541021
ace inhibitor at last follow up,C0003015;C4541021
arb at enrollment,C3888198;C1516879;C1696073;C3888021
arb at last follow up,C3888198;C0589120;C1522577;C1704685;C3274571
ace inhibitor or arb at enrollment,C0003015;C4541021;C3888198;C1516879;C1696073;C3888021
ace inhibitor or arb at last follow up,C0003015;C4541021;C3888198;C0589120;C1522577;C1704685;C3274571
beta blocker at enrollment,C0001645;C1516879;C1696073;C3888021
beta blocker at last follow up,C0001645;C0589120;C1522577;C1704685;C3274571
loop at enrollment,C0445022;C1516879;C1696073;C3888021
loop at last follow up,C0445022;C0589120;C1522577;C1704685;C3274571
potassium sparing at enrollment,C0032821;C0202194;C0304475;C0597277;C3714637;C1516879;C1696073;C3888021
potassium sparing at last follow up,C0032821;C0202194;C0304475;C0597277;C3714637;C0589120;C1522577;C1704685;C3274571
thiazide at enrollment,C0541746;C1516879;C1696073;C3888021
thiazide at last follow up,C0541746;C0589120;C1522577;C1704685;C3274571
digoxin at enrollment,C0012265;C1516879;C1696073;C3888021
digoxin at last follow up,C0012265;C0589120;C1522577;C1704685;C3274571
aspirin at enrollment,C0004057;C1516879;C1696073;C3888021
aspirin at last follow up,C0004057;C0589120;C1522577;C1704685;C3274571
warfarin at enrollment,C0043031;C1516879;C1696073;C3888021
warfarin at last follow up,C0043031;C0589120;C1522577;C1704685;C3274571
statin at enrollment,C0360714;C1516879;C1696073;C3888021
statin at last follow up,C0360714;C0589120;C1522577;C1704685;C3274571
hypercholesterolemia was defined as a low density lipoprotein cholesterol level at enrollment of more than $nmbr$ mg per deciliter $nmbr$ $nmbr$ mmol per liter after an overnight fast nonsustained ventricular tachycardia was defined as $nmbr$ or more consecutive ventricular beats at a heart rate of more than $nmbr$ beats per minute to convert weight to kilograms divide by $nmbr$ $nmbr$ to convert values for creatinine to micromoles per liter multiply by $nmbr$ $nmbr$ data for follow up medication were available for $nmbr$ patients amiodarone $nmbr$ placebo $nmbr$ and icd $nmbr$ ace de notes angiotensin converting enzyme and arb angiotensin ii receptor blocker p,C0020443;C1522133;C1704788;C3539106;C1516879;C1696073;C3888021;C0439241;C0439190;C0750194;C2919575;C1883530;C0439232;C0700321;C0702093;C1282918;C2347166;C0439209;C0332849;C0042295;C0010294;C1561535;C0439300;C1719797;C2911648;C1511726;C3245479;C3714741;C0470187;C0002598;C0022709;C0011198;C0017480;C3541240;C0521942;C3536793
amiodarone vs placebo no hazard ratio $nmbr$ $nmbr$ cl,C0002598;C0032042;C1696465;C1706408;C2985465;C0596019
icd therapy vs placebo no hazard ratio $nmbr$ $nmbr$ cl,C0039798;C0087111;C1363945;C0032042;C1696465;C1706408;C2985465;C0596019
white race,C0007457;C0043157
nonwhite race,C0034510;C1706779;C3853635
lvef,C0428772;C0488728
lvef $nmbr$,C0428772;C0488728
qrs,
qrs $nmbr$ msec $nmbr$ min walk test,C0439223;C4277740
$nmbr$ $nmbr$ ft,C1881534;C3890579
$nmbr$ ft,C1881534;C3890579
beta blocker,C0001645
no beta blocker,C0001645
characteristic age,C1521970;C0001779
aspirin n $nmbr$ $nmbr$,C0004057
total n $nmbr$ $nmbr$,C0439175;C0439810
mean sd yr,C0444504;C0439234;C2347634;C2348143
past or never,C2003901
menopausal status and use of hrt y,C1513126;C1524063;C0282402
premenopausal,C0279752
uncertain,C0087130;C4085655
postmenopausal and current hrt,C0232970;C0521116;C0282402;C1705970
postmenopausal and no hrt,C0232970;C0282402
hypertension t,C0020538;C1963138
blood pressure,C0005823;C1271104;C1272641
$nmbr$ $nmbr$ $nmbr$ $nmbr$ mm hg,C0439475
$nmbr$ $nmbr$ mm hg,C0439475
parental history of myocardial infarction before $nmbr$ yr of age,C0030551;C1275835;C0439234;C0001779
$nmbr$ yr risk of coronary heart disease ^,C0439234;C1277690
no of risk factors,C0035648;C1553898
total no,C0439175;C0439810
major cv event,C0441471;C4019010
ischemic stroke,C0948008
asp,C0206293;C0206298;C1332656;C1528298;C3541260;C3890396;C4048238;C4321307;C4553371
pla,C0456170
rr $nmbr$ ci,C0008107;C3259781
body mass indexf,C0518010
menopause and hrt,C0025320;C0567312;C0282402
postmenopausal current hrt,C0232970;C0282402
postmenopausal no hrt,C0232970;C0282402
male sex no,C0086582
white race no f,C0007457;C0043157;C0016327
hyperlipidemia no,C0020473;C0428465;C4555212
diabetes mellitus no,C0011849
prior percutaneous coronary intervention no,C0332152;C1532338;C2826257
anterior myocardial infarction no,C0340293
fibrinolytic agent no t,C0016018;C2603360
tenecteplase,C0872913
reteplase,C0256103
alteplase,C0032143
streptokinase,C0038418
initial aspirin no,C0205265;C0004057;C1279901;C1555582;C1705685
initial heparin no,C0019134;C0770546
unfractionated heparin,C0019134;C2825026
low molecular weight heparin,C0019139;C3536766
both,
neither,
time from onset of symptoms to start of fibrinolytic therapy hr,C1320528;C0439659;C0040044
angiography no,C0002978
time to angiography hr,C0040223;C3541383
cardiac medications during index hospitalization no,C0013227;C0802604;C2598133;C4284232
ace inhibitors or angiotensin receptor blockers^,C0003015;C0521942;C0815017
open label clopidogrel after completion of study drug,C1709323;C0070166
ticlopidine after completion of study drug,C0040207;C0013175
patients with end point,C0030705;C2349179;C2826544
reduction in odds,C0301630;C0392756;C1293152;C4551656
clopidogrel,C0070166
overall,C0282416;C1561607
nonanterior,
types of fibrinolytic agent,C0332307;C0016018
fibrin specific,C0205369;C1552740
non fibrin specific,C0205370;C0015982
predominant type of heparin,C0332307;C1547052
low molecular weight,C0041667
unfractionated,
variables $nmbr$,C0439828
eze $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
feno $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
feno $nmbr$ mg eze $nmbr$ mg n $nmbr$,C1319635
metabolic syndrome b,C0524620
ldl c mmol l,C1532563
tc mmol l,C0039411;C1532563;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
hdl c mmol l,C3715113;C1532563
tg mmol l c,C0337445;C1532563
non hdl c mmol l,C1518422;C1532563
apo b g l,C1447574;C4521365
apo a l g l,C0628062
hscrp mg l c,C0439268
fibrinogen pmol l c,C0016006;C0439284;C1167394;C2587184;C3540039
feno,
feno eze,
tg,C0337445
tg $nmbr$ $nmbr$,C0337445
normal or increased gfr $nmbr$ ml mln per $nmbr$ $nmbr$ m^,C0205307;C0231683;C0439166;C2347086;C4553972;C1417190;C3815103
mild decrease in gfr $nmbr$ $nmbr$ ml mln per $nmbr$ $nmbr$ m^,C0392756;C0547047
moderate or severe decrease in gfr,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0392756;C0547047
$nmbr$ chlorthalidone,C0008294
amlodipine,C0051696
ii lisinopril i,C0021966;C0221138
chlorthalidone,C0008294
ii lisinopril,C1710602;C0065374;C4082587
$nmbr$ lisinopril,C0065374
no randomized,C0034656;C3815594
age mean sd y ethnicity no,C0015031;C0243103
biack non hispanic,C1518424
biack hispanic,C0086409
baseline systolic blood pressure mean sd mm hg,C4274438;C0439475
baseline diastolic blood pressure mean sd mm hg,C4274392;C0439475
history of coronary heart disease no,C0683519;C0730226;C0850708;C0944983
estimated gfr mean sd mlvmin per $nmbr$ $nmbr$ m^,C0017654;C0444504;C2347634;C2348143;C1424601
eligibility risk factors no t,C0035648;C1553898;C2603360
current cigarette smoking,C0239059;C0700219
atherosclerotic cardiovascular disease,C0004153
history of coronary revascularization,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
st segment depression or t wave inversion on ecg,C0520887;C0520888
type $nmbr$ diabetes meiiitus,C1320657
low hdl c,C0151691
lvh by ecg,C0232306
lvh by echocardiography,C0149721;C0013516
total no of events total no of participants,C0439175;C0439810;C0679646
mean se $nmbr$ year rates per $nmbr$ population,C0871208;C1521828
rr $nmbr$ cl [ value],C4554402;C0596019;C1522609
$nmbr$ chlorthalidone amlodipine,C0008294;C0051696
lisinopril,C0065374
ii chiorthaiidone amiodipine,C1710602;C4082587
ii $nmbr$ amlodipine lisinopril chlorthalidone chlorthalidone,C0051696;C0008294
total by baseline diabetic status,C0439175;C0439810
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ ] $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ ],
diabetic participants,C0241863;C0679646
nondiabetic participants,C0679646
by gfr stratum for all participants ml min per $nmbr$ $nmbr$ m,C0017654;C0439445;C1424601
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ ] $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ ],
by gfr stratum for diabetic participants mt min per $nmbr$ $nmbr$ m,C0017654;C0241863;C1424601
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ ] $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ ],
total no of events of participants total no of participants,C0439175;C0439810;C0679646
rr $nmbr$ aci [p value],C0814206;C1510682;C2346870;C4050575;C1709380
$nmbr$ amlodipine chlorthalidone,C0051696;C0008294
$nmbr$ lisinopril chlorthalidone,C0065374;C0008294
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ ],
by baseline diabetic status,C0168634;C0449438;C1442488
by gfr stratum tor all participants ml min per $nmbr$ $nmbr$ m^,C0076836;C1199517;C1419603;C3539732;C0679646;C0439445
by gfr stratum tor diabetic participants ml min per $nmbr$ $nmbr$ m,C0017654;C0439445;C1424601
vertebral fracture and or t score s $nmbr$ $nmbr$,C0080179;C0718146
vertebral fracture and or t score $nmbr$ $nmbr$,C0080179;C3854607
alendronate n $nmbr$,C0102118
mean age years,C0444504;C1510829;C2347634;C2348143
mean years since menopause,C0439234;C0025320;C0567312
mean femoral neck t score,C3533236;C0015815
mean lumbar spine t score,C3533236;C0024091;C3887615
$nmbr$ $nmbr$ q $nmbr$,
number of prevalent vertebral fractures,C0237753;C0449788
$nmbr$ or more,
history of falls in year before randomization,C1561668;C2919132;C0439234;C0439508
prior clinical fracture since age $nmbr$,C0016658;C0001779
age group,C0027362;C2348001
hip,C0019552;C0022122;C1505163;C3538851;C4284725
spine,C0037949;C2752558
wrist,C0043262;C1322271
hip wrist or spine,C0043262;C1322271;C0037949;C2752558
alendronate,C0102118
$nmbr$ to,
ezetimibe $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
number of patients $nmbr$ years,C2360800;C0439234
number of females,C0237753;C0449788
weight mean sd kg,C0022718;C0439209;C4054209
body mass index mean sd kg m $nmbr$,C0022718;C0439209;C4054209
duration of hypercholesterolemia mean sd years,C0449238;C2926735
patient history of disease,C0683519;C0730226;C0850708;C0944983
dm,C0011816;C3250443
atorvastatin dose,C0178602;C0869039;C1114758
$nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
baseline lipids mean sd mmol $nmbr$,C0023779;C0439190
tc,C0039411;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
non hdl c,C1518422;C3715113
ldl c hdl c ratio,C0428621
tc hdl c ratio,C0456603;C1547037
apo apolipoprotein dm diabetes mellitus hdl c high density lipoprotein cholesterol ldl c low density lipoprotein cholesterol tc total cholesterol,C0202069;C0369300
tg triglycerides median values standard deviation for medians,C0871420
mean baseline ldl c mmol l,C0168634;C1532563;C1442488
population,C0032659;C1257890
pbo,C0031962
eze $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
treatment stratum^,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
atv $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
p $nmbr$ $nmbr$,C0369773;C2603361
atv $nmbr$ mg study protocol,C1507394;C2348563;C2599718
$nmbr$ yrs sex,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
$nmbr$ $nmbr$ kg m $nmbr$ hypertension,C0022718;C0439209;C4054209;C0020538;C1963138
baseline ldl c,C0168634;C1442488
$nmbr$ $nmbr$ mmol l,C1532563
atv atorvastatin ldl c low density lipoprotein cholesterol p values pertain to treatment by stratum interaction test for stratum or treatment by subgroup interaction test for subgroups multiplicity adjustments were not applied to this predefined subgroup analysis of ldl c goal attainment [expressed as number of patients reaching ldl c goal at week $nmbr$ number of patients above goal at baseline ^treatment stratum was defined by intake of atv $nmbr$ or $nmbr$ mg,C0042295;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744;C1079230;C0237455;C1515021;C0376209;C0456081;C2945673;C4048755;C0680230;C2360800;C2584321;C0018017;C1571704;C1704788;C3539106;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
alcohol use drinks wk,C0332174;C0439230
physical activity kcal wk,C0332174;C0439230
menopausal status and use of ht,C1513126;C1524063;C0018510;C0677607
postmenopausal and current ht,C0232970;C0018510;C0677607
postmenopausal and no ht,C0232970;C0018510;C0677607
family history of cancerf,C0241889
randomized to receive vitamin e,C0034656;C3815594;C1514756;C0042874;C3714803
randomized to receive beta carotene,C0034656;C3815594;C1514756;C0053396;C0696105
relative risk $nmbr$ confidence interval,C0242492;C0009667
p for interaction,C0369773;C2603361
$nmbr$ aspirin n $nmbr$ $nmbr$,C0004057
$nmbr$ placebo n $nmbr$ $nmbr$,C0032042;C1696465;C1706408
$nmbr$ vitamin e n $nmbr$ $nmbr$,C0042874;C3714803
never rarely,C2003901;C0522498
at least $nmbr$ mo,C0026544;C0332177
multivitamin use,C0042153;C0457083;C1947944
menopausal status and hormone therapy use,C1513126;C0042153;C0457083;C1947944
postmenopausal current hormone,C0019932;C4521914
therapy use,C0042153;C0457083;C1947944
postmenopausal,C0232970
never or past,C2003901
hormone therapy use,C0042153;C0457083;C1947944
hypertension^,C0020538;C1963138
parental history of myocardial infarction before age $nmbr$ y,C0030551;C1275835;C0001779
major cardiovascular event,C0205082;C1320716;C0205164;C4318856;C4521762
total invasive cancer,C0439175;C0677898;C0439810
$nmbr$ no of events,C0441471;C3541888
$nmbr$ p value,C1709380
$nmbr$ vitamin e,C0042874;C3714803
$nmbr$ placebo,C0032042;C1696465;C1706408
age yt,C0001779;C1412122
body mass indext,C0518010
postmenopausal current hormone therapy use,C0042153;C0457083;C1947944
postmenopausal never or past hormone therapy use,C0232970;C2003901;C0279025;C0042153;C0457083;C1947944
diabetes^,C0011847;C0011849
randomized to receiveaspirin,C0034656;C3815594
parental history of mi before age $nmbr$ y,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0001779
$nmbr$ year risk of chd,C0439234;C1282512;C0439508
sdc $nmbr$ $nmbr$ $nmbr$ $nmbr$ ng ml,C1419891;C0439275;C3273112
race non white,C0007457;C0043157;C0220938
previous digoxin use,C0042153;C0457083;C1947944
previous mi,C0205156;C3810814;C1552607
current angina,C0521116;C0002962;C1705970
ischemic etiology,C0015127;C1314792;C1524003
nyha functional class,C1882083;C0205245;C0542341;C2700217
vasodilator therapy,C0039798;C0087111;C1363945
lvef u,C0428772;C0439148;C0488728
duration of chf months,C0449238;C2926735
sbp mm hg,C0085805;C0439475
dbp mm hg,C0536221;C0439475;C3813197;C4281799
ct ratio,C0456603;C1547037
chf score u,C0018802;C0439148
egfr ml min $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
sdc ng ml,C1419891;C0439275;C3273112
na,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882
time sample drawn h,C0033727;C0369286;C0441932;C0564385;C4528284
lrg,C1428862
hrg,C1437978;C1705020
atenolol,C0004147
ns,C0038944;C1112705;C1705982
sex women n [ ],C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
race white n [ ],C0034510;C0007457;C0043157;C0220938;C1706779;C3853635
heart rate min $nmbr$,C0702093;C1524029;C3813700
cornell voltage duration mv ms,C2349943;C3539704;C3713294
sokolow lyon voltage mv,C1454484;C1705503;C4281602
serum glucose mmol l,C0202041;C1532563;C3534430
total cholesterol mmol l,C0201950;C1532563;C0543421
hdl cholesterol mmol l,C0023822;C1532563;C0392885
serum creatinine mmol l,C0201976;C1532563;C0600061
urine albumin creatinine mg mmol,C0567349;C2348885
bp component mm hg,C0037623;C0439475;C1415692;C1708288;C4318478
sbp baseline,C0168634;C1442488
sbp last,C0085805
sbp difference,C1705241;C1705242
difference in sbp between treatment,C1705241;C1705242;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
mean arterial pressure baseline,C0443150
mean arterial pressure last,C0428886
mean arterial pressure difference,C0563547
end point,C2349179;C2826544
higher risk n $nmbr$,C0332167;C3272283;C4050568;C4319571
lower risk n $nmbr$,C3272281;C3538919
adjusted hr,C0456081
unadjusted hr,C1439367
primary composite end point,C2986535;C0205199;C1547335
components,C0449432
other prespecified end points,C2349179
hospitalization for,C0019993
sudden cardiac death,C0085298
new onset atrial fibrillation,C0741281
endpoint,C2349179;C2826544
pvalue,
primary composite endpoint,C2986535;C0205199;C1547335
demographic and clinical,C0011298;C0205210
cornell voltage duration product mm ms,C2349943;C3539704;C3713294
medical history n,C0262926;C1704706
any vascular disease,C0042373
isolated systolic hypertension,C0745133
with aspirin n $nmbr$ $nmbr$,C0004057
without aspirin n $nmbr$ $nmbr$,C0004057
sys ns dia,C0038944;C1706546;C1112705;C1705982
dates of recruitment,C0011008;C2348077
year of publication of primary results,C0439234;C0439508
mean duration offollow up years,C0444504;C0439234;C2347634;C2348143
treatment comparison mg day t,C0039798;C0439422;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
number of patients,C2360800
age range years,C1510829;C1514721;C2348147;C3542016
baseline history of vascular disease,C0683519;C0730226;C0850708;C0944983
ml c,C0439526;C1705224;C3887665
itherchdt,
other vasculars,
noneh,
s $nmbr$ $nmbr$ vs placebo,C0032042;C1696465;C1706408
woscops,
p $nmbr$ vs placebo,C0369773;C2603361;C0032042;C1696465;C1706408
care,C1947933
post cabg,C0687676;C0010055;C1704687;C3469826
l $nmbr$ $nmbr$ vs l $nmbr$ $nmbr$ $nmbr$,C0439394;C1706495;C3642217
afcaps,
l $nmbr$ $nmbr$ vs placebo,C0439394;C1706495;C3642217;C0032042;C1696465;C1706408
$nmbr$ $nmbr$ men,C0025266
texcaps,
$nmbr$ $nmbr$ women,C0043210
lipid,C0023779
gissi prevention $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0199176;C1706420;C2700409
p $nmbr$ vs no treatment $nmbr$,C0369773;C2603361;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
lips,C0023759
f $nmbr$ vs placebo,C0016327;C0032042;C1696465;C1706408
hps,C0242994
s $nmbr$ vs placebo,C0032042;C1696465;C1706408
prosper,
allhat llt,C2347090
p $nmbr$ vs usual care,C0369773;C2603361;C3538928;C1947933
^ $nmbr$,
ascot lla,C0718674
a $nmbr$ vs placebo,C0032042;C1696465;C1706408
alert,C0239110;C2004580;C3665546;C3669039;C4084853;C4553014
cards,C2930619;C3275277
$nmbr$ s scandinavian simvastatin survival study $nmbr$ woscops west of scotland coronary prevention study $nmbr$ care cholesterol and recurrent events $nmbr$ post cabg post coronary artery bypass graft $nmbr$ afcaps texcaps air force texas coronary atherosclerosis prevention study $nmbr$ lipid long term intervention with pravastatin in ischaemic disease $nmbr$ gissi prevention gruppo italiano per lo studio della sopravvivenza nell infarto miocardico $nmbr$ lips lescol intervention prevention study $nmbr$ hps heart protection study $nmbr$ prosper prospective study of pravastatin in the elderly at risk $nmbr$ allhat llt antihypertensive and lipid lowering treatment to prevent heart attack trial $nmbr$ ascot lla anglo scandinavian cardiac outcomes trial lipid lowering arm $nmbr$ alert assessment of lescol in renal transplantation $nmbr$ cards collaborative atorvastatin diabetes study $nmbr$ s simvastatin l lovastatin p pravastatin f uvastatin a atorvastatin mean duration of follow up based on survival times within each trial overall mean is weighted by trial speci c variances of logrank o e for major vascular events all trials included dietary intervention woscops gissi prevention lipid $nmbr$ s lips and hps provided dietary advice afcaps texcaps post cabg care allhat alert cards and prosper used american heart association aha step $nmbr$ diet and care intensi ed to step $nmbr$ diet if ldl cholesterol $nmbr$ $nmbr$ mmol l $nmbr$ mg dl other chd includes patients with a history of other symptomatic chd but excludes those with a history of mi as already counted in mi column other vascular includes history of intracerebral bleed transient ischaemic attack ischaemic stroke unknown stroke and peripheral artery disease none includes individuals without a history of mi symptomatic chd intracerebral bleed transient ischaemic attack ischaemic stroke unknown stroke or peripheral artery disease,C1705493;C1706420;C2347647;C0085542;C0679698;C1096775;C0033522;C1709709;C0001792;C0003364;C1999167;C0023779;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0309872;C0027051;C0441994;C2003888;C1261322;C1516048;C0846101;C0024027;C0016327;C0449238;C2926735;C1527178;C1705938;C0444504;C2347634;C2348143;C0005910;C0043100;C1305866;C0441471;C3541888;C0012171;C0023759;C0242994;C2930619;C3275277;C0012155;C0012159;C1519433;C2983588;C3668949;C3538926;C1532980;C0280604;C3542407;C0332257;C1552866;C2700399;C0679831;C0231220;C0332196;C2828389;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0750480;C1705566;C0005847;C1558950;C1801960;C0455536;C2937358;C1704436;C4025272;C0027361;C0237401
groups,C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429
events treatment $nmbr$,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
control $nmbr$,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
rr cl,C4554402;C0596019
heterogeneity trend test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
previous disease,C0205156;C0012634;C1552607
post mi,C0856742
other chd,C0280604;C3542407
xho p o $nmbr$,C4050013
$nmbr$ $nmbr$ o $nmbr$ o $nmbr$ o,C0483204
s $nmbr$,
x $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$,
xi $nmbr$ $nmbr$ p $nmbr$,C1720296
treated hypertension,C0020538;C1963138
x l $nmbr$ p $nmbr$ $nmbr$,
x $nmbr$ l p $nmbr$ $nmbr$,
x $nmbr$ $nmbr$ l p $nmbr$ $nmbr$,
^ $nmbr$ $nmbr$,
ldl cholesterol mmol l,C0023824;C1532563;C0202117
xi o $nmbr$ p o $nmbr$,C1720296
sso $nmbr$,
o $nmbr$ ii,C1710602;C4082587
$nmbr$ $nmbr$ o $nmbr$ o o $nmbr$,C0483204
triglycerides mmol l,C0041004;C1532563
$nmbr$ $nmbr$ l $nmbr$,C0439394;C1706495;C3642217
$nmbr$ io $nmbr$,C1046794;C3146236
xi $nmbr$ $nmbr$ p $nmbr$ l,C1720296
xi $nmbr$ l p $nmbr$ $nmbr$,C1720296
x $nmbr$ $nmbr$ p $nmbr$ $nmbr$,
xi l $nmbr$ p $nmbr$ $nmbr$,C1720296
xi $nmbr$ $nmbr$ p o l,C1720296
s $nmbr$ $nmbr$,
o $nmbr$ i i,C0021966;C0221138
xi $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C1720296
ssi $nmbr$,
xi oo p o $nmbr$,C1720296
pioglitazone n $nmbr$,C0071097
patients characteristics,C0815172
time since diagnosis of diabetes years median iqr,C0556970;C0011847;C0011849
body mass index kg m $nmbr$ mean sd,C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
blood pressure systolic diastolic mm hg mean sd,C0428886;C2699239
past smoker,C0337664
microvascular disease,C0443258;C0012634
blood glucose lowering treatment,C0005802;C0441994;C2003888;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
metformin only,C0025598
sulphonylureas only,C0038766
metformin sulphonylureas,C0025598;C0038766
insulin only,C0021641;C1533581;C1579433;C3714501
insulin metformin,C0021641;C0025598;C1533581;C1579433;C3714501
insulin sulphonylureas,C0021641;C0038766;C1533581;C1579433;C3714501
insulin metformin sulphonylureas,C0021641;C0038766;C1533581;C1579433;C3714501
other combination,C0205195;C1947911;C3811910
diet only,C0012155;C0012159;C1519433;C2983588;C3668949
laboratory data,C1511726;C3245479;C3714741
hba $nmbr$ c median iqr,C0019016;C0549183;C0876920;C2347635;C2348144;C2939193;C1825777;C3538758
ldl cholesterol mmol l median iqr,C0023824;C0202117
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ s,
hdl cholesterol mmol l median iqr,C0023822;C0392885
triglycerides mmol l median iqr,C0041004;C1532563
creatinine ^mol l median iqr,C0010294;C0347982;C1561535
micral test result,C0456984;C0587081
negative,C0205160;C1513916;C2825415;C2825491;C3853545
about $nmbr$ mg l,C0439268
about $nmbr$ mg l or more,C0439268
enact $nmbr$ trial,C0008976
enact $nmbr$ trial rerandomization to natalizumab n $nmbr$,C0008976;C1172734
natalizumab n $nmbr$ f,C1172734;C0016327
rerandomization to placebo n $nmbr$ f,C0032042;C0016327;C1696465;C1706408
$nmbr$ $nmbr$ j,
duration of disease mo,C0872146;C0026544;C0332177
intestinal area involved no,C0017446;C0205146;C1314939
ileum,C0020885
ileum and colon,C0020885;C0009368;C3888384
colon,C0009368;C3888384
data missing or no drug given,C1511726;C3245479;C3714741;C1551393;C1705492;C3272743;C0013227;C1254351
previous segmental resection no,C0205156;C2987624;C1552607
cdai score,C0449820;C4050231
c reactive protein,C0006560;C1413716;C4048285
elevated at wk $nmbr$ no,C0205250;C3163633
week $nmbr$ mg liter,C0024671;C0475211;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mean,C0444504;C2347634;C2348143
week $nmbr$ mg liter^,C0024671;C0475211;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
elevated at wk $nmbr$ no $nmbr$,C0205250;C3163633
concomitant medication no,C0013227;C3244316;C4284232
corticosteroids,C0001617;C3539185;C3540725;C3540726;C3540727
prednisone,C0032952
budesonide,C0054201
immunosuppressants,C0021081
azathioprine,C0004482
mercaptopurine,C0000618
methotrexate,C0025677
antibiotics,C0003232;C0003237;C3540704;C3540705;C3540706;C3540707;C3540708;C3540709;C3540710
$nmbr$ aminosalicylates i i,C0021966;C0221138
$nmbr$ corticosteroids or immunosuppressants,C0001617;C3539185;C3540725;C3540726;C3540727;C0021081
corticosteroids and immunosuppressants,C0001617;C3539185;C3540725;C3540726;C3540727;C0021081
previous receipt of therapy against tnf a no,C0039798;C0087111;C1363945;C1448177;C1710304
refractory to such therapy no,C0205269;C0039798;C0087111;C1363945
current smoker $nmbr$ cigarettes day no,C0332173;C0439228;C0439505
figure $nmbr$ facing page percentage of patients in the enact $nmbr$ trial with a clinical response at each visit panel a in remission at each visit panel b with a response at week $nmbr$ panel c and in remission at week $nmbr$ panel d,C0439165;C1549488;C1561533;C0008976;C1096775;C0441833;C1706365;C1999270;C0544452;C0687702;C0545082;C1512346;C2826704;C0332174;C0441837;C0439230
a response was defined as a decrease from baseline in the cdai score of at least $nmbr$ points remission was de fined as a decrease in the cdai score to less than $nmbr$ points significant differences between the treatment groups are shown,C0871261;C1704632;C1706817;C2911692;C1704788;C3539106;C0168634;C1442488;C0011198;C0017480;C3541240;C0205232;C0687757;C0449820;C4050231;C0237881;C0750502;C1546944;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C1547282
clopidogrel n $nmbr$ $nmbr$,C0070166
age at entry years,C1510829;C1705654
time since onset h,C0449244;C0033727;C0369286;C0441932;C0564385;C4528284
ecg abnormality at entry,C1623258;C1704258
st elevation,C0520886
bundle branch block,C0006384;C1879286
st depression without st elevation,C0520887
ii or iii,C0439070;C1705160
previous disease and drug use,C0205156;C0012634;C1552607;C0242510
previous hypertension,C0020538;C1963138
aspirin before admission,C0004057;C0184666;C0809949
$nmbr$ blocker before admission,C0184666;C0809949
fibrinolytic agent before randomisation,C0016018;C0034656
non trial treatment during hospital stay,C0019948;C3166479
non trial antiplatelet,C1518422;C0008976
fibrinolytic agents before or after entry,C0016018;C1705654
anticoagulant,C0003280;C0848112;C3536711
antiarrhythmic,C0003195;C3537142
nitrate oral or intravenous,C0442027;C4521986;C0348016
calcium antagonist,C0006684
metoprolol n $nmbr$ $nmbr$,C0025859
ai $nmbr$,C0003504;C4551710
p blocker before admission,C0369773;C0184666;C0809949;C2603361
non trial p blocker,C1518422;C0008976
score $nmbr$ $nmbr$,C0449820;C4050231
mfns n $nmbr$,
mean age y range,C1514721;C2348147;C3542016
gender male,C0086582;C1706180;C1706428;C1706429
mean baseline nasal congestion score,C3533236;C0027424;C4554631
eze simva $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
atv $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
number of females n,C0237753;C0449788
race n,C0034510;C1706779;C3853635
body mass index mean sd kg m,C0022718;C0439209;C4054209
duration of hypercholesterolaemia mean sd year,C0449238;C2926735
patient history of disease n,C0683519;C0730226;C0850708;C0944983
concomitant therapies n,C1707479
drugs used in diabetes,C0013227;C3687832;C1273517;C0011847;C0011849
antithrombotic agents,C1704311
antihypertensive agents,C0003364
cardiac therapy,C3654025
peripheral vasodilators,C0724804
vasoprotectives,C0304533
baseline lipids mean sd mmol l,C0023779;C1532563
tgt,C1421391;C1428265;C4321338
apo bt,
apo apolipoprotein dm diabetes mellitus hdl c high density lipoprotein cholesterol ldl c low density lipoprotein cholesterol tc total cholesterol tg triglycerides includes agents acting on the renin angiotensin system beta blocking agents calcium channel blockers and diuretics median values [standard deviation for medians calculated by q $nmbr$ q $nmbr$ $nmbr$ $nmbr$ ] includes cardiac glycosides antiarrhythmics class i and iii vasodilators used in cardiac diseases and other cardiac preparations expressed as g l,C0062152;C0332257;C1552866;C2700399;C0006684;C0549183;C0042295;C0876920;C2347635;C2348144;C2939193;C0871420;C0444686;C1441506;C0441885;C1319793;C2698967;C0439070;C0042402;C1705160;C1273517;C0018799;C1521827;C3812761;C0439294;C0456615
$nmbr$ years,C0439234
non white,C0007457;C0043157;C0220938
$nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
left ventricular ejection fraction mean sd,C0428772;C2699239;C0488728
nyha functional class $nmbr$,C1882083;C0205245;C0542341;C2700217
$nmbr$ $nmbr$ $nmbr$ q,
lll iv,C0022326;C4265176
$nmbr$ $nmbr$ $nmbr$ j,
history congestive heart failure,C0019664;C0018802;C0019665;C0262512;C0262926;C1705255;C2004062
chronic obstructive pulmonary disease,C0024117
cerebrovascular accident tia,C0007787;C0917805;C1054154
preoperative use p blocker,C0445204;C0042153;C0457083;C1947944
angiotensin receptor blocker,C0034787;C1622222
nsaid,C0003211;C3536840
baseline characteristics,C4684572
postoperative use of p blocker,C0032790;C1524063
operative procedure,C0543467;C0677612
cabg surgery by no of vessels $nmbr$,C0042381;C3714645
type no of valves repaired replaced mitral,C0332307;C1547052;C0396849;C0559956;C1299987
aortic,C0003483
multiple,C0439064
type of surgery cabg only,C0332307;C1547052
valve repair replacement with or without cabg,C0035139;C0559956;C1555302;C4553149;C0010055
valve repair replacement only,C0035139;C0559956;C1555302;C4553149
time mean sd min procedure,C0184661;C2700391;C3274430;C3539779
pump,C0182537
cross clamp,C0175721;C1883710;C3810601
total no of patients,C0439175;C0439810;C0030705
no of patients with atrial tachyarrhythmia,C0030705;C0018792;C0080203
hazard ratio $nmbr$ cl,C2985465;C0596019
absolute risk reduction $nmbr$ cl,C3179139;C0596019
no needed to treat $nmbr$ cl,C0027552;C0686904
i amiodarone,C0021966;C0002598;C0221138
type of surgery cabg,C0332307;C1547052
valve replacement repair with or without cabg,C0043240;C0374711;C4319951;C0010055
preoperative p blocker use yes,C1549445;C1705108;C1710701
tenecteplase and pci n $nmbr$,C0872913;C4049621
pci alone n $nmbr$,C0205171;C0439044;C0679994
height cm,C0489786
ii iii,C0439070;C1705160
congestive heart failure at randomisation,C0018802;C0034656
previous infarction,C0205156;C0021308;C1552607
previous congestive heart failure,C0205156;C0018802;C1552607
previous pci,C0205156;C4049621;C1552607
previous coronary artery bypass graft,C2144990
glucosamine n $nmbr$,C0017718
chondroitin sulfate n $nmbr$,C0008466
glucosamine chondroitin sulfate n $nmbr$,C0017720
celecoxib n $nmbr$,C0538927
hispanic no,C0086409
duration of osteoarthritis symptoms yr,C0436359;C0029408
time since diagnosis of osteoarthritis yr,C0040223;C3541383
no of $nmbr$ mg acetaminophen tablets day,C0439422;C1243102
ara functional class no,C0205245;C0456387;C1518526;C1705943;C0542341;C2700217
unknown,C0439673;C3541433;C4050014
kellgren and lawrence radiographic reading grade $nmbr$ no,C0441800;C0919553;C3244287
global assessment of disease status score,C0281858;C3176928
physician,C0031831;C0804815
patient,C0030705
joint swelling effusion or both on clinical examination no,C1253936;C1963136;C4554335;C0031809
womac score,C0449820;C4050231
pain subscale,C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
stiffness subscale,C0427008
function subscale,C0031843;C0542341;C0700205;C1705273
normalized,C1882115
health assessment questionnaire score,C2960025
alternative disability,C1523987;C0231170
pain,C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
sf $nmbr$ score,C0449820;C4050231
physical component,C0449432;C1705248
mental component,C0449432;C1705248
glucosamine,C0017718
chondroitin sulfate,C0008466
glucosamine chondroitin sulfate,C0017720
celecoxib,C0538927
all randomized patients,C0034656;C0030705;C3815594
primary outcome $nmbr$ decrease in womac pain score,C0392756;C0547047
at end of follow up no,C0444930;C2746065
secondary outcomes,C0027627;C1274040;C0175668;C0205436
omeract oarsi response,C0871261;C1704632;C1706817;C2911692
$nmbr$ decrease in womac pain score,C0392756;C0547047
womac pain score,C0582148
change from baseline,C0392747;C0443172;C1705241;C4319952
at end of follow up,C0444930;C2746065
womac stiffness score,C0449820;C4050231
womac function score,C0449820;C4050231
normalized womac score,C0449820;C4050231
haq alternative disability score,C0449820;C4050231
haq pain score,C0102923;C0582148;C0451208
patient s global assessment of response to therapy score,C0030705;C0281858;C0871261;C1704632;C1706817;C2911692;C0449820;C4050231
patient s global assessment of disease status score,C0030705;C0281858;C3176928
physician s global assessment of disease status score,C0031831;C0804815;C0281858;C3176928
joint swelling effusion or both on clinical examination,C1253936;C1963136;C4554335;C0031809
at baseline no,C0168634;C1442488
at end of follow up no total no,C0444930;C2746065;C0439175;C0439810
no of $nmbr$ mg tablets of acetaminophen,C0024671;C1243102;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
patients with moderate to severe pain womac pain score $nmbr$ $nmbr$,C0030705;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0582148
at baseline,C0168634;C1442488
patients with mild pain womac pain score $nmbr$ $nmbr$,C0030705;C0278138;C4522280
figure $nmbr$ pairwise comparisons of the overall likelihood of a response,C1707455;C0871258
subgroups those with mild pain and those with moderate severe pain,C1079230;C0278138;C4522280;C0278140;C4050465;C4521229
baseline characteristic,C0168634;C1521970;C1442488
mtx plus placebo,C0025677;C1417487
mtx plus infliximab,C0025677;C1417487
coefficient,C1707429
swollen joint count $nmbr$ $nmbr$,C0451521
tender joint count $nmbr$ $nmbr$,C0451530
rf mg dl,C0035448;C0439269;C0201660;C0748398;C1547111
crp mg dl,C3890735;C0439269;C4048285
esr mm hour,C0439227;C0564385
baseline shs $nmbr$ $nmbr$,C0168634;C1442488
j $nmbr$ coefficient,C1707429
or $nmbr$ ci,C0008107;C3259781
age per $nmbr$ years,C1510829
sex male,C0086582
swollen joint count $nmbr$ $nmbr$ per swollen joint,C0451521;C0152031;C4554794;C4696257
tender joint count $nmbr$ $nmbr$ per tender joint,C0451530;C0240094;C4554549;C4696258
rf mg dl per unit,C0439269
crp mg dl per unit,C0439269
esr mm hour per unit,C3811131;C0456685
shs $nmbr$ $nmbr$ per $nmbr$ score,C0449820;C4050231
baseline inflammation markers,C0021368;C0005516
changes in shs,C0392747;C0443172
normal crp and,C3890735;C4048285
esr,C3811131
high crp or esr,C3890735;C4048285;C3811131
high crp and esr,C3890735;C4048285;C3811131
figure $nmbr$ change in radiographic progression by modified sharp van der heijde vdh s score from baseline to week $nmbr$ in the active controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset aspire trial,C0392747;C0443172;C1705241;C4319952;C0449820;C4050231;C0332174;C0439230;C0681867;C1514756;C0666743;C3899278;C0008976
shown are tertiles of baseline c reactive protein crp levels a erythrocyte sedimentation rate esr b and vdh s score c by treatment group methotrexate [mtx] plus placebo [placebo] or mtx plus infliximab [infliximab] p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group,C1547282;C0168634;C0201657;C1442488;C1176468;C1619634;C0441837;C0032042;C1696465;C1706408;C0025677;C0666743;C0072053
figure $nmbr$ change in radiographic progression by modified sharp van der heijde score from baseline to week $nmbr$ in the aspire trial by tertile of week $nmbr$ $nmbr$ joint disease activity scores das $nmbr$,C0392747;C0443172;C1705241;C4319952;C0557775;C0449820;C4050231;C0332174;C0439230;C0008976;C4706353
figure $nmbr$ change in radiographic progression by modified sharp van der heijde score from baseline to week $nmbr$ by tertiles of crp levels a esr b and swollen joint count c averaged over time during the aspire trial,C0392747;C0443172;C1705241;C4319952;C0557775;C0449820;C4050231;C0332174;C0439230;C3890735;C0441889;C4048285;C3811131;C0451521;C1510992;C2825518;C0008976
crp esr and swollen joint counts averaged over time during the trial were estimated by the area under the curve method p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group see figure $nmbr$ for definitions and explanation of treatment groups,C3890735;C3811131;C4048285;C0451521;C1510992;C2825518;C0008976;C0750572;C0017446;C0205146;C0025663;C0021966;C0221138;C0449851;C0871511;C0025677;C1417487;C1550452;C1704788;C3539107;C3888054;C0681841;C0374505
$nmbr$ abciximab n $nmbr$,C0288672
insulin treated diabetes,C0011847;C0011849
prior aortocoronary bypass surgery,C0455610;C0010055
elevated troponin $nmbr$ $nmbr$ pg l,C0041199;C0439278
elevated creatine kinase mb $nmbr$ u l,C0010290;C0439339;C0523584
hours from clopidogrel loading mean sd,C0439227;C0070166
multivessel disease,C0012634
target vessel,C0449618
left main artery,C0205091;C0003842;C0226004;C0443246;C1552822
left anterior descending artery,C0226032
right coronary artery,C1261316
complex lesions^,C0439855;C0221198;C1704241
lesion length mean sd mm,C4330985;C4554674
vessel size mean sd mm,C4330985;C4554674
diameter stenosis mean sd,C0552409;C2699239
type of intervention,C3274412
drug eluting stent,C1322815
bare metal stent,C2825200
balloon angioplasty,C0002996;C0002997
concomitant drug therapy at discharge,C0013216;C0013217
calcium antagonists,C0006684
primary end point no of events total no,C2986535;C0439175;C0439810
all participants,C0679646
troponin level,C0441889;C0456079;C1547707;C2946261
$nmbr$ $nmbr$ g l,C0439294;C0456615
clopidogrel pretreatment duration,C0449238;C2926735
$nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
body mass indexj,C0518010
measured at clinic visit with automated device,C0444706;C3541902;C0025080;C0699733
measured at clinic visit with usual device,C0444706;C3541902;C0025080;C0699733
measured at home with automated device,C0442519;C0025080;C0699733
lower than normal range ^,C0441994;C1548802;C2003888
glucose mg dl,C0017725;C0439269
insulin iu,C0049272;C0439453;C0694756
insulin glucose ratio,C0456603;C1547037
subgroups,C1079230
relative risk $nmbr$ ci,C0008107;C3259781
at home systolic pressure $nmbr$ mm hg,C0871470;C0439475
at home systolic pressure,C4534363;C0871470
at home diastolic pressure $nmbr$ mm hg,C0428883;C0439475
at clinic systolic pressure $nmbr$ mm hg,C0871470;C0439475
at clinic systolic pressure,C0002424;C0871470;C0442592
at clinic diastolic pressure $nmbr$ mm hg,C0428883;C0439475
at clinic diastolic pressure,C0002424;C0428883;C0442592
weight,C0005910;C0043100;C1305866;C1705104
$nmbr$ lb,
enoxaparin n $nmbr$ $nmbr$,C0206460
fondaparinux n $nmbr$ $nmbr$,C1098510
time from onset of pain to randomization hr,C0449244;C0034656
diagnosis at study entry no,C1704656;C4068481
suspected myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
current or former smoker,C0521116;C1705970;C0337671
any electrocardiographic abnormality no,C0522055
st segment depression $nmbr$ mm no,C4330985;C4554674
medications at the time of randomization no,C0013227;C0802604;C2598133;C4284232
clopidogrel or ticlopidine,C0070166;C0040207
ace inhibitor or arb,C0003015;C4541021;C3888198
lipid lowering agent,C0086440
medications in the hospital after randomization no,C0013227;C0802604;C2598133;C4284232;C0034656
procedures in the hospital no,C0025664;C0184661;C2700391;C3538935
coronary angiography,C0085532;C1548829
pci,C4049621
procedures after discharge no,C0012621;C0030685;C2926602
panel a,C0441833;C1706365;C1999270
no of,
percentage of patients with event,C0439165;C1549488;C1561533;C0441471;C4019010
interaction p value,C1704675;C1709380
fondaparinux,C1098510
creatinine,C0010294;C1561535
at or above median,C0549183;C0876920;C2347635;C2348144;C2939193
less than median,C0549183;C0876920;C2347635;C2348144;C2939193
heparin at randomization,C0019134;C0770546
revascularization in $nmbr$ days,C0581603;C0439228
catheterization laboratory in center,C0007430;C0022877;C3244292;C4283904
panel b,C0441833;C1706365;C1999270
percentage of p,C0439165;C1549488;C1561533
atients with event,C0441471;C4019010
catheterization laboratory in,C0007430;C0022877;C3244292;C4283904
center,C0205099;C3810851
unfractionated heparin n $nmbr$ $nmbr$,C0019134;C2825026
age $nmbr$ yr no,C0001779;C0439234
white race no total no f,C0007457;C0043157;C0439175;C0439810;C0016327
hypertension no total no,C0020538;C1963138;C0439175;C0439810
hyperlipidemia no total no,C0020473;C0428465;C4555212;C0439175;C0439810
current smoker no total no,C3173209;C3241966;C0439175;C0439810
diabetes mellitus no total no,C0011849;C0439175;C0439810
prior myocardial infarction no total no,C0027051;C0428953;C2926063;C3810814;C4552959;C0439175;C0439810
prior angina pectoris no total no,C0332152;C0002962;C2826257;C0439175;C0439810
prior percutaneous coronary intervention no total no,C0332152;C1532338;C2826257;C0439175;C0439810
anterior myocardial infarction no total no,C0340293;C0439175;C0439810
long term treatment with aspirin no total no,C0023977;C0004057;C0439175;C0439810
unfractionated heparin within $nmbr$ hr before randomization no total no,C0019134;C2825026;C0034656;C0439175;C0439810
lmwh within $nmbr$ days before randomization no total no,C0019139;C3536766;C0034656;C0439175;C0439810
creatinine clearance ml min,C0812399;C0439445
killip class no i,C1881332;C0021966;C0221138
data missing,C1511726;C3245479;C3714741;C1551393;C1705492;C3272743
timi risk score no total no c,C0035647;C0449820;C4050231;C4552904;C0439175;C0439810
time from symptom onset to start of fibrinolytic therapy hr,C0449244;C0439659;C0040044
fibrinolytic therapy no,C0040044
time from fibrinolytic therapy to study drug administration no total no,C0040223;C3541383;C0150270;C3469597;C0439175;C0439810
$nmbr$ min,C0702093;C1524029;C3813700
$nmbr$ $nmbr$ min,C0702093;C1524029;C3813700
ace inhibitors or angiotensin receptor blockers,C0003015;C0521942;C0815017
statin,C0360714
statistics,C0038215;C0600673
w,
ni,C0028075;C2348274;C3869926;C3869927
mean s d,C0444504;C2347634;C2348143
dbp mmhg,C0536221;C0439475;C3813197;C4281799
sbp mmhg,C0085805;C0439475
hemoglobin gm dl,C0017480;C3642216;C3854019
albuminuria g g,C0001925;C1319635
in,
gm,C0017480;C3854019
proteinuria $nmbr$ g day,C0033687;C0439417;C1962972;C4554346
bmi body mass index dbp diastolic blood pressure gm geometric mean sbp systolic blood pressure the analysis was based on observed data without imputation on missing values asubgroup of patients in whom $nmbr$ h urine was collected see materials and methods section,C0488055;C0871470;C1306620;C0002778;C0936012;C1524024;C1527178;C1705938;C2699638;C0030705;C0042036;C0042037;C2963137;C0042789;C0520510;C1947903;C0152060;C0700320;C1522472;C1552923;C1705191;C3714523
pre specified hr $nmbr$ cl,C2826245;C0596019
adjusted hr $nmbr$ cl,C0456081;C0596019
n event rate,C0871208;C1521828
w event rate,C0871208;C1521828
bp blood pressure ci confidence interval esrd end stage renal disease hr hazard ratio all patients except patients with other race were included with missing covariates imputed event no of patients with esrd rate event rate per $nmbr$ years of follow up pre specified a cox model with treatment group and region as covariates and baseline proteinuria level o or x $nmbr$ g g as strata adjusted a multivariate cox model with treatment group time varying systolic and diastolic bp as covariates pre specified analysis and adjusted for time varying bp,C1442095;C0030705;C0034510;C1706779;C3853635;C0332257;C0441471;C4019010;C0589120;C1522577;C1704685;C3274571;C2826245;C1565830;C0679845;C0017446;C0205147;C0168634;C0033687;C1962972;C4554346;C1442488;C1319635;C0456081;C0428883;C0037623;C1415692;C1708288;C4318478
baseline to year $nmbr$,C0168634;C1442488
relative risk $nmbr$ cl,C0242492;C0596019
age $nmbr$,C0001779
age a $nmbr$,C0001779
non black,C0005680;C0027567;C0085756;C0439541
diabetic,C0241863
non diabetic,C1518422;C0241863
year $nmbr$,C0439234;C0439508
gender n,C0079399;C1522384
age years mean range,C1514721;C2348147;C3542016
diagnoses risk factors n,C0035648;C1553898
lipid and lipoprotein values mg dl,C0023779;C0023820;C0439269
hs crp mg l,C3890735;C0439268;C4048285
c,
non c,C1518422
known chd,C0280604;C3542407
hyper tension,C0020538;C1963138
baseline ldl c $nmbr$ mg dl,C0168634;C0439269;C1442488
apo b,C0003593;C3252643
apo a i,C0085201;C1677784
entire cohort,C0009247;C0599755
simva n $nmbr$,
eze simva n $nmbr$,
female simva n $nmbr$,C0043210;C0086287;C1705497;C1705498
female eze simva n $nmbr$,C0043210;C0086287;C1705497;C1705498
male simva n $nmbr$,C0086582;C1706180;C1706428;C1706429
male eze simva n $nmbr$,C0086582;C1706180;C1706428;C1706429
caucasian simva n $nmbr$,C0007457;C0043157
caucasian eze simva n $nmbr$,C0007457;C0043157
non caucasian simva n $nmbr$,C0007457;C0043157
$nmbr$ $nmbr$ io i,C0021966;C0221138
non caucasian eze simva n $nmbr$,C0007457;C0043157
$nmbr$ years simva n $nmbr$,C0439234
$nmbr$ years eze simva n $nmbr$,C0439234
gender n ],C0079399;C1522384
race n ],C0034510;C1706779;C3853635
diagnoses risk factors n ],C0035648;C1553898
$nmbr$ mg dl simva n $nmbr$,C0439269
$nmbr$ mg dl eze simva n $nmbr$,C0439269
$nmbr$ mg dl simva $nmbr$,C0439269
$nmbr$ mg dl eze simva $nmbr$,C0439269
chd status,C0280604;C0449438;C3542407
chd simva $nmbr$,C0280604;C3542407
chd eze simva $nmbr$,C0280604;C3542407
no chd simva $nmbr$,C0280604;C3542407
no chd eze simva n $nmbr$,C0280604;C3542407
simva,
eze simva,
$nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
entire cohort gender,C0079399;C1522384
caucasian,C0007457;C0043157
non caucasian,C0007457;C0043157
$nmbr$ years baseline ldl c,C0439234;C0168634;C1442488
$nmbr$ mg dl chd status,C0439269;C0449438
chd,C0280604;C3542407
no chd,C0280604;C3542407
p $nmbr$ $nmbr$ for between treatment difference with same dose of simvastatin for entire cohort data are expressed as least squares mean standard error simva simvastatin eze ezetimibe chd coronary heart disease,C0369773;C2603361;C1705241;C1705242;C1511726;C3245479;C3714741;C0023189;C0010068
select lipids and lipoproteins,C1707391;C0023779;C0023820
eze simva gender,C0079399;C1522384
female simva,C0043210;C0086287;C1705497;C1705498
female eze simva,C0043210;C0086287;C1705497;C1705498
male simva,C0086582;C1706180;C1706428;C1706429
male eze simva,C0086582;C1706180;C1706428;C1706429
caucasian simva,C0007457;C0043157
caucasian eze simva,C0007457;C0043157
non caucasian simva,C0007457;C0043157
non caucasian eze simva,C0007457;C0043157
$nmbr$ years simva,C0439234
$nmbr$ years eze simva,C0439234
$nmbr$ years eze simva baseline ldl c,C0439234;C0168634;C1442488
$nmbr$ mg dl simva,C0439269
$nmbr$ mg dl eze simva,C0439269
chd simva,C0280604;C3542407
chd eze simva,C0280604;C3542407
no chd simva,C0280604;C3542407
no chd eze simva,C0280604;C3542407
p $nmbr$ $nmbr$ for eze simva pooled across doses vs simva pooled across doses for the entire cohort data are presented as least squares mean standard error median se for tg for the entire cohort and also for each selected subgroup simva simvastatin eze ezetimibe tc total cholesterol tg triglycerides hdl c high density lipoprotein cholesterol non hdl c non high density lipoprotein cholesterol apo apolipoprotein,C0369773;C2603361;C1709595;C2349200;C4522255;C1511726;C3245479;C3714741;C0449450;C0023189;C0337445;C0009247;C0599755;C1079232;C0003591
clinical ae n,C0205210;C3887670
laboratory ae n,C0022877;C3244292;C4283904
any clinical ae,C0205210;C3887670
drug related ae,C0013227;C3887670;C1254351
serious ae,C0205404;C3887670
discontinuations due to ae,C0457454;C0678226
myopathyt,
deaths,C0011065;C1306577
alt and or ast $nmbr$ times uln consecutive,C1266129;C4553172;C0040223;C1519815;C1632851;C1707491
cpk $nmbr$ times uln,C0040223;C1519815;C1632851
simva $nmbr$,
eze simva $nmbr$,
female simva $nmbr$,C0043210;C0086287;C1705497;C1705498
$nmbr$ [ $nmbr$,
female eze simva $nmbr$,C0043210;C0086287;C1705497;C1705498
male simva $nmbr$,C0086582;C1706180;C1706428;C1706429
$nmbr$ c $nmbr$,
male eze simva $nmbr$,C0086582;C1706180;C1706428;C1706429
caucasian simva $nmbr$,C0007457;C0043157
caucasian eze simva $nmbr$,C0007457;C0043157
non caucasian simva $nmbr$,C0007457;C0043157
non caucasian eze simva $nmbr$,C0007457;C0043157
$nmbr$ years simva $nmbr$,C0439234
$nmbr$ years eze simva $nmbr$,C0439234
$nmbr$ mg dl simva n $nmbr$ ],C0439269
$nmbr$ $nmbr$ ],
$nmbr$ mg dl simva $nmbr$ $nmbr$ ],C0439269
$nmbr$ mg dl eze simva $nmbr$ $nmbr$,C0439269
chd simva $nmbr$ $nmbr$ ],C0280604;C3542407
chd eze simva n $nmbr$ ],C0280604;C3542407
no chd simva n $nmbr$ ],C0280604;C3542407
no chd eze simva $nmbr$ $nmbr$,C0280604;C3542407
determined by investigator to be possibly probably or definitely related to study drug tmyopathy defined as cpk $nmbr$ x uln with associated muscle symptoms with no other plausible etiology ^consecutive defined as two or more measurements at least one week apart or one measurement $nmbr$ days after the last dose of study drug presumed consecutive two patients had incomplete data to assess chd status simva simvastatin eze ezetimibe ae adverse event alt alanine aminotransferase ast aspartate aminotransferase cpk creatine phosphokinase uln upper limit of normal,C0521095;C0035173;C2362652;C0750492;C0439849;C0445223;C1704788;C3539106;C0521989;C0242485;C1442452;C3844320;C0678766;C3242203;C1516048;C1282910;C0439801;C1549649;C2349209;C0205307;C0231683;C0439166;C2347086;C4553972
aspirin dipyridamole n $nmbr$,C0732279
aspirin alone n $nmbr$,C0004057;C0205171;C0439044;C0679994
randomisation scheme,C0034656;C1519193
three arm,C0205449;C0446516;C3715044;C4553528
two arm,C0446516;C3715044;C4553528
transient monocular blindness,C0149793
transient ischaemic attack,C0007787;C0917805
minor ischaemic stroke,C0026193;C0948008;C0205165
time from longest event to randomisation,C0040223;C3541383;C0034656
$nmbr$ week to $nmbr$ month,C0332174;C0439230
$nmbr$ $nmbr$ months,C0439231
rankin grade,C0441800;C0919553;C3244287
$nmbr$ no symptoms,C0683368;C1457887
$nmbr$ minor symptoms no limitations,C0683368;C1457887;C0449295
$nmbr$ some restrictions no help needed,C0443288;C1269765;C1552861;C0027552;C0686904
$nmbr$ help needed still independent,C0085862;C1290940;C1299583
additional investigations,C2359834
ct or mr scan of the brain,C0007673;C3540513;C3813556;C3888140;C0596217;C0881827
any infarct,C0021308
any relevant infarct,C2347946;C0021308
ultrasound carotid arteries,C0948945
stenosis $nmbr$,C0678234;C1261287;C2632116
intermittent claudication,C0021775
vascular intervention,C0184661;C0886296;C1273869
hyperlipidaemia,C0020473;C0428465;C4555212
systolic mean sd,C0039155;C2699239
diastolic mean sd,C0012000;C2699239
type of vessel involved,C1282017;C1314939
large vessel,C0225990
small vessel,C0225988
unspecified,C0205370;C1549663;C2983689;C4048188
antithrombotic drug use at time of event,C0242510
oral anticoagulants,C0354604
dose of aspirin,C4696290
figure $nmbr$ subgroup analyses for primary outcome event,C2986480;C1624730
estimated gfr at baseline ml min $nmbr$,C0017654;C1424601
m $nmbr$,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ n $nmbr$,C0369718;C0441922
$nmbr$ $nmbr$ n $nmbr$,C0369718;C0441922
female sex n of patients,C0086287
race white n of patients,C0007457;C0043157
medical history n of patients,C0262926
documented mi,C1301725;C3810814;C1609436
current cigarette n,C0521116;C0677453;C1704760;C3890423;C1705970
mean blood pressure mm hg,C0428886;C0439475;C0488053
laboratory determinations,C0022877;C0680730;C3244292;C4283904
mean serum creatinine mg dl,C0201976;C0439269;C0600061
lv ejection fraction $nmbr$ and,C0489482;C2700378
n of patients,C0369718;C0441922
lv ejection fraction n $nmbr$,C0489482;C2700378
medications n of patients,C0013227;C0030705;C0802604;C2598133;C4284232
aspirin antiplatelet medication,C0085826
lipid lowering drug,C0086440
diuretic any,C0012798
hrt use,C0042153;C0457083;C1947944
egfr category,C0683312;C3889287
trandolapril n $nmbr$,C0076891
multivariable adjusted hr $nmbr$ ci,C0008107;C3259781
events n,C0441471;C3541888
hr $nmbr$ ci,C0008107;C3259781
trandolapril,C0076891
egfr $nmbr$,C1739039;C3811844;C3812682
egfr $nmbr$ $nmbr$ $nmbr$ $nmbr$ vs egfr $nmbr$,C1739039;C3811844;C3812682
reference,C1514811;C1706462
cardiovascular mortality or mi,C0026565;C0026566;C3810814
cardiovascular mortality mi or revascularization,C0007226;C3810814;C3887460;C0581603
hope n $nmbr$,C0392347
hope patients with coronary artery disease n $nmbr$,C0741926
europa n $nmbr$ l $nmbr$,C0242751
peace n $nmbr$,C0680443
previous stroke ortransient ischaemic attack,C0038454;C0745413;C4554100
peripheral artery disease,C1704436;C4025272
serum cholesterol mg l,C0587184;C0439268
diastolic blood pressure mm hg medications,C0849164
antiplatelet agents,C0085826
lipid lowering agents,C0086440
pci percutaneous coronary intervention cabg coronary artery bypass graft for hope $nmbr$ mg l for europa $nmbr$ mg l or on a lipid lowering treatment for peace data are mean sd data are mean sd unless otherwise indicated,C0010055;C0242751;C0439268;C0023767;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C1511726;C3245479;C3714741;C0444504;C2699239;C2347634;C2348143;C1444656
$nmbr$ year rates in placebo groups,C0871208;C1521828
interactior $nmbr$ p,
with antiplatelets,
without antiplatelets,
with lipid lowering agents,C0086440
without lipid lowering agents,C0086440
with p blockers,C0369773;C2603361
without p blockers,C0369773;C2603361
all of the above,
one of the above,C0205447
two of the above,C0205448
none of the above,
with revascularisation,C0581603
without revascularsation,
revascularisation antiplatelets lipid lowering agents p blockers,C0086440
revascularisation but no antiplatelets lipid lowering agents or p blockers,C0581603;C0086440;C0369773;C2603361
no pretreatment,C1550147;C2709094;C3539075;C3539076
ufh only,
enoxaparin only,C0206460
unadjusted p value,C1439367;C1709380
region,C0017446;C0205147
australia new zealand,C0027978;C0324547
latin america,C0023122
ecg at time of qualifying symptoms,C1623258;C0040223;C3541383;C1514624;C0683368;C1457887
st segment elevation,C0520886
inclusion criteria,C1512693
age is $nmbr$ vrs significant ecg changes and no positive bi omark ers,C0001779;C0237881;C0855329;C0750502;C1546944;C1704489;C2931783
age is $nmbr$ vrs positive biomarkers and no si gni fi canr ecg changes,C0001779;C0439178;C0005516;C1446409;C1514241;C2825490;C3812269;C4050619;C0855329
si gni fi canr ecg changes positive biomarkers and age,C0855329;C0005516;C0001779
age is $nmbr$ vrs significant ecg changes and positive biomarkers,C0001779;C0237881;C0855329;C0750502;C1546944;C0439178;C0005516;C1446409;C1514241;C2825490;C3812269
time to randomization h,C0040223;C3541383
hvpertension,
hvpercholesterolemia,
familv historv of cad,C1504769;C2239547;C3813548;C4284121
medical historv,C0199168;C0205476
chf,C0018802
transient ischemic attack,C0007787;C0917805
diet group n $nmbr$,C0012155;C0441848;C0012159;C1519433;C2983588;C3668949
diet plus pravastatin group n $nmbr$,C0012155;C0012159;C1519433;C2983588;C3668949
current past smoker,C3173209;C3241966
lipid concentrations,C0023779;C0086045
$nmbr$ ^ $nmbr$ $nmbr$,
triglyceride mmol l t,C0041004;C1532563
lipoprotein a mmol l,C0065058;C1532563;C0125953;C1096202;C1439335
medications,C0013227;C0802604;C2598133;C4284232
antihypertensive drugs,C0003364
ace inhibitors arb,C0003015;C3888198
$nmbr$ blockers,
reported by physicians tdata are median iqr all data are mean sd or number unless otherwise indicated,C1709908;C0031831;C0549183;C0876920;C2347635;C2348144;C2939193;C1511726;C3245479;C3714741;C0444504;C2699239;C2347634;C2348143;C0237753;C0449788;C1444656
ace angiotensin converting enzyme arb angiotensin receptor blockers,C0521942;C0815017
p value for interaction,C1709380;C1704675
o $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0483204
ldl cholesterol,C0023824;C0202117
hdlcholesterol,
current past,C0521116;C1705970
hr is,
with t $nmbr$ dm n $nmbr$,C2986835;C0011816;C3250443
without t $nmbr$ dm n $nmbr$,C2986835;C0011816;C3250443
rosuva $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
duration of hypercholesterolemia yr,C0449238;C2926735
current smoker n,C3173209;C3241966
nob systolic blood pressure mm hg,C0488055;C0439475;C0871470;C1306620
history of hypertension n,C0455527
history of chd n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
history of pvd n,C4534349
statin potency stratum n,C0360714
low potencyc,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
high potencyc,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
concomitant medications,C0013227;C0802604;C2598133;C4284232
drugs used in diabetes n,C0013227;C3687832;C1273517;C0011847;C0011849
antithrombotic agents n,C1704311
antihypertensive agents n,C0003364
cardiac therapy n d,C3654025
parameter statistics,C0038215;C0600673
rosuva $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ez simva $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
all rosuva,
all ez simva,C0206578
baseline mean mg dl],C0168634;C0439269;C1442488
mmol l],C1532563
c $nmbr$ $nmbr$ ],
se],C0036919
treatment difference,C1705241;C1705242
$nmbr$ y,
$nmbr$ j $nmbr$,
se]tf hdl c,C0036919;C4048299;C3715113;C4048587
baseline mean mg dl,C0168634;C0439269;C1442488
cl $nmbr$ ],C0596019
se]tf total c,C0036919;C0439175;C0439810
se]t,C0036919;C2603360
$nmbr$ q,
se]tf,C0036919;C4048299;C4048587
baseline median mg dl,C0168634;C0439269;C1442488
$nmbr$ ell ll,C1427925;C3273466
$nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
$nmbr$ ell ll non hdl c,C1427925;C3273466;C1518422;C3715113
ldl c hdl c,C3715113
baseline mean,C0444504;C2347634;C2348143
se t,C0036919
[ $nmbr$ $nmbr$ ],
total c hdl c,C0439175;C3715113;C0439810
cse],
$nmbr$ g,C0439267
cg ld,C0043444;C0694649;C1567075;C3540479
hscrp,
baseline median [mg l],C0549183;C0876920;C2347635;C2348144;C2939193;C0439268
$nmbr$ ci] $nmbr$,C0008107;C3259781
$nmbr$ ci]h,C0008107;C3259781;C0033727;C0369286;C0441932;C0564385;C4528284
parameter,C0549193;C1704769;C2350001
diabetes mellitus n $nmbr$ $nmbr$,C0011849
neither n $nmbr$ $nmbr$,C0369718;C0441922
pbo statin n $nmbr$,C0031962;C0360714
eze statin n $nmbr$,C0360714
age years mean _ sd sex n,C1510829;C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
metabolic syndrome characteristics n,C0524620;C1521970
waist circumference women $nmbr$ in $nmbr$ cm men $nmbr$ in $nmbr$ cm tc $nmbr$ c $nmbr$ mg dl,C0455829;C0043210;C0025266;C0039411;C0439269;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
_ $nmbr$ $nmbr$ mmol l hdl c women $nmbr$ mg dl $nmbr$ $nmbr$ mmol l men $nmbr$ mg dl,C3539687
hypertension bp $nmbr$ $nmbr$ mmhg or using antihypertensive medication,C0020538;C0439475;C1963138;C1524063;C0003364
fc $nmbr$ mg dl _ $nmbr$ $nmbr$ mmol l or history of diabetes,C0439268;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
key fc fasting glucose bp this category did not include ar have $nmbr$ of the indicated charac,C0037623;C1415692;C1708288;C4318478;C0683312;C3889287;C1518422;C0332257;C1552866;C2700399;C1436327;C2986463;C3884535;C4521369;C1444656
blood pressure pbo y patients with diabe teristics ncep atp i,C0005823;C0030705;C1271104;C1272641
placebo eze tes fc j $nmbr$ rr $nmbr$ definition,C1550452;C1704788;C3539107;C3888054
ezetimibe tc triglycerides hdl c lg dl l $nmbr$ $nmbr$ mmol l] to qualify as having,C0039411;C0023128;C0694651;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
high density lipoprotein cholesterol metabolic syndrome patients were to,C0023822;C0030705
lipid measure,C0079809;C0242485
metabolic syndrome,C0524620
neither pbo statin eze statin,C0031962;C0360714
pbo statin $nmbr$,C0031962;C0360714
ze statin,C0360714
pbo statin,C0031962;C0360714
eze statin,C0360714
ldl c mmol l mean,C0444504;C2347634;C2348143
n $nmbr$ n $nmbr$,C0369718;C0441922
baseline,C0168634;C1442488
at six weeks,C0205452;C0439230
change,C0392747;C0443172;C1705241;C4319952
tg mmol l median,C0549183;C0876920;C2347635;C2348144;C2939193
hdl c mmol l mean,C0444504;C2347634;C2348143
non hdl c mmol l mean,C0444504;C2347634;C2348143
total c mmol l mean,C0444504;C2347634;C2348143
apo b apo a l ratio mean,C0444504;C2347634;C2348143
hs crp mg l median,C0549183;C0876920;C2347635;C2348144;C2939193
key tc triglyceride hs crp ldl c low density lipoprotein fc fasting glucose ncep atp this category did not include ar to have _ $nmbr$ of the indicated char least square means except tc an note all treatment by subgroup,C2744579;C4552600;C0683312;C3889287;C1518422;C0332257;C1552866;C2700399;C1436327;C2986463;C3884535;C4521369;C0023189;C1704970;C1316572;C1317574;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
c reactive protein high sensitivity assay mitt modified intent to treat pbo cholesterol cl confidence intervals hdl c high density lipoprotein cholest national cholesterol education program adult treatment panel y patients with diabetes fc _ $nmbr$ mg dl [ $nmbr$ $nmbr$ mmol l] to qualify as having acteristics described in methods ncep atp iii definition baseline values are rr d hs crr for which medians are presented p $nmbr$ $nmbr$,C0162425;C1283828;C1550453;C2699193;C3165426;C0439268;C1552738;C0456580;C0549183;C0449450
placebo eze ezetimibe erol apo apolipoprotein metabolic syndrome patients were eans and percentage changes are,C0524620;C0030705;C0392747;C0443172
age $nmbr$ y n $nmbr$,C0001779
hypercholesterolemia $nmbr$ mg dl,C0020443;C0439269;C1522133
prior coronary artery bypass surgery,C0010055
interval from clopidogrel loading h,C1272706;C1552654;C1552713
elevated troponin t $nmbr$ $nmbr$ xg l,C0077404;C1420827
therapy at discharge,C0039798;C0087111;C1363945
figure $nmbr$ incidence of major bleeding top $nmbr$ day mortality middle and $nmbr$ day combined incidence of death myocardial infarction and urgent target vessel revascularization tvr according to age quartiles and assigned treatment mi denotes myocardial infarction and tvr target vessel revascularization,C0021149;C0220856;C0449618;C0001779;C0039798;C3810814;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0027051;C0428953;C2926063;C4552959;C0581603
age dependent effect of abcixima,C1280500;C1518681;C2348382
death or myocardial infarction,C0011065;C1306577;C4082313;C4552775;C0027051;C0428953;C2926063;C3810814;C4552959
target vessel revascularization,C0449618;C0581603
mace,C0349381;C0949745;C1445339
major bleeding,C0205082;C0019080;C0205164;C4318856;C4521762
hemorrhagic stroke,C0553692
minor bleeding,C0026193;C0019080;C0205165
blood transfusion,C0005841;C0281867
profound thrombocytopenia,C0040034;C0392386
moderate thrombocytopenia,C0040034;C0392386
mild thrombocytopenia,C1856453
aged ^ $nmbr$ years,C0001779;C0439234;C0001792;C1999167
aged,C0001779;C0001792;C1999167
p value aged $nmbr$ vs,C1709380;C0001779;C0001792;C1999167
z\tonastaiin,
all,
aiorvasiaiin,
while ethnic origin,C0015031
l $nmbr$ $nmbr$ $nmbr$,C0439394;C1706495;C3642217
systolic blood pressure mmhg,C0488055;C0439475;C0871470;C1306620
hl $nmbr$ $nmbr$,C1453952;C4085347
diastolic blood pressure mmhg,C0428883;C0439475;C1305849
macroalbuminuria,
retinopathy,C0035309;C1962966
duration diabetes years,C0011847;C0439234;C0011849
hi ah,C0018619;C1836672;C0239849;C1412082;C1412316;C1431594;C4552857
ldl cholesicrol minol l,
kdl cholesterol mmol,C0008377;C0439190
i idl cholesterol mg dl,C0619865;C0439269
total cholesterol mmo $nmbr$ $nmbr$,C0201950;C0543421
toial cholcsierol mg dl,C0439269
trigl yeerides m mol l,C0347982
apolipoproiein a $nmbr$ tng $nmbr$,
apolipoproiein b mij $nmbr$,
$nmbr$ j $nmbr$ $nmbr$,
diabetes treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
bi $nmbr$ $nmbr$,
$nmbr$ h $nmbr$,C0033727;C0369286;C0441932;C0564385;C4528284
oral hypoglycemic drugs only,C0359086
$nmbr$ j $nmbr$ $nmbr$ $nmbr$,
insulin and oral hypoglycemic drugs,C0021641;C1533581;C1579433;C3714501;C0359086
blood pressure lowering treatment,C0596197
a blocker,
i blocker,C0021966;C0221138
calcium aniagonisi,C0006675;C0006726;C2936886;C3540037;C3714611
$nmbr$ h $nmbr$ $nmbr$,C0033727;C0369286;C0441932;C0564385;C4528284
ace inhibitor or angiotensin ii receptor,C0003015;C4541021;C0003011
aniagonisi,
diurciic,
atv n,C0210243;C0674679;C1145759;C1334862
pbo n,C0031962
rrr,
total population,C3258257
age ^ $nmbr$,C0001779
age interaction,C0001779;C1704675
acute coronary event,C0205178;C0741923
aqe ^ $nmbr$,
aqe,
coronary revascularization,C0877341
aqe i $nmbr$,C0021966;C0221138
fatal and nonfatal stroke,C1302234;C1705232;C0038454;C4554100
infliximab $nmbr$ mg kg,C0666743;C0439272
patients randomized,C0030705;C0034656;C3815594
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
psoriasis duration yrs,C0033860;C0449238;C2926735
psoriatic arthritis,C0003872
bsa,
pasi score $nmbr$ $nmbr$,C0449820;C4050231
dlqi $nmbr$ $nmbr$,C3899393
prior therapy,C1514463
biologic agents,C0005515
topical therapy,C0039798;C0087111;C1363945
uvb,C0454530;C0564461
puva,C0853073;C1704892
acitretin,C0050559
cyclosporin,C0010592;C0010594
placebo n,C0032042;C1696465;C1706408
infliximab combined $nmbr$ mg kg and $nmbr$ mg kg n,C0205195;C0439272
difference,C1705241;C1705242
$nmbr$ ci for difference,C0008107;C3259781
baseline pasi score,C0449820;C4050231
\ $nmbr$,
baseline bsa involvement,C0168634;C1314939;C1442488
dissatisfied with stopped $nmbr$ prior systemic therapy because of side effects,C0870433;C4085546;C0001688;C0877248;C0879626
dissatisfied with stopped $nmbr$ prior systemic therapies because of side effects,C0870433;C4085546;C0001688;C0877248;C0879626
prior use of $nmbr$ systemic therapies,C1524063;C1515119
prior use of biologic agents,C1524063;C0005515
etoricoxib n $nmbr$ $nmbr$,C0972314
diclofenac n $nmbr$ $nmbr$,C0012091
arthritis type,C0332307;C1547052
osteoarthritis,C0029408
rheumatoid arthritis,C0003873
weight in kg mean sd,C0005910;C0043100;C1305866;C1705104
bmi in kg m $nmbr$ mean sd,C0578022;C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
hispanic american,C0019576
multiracial,C1881928
othert,
dyslipidaemiaj,
current cigarette smoker,C3173209;C3241966
established atherosclerotic cv disease,C0333482;C0007222
$nmbr$ cv risk factors^ or established atherosclerotic cv disease,C0035648;C1553898;C0333482;C0007222
low dose aspirin use,C0042153;C0457083;C1947944
cardiac mediations,C0018787;C0680727;C1522601
anti arthritic medications,C0013227;C0802604;C2598133;C4284232
cox $nmbr$ selective nsaid,C0003211;C3536840
traditional nsaid,C0003211;C3536840
paracetamol,C0000970
high dose aspirin,C0444956;C0004057
glucocorticoid,C0017710
dmard,C0242708
etoricoxib,C0972314
diclofenac,C0012091
n pyr,C0369718;C0441922
established ascvd,C0443211;C3665365;C1272684
established ascvd or $nmbr$ cv risk factors,C0443211;C3665365;C1272684;C0035648;C1553898
low dose aspirin use at baseline,C0042153;C0457083;C1947944
disease,C0012634
oa,C0029408;C3887876
ra,C3538806;C4048756
etoricoxib dose,C0178602;C0869039;C1114758
unfractionated heparin or enoxaparin plus glycoprotein iib iiia inhibitors n $nmbr$,C0019134;C2825026;C0206460;C0016011
bivalirudin plus glycoprotein iib iiia inhibitors n $nmbr$,C0168273;C0016011
bivalirudin alone n $nmbr$,C0168273;C0205171;C0439044;C0679994
male sex no medical history no total no,C0086582;C0262926;C1704706;C0439175;C0439810
insulin requiring diabetes,C0011847;C0011849
elevation of cardiac biomarker levels no total no,C0439775;C0702240;C0439175;C0439810
elevation of troponin levels no total no,C0439775;C0702240;C0439175;C0439810
st segment deviation $nmbr$ mm no total no,C4330985;C4554674;C0439175;C0439810
elevation of cardiac biomarker levels or st seg ment deviation $nmbr$ mm no total no,C0439775;C0702240;C4330985;C4554674;C0439175;C0439810
timi risk score no total no f,C0035647;C0449820;C4050231;C4552904;C0439175;C0439810;C0016327
variable demographic characteristics,C0683970
rosiglitazone n $nmbr$,C0289313
metformin n $nmbr$,C0025598
glyburide n $nmbr$,C0017628
race or ethnic background no f,C0034510;C1706779;C3853635;C0015031;C0016327
region no,C0017446;C0205147
time since diagnosis of diabetes no,C0040223;C3541383
anthropometric characteristics,C1521970
waist circumference cm,C0455829
hip circumference cm,C0562350
systolic mm hg,C0039155;C0439475
diastolic mm hg,C0012000;C0439475
antihypertensive therapy no,C0585941
fasting plasma glucose mg dl,C0202042;C0439269;C0455280
glycated hemoglobin,C0017853
fasting insulin pmol liter,C0015663;C0021641;C0475211;C1533581;C1579433;C3714501
insulin sensitivity,C0920563;C4049919
^ $nmbr$ cell function,C0007613
gad positive no ^,C0439178;C1446409;C1514241;C2825490;C3812269
lipids,C0023779
lipid lowering therapy no,C0585943
the test for heterogeneity interaction indicates whether the treatment effect varied significantly among the sub groups the hochberg method was applied to each of the two comparisons of the treatment groups bmi denotes body mass index the weight in kilograms divided by the square of the height in meters,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744;C1518681;C0025663;C0449851;C0871511;C4048755;C0374505;C0005893;C0578022;C1305855;C0005910;C0043100;C1305866;C1705104;C0332849;C0205120;C1552595;C0441074
p value for heterogeneity rosiglitazone versus metformin,C1709380;C0019409;C0242960;C0025598
p value for heterogeneity rosiglitazone versus glyburide,C1709380;C0019409;C0242960;C0017628
$nmbr$ $nmbr$ $nmbr$ $nmbr$ kg,C0022718;C0439209;C4054209
$nmbr$ $nmbr$ kg,C0022718;C0439209;C4054209
waist circumference,C0455829
$nmbr$ $nmbr$ cm,
$nmbr$ cm,
baseline fasting plasma glucose,C0202042;C0455280
i $nmbr$ mg d n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0369718;C0441922
$nmbr$ mg d n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0369718;C0441922
general health self reported,C0424575;C4018875;C0681906;C2700446
very good or excellent,C3641222;C1548784;C1961136
good,C0205170
fair or poor,C2911689;C0032854;C0542537;C2700379
walk for exercise,C0080331;C0015259;C1522704
fall in last $nmbr$ mo,C0085639;C0238715;C4553726
baseline vertebral fracture,C0168634;C0080179;C1442488
history of clinical fracture $nmbr$ years old,C1272071;C0205210
high fracture risk stratum,C0332167;C3272283;C4050568;C4319571
former,C0205156;C0750523
duration of alendronate use mean sd y,C1881378;C2826775
current alendronate use,C0042153;C0457083;C1947944
current use of hormone therapy,C1524063;C0279025
or raloxifene,C0244404
time since start of fit mean sd y,C1301880;C0036572;C2349186;C4048158;C4553125
time since end of fit mean sd y,C1522314;C0036572;C2349186;C4048158;C4553125
flex baseline bmd mean sd g cm $nmbr$,C0168634;C0439267;C1442488
total hip,C0019552;C0022122;C1505163;C3538851;C4284725
femoral neck,C0015815
lumbar spine,C0024091;C3887615
forearm,C0016536
total body,C0229960
flex baseline bmd t score,C0449820;C4050231
at femoral neck mean sd,C0015815;C2699239
$nmbr$ $nmbr$ to,
serum bone specific alkaline,C0205369;C1552740;C1979842
phosphatase mean sd ng mlf,C0017887;C0066495;C0028074
serum c terminal telopeptide of,C0229671;C1707271;C1546774;C1550100
type $nmbr$ collagen mean sd ng ml,C0009325;C0439275
serum n propeptide of type $nmbr$ collagen,C1709708;C1875696
mean sd ng ml,C0444504;C0439275;C2347634;C2348143
dietary calcium intake mean sd mg d,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
early routine,C1279919;C0205547
post fibrinolysis angioplasty n $nmbr$,C0016017;C0162577;C1548817;C1305868
primary angioplasty n $nmbr$,C0205225;C0162577;C1548817;C0439612;C0439631
age year,C0439234;C0439508
male sex n,C0086582
current smoking n,C0037369;C0453996;C1881674
cholesterol $nmbr$ $nmbr$ mmol l n,C0008377;C1532563
family history n,C0241889
previous angina n,C0205156;C0002962;C1552607
previous angioplasty n,C0205156;C0162577;C1548817;C1552607
heart rates beats minutes,C0439385
medical treatment,C0679624
aspirin n,C0004057
beta blockers n,C0001645
ace inhibitors n,C0003015
calcium antagonists n,C0006684
time from symptoms to treatment,C0040223;C3541383;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
interval from onset of symptoms,C1272706;C1552654;C1552713
to randomization,C0034656
interval from randomization to angiography,C1272706;C1552654;C1552713;C0002978
angiographic features,C1521970;C1706388;C2346469;C2348519
infarct related artery location,C0450429;C1515974;C4284930;C4284931
left anterior descending n,C0441998;C0205386;C1547177;C0369718;C0441922
left circumflex n,C0205091;C0443246;C1552822
rca n,
number of vessels disease,C0237753;C0449788
non stenotic vessels n,C0333181;C0005847;C4049883
single vessel disease n,C0037179;C0042373;C0087136;C0205171
double vessel disease n,C0205173;C0042373;C1705764;C1705765
triple vessel disease n,C0856738
degree of stenosis of diameter,C4034225;C1301886
evidence or thombus n,C3887511
figure $nmbr$ increment in endsystolic volume index and the relative risk of death reinfarction or revascularization at $nmbr$ months in the early routine post brinolysis group when compared with the primary angioplasty group according to various characteristics horizontal bars indicate the $nmbr$ con dence intervals,C1705117;C4035091;C0425043;C0581603;C0439231;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1707455;C0680395;C1707156;C3274014;C3541345;C1272706
vildagliptin $nmbr$ mg daily,C0024671;C0332173;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
rosiglitazone $nmbr$ mg daik,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
hispanic or latino,C0086409;C0086528
all other,
bmi group kg m^,C0022718;C0439209;C4054209
alc,C1424945;C3811058
alc group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
fpg mmol $nmbr$,C0439190
disease duration years,C0872146;C0439234
rosiglitazone $nmbr$ mg daily,C0024671;C0332173;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
adjusted mean change kg,C0022718;C0439209;C4054209
whole cohort,C0009247;C0599755
bmi $nmbr$,C0578022
etoricoxib group n $nmbr$ $nmbr$,C0972314;C0441848
diclofenac group n $nmbr$ $nmbr$,C0012091;C0441848
ppi use,C0042153;C0457083;C1947944
traditional nsaid use,C3897349;C0003211;C3536840
cox $nmbr$ selective inhibitor use,C0042153;C0457083;C1947944
systemic corticosteroid use,C0239126
methotrexate use,C0042153;C0457083;C1947944
other dmard use,C0042153;C0457083;C1947944
history of upper,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
gastrointestinal event,C0441471;C4019010
regular ppi use,C0042153;C0457083;C1947944
no regular ppi use,C0042153;C0457083;C1947944
regular aspirin use,C0042153;C0457083;C1947944
no regular aspirin use,C0042153;C0457083;C1947944
etoricoxib n $nmbr$,C0972314
diclofenac n $nmbr$,C0012091
history of upper gastrointestinal event,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
corticosteroid use,C0239126
established atherosclerotic cardiovascular disease,C0443211;C0004153;C1272684
n n,C0369718;C0441922
patients with any clinical event,C0030705;C0205210
aspirin use p $nmbr$ $nmbr$ t,C0004057;C0042153;C0457083;C1947944
ppi use p $nmbr$ $nmbr$ t,C0358591;C0042153;C0457083;C1947944;C0871125;C3811894
patients with complicated events,C0030705;C0231242
patients with uncomplicated events,C0030705;C0441471;C3541888
patients with any clinical,C0030705;C0205210
event p $nmbr$ $nmbr$ o,C0441471;C4019010
no aspirin or ppi,C0004057;C0358591;C0871125;C3811894
ppi but no aspirin,C0358591;C0871125;C3811894
aspirin but no ppi,C0004057;C0358591;C0871125;C3811894
aspirin and ppi,C0004057;C0358591;C0871125;C3811894
patients with complicated events p $nmbr$ $nmbr$,C0030705;C0231242
$nmbr$ $nmbr$ $nmbr$ ^ $nmbr$,
patients with uncomplicated events p o $nmbr$,C0030705;C0441471;C3541888
combinations of aspirin and ppi use p $nmbr$ $nmbr$ t,C0453882;C3539181;C3539182;C3539954;C3539955;C3539956;C3539957;C3539959;C3539960;C3539961;C3539962;C3539963;C3539964;C3539965;C3539966;C3539967;C3539968;C3539969;C3539970;C3539971;C3539972;C3539973;C3539974;C3539975;C3539976;C3539977;C3539978;C3539979;C3540026;C3540027;C3540028;C3540030;C3540031;C3540719;C3540720;C3540721;C3540722;C3540723;C3540724;C3540740;C3854036;C0358591;C0042153;C0457083;C1947944;C0871125;C3811894
etoricoxib $nmbr$ mg n $nmbr$ n,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
diclofenac $nmbr$ mg n $nmbr$ n,C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
age mean yrs sd,C0001779;C2699239
sex n,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
native american,C0282204;C1515945
body mass index mean kg m^ sd,C0022718;C0439209;C4054209;C2699239
primary study joint n,C0205225;C0022417;C0392905;C1706309;C0439612;C0439631
knee,C0022742;C0022745;C1963703
hand,C0018563;C1552914
left shoulder,C0524469
acr functional class n,C0205245;C0456387;C1518526;C1705943;C0542341;C2700217
class i,C0441885;C1319793;C2698967
class ii,C0441886;C2698968
class $nmbr$,C0456387;C1518526;C1705943
prior antiinflammatory antirheumatic products n,C0003209;C0003191;C1515999
rofecoxib,C0762662
valdecoxib,C0913246
ibuprofen,C0020740
naproxen,C0027396
prior analgesic products n,C0332152;C0002771;C2826257
acetaminophen,C0000970;C2917659
history of upper gl events perforations ulcers bleeding n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
low dose aspirin use strata n,C2608320;C0042153;C0457083;C1947944
user,C1548600;C1706077
nonuser,
increased risk for thrombotic cardiovascular event^ n,C1273410
history of diagnosed hypertension prior to randomization n,C0455527;C0011900;C0034656
baseline aspirin use strata,C0004057;C0042153;C0457083;C1947944
patient years,C0030705;C0439234
pt years $nmbr$,C0032743;C0439234;C0699718
continued use of gpa,C0549178;C1524063
new use of gpa,C0205314;C1524063
parameters,C0449381
infliximab,C0666743
$nmbr$ mg kg n $nmbr$,C0439272
combined n $nmbr$,C0205195
sex female n,C0086287
race white n,C0034510;C0007457;C0043157;C0220938;C1706779;C3853635
disease characteristics,C0599878
disease duration yr mean sd,C0872146;C2699239
mayo score mean sd,C0444504;C2699239;C2347634;C2348143
aminosalicylates,C0368663
immunomodulatory agents,C0005525
extent of disease n,C0449279;C4553144
left side only,C0205091
extensive,C0205231
health related quality of life,C4279947
ibdq mean sd,C0444504;C2699239;C2347634;C2348143
sf $nmbr$ pcs mean sd,C0037712;C2699239
sf $nmbr$ mcs mean sd,C0037712;C2699239
no of individuals,C0027361;C0237401
i rosuvastatin n $nmbr$,C0021966;C0221138
i placebo n $nmbr$,C0021966;C0032042;C1696465;C1706408;C0221138
blood pressure mean sd mm hgt,C0428886;C2699239
fasting blood glucose mean sd mg dlt,C1413248;C3273706
impaired renal function,C1565489
estimated glomerular filtration rate,C3811844
normal $nmbr$ mlvmin per $nmbr$ $nmbr$ m $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
mild decrease $nmbr$,C0392756;C0547047
moderate decrease $nmbr$,C0392756;C0547047
concomitant medication use,C0521115;C0240320
antihypertensive,C0003364
the metabolic syndrome^,C0524620
body mass index $nmbr$ t,C0005893;C0578022;C1305855
triglycerides $nmbr$ mg dl $nmbr$ $nmbr$ mmol l,C0439268
diastolic blood pressure $nmbr$ mm hg,C0428883;C0439475;C1305849
systolic blood pressure $nmbr$ mm hg,C0488055;C0439475;C0871470;C1306620
or taking antihypertensive medication,C1290952
fasting blood glucose $nmbr$ mg dl $nmbr$ $nmbr$ mmol l,C0439268
$nmbr$ chd risk factors,C0035648;C1282512;C1553898
chd risk factors,C0035648;C1282512;C1553898
family history of premature chd,C0241889;C0151526;C0205252;C4018905
smoking during the previous month,C2114448;C0332177;C0439231
hypertension $nmbr$ $nmbr$ mm hg or taking,C0020538;C0439475;C1963138
$nmbr$ mg dl $nmbr$ $nmbr$ mmol l,C0439268
mean of maximum cimt mean sd mm,C0444504;C0806909;C1552615;C2826546;C2347634;C2348143
$nmbr$ carotid artery sites,C0007272;C0205145;C0162859
common carotid artery sites,C0007272;C0205145;C0162859
carotid bulb sites,C0007281;C0205145
internal carotid artery sites,C0007276;C0205145
mean of mean cimt mean sd mm,C0444504;C2347634;C2348143
tolvaptan n $nmbr$,C1176308
otherf,
ejection fraction mean sd,C0489482;C2699239;C2700378
ischemic heart failure etiology,C0015127;C1314792;C1524003
previous hospitalization for heart failure,C0205156;C3898876;C1552607
nyha class,C1882083
chronic renal insufficiency,C0403447;C1561643
valvular disease mitral,C3258293;C0746591
baseline therapy,C0039798;C0087111;C1363945
ace inhibitors arbs,C0003015;C3888198
aldosterone blockers,C0002006
baseline cardiovascular assessment,C4684571
dyspnea frequent continuous,C0013404;C0549178;C1963100
orthopnea frequent continuous,C0085619;C0549178
rales,C0034642;C0240859
pedal edema slight moderate marked,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0522501;C1706089
jugular venous distention $nmbr$ cm,C0425687
all cause mortality,C0015127;C0026565;C0026566;C1524003
cardiovascular death or heart failure hospitalization,C0011065;C1306577;C4082313;C4552775;C3898876
no of deaths,C0011065;C1306577
tolvaptan,C1176308
western europe,C0043129
eastern europe,C0015177
etiology,C0015127;C1314792;C1524003
dyspnea,C0013404;C1963100
frequent or continuous,C0332183;C0549178
none or seldom,C0522498
congestion,C0700148;C2826600
not severe,C4316743
severe,C0205082;C4050465;C4050466
systolic bp mm hg,C0871470;C0439475
new york heart association class,C1882083
serum sodium meq l,C0523891;C0439375
serum urea nitrogen mg dl,C0600137;C0439269;C1291218;C3683557
avp pg ml,C1098706;C0439297;C1568204;C1708407
b natriuretic peptide pg ml,C0070338;C0439297
p blocker use,C0042153;C0457083;C1947944
ace inhibitor or arb use,C0003015;C4541021;C0042153;C0457083;C1947944
aldosterone use,C0042153;C0457083;C1947944
younger subjects aged,C0681850;C1550501;C1706203;C2349001;C2697811;C0001779;C0001792;C1999167
older subjects aged $nmbr$ years,C0001779;C0439234;C0001792;C1999167
sertraline,C0074393;C0524265
married,C0024841;C0555047
education years,C0013621;C0439234;C0013622;C0013658;C0039401
controls n $nmbr$,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
epa treatment n $nmbr$,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
bmi kg m $nmbr$ cardiovascular history,C0022718;C0439209;C4054209;C1880008
cabgorptca,
hypertension serum lipid values,C0428462;C0042295
triglyceride mmol l blood pressure,C0005823;C1271104;C1272641
hmgcoa rl,C1419337;C3539667
pravastatin,C0085542
other statin,C0360714
antiplatelet agent,C0085826
other antihypertensive agents,C0003364
hypoglycaemic agents,C0020616
data are number of patients or mean sd unless otherwise indicated cabg coronary artery bypass grafting ptca percutaneous transluminal coronary angioplasty ldl low density lipoprotein hdl high density lipoprotein iqr i nterquarti le range hmg coa ri $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a reductase inhibitor bmi body mass index which is weight in kg divided by the square of height in metres median iqr,C1511726;C3245479;C3714741;C2360800;C0444504;C2699239;C2347634;C2348143;C0428776;C0005910;C0043100;C1305866;C1705104;C0332849;C0205120;C1552595;C0549183;C0876920;C2347635;C2348144;C2939193
control n $nmbr$,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
epa n $nmbr$,
interaction p,C1704675
previous cad,C1504769;C2239547;C3813548;C4284121
non smoker,C0337672;C0425293;C4554605
hypertension absent,C0020538;C1963138;C0332197;C4285062
triglyceride mm,C4330985;C4554674
ol l,
data are number of patients or hazard ratio $nmbr$ cl p values are forthe test of heterogeneity cad coronary artery disease bmi body mass index which is weight in kg divided by the square of height in metres ldl low density lipoprotein hdl high density lipoprotein there is a deficit of clinical data in some patients with the events,C1511726;C3245479;C3714741;C2360800;C1532109;C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744;C0005910;C0043100;C1305866;C1705104;C0332849;C0205120;C1552595;C0023823;C0023821;C0162429;C2987487;C0030705;C0441471;C3541888
ranolazine n $nmbr$,C0073633
age $nmbr$ y,C0001779
weight median iqr kg,C0022718;C0439209;C4054209
body mass index median iqr,C0005893;C0578022;C1305855
comorbidities,C0009488
cardiac history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
prior ml,C0439526;C1705224;C3887665
prior coronary revascularization,C0332152;C0877341;C2826257
prior heart failure,C0018801;C0018802;C4554158
estimated creatinine clearance,C0750572;C0812399
index event,C0441471;C4019010
non st elevation ml,C0439526;C1705224;C3887665
st segment depression $nmbr$ $nmbr$ mv,C1454484;C1705503;C4281602
timi risk scoret,C0035647;C4552904
time from onset of pain to randomization median iqr h,C0449244;C0033727;C0369286;C0441932;C0564385;C4528284
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
coronary angiography during the index hospitalization,C0085532;C1548829
cardiac medications during index hospitalization,C0013227;C0802604;C2598133;C4284232
and or discharge,C0012621;C0030685;C2926602
heparin,C0019134;C0770546
glycoprotein llb llla receptor inhibitor,C0017968;C1999216
thienopyridine,C1120149
ace inhibitor or angiotensin ii receptor blocker,C0003015;C4541021;C0521942;C3536793
abbreviations ace angiotensin converting enzyme iqr interquartile range ml myocardial infarction si conversion to convert creatinine clearance to ml s multiply by $nmbr$ $nmbr$ data are expressed as no total unless otherwise specified festimated using cockroft gault equation tthe timi risk score was used to categorize patients at low $nmbr$ $nmbr$ intermediate $nmbr$ $nmbr$ and high $nmbr$ $nmbr$ risk $nmbr$,C0022709;C0439836;C0439390;C1511726;C3245479;C3714741;C0439175;C0439810;C0205369;C1524063;C0035647;C0449820;C4050231;C4552904;C1273517;C0871968;C0030705;C0205103;C1550465;C2827755;C3889971;C0332167;C3272283;C4050568;C4319571
no of events sample size i i,C0242618;C3811654
kaplan meier rates i i,C0021966;C0221138
ranolazine,C0073633
hr $nmbr$ cl,C0596019
pfor interaction,C1151635;C1704675
] $nmbr$,
timi risk score,C0035647;C0449820;C4050231;C4552904
] j $nmbr$,
st segment depression $nmbr$ mm,C4330985;C4554674
creatinine clearance,C0812399
$nmbr$ mlymin,
early invasive,C0205281;C1334278
etanercept n $nmbr$,C0717758
demographic characteristics,C0683970
female no,C0043210;C0086287;C1705497;C1705498
age mean min max yrs,C0001779;C0444504;C2347634;C2348143
duration of ra mean min max yrs,C0449238;C2926735
comorbid diseasesa diabetesb,
insulin dependentc,C0021641;C1533581;C1579433;C3714501
oral hypoglycaemics only,C0359086
comorbidities other than diabetes,C0009488;C0011847;C0011849
chronic pulmonary disease,C0746102
pneumonia in past year,C0032285;C0439234;C0439508
recurrent infections $nmbr$ per year,C0239998;C0439234;C0439508
bronchitis,C0006277
sinusitis,C0037199;C4553555
urinary tract infection,C0042029;C0262655;C4554638
cardiovascular risk factors no,C0850624
coronary artery disease,C0010054;C0010068;C1956346
congestive heart failure definite,C0018802;C0439544;C1704787
at least two cardiovascular risk factors,C0035648;C0850624
medically important infectionsa,C3898777;C4084912
serious adverse events,C1519255
etanercept,C0717758
patients with diabetesb,C0030705
patients without diabetesb,C0030705
patients with chronic,C0030705;C0205191
pulmonary disease,C0024115
patients without chronic,C0030705;C0205191
adalimumab group n $nmbr$ t,C0036669
men n,C0025266
mean age sd y,C0444504;C0001779;C2347634;C2348143
mean weight sd kg,C0022718;C0439209;C4054209
intestinal area involved n,C0021853;C0017446;C0205146
rectum,C0034896
perianal or anus,C0442158;C0003461
gastroduodenal,C0450199
jejunum,C0022378
abdominal or perianal fistula at baseline n,C0000726;C0267561;C0168634;C1442488
mean cdai score sd,C3533236;C2699239
mean baseline ibdq score sd crp concentration mg l,C3533236;C0439268
median range,C1514721;C2348147;C3542016
crp concentration $nmbr$ mg l n \,C0086045;C0439268;C1446561;C3827302
previous loss of response to infliximab n,C0205156;C1517945;C1552607;C0666743
previous intolerance of infliximab n,C0231199;C1744706;C2355652
acute reaction,C0205178;C0443286
delayed reaction,C0205421;C0443286;C1545665;C3272602
acute and delayed reaction,C0205178;C0205421;C0443286;C1545665;C3272602
previous loss of response to and intolerance of infliximab n,C0205156;C1517945;C1552607;C0231199;C1744706;C2355652
antibodies to infliximab n,C3533054
indeterminate,C0205258
concomitant medication n,C0521115;C0013227;C3244316;C4284232
steroids,C0038317
any immunosuppressive agent,C0021081
$nmbr$ aminosalicylates,C0368663
placebo croup n n,C0032042;C0010380;C1696465;C1706408
adalimumab croup n n,C1122087;C0010380
primary analysis,C0002778;C0936012;C1524024
remission in overall population,C0544452;C0687702
prespecified subgroup analyses,C2986480
remission,C0544452;C0687702
patients with previous loss of response to infliximab,C0030705;C0205156;C1552607;C0666743
patients with previous intolerance of infliximab,C0030705;C0205156;C1552607
patients with baseline crp concentration,C0030705;C0086045;C1446561;C3827302
patients with baseline crp concentration $nmbr$ mg l,C0030705;C0439268
additional subgroup analyses,C1524062;C2986480
patients not receiving immunosuppressive agents at baseline,C0030705;C1518422;C1514756;C0021081;C0168634;C1442488
patients receiving immunosuppressive agents at baseline,C0030705;C1514756;C0021081;C0168634;C1442488
patients not receiving corticosteroids at baseline,C0030705;C1518422;C1514756;C0001617;C3539185;C3540725;C3540726;C3540727
patients receiving corticosteroids at baseline,C0030705;C1514756;C0001617;C3539185;C3540725;C3540726;C3540727
patients with previous loss of response to and intolerance of infliximab,C0030705;C0205156;C1552607;C0231199;C1744706;C2355652
patients who received negative results on test for antibodies to infliximabt,C1334932;C0003241
patients who received indeterminate results on test for antibodies to infliximabt,C0456984;C0003241
patients who received positive results on test for antibodies to infliximabt,C1335447;C0003241
pooled simvastatin factorial studies,C0074554;C2826344
atorvastatin factorial study,C0286651;C2826344
simvastatin monotherapy n $nmbr$ $nmbr$,C0074554
ezetimibe simvastatin n $nmbr$ $nmbr$,C1532737
atorvastatin monotherapy n $nmbr$,C0286651
ezetimibe simvastatin n $nmbr$,C1532737
body mass index kg nr,C0027496;C3844738
crp mg l median sd,C0439268;C2699239
tg mg dl median sd,C0439269;C2699239
apolipoprotein b mg dl,C0003593;C0439269
hdl mg dl,C3715113;C0439269
figure $nmbr$ geometric mean percentage difference between treatment groups in crp levels from baseline across patient subgroups values in parentheses represent the number of patients in the pooled simvastatin and pooled ezetimibe simvastatin groups respectively the treatment by subgroup interaction term was p $nmbr$ $nmbr$ for all subgroups indicating consistency of the treatment effect across subgroups,C1705241;C1705242;C3890735;C0441889;C4048285;C0030705;C0042295;C1882932;C2360800;C1709595;C0074554;C2349200;C4522255;C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0369773;C2603361;C0332529;C1547017;C1079230
tiotropium,C0213771
total randomised n,C0439175;C0439810
male n,C0086582;C1706180;C1706428;C1706429
smoking history pack years,C1519384;C1277691
screening visit $nmbr$,C0545082;C1512346;C2826704
fev $nmbr$ l pre bronchodilator,C3714541;C2599602
fev $nmbr$ predicted normal,C0520835;C0681842;C1882327
fev $nmbr$ fvc,C3714541
fvc l,C3714541
nice classification of copd severity of obstruction n [ $nmbr$ ],C0008902;C0008903;C0678229
mild fev $nmbr$ predicted,C0681842;C1882327
moderate $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
severe fev,C0205082;C3714541;C4050465;C4050466
pulmonary medication during baseline,C0013227;C3244316;C4284232
laba n,
laba no ics n,C0815320;C4551720
ics n,C0815320;C4551720
ics no laba n,C0815320;C4551720
laba plus ics n,C0815320;C4551720
no laba no ics n,C0815320;C4551720
saba use occasions weekt,C0042153;C0457083;C1947944
trough fev response l,C0444506;C0871261;C1704632;C1706817;C2911692
trough fvc response l,C0444506;C0871261;C1704632;C1706817;C2911692
effect size^,C0814843
laba tiotropium n $nmbr$ placebo n $nmbr$,C0213771;C0032042;C1696465;C1706408
ics tiotropium n $nmbr$ placebo n $nmbr$,C0213771;C0032042;C1696465;C1706408
ics no laba tiotropium n $nmbr$ placebo n $nmbr$,C0815320;C4551720;C0213771;C0032042;C1696465;C1706408
laba plus ics tiotropium n $nmbr$ placebo n $nmbr$,C0213771;C0032042;C1696465;C1706408
no laba no ics tiotropium n $nmbr$ placebo n $nmbr$,C0213771;C0032042;C1696465;C1706408
trough fev response l i,C0021966;C0221138
effect size,C0814843
fev $nmbr$ predicted,C0681842;C1882327
tiotropium n $nmbr$ placebo n,C0213771;C0032042;C1696465;C1706408
fev,C3714541
placebo group n $nmbr$ j,C0441844
certolizumab group n $nmbr$,C1872109;C0441848
mean age yr range,C1514721;C2348147;C3542016
mean body mass indexj,C0444504;C0518010;C2347634;C2348143
duration of disease yr^ mean,C0872146;C0439234
geometric mean ofcrp mg liter range,C1514721;C2348147;C3542016
disease site no ^,C0205145;C1515974;C2825164
terminal ileum,C0227327
lleocolon,
previous infliximab therapy,C0205156;C4076075;C1552607
any therapy no,C0039798;C0087111;C1363945
median infusions no range,C0549183;C0574032;C0876920;C2347635;C2348144;C2939193;C1514721;C2348147;C3542016
previous hypersensitivity reaction no,C0205156;C0020517;C1552607
resection performed no,C0015252;C0728940;C0884358
concurrent treatment at study entry no,C0679827;C1521826;C3161471
glucocorticoids only,C0017710;C3540777;C3540778
immunosuppressive agents only,C0021081
glucocorticoids combined with immunosuppressive agents,C0017710;C3540777;C3540778;C0205195;C0021081
neither glucocorticoids nor immunosuppressive agents,C0017710;C3540777;C3540778;C0021081
certolizumab group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
no total,C0439175;C0439810
a decrease of $nmbr$ points in the cdai score,C0392756;C0547047;C0449820;C4050231
with baseline crp level of $nmbr$ mg liter,C0441889;C0456079;C1547707;C2946261
at week $nmbr$,C0332174;C0439230
at weeks $nmbr$ and $nmbr$,C0439230
no immunosuppressive agents at baseline,C0021081;C0168634;C1442488
immunosuppressive agents at baseline,C0021081;C0168634;C1442488
no glucocorticoids at baseline,C0017710;C3540777;C3540778
glucocorticoids at baseline,C0017710;C3540777;C3540778
no previous treatment with infliximab,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
previous treatment with infliximab,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
patients with remission,C1277626
placebo group n $nmbr$ f,C0441840
male sex no of patients,C0086582;C0030705
duration of disease yr,C0872146;C0439234
current smoker no of patients,C3173209;C3241966;C0030705
crp mg liter^,C0024671;C0475211;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
geometric mean,C2986759
disease site no of patients,C0205145;C1515974;C2825164;C0030705
ileocolon,
previous infliximab therapy no of patients,C0205156;C4076075;C1552607;C0030705
no of infusions,C0574032
previous acute hypersensitivity reaction to infliximab no of patients,C0205156;C0413234;C1552607;C0030705
previous bowel resection performed no of patients,C0205156;C0741614;C1552607;C0884358;C0030705
concurrent treatment of crohn s disease at study entry no of patients ff,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C2985574;C1705654;C0030705;C4554348
glucocorticoids plus immunosuppressive agents,C0017710;C3540777;C3540778
figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter,C1280519;C1707887;C1872109;C0030705;C0871261;C1704632;C1706817;C2911692;C0441837;C1547282;C0034746;C0032659;C1257890;C0332174;C0439230;C0441889;C0456079;C1547707;C2946261;C0441833;C1706365;C1999270;C0439165;C1549488;C1561533;C0205210;C1704788;C3539106;C0087111;C1292734;C1522326;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0475211
fondaparinux n $nmbr$,C1098510
age median range years,C1510829;C0549183;C0876920;C2347635;C2348144;C2939193
risk factor for venous thromboembolism no,C3495424;C3496592
obesity,C0028754;C1963185
history of venous,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
thromboembolism,C0040038
nyha grade iii or iv,C0205617;C0450094;C0475271;C0687697;C3889290;C4050000;C4283820;C4283821;C4283822;C0022326;C4265176
chronic obstructive pulmonary,C0205191;C0549186;C0024109;C2707265;C2709248;C4522268
inflammatory bowel disease,C0021390
cancer surgery,C0920424
no of risk factors for venous thromboembolism no,C0035648;C1553898;C1861172
creatinine clearance no,C0812399
$nmbr$ $nmbr$ ml min $nmbr$,C0439445
$nmbr$ ml min $nmbr$,C0439445
randomised treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
active n $nmbr$,C0205177;C3853793;C3888249
age when diabetes first diagnosed years mean sd,C0001779;C0011847;C2699239;C0011849
previous vascular disease,C0205156;C0042373;C1552607
history of major macrovascular disease n,C0683519;C0730226;C0850708;C0944983
history of myocardial infarction n,C1275835
history of stroke n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
history of major microvascular disease n,C0683519;C0730226;C0850708;C0944983
history of macroalbuminuriat n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
history of microvascular eye disease n,C0683519;C0730226;C0850708;C0944983
blood pressure control,C0005823;C1271104;C1272641
systolic blood pressure mm hg mean sd,C0428886;C2699239
diastolic blood pressure mm hg mean sd,C0428886;C2699239
history of currently treated hypertension n,C0455527;C0521116
other major risk factors,C0035648;C1553898
serum total cholesterol mmol l mean sd,C0587184;C2699239;C1287371
serum hdl cholesterol mmol l mean sd,C0428472;C2699239
urinary albumin creatinine ratio pg mg median iqr,C0486293;C1318293
microalbuminuria n,C0730345
serum creatinine pmol l mean sd,C0201976;C2699239;C0600061
serum haemoglobin a $nmbr$ c concentration mean sd,C0683149;C2699239
number of patients with event,C2360800;C0441471;C4019010
relative risk reduction $nmbr$ cl,C0242492;C0596019
pctindopnl indapamide n $nmbr$,C0021186
$nmbr$ oto $nmbr$,
$nmbr$ ito $nmbr$,C0022283
history of macrovascular disease,C0683519;C0730226;C0850708;C0944983
history of microvascular disease,C0683519;C0730226;C0850708;C0944983
treatment with any bp lowering drugs,C3469597;C0037623;C1415692;C1708288;C4318478
treatment with open label perindopril,C3640652;C0136123
treatment with statins,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
treatment with anti platelet drugs,C3469597
combined macro micro,C0085672;C1553035;C3811161;C4049106
european trial,C0239307;C0008976;C1535514
non european trial,C0239307;C0008976;C1535514
combined trials,C0205195;C0008976
dronedarone n $nmbr$,C0766326
race no f,C0034510;C1706779;C3853635;C0016327
body mass index no,C0005893;C0578022;C1305855
cardiovascular history no,C1880008
structural heart disease,C1290384
coronary artery disease^,C0010054;C0010068;C1956346
cardiac valvular disease,C0018824
nonischemic cardiomyopathy,C0878544
implanted pacemaker,C0848753
implanted cardioverter defibrillator,C0021102;C0810516;C2828363
rheumatic heart disease,C0035439
hypertrophic cardiomyopathy,C0007194;C4551472
congenital heart disease,C0152021
left atrial anteroposterior diameter mm,C4330985;C4554674
congestive heart failure no,C0018802
any disease,C0012634
nyha class i,C1882084
nyha class ii,C1882085
symptoms of atrial fibrillation in the $nmbr$ months before randomiza,C0683368;C1457887;C0439231
tion no,
recent cardioversion within $nmbr$ days before randomization,C0332185;C0013778;C0034656
concomitant cardiovascular therapy no,C1707479
calcium channel blocker ratelowering,C0006684;C3536851;C4521885
beta blocker except sotalol,C0001645;C0037707
oral anticoagulant,C0354604
long term antiplatelet therapy,C0443252;C1096021
previous antiarrhythmic treatment no,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
class ia,C0020980;C0694634;C1947960
class ib,C2744579;C3890035;C4283819
class ic,C0020750;C4554818
class iii,C0441887;C2698969
class iv,C0441888;C2698970
amiodarone,C0002598
sotalol,C0037707
hazard ratio for event $nmbr$ ci,C2985465;C0008107;C3259781
left atrial diameter,C0225860;C0225861
$nmbr$ mm,C4330985;C4554674
heart failure criteria met,C0428210;C1550543;C4317104
conversion to sinus rhythm in,C1321500
previous use of amiodarone,C1524063;C0002598
yes stopped for trial,C1549445;C1705108;C1710701;C1272691;C0008976
previous use of antiarrhythmic drugs,C1524063
sample size n,C0242618
age in years mean,C1510829;C0444504;C2347634;C2348143
$nmbr$ to $nmbr$ y n,
$nmbr$ y n,
education in years mean,C0013621;C0013622;C0013658;C0039401
clinic research experience n,C0002424;C0035168;C0242481;C0442592
on bp medication n,C0037623;C0013227;C3244316;C4284232;C1415692;C1708288;C4318478
hx of diabetes n,C0262926;C3814444
chd n,C0280604;C3542407
baseline ecg with lvh n,C0168634;C0232306;C1442488
ascvd n,C3665365
bmi kg m $nmbr$ mean,C0022718;C0439209;C4054209;C0444504;C2347634;C2348143
glucose mg dl mean,C0444504;C2347634;C2348143
potassium meq dl mean,C0444504;C2347634;C2348143
creatinine mg dl mean,C0444504;C2347634;C2348143
geographic region,C0017446
south n,C1710133
pr virgin islands n,C0279759;C0042752;C0279766;C1418864;C3538934;C3538935;C3889640;C4048189;C4082178;C4082184;C4085573;C4552913;C4552914
others n,C1955473;C3539125
time in trial,C0040223;C3541383;C0150312;C0008976;C0332285;C1707101
no with visit,C0545082;C1512346;C2826704
sbp dbp mean,C0444504;C2347634;C2348143
no of drugs,C0013227;C3687832
on step $nmbr$ drug,C0013227;C1254351
sd,C2699239
figure percentage of subgroup with bp controlled sbp,C0439165;C1549488;C1561533;C0037623;C0085805;C1415692;C1708288;C4318478
aged a $nmbr$ years,C0001779;C0001792;C1999167;C0439234
diff_measure dm added this as table had multiple headings,C0011816;C3250443;C1524062;C0039224;C1706074;C0439064
bl,C0005918;C0006413;C1552663;C2827109
diff_measure,C0079809;C0242485
am_delta,C0439097;C1705241;C3146239;C3538806;C3540585;C3815527
$nmbr$ $nmbr$ o lt,C0023376;C0230426;C3887647;C4521399
$nmbr$ $nmbr$ $nmbr$ $nmbr$ t,C2603360
body weight kg,C0022718;C0439209;C4054209
$nmbr$ $nmbr$ l ot,C1318464;C1418208;C1705587
responder analyses achieving alc,C0002778;C0936012;C1524024;C1424945;C3811058
n responders,C0369718;C0441922
$nmbr$ $nmbr$ $nmbr$ t,C2603360
baseline alc,C1424945;C3811058
fasting lipids mmol $nmbr$,C0015663;C0023779;C0439190
am_ delta,C0439097;C1705241;C3146239;C3538806;C3540585;C3815527
ldl,
hdl,C3715113
non hdl,C1518422;C3715113
vldl,C0523560
blood pressure mmhg,C0005823;C0439475;C1271104;C1272641
mean_delta,C0439097;C1705241;C3146239;C3538806;C3540585;C3815527
subgroup analyses,C2986480
bl alc,C1424945;C3811058
blaic $nmbr$ $nmbr$,
blaic,
bl bmioo kg m^,C0022718;C0439209;C4054209
bl bml $nmbr$ kg m^,C0022718;C0439209;C4054209
bl bm $nmbr$,C0005918;C0006416;C0006413;C1552663;C2827109
bl bml,C0005918;C0006413;C1552663;C2827109
bl bml $nmbr$ ke m^,C0005918;C0022558;C0006413;C1552663;C2827109
e characteristic n,C1521970
toricoxib $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
age mean years sd,C1510829;C2699239
female $nmbr$,C0043210;C0086287;C1705497;C1705498
caucasian $nmbr$,C0007457;C0043157
body mass index mean kg m $nmbr$ sd,C0022718;C0439209;C4054209;C2699239
previous anti inflammatory antirheumatic products n,C0432633
meloxicam,C0083381
piroxicam,C0031990
indomethacin,C0021246
previous analgesic products n,C0205156;C0002771;C1552607
history of upper gi events perforations ulcers and bleeding n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0019080
non user $nmbr$,C1518422;C1548600;C1706077
increased risk for thrombotic cardiovascular,C4699158;C0007226;C3887460
event n,C0441471;C4019010
history of diagnosed hypertension n,C0455527;C0011900
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ pty $nmbr$,
treatment group,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
air n $nmbr$,C0001861;C3536832
ig n $nmbr$,C0021027;C0305052;C0360506
air ig n $nmbr$,C0001861;C0021027;C0305052;C0360506;C3536832
$nmbr$ $nmbr$ $nmbr$ $nmbr$ a,
gender [n ],C0079399;C1522384;C0369718;C0441922
origin [n ],C0079946;C0439659;C1550512;C0369718;C0441922
african,C0027567
duration of diabetes years,C0449238;C2926735
oam use [n ],C0042153;C0457083;C1947944;C0369718;C0441922
insulin secretagogue,C0021641;C4704833;C1533581;C1579433;C3714501
biguanides,C0005382;C0360396;C3540012
tzd,
baseline insulin dose u kg [lsm se ],C0366513;C1300561;C0036919
baseline a $nmbr$ c [lsm se ],C0168634;C0036919;C1442488
a $nmbr$ c [n ],C1272460
prior insulin use years,C0240016;C0439234
algorithm $nmbr$,C0002045;C1553907
number,C0237753;C0449788
female male,C0086582;C1706180;C1706428;C1706429
duration since diagnosis years,C0449238;C2926735
time since start insulin years,C1301880
hba $nmbr$ c baseline,C0168634;C1442488
fbg baseline,C0168634;C1442488
premixed insulin only,C0021641;C1533581;C1579433;C3714501
premixed insulin with oads,C0021641;C1533581;C1579433;C3714501
insulin glargine oad,C0907402
insulin glargine oad od prandial,C0229089;C0439164;C1512019;C3273373;C3665488;C1998602;C4553624
insulin glargine oad bd prandial,C0005126;C2344255;C4050145;C1998602;C4553624
fbg mg dl,C0439269
fbg mmol l,C1532563
rosuvastatin,C0965129
mean yr,C0444504;C0439234;C2347634;C2348143
$nmbr$ yr no,C0439234
nyha class no,C1882083
past or current angina pectoris,C0521116;C0002962;C1705970
current atrial fibrillation or flutter on ecg,C0004238;C0344434;C1963067;C0016385;C2242390
pacemaker,C0030163;C0810633;C1546728;C3275122;C3853703
implantable cardioverter defibrillator,C0162589;C2825184
laboratory measurements,C0681902
cholesterol mmol liter,C0008377;C0475211
apob apoa l ratio,C0456603;C1547037
triglycerides mmol liter,C0041004;C0475211
serum creatinine,C0201976;C0600061
$nmbr$ tmol liter no,C0475211
estimated gfr,C0017654;C1424601
nt pro bnp pmol liter j,C0669479;C0754710
hscrp mg liter,C0024671;C0475211;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
current medication no,C0746467
loop diuretic,C0354100;C3536704
loop or thiazide diuretic,C0445022;C0012802;C3536861
aldosterone antagonist,C0002007;C2757004;C3536833
digitalis glycoside,C0012253
antiarrhythmic therapy,C0039798;C0087111;C1363945
antiplatelet therapy,C1096021
anticoagulant therapy,C0150457
antiplatelet or anticoagulant therapy,C0150457
placebo no of events no,C0032042;C1696465;C1706408;C0441471;C3541888
rosuvastatin of patients rate,C0965129;C0030705
iii and iv,C0439070;C1705160;C0022326;C4265176
$nmbr$ mm hg,C0439475
heart rate,C0018810
$nmbr$ $nmbr$ bpm,
previous revascularization,C0205156;C0581603;C1552607
cardiac rhythm,C0232187
sinus rhythm,C0232201
ldl cholesterol level,C0023824;C0201950;C0202117;C0428466
$nmbr$ $nmbr$ mmol liter,C0439190;C0475211
apob apoa i ratio,C0456603;C1547037
hdl cholesterol level,C0201950;C0428466
triglyceride level,C0428475
$nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0439445
nt pro bnp,C0669479;C0754710
$nmbr$ $nmbr$ pmol liter,C0439192;C0475211
hscrp level,C0441889;C0456079;C1547707;C2946261
$nmbr$ $nmbr$ mg liter,C0024671;C0475211;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
assigned to topiramate,C1516050;C1552601
assigned to placebo,C1516050;C1552601
migraine occurrence days month,C0149931;C0556971
migraine duration h,C0033727;C0369286;C0441932;C0564385;C4528284
migraine severity score,C0149931;C0457451
acute medication intake days month,C0013227;C0556971;C3244316;C4284232
midas score,C0449820;C4050231
patients assessed,C0030705;C1516048
hit $nmbr$ score,C0449820;C4050231
sf $nmbr$ mcs score,C0449820;C4050231
sf $nmbr$ pcs score,C0449820;C4050231
participants with metabolic syndrome,C0679646;C0524620
participants without metabolic syndrome,C0679646;C0524620
number randomized,C0237753;C0449788;C0034656;C3815594
womens,
years of education,C0439234;C0013621;C0013622;C0013658;C0039401
antihypertensive treatments,C0003364;C0087111
atherosclerotic cvd,C0333482;C0007222
history ol mi or stroke,C0019664;C3810814;C0019665;C0262512;C0262926;C1705255;C2004062;C0038454;C4554100
history ol coronary revascularization,C0019664;C0877341;C0019665;C0262512;C0262926;C1705255;C2004062
other ascvd,C3665365
st t wave,C0036056;C0429103;C3272372
lelt ventricular hypertrophy,C0340279
history ol chd at baselines,C0280604;C3542407
bmi kg m,C0022718;C0439209;C4054209
fasting glucose,C0015663;C0017725
cardiovascular metabolic syndrome risk lactors,C0007226;C0524620;C3887460
fasting glucose $nmbr$ mg dl,C0015663;C0439269
bmi $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
fasting triglycerides $nmbr$ mg dl,C0015663;C0041004;C0439269
low hdl cholesterol,C0151691
high blood pressure,C0020538;C2926615
lipid trial participantss,C0023779;C0008976
table_group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
comparison,C1707455
with metabolic syndrome,C0524620
without metabolic syndrome,C0524620
a,
amlodipine chlorthalidone,C0051696;C0008294
combined cvd,C0205195;C0007222
esrd,C0022661;C0035078;C2316810
b,
lisinopril chlorthalidone,C0065374;C0008294
categories of urinary acr ^g mg,C0683312;C1300563
p for trend,C0369773;C2603361
lowest normal n $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
low normal n $nmbr$,C0205251;C0205307;C0231683;C0439166;C2347086;C4553972;C1550472;C3890211;C4048187;C4321351;C4522223
medium normal n $nmbr$,C0009458;C0205307;C0231683;C0439166;C2347086;C4553972;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283
high normal n $nmbr$,C0205250;C0205307;C0231683;C0439166;C2347086;C4553972;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
low medium microalbuminuria n $nmbr$,C0205251;C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283;C1550472;C3890211;C4048187;C4321351;C4522223
high microalbuminuria to macroalbuminuria n $nmbr$,C0205250;C0730345;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
male acr definition ^ g mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
female acr definition ^g mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
female sex n,C0086287
white n medical history n,C0262926;C1704706
prior angina pectoris,C0332152;C0002962;C2826257
prior cabg,C0332152;C0010055;C2826257
prior ptca or cabg,C0332152;C2936173;C2826257;C0010055
current smoker n of patients,C3173209;C3241966
dbp $nmbr$ or sbp $nmbr$ mm hg laboratory determinations,C0536221;C3813197;C4281799;C0439475;C0680730
egfr ml mn $nmbr$ $nmbr$ m $nmbr$,C0026327;C0026405;C4285072
mean serum potassium mg dl,C0302353;C0439269;C0543465
mean serum cholesterol mg dl,C0587184;C0439269
lv function $nmbr$ $nmbr$ and,C0031843;C0542341;C0700205;C1705273
j $nmbr$ blocker,
potassium sparing diuretic,C0304490;C3536751
other diuretic,C0012798
digitalis,C0012252;C0304520
active treatment,C1704532
hr and $nmbr$ ci,C0008107;C3259781
low to medium microalbuminuria n $nmbr$,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
urinary acr,C1412134;C1515941
primary outcome n $nmbr$,C0205225;C0439612;C0439631
$nmbr$ $nmbr$ reference,C1514811;C1706462
cardiovascular death n $nmbr$,C0007226;C0011065;C1306577;C4082313;C4552775;C3887460
all cause mortality n $nmbr$,C0015127;C0026565;C0026566;C1524003
primary,C0205225;C0439612;C0439631
companion $nmbr$ $nmbr$ hours,C0031268;C0439227;C0335343;C0682323
companion wake up stroke,C0038454;C4554100
mean age y mean sd,C0001779;C2699239
men women,C0025266;C0043210
mean weight kg mean sd,C0005910;C2699239;C0043100;C1305866;C1705104
location,C0450429;C1515974;C4284930;C4284931
south africa,C0037712
australia,C0004340
ct findings,C2607943;C2926606;C3539655
$nmbr$ subjects,C0681850;C1550501;C1706203;C2349001;C2697811
$nmbr$ patients,C0030705
new stroke,C0038454;C4554100
old stroke,C1536121
previous tia,C0007787;C0917805;C1054154
previous stroke,C0038454;C4554100
mean systolic bp mmhg mean sd,C0871470;C2699239
mean diastolic bp mmhg mean sd,C0428883;C2699239
mean serum glucose mg dl mean sd,C0202041;C2699239;C3534430
figure $nmbr$ the distribution of scores on the mrs a and the ef cacy results at $nmbr$ months using the adjusted dichotomous responder analysis b in patients enrolled in the primary cohort is demonstrated for patients treated either with abciximab or placebo in addition the rates of favorable outcomes for patients with a baseline nihss score of $nmbr$ to $nmbr$ desired mrs score $nmbr$ $nmbr$ to $nmbr$ desired mrs score of $nmbr$ to $nmbr$ or $nmbr$ to $nmbr$ desired mrs score $nmbr$ to $nmbr$ are shown b,C0520511;C1704711;C1522706;C2349188;C3714939;C3854213;C1274040;C1546471;C2825142;C1524063;C0002778;C0030705;C0936012;C1524024;C4684790;C0009247;C0599755;C1522326;C0288672;C0032042;C1696465;C1706408;C0871208;C1521828;C0168634;C1442488;C0449820;C4050231;C1547282
subgroups based on clinical and demographic characteristics also demonstrated a lack of efficacy in the primary outcomes,C1079230;C1527178;C1705938;C0683970;C0235828;C0205225;C1274040;C0439612;C0439631
baseline hb $nmbr$ g $nmbr$ $nmbr$ n $nmbr$,C0062408
baseline hb $nmbr$ g i $nmbr$ n $nmbr$,C0062408;C0086706
$nmbr$ placebo n $nmbr$,C0032042;C1696465;C1706408
race or ethnicity n,C0034510;C1706779;C3853635;C0015031;C0243103
diastolic bp mm hg,C0428883;C0439475
uacr mgg $nmbr$ gm,C0017480;C3854019
serum creatinine limo $nmbr$ $nmbr$,C0201976;C0600061
egfr ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
triglycerides mmolt $nmbr$ gm,C0017480;C3854019
serum albumin g $nmbr$ $nmbr$,C0036773;C0439267;C0728877
hemoglobin g $nmbr$ $nmbr$,C1319312
calcium mmol $nmbr$ $nmbr$,C0006675;C0439190;C0006726;C2936886;C3540037;C3714611
phosphorus mmol $nmbr$ $nmbr$,C0031705;C0439190;C0080014;C3714498
difference $nmbr$,C1705241;C1705242
p valuec,C0369773;C2603361
change $nmbr$,C0392747;C0443172;C1705241;C4319952
hemoglobin gl,C0018229;C1423073;C1427674
for combined hemoglobin groups,C0205195;C1626828
hemoglobin g $nmbr$,C1319312
for baseline hemoglobin $nmbr$ g $nmbr$,C0168634;C1319312;C1442488
hemoglobin g r $nmbr$,C0205090;C0684010;C2603358
uacr mgg $nmbr$,
gmr,C1522544;C1704695
reduction,C0301630;C0392756;C1293152;C4551656
p value $nmbr$,C1709380
gm geometric mean gmr geometric mean ratio over baseline uacr urinary albumimcreatinine ratio reduction $nmbr$ x $nmbr$ ratio of gmr for losartan versus gmr for placebo amean of change with change calculated as difference between time indicated and baseline as measured for each participant difference of changes between treatment groups cp values compare differences from no change,C0456603;C1547037;C0126174;C1522544;C1704695;C0392747;C0443172;C1705241;C4319952;C0444686;C1441506;C0040223;C3541383;C1444656;C0168634;C1442488;C1705242;C0006938;C0042295;C4050020;C1707455
bsl hb gl $nmbr$,C0018229;C1423073;C1427674
rrr $nmbr$ cl,C0596019
p valuea,C0369773;C2603361
interaction $nmbr$,C1704675
k rate,C0871208;C1521828
cox bsl onlyc,C1565830;C1549954
cox bsl yr $nmbr$ hbd,C1549954;C0439234
esrd or death,C0022661;C0035078;C2316810;C0011065;C1306577;C4082313;C4552775
bsl baseline cl confidence interval esrd end stage renal disease hb hemoglobin k rate of events per $nmbr$ patient years of follow up rrr relative risk reduction yr year ^treatment effect of losartan versus placebo interaction test between treatment group and hemoglobin group $nmbr$ g i $nmbr$ cmultivariate cox model with baseline log urinary albumimcreatinine ratio serum albumin serum creatinine and hemoglobin as covariates dmultivariate cox model with baseline log urinary albumimcreatinine ratio serum albumin serum creatinine and hemoglobin and change in hemoglobin at year $nmbr$ as covariates,C0026538;C1554093;C3242279;C3242455;C0237455;C1565830;C3161035;C3274659;C3714583;C3853906;C0019046;C0201976;C0600061;C0392747;C0443172;C1705241;C4319952;C0439234;C0439508
hemoglobin category,C0683312;C3889287
no anemia bsl hb $nmbr$ g i $nmbr$ yr $nmbr$ $nmbr$ g i $nmbr$,C1319635
improving anemia bsl hb $nmbr$ g i $nmbr$ yr $nmbr$ $nmbr$ g i $nmbr$,C1272745;C1319635
new anemia bsl hb $nmbr$ g i $nmbr$ yr $nmbr$ $nmbr$ g i $nmbr$,C1319635
persistent anemia bsl hb $nmbr$ g i $nmbr$ yr $nmbr$ $nmbr$ g i $nmbr$,C1319635
missing hb at yr $nmbr$,C0019046;C0439234
bsl baseline cl confidence interval esrd end stage renal disease hb hemoglobin hr hazard ratio k rate of events per $nmbr$ patient years of follow up yr year multivariate cox model with hemoglobin category and baseline urinary albumimcreatinine ratio serum albumin serum creatinine and hemoglobin as covariates,C0026538;C0030705;C0439234;C0683312;C3889287;C0201976;C0600061;C0019046
men total n $nmbr$,C0025266;C0439175;C0439810
diet n $nmbr$,C0012155;C0012159;C1519433;C2983588;C3668949
diet pravastatin n $nmbr$,C0012155;C0012159;C1519433;C2983588;C3668949
total n $nmbr$,C0439175;C0439810
mean sd y,C0444504;C2347634;C2348143
sbp mean sd mm hg,C0085805;C0439475
dbp mean sd mm hg,C0444504;C0439475;C2347634;C2348143
smoker n,C0337664
drinking n,C0001948;C0684271;C0369718;C0441922
lipid values mmol l,C0023779;C1532563
tc mean sd,C0039411;C2699239;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
ldl c mean sd,C0444504;C2699239;C2347634;C2348143
hdl c mean sd,C0444504;C2699239;C2347634;C2348143
tg median interquartile range,C0337445;C1711350
lp a mean sd,C0065058;C2699239;C1439335;C4553379
incidence rate no $nmbr$ person years,C1708485;C0027361;C0439234;C2347489
heterogeneity p value,C0019409;C1709380;C0242960
chd men,C0280604;C0025266;C3542407
diet $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0012155;C0012159;C1519433;C2983588;C3668949
diet pravastatin $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0012155;C0085542;C0012159;C1519433;C2983588;C3668949
chd cerebrovascular disease men $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0007820;C0025266
hazard ratiof $nmbr$ ci,C0008107;C3259781
diet,C0012155;C0012159;C1519433;C2983588;C3668949
diet pravastatin,C0012155;C0085542;C0012159;C1519433;C2983588;C3668949
chd cerebral infarction,C0280604;C0007785;C3542407
$nmbr$ years $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0439234
id genotype,C0009450;C0017431;C0600091;C1441613
ii n $nmbr$,C1710602;C4082587
id n $nmbr$,C0009450;C0600091;C1441613
dd n $nmbr$,C3538867;C3814791
race or ethnic group no,C0034510;C1706779;C3853635;C0015031;C1879937
body mass index $nmbr$,C0005893;C0578022;C1305855
known duration of diabetes yr,C0449238;C2926735
not available,C0686905
use of antihypertensive drugs,C1524063
coronary revascularization procedure,C0877341
lipid disorder,C0154251
amputation,C0002688;C0332840;C1546539
neuropathy,C0442874
laboratory variables,C0022877;C0439828;C3244292;C4283904
urinary albumin creatinine ratio median mg g range,C1514721;C2348147;C3542016
serum creatinine mg dlb,C0752347;C3890365
glomerular filtration rate $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0017654;C0439445;C1561549
serum cholesterol mg dld,C1414063;C2826331
serum triglycerides mg dle,C0024138;C3542918
hemoglobin g dlf,C1319312
glycosylated hemoglobin,C0017853
serum albumin g dl,C0036773;C0439267;C0728877
mean sd values are presented for all variables except medical history race or ethnic group and sex n and urinary albumin creatinine ratio median range abody mass index is the weight in kilograms divided by the square of the height in meters bto convert values to micromoles per liter multiply by $nmbr$ $nmbr$ estimated using the modified equation from the modification of diet in renal disease study dto convert values to millimoles per liter multiply by $nmbr$ $nmbr$ eto convert values to millimoles per liter multiply by $nmbr$ $nmbr$ ^to convert values to millimoles per liter multiply by $nmbr$ $nmbr$,C0444504;C0042295;C2347634;C2348143;C0449450;C0439828;C0034510;C1706779;C3853635;C0015031;C1879937;C0009253;C0036864;C0079399;C0804628;C1314687;C1522384;C0600653;C0918012;C1552854;C1637833;C2986546;C0005910;C0043100;C1305866;C1705104;C0332849;C0205120;C1552595;C0439194;C0475211;C0750572;C1524063;C0552449;C0086153;C3671772;C0022658;C1532563;C1719797;C2911648;C0439190
losartan n n,C0126174
placebo n n,C0032042;C1696465;C1706408
adjusted $nmbr$ risk reduction losartan vs placebo $nmbr$ cl,C1137094;C0126174;C0032042;C0596019;C1696465;C1706408
f,C0016327
composite endpoint of doubling of serum creatinine esrd,C2349179;C2826544
or death,C0011065;C1306577;C4082313;C4552775
id,C0009450;C0600091;C1441613
dd,C3538867;C3814791
doubling of serum creatinine,C0205173;C1705764
or esrd,C0022661;C0035078;C2316810
ci confidence interval esrd end stage renal disease n n number of patients who had an event total number of patients aadjusted with terms including treatment losartan or placebo geographic region genotype and the treatment genotype interaction bp value for treatment genotype interaction i e comparison of the losartan treatment effect between the $nmbr$ genotype groups,C0022661;C2360800;C0233324;C1515273;C1705313;C2826302;C0017446;C0017431;C0037623;C1415692;C1708288;C4318478;C1707455;C1518681;C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429
rosiglitazone,C0289313
metformin,C0025598
glyburide,C0017628
time since diagnosis of diabetes,C0040223;C3541383
$nmbr$ $nmbr$ years,C0439234
a $nmbr$ c,
fasting insulin pmol l,C0015663;C0021641;C0439284;C1533581;C1579433;C3714501
estrogen containing hormones,C0014939;C0019932;C2936882;C4542544
calcium supplements,C3540037
bisphosphonates,C0012544;C3541401
glucocorticoids,C0017710;C3540777;C3540778
thiazide diuretics,C0012802
loop diuretics,C0354100
py $nmbr$ $nmbr$,C0030428;C3538810
py,C0030428;C3538810
number of patients with fractures,C2360800;C0016658
fractures site not specified,C0449676;C1518422;C0205369
lower limb fractures,C0596838
hip fracture,C0019557;C0149531;C4552776
others,C1955473;C3539125
ankle fracture,C0159877;C4552974
femur fracture,C0015802
fibula fracture,C0149699
foot fracture,C0272774
lower limb fracture,C0596838
patella fracture,C0159849
tibia fracture,C0040185
skull and facial bone fractures,C0037303;C2951888;C0743751
spinal fractures,C0080179;C0518450
thoracic cage fractures,C0222762;C0016658
upper limb fractures,C0178316
clavicle fracture,C0159658
hand fracture,C0435632
humerus fracture,C0020162
radius fracture,C0034628
upper limb fracture,C0178316
wrist fracture,C0435630;C4553927
py $nmbr$,C0030428;C3538810
pelvic fractures,C0149531
forearm fracture,C1305215
black participants,C0005680;C0679646;C0027567;C0085756;C0439541
nonblack participants,C0679646
i with mets n $nmbr$,C0021966;C0221138
i without mets n $nmbr$,C0021966;C0221138
$nmbr$ $nmbr$ $nmbr$ b,
years of education mean sd,C0439234;C0013621;C0013622;C0013658;C0039401
$nmbr$ $nmbr$ $nmbr$ $nmbr$ c,
currentd,
antihypertensive treatment,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
treated,C1522326
untreated,C0332155
history of mi or stroke d,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0038454;C4554100
history of coronary revascularization d,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
$nmbr$ $nmbr$ $nmbr$ c,
other atherosclerotic cvdd e,C0333482;C1859330
st t wave abnormality d,C0036056;C1839341;C3272372
lvh by ecg or echocardiographyd,C0232306
glycemic status f,C0449438;C0016327
impaired fasting glucose,C1272092
normoglycemic,C0580545
history of chd at baseline d g,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0168634;C1442488;C0439267
lipid trial participants,C1997894;C2242969
systolic mean sd mm hg h,C0456680
diastolic mean sd mm hg,C0012000;C0439475
serum potassium level mean sd meq l,C0302353;C0439375;C0543465
fasting serum glucose level mean sd mg dl,C0202045;C0439269
serum creatinine level mean sd mg dl,C0600061;C0439269
tc level mean sd mg dl,C0039411;C0439269;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
ldl c level mean sd mg dl,C0441889;C0439269;C0456079;C1547707;C2946261
hdl c level mean sd mg dl,C0441889;C0439269;C0456079;C1547707;C2946261
hdl c level $nmbr$ mg dld,C1414063;C2826331
fasting triglyceride level mean sd mg dl,C0015663;C0428475;C0439269
cv mortality,C0026565;C0026566
combined chd,C0280604;C3542407
non black participants,C0005680;C0679646;C0027567;C0085756;C0439541
i $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0021966;C0221138
ii $nmbr$ $nmbr$ $nmbr$ $nmbr$,C1710602;C4082587
doxazosin,C0114873
figure $nmbr$ comparisons of doxazosin mesylate with chlorthalidone data are expressed as hazard ratios $nmbr$ confidence intervals with event rates [ses] and numbers of events given for each drug by race and metabolic cardiometabolic syndrome mets status chd indicates coronary heart disease cv cardiovascular cvd cv disease and esrd end stage renal disease,C1707455;C0077770;C1511726;C3245479;C3714741;C2985465;C0009667;C0871208;C1521828;C4330837;C0013227;C1254351;C0034510;C1706779;C3853635;C0280604;C3542407;C0010054;C0010068;C1956346;C0022661
p women vs men,C0369773;C0043210;C2603361;C0025266
overaii n $nmbr$,
atenoioi n $nmbr$,
biack,
systoiic biood pressure mm hg,C0033095;C0439475;C0460139;C1306345;C4284008
diastoiic biood pressure mm hg,C0033095;C0439475;C0460139;C1306345;C4284008
body mass index kg m^,C0022718;C0439209;C4054209
corneii product mm ms,C2349943;C3539704;C3713294
sokoiow lyon voitage mv,C1454484;C1705503;C4281602
current smokers n medicai history n,C3173209;C3241966
isoiated systoiic hypertension,C0020538;C1963138
cerebrovascuiar disease,C0012634
peripherai arteriai disease,C0012634
adjusted hr losartan vs atenolol,C0456081;C0126174;C0004147
women n $nmbr$ events,C0441471;C3541888
women n $nmbr$,C0043210
events,C0441471;C3541888
ratet n,
primary composite^,C0205199;C1547335
cardiovascuiar mortaiity,
myocardiai infarction,C0021308
totai mortaiity,
hospitaiization for angina,C0002962
hospitaiization for heart faiiure,C0018787
vildagliptin $nmbr$ mg daily glimepiride,C0024671;C0061323;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
viidagliptin $nmbr$ mg daily glimepiride,C0024671;C0061323;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
placebo glimepiride,C0032042;C0061323;C1696465;C1706408
age years mean s d,C1510829;C0444504;C2347634;C2348143
hispanic latino,C0086409;C0086528
bmi kg m^ mean s d,C0022718;C0439209;C4054209;C0444504;C2347634;C2348143
hbaic mean s d,C0444504;C2347634;C2348143
hbaic group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
fpg mmol l mean s d,C0439433
disease duration years mean s d,C0872146;C0439234
duration of sulphonylurea use months mean s d,C1881378;C2826775
fig $nmbr$ a mean s e change from baseline to end point in haemoglobin a $nmbr$ c hba $nmbr$ c in patients aged,C0349966;C1337208;C0444504;C2347634;C2348143;C0392747;C0443172;C1705241;C4319952;C2349179;C2826544;C0001779;C0001792;C1999167
amlodipine valsartan $nmbr$ $nmbr$ mg n $nmbr$,C1962523;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
amlodipine valsartan $nmbr$ $nmbr$ mg n $nmbr$ i,C0021966;C0221138
total study population n $nmbr$,C3258257
age ya,C0001779
age category,C0683312;C3889287
mssbp mm hga,C4330985;C4554674
msdbp mm hga,C4330985;C4554674
sitting pulse bpma,C0277814;C0232117;C0391850;C1947910;C2584297;C4050224
prior treatment,C1514463
arb,C3888198
acei,
ccb,C0006684
severity of hypertensionb,C0439793;C0522510
more severe,C0205082;C4050465;C4050466
less severe,C0205082;C4050465;C4050466
diabetic status,C0241863;C0449438
nondiabetic,
abbreviations acei angiotensin converting enzyme inhibitor arb angiotensin receptor blocker bpm beats per minute ccb calcium channel blocker msdbp mean sitting diastolic blood pressure mssbp mean sitting systolic blood pressure values are no unless otherwise indicated amean sd bmore severe $nmbr$ and $nmbr$ and $nmbr$ and $nmbr$ and,C0034787;C1622222;C1319893;C0042295;C1444656;C2699239;C0205082;C4050465;C4050466
amlodipine valsartan $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
amlodipine wlsartan i $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
amlodipine valsartan $nmbr$ $nmbr$ vs $nmbr$ $nmbr$ mg,C1962523;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mssbp msdbp,
change from,C0392747;C0443172;C1705241;C4319952
week and,C0332174;C0439230
baseline mm hg,C0168634;C0439475;C1442488
difference in change,C1705241;C1705242
disease severity,C0521117
sem,
$nmbr$ ci p value,C0008107;C1709380;C3259781
endpoint week $nmbr$,C0332174;C0439230
intent to treatb,C0162425;C1283828;C1550453
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
less severe $nmbr$,C0205082;C4050465;C4050466
more severe^,C0205082;C4050465;C4050466
mean sd age years,C0444504;C1510829;C2347634;C2348143
mean sd bmi kg m $nmbr$,C0022718;C0439209;C4054209
current $nmbr$ cigs day,C0332173;C0439228;C0439505
exercise,C0015259;C1522704
$nmbr$ week,C0332174;C0439230
$nmbr$ $nmbr$ week,C0332174;C0439230
$nmbr$ $nmbr$ month,C0332177;C0439231
postmenopausal hormone use,C0042153;C0457083;C1947944
aspirin group n $nmbr$ $nmbr$ $nmbr$ $nmbr$ person years,C0027361;C0439234;C2347489
placebo group n $nmbr$ $nmbr$ $nmbr$ $nmbr$ person years,C0027361;C0439234;C2347489
newly diagnosed asthma n,C0011900;C0004096;C2984299
stratified analyses,C0002778;C0936012;C1524024
active,C0205177;C3853793;C3888249
mets,C0812270;C1705694;C2939420
non mets,C0812270;C1705694;C2939420
placebo dr $nmbr$,C0013014;C0031831;C1707664;C2348314;C3540849
eze simva $nmbr$ $nmbr$ mg dr $nmbr$,C0013014;C0031831;C1707664;C2348314;C3540849
feno $nmbr$ dn $nmbr$,C1333964;C1707618
eze simva $nmbr$ $nmbr$ mg feno $nmbr$ mg dn $nmbr$,C1333964;C1707618
placebo dn $nmbr$,C1333964;C1707618
eze simva $nmbr$ $nmbr$ mg dn $nmbr$ c $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
feno $nmbr$ mg dn $nmbr$,C1333964;C1707618
waist circumference cm mean sd,C0455829;C2699239
diagnosis of diabetes n,C0011900;C1704338;C1704656
tg mg dl,C0337445;C0439269
non hdl c mg dl,C1518422;C0439269
apo b mg dl,C0003593;C0439269;C3252643
tc mg dl,C0039411;C0439269;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
apo a i mg dl,C0085201;C0439269;C1677784
data are expressed as median sd except,C1511726;C3245479;C3714741;C0549183;C0876920;C2347635;C2348144;C2939193
data are expr,C1511726;C3245479;C3714741
ssed as ls means,C0023668;C1704970
by treatment arm,C1522541
icd,C0021122
syncope,C0039070;C3541349;C4554644
by cause of death,C0007465;C4050444
sudden death,C0011071;C1964022;C4554103
all patients $nmbr$ $nmbr$,C0030705
verapamil sr $nmbr$ $nmbr$,C1527129
atenolol $nmbr$ $nmbr$,C0004147
sbp mean sd mmhg,C0085805;C0439475
dbp mean sd mmhg,C0444504;C0439475;C2347634;C2348143
heart rate mean sd b p m,C0018810;C0444504;C2347634;C2348143
age mean sd year,C0439234;C0439508
arrhythmias,C0003811
heart failure class i iii,C0441887;C2698969
renal impairment,C1565489
smoking ever,C0037369;C0453996;C1881674
sbp systolic blood pressure sd standard deviation dbp diastolic blood pressure b p m beats per minute mi myocardial infarction tia transient ischaemic attack,C1305849;C0439385;C0007787
verapamil sr strategy,C1527129;C0679199
atenolol strategy,C0004147;C0679199
adverse outcome,C1274040
non fatal mi,C1302234;C3810814;C1705232
non fatal stroke,C0038454;C4554100
no prior mi,C0332152;C3810814;C2826257
denosumab n $nmbr$,C1690432
all n $nmbr$,C0369718;C0441922
$nmbr$ yr since menopause,C0439234;C0025320;C0567312
years since menopause,C0439234;C0025320;C0567312
bodymass index kg m $nmbr$,C0022718;C0439209;C4054209
lumbar spine bmd t score,C0449820;C4050231
serum ctx ng ml,C0010377;C0439275;C0631180;C3539598
serum p $nmbr$ np ^g liter,C0065827;C0475211;C1706141;C3887659
serum trap $nmbr$ b u liter,C0184047;C0475211;C1336677;C1566918;C1706005;C1710330;C3887583
site,C0205145;C1515974;C2825164
stratum,
difference from baselinea,C1705241;C1705242
difference from placeboa,C1705241;C1705242
ls mean,C0444504;C2347634;C2348143
ci b,C0008107;C3259781
p value c,C1709380
denosumab,C1690432
trochanter,C0162370
one third radius,C0034627;C1306504
total body without head,C0229960;C0018670;C1706305
volumetric bmd by qct,C0445383;C0412669
aggressive n $nmbr$,C0001807;C0580822
standard n $nmbr$,C1442989;C2828392
gender women n,C0079399;C0043210;C1522384
body mass index bmi kg m $nmbr$,C0022718;C0439209;C4054209
waist cm,C0230097
ale,C0678386;C2632076
diabetes therapy,C3274787;C3539002
lifestyle,C0023676
oral hypoglycemics,C0359086
insulin plus oral,C0021641;C1533581;C1579433;C3714501
egfr,C1739039;C3811844;C3812682
aspirin use $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
carotid,C0741968
imt mm,C4330985;C4554674
arterial area mm $nmbr$,C4330985;C4554674
plaque score $nmbr$ $nmbr$,C0429153
sk $nmbr$,
plaque n,C0011389;C0241148;C0332461;C0333463;C4316797
cardiac,C0018787;C1522601
lv mass,C0455825
lv mass index g m $nmbr$ $nmbr$,C0455825;C0439267
lv ejection fraction,C0489482;C2700378
abbreviations egfr estimated glomerular filtration rate imt intimal medial thickness lv left ventricular two sample comparison t tests were calculated based on log transformed variables geometric mean with $nmbr$ confidence interval in parenthesis,C3811844;C0871472;C1527178;C1705938;C0009667
imt $nmbr$,C0334121;C1704614;C4318736
aggressive $nmbr$,C0001807;C0580822
standard $nmbr$,C1442989;C2828392
group dif $nmbr$,C0812246;C1710304
p val $nmbr$,C0042285;C0523975
lvmi $nmbr$,
inter,C0205103;C1548610
non hdl mg dl,C1518422;C0439269
$nmbr$ l $nmbr$,C0439394;C1706495;C3642217
current smoker yes,C1549445;C1705108;C1710701
primary prevention subgroup,C1079230;C1515021
secondary prevention subgroup,C1079230;C1515021
no epa group n $nmbr$,C0441848
epa group n $nmbr$,C0441848
cerebral thrombosis,C0079102;C0151945;C0795687
cerebral embolism,C0007780
tia,C0007787;C0917805;C1054154
cerebral hemorrhage,C2937358
subarachnoid hemorrhage,C0038525
triglyceride mmol l,C0041004;C1532563
aa mol,C0027960;C0324740;C0439189;C1456781;C1824986;C3665593
epa mol,C0027960;C0324740;C0439189;C1456781;C1824986;C3665593
epa aa ratio,C0456603;C1547037
sbp indicates systolic blood pressure dbp diastolic blood pressure aa arachidonic acid epa eicosapentaenoic acid values for age bmi total cholesterol ldl cholesterol hdl cholesterol sbp dbp aa epa and epa aa ratio represent the mean values represent the median interquartile range p values are for the differences between the no epa and epa groups,C0085805;C1305849;C0042295;C2699193;C0456603;C1547037;C1882932;C0444504;C2347634;C2348143;C1711350;C1709380;C1705241;C1705242;C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429
standard deviation triglyceride,C0871420;C0041004
no epa group no of events,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C0441471;C3541888
epa group no of events,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C0441471;C3541888
primary and secondary prevention subgroups adjusted for age gender hypertension diabetes mellitus and smoking hr indicates hazard ratio $nmbr$ cl $nmbr$ confidence interval tia transient ischemic attack,C0205225;C0439612;C0439631;C0679699;C1079230;C4300468;C0037369;C0453996;C1881674;C0009667;C0007787
metoprolol group n $nmbr$,C0025859;C0441848
preoperative heart rate beats per minute,C0439385
preoperative blood pressure mm hg patients fulfilling eligibility criteria,C0005823;C0030705;C1271104;C1272641;C1550543;C1512693
stroke thought due to atherothrombotic disease,C0039869;C4319827
hospitalisation for chf within $nmbr$ years of randomisation,C0019993;C0018802;C0439234;C0034656
undergoing major vascular surgery,C0679637
three of seven risk factors,C0035648;C1553898
intrathoracic or intraperitoneal surgery,C0595836;C0038894;C0038895;C0543467;C1274039
any history of congestive heart failure,C0455531
diabetes and currently on an oral hypoglycaemic agent orinsulin,C0011847;C0011849;C0521116;C0359086
preoperative serum creatinine $nmbr$ pmol l,C0201976;C0439284;C0600061
history of a transient ischaemic attack,C0455536
emergent urgent surgery,C0750573;C2188405
other cardiovascular risk factors,C0850624
pre operative cardiac medications,C2347660
low molecular weight heparin or intravenous unfractionated heparin,C0019139;C3536766;C0354566
surgery,C0038894;C0038895;C0543467;C1274039
vascular,C0005847;C1558950;C1801960
intraperitoneal,C0442120
orthopaedic,C0029355
anaesthesia analgesia,C0002905
general,C0205246;C3812897;C3891294;C4521767
spinal,C0521329
lumbar epidural,C0581283
general andthoracic epidural,C0228134;C0812144
general and lumbar epidural,C0205246;C3812897;C3891294;C4521767;C0581283
regional anaesthesia,C0002911
data are mean sd or n ace angiotensin converting enzyme arb angiotensin receptor blocker chf congestive heart failure any use in $nmbr$ h before surgery except for aspirin which only required any use in the $nmbr$ days before surgery,C1511726;C3245479;C3714741;C0444504;C2699239;C2347634;C2348143;C0034787;C0018802;C1622222;C0042153;C0457083;C1947944;C0038894;C0038895;C0543467;C1274039;C1514873
figure $nmbr$ subgroup analyses for the primary outcome,C2986480;C0205225;C0439612;C0439631
valsartan n $nmbr$,C0216784
valsartan hctz n $nmbr$,C0216784;C0020261
age median interquartile range y,C0001779;C1711350
age group no y,C0027362;C2348001
body mass index category no l,C0683312;C3889287;C0439394;C1706495;C3642217
lean,
overweight $nmbr$ to,C0497406
obese $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
weight median interquartile range kg,C0022718;C0439209;C4054209
smoking status no,C1519386
concomitant therapy no,C1707479
hormone therapy,C0279025
oral contraceptives,C0009905
hctz hydrochlorothiazide based on wilcoxon $nmbr$ sample rank sum tests for age and body mass index t tests for systolic and diastolic blood and $nmbr$ tests for categorical variables t data were missing for some patients,C0020261;C1527178;C1705938;C0001779;C0005893;C0871472;C0578022;C1305855;C0005767;C0005768;C0229664;C0022885;C0392366;C1551393;C1705492;C3272743
pressure,C0033095;C0460139;C1306345;C4284008
valsartan n n,C0216784
valsartan hctz n n,C0216784;C0020261
entire evaluable cohort,C0009247;C0599755
current nonsmokers,C0337672;C4554605
hctz hydrochlorothiazide based on a _ $nmbr$ test t data were missing for some patients,C0020261;C1527178;C1705938;C1551393;C1705492;C3272743
valsartan,C0216784
valsartan hctz,C0216784;C0020261
current nonsmoker,C0337672;C0425293;C4554605
diabetes status,C1317301
hctz hydrochlorothiazide data were missing for some patients,C1511726;C3245479;C3714741;C1551393;C1705492;C3272743
characteristic and treatment,C1521970;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
primary pci n $nmbr$,C0205225;C0439612;C0439631
abciximab facilitated pci n $nmbr$,C0288672;C4049621
combination facilitated pci n $nmbr$,C0205195;C1947911;C3811910
family history of cad diagnosed at,C0241889;C1504769;C2239547;C3813548;C4284121;C0011900
past or current,C0521116;C1705970
patients treated with insulin,C0030705;C0332293;C0021641;C1533581;C1579433;C3714501
previous mi no,C0205156;C3810814;C1552607
previous chf no,C0205156;C0018802;C1552607
hypertension no hypercholesterolemia no,C0020538;C1963138;C0020443;C1522133
patients treated,C0030705;C1522326
location of infarction no,C0450429;C1515974;C4284930;C4284931
inferior or posterior,C0542339;C0678975;C0205095
not localized,C1518422;C0392752
interval from symptom onset to qualifying ecg obtained in the er hr,C1272706;C1552654;C1552713;C1514624;C1623258;C1301820;C3810541;C3811131
door to balloon time hr,C4296144
peak procedural act sec,C0079613;C0565930;C1704930;C1869853;C3890007;C4048375
ace inhibitors through hospital discharge or day $nmbr$,C0003015;C0586003;C0332173;C0439228;C0439505
beta blockers through hospital discharge or day $nmbr$,C0001645;C0586003;C0332173;C0439228;C0439505
primary pci no,C0205225;C0439612;C0439631
combination facilitated pci,C0205195;C4049621;C1947911;C3811910
hazard ratio $nmbr$ confidence interval,C2985465;C0009667
baseline killip class,C0168634;C1881332;C1442488
history of diabetes mellitus,C0455488
no or unknown,C0439673;C3541433;C4050014
not anterior,C1518422;C0205094
geographic location,C0017446
rest of the world,C0035253;C1622890
hub,C0063034;C1414372;C1708389
spoke,
time from symptom onset to randomization,C0449244;C0034656
$nmbr$ hr,
time from qualifying ecg to balloon inflation,C0040223;C3541383;C1514624;C1623258;C0021398;C1318493
slowest third,C0439834;C0205437
middle third,C0442050
fastest third,C0015663;C0205437;C0456962;C2985769
time from symptom onset to balloon inflation,C0449244;C0021398;C1318493
index pci performed,C0600653;C4049621;C0918012;C1552854;C1637833;C2986546;C0884358
pci delay due to low risk,C0205421;C0678226
enrollment in lmwh substudy,C1516879;C1696073;C3888021
high risk,C0332167;C3272283;C4050568;C4319571
sal n $nmbr$ $nmbr$,C0036140;C0037494;C0206136
fp n $nmbr$ $nmbr$,C0016704;C1419068;C1419906;C3541238;C3541412
sfc n $nmbr$ $nmbr$,C4521536
mean age sd yr,C0001779;C0439234
mean body mass index sd kg m $nmbr$,C0022718;C0439209;C4054209
baseline post bronchodilator fev $nmbr$ sd ml,C0439526;C1705224;C3887665
predicted post bronchodilator fev sd ml,C0439526;C1705224;C3887665
region n,C0017446;C0205147
asia pacific,C0003980
number of subjects in analysis,C0237753;C0449788;C0002778;C0936012;C1524024
baseline mean fev $nmbr$ sd ml,C0439526;C1705224;C3887665
adjusted rate of fev $nmbr$ decline se ml yr,C0456081;C0871208;C1521828
effect of covariates on slopes,C1280500;C1518681;C2348382;C0807955
current n $nmbr$ $nmbr$,C0521116;C1705970
former n $nmbr$ $nmbr$,C0205156;C0750523
female n $nmbr$ $nmbr$,C0043210;C0086287;C1705497;C1705498
male n $nmbr$ $nmbr$,C0086582;C1706180;C1706428;C1706429
$nmbr$ n $nmbr$,C0369718;C0441922
$nmbr$ $nmbr$ n $nmbr$ $nmbr$,C0369718;C0441922
predicted fev $nmbr$,C0681842;C3714541;C1882327
$nmbr$ n $nmbr$ $nmbr$,C0369718;C0441922
united states n $nmbr$ $nmbr$,C0041703
asia pacific n $nmbr$,C0003980
eastern europe n $nmbr$ $nmbr$,C0015177
western europe n $nmbr$ $nmbr$,C0043129
other n $nmbr$,C0369718;C0441922
ethnic origin,C0015031
white n $nmbr$ $nmbr$,C0007457;C0043157;C0220938
black n $nmbr$,C0005680;C0027567;C0085756;C0439541
asian n $nmbr$,C0078988
american hispanic n $nmbr$,C0596070;C0086409
$nmbr$ to $nmbr$ n $nmbr$ $nmbr$,C0369718;C0441922
exacerbations in the year before study,C4086268;C0439234;C0439508;C0557651;C2603343
baseline sgrq total score,C0168634;C2964552;C1442488
with dm n proactive intervention n $nmbr$ a,C0011816;C0184661;C0886296;C1273869;C3250443
without dm n $nmbr$ i $nmbr$,C0021966;C0221138
usual care n $nmbr$ a,C3538928;C1947933
proactive intervention n $nmbr$ a,C0184661;C0886296;C1273869
usual care n $nmbr$ la,C0023031;C0023749;C0230347;C2346906;C4553351
sbp mm hg mean sdc,C1419891;C3273112
i $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0021966;C0221138
dbp mm hg mean sdc,C1419891;C3273112
heart rate beats min mean sd,C0425583;C2699239
tc mg dl mean sd,C0439269;C2699239
ldl c mg dl mean sd,C0439269;C2699239
hdl c mg dl mean sd,C0439269;C2699239
tg mg dl mean sd,C0439269;C2699239
$nmbr$ year framingham chd risk,C0439234;C1282512;C0439508
$nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
treated patients with baseline and $nmbr$ post baseline ef cacy measurement bp value for treatment group comparison proactive intervention vs usual care was calculated based on a $nmbr$ sample t test for continuous variables and chi square test for categorical variables cbp values were measured at baseline week $nmbr$ whereas information on all of the other variables listed was collected during screening abbreviations bmi body mass index bp blood pressure chd coronary heart disease crucial cluster randomized usual care vs caduet investigation assessing long term risk dbp diastolic blood pressure dm diabetes mellitus hdl c high density lipoprotein cholesterol ldl c low density lipoprotein cholesterol sd standard deviation sbp systolic blood pressure tc total cholesterol tg triglyceride,C0332293;C0030705;C0037623;C1415692;C1708288;C4318478;C3538928;C1947933;C1527178;C1705938;C0549178;C0439828;C0008041;C0042295;C0444706;C3541902;C1533716;C0745732;C3272378;C1516695;C1516698;C0220825;C1261322;C1552578;C1516048;C0062152
pro active intervention,C0184661;C0886296;C1273869
usual care,C3538928;C1947933
odds ratio,C0028873
value,C1522609
proportion,C1709707
with dm,C0011816;C3250443
bp goal attainment,C0037623;C0680230;C1415692;C1708288;C4318478
or $nmbr$ $nmbr$ $nmbr$ cl $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0596019
ldl c goal attainment,C0680230
dual bp ldl c goal attainment,C0037623;C0680230;C1415692;C1708288;C4318478
without dm,C0011816;C3250443
ap $nmbr$ $nmbr$ bp $nmbr$ $nmbr$ cp $nmbr$ $nmbr$ the study speci c bp targets were sbp $nmbr$ mm hg and dbp $nmbr$ mm hg or sbp $nmbr$ mm hg and dbp $nmbr$ mm hg in those with dm the ldl c target was $nmbr$ mg dl or $nmbr$ mg dl depending on risk factor status at baseline in accordance with ncep atp iii guidelines odds ratio and p value calculated based on generalized linear mixed model with generalized estimating equations method that includes compound symmetry covariance matrix for subjects from the same site an interaction between treatment effect and dm status was observed for bp goal attainment p $nmbr$ $nmbr$ and dual bp ldl c goal attainment p $nmbr$ $nmbr$ among patients with or without dm calculated based on a mixed effects linear model not adjusted for differences in baseline values abbreviations bp blood pressure dbp diastolic blood pressure dm diabetes mellitus ldl c low density lipoprotein cholesterol ncep atp iii national cholesterol education program adult treatment panel iii or odds ratio sbp systolic blood pressure,C0006938;C4050020;C1521840;C2986546;C0085805;C0439475;C0536221;C3813197;C4281799;C0011816;C3250443;C0439269;C0035648;C0449438;C0168634;C1442488;C1527178;C1705938;C0025663;C0449851;C0871511;C0332257;C1552866;C2700399;C1704640;C1706515;C4050026;C4319583;C4553629;C0205145;C1515974;C2825164;C1704675;C1518681;C1441672;C0680230;C0030705;C0444686;C1441506;C0205430;C0023732;C3160715;C1518422;C0456081;C0005810;C0005844;C0600103;C0488055;C0871470;C1306620
end of follow up,C0444930;C2746065
intensive control,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
standard control,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
age when diabetes first diagnosed yr,C0001779;C0011847;C0439234;C0011849
duration of diabetes yr,C0449238;C2926735
australia and new zealand,C0004340;C0027978;C0324547
asia,C0003980
history of major macrovascular disease no,C0683519;C0730226;C0850708;C0944983
history of major microvascular disease no,C0683519;C0730226;C0850708;C0944983
macroalbuminuriaf,
microvascular eye diseased,C0015392;C0700042
history of microalbuminuria no,C3532606
blood glucose control,C3267174
glycated hemoglobin nonstandardized level,C0202054
glycated hemoglobin standardized level,C0202054
fasting blood glucose mmol liter,C0428568;C0475211;C1261430
serum cholesterol mmol liter,C0587184;C0475211
serum triglycerides mmol liter,C0542495;C0475211
serum triglycerides pmol liter,C0542495;C0475211
serum creatinine pmol liter,C0201976;C0475211;C0600061
current smoking no,C0037369;C0453996;C1881674
glucose lowering drug,C0017725;C0441994;C2003888;C0013227;C1254351
gliclazide modified release no ^,C0017631;C1709058;C4544813
other sulfonylurea no,C0038766;C3536898
metformin no,C0025598
thiazolidinedione no,C0289779;C1257987;C3537039
acarbose no,C0050393
glinide no,C2266929
any oral hypoglycemic drug no,C0359086
insulin no,C0021641;C1533581;C1579433;C3714501
none no,
other drugs,C0013227;C3687832
aspirin no,C0004057
other antiplatelet agent no,C0085826
statins no,C0360714
other lipid modifying drug no,C0023779;C0392747;C0013227;C1254351
any blood pressure lowering drug no,C0003364
mean glycated hemoglobin reduction during characteristic follow up $nmbr$ ci percent,C0162119
intensive control n $nmbr$ no of patients percent,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389;C0030705;C0439165
standard control n $nmbr$ no of patients percent,C1442989;C0243148;C1550141;C1882979;C2587213;C3274648;C4553389;C2828392;C0030705;C0439165
relative risk reduction $nmbr$ cl percent,C0242492;C0439165
blood glucose,C0005802
treatment with any blood pressure,C0596197
lowering drugs,C0441994;C2003888;C0013227;C3687832
treatment with antiplatelet drugs,C3469597
intensive therapy n $nmbr$,C0039798;C0087111;C1363945
standard therapy n $nmbr$,C2936643
median duration of diabetes yr,C0449238;C2926735
previous cardiovascular event,C0205156;C1320716;C1552607
race or ethnic group f,C0034510;C1706779;C3853635;C0441840
education,C0013621;C0013622;C0013658;C0039401
less than high school,C0599395;C0683862;C0870649
high school graduate,C0870649;C1549971
some college,C0557806
college degree or higher,C0441889;C0449286;C0542560;C2348088;C0205250
cigarette smoking status,C1519386
any sulfonylurea,C0038766;C3536898
any thiazolidinedione,C0289779;C1257987;C3537039
any antihypertensive agent,C0003364
any thiazide diuretic,C0012802;C3536861
fasting serum glucose mg dl,C0202041;C0439269;C3534430
median triglyceride mg dl,C0041004;C0439269
potassium mg dl,C0032821;C0439269;C0202194;C0304475;C0597277;C3714637
oxypurinol n $nmbr$,C0030086
age yrs mean sd,C0001779;C2699239
nyha functional class iii,C1882086;C0205245;C0542341;C2700217
lvef mean sd,C0428772;C2699239;C0488728
$nmbr$ mwt m,
carvedilol,C0054836
spironolactone,C0037982
idiopathic,C0332240
hypertensive,C0857121
hospitalized,C0701159
er visit,C0545082;C1512346;C2826704
new hf medication,C0013227;C3244316;C4284232
on maximum tolerated medications median $nmbr$ th to $nmbr$ th quartile sua mg dl,C0013227;C0439269;C0802604;C2598133;C4284232
sua,
mean $nmbr$ th to $nmbr$ thquartile bnp pg ml,C0039725;C0039738;C1420718;C4282123;C4285344
v alsartan hctz n,C0020261
valsartan n,C0216784
mean age years sd,C1510829;C2699239
msdbp mmhg sd,C0439475;C2699239
mssbp mmhg sd,C0439475;C2699239
mean weight kg sd,C0005910;C2699239;C0043100;C1305866;C1705104
mean bmi kg m $nmbr$ sd,C0022718;C0439209;C4054209;C2699239
serum creatinine mean sd pmol l,C0201976;C0439284;C0600061
bmi body mass index hctz hydrochlorothiazide msdbp mean sitting diastolic blood pressure mssbp mean sitting systolic blood pressure sd standard deviation,C1828170
arm,C0446516;C3715044;C4553528
risk,C0035647;C4552904
severity,C0439793;C0522510
mssbp,
mssbp $nmbr$ mmhg,C0439475
j $nmbr$ $nmbr$,
sildenafil n $nmbr$,C0529793
mean sd age y mean bmi category,C0683312;C3889287
missing ed duration y,C1551393;C0449238;C2926735;C1705492;C3272743
range ed etiology n,C0015127;C1314792;C1524003
mixed,C0205430;C3160715
organic,C0747055
psychogenic,C0458006
mean iief ef score mean iief domain score by bmi,C3533236;C0578022
ef domain,C1880389;C1883221;C3541951
os domain,C1880389;C1883221;C3541951
is domain luts severity,C0439793;C0522510
moderate,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
mean total ipss mean ipss by bmi,C0439175;C0439810
storage subscore,C0337174;C1698986;C1753314
voiding subscore,C0042034;C4067975
mean qmax score by bmi,C3533236;C0578022
sd standard deviation bmi body mass index ed erectile,C1305855;C3538926;C0030847
dysfunction ef erectile function iief i,C0021966;C0221138
nternational index of,C0600653;C0918012;C1552854;C1637833;C2986546
erectile function ipss,C1019118;C1998280;C2827405;C3811063
international prostate symptom score,C1998280
luts lower urinary tract symptoms is,C0574785
intercourse satisfac,C0009253
tion os overall satisfaction qmax maximal urinary flow rate,C4086680;C0429784
famotidine $nmbr$ mg n $nmbr$,C0015620;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
sex male female n,C0086287
weight kg bmi kg m $nmbr$,C0005910;C1319635;C0043100;C1305866;C1705104
smoking status ongoing n,C1519386;C0549178
smoking status previous n,C1519386;C0205156;C1552607
alcohol consumption yes n,C0001948;C1549445;C1705108;C1710701
caffeine consumption yes n,C0948365;C1549445;C1705108;C1710701
hiatal hernia yes n,C3489393;C1549445;C1705108;C1710701
helicobacter pylori infection n,C0850666
pepsinogen i ii ratio,C0456603;C1547037
days with heartburna days,C0439228
severity of heartburnb,C0439793;C0522510
atenolol strategy n $nmbr$ $nmbr$,C0004147;C0679199
verapamil sr strategy n $nmbr$ $nmbr$,C1527129;C0679199
demographic,C0011298
age mean sd years,C1510829;C0444504;C2347634;C2348143
race ethnicity no,C0015031;C0243103
history of ml,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
chronic stable angina,C0340288
unstableangina,
dyslipidemia $nmbr$,C0242339
stroke ortiab,C0038454;C4554100
renal insufficiency $nmbr$,C0035078;C1565489
diabetes $nmbr$,C0011847;C0011849
obese,C0028754
ever smoker,C3887636;C0337664
medications no,C0013227;C0802604;C2598133;C4284232
aspirin antiplatelet,C0004057
antidiabetic,C0935929
lipid lowering,C0023779;C0441994;C2003888
potassium,C0032821;C0202194;C0304475;C0597277;C3714637
hrt,C0282402
systolic mean sd mm hg,C0039155;C0439475
controlled $nmbr$ no,C2587213;C2911690
bmi body mass index hrt hormone replacement therapy lvh left ventricular hypertrophy nsaids nonsteroidal anti inflammatory drugs pvd peripheral vascular disease tia transient ischemic attack ahistory of and or currently taking lipid lowering or antidiabetic medications bp $nmbr$ $nmbr$ for verapamil sustained release sr vs atenolol chistory of or currently have elevated serum creatinine but less than $nmbr$ mg dl dblood pressure control defined as,C3687361;C0521116;C0023779;C0441994;C2003888;C0037623;C1415692;C1708288;C4318478;C1527129;C1710261;C0004147;C0700225;C0439269;C0033095;C0460139;C1306345;C4284008;C1704788;C3539106
haplotype,C0018591
no copies gly $nmbr$ glu $nmbr$ $nmbr$ c,C1948062;C0068000
verapamil sr,C1527129
incidence,C0021149;C0220856
v total n $nmbr$,C0439175;C0439810
rerapamil sr strategy n $nmbr$,C0753208;C0679199;C1709991;C3813610;C3890900;C3891546
atenolol strategy n $nmbr$,C0004147;C0679199
mean age y sd,C0001779;C2699239
female race ethnicity,C0015031;C0243103
smoking history ever,C1519384;C3887636
dyslipidemia,C0242339
cancer medications,C0013227;C0802604;C2598133;C4284232
baseline sbp mm hg,C0085805;C0439475
baseline dbp mm hg,C0168634;C0439475;C1442488
baseline heart rate beat min,C0702093;C1524029;C3813700
values are expressed as percentages unless otherwise indicated bmi body mass index cabg coronary artery bypass ischemic attack nsaids nonsteroidal anti inflammatory drugs sbp systolic bp dbp diastolic bp history of or currently taking antidiabetic or lipid lowering medications,C0042295;C0439165;C1549488;C1561533;C1553893;C0521116;C0935929;C0023779;C0441994;C2003888;C0013227;C0802604;C2598133;C4284232
graft pci percutaneous coronary intervention tia transient,C0040704;C0205374
verapamil sr n $nmbr$ no,C1527129
atenolol n $nmbr$ no,C0004147
nontatal ml,C0439526;C1705224;C3887665
fatal and nonfatal ml,C1302234;C1705232;C0439526;C1705224;C3887665
cv death,C0011065;C1306577;C4082313;C4552775
tg $nmbr$ hdl $nmbr$ n $nmbr$,C0337445;C3715113
tg $nmbr$ hdl,C0337445;C3715113
smoker a,C0337664
drinker a,C0556338
clinical history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
hypertension $nmbr$,C0020538;C1963138
systolic mmhg,C0039155;C0439475
diastolic mmhg,C0012000;C0439475
lipid profile,C1979963;C2003903
triglyceride mg dl d,C0041004;C0439269
fatty acid composition,C0486616;C1555710
data represent number of patients or mean standard deviation unless otherwise indicated a self reported information bc physician diagnosed diabetes or fasting plasma glucose $nmbr$ mg dl or hemoglobin a $nmbr$ c $nmbr$ $nmbr$ d physician diagnosed hypertension or systolic blood pressure $nmbr$ mmhg or diastolic blood pressure $nmbr$ mmhg median interquartile range ldl low density lipoprotein hdl high density lipoprotein tg triglyceride,C1511726;C3245479;C3714741;C1882932;C2360800;C1828170;C1444656;C0011847;C0011849;C0202042;C0439269;C0455280;C0020538;C1963138;C0488055;C0439475;C0871470;C1306620;C0065191
$nmbr$ $nmbr$ $nmbr$ ci $nmbr$ $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0008107;C3259781
rivastigmine n $nmbr$,C0649350
$nmbr$ $nmbr$ years n,C0439234
$nmbr$ years n,C0439234
overall male female,C0043210;C0086287;C1705497;C1705498
ethnic origin n,C0015031
oriental,C0078988;C0699027
formal education years,C0681344;C0439234
duration of dementia symptoms months,C0436359;C0011265;C0497327
criteria for subcortical vad by mri,C0243161;C0077973;C0024485;C1824234;C3890166
mean sd baseline scores,C3533236;C0168634;C1442488
mhis score,C0449820;C4050231
vadas score,C0449820;C4050231
mmse score,C0449820;C4050231
adcs adl score,C0449820;C4050231
gds score,C0449820;C4050231
npi $nmbr$ score,C0449820;C4050231
younger patients aged $nmbr$ years,C0001779;C0439234;C0001792;C1999167
older patients aged $nmbr$ years,C0001779;C0439234;C0001792;C1999167
rivastigmine,C0649350
supine after $nmbr$ minutes change from baseline,C0038846;C0392747;C0443172;C1705241;C4319952;C0168634;C1442488
notable abnormalities,C0000768;C0000769
high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
standing after $nmbr$ minute change from baseline,C0231472;C0392747;C0443172;C1705241;C4319952;C0168634;C1442488
standing after $nmbr$ minutes change from baseline,C0231472;C0392747;C0443172;C1705241;C4319952;C0168634;C1442488
normal or increased baseline gfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972;C0017654;C0439445;C1424601
mildlydecreased baseline gfr $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0017654;C0439445;C1424601
patients randomly assigned,C0030705;C1516050;C1552601
age at lipid randomization y,C0001779;C0065033
body mass index kg m $nmbr$ baseline systolic blood,C0022718;C0439209;C4054209;C0005767;C0005768;C0229664
pressure mm hg,C0033095;C0439475;C0460139;C1306345;C4284008
baseline diastolic blood,C0005767;C0005768;C0229664
history of coronary heart disease at,C0683519;C0730226;C0850708;C0944983
history of mi or stroke history of coronary,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
other atherosclerotic cvd st depression on,C0007222;C0520887
electrocardiogram,C0013798;C1547122;C1623258
estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$ lipid baseline lipid profile,C0017654;C0439445;C1424601;C1979963;C2003903
fasting triglycerides,C0015663;C0041004
randomly assigned to ace,C1516050;C1552601
inhibitor,C1999216
randomly assigned to calcium channel blocker,C1516050;C1552601
randomly assigned to diuretic,C1516050;C1552601
esrd or $nmbr$ dedine in gfr,C0022661;C0035078;C2316810;C0017654;C1424601
esrd or $nmbr$ decline in gfr,C0022661;C0035078;C2316810;C0017654;C1424601
gfr $nmbr$ $nmbr$,C0017654;C1424601
gfr,C0017654;C1424601
aspirin erdp n $nmbr$ $nmbr$,C0004057
europe israel or australia,C0015176;C0022271;C0004340
latin america or south africa,C0023122;C0037712
united states or canada,C0041703;C0006823
chinese,C0008120;C0152035
south asian,C1519427
other asian,C0078988
white european,C0239307;C1535514
native latin,C0302891
bmi^,C0578022
tobacco use,C0040335;C0543414;C0841002;C3853727
currently,C0521116
previously,
no regular consumption,C0009830;C1947907
$nmbr$ $nmbr$ drinks wk,C0332174;C0439230
$nmbr$ drinks wk,C0332174;C0439230
exercise category,C3669314
sedentary,C0205254
some physical activity,C0015259;C0026606
intense physical activity,C0015259;C0026606
time from qualifying stroke to randomization,C0040223;C3541383;C1514624;C0038454;C4554100
median days,C0549183;C0439228;C0876920;C2347635;C2348144;C2939193
$nmbr$ $nmbr$ days,C0439228
$nmbr$ days,C0439228
toast classification of qualifying stroke,C1710306;C4521230;C1514624;C0038454;C4554100
large artery atherosclerosis,C0003850;C0004153
cardioembolism,
small artery occlusion lacune,C0226001;C0241970
acute stroke of other determined cause,C0751956;C0015127;C1524003
stroke of undetermined cause,C0038454;C0015127;C1524003
score on modified rankin scale,C4049715
baseline nihss score,C0449820;C4050231
previous stroke or tia,C0038454;C4554100;C0007787;C0917805;C1054154
atherosclerotic disease,C0333482;C0012634
ischemic coronary artery disease,C0852149
paod,
deep vein thrombosis,C0149871
aspirin erdp clopidogrel no of patients total no,C0004057;C0070166;C0030705;C0439175;C0439810
prespecified analysis,C0002778;C0936012;C1524024
any recurrent stroke,C2242682
other atherosclerotic event,C0441471;C4019010
stroke risk score,C0449820;C4050231
$nmbr$ $nmbr$ low risk,C3272281;C3538919
$nmbr$ $nmbr$ moderate risk,C0035647;C4552904
$nmbr$ high risk,C0332167;C3272283;C4050568;C4319571
randomization to placebo or telmisartan,C0034656;C0032042;C1696465;C1706408;C0248719
telmisartan,C0248719
statin use,C0042153;C0457083;C1947944
ace inhibitor use,C0042153;C0457083;C1947944
time from onset of qualifying stroke to randomization,C0449244;C1514624;C0038454;C4554100
slo days,C1416602;C0439228;C3539661
small artery occlusion,C0226001;C0264995
undetermined other or cardioembolism,C0205258;C3536725;C4082977
post hoc analysis,C0002778;C0936012;C1524024
medical history of hypertension,C0455527;C0262926
baseline systolic blood pressure,C4274438
telmisartan n $nmbr$ $nmbr$,C0248719
ethnic group no,C0015031;C1879937
clinical history no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
use of medication at baseline no,C1524063;C0168634;C1442488
index stroke $nmbr$ days before randomization no,C0456712;C0439228
toast classification,C1710306;C4521230
score on modified rankin scale no,C4049715
baseline nih stroke scale no ^,C1697238;C3484372
a stroke,C0038454;C4554100
no of events no of patients,C0441471;C3541888;C0030705
all recurrent strokes,C1836785
use of ace inhibitor,C1524063;C0003015;C4541021
^ $nmbr$ mm hg,C0439475
low risk $nmbr$ $nmbr$,C3272281;C3538919
moderate risk $nmbr$ $nmbr$,C0035647;C4552904
high risk $nmbr$,C0332167;C3272283;C4050568;C4319571
b major cardiovascular events,C0205082;C1320716;C0205164;C4318856;C4521762
all major cardiovascular events,C0205082;C1320716;C0205164;C4318856;C4521762
sl $nmbr$ mm hg,C0439475
^ $nmbr$ days,C0439228
rosuvastatin n $nmbr$,C0965129
heart disease risk factors,C0741920
heart rate beats per min,C0425583;C0439385
admission for hf in previous year,C0184666;C0809949;C0439234;C0439508
previous ami,C0205156;C4319936;C1552607
history of atrial fibrillation,C0729790
copd,C0024117;C1412502;C3714496
neoplasia,C0027651;C1882062
heart failure cause,C0015127;C1524003
ischaemic,C0475224
dilatative,
other cause,C0015127;C1524003
non detectable unknown,C0439673;C3541433;C4050014
physical examinations,C0031809
pulmonary rales,C0034642
third heart sound,C0232237;C0232278
mitral insufficiency,C0026266
aortic stenosis,C0003507
ecg findings,C0438154
qrs $nmbr$ ms,C2349943;C3539704;C3713294
pathological q waves,C0429090
arbs,C3888198
diuretic drugs,C0013227;C3687832
oral anticoagulant drugs,C0354604
other antiplatelet agents,C0085826
data are mean sd or number bmi body mass index sbp systolic blood pressure dbp diastolic blood pressure lvef left ventricular ejection fraction hf heart failure ami acute myocardial infarction cabg coronary artery bypass graft pci percutaneous coronary intervention icd implantable cardioverter de brillator copd chronic obstructive pulmonary disease ace angiotensin converting enzyme arbs angiotensin receptor blockers available for $nmbr$ patients $nmbr$ rosuvastatin $nmbr$ placebo,C1511726;C3245479;C3714741;C0444504;C2699239;C2347634;C2348143;C0521942;C0815017;C0470187;C0030705
rosuvastatin events patients,C0441471;C0030705;C3541888
placebo events patients,C0032042;C0030705;C1696465;C1706408
age $nmbr$ years median,C0549183;C0876920;C2347635;C2348144;C2939193
ischaemic cause,C0015127;C1524003
non ischaemic cause,C0015127;C1524003
nyha ii,C1710602;C4082587
nyha iii or iv,C0439070;C1705160;C0022326;C4265176
total cholesterol $nmbr$ $nmbr$ mmol lt,C0023376;C0230426;C3887647;C4521399
we recorded no significant interactions for any subgroup analysis nyha new york heart association lvef left ventricular ejection fraction $nmbr$ cl was calculated by cox proportional hazards model tmedian value data for total cholesterol were available for $nmbr$ patients $nmbr$ rosuvastatin $nmbr$ placebo,C0034869;C3853788;C0237688;C0428772;C0444686;C1441506;C0201950;C0543421;C0470187;C0030705
n $nmbr$ pufa n $nmbr$,C0369718;C0032615;C0441922
placebo n $nmbr$ l,C0032042;C1696465;C1706408
bmi kg rrr,C0022718;C0439209;C4054209
cause of heart failure,C0015127;C1524003
physical examination,C0031809;C1744699
statin open,C0360714;C0175566
data are mean sd or number pufa polyunsaturated fatty acids bmi body mass index sbp systolic blood pressure dbp diastolic blood pressure nyha newyork heart association lvef left ventricular ejection fraction hf heartfailure ami acute myocardial infarction cabg coronary artery bypass graft pci percutaneous coronary intervention icd implantable cardioverter defibrillator copd chronic obstructive pulmonary disease ace angiotensin converting enzyme arbs angiotensin receptor blockers available for $nmbr$ patients $nmbr$ n $nmbr$ pufa $nmbr$ placebo,C1511726;C3245479;C3714741;C0444504;C2699239;C2347634;C2348143;C0521942;C0815017;C0470187;C0030705
n $nmbr$ pufa events patients,C0032615;C0030705
nyhaii,
nyhaiiioriv,
we recorded no significant interactions for any subgroup analysis pufa polyunsaturated fatty acids nyha new york heart association lvef left ventricular ejection fraction $nmbr$ cl was calculated with a cox proportional hazards model tmedian value data for total cholesterol were available for $nmbr$ patients $nmbr$ n $nmbr$ pufa $nmbr$ placebo,C0034869;C3853788;C0237881;C1704675;C0750502;C1546944;C0232174;C0596019;C0444686;C1441506;C0201950;C0543421;C0470187;C0030705
parameter mean s d,C0549193;C0444504;C2347634;C2348143;C1704769;C2350001
total study itt population n $nmbr$,C3258257
asian itt population total n $nmbr$,C0078988;C0032659;C1257890
asian itt population by treatment group,C1257890
combination n $nmbr$,C0205195;C1947911;C3811910
dutasteride n $nmbr$,C0754659
tamsulosin n $nmbr$,C0257343
time since first luts years,C0556970;C0205435;C1279901
prostate volume cm $nmbr$,C1441416
mean total serum psa,C2986589;C0229671;C1546774;C1550100
ngml total mean ipss score,C2964552
qmax ml s,C0439526;C1705224;C3887665
bii score,C0449820;C4050231
bph related health status,C0005001;C0018759;C1704272
sexually active,C0241028
previous a blocker use,C0205156;C1552607;C0042153;C0457083;C1947944
previous $nmbr$ ari use,C0042153;C0457083;C1947944
chondroitin,C0008454
g c,C0439267
structural,C0678594
gait,C0016928
subjects n,C0681850;C1550501;C1706203;C2349001;C2697811
age in years mean sd,C1510829;C0444504;C2347634;C2348143
haq pain scale mean,C0444504;C2347634;C2348143
years duration oa,C0029408;C3887876
symptoms mean sd,C0444504;C2699239;C2347634;C2348143
percentages,C0439165;C1549488;C1561533
bmi $nmbr$ $nmbr$ overweight,C0578022;C0497406
bmi $nmbr$ obese,C0578022;C0028754
knees n,C0022742
kl $nmbr$,C1366480;C1416656;C1704887
mean of jsw mm,C0444504;C2347634;C2348143
median of jsw,C0549183;C0876920;C2347635;C2348144;C2939193
interquartile range mm,C4330985;C4554674
figure $nmbr$ treatment effect relative to placebo for jsw loss stratified by kellgren and lawrence grade adjusted mean two year loss in joint space is shown for $nmbr$ subjects and $nmbr$ knees jsw joint space width,C1518681;C3875154;C1517945;C0205363;C0224497;C1547282;C0681850;C1550501;C1706203;C2349001;C2697811
figure $nmbr$ treatment versus placebo odds ratio for jsw progression $nmbr$ $nmbr$ mm by kellgren and lawrence grade data from $nmbr$ subjects and $nmbr$ knees are shown here as a odds ratio of progression jsw joint space width,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0032042;C0028873;C1696465;C1706408;C1511726;C3245479;C3714741;C0022742;C0224497
prior lower gi clinical event,C0441471;C4019010
prior upper gi clinical event,C0441471;C4019010
proton pump inhibitor use,C0042153;C0457083;C1947944
cox $nmbr$ selective nsaid use,C0042153;C0457083;C1947944
rates per $nmbr$ patient years,C0871208;C1521828
prior lgi event,C0441471;C4019010
no prior lgi event,C0441471;C4019010
no aspirin,C0004057
nonsmoker,C0337672;C0425293;C4554605
corticosteroid,C0001617;C3536709
no corticosteroid,C0001617;C3536709
ascvd,C3665365
no ascvd,C3665365
femaleb,
prior ugi event,C0441471;C4019010
no prior ugi event,C0441471;C4019010
total population n,C3258257
bmi category,C0683312;C3889287
$nmbr$ $nmbr$ $nmbr$ $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
$nmbr$ $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
white not of hispanic origin,C0007457;C0043157;C0220938;C0086409
african american,C0085756
american indian or alaskan native,C0002460;C0238611;C0302891
asian or pacific islander,C0078988;C0242191
unknown none of the above,C0439673;C3541433;C4050014
family history of diabetes,C1313937
exercise once weekly,C0015259;C1522704;C0558293
alcohol consumption once weekly,C0001948;C0558293
history of hyperlipidemia,C4695788
baseline use of hormone therapy,C1524063;C0279025
available baseline blood specimen n,C0168634;C0178913;C1442488
total cholesterol to hdl cholesterol ratio,C0369300
non hdl cholesterol mmol l,C0729627;C1532563;C1535899
hscrp mg l,C0439268
aspirin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
p inleraclion,C0369773;C2603361
no evenls,
evenls per $nmbr$ $nmbr$ palienl years,C0439234
$nmbr$ $nmbr$ $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
family history ol diabetes,C1313937
hyperlension,
menopause and ht,C0025320;C0567312;C0018510;C0677607
uncerlain,
poslmenopausal ht,C0018510;C0677607
poslmenopausal no ht,C0018510;C0677607
tolal choleslerol,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ mmol l,C1532563
ldl choleslerol,
hdl choleslerol,C3715113
tolal choleslerol lo hdl choleslerol ralio,C0206579;C1232424
non hdl choleslerol,C1518422;C3715113
$nmbr$ $nmbr$ $nmbr$ $nmbr$ mg l,C0439268
$nmbr$ $nmbr$ mg l,C0439268
tiotropium n $nmbr$,C0213771
smoking history pack yr,C1519384;C0439234
duration of copd yr,C0449238;C2926735
baseline spirometry,C0168634;C0037981;C1442488
before bronchodilation,C1371299;C3537072
fev $nmbr$ liters,C3714541;C0475211
fev $nmbr$ of predicted value,C3714541;C0681842;C1522609;C1882327
fvc liters,C3714541;C0475211
ratio of fev $nmbr$ to fvc,C0456603;C1547037;C3714541
after bronchodilation,C1371299;C3537072
gold stage f,C0018026;C0016327;C1304897
sgrq total score units,C0439148;C1519795;C3853603
respiratory medication,C0418986
any,
inhaled anticholinergic,C0242896;C3537004
short acting,C1282927;C1806781;C2350002
long acting,C0205166;C1706317
inhaled j $nmbr$ agonist,C0004048;C2987634
inhaled,C0004048
oral,C0442027;C4521986
theophylline compound,C0205198;C1706082
mucolytic agent,C0026698
leukotriene receptor antagonist,C0595726;C3537183;C4521995
supplemental oxygen,C4534306
subgroup by treatment interaction p value,C1079230;C1515021
mean se,C0444504;C0036919;C2347634;C2348143
atio pla,C0456170
full cohort,C0009247;C0599755
gold stage,C0205390;C1300072;C1306673
i ii,C1710602;C4082587
e europe,C0015176
usa,C0041703
w europe,C0015176
reversibility,C0449261
concomitant medication,C0013227;C3244316;C4284232
laba,
ics,C0815320;C4551720
laba ics,C0815320;C4551720
anticholinergic,C0242896;C3537004
anticholinergics,C0242896;C3537307;C3540711
colesevelam hydrochloride group n $nmbr$,C0541154;C0441848
height cm mean sd,C0444504;C2699239;C2347634;C2348143
weight kg mean sd,C0005910;C2699239;C0043100;C1305866;C1705104
hbalc mean sd,C0444504;C2699239;C2347634;C2348143
fasting plasma glucose mg dl mean sd,C0202042;C2699239;C0455280
oral anti dm drug status no,C0442027;C4521986
metformin alone,C0025598;C0205171;C0439044;C0679994
metformin other oral anti dm drugs,C0025598;C0029167;C0175795;C0304289
concomitant medications in $nmbr$ of subjects no,C0013227;C0802604;C2598133;C4284232
angiotensin ii antagonists,C0003009;C0243076;C1366631;C3714928
p blocking agents selective,C0233660;C0332206
hmg coa reductase inhibitors,C0360714;C2756999;C3539119
multivitamins,C0301532;C3714835
other plain vitamin preparations,C0042890
platelet aggregation inhibitors excluding heparin,C0032177;C0019134;C0770546
propionic acid derivatives,C0033482;C0695274;C3540752
proton pump inhibitors,C0358591;C1384478;C3540020
thiazides,C0541746
thyroid hormone,C0040135;C4522017
concomitant oral anti dm drugs no a,C0029167;C0175795;C0304289
sulfonylureasb,
thiazolidinedionesc,
a glucosidase inhibitors $nmbr$,C1512211
nateglinide and repaglinide,C0903898;C0246689
abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol,C0022709;C1305855;C0444686;C1441506;C0439209;C0332849;C0489786;C0681850;C1550501;C1706203;C2349001;C2697811;C1515187;C0442027;C4521986;C0013227;C1254351;C4288115;C3687832;C0042295;C0541154;C0032042;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1696465;C1706408;C0332257;C1552866;C2700399;C0008287;C0017642;C0040372;C0872972;C0289313;C0795660;C1512211;C0050393;C0066535
rolofylline dose,C0178602;C0869039;C1114758
$nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
male n n,C0086582;C1706180;C1706428;C1706429
ischemic heart disease,C0010054;C0151744
atrial fibrillation atrial flutter,C0155709
nyha class when patient was last in stable condition before admission,C1882083;C0030705;C0677946;C3538874;C0184666;C0809949
bnp o $nmbr$ pg ml or nt pro bnp o $nmbr$ pg ml n,C0054015;C0439297;C1095989;C1417808;C2982014;C4284038
creatinine clearance by c g ml min,C0151280
medications on admission,C0013227;C0802604;C2598133;C4284232;C0457453
aldosterone inhibitor,C0002007
iv nitrates,C0022326;C0028125;C4265176
rank based on treatment placebo,C0032042;C1696465;C1706408
baseline variable,C0439828;C4553760
placeboa,
atorvastatinb,
treatment lipid interaction,C0023779;C1704675
unadjusted hr $nmbr$ ci for $nmbr$ sd increment,C0008107;C3259781
likelihood test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
unadjusted hr $nmbr$ ci for $nmbr$ standard deviation increment,C0008107;C3259781
apob apoa i,C0085201;C1677784
$nmbr$ e $nmbr$,
ldlc hdlc,C1416822;C1704429
ldlc,C1416822
apob,C0003593;C3252643
apoa i,C0085201;C1677784
non hdlc,C1518422;C1704429
tc hdlc,C0039411;C1704429;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
febuxostat $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
allopurinol $nmbr$ mg n $nmbr$,C0002144;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
minority,C0026192
cardiovascular disease,C0007222
gout history mean sd years,C0018099;C0439234
history presence of tophi,C0150312;C0392148;C3854307
recent use of allopurinol within $nmbr$ days of,C1524063;C0002144;C0439228
randomization,C0034656
mild to moderate renal impairment,C1299392;C1565489
chlorthalidone vs amlodipine,C0008294;C0051696
chlorthalidone vs lisinopril,C0008294;C0065374
chlorthalidone vs doxazosin,C0008294;C0114873
hr $nmbr$ ci univariate cox proportional hazard regression,C0684320;C0684321;C1836830
pef,C0030771;C1518922;C1542834
ref,C1425988
no ef data,C1511726;C3245479;C3714741
hr $nmbr$ ci multivariate cox proportional hazard regression,C0684320;C0684321;C1836830
hospitalized hf,C0018488;C1313497;C1538440;C3273279
irbesartan n $nmbr$,C0288171
clinical,C0205210
electrocardiographic findings no,C0438154
left bundle branch block,C0023211;C0344420;C2828132
atrial fibrillation or flutter,C0004238;C0344434;C1963067;C0016385;C2242390
cause of heart failure no,C0015127;C1524003
ischemia,C0022116;C4321499
hospitalization for heart failure within previous $nmbr$ mo no,C3898876;C0026544;C0332177
angina symptoms^,C0858277
pci orcabg,C4049621
stroke or transient ischemic attack,C0038454;C4554100;C0007787;C0917805
quality of life,C0034380;C0518214
score on the minnesota living with heart failure scaled,C0449820;C4050231;C0018801;C0018802;C4554158;C0175659;C0349674;C1947916
hemoglobin,C0019046
mean g dl,C0444504;C0439267;C2347634;C2348143
anemia no,C0002871;C1000483;C4554633
mean ml min $nmbr$ $nmbr$ m $nmbr$ of body surface area,C0444504;C0439445;C2347634;C2348143;C0005902
potassium mmol liter,C0032821;C0475211;C0202194;C0304475;C0597277;C3714637
nt probnp pg ml,C0669479;C0439297;C0754710
medication no,C0013227;C3244316;C4284232
diureticff,
loop,C0445022
thiazide,C0541746
antiarrhythmic drug,C0003195;C0301380
antiplatelet,
plus minus values are means sd percentages may not total $nmbr$ because of rounding the body mass index is the weight in kilograms divided by the square of the height in meters to convert the values for creatinine to micromoles per liter multiply by $nmbr$ $nmbr$ ace denotes angiotensin converting enzyme cabg coronary artery bypass grafting nt probnp n terminal pro b type natriuretic peptide nyha new york heart association and pci percutaneous coro nary intervention race was reported by the investigators one patient in nyha class i was mistakenly included in the placebo group this category includes any angina like symptoms at any time in the past with no confirmation of diagnosis of coro nary heart disease required possible scores range from $nmbr$ to $nmbr$ with lower scores indicating a better quality of life anemia was defined by world health organization criteria as a hemoglobin level of less than $nmbr$ g per deciliter in men and less than $nmbr$ g per deciliter in women nt probnp levels are influenced by a variety of factors including age sex body mass index and renal function no clinically useful normal range has been established some patients were taking both loop and thiazide diuretics,C0042295;C0439165;C1549488;C1561533;C0439175;C0439810;C0332490;C0005893;C0578022;C1305855;C0005910;C0043100;C1305866;C1705104;C0332849;C0205120;C1552595;C0441074;C0010294;C1561535;C0439300;C1719797;C2911648;C1452534;C4284014;C0040744;C1279380;C0034510;C1706779;C3853635;C1709908;C1882084;C0332257;C0032042;C1696465;C1706408;C0683312;C3889287;C1552866;C2700399;C0858277;C0040223;C3541383;C0521091;C0596672;C0441994;C0449820;C1548802;C2003888;C0002871;C1000483;C4554633;C1704788;C3539106;C1281911;C0439267;C0439241;C0025266;C0669479;C0754710;C0814287;C0232804;C3827682;C0086715;C0443211;C1272684;C0030705;C0445022;C0012802
irbesartan,C0288171
no of patients no of events $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0030705;C0441471;C3541888
use of beta blocker,C1524063;C0001645
hospitalization for heart failure within $nmbr$ mo,C3898876;C0026544;C0332177
the plot shows hazard ratios and $nmbr$ confidence intervals for the primary outcome with patients stratified according to eight sub groups prespecified in the statistical analysis plan no heterogeneity was observed for these subgroups,C1547282;C2985465;C0009667;C0205225;C0439612;C0439631;C0030705;C0205363;C0205454;C3889277;C0019409;C0242960;C1441672;C1079230
atorvastatin $nmbr$ mg ezetimibe $nmbr$ mg n $nmbr$,C1319635;C3643658
atorvastatin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ncep atp iii risk factors,C0035648;C1553898
the $nmbr$ substrata with baseline bl ldl cholesterol $nmbr$ to $nmbr$ mg dl and $nmbr$ to $nmbr$ mg dl were combined to make $nmbr$ group with bl ldl cholesterol $nmbr$ to $nmbr$ mg dl because of small numbers of patients included in the substrata with $nmbr$ to $nmbr$ mg dl bl hdl cholesterol cutoffs were $nmbr$ or $nmbr$ mg dl for men and $nmbr$ or $nmbr$ mg dl for women bars indicate se bmi body mass index e ezetimibe $nmbr$ mg hdl c hdl cholesterol ldl c ldl cholesterol tg triglycerides,C0023824;C0202117;C0439269;C0205195;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C2360800;C0332257;C0023822;C1442160;C0392885;C0025266;C0043210;C0062152
other forms of atherosclerosis^,C0348078;C0376315
multiple $nmbr$ chd risk factors that confer a $nmbr$ year risk of chd $nmbr$,C0035648;C1282512;C1553898;C0439234;C0439508
family history of premature chdj,C0241889;C0151526;C0205252;C4018905
metabolic syndrome $nmbr$ of $nmbr$ characteristics,C0524620;C1521970
waist circumference s $nmbr$ men or $nmbr$ cm women,C0455829;C0025266;C0043210
triglycerides $nmbr$ mg dl,C0041004;C0439269
fasting blood glucose $nmbr$ mg dl,C0428568;C0439269;C1261430
visit $nmbr$ ldl cholesterol strata,C0023824;C0202117
values expressed as mean sd or number percent two patients were missing values for body mass index other forms of atherosclerosis are peripheral arterial disease abdom inal aortic aneurysm symptomatic carotid artery disease transient isch emic attack and stroke family history of premature chd de ned as chd in male rst degree relative aged $nmbr$ years or female rst degree relative $nmbr$ years blood pressure $nmbr$ $nmbr$ mm hg on antihypertensive medication or diagnosis of hypertension based on medical history n number of randomly assigned patients ncep atp national cholesterol education program adult treatment panel,C0042295;C0444504;C2347634;C2348143;C0205448;C0030705;C1881192;C0348078;C0376315;C0277793;C1261512;C1304680;C0260518;C1261367;C0280604;C3542407;C0439475;C0003364;C0011900;C1704338;C1704656;C1527178;C1705938
values expressed as mean sd or number percent two patients were missing values for body mass index other forms of atherosclerosis are peripheral arterial disease abdom inal aortic aneurysm symptomatic carotid artery disease transient isch emic attack and stroke family history of premature chd dened as chd in male rst degree relative aged $nmbr$ years or female rst degree relative $nmbr$ years blood pressure $nmbr$ $nmbr$ mm hg on antihypertensive medication or diagnosis of hypertension based on medical history n number of randomly assigned patients ncep atp national cholesterol education program adult treatment panel,C0042295;C0444504;C2347634;C2348143;C0205448;C0030705;C1881192;C0348078;C0376315;C0277793;C1261512;C1304680;C0260518;C1261367;C0280604;C3542407;C0439475;C0003364;C0011900;C1704338;C1704656;C1527178;C1705938
benazepril amlodipine group n $nmbr$,C0051696;C0441848
benazepril hydrochlorothiazide group n $nmbr$,C0717481;C0441848
race or ethnic group no f,C0034510;C1706779;C3853635;C0015031;C1879937;C0016327
nordic countries,C0036273
body mass index blood pressure mm hg,C0005893;C0439475;C0578022;C1305855
pulse beats min,C0232117;C0439385;C0391850;C1947910
estimated glomerular filtration rate ml min $nmbr$ $nmbr$ m $nmbr$ of body surface area,C3811844;C0439445;C0005902
serum values^,C0229671;C0042295;C1546774;C1550100
high density lipoprotein cholesterol mg dl,C0023822;C0439269
previous antihypertensive treatment no,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
no of agents,C0450442;C1254351;C1521826
antiplatelets agents,C0085826
risk factors no,C0035648;C1553898
previous hospitalization for unstable angina,C0019993;C0002965
renal disease,C0022658
previous coronary revascularization,C0205156;C0877341;C1552607
number of patients or mean sd,C2360800;C0444504;C2699239;C2347634;C2348143
sitagliptin n $nmbr$,C1565750
nationality,C0027473
indian,C1524069
korean,C1556095
weight range kg,C0022718;C0439209;C4054209
body mass index range kg m $nmbr$,C0022718;C0439209;C4054209
duration of type $nmbr$ diabetes mellitus years,C0449238;C2926735
all randomized patients range,C1514721;C2348147;C3542016
naive to antihyperglycemic agent therapy,C0020616;C0039798;C0087111;C1363945
fpg range mmol l,C1514721;C1532563;C2348147;C3542016
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
ls mean change from baseline $nmbr$ ci,C0392747;C0443172;C1705241;C4319952
ls mean between group difference $nmbr$ ci,C2347634;C0008107;C3259781
hba $nmbr$ c all countries,C0019016;C0454664;C1825777;C3538758
sitagliptin,C1565750
china,C0008115
india,C0021201;C2700456
korea,C0022771
sitagliptin $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ fasting plasma glucose fpg mmol l,C0202042;C1532563;C0455280
all countries,C0454664
sitagliptin $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ h postprandial plasma glucose ppg mmol l,C2827804;C0202042;C0455280
week o baseline mean sd,C0168634;C2699239;C1442488
ls mean difference between treatment groups $nmbr$ ci,C1705241;C2347634;C1705242
fasting indices,C0015663;C4033634
fasting insulin miu ml,C0015663;C0021641;C0439457;C1533581;C1579433;C3714501
placebo $nmbr$,C0032042;C1696465;C1706408
sitagliptin $nmbr$,C1565750
fasting proinsulin pmol l,C0015663;C0033362;C0439284;C3813208
fasting c peptide ng ml,C0015663;C0006558;C0439275
homa b,
homa ir,C0022065;C0022071;C1448132
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ z,
quicki,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ y,
postprandial indices,C0376674;C4033634
$nmbr$ h postprandial insulin miu ml,C0021641;C0439457;C1533581;C1579433;C3714501
$nmbr$ h postprandial proinsulin pmol l,C2827799;C0033362;C3813208
$nmbr$ h postprandial c peptide ng ml,C2827809;C0006558
insulinogenic index dinsulino_ $nmbr$ o min dglucoseo $nmbr$ o min,C0600653;C0702093;C1524029;C3813700;C0918012;C1552854;C1637833;C2986546
placebo $nmbr$ o $nmbr$,C0032042;C1696465;C1706408
composite index of insulin sensitivity isi,C0600653;C0918012;C1552854;C1637833;C2986546
disposition index,C0743223;C0600653;C0918012;C1552854;C1637833;C2986546;C1705555
no hypertension n $nmbr$,C0020538;C1963138
hypertension n $nmbr$,C0020538;C1963138
ecg abnormality resting,C0035253;C1512899
tc mmol l mg dl,C1532980
ldl c mmol l mg dl,C1532980
hdl c mmol l mg dl,C1532980
tg mmol l mg dl [median],C1532980;C0549183;C0876920;C2347635;C2348144;C2939193
antihypertensive drug,C0003364
total antihypertensive use,C0042153;C0457083;C1947944
^ blocker,
angiotensin ii receptor blocker,C0521942;C3536793
event patients in group incidence $nmbr$ person year,C0030705;C0021149;C0220856
diet group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
diet pravastatin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
non dm,C1518422;C0011816;C3250443
uncontrolled,C0205318
controlld,
with placebo n $nmbr$ $nmbr$,C0032042;C1696465;C1706408
with alogliptin $nmbr$ $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
with alogliptin $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
age group n,C0441848
black african american,C0085756
native hawaiian other,C0337920
alaska native,C0682125
baseline hba $nmbr$ c n,C0168634;C0019016;C1825777;C3538758;C1442488
patients $nmbr$,C0030705
diabetes duration years,C0011847;C0439234;C0011849
glyburide dose duringthe study mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
with placebo,C0032042;C1696465;C1706408
with alogliptin $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
with alogliptin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
n $nmbr$ $nmbr$,C0369718;C0441922
baseline hba $nmbr$ c,C0168634;C0019016;C1825777;C3538758;C1442488
male n $nmbr$,C0086582;C1706180;C1706428;C1706429
female n $nmbr$,C0043210;C0086287;C1705497;C1705498
hispanic or latino n $nmbr$,C0086409;C0086528
not hispanic or latino n $nmbr$,C1518424;C0086528
baseline body mass index,C0005893;C0578022;C1305855
$nmbr$ kg m $nmbr$ n $nmbr$,C0022718;C0439209;C4054209;C0369718;C0441922
aliskiren n $nmbr$,C1120110
hydochlorothiazide n $nmbr$,
obese patients n,C0028754;C0030705
diabetes mellitus n,C0011849
duration of hypertension y,C0449238;C2926735
mssbp mm hg,C0439475
msdbp mm hg,C0439475
values are presented as mean sd unless stated otherwise data shown are for the randomized population body mass index values were missing from $nmbr$ patients in the aliskiren group and $nmbr$ patients in the hydrochlorothiazide group obesity was defined as body mass index $nmbr$ kg m $nmbr$ metabolic syndrome was defined according to the third report of the national cholesterol education program expert panel on detection evaluation and treatment of high blood cholesterol in adults adult treatment panel iii criteria $nmbr$ as any $nmbr$ of the following waist circumference $nmbr$ cm for men or $nmbr$ cm for women triglycerides $nmbr$ mg dl high density lipoprotein cholesterol $nmbr$ mg dl for men or $nmbr$ mg dl for women mssbp $nmbr$ mm hg or msdbp $nmbr$ mm hg fasting glucose $nmbr$ mg dl by medical history aliskiren n $nmbr$ hydrochlorothiazide n $nmbr$,C0042295;C0449450;C0444504;C2347634;C2348143;C1511726;C3245479;C3714741;C1547282;C0005893;C0578022;C1305855;C1551393;C1705492;C3272743;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C0030705;C0020261;C1704788;C3539106;C0524620;C0220825;C1261322;C0596197;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0455829;C0025266;C0023822;C0439269;C0439475;C0262926;C1704706
aliskiren,C1120110
hydrochlorothiazide,C0020261
$nmbr$ y n $nmbr$,
baseline mssbp msdbp mm hg,C0168634;C0439475;C1442488
change in bp mm hg,C1268766;C0439475
msdbp,
changes from baseline in mssbp and msdbp are shown as least squares mean sem p $nmbr$ $nmbr$ vs $nmbr$ y,C0392747;C0443172;C1547282;C0023189
placebo statin n $nmbr$ $nmbr$,C0032042;C0360714;C1696465;C1706408
ezetimibe $nmbr$ mg statin n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
cad,C1504769;C2239547;C3813548;C4284121
crp mean mg dl sd,C0439269;C2699239
ldl cholesterol mean mg dl sd,C0023824;C2699239;C0202117
triglycerides mean mg dl sd,C0439269;C2699239
high density lipoprotein cholesterol mean mg dl sd,C0023822;C2699239
figure $nmbr$ treatment differences [ezetimibe statin] [placebo statin] in least squares ls mean percentage change from baseline in crp among subgroups of patients with ongoing statin treatment there were no signif icant treatment by subgroup interactions bmi body mass index dm diabetes mellitus hdl c high density lipoprotein cholesterol ldl c ldl cholesterol tg triglycerides,C1705241;C1705242;C1142985;C0360714;C0032042;C1696465;C1706408;C0392747;C0443172;C4319952;C3890735;C4048285;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0062152
parameter variable,C0439828;C4553760
amlodipine vaisartan n $nmbr$,C0051696
age $nmbr$ years n,C1510829
f emale,C0016327
race ethnicity n,C0034510;C0015031;C0243103;C1706779;C3853635
hispanic black,C0005680;C0027567;C0085756;C0439541
mean bmi kg m $nmbr$ s d,C1275571
mean blood pressure mmhg s d j,C0428886;C0488053
severity n,C0439793;C0522510
mean pulse pressure mmhg s d,C0445074;C2347155
populations,C0032659;C1257890
intent to treat population n,C0087111;C0032659;C1257890;C1292734;C1522326
safety population n,C0036043;C0032659;C1257890;C1705187
figure $nmbr$ change in mean sitting systolic blood pressure mssbp mm hg from baseline to week $nmbr$ by treatment strategy and selected subgroups in black patients with stage $nmbr$ hypertension bmi body mass index ci confidence interval ish isolated systolic hypertension n is the number of intent to treat patients of the respective subgroup,C3484017;C3484018;C0168634;C1442488;C0039798;C0679199;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C1079230;C0005680;C0027567;C0085756;C0439541;C1305855;C0745133;C0237753;C0449788;C0030705;C1292734
all patients n $nmbr$,C0030705
patients with fistulas at baseline,C0030705;C0016169;C0168634;C1442488
adalimumab n $nmbr$,C1122087
all patients with fistulas n $nmbr$,C0030705;C0016169
male no,C0086582;C1706180;C1706428;C1706429
baseline cdai score mean sd,C0168634;C2699239;C1442488
crp concentration $nmbr$ $nmbr$ mg dl $nmbr$ mg l n,C2827881
previous tnf antagonist exposure n,C0205156;C0231491;C1552607
any glucocorticoid,C0017710
$nmbr$ mercaptopurine,C0000618
no draining fistulas,C0013103;C0180499;C4265177;C0016169
week $nmbr$ of patients,C0332174;C0439230;C0030705
no baseline immunosuppressant use,C0042153;C0457083;C1947944
both adalimumab groups n $nmbr$ baseline immunosuppressant use,C0042153;C0457083;C1947944
$nmbr$ p $nmbr$ $nmbr$,C0369773;C2603361
both adalimumab groups n $nmbr$ no baseline cd related antibiotic use,C1122087;C0441848;C0042153;C0457083;C1947944
both adalimumab groups n $nmbr$ baseline cd related antibiotic use,C0042153;C0457083;C1947944
both adalimumab groups n $nmbr$,C1122087;C0441848
exenatide,C0167117
biasp $nmbr$,
bid,
qd,C0332173
subjects randomized,C0681850;C1550501;C1706203;C2349001;C2697811;C0034656;C3815594
american indian alaska native,C0886378
black or african american,C0005680;C0027567;C0085756;C0439541
not hispanic or latino,C1518424;C0086528
subject completion status n,C3891295
completed trial,C0205197;C0008976;C3854010
discontinued,C1444662
adverse eventy,
ineffective therapy,C0039798;C0087111;C1363945
non compliance,C0376405;C0457432
otherz,
diabetic history years x,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
figure $nmbr$ b mean change in hba $nmbr$ c values from baseline was plotted against baseline hba $nmbr$ c values of $nmbr$ $nmbr$ for exenatide biasp $nmbr$ qd and biasp $nmbr$ bid number of subject data values used exenatide $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively biasp $nmbr$ qd $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively and biasp $nmbr$ bid $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively,C0565965;C0019016;C1825777;C3538758;C0168634;C1442488;C0042295;C0167117;C0332173;C0243174
dexlansoprazole mr,C0024485;C1417249;C2347167;C3254418;C4050513
$nmbr$ mg qd n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
non hispanic or latino,C1518424;C0086528
native hawaiian or other pacific islander,C0337920;C0242191
age y mean s d,C0001779;C0444504;C2347634;C2348143
weight kg mean s d,C0005910;C1275571;C0043100;C1305866;C1705104
height cm mean s d,C0439392;C0444504;C2347634;C2348143
bm $nmbr$ kg m $nmbr$ mean s d,C0022718;C0439209;C4054209;C0444504;C2347634;C2348143
helicobacter pylori negative n,C4688581
eo severity by la classification at baseline baseline of the healing study n,C0439793;C0522510;C0168634;C0043240;C0205249;C1442488
d,
duration of treatment in the healing study n,C0444921;C0043240;C0205249
previous treatment in the healing study n,C1521826;C3161471
dexlansoprazole mr $nmbr$ mg qd,C0024485;C0332173;C1417249;C2347167;C3254418;C4050513
lansoprazole $nmbr$ mg qd,C0024671;C0332173;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
characteristic age mean sd yr,C0001779;C0439234
dronedarone n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0766326
placebo n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0032042;C1696465;C1706408
all n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0369718;C0441922
structural heart disease no f,C1290384;C0016327
coronary heart disease no,C0010054;C0010068;C1956346
valvular heart disease no,C0018824;C1963123
nonischemic cardiomyopathy no,C0878544
history of chf nyha class ii or iii no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0439070;C1705160
lvef no i,C0428772;C0488728;C0021966;C0221138
lone atrial fibrillation no,C0340489
pacemaker no,C0030163;C0810633;C1546728;C3275122;C3853703
medications in use at baseline no,C0013227;C0802604;C2598133;C4284232;C0150312;C0042153;C0457083;C1947944;C0332285;C1707101
vitamin k antagonists,C3653316
early eptifibatide group n $nmbr$,C0253563;C0441848
delayed eptifibatide group n $nmbr$,C0205421;C0441848;C1545665;C3272602
median yr,C0549183;C0439234;C0876920;C2347635;C2348144;C2939193
interquartile range yr,C1711350;C0439234
region ofenrollment,C0017446;C0205147
middle east africa or asia pacific,C0001741;C0003980
median ml min,C0549183;C0439445;C0876920;C2347635;C2348144;C2939193
interquartile range ml min,C1711350;C0439445
killip class ii iii or iv,C2697846;C0022326;C4265176
qualifying high risk features,C1514624;C0035648
age $nmbr$ yr elevated biomarkers and st segment changes,C0001779;C0005516;C0232326
age $nmbr$ yr and elevated biomarkers,C0001779;C0439234;C0205250;C0005516;C3163633
elevated biomarkers and st segment changes,C0205250;C0005516;C3163633;C0232326
age $nmbr$ yr and st segment changes,C0001779;C0439234;C0232326
age $nmbr$ $nmbr$ yr elevated biomarkers and previous vascular,C0001779;C0005516;C0005847;C1558950;C1801960
presentation to tertiary care hospital,C0449450;C0337954
randomized,C0034656;C3815594
low $nmbr$ $nmbr$,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
intermediate $nmbr$ $nmbr$,C0205103;C1550465;C2827755;C3889971
high $nmbr$ $nmbr$,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
medical therapy during index hospitalization,C0418981;C0019993
antithrombin,C0003438;C0003440;C4521254
unfractionated heparin only,C0019134;C2825026
low molecular weight heparin only,C0019139;C3536766
both unfractionated heparin and low molecular weight heparin,C0019134;C2825026;C0019139;C3536766
neither unfractionated heparin nor low molecular weight heparin,C0019134;C2825026;C0019139;C3536766
at any time,C0040223;C3541383
early use intended,C0042153;C0457083;C1947944;C1283828;C1551357
temporal data and management strategy,C1511726;C3245479;C3714741;C0001554;C0679199;C0376636;C1273870;C3273539
time from onset of symptoms to presentation hr,C1320528;C0449450
time from presentation to randomization hr,C0040223;C3541383;C0034656
time from randomization to study drug initiation hr,C0040223;C3541383;C0013175;C0589507;C1158830;C1704686
time from randomization to coronary angiography hr,C0040223;C3541383;C0085532;C1548829
pci no,C4049621
time from randomization to pci hr,C0040223;C3541383;C4049621
duration of infusion before pci hr,C0449238;C2926735;C4049621
duration of infusion after pci hr,C0449238;C2926735;C4049621
cabg no,C0010055
time from randomization to cabg hr,C0040223;C3541383;C0010055
duration of infusion before cabg hr,C0449238;C2926735;C0010055
medical management only no,C0199168;C0001554;C0376636;C1273870;C3273539;C0205476
duration of infusion during medical management hr,C0449238;C2926735;C0199168;C0001554;C0376636;C1273870;C3273539;C0205476
early eptifibatide,C1279919;C0253563
delayed eptifibatide,C0205421;C0253563;C1545665;C3272602
troponin,C0041199
positive,C0439178;C1446409;C1514241;C2825490;C3812269
early clopidogrel intended,C1279919;C0070166;C1283828;C1551357
time to randomization,C0040223;C3541383
heparin use,C0239945
unfractionated only,
low molecular weight only,C0041667
type of hospital care,C0332307;C1547052
tertiary,C0205372
region of the world,C0017446;C0205147
region ofthe world,C0017446;C2700280;C0205147
patient characteristics,C0815172
arterial hypertension n,C0020538
insulin requiring,C0021641;C1533581;C1579433;C3714501
history of mi n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
history of cabg surgery n,C0455610;C0010055
infarct characteristics,C0021308;C1521970
infarct localization n,C0021308;C0475264;C1744691
killip class n,C1881332
arterial blood pressure mm hg,C1272641;C0439475
peak creatine kinase mb u l,C0010290;C0439339;C0523584
value for nteraction,C1522609
$nmbr$ $nmbr$ yrs,
history of mi,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
infarct localization,C0475264;C1744691
non anterior,C1518422;C0205094
interval pain onset to admission,C1507009;C0184666;C0809949
interval study drug to pci,C1272706;C0013175;C1552654;C1552713
interval clopidogrel to pci,C1272706;C0070166;C1552654;C1552713
clopidogrel plus aspirin n $nmbr$,C0070166;C0004057
aspirin n $nmbr$,C0004057
chads $nmbr$ ^,C0007928;C1413373
mean score,C3533236
score no,C0449820;C4050231
history of atrial fibrillation type no,C0729790;C0332307;C1547052
permanent,C0205355
paroxysmal,C0205311
persistent,C0205322;C0332996
atrial fibrillation duration no,C0449238;C2926735
$nmbr$ mo to $nmbr$ yr,C0026544;C0332177
history of hypertension no,C0455527
history of stroke or tia no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0007787;C0917805;C1054154
history of ischemic heart disease no,C0683519;C0730226;C0850708;C0944983
peripheral artery disease no,C1704436;C4025272
cardiac pacemaker no,C0030163;C0037189
ecg findings at baseline no,C0438154;C0168634;C1442488
atrial flutter,C0004239;C0344423;C1963068
medication use at baseline no,C0240320;C0168634;C1442488
vka,
antiarrhythmic agent,C0003195;C0301380
reason for enrollment in active a no,C0392360;C0205177;C3853793;C3888249
specific risk of bleeding^,C0205369;C3251812;C1552740
physician s judgment that vka inappropriate],C0031831;C0804815;C0022423;C1548788;C3537135;C3542467
patient s preference not to take vka only reason,C0030705;C0558295;C1549513;C1518422;C1515187;C0392360
western europe and israel,C0043129;C0022271
clopidogrel plus aspirin yr,C0070166;C0004057
aspirin only,C0004057
stroke or tia,C0038454;C4554100;C0007787;C0917805;C1054154
mi or cad,C3810814;C1504769;C2239547;C3813548;C4284121
chads $nmbr$ score,C0449820;C4050231
vka therapy,C0039798;C0087111;C1363945
persistent or paroxysmal,C0205322;C0332996;C0205311
reason for enrollment in active a,C0392360;C0205177;C3853793;C3888249
risk of bleeding,C3251812
physician s judgment that vka inappropriate,C0031831;C0804815;C0022423;C1548788;C3537135;C3542467
physician s judgment that vka,C0031831;C0804815;C0022423
inappropriate,C1548788;C3537135;C3542467
patient s preference not to take,C0030705;C0558295;C1549513;C1518422;C1515187
vka only reason,C0392360
all subjects,C0681850;C1550501;C1706203;C2349001;C2697811
no diabetes mellitus,C0011849
weight median $nmbr$ th $nmbr$ th percentiles kg,C0022718;C0439209;C4054209
body mass index median $nmbr$ th $nmbr$ th percentiles kg m $nmbr$,C0022718;C0439209;C4054209
time from onset of pain to randomization median $nmbr$ th $nmbr$ th percentiles n,C0449244;C0034656;C0039725;C0039738;C1420718;C4282123;C4285344
treatment before randomization,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
oral hypoglycemic agent,C0359086
hab $nmbr$ c mean sem,C0444504;C2347634;C2348143
low density lipoprotein cholesterol median $nmbr$ th $nmbr$ th percentiles mg dl,C0023824;C0439269
high density lipoprotein cholesterol median $nmbr$ th $nmbr$ th percentiles mg dl,C0023822;C0439269
ranozaline,
$nmbr$ $nmbr$ $nmbr$ ci $nmbr$ $nmbr$ to $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0008107;C3259781;C0369773;C2603361
$nmbr$ $nmbr$ $nmbr$ cl $nmbr$ $nmbr$ to $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0596019;C0369773;C2603361
inclusion criteria no,C1512693
$nmbr$ episodes of atrial fibrillation in previous $nmbr$ mo,C0332189;C0004238;C0344434;C1963067;C0026544;C0332177
cardioversion in previous $nmbr$ wk,C0013778;C0205156;C1552607
duration of last qualifying episode of atrial fibrillation $nmbr$ days,C0449238;C2926735;C1514624;C0332189;C0004238;C0344434;C1963067
heart failure lvef,C0428772;C0488728
history of hypertension for $nmbr$ mo or more,C0455527;C0026544;C0332177
history of stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
documented coronary artery disease,C0010054;C0010068;C1956346
atrial fibrillation alone,C0004238;C0344434;C1963067;C0205171;C0439044;C0679994
coexisting conditions no,C0012634;C0348080;C1705253;C3864998
peripheral embolism,C0013922;C1704212
previous transient ischemic attack,C0007787;C0917805
renal dysfunction,C1565489;C3279454
alcohol abuse,C0085762;C4050601
electrocardiographic findings at randomization,C0438154;C0034656
qrs interval $nmbr$ msec no,C0520880;C0439223
left ventricular hypertrophy no,C0149721;C3484363
pathologic q waves no,C0429089;C1305738
concomitant cardiovascular therapies no,C1707479
class $nmbr$ antiarrhythmic agents,C0003195;C0301380
hf lvd or both,C0018488;C1313497;C1538440;C3273279
use of antiarrhythmic agent,C1524063;C0003195;C0301380
use of beta blockers,C1524063;C0001645
af alone,C0344434;C4049859;C0205171;C0439044;C0679994
af alone refers to atrial fi brillation without coexisting cardiovascular conditions but with left atrial dilatation ace denotes angiotensin con verting enzyme hf heart failure and lvd left ventricular dysfunction,C0344434;C4049859;C0205171;C0439044;C0679994;C0205543;C0018792;C0007222;C1452534;C4284014;C0003018;C4521302;C0387288;C0014442;C0018801;C4521602;C0242698
ischemia on cecg n $nmbr$ $nmbr$,C0022116;C4321499
no ischemia n $nmbr$ $nmbr$,C0022116;C4321499
age $nmbr$ yrs,C0001779
body mass index kg m $nmbr$ median q $nmbr$ q $nmbr$,C0022718;C0439209;C4054209;C0549183;C0876920;C2347635;C2348144;C2939193
prior revascularization,C0332152;C0581603;C2826257
creatinine clearance $nmbr$ ml min,C0812399;C0439445
non st segment elevation mi,C1518422;C0520886
st segment depression $nmbr$ $nmbr$ mv on admission,C1454484;C1705503;C4281602;C0457453
elevated troponin $nmbr$ $nmbr$ mg l,C0041199;C0439268
elevated bnp $nmbr$ pg ml,C0054015;C0439297;C1095989;C1417808;C2982014
intent of early invasive strategy,C0162425;C1283828;C1550453
intent of conservative strategy,C0162425;C1283828;C1550453
revascularization during index hospitalization,C0581603;C0019993
ace inhibitors or arbs,C0003015;C3888198
cardiac medications at discharge,C0018787;C0806915;C1522601
primary end point,C2986535
ischemia on cecg,C0022116;C4321499
no p value for ischemia ischemia hr $nmbr$ ci interaction,C1709380;C0008107;C3259781
$nmbr$ yrs of age n $nmbr$ $nmbr$,C0001779
no prior htn n $nmbr$ $nmbr$,C0332152;C0020538;C2826257
prior htn n $nmbr$ $nmbr$,C0332152;C0020538;C2826257
no dm n $nmbr$ $nmbr$,C0011816;C3250443
dm n $nmbr$ $nmbr$,C0011816;C3250443
no prior angina n $nmbr$ $nmbr$,C0332152;C0002962;C2826257
prior angina n $nmbr$ $nmbr$,C0332152;C0002962;C2826257
no prior mi n $nmbr$ $nmbr$,C0332152;C2826257
prior mi n $nmbr$ $nmbr$,C0332152;C2826257
no prior revascularization n $nmbr$ $nmbr$,C0332152;C0581603;C2826257
prior revascularization n $nmbr$ $nmbr$,C0332152;C0581603;C2826257
no prior hf n $nmbr$ $nmbr$,C0332152;C0018488;C1313497;C1538440;C3273279;C2826257
prior hf n $nmbr$ $nmbr$,C0332152;C0018488;C1313497;C1538440;C3273279;C2826257
unstable angina n $nmbr$ $nmbr$,C0002965
nstemi n $nmbr$ $nmbr$,C3537184;C4255010
no stsd $nmbr$ mm on admission n $nmbr$ $nmbr$,C0184666;C0809949
stsd $nmbr$ mm on admission n $nmbr$ $nmbr$,C0184666;C0809949
low trs $nmbr$ $nmbr$ n $nmbr$ $nmbr$,C0205251;C0266427;C0968917;C1150746;C1550472;C3890211;C4048187;C4321351;C4522223
moderate trs $nmbr$ $nmbr$ n $nmbr$ $nmbr$,C0205081;C0266427;C0968917;C1150746;C1881878;C4049705;C4049706;C4085643;C4321335
high trs $nmbr$ $nmbr$ n $nmbr$ $nmbr$,C0205250;C0266427;C0968917;C1150746;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
conservative strategy n $nmbr$ $nmbr$,C0679199
early invasive strategy n $nmbr$ $nmbr$,C0205281;C0679199;C1334278
ef $nmbr$ n $nmbr$ $nmbr$,
ef,
negative ctnl n $nmbr$ $nmbr$,C0205160;C1513916;C2825415;C2825491;C3853545
positive ctnl n $nmbr$,C0439178;C1446409;C1514241;C2825490;C3812269
normal bnp ^ $nmbr$ pg ml n $nmbr$ $nmbr$,C0054015;C0439297;C1095989;C1417808;C2982014
elevated bnp $nmbr$ pg ml n $nmbr$ $nmbr$,C0054015;C0439297;C1095989;C1417808;C2982014
medal,C0524670
edge ii,C1710602;C4082587
edge,C0205154;C2697523
$nmbr$ mg cohort,C0009247;C0599755
etoricoxib $nmbr$ mg n $nmbr$ $nmbr$ n,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
diclofenac $nmbr$ mg n $nmbr$ $nmbr$ n,C0012091;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
baseline creatinine clearance,C0168634;C0812399;C1442488
$nmbr$ $nmbr$ ml s m $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n,C0439390;C0439445;C0369718;C0441922
history of chf,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
cigarette users,C0677453;C1706077;C1704760;C3890423
history of symptomatic,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
ascvdor $nmbr$ cv risk factors,C0035648;C1553898
prior use of systemic,C1524063;C0205373
corticosteroidsa,
baseline anti hypertensive usea,C0168634;C0003364;C1442488
ranolazine n $nmbr$ $nmbr$,C0073633
age yrs median $nmbr$ th $nmbr$ th,C0001779;C0039725;C0039738;C1420718;C4282123;C4285344
weight kg median $nmbr$ th $nmbr$ th,C0005910;C0022718;C0439209;C4054209;C0043100;C1305866;C1705104
risk factors for atherosclerosis,C0035648;C1553898
prior coronary revascularization pci or cabg,C0877341;C4049621;C0010055
prior known stenosis $nmbr$,C0678234;C1261287;C2632116
ccsc at $nmbr$ month before enrollment,C1516705;C0332177;C0439231;C1516879;C1696073;C3888021
coronary angiography during the index hospital stay,C0085532;C1548829
cardiac medications during index hospital stay and or discharge,C0013227;C0802604;C2598133;C4284232;C0012621;C0030685;C2926602
calcium channel blockerf,C0006685
long acting nitratef,C0205166;C1706317
data are expressed as n total unless otherwise speci ed systeme international unit conversion to convert creatinine clearance to ml s multiply by $nmbr$ $nmbr$ estimated with cockroft gault equation at discharge ace angiotensin converting enzyme cabg coronary artery bypass graft ccsc canadian cardiovascular society classi cation mi myocardial infarction pci percutaneous coronary intervention,C1511726;C3245479;C3714741;C0439175;C0439810;C0439453;C0439836;C0439390;C0750572;C0552449;C0030685
randomization to end of study,C0034656;C0444930;C2746065
major secondary end pointf,C0027627;C0175668;C0205436
cv death or ml,C0011065;C1306577;C4082313;C4552775;C0439526;C1705224;C3887665
recurrent ischemia,C0022116;C4321499
worsening angina,C0332271;C1457868;C1546960;C0002962
severe recurrent ischemia,C0022116;C4321499
intensification of antianginal therapy,C1511484
$nmbr$ days until end of study landmark analysis,C2826182;C0002778;C0936012;C1524024
data are reported as n event rates in parentheses are kaplan meier estimates at $nmbr$ year cardiovascular cv death myocardial infarction mi or recurrent ischemia cv death mi or severe recurrent ischemia,C1511726;C3245479;C3714741;C0684224;C0700287;C4319718;C1720943;C0027051;C0011065;C3810814;C1306577;C4082313;C4552775;C0022116;C4321499
new anti anginal therapy,C3242274;C1874267;C3537168
effect of ranolazine compared with placebo on angina and recurrent ischemia,C1280500;C1518681;C2348382;C1707455;C0032042;C1696465;C1706408;C0002962;C0022116;C4321499
in patients with a history of chronic angina who have presented with an acute,C0679831;C0002962;C0449450;C0205178
coronary syndrome ci confidence interval hr hazard ratio,C0009667;C2985465
tadalafil $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
tadalafil $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ed severity visit $nmbr$,C0545082;C1512346;C2826704
normal or mild iief ef $nmbr$ $nmbr$ n,C0205307;C0231683;C0439166;C2347086;C4553972;C2945599;C3641331
moderate iief ef $nmbr$ $nmbr$ n,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
severe iief ef $nmbr$ $nmbr$ n,C0205082;C3641331;C4050465;C4050466
ed duration visit $nmbr$,C0545082;C1512346;C2826704
$nmbr$ moto,
$nmbr$ yr n,C0439234
iief ef domain score visit $nmbr$,C0545082;C1512346;C2826704
iief ef domain score visit $nmbr$ y,C0449820;C0545082;C1512346;C2826704;C4050231
tadalafil,C1176316
p values,C1709380
$nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
interaction,C1704675
$nmbr$ yr n $nmbr$,C0439234
bph luts severity,C0439793;C0522510
moderate ipss,C1019118;C1998280;C2827405;C3811063
severe ipss $nmbr$ n $nmbr$,C0205082;C1019118;C1998280;C2827405;C3811063;C4050465;C4050466
psa,C3810537;C3813209
$nmbr$ $nmbr$ ng ml n $nmbr$,C0439275
prior a blocker use,C0332152;C2826257;C0042153;C0457083;C1947944
yes n $nmbr$,C1549445;C1705108;C1710701
no n $nmbr$,C0369718;C0441922
prior ed therapy,C1514463;C3538926
variable_level,C0441889;C0456079;C1547707;C2946261
moderate ckd,C0205081;C1561643;C1881878;C4049705;C4049706;C4085643;C4321335
normal mild ckd,C0205307;C1561643;C0231683;C0439166;C2347086;C4553972
chd cl all,C0280604;C0596019;C3542407
cvd,C0007222
total mortality all,C0026565;C0026566
sal $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
fp $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
sfc $nmbr$ mg $nmbr$ mg,C4521536;C1319635
total pack yrs,C0439175;C0439810
baseline fev $nmbr$,C0168634;C3714541;C1442488
o $nmbr$,C0483204
probability of event,C0033204;C0441471;C4019010
non ics,C0815320;C4551720
ng n $nmbr$ $nmbr$,C0017887;C0028074
lgm n $nmbr$,
non epa n $nmbr$,C1518422
average age year,C0439234;C0439508
drinker,C0556338
triglyceride median mg dl $nmbr$ [ $nmbr$ $nmbr$ percentile,C0439269;C1264641
$nmbr$ [ $nmbr$ $nmbr$,
$nmbr$ [ $nmbr$ $nmbr$ ],
fatty acid profile,C1979963;C2003903
glucose metabolism,C0596620
hba c,C0019016;C1825777;C3538758
$nmbr$ ll,
data are reported as percentage or mean standard deviation unless otherwise indicated ng normoglycemia igm impaired glucose metabolism ldl low density lipoprotein hdl high density lipoprotein fpg fasting plasma glucose a median interquartile range p $nmbr$ $nmbr$ vs ng p $nmbr$ $nmbr$ vs ng,C1511726;C3245479;C3714741;C0684224;C0700287;C4319718;C1828170;C0455280;C0549183;C1711350;C0876920;C2347635;C2348144;C2939193;C0017887;C0028074
igm n $nmbr$,C1706005
triglyceride median mg dl a [ $nmbr$ $nmbr$ percentile],C0041004;C0439269;C1264641
$nmbr$ [ $nmbr$ $nmbr$ js,C1552154
diastolic fmmhff,C0012000
data are reported as percentage or mean standard deviation unless otherwise indicated ng normoglycemia igm impaired glucose metabolism ldl low density lipoprotein hdl high density lipoprotein fpg fasting plasma glucose a median interquartile range p $nmbr$ $nmbr$ vs non epa p $nmbr$ $nmbr$ vs non epa,C1511726;C3245479;C3714741;C0684224;C0700287;C4319718;C1828170;C0455280;C0549183;C1711350;C0876920;C2347635;C2348144;C2939193;C1518422
non epa number of,C0237753;C0449788
epa hr events,C0441471;C3541888
ng,C0017887;C0028074
igm,
interaction p $nmbr$ $nmbr$,C1704675
age y gender n,C0001779;C0079399;C1522384
african descent,C0205386;C0680043
weight kg duration of pah n,C0449238;C2926735
$nmbr$ y pathogenesis n,C0543483;C0699748
idiopathic familial,C0015576;C0241888
anorexigen use,C0042153;C0457083;C1947944
connective tissue disease,C0009782
associated with an atrial septal defect,C0332281;C0018817
surgical repair of vsd or pda $nmbr$ year duration,C0374711;C0018818;C0449238;C2926735
concomitant use of bosentan n,C1524063;C0252643
six minute walk distance m,C3900196
borg dyspnea score who functional class n,C0013404;C0205245;C0542341;C2700217;C1963100
hemodynamic parameters at baseline in the patients enrolled in the hemodynamic substudy,C0019010;C0449381;C4281788;C0030705;C4684790
mean pulmonary artery pressure mm hg,C0428642;C0439475
cardiac index l mn m $nmbr$,C0026327;C0026405;C4285072
pulmonary vascular resistance dyne s cm $nmbr$,C0308914;C0600130
all itt sutajects,
bosentan use,C0042153;C0457083;C1947944
pah etiology,C0015127;C1314792;C1524003
repaired s p shunts,C0205340;C0232180;C0542331;C1442858
baseline $nmbr$ mlnute walk distance,C0168634;C0429886;C1442488
$nmbr$ meters,C0441074
medan $nmbr$ year old,C0439234;C0580836;C0439508
baseline who function class,C0456387;C1518526;C1705943
lor ii,C1710602;C4082587
iii or iv,C0439070;C1705160;C0022326;C4265176
table $nmbr$ not standard baseline characteristics table,C0039224;C1706074
fig $nmbr$ per cent change from baseline in ldl cholesterol subclasses in the mitt population panel a subgroup with tgs,C0349966;C3272907;C1337208;C0023824;C0445604;C1079230;C1515021
saxa $nmbr$ mg $nmbr$ metformin n $nmbr$ $nmbr$,C0024671;C0025598;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
saxa $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
metformin n $nmbr$ $nmbr$,C0025598
age $nmbr$ years t,C1510829
sexy,
racey z,
$nmbr$ t,C2603360
fpg mg dl x,C0439269
figure $nmbr$ hba $nmbr$ c adjusted mean change subgroup analysis by baseline hba $nmbr$ c hba $nmbr$ c glucosylated haemoglobin saxa saxagliptin,C0019016;C2986480;C1825777;C3538758;C1611934
golimumab,C2353893
proportion of patients who achieved acr $nmbr$ n n,C1709707;C0030705
combined golimumab groups,C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429
dmard at baseline,C0242708;C0168634;C1442488
number of previous tnfa inhibitors,C0237753;C0449788
anti ccp antibodies,C1624602
rheumatoid factor,C0035448;C0201660
reason for discontinuation of previous tnfa inhibitor,C0392360;C0205156;C1552607
patient assessment of pain $nmbr$ $nmbr$ cm vas,C0679830
lack of effectiveness,C0235828
patient global assessment of disease activity $nmbr$ $nmbr$ cm vas,C4054228;C0042815;C3536884;C3827561
unrelated to effectiveness,C0445356;C1704623
physician global assessment of disease activity $nmbr$ $nmbr$ cm vas,C4050369;C0042815;C3536884;C3827561
assessment of physical function $nmbr$ $nmbr$ haq di,C0031809
c reactive protein concentration mg l,C0006560;C0439268;C1413716;C4048285
erythrocyte sedimentation rate mm h,C1176468;C0456680;C1619634
das $nmbr$ score,C0449820;C4050231
facit f score,C3272505;C0449820;C4050231
methotrexate treatment,C0746573
hydroxychloroquine treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
sulfasalazine treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
no methotrexate hydroxychloroquine or sulfasalazine treatment,C0025677;C0020336;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
treatment for latent tuberculosis^,C0749724
zoledronic acid,C0257685
age at menopause yr,C1625754;C1629609
americas,C0002454;C0596070
bmi kg m $nmbr$ a,C0578022;C1532718
bmia,
weight kg a,C0022718;C0439209;C4054209
height loss,C0424641
$nmbr$ $nmbr$ to $nmbr$ cm,
baseline vfx,C0168634;C1442488
history of falls,C1561668;C2919132
physical activity hours walking wk,C0015259;C0439227;C0026606;C0080331;C4283795;C4321241;C4321242;C0332174;C0439230
prior bisphosphonate usage,C0012544;C0457083;C2267018
total hip bmd g cm $nmbr$,C0019552;C0022122;C1505163;C3538851;C4284725
standardized total hip bmd g cm $nmbr$,C0019552;C0022122;C1505163;C3538851;C4284725
femoral neck bmd g cm $nmbr$,C0015815;C0439267
femoral neck t score,C0449820;C4050231
femoralneck t scorebybaselinevfxstatus,
$nmbr$ $nmbr$ vfx,
$nmbr$ ml min,C0439445
category,C0683312;C3889287
mean change in fn bmd,C0392747;C0443172;C1705241;C4319952
least squares mean between treatment difference $nmbr$ ci,C0023189;C0444504;C2347634;C2348143
p value within category,C1709380;C0683312;C3889287
p value interaction,C1709380;C1704675
and vfx status,C0449438
op no vfx,
op vfx,
no op no vfx,
no op vfx,
height loss cm,C0424641
prior bp use,C0042153;C0457083;C1947944
crcl ml min,C1846718;C0439445
$nmbr$ mg kg,C0439272
combined,C0205195
patients randomized n,C0030705;C0034656;C3815594
white race n,C0007457;C0043157
disease duration y,C0872146
colonic area involved,C0017446;C0205146;C1314939
left side n,C0205091
extensive n,C0205231
mayo clinic scoreb,C0002424;C0442592
c reactive proteinc,C0205332
mean mg dl,C0444504;C0439269;C2347634;C2348143
median mg dl,C0549183;C0439269;C0876920;C2347635;C2348144;C2939193
elevated crp n,C0742906
any ulcerative colitis medication,C0013227;C3244316;C4284232
$nmbr$ mg day,C0439422
immunomodulators,C0001551;C0005525;C1527392
refractory to corticosteroids n,C0205269;C0001617;C3539185;C3540725;C3540726;C3540727
smoking status n,C1519386
prior smoker,C0337671
infliiimab i,C0021966;C0221138
hazard inleraction,C0598697
ratio,C0456603;C1547037
study,C0557651;C2603343
act $nmbr$,C0079613;C1704930;C1869853;C3890007;C4048375
nap,C0870935;C1423800;C4283878
inhixanab $nmbr$ mgikg versus piacom,
inflotmas io mgluj versus piecew,C1046794;C3146236
cortteosterom relrsclory status,C0449438
uc disease durslion,C0012634
ss years,C2699257;C0439234;C3891295;C4551874
$nmbr$ yearstos is years,C0439234
ibs $nmbr$ $nmbr$,C0022104;C0432306
is years,C0439234
$nmbr$ z $nmbr$ $nmbr$ $nmbr$,
exlertl ot disease,C1318464;C0012634;C1418208;C1705587
umied,
extenswe,
batellna c reective protein,C0033684
$nmbr$ $nmbr$ tng cll,C0023434
$nmbr$ mgrdl,
baseline mayo score,C0449820;C4050231
center location,C0450429;C1515974;C4284930;C4284931
czech repumc,C0337799
nc,C0027964;C0028407;C0067895;C0265987
israel,C0022271
southern hemisphere,C1710133
s asa compounds at baseline,C0205198;C1706082
recervini,
$nmbr$ $nmbr$ s s,C0565930;C2603362
noirecerving,
coiticosieroids at baseline,C0168634;C1442488
$nmbr$ mgday p eq,C0205163;C0439185
ssomgdayp eq,C0205163;C0439185
$nmbr$ up and or aza at baseline,C0004482;C0168634;C1442488
recervng,
not receiving,C1518422;C1514756
conieosieroids and or $nmbr$ mp,C0024944
and or aza at baseline,C0004482;C0168634;C1442488
noliecervrig,
$nmbr$ $nmbr$ s,
combined infliximab,C0205195;C0666743
hazard interaction,C0598697;C1704675
gertder,
baseline age,C0168634;C0001779;C1442488
baseline smoking status,C0168634;C1519386;C1442488
previous segments resection s,C0015252;C0728940
other uc related gi surgical procedure,C0439849;C0543467;C0445223
glulisine oad,
glulisine monotherapy,
oad only,
itt patients n,C0030705
mean age s d years,C0444504;C0001779;C2347634;C2348143;C0439234
mean bmi s d kg m $nmbr$,C0444504;C0578022;C2347634;C2348143;C0022718;C0439209;C4054209
mean hba $nmbr$ c s d,C0444504;C0019016;C1825777;C3538758;C2347634;C2348143
treatment with sulphonylurea n,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
treatment with sulphonylurea biguanide n,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
fig $nmbr$ change in hba $nmbr$ c from baseline to study endpoint intention to treat population hba $nmbr$ c glycosylated haemoglobin a $nmbr$ c oad oral antidiabetic drugs s e standard error,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488;C0013175;C1710181
fig $nmbr$ mean s e hba $nmbr$ c levels fpg levels $nmbr$ h ppg levels and total daily glulisine dose in itt population $nmbr$ h ppg $nmbr$ hour postprandial plasma glucose fpg fasting morning plasma glucose hba $nmbr$ c glycosylated haemoglobin a $nmbr$ c oad oral antidiabetic drugs s e standard error,C0444504;C2347634;C2348143;C0019016;C0033727;C0369286;C0441932;C0564385;C4528284;C1825777;C3538758;C2348070;C0202042;C0455280;C0015663;C1955477;C1710181
placebo pioglitazone n $nmbr$,C0032042;C0071097;C1696465;C1706408
alogliptin $nmbr$ $nmbr$ mg pioglitazone n $nmbr$,C3535925;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
alogliptin $nmbr$ mg pioglitazone n $nmbr$,C3535925;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ n,C0369718;C0441922
non hispanic,C1518424
diabetes history mean sd years,C0011847;C0439234;C0011849
pioglitazone dose mean sd mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
other hypoglycemic agent n,C0020616
sulfonylurea,C0038766;C3536898
$nmbr$ n of patients,C0369718;C0441922
figure $nmbr$ least squares ls mean changes from baseline to week $nmbr$ last observations carried forward in glycosylated hemoglobin hba $nmbr$ c in patients with baseline values of hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ p $nmbr$ $nmbr$ yp $nmbr$ $nmbr$ vs placebo,C0392747;C0443172;C0332174;C0439230;C0439780;C0062259;C0042295;C0019016;C1825777;C3538758;C0369773;C1520214;C2603361;C0032042;C1696465;C1706408
simvastatin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
simvastatin $nmbr$ mg plus fenofibrate $nmbr$ mg n $nmbr$,C1319635
lowest tg tertile,C1708760;C0337445
tgs mg dl,C1156212;C0439269;C1537574
non hdl cholesterol mg dl,C0729627;C0439269;C1535899
apob mg dl,C0003593;C0439269;C3252643
non hdl cholesterol apob ratio,C2938854
middle tg tertile,C0444598;C0337445;C0549183;C1552826
highest tg tertile,C1522410;C0337445
data are presented as mean sd n $nmbr$ for ldl cholesterol n $nmbr$ for ldl cholesterol signi cantly different from baseline values by repeated measures analysis of variance p $nmbr$ $nmbr$ signi cantly different from baseline values by repeated measures analysis of variance p $nmbr$ $nmbr$ signi cantly different from baseline values by repeated measures analysis of variance p $nmbr$ $nmbr$,C1511726;C3245479;C3714741;C0449450;C0444504;C2347634;C2348143;C0023824;C0202117;C1705242;C0042295;C0871881;C0002780
with tamsulosin,C0257343
without tamsulosin,C0257343
no japanese,C0376247;C1556094
time since bph diagnosis years,C0556970;C0005001;C1704272
no previous alpha blocker use,C0042153;C0457083;C1947944
ipss unit,C0439148;C0439453;C1509845;C1519795;C1704753;C1880519;C3853603
prostate volume ml,C0439526;C1705224;C3887665
intervention group n $nmbr$,C0441848
hispanic latin american,C0019576
hawaiian pacific islander,C0337920;C0242191
age $nmbr$ years or more,C1510829
previous transient ischaemic attack ischaemic stroke previous warfarin use,C0042153;C0457083;C1947944
less than $nmbr$ year,C0439234;C0439508
$nmbr$ year or more,C0439234;C0439508
no estimate,C0750572
atrial fibrillation pattern,C0004238;C0449774;C0344434;C1963067
atrial fibrillation onset,C0206132;C0332162
left ventricular ejection,C2733342
fraction,C1264633;C1554103
figure $nmbr$ primary e cacy results by patient subgroup,C0205225;C1547647;C0439612;C0439631
p value for trend,C1709380;C1521798;C4554533
age of completion of highest education years sd,C1510829;C0013621;C0013622;C0013658;C0039401
history of major cardiovascular disease n,C0455539;C0205082;C0205164;C4318856;C4521762
myocardial infarction n,C0027051;C0428953;C2926063;C3810814;C4552959
stroke n,C0038454;C4554100
macroalbuminuria n,
major diabetic eye disease n,C0205082;C0342245;C0205164;C4318856;C4521762
past smoker n,C0337664
current alcohol use n,C0521116;C0001948;C1705970
hba $nmbr$ c sd,C0019016;C2699239;C1825777;C3538758
systolic bp mmhg sd,C0871470;C2699239
diastolic bp mmhg sd,C0428883;C2699239
serum total cholesterol mmol l sd,C0587184;C2699239;C1287371
serum creatinine ^mol l,C0201976;C0347982;C0600061
estimated gfr ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$ sd a,C0017654;C0439445;C1424601;C2699239
uacr mg mmol interquartile range b,C0567349;C1711350;C2348885
number of events patients,C4330837
perindopril,C0136123
major cardiovascular events,C0205082;C1320716;C0205164;C4318856;C4521762
mmse $nmbr$,C0451306
mmse,C0451306
all cause death,C0011065;C1306577;C4082313;C4552775
shfm annual mortality,C0026565;C0026566
quintile $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ n $nmbr$,C1508496
randomized treatment n,C0034656;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C3815594
nyha class iii n,C1882086
ischemic hf n,C0475224;C0018488;C1313497;C1538440;C3273279
furosemide equivalent mg kg,C0016860;C0439272
digoxin n,C0012265
ace i or arb n,C0021966;C0221138;C3888198
j $nmbr$ blocker n,
statin n,C0360714
carvedilol n,C0054836
qrs $nmbr$ ms n,C2349943;C3539704;C3713294
qrs width ms,C2349943;C3539704;C3713294
$nmbr$ min walk distance ft,C1881534;C3890579
quintile n,C1508496
total deaths n,C0439175;C0011065;C1306577;C0439810
placebo mortality rate events per $nmbr$ person y,C0441471;C3541888
relative risk comparing icd therapy and placebo,C0242492;C1707455;C0039798;C0087111;C1363945;C0032042;C1696465;C1706408
relative risk $nmbr$ cl comparing icd therapy and placebo using a linear interaction term in the model shfmxicd,C0242492;C0596019;C1707455;C0039798;C0087111;C1363945;C0032042;C1696465;C1706408;C1524063;C0233324;C1515273;C1705313;C2826302
ii $nmbr$,C1710602;C4082587
iii $nmbr$,C0439070;C1705160
iv $nmbr$,C0022326;C4265176
v $nmbr$,
gold stage ii,C0018026;C0441767;C1304897
gold stage iii,C0018026;C0441771;C1304897
gold stage iv,C0022326;C4265176
fev $nmbr$ l,C3714541
prebronchodilator,C2599602
postbronchodilator,C2599594
duration of copd years,C0449238;C2926735
control,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
ratio $nmbr$ ci,C0008107;C3259781
one or more copd exacerbations n n [ ],C0205447;C0740304
median time to first exacerbation months [ $nmbr$ ci],C0205435;C0556969;C1279901;C0008107;C3259781
mean number of exacerbations per patient year [ $nmbr$ ci],C0444504;C0237753;C0449788;C2347634;C2348143;C0030705;C0439234;C0439508;C0008107;C3259781
dabigatran $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
warfarin,C0043031
male sex no total no,C0086582;C0439175;C0439810
type of atrial fibrillation no total no,C0332307;C1547052;C0439175;C0439810
chads $nmbr$ scoref,C0007928;C1413373
$nmbr$ or $nmbr$ no total no,C0439175;C0439810
$nmbr$ no total no,C0439175;C0439810
$nmbr$ $nmbr$ no total no,C0439175;C0439810
previous stroke or transient ischemic attack no total,C0038454;C4554100;C0007787;C0917805;C0439175;C0439810
heart failure no total no,C0018801;C0018802;C4554158;C0439175;C0439810
medications in use at baseline no total no,C0013227;C0802604;C2598133;C4284232;C0150312;C0042153;C0457083;C1947944;C0332285;C1707101;C0439175;C0439810
arb or ace inhibitor,C3888198;C0003015;C4541021
stating,C1301808;C1442792;C3148680
proton pump inhibitor,C0358591;C3536754;C4521480
h $nmbr$ receptor antagonist,C0033727;C4543207;C0369286;C0441932;C0564385;C4528284
long term vka therapy,C0039798;C0087111;C1363945
patients total no,C0439175;C0439810
dabigatran $nmbr$ mg $nmbr$ mg per yr,C1319635;C0439234
hazard ratio with dabigatran $nmbr$ mg $nmbr$ cl,C2985465;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
p value for interaction dosage with dabigatran $nmbr$ mg,C1709380;C0178602;C2986497;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
b i,C0021966;C0221138
g,C0439267
$nmbr$ kg,C0022718;C0439209;C4054209
bi,
european or arab,C0239307;C1535514;C0282540;C1561448
r,C0205090;C0684010;C2603358
$nmbr$ $nmbr$ ml min,C0439445
$nmbr$ or $nmbr$,
h,C0033727;C0369286;C0441932;C0564385;C4528284
symptomatic heart fail,C0018787;C0231175
ure,
stroke ortia,C0038454;C4554100
k,C0597277;C1708601
u,C0439148
central europe,C0682369
south asia,C1710133;C0003980
east asia,C0015631
j,
aspirin use at baseline,C0042153;C0457083;C1947944
b h,C0033727;C0369286;C0441932;C0564385;C4528284
amiodarone use at baseline yes $nmbr$ $nmbr$,C0042153;C0457083;C1947944
ppi use at baseline,C0042153;C0457083;C1947944
$nmbr$ ],
patients characteristics age years mean sd,C1510829;C2699239
risk factors bmi kg m $nmbr$ mean sd,C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
sbp mmhg mean sd,C0085805;C2699239
heart rate b p m mean sd,C0018810;C0444504;C2699239;C2347634;C2348143
alcohol consumption n,C0001948
nyha class n ii,C1882085
admission for hf in previous year n,C0184666;C0809949;C0205156;C0439234;C0439508;C1552607
previous ami n,C0205156;C1552607
previous stroke n,C0205156;C0038454;C4554100;C1552607
cabg n,C0010055
pci n,C4049621
icd n,C0021122
pacemaker n,C0030163;C0810633;C1546728;C3275122;C3853703
history of paroxysmal atrial fibrillation n,C0729790
peripheral vascular disease n,C0085096
chronic obstructive pulmonary disease n,C0024117
neoplasia n,C0027651;C1882062
ischemic aetiology n,C0475224;C0015127;C1314792;C1524003
pulmonary rales n,C0034642
third heart sound n,C0232237;C0232278
mitral insufficiency n,C0026266
aortic stenosis n,C0003507
qrs $nmbr$ ms n available for $nmbr$ patients,C2349943;C3539704;C3713294;C0470187;C0030705
left ventricular hypertrophy n,C0149721;C3484363
total cholesterol mg dl mean sd available for $nmbr$ patients,C0201950;C2699239;C0543421;C0470187;C0030705
ldl cholesterol mg dl mean sd available for $nmbr$ patients,C0023824;C2699239;C0202117;C0470187;C0030705
hdl cholesterol mg dl mean sd available for $nmbr$ patients,C0023822;C2699239;C0392885;C0470187;C0030705
triglycerides mg dl mean sd available for $nmbr$ patients,C0439269;C2699239;C0470187;C0030705
laboratory examination,C0260877
haemoglobin g dl mean sd available for $nmbr$ patients,C0439267;C2699239;C0470187;C0030705
potassium meql mean sd available for $nmbr$ patients,C0032821;C2699239;C0202194;C0304475;C0597277;C3714637;C0470187;C0030705
ace inhibitors arbs n,C0003015;C3888198
spironolactone n,C0037982
diuretic drugs n,C0012798;C0013227;C3687832
digitalis n,C0012252;C0304520
oral anticoagulant drugs n,C0354604
aspirin other antiplatelet agents n,C0004057;C0085826
nitrates n,C0028125
amiodarone n,C0002598
age $nmbr$ years $nmbr$,C1510829
ischemic aetiology,C0015127;C1314792;C1524003
non ischaemic aetiology,C0015127;C1314792;C1524003
nyha lll iv,C0022326;C4265176
history of paroxysmal af,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
no history of paroxysmal af,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
total cholesterol $nmbr$,C0201950;C0543421
total cholesterol $nmbr$ $nmbr$ mg dl,C0201950;C0439269;C0543421
fluvastatin n $nmbr$,C0082608
male sex no risk factors,C0086582;C0035648;C1553898
myocardial infarction no,C0027051;C0428953;C2926063;C3810814;C4552959
angina pectoris no,C0002962
stroke or tia no,C0038454;C4554100;C0007787;C0917805;C1054154
renal insufficiency no,C0035078;C1565489
copd no medication use,C0024117;C1412502;C3714496;C0240320
beta blocker no,C0001645
antiplatelet no,
anticoagulant no,C0003280;C0848112;C3536711
ace inhibitor no,C0003015;C4541021
calcium antagonist no,C0006684
angiotensin ll receptor antagonist no,C0003018;C4521302;C4543207
nitrate no,C0028125;C0699857;C3848573
diuretic no surgery,C0012798;C0038894;C0038895;C0543467;C1274039
carotid artery no,C0007272;C0162859
abdominal aortic no,C0000726;C0003483
open no,C0175566
endovascular no,C0524425
lower limb arterial no,C0003842;C0221464
p value for heterogeneity,C1709380;C0019409;C0242960
type of surgery,C0332307;C1547052
open,C0175566
endovascular,C0524425
baseline high sensitivity crp,C3890735;C4048285
baseline ldl cholesterol,C0023824;C0202117
baseline total cholesterol,C0201950;C0543421
cardiac risk,C0035647;C4552904
intermediate,C0205103;C1550465;C2827755;C3889971
temporary discontinuation of study drug,C0457454;C1444662;C4552847
dexlansoprazole mr n $nmbr$,C0024485;C1417249;C2347167;C3254418;C4050513
lansoprazole n $nmbr$,C0050940
mean age s d year,C0444504;C0001779;C2347634;C2348143;C0439234;C0439508
missing,C1551393;C1705492;C3272743
mean bmii s d kg m $nmbr$,C0022718;C0439209;C4054209
alcohol users n,C0556297
smokers n,C0337664
caffeine users n,C3532939
amlodipine valsartan $nmbr$ $nmbr$ mg v $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
amlodipine $nmbr$ mg v $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
baseline msdbp mmhg mean sd,C0168634;C2699239;C1442488
baseline mssbp mmhg mean sd,C0168634;C2699239;C1442488
duration of hypertension months,C0449238;C2926735
mean sitting diastolic blood pressure,C1319894
amlodipine and valsartan,C0051696;C0216784
mean sitting systolic blood pressure,C1319893
observation,C0302523;C0700325;C1964257;C3889687
$nmbr$ mg a,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
participants,C0679646
mean sd age y,C0444504;C0001779;C2347634;C2348143
minimum maximum,C0806909;C1552615;C2826546
study eye characteristics,C1568011;C0015392;C0700042
mean sd e etdrs visual acuity letter score snellen equivalent,C0205163;C0439185
duration of macular edema mo,C0449238;C2926735
iop mm hg,C0578862;C0439475
iop lowering medication,C0578862;C0441994;C2003888;C0013227;C3244316;C4284232
phakic,
imaging data mean sd,C0011923;C2699239;C0079595
oct center point thickness pm,C0030266;C4049155
total macular volume mean sd mm $nmbr$,C4330985;C4554674
area of retinal thickening within the grid mean sd dab,C0017446;C0205146;C0086162;C1081457
area of retinal hemorrhage within the grid mean sd dab,C0017446;C0205146;C0086162;C1081457
area of fluorescein leakage within the grid mean sd dab,C0017446;C0205146;C0086162;C1081457
$nmbr$ da of capillary nonperfusion in the eyec,C0011318;C3668815
mean sd nonstudy eye e etdrs visual acuity letter score,C3533236;C0042812
other clinical characteristics,C0683325
history of cancer,C0455471
abbreviations da disc area e etdrs electronic early treatment diabetic retinopathy study iop intraocular pressure oct optical coherence tomography,C3161471;C0920367
rasagiline $nmbr$ mg day,C0525678;C0439422
delayed start group n $nmbr$,C0205421;C0441848;C1545665;C3272602
early start group n $nmbr$,C0439659;C0441848
time since diagnosis mo,C0040223;C3541383
total updrs score range $nmbr$ $nmbr$ y,C2964552;C1514721;C2348147;C3542016
motor subscale range $nmbr$ $nmbr$,C1514721;C2348147;C3542016
adl subscale range $nmbr$ $nmbr$,C1514721;C2348147;C3542016
hoehn and yahr stage range $nmbr$ $nmbr$,C1514721;C2348147;C3542016
result,C1274040;C1546471;C2825142
s e,
$nmbr$ c i,C1547546
first primary change in updrs score wk wk $nmbr$ $nmbr$,C0392747;C0443172;C1705241;C4319952
$nmbr$ mg day placebo,C0032042;C1696465;C1706408
second primary estimated change in total updrs score from baseline to wk $nmbr$,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488
$nmbr$ mg day early start,C0439422;C0439659
$nmbr$ mg day delayed start,C0439422;C0439659
$nmbr$ mg day early start delayed start,C0439422;C0205421;C1545665;C3272602
third primary change in updrs score wk wk $nmbr$ $nmbr$,C0392747;C0443172;C1705241;C4319952
secondary change in total updrs score from baseline to final visit in phase $nmbr$,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488;C0205390;C1710475
rituximab n $nmbr$,C0393022
age mean yr sd,C0001779;C2699239
gender no,C0079399;C1522384
disease duration mean yr sd,C0872146;C2699239
since onset,C0206132;C0332162
since diagnosis,C0011900;C1704338;C1704656
prior ms treatment with ifn beta or,C1514463;C0015980
glatiramer acetate no,C0289884
no prior ms therapies,C1514463;C2349943;C3539704;C3713294
ended $nmbr$ days before trial entry,C0439228;C0008976
edss score,C0449820;C4050231
median min max,C0549183;C0702093;C1524029;C3813700;C0876920;C2347635;C2348144;C2939193
edss stratification no,C0451246;C1514983;C3887783
total gadolinium enhancing lesion count no,C0439175;C0016911;C0439810;C2349975;C0750480;C1705566
brain volume cm $nmbr$,C1113695
t $nmbr$ lesion volume mm $nmbr$,C4330985;C4554674
msfc timed $nmbr$ foot walk test median seconds,C0560030
age gd lesion,C0221198;C1546698
effect estimate,C1280500;C0750572;C1518681;C2348382
age $nmbr$ gd lesion $nmbr$ n $nmbr$,C0001779;C0221198;C1546698
hr $nmbr$ $nmbr$ $nmbr$ cl $nmbr$ $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0596019
age $nmbr$ n $nmbr$,C0001779
reteplase abciximab facilitated pci n $nmbr$,C0256103;C0288672
treated with insulin,C0332293;C0021641;C1533581;C1579433;C3714501
previous chf,C0205156;C0018802;C1552607
location of infarction,C0450429;C1515974;C4284930;C4284931
inferior posterior,C0542339;C0205095;C0678975
primary pci,C0205225;C0439612;C0439631
ret abx facil pci,C0389252;C4049621
i $nmbr$,C0021966;C0221138
no unknown,C0439673;C3541433;C4050014
sites,C0205145
time of symptom onset to randomization hrs,C1320528;C0034656;C1568891
time of qualifying ecg to balloon inflation hrs,C0040223;C3541383;C1514624;C1623258;C0021398;C1318493
tertile $nmbr$,
time of symptom onset to balloon inflation hrs,C1320528;C0021398;C1568891;C1318493
tertile $nmbr$ index pci performed,C0600653;C4049621;C0918012;C1552854;C1637833;C2986546;C0884358
enrollment in lmwh,C1516879;C1696073;C3888021
abx facil pci,C4049621
n_,C0369718;C0441922
cutoffs,C1442160
combo facilitated pci,C4049621
abciximab facilitated pci,C0288672;C4049621
combo vs primary,C0205225;C0439612;C0439631
abciximab vs primary,C0288672;C0205225;C0439612;C0439631
timi $nmbr$,
timi $nmbr$ and spoke,
timi $nmbr$ and spoke and time $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
alteplase n $nmbr$,C0032143
baseline nihss,C0168634;C1697238;C1442488
median iqr,C0549183;C0876920;C2347635;C2348144;C2939193
previous use of antiplatelet drugs,C1524063
atrial flutter fibrillation,C0155709
never smoked,C0037366;C0439994;C1881674
ex smoker,C0337671;C4555205
time to treatment initiation min,C3494202;C0589507;C1158830;C1704686
time to treatment min t,C3494202;C0702093;C1524029;C3813700
odds ratio $nmbr$ cl,C0028873;C0596019
nihss at baseline,C1697238;C0168634;C1442488
previous diabetes,C0011847;C0011849
arial flutter or fibrillation,C0016385;C2242390;C0232197
previous chronic use of antiplatelet drugs,C1524063
itt population,C0032659;C1257890
intention to treat,C0162425;C1283828
intention to treat without st segment elevation myocardial infarction,C0162425;C1283828;C1536220
intention to treat with st segment elevation myocardial infarction,C0162425;C1283828;C1536220
cangrelor n $nmbr$,C1121991
race or ethnic group no total no f,C0034510;C1706779;C3853635;C0015031;C1879937;C0439175;C0439810;C0016327
interquartile range height cm,C1711350;C0489786
stable angina no,C0340288
unstable angina no,C0002965
myocardial infarction without st segment elevation no,C1536220
st segment elevation myocardial infarction no,C1536220
other medical history no total no,C0262926;C1704706;C0439175;C0439810
family history of coronary artery disease,C2317524
ptca or pci,C2936173;C4049621
periprocedural medications no total no,C0013227;C0802604;C2598133;C4284232;C0439175;C0439810
bivalirudin,C0168273
glycoprotein iib iiia inhibitors,C0016011;C0243077
study treatment no total no,C1521826;C0439175;C0439810
no of target vessels,C0449618
non drug eluting stent,C1518422;C1322815
angiographic complications site reported no total no,C0205145;C1515974;C2825164;C0684224;C0700287;C4319718;C0439175;C0439810
threatened abrupt vessel closure,C0185003;C1521802
unsuccessful procedure,C0184661;C2700391;C3274430;C3539779
abrupt vessel closure,C0185003;C1521802
new or suspected thrombus,C0205314;C0087086;C0302148;C3146237
acute stent thrombosis,C0205178;C3897493
need for urgent coronary artery bypass grafting,C0439609;C0010055;C3272275
intravenous study drug administered no,C0683092;C1521801
bolus administered no,C1186706;C1511237;C1705509;C3812160;C1521801
infusion administered no total no,C0574032;C1827465;C1521801;C0439175;C0439810
duration of infusion hr,C0449238;C2926735
oral study drug administered no total no,C0013175;C1521801;C0439175;C0439810
figure $nmbr$ odds ratios for the primary end point according to diagnosis at enrollment in the modified intention to treat population,C0028873;C2986535;C0011900;C1704338;C1704656;C0087111;C0032659;C1257890;C1292734;C1522326
hs crp,C3890735;C4048285
hs crp $nmbr$ $nmbr$ mg l,C3890735;C0439268;C4048285
p all vs all,C0369773;C2603361
all n $nmbr$ f,C0369718;C0016327;C0441922
^ $nmbr$ y n,
nyha class n,C1882083
atrial fibrillation or flutter ecg,C0004238;C0344434;C1963067;C0016385;C1623258;C2242390
serum creatinine mol,C0027960;C0324740;C0439189;C1456781;C1824986;C3665593
serum creatinine $nmbr$ mmol l n,C0201976;C0600061
egfrmdrd ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$,C0439445
egfrmdrd,
nt probnp pmol l^,C0669479;C0439284;C0754710
medication n,C0013227;C3244316;C4284232
antiplatelet or anticoagulant,C0003280;C0848112;C3536711
type of hospitalization,C3177060
placebo n rate,C0871208;C1521828
rosuvastatin n rate,C0871208;C1521828
p subgroup,C1079230;C1515021
all cause,C0015127;C1524003
hospitalizations n,C0019993
cardiovascular,C0007226;C3887460
worsening heart failure,C0332271;C1457868;C1546960;C0018801;C0018802;C4554158
noncardiovascular,
item,C1551338;C4554251
baseline median iq range,C1514721;C2348147;C3542016
$nmbr$ month follow up median iq range,C1514721;C2348147;C3542016
difference median,C0549183;C0876920;C2347635;C2348144;C2939193
p net difference,C1705241;C1705242
triglycerides mmol lf,C1416933;C2986618;C4554443
placebo n rate $nmbr$,C0871208;C1521828
rosuvastatin n rate $nmbr$,C0871208;C1521828
hazard ratio $nmbr$,C2985465
$nmbr$ ci $nmbr$,C0008107;C3259781
subgroup p value $nmbr$,C1079230;C1709380;C1515021
interaction p value $nmbr$,C1704675;C1709380
primary endpoint $nmbr$,C2986535
all randomized,C0034656;C3815594
hs crp j $nmbr$ $nmbr$ mg l,C3890735;C0439268;C4048285
coronary events $nmbr$,C0741923
hs crp _ $nmbr$ $nmbr$ mg l,C3890735;C0439268;C4048285
all cause mortality or hosp for worsening hf hs crp,C0015127;C0026565;C0026566;C1524003;C0332271;C1457868;C1546960;C3890735;C4048285
no of events rate,C0441471;C0871208;C1521828;C3541888
placebo rosu vastatin,C0032042;C1099881;C1696465;C1706408
primary endpoint,C2986535
hscrp $nmbr$ $nmbr$ mg l,C0439268
hscrp $nmbr$ $nmbr$ mga,C0065879
$nmbr$ $nmbr$ ^ $nmbr$ $nmbr$ $nmbr$,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ z $nmbr$ ze,
$nmbr$ $nmbr$ $nmbr$ d $nmbr$,
$nmbr$ $nmbr$ j z $nmbr$ $nmbr$ e,
coronary endpoint,C2349179;C2826544
$nmbr$ $nmbr$ c $nmbr$ $nmbr$ $nmbr$,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ s $nmbr$,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ ^ $nmbr$,
hosp worsening hf,C0332271;C1457868;C1546960;C0018488;C1313497;C1538440;C3273279
$nmbr$ $nmbr$ $nmbr$ ^ $nmbr$ $nmbr$ $nmbr$,
all cause mort hf hosp,C0015127;C0018488;C1313497;C1538440;C3273279;C1524003
hscrp $nmbr$ $nmbr$ mga $nmbr$ $nmbr$ $nmbr$ x $nmbr$ $nmbr$ $nmbr$,C0065879
$nmbr$ $nmbr$ $nmbr$ z $nmbr$,
$nmbr$ $nmbr$ ^ $nmbr$ $nmbr$ j,
lm $nmbr$ $nmbr$,C1261082;C1551056
glargine $nmbr$,C0907402
sex male female,C0086287
race ethnicity zz,C0015031;C2347310;C0243103
black african,C0337824
descent,C0205386;C0680043
hbaie,
concomitant oral glucose lowering agents zz,C0442027;C0017725;C4521986;C0441994;C2003888;C0450442;C2347310;C1254351;C1521826
met su tzd,C0428210;C0038642;C1705534;C1550543;C4317104
su tzd,C0038642;C1705534
su met,C0428210;C1550543;C4317104
met tzd,C0428210;C1550543;C4317104
mmf n $nmbr$,C0083765;C0209368;C3848524
ivc n $nmbr$,C4085887
age at diagnosis of sle years,C1828181;C3173302
time since diagnosis of sle years,C0556970;C0011900;C1704338;C1704656
age at diagnosis of ln years,C1828181;C3173302
time since diagnosis of ln years,C0556970;C0011900;C1704338;C1704656
renal biopsy class,C0456387;C1518526;C1705943
class iii iii v,C0441887;C2698969
class iv iv v,C0441888;C2698970
class iv only,C0441888;C2698970
class v only,C0456387;C1518526;C1705943
scarring on renal biopsy,C0194073
$nmbr$ $nmbr$ $nmbr$ a,
urine p cr,C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
$nmbr$ $nmbr$ $nmbr$ $nmbr$ d,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ e,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ f,C0016327
estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$,C0017654;C0439445;C1424601
serum albumin concentration g l,C0439294;C0456615
$nmbr$ $nmbr$ $nmbr$ $nmbr$ g,C0439267
$nmbr$ $nmbr$ $nmbr$ $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
patients with negative anti dsdna,C0030705;C0741099
antibody binding level at baseline,C0428536
geometric anti dsdna antibody binding level,C0428536
$nmbr$ $nmbr$ $nmbr$ $nmbr$ i,C0021966;C0221138
$nmbr$ $nmbr$ $nmbr$ $nmbr$ j,
patients with low,C0030705;C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
concentrations at baseline,C0086045;C0168634;C1442488
geometric c $nmbr$ concentration mg dl,C0086045;C0439269;C1446561;C3827302
$nmbr$ $nmbr$ $nmbr$ $nmbr$ k,C0597277;C1708601
selena sledai total score,C0451528;C2964552
dabigatran n $nmbr$,C2348066
warfarin n $nmbr$,C0043031
estimated creatinine clearance ml min,C0812399;C0439445
type of index event no,C1561488;C0600653;C0918012;C1552854;C1637833;C2986546
deep vein thrombosis only,C0149871
pulmonary embolism only,C0034065
both deep vein thrombosis and pulmonary embolism,C0149871;C0034065
neither deep vein thrombosis nor pulmonary embolism^,C0149871;C0034065
cancer no,C0006826;C0998265;C1306459
previous venous thromboembolism no,C0205156;C1861172;C1552607
parenteral anticoagulation,C0003281;C2917212;C2919015;C3537050
treatment before randomization days,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
treatment after randomization in the single dummy phase days],C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0037179;C0439228;C0087136;C0205171
unfractionated heparin no,C0019134;C2825026
low molecular weight heparin no,C0019139;C3536766
fondaparinux no,C1098510
double dummy phase,C0205390;C1710475
exposure to study drug days,C0332157
adherence to study regimen no,C1510802;C0040808;C2945654
percent of the time that inr was in the therapeutic range,C0439165;C0040223;C3541383;C0525032;C1704538;C0460097
dabigatran,C2348066
percentages of patients with event,C0439165;C1549488;C1561533;C0441471;C4019010
\ge category,C0683312;C3889287
weight category,C0683312;C3889287
bmi category kg m $nmbr$,C0022718;C0439209;C4054209
creatinine clearance category [ml min],C0683312;C3889287;C0439445
$nmbr$ ml mln,C1417190;C3815103
previous vte,C0205156;C0630906;C1552607
initial symptomatic pe,C0070939;C1880476;C4284304
active cancer at baseline,C0006826;C0998265;C1306459
measure,C0079809;C0242485
fenofibric acid,C0060179
low dose statin,C0445550;C0360714;C1708745
fenofibric acid low dose statin,C0060179;C0360714
mean percentage change from baseline to final visit,C0392747;C0443172;C1705241;C4319952;C0545082;C1512346;C2826704
final,C0205088;C1546485;C3853528
efficacy variable,C0439828;C4553760
fenofibric acid i low dose statin,C0060179;C0360714
final mean,C0444504;C2347634;C2348143
change mean se,C0392747;C0036919;C0443172;C1705241;C4319952
apoal,
change meanlse,C0392747;C0443172;C1705241;C4319952
baseline median,C0549183;C0876920;C2347635;C2348144;C2939193
change median q $nmbr$ q $nmbr$,C0392747;C0443172;C1705241;C4319952
vldl c,C0523560
total c,C0439175;C0439810
moderate dose statin,C1709056;C0360714
fenofibric acid moderate dose statin,C0060179;C0360714
change meantse,C0392747;C0443172;C1705241;C4319952
safety variable,C0439828;C4553760
fenofibric acid $nmbr$ low dose statin,C0060179;C0360714
fenofibric acid i moderate dose statin,C0060179;C0360714
investigator reported aes,C1412268;C2699274
any treatment emergent ae,C0039798;C3887670;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
myalgia,C0231528;C4552646
rhabdomyolysis,C0035410;C4552660
laboratory evaluations,C0022877;C0220825;C3244292;C4283904
alt $nmbr$ x uln on two consecutive visits,C1519815;C0205448
ast $nmbr$ x uln on two consecutive visits,C1519815;C0205448
ck $nmbr$ xuln,C0009212;C0010287;C1872855
creatinine $nmbr$ $nmbr$ x baseline and above uln,C0168634;C1442488;C1519815
creatinine $nmbr$ x baseline,C0168634;C1442488
mean change s in fasting blood glucose [mg dl mmol l ],C0392747;C0443172;C1705241;C4319952;C0428568;C1261430;C0439268
f $nmbr$ $nmbr$ i $nmbr$ $nmbr$,C0021966;C0221138
neither t $nmbr$ dm nor mets,C0011816;C3250443;C0812270;C1705694;C2939420
metabolic syndrome w o t $nmbr$ dm,C0524620;C0796110
t $nmbr$ dm,C0011816;C3250443
a $nmbr$ ez $nmbr$,C0206578
mean age years s d,C0444504;C1510829;C2347634;C2348143
other forms of,C0348078;C0376315
atherosclerosis^ n,C0003850;C0004153
multiple $nmbr$ chd risk,C0439064;C1282512
factors that confer a,C1521761;C2827422
$nmbr$ year risk for chd,C0439234;C1282512;C0439508
family history of premature,C0241889;C0151526;C0205252;C4018905
tg $nmbr$ mg dl n o,C0337445;C0439269
hbalc mean s d,C0444504;C2347634;C2348143
baseline ldl c strata n o,C0168634;C1442488
$nmbr$ and $nmbr$ mg dl,C0439269
$nmbr$ and,
parameter mg dl,C0549193;C0439269;C1704769;C2350001
mets w o t $nmbr$ dm,C0812270;C1705694;C2939420
a $nmbr$ ez $nmbr$ a $nmbr$ n $nmbr$ n $nmbr$,C0206578;C0369718;C0441922
a $nmbr$ ezio a $nmbr$ n $nmbr$ n $nmbr$,C0369718;C0441922
treatment difference $nmbr$ ci,C0008107;C3259781
apolipoprotein b^,C0003593
apolipoprotein a i,C0085201;C1677784
total cholesterol hdl c,C0023822
apo b apo a l,C1447574;C4521365
non hdl c hdl c,C1518422;C3715113
treatment difference $nmbr$ cl,C0039798;C0596019;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
age y mean sd,C0001779;C2699239
men with ed n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0025266;C3538926
men without ed n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0025266;C3538926
previous a blocker,C0205156;C1552607
use,C0042153;C0457083;C1947944
sexually active $nmbr$,C0241028
coronary artery,C0205042
calcium channel,C0006685
blocker,
angiotensin,C0003018;C4521302
converting enzyme inhibitor,C0014432;C0919438;C4521603
angiotensin receptor,C0034787;C1622222
oral diabetic agent,C0450442;C1254351;C1521826
ipss mean sd,C0444504;C2699239;C2347634;C2348143
ipss qol,C1019118;C0518214;C1998280;C2827405;C3811063
bii mean sd,C0444504;C2699239;C2347634;C2348143
moderate to,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
mild ed,C2945599;C3538926
severe ed,C0205082;C3538926;C4050465;C4050466
mild ed severe ed,C2945599;C0205082;C4050465;C4050466
ipss ls mean se,C0023668;C0036919
ipss qol ls,C0518214;C0023668
mean se bii ls mean se,C0036919;C0023668
a $nmbr$ e $nmbr$ n $nmbr$,C1272460
a $nmbr$ $nmbr$ n $nmbr$,C0369718;C0441922
mean age years race,C0034510;C1706779;C3853635
body mass index $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
$nmbr$ concomitant medication,C0013227;C3244316;C4284232
other forms of atherosclerosis,C0348078;C0376315
diabetes mellitus type $nmbr$ or $nmbr$,C1320657
metabolic syndrome visit $nmbr$ low density lipoprotein cholesterol strata,C0524620;C0023824
$nmbr$ but,
figure $nmbr$ percentage of change from treated baseline in ldl cholesterol at week $nmbr$ a and week $nmbr$ b in prespeci ed subgroups treated with ezetimibe added to atorvastatin $nmbr$ mg versus up titration to atorvastatin $nmbr$ mg or atorvastatin $nmbr$ $nmbr$ mg a $nmbr$ atorvastatin $nmbr$ mg a $nmbr$ $nmbr$ $nmbr$ weeks of atorvastatin $nmbr$ mg followed by $nmbr$ weeks of atorvastatin $nmbr$ mg bl baseline bmi body mass index e ezetimibe $nmbr$ mg hdl c hdl cholesterol hs crp high sensitivity c reactive protein ldl c ldl cholesterol tg triglycerides,C0439165;C1549488;C1561533;C0168634;C1442488;C0332174;C0439230;C1706331;C0332293;C1142985;C1524062;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0547043;C0162621;C0332283;C0062152
mn na ve population,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882;C0032659;C1257890
uplift population,C0032659;C1257890
all mn na ve patients,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882;C0030705
all non mn,C0026327;C0026405;C4285072
sex m f,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384;C0016327
active smokers,C0205177;C0337664;C3853793;C3888249
copd history yrs,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
pre fev $nmbr$ pred,C0032952;C0044955
post fev $nmbr$ pred,C0032952;C0044955
pre fvc pred,C0032952;C0044955
post fvc pred,C0032952;C0044955
$nmbr$ day l,C0332173;C0439228;C0439505
$nmbr$ month l,C0332177;C0439231
$nmbr$ yrs l,
decline ml yr $nmbr$,C0439526;C0439234;C1705224;C3887665
pre fev $nmbr$,C0332152;C3714541;C0740175;C2257086;C3669034
post fev $nmbr$,C0687676;C3714541;C1704687;C3469826
pre fvc,C0332152;C3714541;C0740175;C2257086;C3669034
post fvc,C0687676;C3714541;C1704687;C3469826
pre svc,C0332152;C0231957;C0740175;C2257086;C3669034
post svc,C0687676;C0231957;C1704687;C3469826
glipizide n $nmbr$,C0017642
duration of diabetes mellitus median iqr y,C0449238;C2926735
dyslipidemia n,C0242339
prior myocardial infarction n,C0027051;C0428953;C2926063;C3810814;C4552959
presenting condition n,C0449450;C0012634;C0348080;C1705253;C3864998
acute coronary syndrome,C0948089
elective procedure,C0747973
baseline procedure n,C0168634;C0184661;C2700391;C3274430;C3539779;C1442488
medication use n,C0240320
other antiplatelet,
fibrate or other lipid lowering agent,C0086440
serum creatinine mean sd mg dl,C0201976;C0439269;C0600061
hemoglobin a $nmbr$ c mean sd,C0019020;C2699239;C3889898
bnp median iqr pg ml,C0054015;C0439297;C1095989;C1417808;C2982014
fasting insulin median iqr gu ml,C0015663;C0439526;C1705224;C3887665
ldl cholesterol mean sd mg dl,C0023824;C0439269;C0202117
hdl cholesterol mean sd mg dl,C0023822;C0439269;C0392885
triglycerides median iqr mg dl,C0041004;C0439269
hscrp median iqr mg l,C0549183;C0439268;C0876920;C2347635;C2348144;C2939193
mmp $nmbr$ median iqr gg l,C0017454;C0018370
as,
eu,C0015179;C3665627
sa,C0036243;C0038702;C1539696;C1825840;C3539736;C4521691
cardiac procedure,C1279986
prior oad,C0332152;C2826257
drug naive,C0013227;C1254351
low dose combination therapy,C0009429;C0556895
metformin monotherapy,C0025598
su monotherapy,C0038642;C1705534
smi,
systolic bp at baseline,C0871470;C0168634;C1442488
s $nmbr$ mmhg,C0439475
$nmbr$ mmhg,C0439475
statin use at baseline,C0042153;C0457083;C1947944
diabetes duration,C0449238;C2926735
s median,C0549183;C0876920;C2347635;C2348144;C2939193
hba $nmbr$ c at baseline,C0019016;C0168634;C1442488;C1825777;C3538758
hdl c at baseline,C3715113;C0168634;C1442488
ldl c at baseline,C0168634;C1442488
triglycerides at baseline,C0041004;C0168634;C1442488
hscrp at baseline,C0168634;C1442488
percent atheroma volume at baseline,C1690016;C3887614
without baseline vertebral fracture,C0168634;C0080179;C1442488
with baseline vertebral fracture,C0168634;C0080179;C1442488
flex pbo,C0031962
flex ain,C0347129
flex aln^,C0729594;C2681220
body mass index kg m^ meanisd,C0022718;C0439209;C4054209
fall in last $nmbr$ months,C0085639;C0238715;C4553726
history of clinical fracture $nmbr$ years,C1272071;C0205210
duration alendronate use years meanisd,C0102118;C0042153;C0457083;C1947944
using alendronate at baseline,C1524063;C0102118;C0168634;C1442488
using hrt or raloxifene at baseline,C1524063;C0282402;C0244404;C0168634;C1442488
time since start of fit years meanisd,C1301880
time from end of fit years meanisd,C1522314
flex baseline bmd g cm^ meanisd,C0168634;C0439267;C1442488
flex baseline bmd t score at femoral neck meanisd,C0449820;C4050231
$nmbr$ $nmbr$ fn t score,C0449820;C4050231
$nmbr$ $nmbr$ fn t score $nmbr$ $nmbr$,C0449820;C4050231
fn t score $nmbr$ $nmbr$,C0449820;C4050231
flex baseline bmd t score at lumbar spine meanisd,C0449820;C4050231
$nmbr$ $nmbr$ ls t score,C0449820;C4050231
$nmbr$ $nmbr$ ls t score $nmbr$ $nmbr$,C0449820;C4050231
ls t score $nmbr$ $nmbr$,C0449820;C4050231
change in femoral neck bmd from fit baseline to flex baseline,C0742135;C0036572;C0168634;C1442488;C2349186;C4048158;C4553125
gained bmd,C1517378
lost bmd,C0745777;C3815882
femoral neck f score at flex baseline,C0016327;C0449820;C4050231
nonvertebral,
morphometric vertebral,C0549207
pbo no o o ^,C0031962;C0483204
ain no,C0347129
pbo no ^,C0031962
nvf at flex baseline $nmbr$ flex fn t score,C0168634;C0449820;C4050231;C1442488
$nmbr$ $nmbr$ flex fn f score $nmbr$,C0449820;C4050231
flex fn f score $nmbr$ $nmbr$,C0449820;C4050231
p value for interaction vertebral fracture at flex baseline,C1709380;C0080179;C0168634;C1442488
$nmbr$ flex fn f score,C0449820;C4050231
nateglinide n $nmbr$,C0903898
race no i,C0034510;C1706779;C3853635;C0021966;C0221138
body mass index^,C0005893;C0578022;C1305855
waist circumference cmj,C0455829
blood pressure while seated mm hg,C0005823;C1271104;C1272641;C0277814;C0439475;C1283233
family history of premature heart disease,C0850707
reduced hdl cholesterol,C0151691
elevated non hdl cholesterol,C0729627;C1535899
history of cardiovascular disease no,C0455539
angina or positive stress test,C0002962;C0015260;C3494508
multivessel coronary artery bypass grafting,C0010055
peripheral arterial stenosis,C4025272
lower limb angioplasty or bypass surgery,C0745788;C1536078
nontraumatic leg or foot amputation,C0023216;C1140621;C0188605
family history of diabetes mellitus no,C0260526;C1313937
plasma glucose mmol per liter,C0202042;C0439190;C0455280
fasting,C0015663
$nmbr$ hr after glucose challenge,C3840385
metabolic syndrome no ^,C0524620
lipids mg dl,C0023779;C0439269
estimated gfr ml min $nmbr$ $nmbr$ m^,C0017654;C0439445;C1424601
ratio of urinary albumin mg to creatinine g,C0456603;C1547037;C0010294;C0439267;C1561535
last study visit,C0545082;C1512346;C2826704
alpha blocker,C0001641
aspirin or other antiplatelet drug,C0004057;C0085826
lipid modulating drug,C0023779;C0443264;C0013227;C1254351
antidiabetic drug i j,C0935929;C0021966;C0221138
section $nmbr$ a,C0152060;C0700320;C1522472;C1552923;C1705191;C3714523
nateglinide n n,C0903898
progression to diabetes,C1735364
hazard ratio $nmbr$ cl nateglinide vs placebo,C2985465;C0903898;C0032042;C1696465;C1706408
two sided p value for hetero geneity,C0205448;C1709380
all patients p $nmbr$ $nmbr$,C0030705
aslan,
fasting plasma glucose,C0202042;C0455280
$nmbr$ hr prandial glucose,C1998602;C0017725;C4553624
[kg m^],C0022718;C0439209;C4054209
[cm female cm male ],C0086582;C1706180;C1706428;C1706429
history of cardiovascular disease,C0455539
ace inhibitor treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
section $nmbr$ b,C0152060;C0700320;C1522472;C1552923;C1705191;C3714523
extended cardiovascular endpoint,C2349179;C2826544
section $nmbr$ c,C0152060;C0700320;C1522472;C1552923;C1705191;C3714523
core cardiovascular endpoint,C2349179;C2826544
sitting blood pressure mmhg,C0580946;C0439475
peripheral artery stenosis,C0038449
stroke of atherosclerotic origin,C0038454;C4554100
glycemic indexes,C1136206
fasting plasma glucose mmol liter,C0202042;C0475211;C0455280
plasma glucose $nmbr$ hr after glucose load mmol liter,C0202042;C0455280
metabolic syndrome no $nmbr$,C0524620
estimated gfr^,C0017654;C1424601
mean ml min $nmbr$ $nmbr$ m^,C0444504;C0439445;C2347634;C2348143
ratio of urinary albumin mg to creatinine g median,C0456603;C1547037;C0549183;C0876920;C2347635;C2348144;C2939193
concomitant medication no ace inhibitor,C0013227;C3244316;C4284232;C0003015;C4541021
any antihypertensive drug,C0003364
aspirin orother antiplatelet drug,C0004057
antidiabetic drug,C0935929
hazard ratio $nmbr$ cl valsartan vs placebo,C2985465;C0216784;C0032042;C1696465;C1706408
all patients p,C0030705
fenofibrate n $nmbr$,C0033228
education no,C0013621;C0013622;C0013658;C0039401
high school graduate or ged,C0870649;C1549971;C1880947
missing data,C4684714
previous cardiovascular event no,C0205156;C1320716;C1552607
previous congestive heart failure no,C0205156;C0018802;C1552607
cigarette smoking status no,C1519386
amputation due to diabetes no,C0678226;C0598284
estimated glomerular filtration rate no,C3811844
$nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0439445
plasma cholesterol mg dl,C0858034;C0439269
plasma triglyceride mg dl,C0032105;C0439269;C1550098;C4521445
patient characteristics at randomization,C0815172;C0034656
age years [median $nmbr$ th to $nmbr$ th percentile ],C1510829;C0039725;C0039738;C1420718;C4282123;C4285344
weight kg m $nmbr$ [median $nmbr$ th to $nmbr$ th percentile ],C0022718;C0439209;C4054209;C0039725;C0039738;C1420718;C4282123;C4285344
bmi kg m $nmbr$ [median $nmbr$ th to $nmbr$ th percentile ],C0022718;C0439209;C4054209;C0039725;C0039738;C1420718;C4282123;C4285344
antidiabetes drug usage [ n ],C0242510;C0369718;C0441922
biguanide metformin,C0005382;C0025598;C3537187;C4317165
thiazolidinedione,C0289779;C1257987;C3537039
a glucosidase inhibitor,C1512211
meglitinide,C0065880
no antidiabetic drug,C0935929
monotherapy,
dual therapy,C0039798;C0087111;C1363945
three or more drugs,C0205449;C0013227;C3687832
patient characterization data are reproduced from morrow et al $nmbr$,C2707520;C1880022;C0040028;C0202311
patients with possible new dm at randomization fpg $nmbr$ $nmbr$,C0030705;C0011816;C3250443;C0034656
fpg month $nmbr$ mg dl,C0332177;C0439269;C0439231
change in fpg $nmbr$ to month $nmbr$ mg dl,C0392747;C0443172;C1705241;C4319952;C0332177;C0439269;C0439231
$nmbr$ $nmbr$ $nmbr$ ci $nmbr$ $nmbr$ $nmbr$ $nmbr$ n $nmbr$,C0008107;C3259781
$nmbr$ $nmbr$ $nmbr$ ci $nmbr$ $nmbr$ $nmbr$ $nmbr$ n $nmbr$ p $nmbr$ $nmbr$,C0008107;C3259781
patients with possible new dm at randomization hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$,C0030705;C0011816;C3250443;C0034656;C0019016;C1825777;C3538758
hba $nmbr$ c month $nmbr$,C0332177;C0439231
change in hba $nmbr$ c $nmbr$ to month $nmbr$,C0392747;C0443172;C1705241;C4319952;C0332177;C0439231
$nmbr$ $nmbr$ $nmbr$ ci $nmbr$ $nmbr$ $nmbr$ $nmbr$ n $nmbr$ a $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0008107;C3259781
febuxostat $nmbr$ mg daily n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
febuxostat $nmbr$ mg daily n $nmbr$ n,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
allopurinol $nmbr$ $nmbr$ mg daily n $nmbr$,C0002144;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
american indian or alaska native,C0002460;C0682125
native hawaiian or other pacific,C0337920
islander,
$nmbr$ to $nmbr$,
non ex drinker,C0457801
drinker $nmbr$ to $nmbr$ drinks week,C0556338;C0332174;C0439230
serum urate mg dl,C0455272;C0439269
years with gout,C0439234;C0018099
completed previous febuxostat study,C2348557;C0205156;C1552607
renal functionb,C0022646
moderately impaired,C0205081;C0221099;C1881878;C4085643;C4321491
mildly impaired,C0750532;C0221099;C2945599
normal,C0205307;C0231683;C0439166;C2347086;C4553972
including hypertension,C0020538;C1963138
use of low dose aspirin $nmbr$,C1524063;C2608320
mg daily,C0024671;C0332173;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
febuxostat $nmbr$ mg daily n $nmbr$ n n,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
renal functiona,C0022646
baseline serum urate mg dl a,C0455272;C0439269
baseline tophusa,C0168634;C1442488
completed prior febuxostat studya,C0205197;C0249529;C3854010
age $nmbr$ y n n,C0001779
white n n,C0007457;C0043157;C0220938
diabetes mellitus n n,C0011849
hypertension n n,C0020538;C1963138
hyperlipidemia n n,C0020473;C0428465;C4555212
metabolic syndrome n n,C0524620
current smoker n n,C3173209;C3241966
prior mi n n,C0332152;C2826257
prior coronary revascularization n n,C0332152;C0877341;C2826257
prior angina n n,C0332152;C0002962;C2826257
prior heart failure n n,C0018801;C0018802;C4554158
timi risk score n n,C0035647;C0449820;C4050231;C4552904
index event n n,C0600653;C0441471;C4019010;C0918012;C1552854;C1637833;C2986546
ua,C0041580;C0042014
nstemi,C3537184;C4255010
time from symptoms to randomization h,C0040223;C3541383;C0033727;C0369286;C0441932;C0564385;C4528284
women n $nmbr$ n n,C0043210
men n $nmbr$ n n,C0025266
angiography and revascularization,C0002978;C0581603
angiography during index hospitalization,C0002978;C0019993
angiographic extent of disease,C0449279;C4553144
$nmbr$ vessel,C0005847
$nmbr$ vessels,C0005847
$nmbr$ vessels or left main,C0005847;C0205091;C0205225;C1542147;C0443246;C1552822
pci during index hospitalization,C4049621;C0019993
cabg during index hospitalization,C0010055;C0019993
gpiib iiia receptor inhibitor,C0016011;C1999216
diabetic treatments,C0241863;C0087111
oral agents,C0450442;C1254351;C1521826
diet alone,C0012155;C0012159;C1519433;C2983588;C3668949;C0205171;C0439044;C0679994
p interaction women vs men,C0369773;C0043210;C2603361;C0025266
p $nmbr$ interaction women vs men,C0369773;C0043210;C2603361;C0025266
azathioprine n $nmbr$,C0004482
infliximab n $nmbr$,C0666743
combination therapy n $nmbr$,C0009429;C0556895
p valued,C0369773;C2603361
white race no t,C0007457;C0043157;C2603360
median age yr,C0001779;C0439234
median body weight kg,C0022718;C0439209;C4054209
median disease duration yr,C0872146;C0439234
median c reactive protein mg dl^,C0006560;C0439269;C1413716;C4048285
crohn s disease activity index score],C0010346;C4706353;C0600653;C0918012;C1552854;C1637833;C2986546
gastrointestinal area involved no total no,C0017446;C0205146;C1314939;C0439175;C0439810
ileum or colon,C0020885;C0009368;C3888384
ileum only,C0020885
colon only,C0009368;C3888384
proximal gastrointestinal tract,C0017189;C0521362
systemic corticosteroids no,C4053960
any type according to daily dose,C0332307;C1547052
budesonide no,C0054201
$nmbr$ aminosalicylic compounds no,C0205198;C1706082
proportion of patients in corticosteroid free clinical remission at week $nmbr$,C1709707;C0030705;C0205210;C0544452;C0687702
ifx aza n $nmbr$,C0020823;C0004482
aza n $nmbr$,C0004482
d value,C1522609
crohn s disease related surgery,C0010346;C0038894;C0038895;C0543467;C1274039
with previous surgery,C0038894;C0038895;C0543467;C1274039
without previous surgery,C0038894;C0038895;C0543467;C1274039
baseline corticosteroid use mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
with corticosteroid treatment $nmbr$,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
duration of crohn s disease yrs,C0449238;C2926735;C0012634
baseline crp mg dl,C0168634;C0439269;C1442488
europe lsrael,C0015176
baseline $nmbr$ asa,C0004057;C3853627
use $nmbr$ asa compounds,C0205198;C1706082
no use of $nmbr$ asa compounds,C1524063;C0004057;C3853627
total group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
ifx n $nmbr$,C0020823
enox,C3147679
no dm,C0011816;C3250443
no prior ml,C0439526;C1705224;C3887665
fibrinolytic,C0040044
fibrin specilic,C0015982
time to rx,C0040223;C3541383
amlodipine valsartan $nmbr$ to $nmbr$ $nmbr$ mg n $nmbr$,C1962523;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
amlodipine $nmbr$ to $nmbr$ mg n $nmbr$,C0051696;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
age sd yrs,C0001779;C2699239
age category n,C0001779;C0683312;C3889287
hypertension severity at baseline n,C0439793;C0522510
diabetic status n,C0241863;C0449438
ish status n,C0449438
bmi n,C0578022
tiotropium nz $nmbr$,C0213771;C0027978
control nz $nmbr$,C0243148;C0027978;C1550141;C1882979;C2587213;C3274648;C4553389
a demographics,C0011298;C1704791
history pack years,C0019664;C1277691;C0019665;C0262512;C0262926;C1705255;C2004062
gold stage [n ],C0205390;C1300072;C1306673;C0369718;C0441922
pre bronchodilator,C2599602
post bronchodilator,C2599594
patients with $nmbr$ $nmbr$ ml increase in fev $nmbr$ post bronchodilator,C0030705;C0439526;C1705224;C3887665;C3714541;C2599594
fvc predicted,C3714541;C0681842;C1882327
b concomitant respiratory medications [n ],C0521115;C0418986;C0369718;C0441922
any pulmonary medication,C0013227;C3244316;C4284232
anti cholinergics long acting,C0242896;C0205166;C1706317
anti cholinergics short acting a,C0242896;C1282927;C1806781;C2350002
b agonists long acting a,C0243192;C2987634;C0205166;C1706317
b agonists short acting a,C0243192;C2987634;C1282927;C1806781;C2350002
leukotriene receptor antagonists,C0595726;C2757015;C3542962
mucolytics,C0026698
steroids inhaled a,C0038317;C0004048
steroids other,C0038317
theophyllines,C0039771
mean yearly decline,C0332181;C0439508
pred,C0032952;C0044955
fev $nmbr$ pre bronchodilator,C3714541;C2599602
fev $nmbr$ post bronchodilator,C3714541;C2599594
fvc pre bronchodilator,C3714541;C2599602
fvc post bronchodilator,C3714541;C2599594
baseline parameter,C0549193;C1704769;C2350001
number of subjects,C0237753;C0449788
asthma duration sd years,C0004096;C0439234;C2984299
fev $nmbr$ percent predicted sd,C0439165;C2699239
am pef sd l min,C0702093;C1524029;C3813700
pm pef sd l min,C0702093;C1524029;C3813700
symptom score sd,C3476546;C2699239
albuterol use sd puffs day,C0332173;C0439228;C0439505
figure $nmbr$ change in am pef by bmi and treatment group bars represent the standard error of the mean,C0030771;C1518922;C1542834;C1707156;C3274014;C3541345;C1882932;C1710181
figure $nmbr$ change in pm pef by bmi and treatment group bars represent the standard error of the mean,C0392747;C0443172;C1705241;C4319952;C0578022;C1707156;C3274014;C3541345;C1882932;C1710181
figure $nmbr$ change in $nmbr$ hour symptoms score by bmi and treatment group bars represent the standard error of the mean,C0436315;C0578022;C1707156;C3274014;C3541345;C1882932;C1710181
nyha ll lll patients with lvef,C1275491;C0030705;C0428772;C0488728
remaining patients,C1527428;C0030705
age years sd,C1510829;C2699239
ischaemic dilated cardiomyopathy,C1960867
non rheumatic valvular heart disease,C1518422;C0264757
non ischaemic dilated cardiomyopathy,C1518422;C1960867
overall population,C0032659;C1257890
hr [ $nmbr$ ci,C0008107;C3259781
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
lvef^ $nmbr$ $nmbr$ and nyha class ii iii at baseline,C0428772;C0488728;C1882086
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
outcome measure,C0086749
time to first cv hospitalization or death from any cause,C0040223;C3541383;C0007465
first cv hospitalization,C0205435;C0019993;C1279901
death from any cause,C0007465
first hospitalization for chf or cv death,C0019993;C0018802;C0011065;C1306577;C4082313;C4552775
indacaterol $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
age yr mean sd,C0001779;C2699239
ics users n,C0815320;C1706077;C4551720
smoking history pack years mean sd,C1277691;C2699239
fevi l mean sd $nmbr$,C0429706;C2699239;C0849974;C1561566;C4528367
fevi predicted mean sd $nmbr$,C0429706;C2699239;C0849974;C1561566;C4528367
fev $nmbr$ fvc mean sd $nmbr$,C0444504;C2699239;C2347634;C2348143
reversibility b $nmbr$ agonist mean sd $nmbr$,C0444504;C2699239;C2347634;C2348143
reversibility anticholinergic mean sd,C0242896;C2699239;C3537004
figure $nmbr$ trough fev $nmbr$ at $nmbr$ weeks differences between active and placebo treatments in patient subgroups divided according to baseline status for age smoking status and inhaled corticosteroid ics use all contrasts versus placebo signi cant at p $nmbr$ $nmbr$ indacaterol both doses was noninferior to tiotropium p $nmbr$ $nmbr$ in all subgroups,C0444506;C3714541;C1705241;C1705242;C1554093;C3242279;C3242455;C0332849;C0168634;C1442488;C0001779;C1519386;C0004048;C0239126;C0009924;C1979874;C0032042;C2825972;C1696465;C1706408;C0178602;C0213771;C1079230
aml val $nmbr$ $nmbr$ mg rr $nmbr$,C0023465;C4554402;C0023467
ami $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
sex n male,C0086582
non elderly,C1518422;C0001792;C1999167
elderly $nmbr$ years,C0001792;C0439234;C1999167
race ethnicity chinese,C0008120;C0152035
bmi kg m $nmbr$ n,C0022718;C0439209;C4054209;C0369718;C0441922
type $nmbr$ diabetes history n,C1320657;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
duration of hypertension years,C0449238;C2926735
mean sitting dbp mmhg,C0277814;C0439475;C2584297;C4050224
mean sitting sbp mmhg,C0085805;C0439475
least square mean se,C0023189;C0036919
difference se,C1705241;C0036919;C1705242
aml val $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ami $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
pad at baseline,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
no pad baseline,C0168634;C1442488
epa,
ezetimibe simvastatin $nmbr$ $nmbr$ mg n $nmbr$,C1532737;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
rosuvastatin $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
current cvd diabetes n,C0007222;C0011847;C0011849
high risk cvd n,C0332167;C3272283;C4050568;C4319571
mean $nmbr$ year cvd risk,C0007222;C0035647;C4552904
type $nmbr$ n,C0332307;C1547052
fasting lipid levels mmol l,C0428460;C1532563
triglycerides median range,C1514721;C2348147;C3542016
percentage patients reaching target,C0439165;C0030705;C1549488;C1561533;C2584321;C1521840;C2986546
exetimibe simvastatin,C0074554
atorvastatin,C0286651
ldl c $nmbr$ $nmbr$ mmol l,C1532563
jbs $nmbr$ secondary prevention only $nmbr$,C0175692;C0679699;C0795841;C1416527
jbs $nmbr$ primary prevention only $nmbr$,C0175692;C0033144;C0795841;C1416527
nice secondary prevention onlyb,C4087029;C0679699
nice primary prevention onlyb,C4087029;C0033144
baseline ldl c $nmbr$ $nmbr$ to $nmbr$ $nmbr$ mmol lc,C0168634;C1442488;C0439190
infliximab naive n $nmbr$,C0666743
infliximab experienced n $nmbr$,C0666743
mean s d age years,C0444504;C1510829;C2347634;C2348143
mean duration of disease years,C0872146;C0439234
location of crohn s disease,C0450429;C1515974;C4284930;C4284931;C0012634
upper gastrointestinal,C1282910;C0521362
resection performed,C0015252;C0728940;C0884358
mean cdai score,C3533236;C0683448;C1413248;C3273706
geometric mean crp concentration mg l,C2986759;C0439268
penetrating disease,C0205321;C0012634
medications at baseline n,C0013227;C0802604;C2598133;C4284232
no corticosteroids or immunosuppressants,C0001617;C3539185;C3540725;C3540726;C3540727;C0021081
figure $nmbr$ maintenance of a response and b remission at week $nmbr$ by prior in iximab use intent to treat population,C0024501;C0871261;C1704632;C1706817;C2911692;C0544452;C0687702;C0332152;C0032659;C1257890
history of myocardial infarction,C1275835
history of cabg surgery,C0455610;C0010055
symptom onset to hospital admission,C4086878;C0184666
intervention,C0184661;C0886296;C1273869
final timi flow grade post ppci,C0205088;C3272266;C1546485;C3853528
macce,
lce n $nmbr$,C1423759;C3273355
lc n $nmbr$,
age mean yr,C0001779;C0439234
men no,C0025266
mean duration of pd yr,C0449238;C2926735
updrs total ii iii,C0439070;C1705160
updrs part ii adl,C0001288;C1420005
updrs part iii motor,C1513492;C1705994
hoehn yahr stage,C0205390;C1300072;C1306673
schwab england score,C0449820;C4050231
pdq $nmbr$,
previous antiparkinson medication no,C0205156;C0003405;C1552607
dopamine agonist use no,C0042153;C0457083;C1947944
lce l dopa carbidopa entacapone lc l dopa carbidopa pd parkinson disease updrs rating scale adl activities of daily living pdq $nmbr$ parkinson disease questionnaire,C1292728;C0337645;C0034394
unified parkinson disease,C0030567;C1521736
olmesartan medoxomil $nmbr$ mg hctz $nmbr$ $nmbr$ mg n $nmbr$,C0386393;C1319635
olmesartan medoxomil $nmbr$ mg n $nmbr$,C0386393;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
age y [mean sd],C0001779;C0444504;C2699239;C2347634;C2348143
$nmbr$ [n ],C0369718;C0441922
males [n ],C0086582;C0369718;C0441922
diabetes mellitus [n ],C0011849;C0369718;C0441922
bmi kg m $nmbr$ [mean sd],C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
sedbp mmhg [mean_ sd]a,C0439475;C0444504;C2699239;C2347634;C2348143
sesbp mmhg [mean _sd]a,C0439475;C0444504;C2699239;C2347634;C2348143
severity ofhypertension [n ]b,C0439793;C0522510;C0369718;C0441922
mild,C2945599
pre treatedforhypertension [n ],C0332152;C0740175;C2257086;C3669034;C0369718;C0441922
pre treatment[n ]c,C1550147;C2709094;C3539075;C3539076;C2349138
calcium channelantagonist,C0006675;C0006726;C2936886;C3540037;C3714611
low ceiling diuretic,C0205251;C0012798;C1550472;C3890211;C4048187;C4321351;C4522223
bp in pre treated patients,C0037623;C1415692;C1708288;C4318478
sedbp mmhg [mean _sd]d,C0439475;C0444504;C2699239;C2347634;C2348143
sesbp mmhg [mean sd]d,C0439475;C0444504;C2699239;C2347634;C2348143
high dose statin,C0444956;C0360714
prevalence of each metabolic syndrome criterion,C0033105;C0220900
met criterion at blt n [ ],C0428210;C0243161;C1550543;C4317104
met criterion at final n [ ],C0243161;C0205088;C1546485;C3853528
elevated tg,C0205250;C0337445;C3163633
elevated blood pressure,C0020538;C0497247
met criterion at bl n [ ],C0243161;C0005918;C0006413;C1552663;C2827109
elevated fasting glucose,C0015663;C0017725
increased waist circumference,C0205217;C0455829;C0442805
met criterion at finalt,C0428210;C0243161;C1550543;C4317104
n a,C1272460
changes a in metabolic syndrome parameters hdl cholesterol,C0392747;C0443172;C0524620;C2357172
bl mean mg dl mmol $nmbr$,C0567349;C2348885
mean a sem,C0444504;C2347634;C2348143
$nmbr$ $nmbr$ lno^,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ ti,C0039247;C0040302;C1553045;C1704756
bl mean mmhg,C0005918;C0439475;C0006413;C1552663;C2827109
mean a sd mmhg,C0444504;C2347634;C2348143;C2699239;C0439475
fasting blood glucose,C0428568;C1261430
mean a sd mg dl mmol $nmbr$,C0444504;C2347634;C2348143;C0567349;C2348885
bl mean cm,C0005918;C0006413;C1552663;C2827109
mean a sdt,C0444504;C2347634;C2348143
tiotropium $nmbr$ mg respimat n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
placebo n z $nmbr$,C0032042;C1696465;C1706408
screening visit,C0545082;C1512346;C2826704
current smoker ex smoker,C3173209;C3241966
time since copd diagnosis yrs,C0040223;C3541383
pre bronchodilator fev $nmbr$ l,C2599602;C3714541
pre bronchodilator fev $nmbr$ predicted normal,C2599602;C0520835
pre bronchodilator fvc l,C2599602;C3714541
pre bronchodilator fev $nmbr$ fvc,C2599602;C3714541
post bronchodilator fev $nmbr$ l a,C2599594;C3714541
post bronchodilator fev $nmbr$ predicted normal a,C2599594;C0520835
reversibility of fev $nmbr$,C0449261;C3714541
post bronchodilator fvc l a,C2599594;C3714541
post bronchodilator fev $nmbr$ fvc a,C2599594;C3714541
randomisation visit baseline,C0168634;C1442488
fvc l proportion taking pulmonary medications b,C1290952;C0024109;C2707265;C2709248;C4522268
any medication,C0013227;C3244316;C4284232
long acting b $nmbr$ agonists,C0243192;C2987634
short acting b $nmbr$ agonists,C0243192;C2987634
inhaled corticosteroids,C0004048;C0001617;C3539185;C3540725;C3540726;C3540727
oral corticosteroids,C0442027;C0001617;C3539185;C3540725;C3540726;C3540727;C4521986
xanthines,C0043318;C3541955
short acting anticholinergics,C0242896;C3537307;C3540711
supplementary oxygen,C0030054
laba users,C1706077
laba non users,C1518422;C1706077
tiotropium $nmbr$ mg respimat n z $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
proportion taking pulmonary medications b,C1290952;C0024109;C2707265;C2709248;C4522268
tiotropiumc,
preamendment,C1548596
postamendment,
extended duration enoxaparin n $nmbr$,C0231448;C0206460;C0231449;C0439792
asian or oriental,C0078988;C0699027
region of enrollment n,C0017446;C0205147
africa asia or the middle east,C0001737;C0003980;C0026068
body mass index $nmbr$ kg m $nmbr$ n,C0022718;C0439209;C4054209;C0369718;C0441922
primary enrollment diagnoses n,C0332137;C0801658
acute infection without septic shock,C0275518;C0036983
acute respiratory insufficiency,C0865850
post acute ischemic stroke,C0751956
acute rheumatic disorders,C0001314
active cancer,C0006826;C0998265;C1306459
fracture,C0016658
multiple diagnoses,C0439064;C0011900
active inflammatory bowel disease,C0205177;C0021390;C3853793;C3888249
risk factors and immobility level n,C0035648;C1553898;C0231441;C0441889;C0456079;C1547707;C2946261
level $nmbr$ immobility,C0441889;C0231441;C0456079;C1547707;C2946261
level $nmbr$ immobility^,C0441889;C0231441;C0456079;C1547707;C2946261
history of vte,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
active or previous cancer,C0205177;C3853793;C3888249;C0006826;C0998265;C1306459
obesity body mass index $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
venous insufficiency,C0042485
chronic heart failure,C0018802;C0264716
chronic respiratory failure,C0264492
chronic inflammatory disease,C1290886
family history of vte,C0241889;C0630906
thrombophilia,C0398623
previous medications n,C0205156;C0013227;C0802604;C2598133;C4284232;C1552607
antiplatelet or anti inflammatory drugs,C0003209
antiplatelet drugs,C0085826;C2963157
anti inflammatory drugs,C0003209
extended duration enoxaparin n n,C0231448;C0206460;C0231449;C0439792
absolute risk difference ci,C0008107;C3259781
vte at day $nmbr$,C0630906;C0332173;C0439228;C0439505
level $nmbr$,C0441889;C0456079;C1547707;C2946261
major bleeding events,C0441471;C3541888
scd,
hradj $nmbr$ ci,C0008107;C3259781
qtc,
$nmbr$ $nmbr$ referent,C1706462
qtc $nmbr$ n $nmbr$,
no prior mi n $nmbr$,C0332152;C2826257
prior mi n $nmbr$,C0332152;C2826257
no prior hf n $nmbr$,C0332152;C0018488;C1313497;C1538440;C3273279;C2826257
prior hf n $nmbr$,C0332152;C0018488;C1313497;C1538440;C3273279;C2826257
bnp,C0054015;C1095989;C1417808;C2982014
bnp $nmbr$ pg ml n $nmbr$,C0054015;C0439297;C1095989;C1417808;C2982014
ef $nmbr$ n $nmbr$,
figure $nmbr$ systolic blood pressure a diastolic blood pressure b and pulse pressure c as a function of age in $nmbr$ year increments and time,C0488055;C0871470;C1306620;C0428883;C1305849;C0949236;C0439234;C1705117;C0439508;C0040223;C3541383
om $nmbr$ mg aml $nmbr$ mg n $nmbr$,C1319635;C0023465;C0023467
om $nmbr$ mg hctz $nmbr$ mg n $nmbr$,C1319635;C0020261
aml $nmbr$ mg hctz $nmbr$ mg n $nmbr$,C1319635;C0020261
om $nmbr$ mg aml $nmbr$ mg hctz $nmbr$ mg n $nmbr$,C1319635;C0020261
age group no,C0027362;C2348001
height mean sd cm,C0489786;C0444504;C2347634;C2348143
bmi mean sd kg m^,C0022718;C0439209;C4054209
bmi category no,C0683312;C3889287
$nmbr$ kg m^ obesity,C0022718;C0439209;C4054209;C0028754;C1963185
chronic kidney disease no t,C1561643;C4553188;C2603360
chronic cardiovascular disease no,C1290380
bp goal no,C0018017;C1571704
baseline sesbp mean sd mm hg,C0168634;C0439475;C1442488
baseline sedbp mean sd mm hg,C0168634;C0439475;C1442488
om $nmbr$ mg aml $nmbr$ mg,C1319635;C0023465;C0023467
om $nmbr$ mg hctz $nmbr$ mg,C1319635;C0020261
aml $nmbr$ mg hctz $nmbr$ mg,C1319635;C0020261
om $nmbr$ mg aml $nmbr$ mg hctz $nmbr$ mg,C1319635;C0020261
bp variable mm hg,C0037623;C0439475;C1415692;C1708288;C4318478
moderate severe n $nmbr$ n $nmbr$,C0205081;C0205082;C4050465;C4050466;C1881878;C4049705;C4049706;C4085643;C4321335
baseline bp mean sd,C0488053;C2699239
change in sesbp ls mean se,C0392747;C0443172;C1705241;C4319952
change in sedbp ls mean se,C0392747;C0443172;C1705241;C4319952
$nmbr$ $nmbr$ $nmbr$ $nmbr$ ll,
cad and or crvd,C1504769;C2239547;C3813548;C4284121
$nmbr$ $nmbr$ a,
mean preoperative abpi of the index,C0444504;C0445204;C2347634;C2348143
limb sd,C0015385;C2699239
pad symptoms,C0683368;C1457887
claudication only,C0021775;C0311395;C1456822
rest pain,C0234253
ulcers gangrene,C0041582;C0017086
distal anastomosis,C0448964
below knee popliteal,C0022742;C0442037;C0022745;C1963703
below knee popliteal crural,C0023216;C1140621
beyond popliteal pedal,C0016504;C0687080
all grafts,C0332835;C1527362
venous,C0042449;C0348013
prosthetic,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ b,
graft occlusionsa,C0181074;C0332835;C1961139
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ c,
amputationsa,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ d,
placebo n[ $nmbr$,C0032042;C1696465;C1706408
salmeterol n [ $nmbr$,C0073992
fp n [ $nmbr$,C0016704;C1419068;C1419906;C3541238;C3541412
sfc n [ $nmbr$,C4521536
age at enrolment years,C1510829;C1516879;C1696073;C3888021
postbronchodilator fev $nmbr$ predicted,C0681842;C1882327
$nmbr$ e $nmbr$ n,
geographical region n,C0017446;C0205147
pack years smoked,C1277691;C0037366;C0439994;C1881674
previous copd treatment n,C0024117;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C1412502;C3714496
ics alone,C0815320;C4551720;C0205171;C0439044;C0679994
laba alone,C0205171;C0439044;C0679994
ics laba,C0815320;C4551720
neither ics nor laba,C0815320;C4551720
previous mi n,C0205156;C1552607
baseline cv treatment n y,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
baseline short acting anticholinergics n,C0168634;C0242896;C3537307;C3540711;C1442488
salmeterol n[ $nmbr$,C0073992
fp n[ $nmbr$,C0016704;C1419068;C1419906;C3541238;C3541412
sfc n[ $nmbr$,C4521536
$nmbr$ e,
baseline cv treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
baseline short acting anticholinergics,C0242896;C3537307;C3540711
severe oab subgroup,C1079230;C1515021
fas,
solifenacin n $nmbr$,C1099677
age cohort no,C2348001
diary variables mean sd,C0376660;C2699239
urgency episodes $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
incontinence episodes $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
micturitions $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
nocturia episodes $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
wt second median,C0549183;C0876920;C2347635;C2348144;C2939193
ppbc score mean sd,C0444504;C2699239;C2347634;C2348143
iuss score mean sd,C0444504;C2699239;C2347634;C2348143
ups score mean sd,C0334463;C2699239;C3542434
oab q score mean sd,C3641332;C2699239
symptom bother,C1457887;C3854129
hrql mean sd,C0444504;C2699239;C2347634;C2348143
coping,C0009967
concern,C2699424
sleep,C0037313
social interaction,C0037420
all n $nmbr$ $nmbr$,C0369718;C0441922
bivalirudin n $nmbr$ $nmbr$,C0168273
heparin plus gpi n $nmbr$ $nmbr$,C0019134;C0770546
symptom onset to pci h,C4086878;C0033727;C0369286;C0441932;C0564385;C4528284
killip class $nmbr$ $nmbr$,C1881332
anemia,C0002871;C1000483;C4554633
$nmbr$ diseased vessels,C0005847
anterior infarct location,C0450429;C1515974;C4284930;C4284931
initial timi flow grade $nmbr$,C0441800;C0919553;C3244287
stent implanted,C0522776
final timi flow grade,C0441800;C0919553;C3244287
heart rate group at baseline,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
$nmbr$ bpm n $nmbr$ l $nmbr$,
cardiac parameters,C0018787;C0449381;C1522601
egfr ml min per $nmbr$ $nmbr$ kg m^,C1739039;C0439402;C3811844;C3812682
duration of heart failure years,C0449238;C2926735
primary cause of heart failure,C0205225;C0015127;C1524003;C0439612;C0439631
non ischaemic,C1518422;C0475224
history of atrial fibrillation and or flutter,C0729790;C0016385;C2242390
treatment at randomisation,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
diuretic agents excluding antialdosterone,C0450442;C1254351;C1521826
antialdosterone agents,C0450442;C1254351;C1521826
cardiac glycosides,C0007158
devices,C0025080;C0220819;C0699733
crt,
heart rate at baseline bpm,C0018810;C0168634;C1442488
ivabradine group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min,C0013806;C2199618;C2363129;C4050504;C1707455;C0032042;C1696465;C1706408;C2986535;C0184666;C0332271;C1457868;C1546960;C0018801;C0018802;C4554158;C0007226;C1555024;C3887460;C1508496;C0018810;C0332257;C1552866;C2700399;C0011065;C1306577;C0456081;C1512806;C0428876;C0812399;C2985465;C0702093;C1524029;C3813700
ivabradine group n $nmbr$,C0257190;C0441848
sex male ethnic origin,C0086582;C0015031
bmi kg m $nmbr$ cardiac parameters,C0022718;C0439209;C4054209;C0018787;C0449381;C1522601
egfr ml min per $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
medical history duration of heart failure years primary cause of heart failure,C0449238;C2926735
history of atrial fibrillation or flutter treatment at randomisation,C0729790;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
diuretic drugs excluding antialdosterone,C0013227;C3687832
test for interaction,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
s $nmbr$ years n $nmbr$,C0439234
no p blocker intake at randomisation n $nmbr$,C1512806;C0034656
p blocker intake at randomisation n $nmbr$,C1512806;C0034656
non ischaemic n $nmbr$,C1518422;C0475224
ischaemic n $nmbr$,C0475224
nyha class ii n $nmbr$,C1882085
nyha class iii or iv n $nmbr$,C1882086;C0022326;C4265176
no history of diabetes n $nmbr$,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
history of diabetes n $nmbr$,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
no history of hypertension n $nmbr$,C0455527
baseline heart rate,C0168634;C0018810;C1442488
$nmbr$ bpm n $nmbr$,
heparin dose regimen,C0019134;C2348331;C0770546
$nmbr$ standard n $nmbr$,C1442989;C2828392
$nmbr$ low n $nmbr$,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
heart failure at entry no,C0018801;C0018802;C4554158
previous events no,C0441471;C3541888
pad,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
electrocardiograph results no,C1274040;C1546471;C2825142
changes at baseline,C0392747;C0443172
st depression $nmbr$ mm,C4330985;C4554674
any dynamic st segment shift,C0333051;C2347509
transient st elevation,C0040704;C0520886;C0205374
positive troponin i or t no,C0439178;C0077401;C1446409;C1514241;C2825490;C3812269;C2603360
time from median iqr h,C0040223;C3541383
symptom onset to hospitalization,C4086878;C0019993
hospitalization to enrollment,C0019993;C1516879;C1696073;C3888021
enrollment to randomization,C1516879;C1696073;C3888021
symptom onset to enrollment,C4086878;C1516879;C1696073;C3888021
symptom onset to randomization,C4086878;C0034656
angiographic characteristics no,C1521970
single vessel disease,C0037179;C0042373;C0087136;C0205171
antithrombotic use before enrollment no,C0042153;C0457083;C1947944
non pci intravenous unfractionated heparin,C1518422;C0354566
subcutaneous unfractionated heparin,C0353681
lmwh,C0019139;C3536766
gpiib iiia inhibitors,C0016011;C0243077
commercially available fondaparinux,C0470187;C1098510
medication use before enrollment no,C0240320;C1516879;C1696073;C3888021
g blockers,C0439267
angiotensin receptor blockers,C0521942;C0815017
oral hypoglycemic agents,C0359086
ticlopidine,C0040207
prasugrel,C1620287
aspirin dose mg d,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
total time of fondaparinux treatment before,C0439175;C0040223;C3541383;C0439810
and after pci median iqr d,C0549183;C0876920;C2347635;C2348144;C2939193
variables,C0439828
all with coenzyme q $nmbr$ n $nmbr$ $nmbr$,C0041536
tertile $nmbr$ n $nmbr$,
p value for trend across tertiles,C1709380;C1521798;C4554533
age $nmbr$ yrs n,C0001779
nyha functional class n,C1882083;C0205245;C0542341;C2700217
cabg or ptca pci,C0010055;C2936173;C4049621
af or atrial flutter,C0344434;C4049859;C0004239;C0344423;C1963068
total cholesterol mmol lt,C0023376;C0230426;C3887647;C4521399
ldl cholesterol mmol lt,C0023376;C0230426;C3887647;C4521399
hdl cholesterol mmol lt,C0023376;C0230426;C3887647;C4521399
apoa $nmbr$ g l,C0439294;C0456615
apob g l,C0439294;C0456615
serum creatinine xmol l,C0201976;C0600061
serum creatinine $nmbr$ xmol l n,C0201976;C0600061
egfrmdrd ml min $nmbr$ $nmbr$ m $nmbr$ bsa,C0369637;C0441923
nt probnp pmol h,C0033727;C0369286;C0441932;C0564385;C4528284
coenzyme q $nmbr$ p g ml,C0041536;C1300565
hazard ratiof,C0598697
$nmbr$ clf,C3540486;C4553190
subgroup p valuef,C1079230;C1515021
all randomized all cause mortality,C0015127;C0026565;C0026566;C1524003
all randomized coronary end point,C2349179;C2826544
all randomized all cause mortality or hospitalization for worsening hf^,C0015127;C0026565;C0026566;C1524003;C0019993;C0332271;C1457868;C1546960;C0018488;C1313497;C1538440;C3273279
type of end point,C0332307;C1547052
subgroup p value,C1079230;C1709380;C1515021
hospitalizations,C0019993
omeprazole,C0028978
age yrf,C0001779
white race no total no,C0007457;C0043157;C0439175;C0439810
negative for helicobacter pylori no total no,C4688581;C0439175;C0439810
nsaid use no total no,C0042153;C0457083;C1947944;C0439175;C0439810
cardiovascular history no total no,C1880008;C0439175;C0439810
acs,C0742343;C4318612
other vascular disease,C0042373
cardiovascular risk factors no total no,C0850624;C0439175;C0439810
current smoking no total no,C0037369;C0453996;C1881674;C0439175;C0439810
current alcohol use no total no,C0521116;C0001948;C1705970;C0439175;C0439810
history of gi bleeding or ulcer no total no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0041582;C3887532;C0439175;C0439810
medications at study entry no total no,C0013175;C1705654;C0439175;C0439810
supplementary figure $nmbr$ hazard ratios for the composite gastrointestinal endpoint in multiple subgroups,C0598697;C0456603;C1610540;C0439064;C1079230
supplementary figure $nmbr$ hazard ratios for the composite cardiovascular endpoint in multiple subgroups with and without various forms of vascular disease,C0598697;C0456603;C1610540;C0439064;C1079230;C0348078;C0042373;C0376315
rolofylline,C0166128
p valuej,C0369773;C2603361
measurements,C0242485
heart rate at rest in the supine position beats min,C0018810;C0035253;C1622890;C0038846;C0439385
respiratory rate breaths min,C0231832;C0439386;C0489258
bnp pg ml h,C2827929
nt probnp pg ml h,C2827929
left ventricular ejection fraction within previous $nmbr$ mo,C0428772;C0488728
heart failure $nmbr$ mo before admission,C0026544;C0332177
biventricular pacemaker,C1719274
copd or asthma,C0024117;C1412502;C3714496;C0004096;C2984299
treatment before admission,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
aldosterone blocker,C0002006
nitrates oral or topical,C0442027;C4521986;C0332237
treatment after admission,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
days of study drug administration $nmbr$ day,C2826182
$nmbr$ or $nmbr$ days,C0439228
medications through day $nmbr$,C0013227;C0802604;C2598133;C4284232
total intravenous loop diuretic mg median,C0549183;C0876920;C2347635;C2348144;C2939193
intravenous inotropes or vasopressors,C0348016;C0042397
intravenous vasodilators,C0443081
medications at discharge or day $nmbr$ if earlier,C0806915;C0332173;C0439228;C0439505;C1279919
figure $nmbr$ a subgroup results for primary endpoint,C1274040;C1546471;C2825142
figure $nmbr$ b subgroup results for death or cardiovascular or renal rehospitalizatiou,C1274040;C1546471;C2825142;C0007226;C3887460;C0022646
placebo mtx n $nmbr$,C0032042;C0025677;C1417487;C1696465;C1706408
rituximab $nmbr$ x $nmbr$ mg mtx n $nmbr$,C0024671;C0025677;C1417487;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
percentage with disease duration,C0439165;C1549488;C1561533
no previous dmard therapy,C0039798;C0087111;C1363945
receiving concomitant corticosteroids,C1514756;C0001617;C3539185;C3540725;C3540726;C3540727
receiving concomitant nsaids and or cox $nmbr$ inhibitors,C1514756;C0521115;C0003211;C0085387
swollen joint count $nmbr$ $nmbr$ possible joints,C0451521;C0332149;C1705910;C2362652
tender joint count $nmbr$ $nmbr$ possible joints,C0451530;C0332149;C1705910;C2362652
c reactive protein mg dl,C0006560;C0439269;C1413716;C4048285
health assessment questionnaire $nmbr$ $nmbr$ range,C1514721;C2348147;C3542016
das $nmbr$ esr,C0051767;C3811131;C0057671
rheumatoid factor positive,C0439178;C1446409;C1514241;C2825490;C3812269
baseline mean mtss,C0168634;C0444504;C2347634;C2348143;C1442488
seropositive rf ve and or acpa ve subgroup,C0035448;C0201660;C0748398;C1547111;C1525410;C1706063;C1079230;C1515021
seronegative rf ve and acpa ve subgroup,C0035448;C0201660;C0748398;C1547111;C1525410;C1706063;C1079230;C1515021
placebo mtx,C0025677;C1417487
rituximab $nmbr$ x $nmbr$ mg mtx,C0025677;C1417487
joint damage outcomes mitt population,C0032659;C1257890
n $nmbr$ t,C0369718;C0441922
week $nmbr$,C0332174;C0439230
change in mtss mean,C0392747;C0443172;C1705241;C4319952
change in erosion score mean,C0392747;C0443172;C1705241;C4319952
patients with no progression,C0030705;C0242656;C0449258
or unadjusted,C1439367
itt,
disease activity outcomes itt population week $nmbr$,C0332174;C0439230
acr $nmbr$,C1412134;C1515941
major clinical response,C0205082;C4055223;C0205164;C4318856;C4521762
mean acrn,C0444504;C2347634;C2348143
eular good response,C0871261;C1704632;C1706817;C2911692
das $nmbr$ esr lda,C0051767;C4553195;C0057671
das $nmbr$ esr remission,C0544452;C0687702
change in das $nmbr$ esr mean i physical function outcomes week $nmbr$,C0392747;C0443172;C1705241;C4319952
change in haq di mean t,C0392747;C0443172;C1705241;C4319952
with haq di decrease $nmbr$ $nmbr$,C0392756;C0547047
fenofibric acid n $nmbr$,C0060179
rosuvastain fenofibric acid n $nmbr$,C0060179
type $nmbr$ diabetes mellitusa,C1320657
metabolic syndromeb,C0311400;C1524026;C2707259
baseline lipids mg dl,C0023779;C0439269
tg median min max,C0337445;C0549183;C0876920;C2347635;C2348144;C2939193
rosuvastatin fenofibric acid,C0965129;C0060179
diabeticb,
final mean mg dl,C0205088;C0439269;C1546485;C3853528
mean change se,C0392747;C0036919;C0443172;C1705241;C4319952
$nmbr$ $nmbr$ c,
hdl c high density lipoprotein cholesterol ldl c low density lipoprotein cholesterol sestandard error tg triglycerides,C0062152
ap value from an ancova with corresponding baseline lipid value as the covariate and with a effect for treatment group,C0002680;C1522609;C3887950;C0023779;C1280500;C1518681;C2348382;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
brandomization was stratified by diabetic status,C0205363;C0241863
crosuvastatin fenofibric acid vs rosuvastatin monotherapy,C0060179;C0965129
drosuvastatin fenofibric acid vs fenofibric acid monotherapy,C0060179
cure trial,C1880198;C0008976
active a,C0205177;C3853793;C3888249
ancestry f,C0016327
european,C0239307;C1535514
latin american,C1553378
age yij,C0001779
without stent,C0038257
with stent,C0038257
metabolizer phenotype,C0031437;C1285572
poor,C0032854;C0542537;C2700379
ultra,C0728475
outcome and metabolizer phenotype,C1274040;C0031437;C1285572
placebo patients with events,C0032042;C0030705;C1696465;C1706408
clopidogrel total no of patients,C0439175;C0439810;C0030705
pvalue for heterogeneity,C0019409;C0242960
first primary composite outcome,C0205199;C1274040;C1547335
second primary composite outcome,C0205199;C1274040;C1547335
placebo patients with events total,C0032042;C0030705;C1696465;C1706408
clopidogrel no of patients,C0070166;C0030705
primary composite outcome,C0205199;C1274040;C1547335
all participants n $nmbr$,C0679646
dha n $nmbr$,C0142831;C2348308
education mean sd ya,C0013621;C0013622;C0013658;C0039401
apoe e $nmbr$ carriers no,C0003595;C0007294;C0523511;C1412481
body mass indexb,C0518010
modified hachinski ischemia scale mean sd c,C0022116;C0175659;C0349674;C1947916;C4321499
smokers no,C0337664
blood pressure mean sd mm hg systolic,C0428886;C0039155
mini mental state examination mean sd d,C0451306;C2699239
cognitive subscale on alzheimer s disease assessment scale mean sd e,C0450989
clinical dementia rating sum of boxes mean sd f,C0451074;C1515051
dha intake on food frequency questionnaire mean sd mg d,C1286336
plasma dha mean sd weight,C0005910;C0043100;C1305866;C1705104
cholinesterase inhibitor use at baseline no,C0042153;C0457083;C1947944
memantine use at baseline no,C0042153;C0457083;C1947944
$nmbr$ mg dabigatran n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
previous stroke or tia n $nmbr$,C0038454;C4554100;C0007787;C0917805;C1054154
no previous stroke or tia n $nmbr$,C0038454;C4554100;C0007787;C0917805;C1054154
on aspirin at baseline,C0004057;C0168634;C1442488
vitamin k antagonist naive,C1096489;C2267235
on statins at baseline,C0360714;C0168634;C1442488
rate per year,C0871208;C1521828
$nmbr$ mg dabigatran,C0024671;C2348066;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
wafarin,
previous stroke or tl a,C0038454;C4554100;C0220928
no previous stroke ortia,C0205156;C0038454;C4554100;C1552607
ischaemic or unknown stroke,C0475224;C0038454;C4554100
previous stroke ortia $nmbr$ $nmbr$,C0205156;C0038454;C4554100;C1552607
previous stroke ortia,C0205156;C0038454;C4554100;C1552607
haemorrhagic stroke,C0553692
total bleeding,C0232100
$nmbr$ gi,C1708130;C3539617;C4050121
intracranial bleeding,C0151699
gastrointestinal major bleed,C0017181;C0205082;C0205164;C4318856;C4521762
previous stroke or tl a $nmbr$ $nmbr$,C0038454;C4554100;C0220928
fenofibric acid $nmbr$ $nmbr$,C0060179
rosuvastain fenofibric acid $nmbr$ $nmbr$,C0060179
$nmbr$ n gender n,C0369718;C0079399;C1522384;C0441922
coronaiy artery disease,C0852949
type $nmbr$ diabetes mellitus,C1320657
metabolic syndrome $nmbr$ baseline lipids mg dl,C0524620;C0439269
fenofibric,
l value,C0439394;C1522609;C1706495;C3642217
j valuc l,
acid,C0001128;C0202406
zt $nmbr$,
mean change,C0392747;C0443172;C1705241;C4319952
se,C0036919
silodosin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
tamsulosin $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
age yr n,C0001779;C0439234
min max,C0702093;C1524029;C3813700
not estimable,C1518422
ipss total score,C1019118;C2964552;C1998280;C2827405;C3811063
ipss storage subscore,C1019118;C0337174;C1698986;C1753314;C1998280;C2827405;C3811063
ipss voiding subscore,C1019118;C0042034;C4067975;C1998280;C2827405;C3811063
qol due to urinary symptoms,C0518214;C0426359
delighted,C3830544
pleased,C3829994;C4264468
mostly satisfied,C0242428;C4049977;C4084799
mostly dissatisfied,C0870433;C4085546
unhappy,C1688635
terrible,C3827840
urine qmax ml s,C0439526;C1705224;C3887665
baseline triglycerides,C0168634;C0041004;C1442488
baseline trig $nmbr$ millycerides g dl,C0168634;C0439267;C1442488
baseline concentration,C0086045;C1446561;C3827302
a $nmbr$ ez n $nmbr$,C0206578
a $nmbr$ n $nmbr$,C0369718;C0441922
a $nmbr$ ez n $nmbr$ a $nmbr$ n $nmbr$,C0206578
triglyceride,C0041004
total ldl c,C0439175;C0439810
ldl $nmbr$ c,
ldu c,
hdl $nmbr$ c,C3715113
study end concentration,C0086045;C1446561;C3827302
acute dvt study,C0557651;C2603343
continued treatment study,C0549178;C3161471
rivaroxaban n $nmbr$,C1739768
standard therapyy n $nmbr$,C1442989;C2828392
male sex no weight no,C0086582;C0005910;C0043100;C1305866;C1705104
missing data initial diagnosis no,C0011900;C1704338;C1704656
dvt,C0149871;C2926618;C3899446
$nmbr$ only $nmbr$ distal,C0205108;C4522154
pe,C0070939;C1880476;C4284304
time from onset of symptoms to randomization days,C1320528;C0034656;C0439228
cause of dvt or pe no,C0015127;C1524003;C0070939;C1880476;C4284304
unprovoked,
recent surgery or trauma,C0038894;C0038895;C0543467;C1274039;C0043251;C1510467;C3263723;C3714660;C4049136
immobilization,C0020944;C4048292
estrogen therapy,C0279494
puerperium,C0034042;C0086839;C1879329
known thrombophilic condition no,C0012634;C0348080;C1705253;C3864998
previous vte no,C0205156;C0630906;C1552607
qveral,
riva roxa ban n n $nmbr$ $nmbr$ $nmbr$,C0683610;C4553947
enoxaparin vka n n $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0206460
wegu,
wssng,
ofl,
mae,C0286540;C4085238
renal fmclicn creatntoe clearance,C0232813;C0699829
$nmbr$ rrmnl,
$nmbr$ $nmbr$ nlmw,
m being,
cardiac disease,C0018799
ns cardiac cisease,C0038944;C0018787;C1522601;C1112705;C1705982
intended durat sm of antccagubficn,C0036154;C4553627
$nmbr$ mortis,
$nmbr$ mentis,
$nmbr$ months,C0439231
m,
rarertd antocagibtcn before andorrtzafon,
pre rtous eptscde s d dvt pe,C0070939;C1880476;C4284304
kheeatne index dvt,C0149871;C2926618;C3899446
sco ita rojs dvt pe,C0070939;C1880476;C4284304
secondary dvt fe,C0027627;C3848561;C0175668;C0205436
ill,C0231218
known t rc iitoji cccndilon,C0205309;C1167159;C1419366
known tiromtcch c ccndifeon,C0205309
no known frtrontxtfufoc cond aon,C0205309;C1856054;C2826243;C4597943
locafon of index dvt,C0600653;C0149871;C2926618;C3899446;C0918012;C1552854;C1637833;C2986546
non extensive,C1518422;C0205231
ms ng,C0017887;C0028074
p o,C0369773;C2603361
mafcaiancy at randorrtzaton,
no adk e cancer,C0006826;C0998265;C1306459
ac tve cancer,C0006826;C0998265;C1306459
modmy al randcnxzaton,C0202311
immobazaton,
no immomtedion,
$nmbr$ j,
miami k antagonist received,C0597277;C0231491;C1708601;C1514756
acenocoumaroi,
redon,
western friroce,C1705493
austrafca and new zealand,C0027978;C0324547
cm,
sonti amenca,
kg,C0022718;C0439209;C4054209
sou ti africa,C0039247;C0001737;C0040302;C1553045;C1704756
rivaroxaban,C1739768
enoxaparin vka,C0206460
n n $nmbr$ $nmbr$,C0369718;C0441922
mate,C0682323;C1260875
renal function creatinine clearance,C0232813;C0699829
sd ml min,C2699239;C0439445
intended duration of anticoagulation,C0449238;C2926735
$nmbr$ montlts,
parenteral anticoagulalion before randomization,C0030547;C0034656;C4522267
malignancy at randomization,C0006826;C1306459;C4282132
no active cancer,C0006826;C0998265;C1306459
uncodable,
vka naive,
vka experienced,
never been on a vka,C2003901
ever been on a vka,
no vka at randomization,C0034656
vka at randomization,C0034656
total randomized,C0439175;C0439810;C0034656;C3815594
dabigatran $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
chads $nmbr$ scoret,C0007928;C1413373
prior transient ischemic attack,C0007787;C0917805
baseline aspirin use,C0042153;C0457083;C1947944
event,C0441471;C4019010
d $nmbr$,
d $nmbr$ vs warfarin,C0043031
y,
interaction pf,C1704675;C3815179
stroke or systemic embolism,C0038454;C4554100;C0013922;C1704212
life threatening bleeding disabling stroke and death,C1546953;C0019080;C2826244;C3537125;C0038454;C4554100;C0011065;C1306577;C4082313;C4552775
gastrointestinal bleeding,C0017181
fa $nmbr$ mg $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
r $nmbr$ mg n $nmbr$,C0687673;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
r $nmbr$ mg fa $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
r $nmbr$ mg $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
body weight kg n,C0005910;C1305866
comorbidities n a,C0009488
metabolic syndrome $nmbr$,C0524620
dm medication n c,C0011816;C0013227;C3244316;C4284232;C3250443
glipizide,C0017642
pioglitazone,C0071097
mean lipid values mg dl,C0023779;C0439269
hdl cd,C0007928;C0034283;C4552032
apobe,
fa $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
r $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
r $nmbr$ mg fa,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
h $nmbr$,C0033727;C0369286;C0441932;C0564385;C4528284
baseline median mg l,C0168634;C0439268;C1442488
final median mg l,C0205088;C0439268;C1546485;C3853528
median change,C0392747;C0443172;C1705241;C4319952
value $nmbr$,C1522609
ada $nmbr$ $nmbr$ n[ $nmbr$,C1060325;C3811629
age years median range,C1514721;C2348147;C3542016
$nmbr$ $nmbr$ e $nmbr$,
$nmbr$ $nmbr$ $nmbr$ e $nmbr$,
disease location,C0450429;C1515974;C4284930;C4284931
extensive colitisy,C0205231
left sided colitisz,C0205091;C0443246
otherx,
disease duration years median range,C1514721;C2348147;C3542016
$nmbr$ $nmbr$ $nmbr$ $nmbr$ e $nmbr$ $nmbr$,
endoscopy subscore,C0014245
rectal bleeding subscore,C0018932;C0267596
pga subscore,C0016410;C3541266;C4050369
stool frequency subscore,C0015733;C0183622
crp mg l median range,C1514721;C2348147;C3542016
$nmbr$ $nmbr$ $nmbr$ $nmbr$ e $nmbr$,
corticosteroid without imm,C0001617;C3536709
imm without corticosteroid,C0205470;C0001617;C3536709
corticosteroid imm,C0001617;C0205470;C3536709
no corticosteroid no imm,C0001617;C3536709;C0205470
mayo,C0454788;C1077578
remission n,C0544452;C0687702
difference from placebo $nmbr$ ci,C1705241;C1705242
$nmbr$ $nmbr$ e $nmbr$ $nmbr$ to $nmbr$ $nmbr$,
mayo $nmbr$ n,C0454788;C1077578
extensive colitis n,C0205231;C0009319;C1963084
no extensive colitis n,C0205231;C0009319;C1963084
corticosteroid without imm n,C0001617;C3536709
immy without corticosteroid n,C0001617;C3536709
imm corticosteroid n,C0205470;C0001617;C3536709
no corticosteroid no imm n,C0001617;C3536709;C0205470
aminosalicylates n,C0368663
no aminosalicylates n,C0368663
crp,C3890735;C4048285
crp $nmbr$ mg l n,C3890735;C0439268;C4048285
weight $nmbr$ $nmbr$ kg n,C0005910;C0022718;C0439209;C4054209;C0043100;C1305866;C1705104
weight $nmbr$ $nmbr$ kg,C0022718;C0439209;C4054209
all patients with opg n $nmbr$,C0030705;C1262886;C1336645;C1412836;C1710303
tertile $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ pg ml n $nmbr$,C0439297
tertile $nmbr$ $nmbr$ $nmbr$ pg ml n $nmbr$,C0439297
p trend,C1521798;C4554533
end points,C2349179
non cv mortality,C0026565;C0026566
hf hospitalization,C0018488;C0019993;C1313497;C1538440;C3273279
combined end points,C0205195;C2349179
coronary,C0018787
all cause mortality or hf hospitalization,C0015127;C0026565;C0026566;C1524003;C0018488;C0019993;C1313497;C1538440;C3273279
cholesterol mmol l,C0008377;C1532563
apob apoa $nmbr$ ratio,C0456603;C1547037
serum creatinine umol lf,C1416933;C2986618;C4554443
egfrmdrd ml min $nmbr$ $nmbr$ $nmbr$ m_ $nmbr$,C0439445
nt probnp pmol l,C0669479;C0439284;C0754710
crp mg l,C3890735;C0439268;C4048285
opg ng ml,C1262886;C0439275;C1336645;C1412836;C1710303
current medication n,C0746467
$nmbr$ cit,C0008864;C0523573;C1427027;C4553421
all randomly assigned,C1516050;C1552601
coronary end point,C2349179;C2826544
all cause mortality or hf hospitalization^,C0015127;C0026565;C0026566;C1524003;C0018488;C0019993;C1313497;C1538440;C3273279
dexlansoprazole mr $nmbr$ mg n $nmbr$,C0024485;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1417249;C2347167;C3254418;C4050513
age at baseline years,C1510829;C0168634;C1442488
ppi use within $nmbr$ months of randomization,C1524063;C0034656
alcohol drinker,C0001962;C0556338;C0001975
caffeine user,C3532939
indacaterol $nmbr$ gg qd,C0017454;C0332173;C0018370
formoterol $nmbr$ gg bid,C0017454;C0018370
salmeterol $nmbr$ gg bid,C0017454;C0018370
tiotropium $nmbr$ gg qd,C0017454;C0332173;C0018370
male female,C0043210;C0086287;C1705497;C1705498
fev $nmbr$ la,C0023031;C0023749;C0230347;C2346906;C4553351
fev $nmbr$ predicteda,C3714541
ics use yes no,C0042153;C0457083;C1947944;C1512698
ex smoker smoker,C0337671;C4555205
history of or current cardiac disorders,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0521116;C0018799;C1705970
treatment duration days,C0444921;C0439228;C3259042
patients treated for $nmbr$ weeks,C0030705;C1522326;C0439230
figure $nmbr$ percentage of patients with ccv aes according to presence or not of cardiovascular risk factors at baseline,C0439165;C1549488;C1561533;C1412268;C2699274;C1518422;C0850624;C0168634;C1442488
ind z indacaterol $nmbr$ $nmbr$ and $nmbr$ z mg doses form z formoterol salm z salmeterol tio z tiotropium pbo z placebo bmi z body mass index kg m $nmbr$ dm z diabetes mellitus,C4049864;C1722260;C0439272;C0011849
carisbamate $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
carisbamate $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
time since epilepsy diagnosis years,C0556970;C0011900;C1704338;C1704656
number of previous reported aeds,C0237753;C0449788
baseline monthly pos seizure rate,C0871208;C1521828
number of co aeds n,C0237753;C0449788
patients with $nmbr$ co aed,C0030705;C0887457
patients with $nmbr$ co aeds,C0030705;C0180309
ugt induction status as randomizeda n,C0205263;C0449438;C0857127
inducing,C0205263
noninducing,
ugt induction status per aeda n,C0205263;C0449438;C0857127
syndrome n,C0039082
symptomatic localization related,C0475264;C1744691;C0439849;C0445223
cryptogenic localization related,C0475264;C1744691;C0439849;C0445223
undetermined,C0205258;C3536725;C4082977
saxa $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
pbo n $nmbr$,C0031962
age category years n,C1510829;C0683312;C3889287
renal impairment n,C1565489
duration of t $nmbr$ dm years,C0449238;C2926735
hba $nmbr$ c category n,C0019016;C0683312;C3889287;C1825777;C3538758
fpg mmol l,C1532563
crcb ml min mean s e,C0444504;C2347634;C2348143
diabetes therapy n,C3274787;C3539002
oral blood glucose lowering drug $nmbr$ $nmbr$ $nmbr$,C0442027;C0005802;C4521986;C0441994;C2003888;C0013227;C1254351
sulphonylurea,C0038766;C3536898
glinide,C2266929
oral blood glucose lowering,C0442027;C0005802;C4521986;C0441994;C2003888
drug and insulint,C0013227;C1254351
saxa $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
baseline hba $nmbr$ c mean s e,C0444504;C2347634;C2348143
week $nmbr$ hba $nmbr$ c mean s e,C0444504;C2347634;C2348143
adjusted change from baseline mean s e,C0392747;C0443172;C1705241;C4319952
difference vs pbof mean s e t,C1705241;C1705242;C0444504;C2347634;C2348143
moderate renal impairment,C0205081;C1565489;C1881878;C4049705;C4049706;C4085643;C4321335
severe renal impairment,C0205082;C1565489;C4050465;C4050466
esrd saxa $nmbr$ $nmbr$ mg n $nmbr$,C0022661;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0035078;C2316810
measures mmol l,C0079809;C1532563;C1879489
baseline fpg mean s e,C0444504;C2347634;C2348143
week $nmbr$ fpg mean s e,C0444504;C2347634;C2348143
adjusted change from baseline,C0392747;C0443172;C1705241;C4319952
mean s e,C0444504;C2347634;C2348143
differencevs pbof,
mean s e t,C0444504;C2347634;C2348143
overall w $nmbr$ $nmbr$ $nmbr$,C0282416;C1561607
combined therapy v $nmbr$ $nmbr$ $nmbr$,C0033972
dutasteride w $nmbr$ $nmbr$ $nmbr$,C0754659
tamsulosin w $nmbr$ $nmbr$ $nmbr$,C0257343
ipss o,C1019118;C1998280;C2827405;C3811063
pv ml,C0439526;C1705224;C3887665
psa level ng ml,C4086720;C0439275
qmaxi rn l s,C2827110;C3540639;C4281819
previous treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
ipss hrql,C1019118;C1998280;C2827405;C3811063
at $nmbr$ years,C0439234
rr reduction $nmbr$ $nmbr$ $nmbr$ $nmbr$ cl,C0301630;C0596019;C0392756;C1293152;C4551656
combined dutasteride ta msu losi n,C0039297;C0024776;C1412759;C1506978;C1705538;C3272501;C4553364
dutasteride,C0754659
tamsulosin,C0257343
incidence o $nmbr$ $nmbr$ cl,C0021149;C0596019;C0220856
combined therapy vsdutasteride,C0033972
combined therapy vsta msu iosin,C0033972;C0024776;C1412759
ipss,C1019118;C1998280;C2827405;C3811063
change in das $nmbr$ $nmbr$ $nmbr$,C0392747;C0443172;C1705241;C4319952
week $nmbr$ responders n $nmbr$,C0332174;C0439230
acr $nmbr$ week $nmbr$ responders n $nmbr$,C0332174;C0439230
all responders n $nmbr$,
no previous dmard mean sd,C0205156;C2699239;C1552607
disease duration yrs mean sd,C0872146;C2699239
mtx dose $nmbr$ mg week,C0332174;C0439230
steroid use,C0281991
rf positive $nmbr$ iu ml,C0035448;C0439458;C0201660;C0748398;C1547111
sjc mean sd,C0444504;C2699239;C2347634;C2348143
tjc mean sd,C0444504;C2699239;C2347634;C2348143
mtss mean sd,C0444504;C2699239;C2347634;C2348143
das $nmbr$ range $nmbr$ $nmbr$ mean sd,C0051767;C2699239;C0057671
pain vas range $nmbr$ $nmbr$ mm mean sd,C0042815;C2699239
haq di range $nmbr$ $nmbr$ mean sd,C3826998;C2699239;C4321476
fas range $nmbr$ $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
crp mean mg l sd,C0439268;C2699239
olmesartan n $nmbr$,C1098320
duration yr,C0449238;C0439234;C2926735
prior treatment no,C1514463
former smoker,C0337671
metabolic syndrome no,C0524620
glucose mmol liter,C0017725;C0475211
overall freedom population n $nmbr$,C0016694;C0032659;C1257890
prevalent vertebral fracture status,C0080179;C0449438
femoral neck bmd t score,C0449820;C4050231
$nmbr$ and or $nmbr$ moderate or severe deformity or both n $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0000768;C0221430;C0302142;C0369718;C0441922
age yr mean sd bmd t score mean sd,C0001779;C3533236
subjects with prevalent vertebral fracture n prevalent vertebral fracture,C0681850;C1550501;C1706203;C2349001;C2697811
numbera,
severitya,
salmeterol n $nmbr$,C0073992
duration of copd yr f,C0449238;C2926735
gold stage c,C0018026;C0441785;C1304897
spirometry after bronchodilation,C0037981;C1371299;C3537072
pulmonary medications,C0013227;C0802604;C2598133;C4284232
anticholinergic drug,C0242896
js $nmbr$ agonists,C0243192;C2987634
long acting^,C0205166;C1706317
inhaled^,C0004048
with tiotropium,C0213771
with long acting j $nmbr$ agonists,C0243192;C2987634
methylxanthines,C0066447
tiotropium salmeterol no of patients total no,C0213771;C0073992;C0030705;C0439175;C0439810
copd severity stage gold,C0018026;C1304897
stage ii,C0441767
stage iii,C0441771
stage iv,C0022326;C4265176
noncurrent smoker,C0337664
use of inhaled glucocorticoids at baseline,C1524063;C0004048;C0168634;C1442488
isolated impaired glucose tolerance no,C0205409;C0271650;C1548221
both impaired glucose tolerance and impaired fasting glucose tolerance no,C0271650
ratio of women to men,C0456603;C1547037;C0025266
family history of diabetes no,C1313937
history of gestational diabetes mellitus no of women,C2183115;C0043210
mean age yr,C0001779;C0439234
mean bmi,C0444504;C0578022;C2347634;C2348143
bmi group no,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
hbaic,
$nmbr$ hr plasma glucose mg dl,C0202042;C0439269;C0455280
fasting plasma insulin mu liter,C0857690;C0475211
lipid levels mg dl,C0428460;C0439269
fasting free fatty acids ^mol liter,C0015663;C0015688;C0347982
incidence rate per $nmbr$ person yr,C1708485;C0027361;C2347489
$nmbr$ s,
men $nmbr$ cm,C0025266
women $nmbr$ cm,C0043210
glucose test,C0337438;C0595310
isolated igt,C0205409;C1548221
ifg and igt,C1334085;C1708411
time since diagnosis of diabetes n,C0040223;C3541383
$nmbr$ to $nmbr$ years,C0439234
acei arb therapy n,C0039798;C0087111;C1363945
urine acr geometric mean cv a b mg g,C2986759;C1300563
^ $nmbr$ mg g n,C1300563
$nmbr$ mg g n,C1300563
mdrd egfr geometric mean cv a b ml,C0439526;C1705224;C3887665
min per $nmbr$ $nmbr$ m $nmbr$,C0702093;C1524029;C3813700
$nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$ n,C0439445;C0369718;C0441922
$nmbr$ to $nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$ n,C0439445;C0369718;C0441922
rosiglitazone versus metformin,C0289313;C0025598
rosiglitazone versus glyburide,C0289313;C0017628
albumin to creatinine ratio acr,C1412134;C1515941
normal acr $nmbr$ mg g,C0205307;C1300563;C0231683;C0439166;C2347086;C4553972
$nmbr$ year cumulative incidence ci,C0008107;C3259781
albuminuria acr $nmbr$ m g g at baseline to normoalbuminuria,C1412134;C1515941;C1319635;C0168634;C1442488
mdrd egfr ml min per $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
normal or high egfr $nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$ at baseline to low egfr,C0205307;C0231683;C0439166;C2347086;C4553972;C0205250;C0439445;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209;C0168634;C1442488
normal egfr $nmbr$ egfr $nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$ at baseline to high egfr $nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$,C0205307;C0439445;C0231683;C0439166;C2347086;C4553972;C0168634;C1442488
without hypertension at baseline to hypertension,C0020538;C1963138
high dose statin pretreatment n $nmbr$,C0444956;C0360714
systemic hypertension,C0020538
clinical presentation,C2708283
medical therapy,C0418981
ace inhibitors sartans,C0003015;C1563745
multivessel pci,C4049621
treated vessel,C1522326;C0005847
left main,C0205091;C0205225;C1542147;C0443246;C1552822
left anterior descending,C0441998;C0205386;C1547177
left circumflex,C0205091;C1880089;C0443246;C1552822
right coronary,C0225808
saphenous vein graft,C0729538
lesions b $nmbr$ c,C0221198
antithrombotic therapy,C0039798;C0087111;C1363945
glycoprotein llb llla inhibitors,C0017968;C0243077
stable angina,C0340288
single vessel pci,C0037179;C0005847;C0087136;C0205171
ilb iiia inhibitors,C4697913;C0243077
no ilb iiia inhibitors,C4697913;C0243077
bosentan n $nmbr$,C0252643
location n,C0450429;C1515974;C4284930;C4284931
japan and south korea,C0022341;C0022773
sex men,C0009253;C0025266;C0036864;C0079399;C0804628;C1314687;C1522384
median duration of symptoms range yr,C0436359;C0439234
median time since diagnosis range yr,C1554109;C0011900;C1704338;C1704656
smoking history n,C1519384
ever smoked current former,C0205156;C0750523
pulmonary function tests of predicted,C0024119;C2598152
mean fvc sd,C0444504;C2699239;C2347634;C2348143
mean dlco sd,C0444504;C2699239;C2347634;C2348143
blood oxygenation mean sd,C0005767;C2699239;C0005768;C0229664
pao $nmbr$ at rest mm hg,C0232555;C1423784;C1427155;C4318615;C0035253;C0439475;C1622890
$nmbr$ $nmbr$ $nmbr$ $nmbr$ s,
aapo $nmbr$ at rest mm hg,C0035253;C0439475;C1622890
digital clubbing n,C0442015;C1883674;C0009080;C0149651;C0369718;C0441922
corticosteroid use $nmbr$ n,C0239126
presence of honeycombing $nmbr$ n,C0150312;C0392148;C3854307;C0332468;C0349384;C0369718;C0441922
baseline dyspnea index mean total score,C3533236
sf $nmbr$ health transition score,C0449820;C4050231
eq $nmbr$ d visual analog score,C0205163;C0439185;C0234621;C0243071
use of supplemental oxygen n,C4067893;C4554557
bosentan,C0252643
median $nmbr$,C0549183;C0876920;C2347635;C2348144;C2939193
us,C0815353;C3889164
baseline fvc l,C0168634;C1442488
median $nmbr$ $nmbr$,C0549183;C0876920;C2347635;C2348144;C2939193
baseline dlco mmol kpa,C0263428;C0439474
min,C0702093;C1524029;C3813700
stage $nmbr$ ckd egfr $nmbr$ to $nmbr$ ml min n $nmbr$,C1739039;C3811844;C3812682;C0439445
stage $nmbr$ ckd egfr $nmbr$ ml n $nmbr$,C0205390;C0439526;C1705224;C3887665;C1300072;C1306673
taking calcium supplements at baseline n,C3540037;C0168634;C1442488
no alcohol consumption on average,C0001948;C1510992;C2825518
over past $nmbr$ years n,C0439234
eq $nmbr$ da health index status score,C0449820;C4050231
opaqb physical function score,C4483112
low trauma fracture since age $nmbr$ n,C0521170;C0001779
prevalent vertebral fracture n,C0080179
serum albumin adjusted calcium mg dl,C0036785;C0439269;C0728876
serum vitamin d nmol l,C0312532
total hip bmd t score,C2964552;C0019552;C0022122;C1505163;C3538851;C4284725
nadroparin n $nmbr$,C0206232
no nadroparin n $nmbr$,C0206232
prostate cancer,C0376358;C0600139;C2984325;C3541264
time since primary diagnosis,C0040223;C3541383
years,C0439234
metastatic disease,C0027627;C2939419;C2939420
karnofsky score $nmbr$,C0449820;C4050231
nsclc,C0007131
squamous cell carcinoma,C0007137;C1302853
pancreatic cancer,C0235974;C0346647;C2984259
nadroparin,C0206232
nadroparin vs control,C0206232;C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
hormone refractory prostate carcinoma,C3887901
$nmbr$ $nmbr$ $nmbr$ ci $nmbr$ $nmbr$ to $nmbr$ $nmbr$,C0008107;C3259781
non small cell lung cancer,C0007131;C2984258;C3539721
facilitated pci n $nmbr$,C4049621
actual or estimated weight kg,C0237400;C0022718;C0439209;C4054209
killip class iv at randomization,C2697847;C0034656
prior cabg surgery,C0455610;C0010055
chronic treatment with aspirin,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
infarct location anterior,C0021308;C0205094
time intervals,C0872291
symptoms onset to first balloon inflation min,C4086878;C0021398;C1318493
randomization to first balloon inflation min,C0034656;C0021398;C1318493
treatment before catheterization,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
bolus of heparin given,C1186706;C1511237;C1705509;C3812160
loading dose of clopidogrel or ticlopidine,C3714444;C0070166;C0040207
glycoprotein llb illa inhibitor,C0017968;C1999216
pci performed,C4049621;C0884358
cabg performed during index hospitalization,C0010055;C0884358;C0019993
treatment during or after catheterization,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0007430
additional heparin,C0019134;C0770546
glycoprotein llb llia inhibitor,C0017968;C1999216
$nmbr$ day mortality,C0026565;C0026566
$nmbr$ day cce,C0332173;C0439228;C0439505
covariates,
or,
assigned treatment by sex interaction,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
fpci vs ppci in women,C0043210
fpci vs ppci in men,C0025266
rolofylline n $nmbr$ $nmbr$,C0166128
ecrcl ml min,C0439445
lvef within $nmbr$ months,C0428772;C0488728
intravenous loop diuretics,C0348016;C0354100
furosemide,C0016860
bumetanide,C0006376
ethacrynic acid,C0014963
torsemide,C0076840
persistent wrf n $nmbr$,C0205322;C0332996
no persistent wrf n $nmbr$ $nmbr$,C0205322;C0332996
bnp pg ml,C0054015;C0439297;C1095989;C1417808;C2982014
n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0369718;C0441922
n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0369718;C0441922
n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0369718;C0441922
n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0369718;C0441922
hgb g dl,C0019029;C0439267;C0019046;C0518015;C1424337
total diuretic dose iv oral on day $nmbr$ mg,C0442027;C4521986
jvp $nmbr$ cm,
heart failure $nmbr$ month before admission,C0332177;C0439231
medical therapy before admission,C0418981;C0184666;C0809949
_ $nmbr$ $nmbr$ _ $nmbr$ $nmbr$ to $nmbr$ $nmbr$,
or per unit for continuous variables,C0439148;C0439453;C1509845;C1519795;C1704753;C1880519;C3853603;C0549178;C0439828
univariable or $nmbr$ ci p value,C0008107;C1709380;C3259781
multivariable or $nmbr$ ci p value,C0008107;C1709380;C3259781
$nmbr$ yrs,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0369773;C2603361
baseline crcl ml min,C0168634;C0439445;C1442488
hemoglobin $nmbr$ men $nmbr$ women,C0019046;C0043210
rolofylline rx,C1425688;C1521941;C2709207
rolofylline n,C0166128
or primary outcome,C0205225;C1274040;C0439612;C0439631
or morbidity and mortality,C0026538;C0220880;C0026565;C0026566
baseline ecrcl $nmbr$ $nmbr$ ml min,C0168634;C0439445;C1442488
rolofylline n $nmbr$,C0166128
or $nmbr$ cl $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0596019
hr $nmbr$ cl $nmbr$ $nmbr$ b $nmbr$ $nmbr$ $nmbr$,C0596019
baseline ecrcl k $nmbr$ to $nmbr$ ml min,C0597277;C1708601;C0439445
hr $nmbr$ cl $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0596019
baseline ecro $nmbr$ mumin,C0168634;C1442488
rolofylline $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
baseline ecrq $nmbr$ $nmbr$ to $nmbr$ ml min,C0168634;C1442488;C0439445
weight kg blood pressure mm hg,C0005823;C0439475;C1271104;C1272641
$nmbr$ $nmbr$ no totalno,
previous stroke or transient ischemic attack no total no,C0038454;C4554100;C0007787;C0917805;C0439175;C0439810
hypertension no total no medications in use at baseline no total no,C0020538;C1963138;C0439175;C0439810;C0013227;C0802604;C2598133;C4284232;C0150312;C0042153;C0457083;C1947944;C0332285;C1707101
long term vitamin k antagonist,C1096489;C2267235
pts,C1419129;C2698747
war,C0043027
dabigatran $nmbr$ vs warfarin p inter,C2348066;C0043031;C0205103;C1548610
age $nmbr$ $nmbr$,C0001779
weight $nmbr$ $nmbr$,C0005910;C0043100;C1305866;C1705104
weight $nmbr$,C0005910;C0043100;C1305866;C1705104
cclear,
cclear $nmbr$ $nmbr$,
cclear $nmbr$,
asa,C0004057;C3853627
no asa,C0004057;C3853627
no amiodarone,C0002598
ppi,C0358591;C0871125;C3811894
noppi,
p inter,C0369773;C2603361;C0205103;C1548610
no ppi,C0358591;C0871125;C3811894
daily dose $nmbr$ mg n $nmbr$,C2348070;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
daily dose $nmbr$ $nmbr$ mg n $nmbr$,C2348070;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
p value anova,C1709380;C0753802
duration of asthma years,C0449238;C2926735
ics mg day,C0815320;C0439422;C4551720
laba use patients,C0042153;C0030705;C0457083;C1947944
fev $nmbr$ post bronchodilator predicted normal,C0520835;C2599594
pef post bronchodilator predicted normal,C0205307;C0231683;C0439166;C2347086;C4553972
acq $nmbr$ score,C0449820;C4050231
exacerbations in previous year,C4086268;C0205156;C1552607
as needed inhalations day,C0332173;C0439228;C0439505
days with asthma symptoms week,C0677547;C0004096;C2984299
night time awakenings week,C0456698
figure $nmbr$ time to first exacerbation in high dose ics $nmbr$ mg day medium dose ics $nmbr$ $nmbr$ mg day and low dose ics $nmbr$ mg day patients,C0040223;C3541383;C1319635;C0439422;C0030705
in this subgroup analysis the shortest time to the first exacerbation was observed in the hd stratum followed by the md and ld strata figure $nmbr$,C2986480;C0040223;C3541383;C1441672;C0332283;C0694649
stratum i,C0021966;C0221138
stratum ii,C1710602;C4082587
r $nmbr$ ezio n $nmbr$,C0687673
r $nmbr$ n $nmbr$,C0687673
american indian or alaska,C0002460;C0001905
$nmbr$ d,
risk group,C0242444
high risk with atherosclerotic vascular disease,C0332167;C3272283;C4050568;C4319571
high risk without atherosclerotic vascular disease,C0332167;C3272283;C4050568;C4319571
moderately high risk without atherosclerotic vascular disease,C0332167;C3272283;C4050568;C4319571
baseline low density lipoprotein cholesterol mg dl,C0023824;C0439269
sal n $nmbr$,C0036140;C0037494;C0206136
fp n $nmbr$,C0016704;C1419068;C1419906;C3541238;C3541412
sfc n $nmbr$,C4521536
total ho population n $nmbr$,C3258257;C0019905;C1832110;C3889614
total population n $nmbr$,C3258257
age at enrollment years,C1510829;C1516879;C1696073;C3888021
geographical region,C0017446;C0205147
post bronchodilator fev $nmbr$ l,C2599594;C3714541
post bronchodilator fev $nmbr$ predicted,C0681842;C1882327
reversibility predicted fev $nmbr$,C0449261;C3714541
pre bronchodilator fev $nmbr$ fvc ratio,C0456603;C1547037
figure $nmbr$ mean change in sgrq total score at $nmbr$ years by region for patients treated by placebo and sfc a lower score indicates better health a test for an interaction between region and treatment effect was not significant p $nmbr$ $nmbr$,C0392747;C0443172;C1705241;C4319952;C0439234;C0017446;C0205147;C0030705;C1522326;C0032042;C1696465;C1706408;C4521536;C0449820;C4050231;C0332272;C0018684;C4522046;C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744;C1518681;C1273937
figure $nmbr$ relationship between change in sgrq total score over the $nmbr$ year study period and change in fev $nmbr$ by age category a negative score indicates improved health using analysis of covariance difference in slopes p $nmbr$ $nmbr$ difference in intercepts p $nmbr$ $nmbr$,C2045651;C2964552;C0392747;C0443172;C1705241;C4319952;C0683312;C3889287;C0449820;C4050231;C0184511;C0018684;C0332272;C1561611;C4084203;C1524063;C0814908;C1705242;C0598981;C3146232;C0369773;C2603361
certolizumab pegol n $nmbr$,C1872109
age range,C1514721;C2348147;C3542016
duration of disease since,C0872146
diagnosis y mean sd,C0011900;C2699239;C1704338;C1704656
baseline cdai mean sd,C0168634;C2699239;C1442488
baseline hbi mean sd,C0168634;C2699239;C1442488
geometric mean of baseline,C2986759;C0168634;C1442488
crp mg l cv,C3538987;C4048877;C4318503
location of disease n,C0450429;C1515974;C4284930;C4284931
isolated upper gastrointestinal disease behavior n,C0810300
inflammatory,C0333348
stricturing,C1261287
penetrating no of resections n,C0205321;C0015252
corticosteroid with or without immunosuppressants,C0001617;C3536709;C0021081
immunosuppressant with or without corticosteroid,C0021081;C0001617;C3536709
corticosteroid or immunosuppressant,C0001617;C3536709;C0021081
corticosteroid and immunosuppressant,C0001617;C3536709;C0021081
neither corticosteroid nor immunosuppressant,C0001617;C3536709;C0021081
hrqol,C4279947;C4300252
ibdq score mean sd,C0444504;C2699239;C2347634;C2348143
total scores total score range $nmbr$ $nmbr$,C1514721;C2348147;C3542016
czp $nmbr$ mg n n,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
age yrs $nmbr$ $nmbr$,C0001779
noncaucasian,
disease location type terminal ileum,C0457464;C0227327
penetrating,C0205321
prior surgery no,C0455610
disease duration,C0872146
$nmbr$ baseline mean,C0444504;C2347634;C2348143
im use no,C1556154
cs use no,C0042153;C0457083;C1947944
im or cs use no,C0042153;C0457083;C1947944
im and cs use no,C0042153;C0457083;C1947944
previous or current im use no,C0205156;C1552607;C0521116;C1556154;C1705970
previous or current cs use no,C0205156;C1552607;C0042153;C0457083;C1947944
previous or current use of im or cs no,C0205156;C1552607;C1524063;C0010182;C0271160;C3540510;C4085345
previous or current use of im and cs no,C0205156;C1552607;C1524063;C0010182;C0271160;C3540510;C4085345
rest of world,C0035253;C1622890
europe zone $nmbr$,C0015176;C1710706
ukraine,C0041580
russia,C0035970
romania,C0035826
poland,C0032356
new zealand,C0027978;C0324547
latvia,C0023128
italy,C0022277
hungary,C0020174
estonia,C0014908
germany,C0017480
czech republic,C0206578
canada,C0006823
brazil,C0006137
belgium,C0004950
austria,C0004348
baseline corticosteroids,C0001617;C3539185;C3540725;C3540726;C3540727
no baseline corticosteroids,C0001617;C3539185;C3540725;C3540726;C3540727
$nmbr$ mg eow n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ mg ew n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
male patients n,C0150904
body weight kg mean s d,C0005910;C1275571;C1305866
involved intestinal area n,C1879646;C0021853
gastroduodenum,C0391900
draining cutaneous fistula at baseline n,C0013103;C0180499;C4265177;C0423772;C0168634;C1442488
baseline cdai score mean s d,C0168634;C0444504;C2347634;C2348143;C1442488
c reactive protein mg dl_,C0006560;C0439269;C1413716;C4048285
previous tnf antagonist use n,C0205156;C0042153;C0457083;C1947944;C1552607
crohn s disease related medication at baseline n,C0010346;C0013227;C3244316;C4284232
charm,C0849759
adhere,C3714578
steroid free remission,C0544452;C0687702
steroid sparing remission,C0544452;C0687702
steroid free cr $nmbr$,C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
remission by baseline steroid doses,C0544452;C0687702
remission by baseline duration of steroid,C0814126;C0038317
used,C1273517
no history of migraine,C0455512
migraine with aura,C0154723
migraine without aura,C0338480
prior migraine,C0332152;C0149931;C2826257
characteristics no of participants,C1521970;C0679646
aspirin $nmbr$ $nmbr$,C0004057
placebo $nmbr$ $nmbr$,C0032042;C1696465;C1706408
aspirin $nmbr$,C0004057
mean systolic blood pressure mm hg sd,C0428886;C2699239;C0488053
history of hypertension^,C0455527
family history of myocardial infarction prior to age $nmbr$,C0455406;C0001779
r r $nmbr$ ci,C0008107;C3259781
rr^ $nmbr$ ci,C0008107;C3259781
major cvd,C0205082;C0007222;C0205164;C4318856;C4521762
cvd death,C0011065;C1306577;C4082313;C4552775
met n $nmbr$,C0428210;C1550543;C4317104
avm n $nmbr$,C0003857;C0279476
$nmbr$ $nmbr$ l $nmbr$ $nmbr$,C0439394;C1706495;C3642217
$nmbr$ l $nmbr$ l $nmbr$ $nmbr$,C3539687
l $nmbr$ $nmbr$,C0439394;C1706495;C3642217
ll $nmbr$ $nmbr$,
african america,C0027567;C0002454
$nmbr$ l $nmbr$ l $nmbr$,C3539687
$nmbr$ l $nmbr$ l,C3539687
duration of diabetes,C0449238;C2926735
$nmbr$ $nmbr$ $nmbr$ l,C0439394;C1706495;C3642217
hbalc mean sd ^,C0444504;C2699239;C2347634;C2348143
fpg mmol l mean sd,C1532563;C2699239
l $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0439394;C1706495;C3642217
fracture history predefined n,C0016658;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
$nmbr$ l l $nmbr$,C3539687
l l,C3539687
history of bone disease predefined n,C0683519;C0730226;C0850708;C0944983
priorbone disease,C0012634
$nmbr$ l,C0439394;C1706495;C3642217
current bone disease,C0521116;C0005940;C1705970
history of other medical conditions n,C0262926
priorother predefined medical conditions,C0012634;C0348080;C1705253;C3864998
priorother not predefined medical conditions,C0012634;C0348080;C1705253;C3864998
current other predefined medical conditions,C0521116;C1705970;C0012634;C0348080;C1705253;C3864998
currentother notpredefined medical conditions,C0012634;C0348080;C1705253;C3864998
risk factor predefined for falling at screening n,C0035648;C0000921;C0085639
any condition,C0012634;C0348080;C1705253;C3864998
maternal history n,C0559473
osteoporosis,C0029456;C4554622
ll $nmbr$,
paternal history n,C0424909
current n,C0521116;C1705970
former n,C0205156;C0750523
years mean sd,C0439234;C2699239
$nmbr$ $nmbr$ ll $nmbr$,
$nmbr$ l $nmbr$ l $nmbr$ $nmbr$ l,C3539687
yes n,C1549445;C1705108;C1710701
units per week mean sd,C0560588;C0444504;C2347634;C2348143
$nmbr$ $nmbr$ $nmbr$ l $nmbr$,C0439394;C1706495;C3642217
avm se,C0003857;C0036919;C0279476
met se,C0428210;C0036919;C1550543;C4317104
$nmbr$ $nmbr$ $nmbr$ n $nmbr$,C0369718;C0441922
$nmbr$ $nmbr$ $nmbr$ $nmbr$ c $nmbr$ r,C0722969
$nmbr$ $nmbr$ $nmbr$ $nmbr$ c $nmbr$,
distal one third of radius,C0450168;C0205447
week $nmbr$ mayo endoscopy subscorea,C0332174;C0014245;C0439230
symptomatic remissionb n n,C0231220
sustained mucosal healingc n n,C0443318;C0026724
mucosal healingc n n,C0026724
sustained mucosal healingc,C0443318;C0026724
p value n n,C1709380
nesiritide n $nmbr$,C0054015
sex no total no,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384;C0439175;C0439810
race no total no f,C0034510;C1706779;C3853635;C0439175;C0439810;C0016327
systolic pressure mm hg,C0871470;C0439475
heart rate at rest beats min,C0018810
bnp pg ml i,C0023806
n terminal pro bnp pg ml,C0669479;C0439297
serum sodium mmol liter,C0523891;C0475211
left ventricular ejection fraction within previous $nmbr$ mo no total no $nmbr$,C0428772;C0488728;C0439175;C0439810
medical history no total no,C0262926;C1704706;C0439175;C0439810
heart failure $nmbr$ yr before admission,C0018801;C0439234;C0018802;C4554158
medical therapy before randomization no total no,C0418981;C0034656;C0439175;C0439810
nitrate oral or topical,C0442027;C4521986;C0332237
digoxin or digitalis glycoside,C0012265;C0012253
hydralazine,C0020223
inotropic agent,C0304509
vasodilator,C0042402;C3537240
use of medication from randomization through $nmbr$ hr no total no,C1524063;C0034656;C0439175;C0439810
time from hospitalization to randomization hr,C0040223;C3541383;C0034656
time from randomization to study drug administration hr,C0040223;C3541383;C0013175;C0150270;C3469597
administration of study drug bolus no total no,C0150270;C0262754;C3469597;C0439175;C0439810
duration of study drug administration hr,C0920470;C2348354
apixaban n $nmbr$,C1831808
risk factors specified as inclusion criteria no f,C0035648;C1553898;C0205369;C1512693;C0016327
myocardial infarction within the previous $nmbr$ yr,C0027051;C0428953;C2926063;C3810814;C4552959
history of cerebrovascular disease,C0585890
heart failure or lvef,C0018801;C0018802;C4554158;C0428772;C0488728
history of impaired renal function,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
no revascularization for index acs event,C0581603;C0441471;C4019010
other medical history no,C0262926;C1704706
index acs event,C0441471;C4019010
time from event to randomization days,C0040223;C3541383;C0034656;C0439228
type of event no,C1561488
st segment elevation myocardial infarction,C1536220
non st segment elevation myocardial infarction,C1536220
elevated cardiac markers no t,C0205250;C1271630;C3163633;C2603360
management of event no,C0001554;C0376636;C1273870;C3273539
medical therapy only,C0418981
use of parenteral antithrombotic agents no,C1524063;C1704311
selected medications no,C0013227;C0802604;C2598133;C4284232
cv death ml ischemic stroke,C0011065;C0948008;C1306577;C4082313;C4552775
subject group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
antiplatelet therapy dual,C0205173;C1554184
single,C0037179;C0087136;C0205171
acs type,C0332307;C1547052
stemi,C1536220;C3538872
non stemi,C3537184
acs treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
apixaban dose or matching placebo,C0178602;C0869039;C1114758;C0032042;C1696465;C1706408
$nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
s $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
level of renal impairment,C0441889;C0456079;C1547707;C2946261
severe or moderate,C0205082;C4050465;C4050466;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
age group years,C1510829
incidence [n n rate per $nmbr$ person years ],C0021149;C0220856;C0871208;C1521828
nnt,C1417750
age group y,C0441858
treatment groups [n nb ],C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0028101;C0919442;C1705347;C4553907
group a n $nmbr$,C0441848
group b n $nmbr$,C0441848
group c n $nmbr$,C0441848
hyperlipidemia^,C0020473;C0428465;C4555212
history of chd,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
history of pci,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
history of carotid artery disease,C0683519;C0730226;C0850708;C0944983
history of peripheral artery disease,C0683519;C0730226;C0850708;C0944983
figure $nmbr$ noninferiority comparison of clopidogrel bisulfate and clopidogrel resinate by the difference in percent p $nmbr$ y $nmbr$ inhibition of the $nmbr$ drugs in all patients and the prespeci ed subgroups the difference in platelet inhibition between clopidogrel resinate and clopidogrel bisulfate did not exceed predetermined limit of noninferiority chd coronary heart disease dm diabetes mellitus,C1707455;C0772326;C2353292;C1705241;C1705242;C1628982;C0013227;C3687832;C0030705;C3538926;C1079230;C1518422;C0439801;C1549649;C2349209
baseline total ipss mean sd,C0168634;C2699239;C1442488
baseline bii mean sd,C0168634;C2699239;C1442488
baseline luts severity n,C0168634;C0439793;C0522510;C1442488
mild ipss,C1019118;C1998280;C2827405;C3811063
moderate $nmbr$ ipss,C1019118;C1998280;C2827405;C3811063
severe ipss $nmbr$,C1019118;C1998280;C2827405;C3811063
qmax category n,C0683312;C3889287
$nmbr$ ml s,C0439526;C1705224;C3887665
qmax ml s mean sd,C0439390;C2699239
pvr volume ml mean sd,C0242852;C2699239;C0456261;C1419141
psa ng ml mean sd,C0439275;C2699239
ed history n yes,C1549445;C1705108;C1710701
ed severity n,C0439793;C0522510
ed duration $nmbr$ yr n,C0449238;C0439234;C2926735
sexually active with female,C0241028;C0043210;C0086287;C1705497;C1705498
partner n yes,C1549445;C1705108;C1710701
pgi s n y,C0523816;C1333690;C1412792;C1704947;C2975867;C3810522;C4522133
cgi s n z,C4526016
previous therapies n,C0205156;C0087111;C1552607
a blockers,
other bph luts therapy,C0039798;C0087111;C1363945
oab therapy,C0039798;C0087111;C1363945
ed therapy,C0039798;C0087111;C1363945
placebo mean change sd,C0032042;C2699239;C1696465;C1706408
tadalafil $nmbr$ mg mean change sd,C0024671;C2699239;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ls mean treatment difference $nmbr$ ci,C0008107;C3259781
baseline luts severity,C0439793;C0522510
moderate n $nmbr$ $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
severe n $nmbr$ $nmbr$,C0205082;C4050465;C4050466
baseline ed severity,C0439793;C0522510
mild n $nmbr$ $nmbr$ $nmbr$,C2945599
characteristic^,C1521970
bud fm $nmbr$ $nmbr$ atg n ^ $nmbr$,C2700462;C2945744
bud $nmbr$ ptg n $nmbr$,C0039512;C1418830
self reported descent n,C0681906;C2700446
mexican,C0240339
puerto rican,C0034043
cuban,C1553379
south or central american,C1710133;C0238914
caribbean,C0043122;C0206155;C1331005
mixed hispanic,C0205430;C0086409;C3160715
total ics dose at entry xg d,C2986497;C0017209;C1292284;C1421532
predose fev^ at screening,C0439565;C3714541;C3812758;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
l,C0439394;C1706495;C3642217
predicted,C0681842;C1882327
predose fev at randomization,C3714541;C0034656
predose fvc l,C0439565;C3714541;C3812758
at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
at randomization,C0034656
predose fev fvc,C0439565;C3714541;C3812758
postdose fev fvc at screening,C3714541;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
reversibility in fev^ at,C0449261;C3714541
screening l,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
pef at baseline l_ min,C0030771;C1518922;C1542834
morning,C0332170
evening,C0587117
figure $nmbr$ post hoc analysis of data stratified by region for a mean changes from baseline to the mean during the randomized treatment period for morning pef and bj mean change from baseline to $nmbr$ weeks for predose fey abbreviations bud budesonide fey forced expiratory volume in $nmbr$ second fm formoterol pef peak expiratory flow pmdi pressurized metered dose inhaler outlier data removed for $nmbr$ patient with baseline pef value of $nmbr$ l min in the bud fm group value with outlier included $nmbr$ $nmbr$ l min,C0687676;C0010992;C1704687;C3469826;C0205363;C0017446;C0205147;C0392747;C0443172;C0444504;C2347634;C2348143;C0030771;C1518922;C1542834;C1705241;C4319952;C0439230;C0016529;C1306036;C1511726;C3245479;C3714741;C0849355;C0030705;C1522609;C0441846
nonobese,
obese $nmbr$ kg m^ $nmbr$,C0022718;C0439209;C4054209
a aml n $nmbr$,C0023465;C0023467
aml n $nmbr$,C0023465;C0023467
mets n,C0812270;C1705694;C2939420
figure $nmbr$ least square mean lsm reductions from baseline to week $nmbr$ in mean sitting systolic blood pressure mssbp in obese body mass index [bmi] $nmbr$ kg nr and nonobese bmi,C0301630;C4551656;C0332174;C0439230;C1319893;C0005893;C0578022;C1305855
figure $nmbr$ least square mean lsm reductions from baseline to week $nmbr$ in a mean sitting systolic blood pressure mssbp and b mean sitting diastolic blood pressure msdbp in subjects with and without the metabolic syndrome mets at baseline error bars repre sent standard error of the mean a aliskiren aml amlodipine,C0301630;C4551656;C0332174;C0439230;C1319893;C1319894;C0524620;C0812270;C1705694;C2939420;C0168634;C1710181;C1442488;C2937472;C0023465;C0023467
figure $nmbr$ percentage of subjects achieving blood pressure bp goals of $nmbr$ kg nr subjects and subjects with and without the metabolic syndrome mets a aliskiren aml amlodipine,C0439165;C1549488;C1561533;C0005823;C0018017;C0681850;C1550501;C1706203;C2349001;C2697811;C0524620;C0812270;C1705694;C2939420;C2937472;C0023465;C0023467
oma oat n $nmbr$,C0028753;C0331496;C0939905;C3539067;C3897364
oat n $nmbr$,C0028753;C0331496;C0939905;C3539067;C3897364
age distribution years n,C1510829
serum total ige iu ml,C1441420;C0439458
fev $nmbr$ predicted at baseline,C0681842;C1882327
number of clinically significant asthma exacerbations in last year prior to baseline,C0237753;C0449788;C0439234;C0439508
number of er visits in last year prior to baseline,C3810541;C1549755;C3811131;C0439234;C0439508
number of hospitalizations in last year prior to baseline,C4086639;C0439234;C0439508
night time awakenings in past $nmbr$ weeks prior to baseline,C0860510;C0439230;C0332152
ocs reduced stopped,C0392756;C1272691
ocs maintained increased,C0205217;C0442805
oma oat,C0028753;C0331496;C0939905;C3539067;C3897364
oat,C0028753;C0331496;C0939905;C3539067;C3897364
mean change from baseline in fev $nmbr$ predicted sd,C0392747;C0443172;C1705241;C4319952;C0681842;C2699239;C1882327
mean number of clinically significant asthma exacerbations,C0444504;C0237753;C0449788;C2347634;C2348143
mean number of combined visits hospitalizations,C4086639
mean change from baseline in acq overall score sd,C0392747;C0443172;C1705241;C4319952;C0282416;C2699239;C1561607
mean change from baseline in the number of,C0392747;C0443172;C1705241;C4319952;C0237753;C0449788
night time awakenings in past $nmbr$ weeks sd,C0860510;C0439230;C2699239
no metabolic syndrome,C0524620
canrenone n z $nmbr$,C0006882
men n [ ],C0025266
heart rate bpm $nmbr$,C0018810
diabetes n [ ],C0011847;C0011849
$nmbr$ [ $nmbr$ ],
placebo n $nmbr$ n,C0032042;C1696465;C1706408
denosumab n $nmbr$ n,C1690432
western europe australia new zealand,C0027978;C0324547
prevalent vertebral fracture,C0080179
prior nonvertebral fracture at age $nmbr$ years,C0016658;C1510829
prior use of osteoporosis medications,C1524063
female subjects n $nmbr$,C0043210;C0086287;C1705497;C1705498
male subjects n $nmbr$ $nmbr$,C0086582;C1706180;C1706428;C1706429
african american black,C0005680;C0027567;C0085756;C0439541
american indian native alaskan,C0682125
serum creatinine level,C0600061
estimated creatinine clearancet,C0750572;C0010294;C1561535
$nmbr$ ml minute,C0439232;C0700321;C0702093;C1282918;C2347166
baseline sua mean sd mg dl,C0168634;C0439269;C1442488
presence of tophi,C0150312;C0392148;C3854307
years since last gout flare,C0439234;C0018099
years with gout mean sd,C0439234;C0018099
obesity bmi $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
baseline renal function eclcr,C0168634;C0232804;C1442488
febuxostat $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
allopurinolt,
normal $nmbr$ ml minute,C0439232;C0700321;C0702093;C1282918;C2347166
mild impairment $nmbr$ to,C0221099;C0684336
moderate or severe impairment,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0221099;C0684336
vorapaxar n $nmbr$,C2974521
median q $nmbr$ q $nmbr$,C0549183;C0876920;C2347635;C2348144;C2939193
region of enrollment,C0017446;C0205147
cardiovascular risk factors,C0850624
renal function ml min,C0232804;C0439445
$nmbr$ $nmbr$ crcl,C1846718
$nmbr$ crcl,C1846718
cardiovascular disease history,C1880008
positive troponin or ck mb,C0439178;C0041199;C1446409;C1514241;C2825490;C3812269;C0010290
symmetric t wave inversions,C0332516;C0520888;C2699744
iii iv,C0022326;C4265176
stratification factors,C1514984
intent to use glycoprotein iib iiia inhibitor,C0162425;C1283828;C1550453
intent to use direct thrombin,C0162425;C1283828;C1550453
antiplatelet at randomization,C0034656
chads $nmbr$ score $nmbr$,C0449820;C4050231
mean systolic blood pressure sd mm hg,C0428886;C0439475;C0488053
mean diastolic blood pressure sd mm hg,C0428886;C0439475;C0488053
type of atrial fibrillation n,C0332307;C1547052
chads $nmbr$ components n,C0007928;C0449432;C1413373
medications in use at baseline n,C0013227;C0802604;C2598133;C4284232;C0150312;C0042153;C0457083;C1947944;C0332285;C1707101
histamine $nmbr$ receptor antagonist,C0019590;C4521896
median time in therapeutic range for warfarin recipients,C1554109;C0043031;C1709854
chads $nmbr$ score per outcome stroke or systemic embolism,C0449820;C4050231;C0013922;C1704212
rate in all participants y,C0871208;C1521828
dabigatran $nmbr$ mg twice daily,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
absolute risk reduction $nmbr$ ci y,C3179139;C0008107;C3259781
total events n,C0439175;C0439810
rate y,C0871208;C1521828
dabigatran $nmbr$ mg vs warfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0043031
vs warfarin,C0043031
major bleeding $nmbr$ to $nmbr$,C0205082;C0019080;C0205164;C4318856;C4521762
$nmbr$ $nmbr$ t,C2603360
vascular death,C0011065;C1306577;C4082313;C4552775
total death,C0011065;C1306577;C4082313;C4552775
placebo plus statin n $nmbr$,C0032042;C1696465;C1706408
extended release niacin plus statin n $nmbr$,C0027996;C1142562
distribution no,C0520511;C1704711
american indian alaskan native or aboriginal canadian,C0886378;C0935542;C0238884
multiracial or other,C1881928
hispanic or non hispanic ethnic group no f,C0086409;C0015031;C1879937;C0016327
presenting history or diagnosis no,C0449450;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0011900;C1704338;C1704656
stroke or cerebrovascular disease,C0038454;C4554100;C0007820
laboratory values in patients with history of diabetes,C0022877;C0042295;C3244292;C4283904;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
insulin tu ml,C0439526;C1705224;C3887665
concomitant medications no,C0013227;C0802604;C2598133;C4284232
use at baseline,C0042153;C0457083;C1947944
duration of prior statin therapy^,C0444917
previous use of niacin or niaspan,C1524063;C0027996;C1142562;C1161310
aspirin or other antiplatelet or anticoagulant agent,C0004057;C0003280
number of copd exacerbations,C0237753;C0449788
change from baseline of morning pef l min,C0392747;C0443172;C1705241;C4319952
tdi units,C0439148;C1519795;C3853603
s d,C0565930;C2603362
x $nmbr$,
study $nmbr$,C0557651;C2603343
indacaterol group n $nmbr$,C1722260;C0441848
duration of copd y,C0449238;C2926735
severity of copd gold $nmbr$,C0439793;C0522510
severe or very severe,C0205082;C4050465;C4050466;C3641272;C4050419
fev $nmbr$ predicted post albuterol,C0687676;C0001927;C1704687;C3469826
fev $nmbr$ fvc post albuterol,C3714541;C0687676;C0001927;C1704687;C3469826
fev $nmbr$ pre albuterol l,C0332152;C0001927;C0740175;C2257086;C3669034
fev $nmbr$ post albuterol l,C0687676;C0001927;C1704687;C3469826
fev $nmbr$ reversibility pre post albuterol,C0332152;C0001927;C0740175;C2257086;C3669034
use of rescue albuterol puffs day,C1524063;C0001927
days without albuterol use,C0439228;C0001927
baseline sgrq score,C0449820;C4050231
no of patients indacaterol placebo,C0030705;C0032042;C1696465;C1706408
treatment difference ml,C0439526;C1705224;C3887665
copd severity gold $nmbr$,C0018026;C1304897
use of ics,C1524063;C0815320;C4551720
albuterol reversibility,C0001927;C0449261
males $nmbr$,C0086582
females $nmbr$,C0086287
waist hip ratio,C0205682
males $nmbr$ $nmbr$,C0086582
females $nmbr$ $nmbr$,C0086287
baseline hemoglobin aj^ values,C0004486;C0042295;C0230613
$nmbr$ $nmbr$ $nmbr$ $nmbr$ n $nmbr$ $nmbr$,C0369718;C0441922
hemoglobin aj^,C0004486;C0230613
diabetes duration y,C0011847;C0011849
baseline alc category,C0683312;C3889287
liraglutide $nmbr$ $nmbr$ mg oad,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
sitagliptin oad,C1565750
giimepiride oad,
rosigiitazone oad,
exenatide oad,C0167117
insuiin giargine oad,
alc at weeko,C1424945;C3811058
l i $nmbr$ $nmbr$,C0021966;C0221138
alc at week $nmbr$,C1424945;C3811058
alc $nmbr$ $nmbr$ $nmbr$ $nmbr$,C1424945;C3811058
of patients,C0030705
$nmbr$ $nmbr$ fi $nmbr$,C4050619
a $nmbr$ c s $nmbr$ s $nmbr$,
$nmbr$ s $nmbr$,
a $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$,
a $nmbr$ c $nmbr$ $nmbr$,
linagliptin n $nmbr$,C2746078
total comparators n $nmbr$,C0439175;C0439810
gender of patients,C0079399;C1522384
race of patients,C0034510;C1706779;C3853635
hba $nmbr$ c mmol mol,C0019016;C3829066;C1825777;C3538758
diabetes duration known of patients,C0011847;C0205309;C0011849
previous oral glucose lowering agents of patients,C0205156;C0017725;C1552607;C0441994;C2003888;C0600419
cv risk factors of patients,C0035648;C1553898
ex current smoker,C3173209;C3241966
egfr using cg mdrd formulae of patients,C1739039;C3811844;C3812682;C1524063;C3839656;C0012164;C0489829;C1705501
severely impaired,C0205082;C0221099
cv medication of patients,C0013227;C3244316;C4284232
acetyl salicylic acid,C0004057
lipid lowering therapy,C0585943
any of the above,
framingham $nmbr$ year cv risk score,C0035647;C0449820;C4050231;C4552904
score,C0449820;C4050231
score $nmbr$ of patients,C0449820;C4050231;C0030705
linagliptin patients with events total patients,C0030705;C0439175;C0439810
total comparators patients with events total patients,C0439175;C0030705;C0439810
cox hr $nmbr$ ci,C0008107;C3259781
cmh rr $nmbr$ ci,C0008107;C3259781
use of rescue medication,C1524063
investigator reported hypoglycaemia,C0020615;C4553659
$nmbr$ no,
white no,C0007457;C0043157;C0220938
black no,C0005680;C0027567;C0085756;C0439541
other no,
taking antihypertensive treatment at,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
baseline no,C0168634;C1442488
treated at baseline mean sd mm hg,C1522326;C0439475
untreated at baseline mean sd mm hg,C0332155;C0439475
eligibility risk factorsa,C0013893;C0035647;C4552904;C1548635
cigarette smoker no,C0337667
ascvd b no,C3665365
history of mi or stroke no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0038454;C4554100
history of coronary revascularization no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
other ascvd no,C3665365
st t wave no,C0036056;C0429103;C3272372
lvh by ecg or echocardiography no,C0232306;C0013516
lvh by minnesota code no,C0149721;C0009219;C0805701;C3889831
diabetes no c,C0011847;C0011849
history of chd at baseline no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0168634;C1442488
lipid trial participants no,C1997894;C2242969
non cardiovascular mortality,C0026565;C0026566
fatal chd nonfatal ml,C0439526;C1705224;C3887665
fatal nonfatal ccvd,C1302234;C1705232
fatal nonfatal hospitalized heart failure,C0018801;C0018802;C4554158
fatal nonfatal hospitalized stroke,C0038454;C4554100
kidney disease usrds,C0022658
age $nmbr$ $nmbr$ y,C0001779
nonblack,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ os,C0229090;C0230028;C0262950;C0393706;C1561953
african americans,C0085756
caucasians,C0007457;C0043157
v hctz n $nmbr$,C0020261
hctz n $nmbr$,C0020261
prior antihypertensive medication n,C0332152;C0003364;C2826257
diabetes status n,C1317301
normoglycemia^,
ifg prediabetes^,C1334085;C0362046;C1708411
cardiometabolic syndrome ^n,C0039082
mean sd egfr ml min $nmbr$ $nmbr$ m $nmbr$,C0444504;C0439445;C2347634;C2348143
mean sd waist circumference cm,C0444504;C0455829;C2347634;C2348143
mean sd fpg mg dl,C0444504;C0439269;C2347634;C2348143
mean sd fasting insulin uu ml,C0444504;C2699239;C2347634;C2348143;C0015663;C0021641;C0439342;C1533581;C1579433;C3714501
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ n $nmbr$,C0369718;C0441922
mean sd ldl c mg dl,C0444504;C0439269;C2347634;C2348143
mean sd hdl c mg dl,C0444504;C0439269;C2347634;C2348143
mean sd triglycerides mg dl,C0041004;C0439269
mean sd mssbp mm hg,C0444504;C0439475;C2347634;C2348143
mean sd msdbp mm hg,C0444504;C0439475;C2347634;C2348143
mean sd $nmbr$ h asbp mm hg,C0033727;C0439475;C0369286;C0441932;C0564385;C4528284
mean sd $nmbr$ h adbp mm hg,C0033727;C0439475;C0369286;C0441932;C0564385;C4528284
v hctz,C0020261
hctz,C0020261
change from baseline to eos mg dl,C0392747;C0443172;C1705241;C4319952;C1623465;C0439269;C1861303
ls mean difference $nmbr$ ci,C0008107;C3259781
fasting insulin,C0015663;C0021641;C1533581;C1579433;C3714501
change from baseline to eos uu ml,C0392747;C0443172;C1705241;C4319952;C1623465;C0439342;C1861303
$nmbr$ $nmbr$ $nmbr$ lf,C1416933;C2986618;C4554443
regadenoson n $nmbr$,C1698215
mean sd years,C0444504;C0439234;C2347634;C2348143
ckd n t,C1561643
stage $nmbr$,C0205390;C1300072;C1306673
cad history and risk factors n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0035648;C1553898
obesity bm $nmbr$ $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
smoking $nmbr$ pack years,C0037369;C1277691;C0453996;C1881674
egfr ml minute $nmbr$ $nmbr$ m $nmbr$,C0439232;C0700321;C0702093;C1282918;C2347166
regadenoson,C1698215
change from baseline stage $nmbr$ ckd,C0597205;C0679846
stable angina n,C0340288
non st segment elevation,C1518422;C0520886
mi n,C3810814
congestive hf,C0018488;C1313497;C1538440;C3273279
number of target vessels,C0237753;C0449788
drug eluting stent n,C1322815
bare metal stent n,C2825200
cangrelor,C1121991
comparator,C1707454;C4553389;C4553390
or [ $nmbr$ cl],C0596019
death udmi idr,C0011065;C1306577;C4082313;C4552775
death q mi idr,C0011065;C1306577;C4082313;C4552775
death q ml stent thrombosis,C0011065;C3897493;C1306577;C4082313;C4552775
diabetic yes,C1549445;C1705108;C1710701
diabetic no,C0241863
prior thienopyridine,C0332152;C1120149;C2826257
gfr $nmbr$,C0017654;C1424601
subjects stratified by baseline pra,C0681850;C1550501;C1706203;C2349001;C2697811;C0205363;C0168634;C1442488
low renin pra,C0633231;C1141951;C1419788;C3274822;C3669212;C4283900
normal high renin pra $nmbr$ $nmbr$ ng ml h n $nmbr$,C1533072;C4050009
received antihypertensive within last $nmbr$ days n,C0003364;C0439228
diabetic n,C0241863
mssbp sd mmhg,C2699239;C0439475
msdbp sd mmhg,C2699239;C0439475
pra median min max ng ml h,C1533072;C4050009
african american n $nmbr$,C0085756
caucasian n $nmbr$ $nmbr$,C0007457;C0043157
alcohol use n,C0001948
drinker $nmbr$ $nmbr$ drinks week,C0332174;C0439230
non ex tobacco user,C1518422;C3853727
tobacco user,C3853727
tophi present n,C0221248;C0150312;C0449450
renal function bn,C0005005;C0034700;C1706574;C4551963
any cardiovascular disease,C0007222
cardiac arrhythmia,C0003811;C0264886;C1560249
use of low dose aspirin $nmbr$ mg daily,C1524063;C2608320
figure $nmbr$ comparative efficacy of urate lowering therapy between african american and caucasian subjects within treatment groups a all subjects b subjects with mild renal impairment eclcr $nmbr$ to $nmbr$ ml min and c subjects with moderate renal impairment eclcr $nmbr$ to $nmbr$ ml min,C1280519;C1707887;C0085756;C0681850;C1550501;C1706203;C2349001;C2697811;C2945599;C1565489;C0439445
semuloparin n $nmbr$,C2700104
hazard ratio $nmbr$ ci j,C2985465;C0008107;C3259781
any vte or vte related death no,C0630906;C0011065;C1306577;C4082313;C4552775
symptomatic deep vein thrombosis,C0231220;C0149871
upper limbs,C1140618
lower limbs,C0023216
proximal,C0205107;C4489236
distal,C0205108;C4522154
pulmonary embolism,C0034065
nonfatal,
symptomatic,C0231220
detected during tumor evaluation,C0442726;C1511790
ne,C0027608;C0028219;C3538705
any vte related death,C0011065;C1306577;C4082313;C4552775
outcome according to primary cancer site no total no,C1274040;C0872338;C0439175;C0439810
lung,C0024109
pancreas,C0030274
stomach,C0038351;C3714551
colon or rectum,C0009368;C3888384;C0034896
bladder,C0005682;C4319531
ovary,C0029939;C0227898
outcome according to stage of cancer no total no,C1274040;C0027646;C0439175;C0439810
metastatic,C0036525;C1522484;C4085632
locally advanced,C1517927;C0205179
outcome according to no of risk factors for vte,C1274040;C0035648;C1553898;C0630906
total phase $nmbr$ pooled n $nmbr$,C0439175;C0205390;C1710475;C0439810
low complement anti dsdna positive n $nmbr$,C0432633
mean selena sledai score sd,C3533236;C2699239
selena sledai $nmbr$,C0451528
proteinuria $nmbr$ g $nmbr$ h,C0033687;C0560020;C1962972;C4554346
anti dsdna $nmbr$ iu ml,C0741099;C0439458
igg $nmbr$ $nmbr$ g l,C0439294;C0456615
low c $nmbr$,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
$nmbr$ $nmbr$ mg day,C0439422
immunosuppressant use,C0042153;C0457083;C1947944
mean slicc damage index score sd,C3533236;C2699239
mean pga score sd,C3533236;C2699239
figure $nmbr$ or for sle responder index rates in univariate disease activity subgroup analysis,C0024141;C0600653;C0918012;C1552854;C1637833;C2986546;C0683962
horizontal lines are $nmbr$ ci vertical dashed reference lines represent or of $nmbr$ which indicates no difference between belimumab and placebo while points to right of lines indicate higher responses for belimumab versus placebo and points to left of line indicate lower responses for belimumab versus placebo point estimates for or for overall treatment effect coloured solid vertical lines are $nmbr$ $nmbr$ for belimumab $nmbr$ mg kg and $nmbr$ $nmbr$ for $nmbr$ mg kg interaction p,C0205126;C0205132;C0008107;C0458097;C3259781;C1882932;C1705241;C1705242;C0032042;C1696465;C1706408;C1552961;C2347617;C3714763;C0205250;C0871261;C0441994;C1548802;C2003888;C0750572;C1518681;C0205128;C1723401;C0439272;C1704675
troponin positive n $nmbr$,C0041199;C0439178;C1446409;C1514241;C2825490;C3812269
troponin negative n $nmbr$,C0041199;C0205160;C1513916;C2825415;C2825491;C3853545
age median [iqr] y,C0549183;C0876920;C2347635;C2348144;C2939193
weight median [iqr] kg,C0549183;C0876920;C2347635;C2348144;C2939193;C0022718;C0439209;C4054209
cardiac biomarker elevation,C0439775;C0702240
st segment deviation timi risk score,C0035647;C0449820;C4050231;C4552904
white blood cell count cellsx $nmbr$,C0023508;C0427512
hemoglobin g dl,C0439267
demographic variable,C0439828;C4553760
vildagliptin $nmbr$ mg bid n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
vildagliptin $nmbr$ mg qd n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
body weight,C0005910;C1305866
$nmbr$ h ppg mmol l,C2827804;C1418888
duration of t $nmbr$ dm,C0449238;C2926735
vildagliptin $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
vildagliptin $nmbr$ mg qd,C0024671;C0332173;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
am s e,
ama s e,C0002461;C0279755;C2825862
bmi at baseline kg m $nmbr$,C0578022;C0022718;C0439209;C4054209
duration of metformin therapy months,C0444917;C0025598
duration of diabetes months,C0449238;C2926735
golimumab $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
sex no male,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384;C0086582;C1706180;C1706428;C1706429
race no white,C0034510;C1706779;C3853635;C0007457;C0043157;C0220938
psa duration years,C0449238;C0439234;C2926735
number of swollen joints $nmbr$ assessed,C0449813
number of tender joints $nmbr$ assessed,C0449813
das $nmbr$ crp,C3890735;C4048285
psa modified shs of hands and feet,C0392747;C0018563;C1552914;C3889737;C0016504;C0347981
erosion score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
jsn score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
total score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
no of patients with $nmbr$ bsa affected,C0030705;C0392760;C1314939
bsa affected,C0392760;C1314939
pasi score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
no of patients with fingernail involvement,C0030705;C0222001;C1314939
no fingernails,C0222001
target nail napsi score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
patients with dactylitis no,C0030705;C0239161
dactylitis score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
patients with enthesitis no,C0030705;C1282952
psa modified mases score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
haq score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
sf $nmbr$ health survey,C0037712;C0018762
pcs score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
mcs score $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
patients taking mtx no,C0025677;C1417487
mean median mtx dose mg week,C0332174;C0439230
golimumab combined n $nmbr$,C2353893;C0205195
change in psa modified shs baseline to week $nmbr$,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230
total score,C2964552
mtx at baseline,C0025677;C1417487
p vs placebo,C0369773;C2603361;C0032042;C1696465;C1706408
no mtx at baseline,C0025677;C1417487
hands,C0018563;C1552914
erosion score,C0449820;C4050231
jsn score,C0449820;C4050231
total hands score,C2964552;C0018563;C1552914
feet,C0016504;C0347981
total feet score,C2964552;C0016504;C0347981
additional radiographic findings at week $nmbr$,C2607943;C2926606;C3539655
no new erosions among patients with $nmbr$ uninvolved joint at baseline,C0333307;C1959609;C0022417;C0392905;C1706309
no new jsn among patients with $nmbr$ uninvolved joint at baseline,C0205314;C0030705;C0022417;C0392905;C1706309
radiographic progression based on change from baseline sdc,C0242656;C0449258;C1527178;C1705938;C1419891;C3273112
total psa modified shs,C2986589;C0392747;C3889737
patients with change from baseline in total psa modified shs $nmbr$,C0030705;C0392747;C0443172;C1705241;C4319952;C0168634;C1442488
diabetes bl,C0005918;C0006413;C1552663;C2827109
idm,C0270221
no pts,C1419129;C2698747
lvh by ecgt blood pressure mm hg,C0149721;C0005823;C1271104;C1272641
sbp,C0085805
dbp,C0536221;C3813197;C4281799
bmi kg m $nmbr$ cholesterol mg dl,C0022718;C0439209;C4054209;C0008377;C0439269
total no of events participants,C0439175;C0439810;C0441471;C0679646;C3541888
unadjusted $nmbr$ y risk per $nmbr$ population se adjusted rate,C0242444;C2987720
adjusted hr $nmbr$ ci compared with no diabetes at bl or at year $nmbr$,C0008107;C3259781;C1707455;C0011847;C0011849;C0005918;C0006413;C1552663;C2827109;C0439234;C0439508
adjusted hr $nmbr$ ci comparing idm with bl,C0008107;C3259781;C1707455;C0270221;C0005918;C0006413;C1552663;C2827109
cvd mortality,C0026565;C0026566
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ p,C0369773;C2603361
non cvd mortality,C0026565;C0026566
nonfatal mi fatal chdt,C1302234;C1705232
lisinopril cvd total,C0439175;C0439810
no cases,C0868928;C1533148
allopurinol $nmbr$ $nmbr$ mg n $nmbr$,C0002144;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
participated in a previous febuxostat studyb n,C0205156;C0249529;C1552607
prior urate lowering therapies n,C1514463;C0441994;C2003888
yes any,C1549445;C1705108;C1710701
febuxostat,C0249529
allopurinol,C0002144
probenecid,C0033209
renal functionc n,C0022646
any cardiovascular diseased,C0007226;C3887460
use of low dose aspirin,C1524063;C2608320
figure $nmbr$ mean percent change from baseline in serum urate at each scheduled visit,C0444504;C3272907;C2347634;C2348143;C0455272;C0086960;C0205539;C1571999
p $nmbr$ $nmbr$ vs allopurinol p $nmbr$ $nmbr$ vs febuxostat $nmbr$ mg p $nmbr$ $nmbr$ vs allopurinol error bars represent standard deviation,C0369773;C2603361;C0002144;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0743559;C1608199;C1882932;C0871420
vorapaxar n $nmbr$ $nmbr$,C2974521
qualifying type of atherosclerosis no,C1514624;C0332307;C1547052
selected clinical characteristics no total no,C1707391;C0683325;C0439175;C0439810
any coronary artery disease,C0010054;C0010068;C1956346
any peripheral arterial disease,C0085096;C1704436
previous cerebrovascular event,C0441471;C4019010
use of antiplatelet agents no total no,C1524063;C0085826;C0439175;C0439810
qualifying myocardial infarction,C1514624;C0027051;C0428953;C2926063;C3810814;C4552959
qualifying peripheral arterial disease,C1514624;C0085096;C1704436
qualifying stroke,C1514624;C0038454;C4554100
dipyridamole,C0012582
use of other medications no,C1524063
angiotensin converting enzyme inhibitor or angiotensin receptor blocker,C0003015;C2757044;C3536837;C4541021;C0034787;C1622222
subgroup overall,C1079230;C1515021;C0282416;C1561607
total no $nmbr$,C0439175;C0439810
vorapaxar placebo $nmbr$ yr,C0032042;C0439234;C1696465;C1706408
hazard ratio $nmbr$ cl $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C2985465;C0596019
qualifying atherosclerosis,C1514624;C0003850;C0004153
thienopyridine at enrollment,C1120149;C1516879;C1696073;C3888021
egfr mumin $nmbr$ $nmbr$ m $nmbr$,C1739039;C3811844;C3812682
europe i,C0021966;C0221138
europe ii,C1710602;C4082587
australia nz,C0004340;C0027978
vorapaxar placebo,C0032042;C1696465;C1706408
overall $nmbr$,C0282416;C1561607
estimated glomerular filtration,C0750572;C0232809
sample size n by treatment,C0242618
american indian alaskan native n,C0886378
asian pacific islander n,C0078988;C0242191
other n,C0369718;C0441922
on antihypertensive treatment n,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
blood pressure at baseline,C0005823;C1271104;C1272641
all participants mm hg sbp mean sd,C0439475;C2699239
dbp mean sd,C0444504;C2699239;C2347634;C2348143
treated at baseline mm hg sbp mean sd,C1522326;C0439475
untreated at baseline mm hg sbp mean sd,C0332155;C0439475
current cigarette smoker n,C3173209;C3241966
type $nmbr$ diabetes n,C1320657
hdl c $nmbr$ mg dl n,C3715113;C0439269
lvh by electrocardiogram n,C0149721;C0013798;C1547122;C1623258
fasting glucose mean sd mg dl,C0015663;C0439269
total cholesterol mean sd mg dl,C0201950;C0439269;C0543421
fasting triglycerides mean sd mg dl,C0015663;C0041004;C0439269
nos $nmbr$ $nmbr$ c t n,C0326287;C1518425
cc,C0008318;C3538933
ct,C0007673;C3540513;C3813556;C3888140
tt,C1452561;C4554543
nos $nmbr$ $nmbr$ a g n,C0326287;C1518425;C0439267
aa,C0282379;C1235746;C1882141;C4554792
ag,C0002037;C0051080;C0152305;C3888235
gg,C0017454;C0018370
nos $nmbr$ glu $nmbr$ asp g t n,C0326287;C0125690;C1518425
gt,C1435727;C1704693;C2697657
number of events event per $nmbr$ person years,C4330837;C0027361;C0439234;C2347489
rates,C0871208;C1521828
genotype specific treatment effect hazard ratio $nmbr$ ci,C0008107;C3259781
genotype by treatment interaction p values,C0017431;C1709380
outcome variant,C1274040;C0205419
genotype,C0017431
aml,C0023465;C0023467
lis,C2247545
chl,C0019829
aml vs lis,C0023465;C0023467;C2247545
aml vs chl,C0023465;C0023467;C0019829
chd primary outcome,C0205225;C1274040;C0439612;C0439631
$nmbr$ c t,
ct tt,C1452561;C4554543
$nmbr$ a g,C0439267
ag gg,C0017454;C0018370
glu $nmbr$ asp g t,C0125690;C0439267
gt tt,C1452561;C4554543
end stage renal disease,C0022661;C2316810
normal or increased egfr,C0205307;C0231683;C0439166;C2347086;C4553972;C1739039;C3811844;C3812682
mild reduction in egfr,C0301630;C0392756;C1293152;C4551656
moderate severe reduction in egfr,C0301630;C0392756;C1293152;C4551656
$nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$,C0439445
$nmbr$ $nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$,C0439445
sample size,C0242618
sbp mmghg mean sd,C0085805;C2699239
dbp mmghg mean sd,C0444504;C2699239;C2347634;C2348143
follow up in trial at $nmbr$ yr,C0589120;C1522577;C1704685;C3274571;C0150312;C0008976;C0332285;C1707101
sample sizea,C0370003;C2347026
taking statins n a,C0360714
mean sd d,C0444504;C2699239;C2347634;C2348143
total number of events participants,C4330837
$nmbr$ yr rate $nmbr$ participants,C0439234;C0679646
a compared wi,C0043193;C1520135
th c,C0039725;C0039738;C1420718;C4282123;C4285344
l compared wit,C0439394;C0043197;C1706495;C3642217
hc,C0020268;C0262499;C1413512
chd total,C0439175;C0439810
cvd total,C0439175;C0439810
stroke total,C0439175;C0439810
hf total,C0439175;C0439810
a compared w,C1707455
l compared wi,C0043193;C1520135
option,C1518601;C1550456
ambition,C0870128
radiate,C0332301
toward,
lithe,
all trials,C0008976
patient population,C0032659;C1257890
mtx ir,C0022065;C0022071;C1448132
mtx naive or free,C0025677;C1417487;C0332296;C1880497;C1996904
anti tnf ir,C0022065;C0022071;C1448132
dmard ir,C0022065;C0022071;C1448132
dmard ir anti tnf ir,C0022065;C0022071;C1448132
$nmbr$ tcz mtx,C0025677;C1417487
$nmbr$ tcz,
mtx,C0025677;C1417487
$nmbr$ tcz mtx mtx,C0025677;C1417487
total n,C0439175;C0439810
tcz mtx n,C0025677;C1417487
$nmbr$ mono,C1551432;C1551969
mtx n,C0025677;C1417487
white tcz mtx n,C0007457;C0025677;C1417487;C0043157;C0220938
white mtx n,C0007457;C0025677;C1417487;C0043157;C0220938
age mean s e,C0444504;C2347634;C2348143
height cm mean s e,C0444504;C2347634;C2348143
weight kg mean s e,C0444504;C2347634;C2348143
ra duration years mean s e,C0444504;C2347634;C2348143
rf positive,C0439178;C1446409;C1514241;C2825490;C3812269
baseline das $nmbr$ mean s e,C0444504;C2347634;C2348143
baseline haq mean s e,C0444504;C2347634;C2348143
baseline sjc mean s e,C0444504;C2347634;C2348143
baseline tjc mean s e,C0444504;C2347634;C2348143
shared epitope a positive,C0237876;C0003316;C1522138;C0439178;C1446409;C1514241;C2825490;C3812269
high dose arb n $nmbr$,C0444956;C3888198
arb ccb n $nmbr$,C3888198;C0006684
$nmbr$ $nmbr$ y n,
body height cm,C0005890;C0487985
bmi $nmbr$ n,C0578022
egfr $nmbr$ n,C1739039;C3811844;C3812682
serum values,C0229671;C0042295;C1546774;C1550100
potassium mmol l,C0032821;C1532563;C0202194;C0304475;C0597277;C3714637
casual plasma glucose mg dl,C0202042;C0439269;C0455280
current alcohol n,C0001962;C0001975
drug therapy n,C0013216;C0013217
previous antihypertensive treatment,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
insulin treatment,C0745343
arb angiotensin ii receptor blocker ccb,C0521942;C0006684;C3536793
calcium channel blocker bmi body,C0242821;C0460148;C1268086;C4082212
mass index,C0600653;C0918012;C1552854;C1637833;C2986546
bp blood pressure egfr estimated glomerular filtration rate men $nmbr$ en $nmbr$ x cr $nmbr$ $nmbr$ x age $nmbr$ $nmbr$ x $nmbr$ $nmbr$ hdl high density lipoprotein,C1363845
x cr $nmbr$ $nmbr$ x age,C0201975;C0001779;C3539604;C3711669;C4084730;C4553336;C4553337
$nmbr$ wom,
data are mean standard deviation for continuous variables and number for categoric variables p,C1511726;C3245479;C3714741;C0871420;C0237753;C0449788
values were calculated using t tests for continuous variables and chi square,C0042295;C0444686;C1441506;C1524063;C0871472;C0439828;C1552646
tests for categoric,C0022885;C0392366
crohn s disease,C0010346;C0012634
ulcerative colitis,C0009324
abatacept $nmbr$ $nmbr$ mg kg n $nmbr$,C1619966;C0439272
abatacept $nmbr$ mg kg n $nmbr$,C1619966;C0439272
mean disease duration y sd,C0872146;C2699239
inadequate response intolerance to prior therapy,C0231199;C1744706;C2355652
oral aminosalicylates,C0442027;C0368663;C4521986
anti tnf agent s,C0450442;C1254351;C1521826
mean hscrp mg l sd,C0439268;C2699239
prednisone use,C0042153;C0457083;C1947944
mean mayo score sd,C3533236;C2699239
extent of disease,C0449279;C4553144
left sided disease only,C0205091;C0012634;C0443246
extensive disease other,C0849867
supplementary figure $nmbr$ subgroup analyses for the rate of primary clinical responses during the induction period,C2986480;C0237629;C0205263;C0439531;C1948053;C0857127
non hispanic latino,C1518424;C0086528
baseline data,C1511726;C3245479;C3714741
gender m f,C0079399;C1522384;C0016327
at c data,C1511726;C3245479;C3714741
final a $nmbr$ c,C0205088;C1546485;C3853528
at c change,C0392747;C0443172;C1705241;C4319952
$nmbr$ $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0369773;C2603361
fpg data,C1511726;C3245479;C3714741
final mg dl,C0205088;C0439269;C1546485;C3853528
fpg change mg dl,C0392747;C0439269;C0443172;C1705241;C4319952
withdrawals n n,C1710677;C2349954;C2825032;C3812880;C4049634
voluntary,C0439656;C3543419
noncompliant,C0457432
all noncompleters,
indacaterol tiotropium n[ $nmbr$,C1722260;C0213771
tiotropium placebo n[ $nmbr$,C0213771;C0032042;C1696465;C1706408
tiotropium placeb n[ $nmbr$,C0213771
sex men women,C0009253;C0043210;C0036864;C0079399;C0804628;C1314687;C1522384
e,
duration of copd years mean sd,C0449238;C2926735
severity of copd n,C0439793;C0522510
moderatey,
pack years mean sd,C1277691;C2699239
fev $nmbr$ predicted post salbutamol,C0681842;C0001927;C1882327
fev $nmbr$ fvc post salbutamol,C3714541;C0001927
fev $nmbr$ litres pre salbutamol mean sd,C0001927;C2699239
fev $nmbr$ litres post salbutamol mean sd,C0001927;C2699239
fev $nmbr$ reversibilityz pre post salbutamol,C0332152;C0001927;C0740175;C2257086;C3669034
fev $nmbr$ litres pre ipratropium mean sd,C0027235;C2699239
fev $nmbr$ litres post ipratropium mean sd,C0027235;C2699239
fev $nmbr$ reversibilityz pre post ipratropium,C0332152;C0027235;C0740175;C2257086;C3669034
differences between indacaterol tiotropium versus tiotropium placebo,C1705241;C1705242;C0032042;C1696465;C1706408
fev $nmbr$ auc $nmbr$ mine $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
trough fev $nmbr$,C0444506;C3714541
copd severityy,C0024117;C1412502;C3714496
moderatez,
$nmbr$ ml $nmbr$ to $nmbr$ n $nmbr$ $nmbr$,C0439526;C1705224;C3887665;C0369718;C0441922
severe or very severe smoking status,C0205082;C4050465;C4050466;C3641272;C1519386;C4050419
ics use,C0042153;C0457083;C1947944
ics non users,C1518422;C1706077
ics users,C0815320;C1706077;C4551720
nonmetabolic syndrome n $nmbr$,C0039082
fpg mmol l mg dl,C1532980
tg mmol l [mg dl],C0337445;C1532563;C0439269
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ ],
diet diet pravastatin,C0012155;C0085542;C0012159;C1519433;C2983588;C3668949
event patients $nmbr$ pt y,C0030705;C0032743;C0699718
non metsyn,C1518422
metsyn,
metsyn with ldl $nmbr$ $nmbr$ mg dl,C0439269
patients with ra as or psa n $nmbr$,C0030705;C3538806;C4048756;C3810537;C3813209
patients without ra as or psa n $nmbr$ $nmbr$,C0030705;C3538806;C4048756;C3810537;C3813209
no of patients with ra,C0030705;C3538806;C4048756
no of patients with as,C0030705
no of patients with psa,C0030705;C3810537;C3813209
history of cardiovascular events,C1880008
angina pectorisf,C0002962
prerandomization statin therapy,C1278454
concomitant therapy,C1707479
ace inhibitors or angiotensin ii blockers,C0003015;C0003009;C1366631;C3714928
atorvastatin $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
simvastatin $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
total cholesterohhdl cholesterol ratio,C0456603;C1547037
ldl cholesterohhdl cholesterol ratio,C0456603;C1547037
apo b apo a i ratio,C0456603;C1547037
no men,C0025266
no women,C0043210
known duration,C0449238;C2926735
of t $nmbr$ dm years,C0011816;C0439234;C3250443
hba $nmbr$ c range,C1514721;C2348147;C3542016
hba $nmbr$ c distribution at baseline,C0520511;C1704711
$nmbr$ h pmg mmol l,C2827804
metformin dose,C0178602;C0869039;C1114758
figure $nmbr$ difference in hba $nmbr$ c least squares ls mean change from baseline at week $nmbr$ by subgroup categories relative to ls mean change for all patients vertical line the n values in parentheses show the number of patients in the sitagliptin group number of patients in the placebo group bmi body mass index,C1705241;C1705242;C0168634;C1442488;C3875154;C0023668;C0205132;C0700221;C1550648;C1552960;C0369718;C0042295;C0441922;C2360800;C0032042;C1305855;C1696465;C1706408
insulin glargine,C0907402
standard care,C1442989;C1947933;C2828392
prior cardiovascular event no j,C0332152;C1320716;C2826257
prior stroke no,C0038454;C4554100
any albuminuria no,C0001925
ankle brachial index,C1328319;C3888326
glycemic characteristics,C1521970
prior diabetes,C0011847;C0011849
use oforal glucose lowering agent no,C0042153;C0017725;C0457083;C1947944;C0441994;C2003888;C0450442;C1254351;C1521826
no use ofdiabetes drugs no,C0240320
new diabetes no,C0011847;C0011849
impaired glucose tolerance or impaired fasting glucose no,C0271650;C1272092
duration ofdiabetes yr,C0449238;C0439234;C2926735
glycemic drugs,C0013227;C3687832
sulfonylurea no,C0038766;C3536898
nonglycemic cardiovascular risk factors systolic blood pressure mmhg,C0232104;C0439475
body mass index waist to hip ratio,C0205682;C1264679
hdl cholesterol mg dl triglycerides mg dl,C3539687
creatinine mg dl urinary albumin to creatinine ratio,C2362049;C0456603;C1547037
other drugs no,C0013227;C3687832
thiazide diuretic,C0012802;C3536861
other blood pressure drug,C0003364
antiplatelet drug,C0085826
insulin glargine n $nmbr$ py,C0030428;C3538810
standard care n $nmbr$ py,C0030428;C3538810
placebo allocation,C0032042;C1706778;C1696465;C1706408
omega $nmbr$ allocation,C1719844;C1706778
a $nmbr$ $nmbr$ $nmbr$ median,C0549183;C0876920;C2347635;C2348144;C2939193
no prior cv event,C0441471;C4019010
prior cv event,C0441471;C4019010
no metformin,C0025598
no statin use,C0042153;C0457083;C1947944
no ace i arb,C0021966;C3888198;C0221138
ace i arb,C0021966;C3888198;C0221138
ifg igt,C1334085;C1708411
new dm,C0011816;C3250443
prior dm,C0011816;C3250443
dabigatran $nmbr$ mg bid n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
prior oac,C0332152;C2826257
crcl sd ml min,C1846718;C0439445
prior history of bleeding on oac,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
pacemaker or icd,C0030163;C0810633;C1546728;C3275122;C3853703;C0021122
dental procedure,C0011331
other diagnostic procedure,C0430022;C1546908
cataract removal,C0007389
colonoscopy,C0009378;C1548837
total hip or knee replacement,C0019552;C0022122;C1505163;C3538851;C4284725;C0086511
cystoscopic procedure,C0184661;C2700391;C3274430;C3539779
inguinal hernia repair,C0021446
laparoscopic cholecystectomy,C0162522
cabg or valve,C0010055;C0184252;C1186983;C1704414;C3888056
colectomy partial or total,C0728938;C1550516;C0439175;C0439810
peripheral angioplasty,C0162577;C1548817
prostate biopsy,C0194804
carotid endarterectomy,C0014099
limb amputation,C0002689
d $nmbr$ n n,C0369718;C0441922
warfarin n n,C0043031
d $nmbr$ vs warfarin rr $nmbr$ ci p value,C0008107;C1709380;C3259781
urgent surgery,C2188405
elective surgery,C0206058
major surgery,C0679637
minor surgery,C0038904
original dabigatran protocol,C0442711;C1507394;C1522729;C2348563;C2599718;C3715209;C4282383
amended dabigatran protocol,C0442711;C1507394;C1522729;C2348563;C2599718;C3715209;C4282383
disease duration b $nmbr$ years n $nmbr$,C0872146;C0439234
disease duration $nmbr$ to b $nmbr$ years n $nmbr$,C0872146;C0439234
disease duration $nmbr$ years n $nmbr$,C0872146;C0439234
age yrs mean,C0444504;C2347634;C2348143
$nmbr$ $nmbr$ n,C0369718;C0441922
baseline cdai,C0683448;C1413248;C3273706
baseline ibdq total score mean,C0444504;C2347634;C2348143
fistula at baseline n,C0016169;C0168634;C1442488
prior,C0332152;C2826257
figure $nmbr$ clinical remission at week $nmbr$ a and week $nmbr$ b by disease duration all patients randomised itt population p values from fisher s exact test,C0205210;C0544452;C0687702;C0332174;C0872146;C0439230;C0042295;C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
general anaesthesia,C0002915;C2930406
neuraxial anaesthesia,C0002903;C0002912;C0002930;C4049933
combination,C0205195;C1947911;C3811910
minimum,C1524031;C1552614;C2826545
maximum,C0806909;C1552615;C2826546
smoker or ex smoker n,C0337664;C0337671;C4555205
$nmbr$ years or,C0439234
figure $nmbr$ comparison of $nmbr$ mg and $nmbr$ mg dabigatran etexilate with enoxaparin treatments for the three outcomes analysed according to the type of anaesthesia a major venous thromboembolism vte and vte related mortality b major bleeding events c major bleeding events plus clinically relevant bleeding events,C1707455;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1571583;C0205449;C1274040;C0680240;C1305863;C1861172;C0630906;C0026565;C0019080;C0026566
data are presented as the odds ratio with $nmbr$ confidence intervals,C1511726;C3245479;C3714741;C0449450;C0028873;C0009667
telmisartan n $nmbr$,C0248719
mri substudy n $nmbr$,C0024485;C1824234;C3890166
sex male no,C0086582
hypertension treated,C0020538;C1963138;C1522326
clinical details,C0205210;C1522508
baseline nihss score median range,C1514721;C2348147;C3542016
regular alcohol consumption per week no,C0205272;C0001948
$nmbr$ drinks,C0452428
$nmbr$ $nmbr$ drinks,C0452428
some,
intense,C0522510
toast classification of qualifying stroke no,C1710306;C4521230;C1514624;C0038454;C4554100
other determined etiology,C0015127;C1314792;C1524003
undetermined etiology,C0478157
antihypertensive medication open label no,C0003364;C1709323
alpha receptor antagonist,C0439095;C4543207;C2003941;C2350010
beta receptor antagonist,C0330390;C4543207;C0439096;C2004068
telmisartan group n $nmbr$,C0248719;C0441848
wml load at baseline mri,C1550025;C1704782;C1708715
total periventricular wml score mean sd,C2964552;C2699239
subcortical wml load diameter mm mean sd,C0552409;C2699239
wml load at follow up mri,C1550025;C1704782;C1708715
wml load at follow up mri stratified by baseline severity of wml load,C1550025;C1704782;C1708715;C0205363;C0168634;C1442488
percent of patients,C0439165;C0030705
mild to moderate,C1299392
t $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ng ml,C2603360;C0439275
no patients,C0030705
hr b p m,
sbp dbp mmhg,C0085805;C0439475
ischaemic aetiology,C0015127;C1314792;C1524003
nyha classes iii iv,C0278962
laboratory values,C0022877;C0042295;C3244292;C4283904
co morbidities,C0009488
atrial fibrillation flutter,C0155709
pharmacological therapy for hf,C0039798;C0087111;C1363945
aceis,
aldosterone receptor antagonists,C1579268
biomarkers at baseline,C0005516;C0168634;C1442488
ptx $nmbr$ ng ml,C0030899;C0439275
all cause mortality per $nmbr$ person years,C0015127;C0026565;C0026566;C1524003
cardiovascular mortality per $nmbr$ person years,C0026565;C0026566
figure $nmbr$ baseline plasma pentraxin $nmbr$ ptx $nmbr$ concentrations in relation to selected clinical characteristics box plots showing the baseline median ptx $nmbr$ concentration in clinical subgroups based on sex age body mass index bmi and estimated glom erular filtration rate egfr,C0683150;C0683325;C1547282;C0086045;C1446561;C3827302;C1527178;C1705938;C0750572;C1739039;C3811844;C3812682
groups were compared with the kruskall wallis or mann whitney tests the number of patients in each category is indicated below the bars,C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429;C1707455;C1708930;C2360800;C0683312;C3889287;C1444656;C1707156;C3274014;C3541345
serum k level and drug treatment,C0302353;C0441889;C0456079;C1547707;C2946261;C0150270;C3469597
baseline $nmbr$ $nmbr$ meq l eos $nmbr$ $nmbr$ meq l,C0168634;C0439375;C1442488
baseline $nmbr$ $nmbr$ meq l eos,C1623465;C1861303
baseline $nmbr$ $nmbr$ or,C0168634;C1442488
val hctz n $nmbr$,C0042285;C0020261;C0523975
aml hctz n $nmbr$,C0023465;C0020261;C0023467
$nmbr$ y no,
diabetes status no,C1317301
normoglycemic $nmbr$,C0580545
prediabeticb,
diabetic $nmbr$,C0241863
egfr ml min $nmbr$ $nmbr$ m $nmbr$ mean sd,C1739039;C0439445;C3811844;C3812682;C0444504;C2699239;C2347634;C2348143
hba $nmbr$ c mean sd,C0019016;C2699239;C1825777;C3538758
baseline serum k meq l,C0302353;C0439375
eos serum k meq l,C0302353;C0439375
figure $nmbr$ postprandial glucose a b c and insulin d e f after oral glucose tolerance test ogtt challenge at baseline and at the end of the study eos in patients with baseline potassium k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l and baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ or $nmbr$ $nmbr$ meq l respectively aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error,C0376674;C0017725;C0021641;C1533581;C1579433;C3714501;C0870536;C1275991;C2827788;C0168634;C1442488;C0444930;C0557651;C2603343;C2746065;C0030705;C0439375;C0597277;C1708601;C0023465;C0023467;C0743559;C1608199;C1882932;C1710181
figure $nmbr$ mean change from baseline to end of the study eos week $nmbr$ in postprandial plasma glucose a and postprandial serum insulin b area under the curve auc from $nmbr$ to $nmbr$ minutes auc $nmbr$ $nmbr$ min aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error,C0392747;C0443172;C1705241;C4319952;C0444930;C2746065;C0202042;C0455280;C0428357;C0376690;C1261415;C0023465;C0023467;C0743559;C1608199;C1882932;C1710181
teaes,
non black n $nmbr$,C0005680;C0027567;C0085756;C0439541
all teaes,
mild teaes,C2945599
moderate teaes,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
severe teaes,C0205082;C4050465;C4050466
drug related teaes $nmbr$,C0013227;C0439849;C0445223;C1254351
discontinuations,C0457454
teaes $nmbr$ in any treatment group,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
dizziness,C0012833;C0042571;C1963093;C4084788;C4085547;C4085548;C4085549;C4553830
headache,C0018681;C4553197
urti,
nasopharyngitis,C0027441
peripheral edema,C0085649
fatigue,C0015672;C3463815;C4050243;C4554645
muscle spasms,C0037763
nausea,C0027497;C1963179;C2984057;C3829611;C4084796;C4085222;C4085661;C4085862;C4255480;C4552888;C4552889;C4553767
hypokalemia,C0020621;C4553966
uti,C0042029;C0077906;C1412376
joint swelling,C0152031
arthralgia,C0003862;C4551938
diarrhea,C0011991;C1963091;C3641756;C4084784;C4084802;C4085317
other teaes,
cough,C0010200;C1961131;C3274924;C4084725;C4084726;C4084727
hypotension,C0020649;C3163620
orthostatic hypotension,C0020651
sedbp,
^^^ $nmbr$ $nmbr$,
sesbp,
tofacitinib $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
duration of rheumatoid arthritis yr,C0449238;C2926735
tender and swollen joints mean no,C0234234;C0444504;C2347634;C2348143
tender,C0234234
swollen,C0038999
mean score on haq di,C3533236;C3826998;C4321476
das $nmbr$ $nmbr$ esr $nmbr$,C0051767;C3811131;C0057671
score of $nmbr$ $nmbr$,C0449820;C4050231
mean score on das $nmbr$ $nmbr$ crp ^,C3533236;C0051767;C0057671
erythrocyte sedimentation rate mm hr,C1176468;C1619634
c reactive protein mg liter,C0006560;C0475211;C1413716;C4048285
positive for rheumatoid factor anti cyclic citrullinated peptide antibodies or both ff,C0741132;C1829901;C4554348
tnf inhibitor,C1448177;C1999216
other biologic agent,C0005515
nonbiologic disease modifying drug other than methotrexate,C0392747;C4036059
prior disease modifying drugs resulting in inadequate response mean no patient,C0012634;C0013227;C3687832;C0332294;C0205412;C0439856;C0030705
tofacitinib,C2930696
gender female,C0043210;C0086287;C1705497;C1705498
anti ccp positive,C0439178;C1446409;C1514241;C2825490;C3812269
dmard biologic ir,C0022065;C0022071;C1448132
region united states,C0017446;C0041703;C0205147
europe $nmbr$,C0015176
colesevelam n $nmbr$,C0541155
country n,C0454664;C1511538
mexico,C0025885
colombia,C3245499
hba $nmbr$ ca mean sd,C0019016;C1825777;C3538758;C0444504;C2699239;C2347634;C2348143
fpg mg dl mean sd,C0439269;C2699239
$nmbr$ hour postload glucose,C0439227;C0017725;C0564385
mg dl mean sd,C0439269;C2699239
fasting insulin iiiu ml mean sd,C0015663;C0021641;C2699239;C1533581;C1579433;C3714501
$nmbr$ years n $nmbr$,C0439234
hispanic n $nmbr$,C0086409
fpg mean sd mg dl,C0444504;C0439269;C2347634;C2348143
duration of diabetes mean sd y,C0449238;C2926735
background treatment n,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
diet and exercise,C0012155;C0012159;C1519433;C2983588;C3668949;C0015259;C1522704
sulfonylureaa,
thiazolidinedioneb,
insulina,
$nmbr$ to $nmbr$ n $nmbr$,C0369718;C0441922
a from baseline,C0168634;C1442488
weight ab,C0005910;C0043100;C1305866;C1705104
total chol mg dl,C0201950;C0439269
baselinec,
endpointc,
endpoint baseline,C0168634;C1442488
endpoint baselinec,C2349179;C2826544
parameter n,C0549193;C1704769;C2350001
vomiting,C0042963;C1963281;C3898969;C4084766;C4084767;C4084768;C4084769
upper respiratory tract infection,C0041912
dyspepsia,C0013395;C4552968
decreased appetite,C0232462
hypoglycemia,C0020615;C4553659
with an sfua,
without an sfua,
alt u l,C1266129;C0439339;C4553172
baselineb,
a from baselineb,
ast u l,C1415181;C0439339;C3891303
upper respiratory tract infection $nmbr$ $nmbr$ $nmbr$,C0041912
$nmbr$ year framingham chd risk $nmbr$ mean sd,C1282512;C2699239
efficacy measures,C0079809;C1879489
difference in ls mean $nmbr$ $nmbr$ cl,C1705241;C1705242
without diabetes,C0011847;C0011849
with diabetes,C0011847;C0011849
low density lipoprotein cholesterol,C0023824
aspirin plus placebo n $nmbr$,C0004057;C0032042;C1696465;C1706408
aspirin plus clopidogrel n $nmbr$,C0004057;C0070166
male sex race or ethnic group f,C0034510;C1706779;C3853635;C0441840
black region or country,C0017446;C0205147;C0454664;C1511538
spain,C0037747
mean blood pressure at screening visit mm hg,C0428886;C0488053
previous clinical stroke or transient ischemic attack,C0038454;C4554100;C0007787;C0917805
current tobacco smoker qualifying event,C3173209;C3241966;C1514624;C0441471;C4019010
transient ischemic attack type of lacunar syndrome,C0455703
pure motor hemiparesis,C1513492;C0018989;C1705994
pure sensory stroke,C0445254;C0038454;C4554100
sensorimotor stroke,C0038454;C4554100
use of aspirin at time of qualifying event,C1524063;C0004057;C0040223;C3541383;C1514624;C0441471;C4019010
use of statin at any follow up visit,C1524063;C0360714;C0589121
vorapaxar group n $nmbr$,C2974521;C0441848
median age iqr years,C0549183;C1510829;C0876920;C2347635;C2348144;C2939193
white ethnic origin,C0007457;C0015031;C0043157;C0220938
time from qualifying myocardial infarction,C0040223;C3541383;C1514624;C0027051;C0428953;C2926063;C3810814;C4552959
previous coronary revascularisation,C0205156;C0877341;C1552607
concomitant drugs,C0013227;C3687832
vorapaxar placebo $nmbr$ yr km,C0032042;C3887676;C1696465;C1706408
hr $nmbr$ ci p value for interaction,C0008107;C1709380;C3259781
prior stroke or tia,C0038454;C4554100;C0007787;C0917805;C1054154
planned thienopyridine at enrollment,C1709561;C1120149
prior stent,C0332152;C0038257;C2826257
azl m cld n $nmbr$,
azl m hctz n $nmbr$,C0020261
$nmbr$ f,C0016327
age categories y n,C2916832
egfr category ml min $nmbr$ $nmbr$ m $nmbr$ n,C0683312;C0439445;C3889287;C0369718;C0441922
moderate impairment,C0221099;C0684336
mild impairment,C0221099;C0684336
chronic kidney disease n,C1561643;C4553188
indacaterol n $nmbr$,C1722260
race caucasian,C0007457;C0043157
severity of copd n gold $nmbr$ moderate,C0439793;C0522510
severe very severea,C0205082;C0442824;C2984081;C4050465;C4050466
fev $nmbr$ pred post albuterol,C0032952;C0044955;C0687676;C0001927;C1704687;C3469826
fev $nmbr$ reversibility b,C3714541;C0449261
baseline dyspnea index score,C0449820;C4050231
gold ii,C1710602;C4082587
gold iii iv,C0022326;C4265176
indacaterol $nmbr$ pg,C0030827;C0072225;C1266240
bdi total score baseline,C0168634;C1442488
tdi total score week $nmbr$,C0332174;C0439230
locf,C2825507
sgrq total score,C2964552
sgrq total score week,C0332174;C0439230
$nmbr$ locf,C2825507
moderate copdb [n z $nmbr$ ],C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0369718;C0441922
severe copdc [n z $nmbr$ ],C0205082;C4050465;C4050466;C0369718;C0441922
indacaterol $nmbr$ mg[n z $nmbr$ ],C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0369718;C0441922
placebo [n z $nmbr$ ],C0032042;C1696465;C1706408;C0369718;C0441922
taiwan,C0039260
japanese,C0376247;C1556094
duration of copd,C0449238;C2926735
ex smoker current,C0521116;C1705970
pack years,C1277691
fev $nmbr$ fvc a,C3714541
reversibility to,C0449261
salbutamol,C0001927
copd severity n,C0024117;C0439793;C0522510;C1412502;C3714496
figure $nmbr$ least squares mean $nmbr$ ci treatment differences versus placebo in sgrq total score symptoms activity and impacts component scores data at week $nmbr$ itt population the dotted line indicates the pre speci ed level of clinical relevance data are least squares mean with $nmbr$ con dence intervals lsm [ $nmbr$ ci] itt z intent to treat sgrq z st george s respiratory ques tionnaire ind z indacaterol p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ versus placebo,C1705241;C1705242;C0032042;C1696465;C1706408;C1511728;C0032659;C1257890;C0205132;C0700221;C1550648;C1552960;C0441889;C0456079;C1547707;C2946261;C0023189;C0444504;C2347634;C2348143;C0162425;C1283828;C1550453;C0521346;C1546767
a overall and subgroups bv statin potency,C0282416;C1561607;C0085166;C0360714;C1511278
low n $nmbr$,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
statin potency medium n $nmbr$,C0360714;C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283
high n $nmbr$,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
caucasian n,C0007457;C0043157
african american n,C0085756
dm n,C0011816;C3250443
$nmbr$ $nmbr$ b b,
total c mg dl,C0439175;C0439269;C0439810
triglyceride mg dl $nmbr$,C0041004;C0439269
total c hdl c ratio,C0456603;C1547037
apoal mg dl,C0439269
lathosterol jimol l,C0064673
$nmbr$ sitosterol p mol l,C0037215;C0347982;C0220914
lathosterol total c imol mmol,C0064673;C0439190
p sitosterol total c imol mmol,C0037215;C0439190;C0220914
p sitosterol lathosterol,C0037215;C0064673;C0220914
baseline sitosterol,C0037215;C0220914
baseline sitosterol cholesterol,C0037215;C0008377;C0220914
baseline sitosterol lathosterol,C0037215;C0064673;C0220914
absolute change,C1549031
triglyceride a,C0041004
$nmbr$ $nmbr$ b,
tc hdl c,C0039411;C3715113;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
percent change,C0392747;C0443172;C1705241;C4319952
bivalirudin n $nmbr$,C0168273
heparin plus a gpi n $nmbr$,C0019134;C0770546
coronary artery treated no,C0205042;C1522326
previous myocardial infarction no,C0027051;C0428953;C2926063;C3810814;C4552959
previous percutaneous coronary intervention,C0205156;C1532338;C1552607
previous coronary artery bypass surgery no,C2144990
estimated gfr ml min,C0017654;C0439445;C1424601
time point,C2348792
ckd,C1561643
chronic cvd,C0205191;C0007222
om $nmbr$ aml $nmbr$ hctz $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
to goal,C0018017;C1571704
week $nmbr$ et,C0332174;C0040028;C0439230
om $nmbr$ aml $nmbr$ hctz $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
om $nmbr$,C0028971;C1705272
aml $nmbr$,C0023465;C0023467
om $nmbr$ aml $nmbr$,C0023465;C0023467
$nmbr$ $nmbr$ cl,C0596019
s fs $nmbr$,C1517317;C3814419
o,C0483204
drug related teaes,C0013227;C0439849;C0445223;C1254351
discontinuations teaes,C0457454
f n,C0016327
s s $nmbr$,C0565930;C2603362
i u uj,C0021966;C0221138
q q $nmbr$ \,
$nmbr$ f $nmbr$ $nmbr$,C0016327
$nmbr$ $nmbr$ si,
$nmbr$ f $nmbr$,C0016327
edema peripheral,C0013604;C0205100;C1717255
$nmbr$ n qi,C0369718;C0376586;C0441922
hvookalemia,
sitagliptin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
body weight kg mean sd,C0005910;C2699239;C1305866
known duration of type $nmbr$ diabetes,C0449238;C2926735
hba $nmbr$ c mean sd [range],C0019016;C2699239;C1825777;C3538758;C1514721;C2348147;C3542016
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
hba $nmbr$ c distribution at baseline n,C0520511;C1704711
b $nmbr$,
$nmbr$ h pmg mmol l mean sd,C2827804;C2699239
fasting insulin pmol l mean sd,C0015663;C0439284;C2699239
conventional treatment n $nmbr$,C2945704
monitoring n $nmbr$,C0150369;C1283169
medical history and risk factors no,C0262926;C1704706;C0035648;C1553898
prior cardiovascular event no,C0332152;C1320716;C2826257
coronary intervention,C0184661;C0886296;C1273869
stent implanted no,C0522776
no of stents implanted,C0038257;C0021102;C2828363
drug eluting stent implanted no,C1322815;C0021102;C2828363
stented vessel no,C0038257;C0005847
left main coronary artery,C1261082
left anterior descending coronary artery,C0226032
left circumflex coronary artery,C0226037
m o nito ring treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
conventional treatment,C2945704
r elative risk $nmbr$ ci,C0008107;C3259781
full po pulatio n,C0443225;C0946289
bm i $nmbr$,C0021966;C0221138
n o diabetes,C0011847;C0011849
no smo king,C1311076;C1364142;C1423784
no acs,C0742343;C4318612
number of stent $nmbr$,C0237753;C0449788
number ste t $nmbr$,C0237753;C0449788
o $nmbr$ o $nmbr$ $nmbr$,C0483204
planned valve surgery n,C0038894;C0038895;C0543467;C1274039
body mass index kg m $nmbr$ sd,C0022718;C0439209;C4054209;C2699239
waist circumference cm sd,C0455829;C2699239
chronic renal failure n,C0022661;C1561643;C2316810
coronary heart disease n t,C0010054;C0010068;C1956346
prior percutaneous coronary intervention n,C0332152;C1532338;C2826257
prior cardiac surgery n,C0455610
coronary bypass n,C0010055
valve surgery n,C0038894;C0038895;C0543467;C1274039
other cardiac surgery n,C0018821;C0524727
prior arrhythmias n,C0332152;C0003811;C2826257
other supraventricular tachycardia,C0039240;C1963244;C3815188
ventricular tachycardia or fibrillation,C0042514;C0344428;C1963247;C4554446;C0232197
congestive heart failure n,C0018802
nyha class n i,C1882084
ejection fraction percent sd,C0489482;C2699239;C2700378
left atrial diameter mm sd,C0225860;C2699239;C0225861
prior implantable cardiodefibrillator n,C0332152;C0021102;C2826257
prior pacemaker n,C0332152;C0030163;C0810633;C1546728;C3275122;C3853703;C2826257
prior cardiac resynchronization therapy n,C1167956
prior af ablation n,C0332152;C0344434;C4049859;C2826257
euroscore logistic median $nmbr$ th $nmbr$ th,C0039725;C0039738;C1420718;C4282123;C4285344
euroscore additive median $nmbr$ th $nmbr$ th,C0039725;C0039738;C1420718;C4282123;C4285344
medications at enrollment n,C0013227;C0802604;C2598133;C4284232
angiotension converting enzyme inhibitor,C0014432;C0919438;C4521603
aldosterone antagonists,C0002007;C2757004
antiplatelets or anticoagulants,C0003280
antiplatelets,
other antiarrhythmics^,C0003195
pfor,C1151635
n $nmbr$ pufa,C0369718;C0032615;C0441922
$nmbr$ cl interaction,C0596019;C1704675
sex male n $nmbr$,C0086582
country argentina n $nmbr$,C0454664;C0003761;C1504311;C1511538
italy n $nmbr$,C0022277
usa n $nmbr$,C0041703
cardiac valve surgery no n $nmbr$,C0018821;C0524727;C0369718;C0441922
hypertension no n $nmbr$,C0020538;C1963138;C0369718;C0441922
nyha class $nmbr$ $nmbr$ no n llll,C1882083;C0369718;C0441922
serum potassium,C0302353;C0543465
$nmbr$ $nmbr$ mmol l n $nmbr$,C1532563
$nmbr$ mm n $nmbr$,C4330985;C4554674
habitual fish intake,C0205353;C0556216
$nmbr$ servings wk n $nmbr$,C0332174;C0439230
phospholipid omega $nmbr$ levels,C0031676;C0441889;C0202177
study drug loading days actual $nmbr$ n $nmbr$,C2826182
peri op beta blockers no n $nmbr$,C0347985;C0001645;C0369718;C0441922
peri op statins no n $nmbr$,C0347985;C0360714;C0369718;C0441922
peri op amiodarone no n $nmbr$,C0347985;C0002598;C0369718;C0441922
peri op ace inhibitors arbs no n $nmbr$,C0003015;C3888198;C0369718;C0441922
on pump time,C0040223;C3541383
l $nmbr$ hrs min n $nmbr$,C0439393;C1568891
cross damp time,C0040223;C3541383
$nmbr$ $nmbr$ hrs min n $nmbr$,C0702093;C1524029;C3813700
canakinumab dose per mo,C0178602;C0869039;C1114758
total group n $nmbr$,C0439175;C0441848;C0439810
blood pressure mm,C4330985;C4554674
geographic site,C0017446
duration of diabetes mellitus y,C0449238;C2926735
previous metformin use,C0042153;C0457083;C1947944
metformin dose mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
glucose mmol l,C0017725;C1532563
insulin pmol l,C0021641;C0439284;C1533581;C1579433;C3714501
il $nmbr$ ng l,C0020898;C0439297;C0021764;C0022271
fibrinogen g l,C0439294;C0456615
canakinumab dose per month,C0178602;C0869039;C1114758
change median baseline crp $nmbr$ mg l,C0168634;C0439268;C1442488
baseline crp,C3890735;C4048285
il $nmbr$,C0020898;C0021764;C0022271
fibrinogen,C0016006;C1167394;C2587184;C3540039
n v n $nmbr$,C0369718;C0441922
v $nmbr$ n $nmbr$,C0369718;C0441922
race asian n,C0034510;C0078988;C1706779;C3853635
mean sd kg m $nmbr$,C0022718;C0439209;C4054209
nonsmoker n,C0337672;C0425293;C4554605
baseline sbp,C0168634;C0085805;C1442488
mean sd mmhg,C0444504;C0439475;C2347634;C2348143
baseline dbp,C0536221;C3813197;C4281799
metabolism and nutrition,C0025519;C0025520;C0028707;C0392209;C0518896;C1442959
disorders soc,C0012634
cardiac disorders soc,C0018799
cerebral infarction,C0007785
cerebral ischemia,C0007785;C0917798
apixaban $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
apixaban $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mean kg,C0022718;C0439209;C4054209
initial diagnosis no,C0011900;C1704338;C1704656
clinical presentation of vte at initial diagnosis no,C2708283;C0630906;C0011900;C1704338;C1704656
associated with transient or reversible risk factor,C0332281;C0040704;C0205374;C0205343;C0035648
risk factors for recurrent vte no f,C0035648;C1553898;C0016327
persistent or permanent immobilization,C0205322;C0332996;C0020944;C4048292
previous deep vein thrombosis or pulmonary embolism,C0205156;C0149871;C1552607;C0034065
known prothrombotic genotype,C0205309;C0017431
use of antiplatelet agents^,C1524063;C0085826
apixaban,C1831808
apixaban $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
apixaban $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
pe with or without dvt,C0070939;C1880476;C4284304;C0149871;C2926618;C3899446
dvt only,C0149871;C2926618;C3899446
normal renal function,C0232805
normal weight bmi,C4229017
overweight bmi $nmbr$ to,C0497406;C0578022
obese bmi $nmbr$,C0028754;C0578022
b a n $nmbr$,
b h n $nmbr$,C0033727;C0369286;C0441932;C0564385;C4528284
previous coronary heart disease,C0010054;C0010068;C1956346
previous chronic kidney disease,C1561643;C4553188
change in retinal pathology,C0392747;C0443172;C1705241;C4319952
$nmbr$ step,C1261552;C1704379;C1705117;C2825408;C3814463
$nmbr$ or $nmbr$ step,C1261552;C1704379;C1705117;C2825408;C3814463
$nmbr$ step or incident vitrectomy or photocoagulation,C1261552;C1704379;C1705117;C2825408;C3814463;C1551358;C0042903;C0023694;C1328010
baseline a $nmbr$ c,C0168634;C1442488
baseline sbp mm,C4330985;C4554674
baseline ldl mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
outcomes during accord,C1274040;C0680240
accord primary n,C0205225;C0439612;C0439631
fatal nonfatal mi n,C1302234;C1705232
fatal nonfatal stroke n,C1302234;C0038454;C4554100;C1705232
concomitant antiplatelet,C0521115
no concomitant antiplatelet,C0521115
de $nmbr$ n $nmbr$,C0011198;C0017480;C3541240
previous htn n,C0205156;C0020538;C1552607
previous dm n,C0205156;C0011816;C3250443;C1552607
previous cad n,C0205156;C1504769;C2239547;C3813548;C4284121;C1552607
previous chf n,C0205156;C0018802;C1552607
chads score n,C0449820;C4050231
previous renal disease n,C0205156;C0022658;C1552607
type of af n,C0332307;C1547052
duration antiplatelet use as of study duration sd,C1881378;C2826775
rate year,C0439234;C0439508
stroke embolism,C0013922;C1704212
all stroke,C0038454;C4554100
major bleed,C0205082;C0019080;C0205164;C4318856;C4521762
minor bleed,C0026193;C0019080;C0205165
all bleed,C0019080
intracranial,C0524466
extracranial,C0580586
with mets,C0812270;C1705694;C2939420
ez simva $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
doubling statin dose,C0178602;C0869039;C1114758
rosuvastatin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
multi racial,C0439064;C3266262
without mets,C0812270;C1705694;C2939420
mitt population,C0032659;C1257890
oral treprostinil n $nmbr$,C0442027;C1145760;C4521986
not provided,C1518422
pah origin cause,C0015127;C1524003
ipah hpah,C0340543;C0637939;C1150929
repaired chd,C0280604;C3542407
hiv,C0019682;C0019699
who functional class ii iii,C0441887;C2698969
$nmbr$ mwd m,
years since pah diagnosis,C0439234;C0011900;C1704338;C1704656
figure $nmbr$ change in $nmbr$ minute walk distance $nmbr$ mwd by covariates results presented as hodges lehmann median estimate of treat ment effect for the change in $nmbr$ mwd at week $nmbr$ by covariate classi cation for the modi ed intent to treat mitt population subgroup interaction probability values provided for covariates p,C0392747;C0443172;C1705241;C4319952;C1274040;C1546471;C2825142;C0449450;C0084844;C1538994;C0332174;C0439230;C0007447;C0162425;C1283828;C1550453;C0032659;C0042295;C1257890
subgoup_name,C0027365;C1547383;C4522128
subgroup_level,C0441889;C0456079;C1547707;C2946261
image only,C1704254;C1704922;C3542466
chads $nmbr$,C0007928;C1413373
r $nmbr$,C0205090;C0684010;C2603358
af pattern,C0344434;C0449774;C4049859
laa ostium,C0444567
laa length,C1444754;C1706316
device watchman filter,C0180860;C0335390
control warfarin,C0243148;C0043031;C1550141;C1882979;C2587213;C3274648;C4553389
aliskiren valsartan n $nmbr$,C2733073
age y sex no,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
$nmbr$ $nmbr$ i $nmbr$ $nmbr$,C0021966;C0221138
bmi kg m $nmbr$ uac no,C0022718;C0439209;C4054209
$nmbr$ $nmbr$ i $nmbr$ $nmbr$ n $nmbr$,
$nmbr$ $nmbr$ mg g,C1300563
$nmbr$ mg g,C1300563
$nmbr$ $nmbr$ i $nmbr$ $nmbr$ n $nmbr$ a,C0021966;C0221138
$nmbr$ hour masbp mm hg,C0439227;C0439475;C0564385
$nmbr$ hour madbp mm hg,C0439227;C0439475;C0564385
uac,
uac $nmbr$ $nmbr$ mg g,C1300563
uac $nmbr$ mg g,C1300563
a v n $nmbr$ v n $nmbr$,C1272460;C0369718;C0441922
a v n $nmbr$,C1272460
v n $nmbr$,C0369718;C0441922
bun mg dl,C0439269
serum potassium meq l,C0302353;C0439375;C0543465
age y $nmbr$ th $nmbr$ th percentiles,C0001779;C1264641
months from qualifying stroke,C0439231;C1514624;C0038454;C4554100
selected clinical characteristics,C1707391;C0683325
rankin scale $nmbr$,C0451405
aspirin alone,C0004057;C0205171;C0439044;C0679994
thienopyridine alone,C1120149;C0205171;C0439044;C0679994
dipyridamole alone,C0012582;C0205171;C0439044;C0679994
aspirin thienopyridine,C0004057;C1120149
aspirin dipyridamole,C0732279
thienopyridine dipyridamole,C1120149;C0012582
other medications at enrollment,C0013227;C0802604;C2598133;C4284232
vorapaxar no $nmbr$ y km,C2974521;C3887676
placebo no $nmbr$ y km,C0032042;C1696465;C1706408;C3887676
efficacy end points,C1280519;C2349179;C1707887
cv death mi or stroke,C0011065;C3810814;C1306577;C4082313;C4552775;C0038454;C4554100
cv death mi stroke or urgent coronary revascularization,C0038454;C4554100;C0439609;C0877341;C3272275
any stroke,C0038454;C4554100
urgent coronary revascularization,C0439609;C0877341;C3272275
bleeding end points,C0019080;C2349179
gusto moderate or severe,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0205082;C4050465;C4050466
gusto severe,C0205082;C4050465;C4050466
timi clinically significant,C0237881;C0750502;C1546944
timi non cabg major,C0205082;C0205164;C4318856;C4521762
timi minor,C0026193;C0205165
fatal bleeding,C1302234;C0019080;C1705232
intracranial hemorrhage,C0151699;C4554169
intracerebral,C0442111
subdural epidural,C0228134;C0812144
active control study,C2347179
placebo control study,C0683952
estimated creatinine clearance ml min i,C0023806
neither deep vein thrombosis nor pulmonary embolism,C0149871;C0034065
immobilization no,C0020944;C4048292
transient,C0040704;C0205374
known thrombophilia no,C0205309;C0398623
active cancer no,C0006826;C0998265;C1306459
previous cancer no,C0006826;C0998265;C1306459
coronary artery disease no,C0010054;C0010068;C1956346
treatment duration before randomization days,C0444921;C3259042
enrolled from re cover study no,C4684790;C0556581;C0180153;C1999244;C3888055;C2986904;C0557651;C2603343
dabigatran group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
enrolled from re cover ii study no,C4684790;C0556581;C0180153;C1999244;C3888055;C2986904;C0557651;C2603343
adherence to study regimen no ff,C1510802;C0040808;C2945654;C4554348
factors dabigatran event incidence n,C0021149;C0220856
wafarin event incidence n,C0021149;C0220856
creatine clearance category $nmbr$ to,C0683312;C3889287
currently smokes,C0521116;C0037369
subgroup w r t re cover,C0180153;C1999244;C3888055
re cover $nmbr$ dabigatran,C0556581;C0180153;C1999244;C3888055;C2986904;C2348066
re cover $nmbr$ warfarin,C0556581;C0180153;C1999244;C3888055;C2986904;C0043031
re cover ii,C0556581;C0180153;C1999244;C3888055;C2986904
non rollover,C0517067;C0543436
symptomatic pe,C0070939;C1880476;C4284304
history of $nmbr$ previous vte excluding index event,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0441471;C4019010
history of non hemor rhagic stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
history of coronary artery disease,C1881055
factors dabigatran,C1521761;C2348066;C2827422
p value for,C1709380
event incidence n,C0021149;C0220856
black or asian,C0005680;C0027567;C0085756;C0439541;C0078988
l $nmbr$ kg,C1637390
creatine clearance category,C0683312;C3889287
$nmbr$ m b m in,C0369637;C0441923
$nmbr$ ^ $nmbr$ t $nmbr$ c u,C2603360;C0439148
qualifying index event as pe,C1514624;C0441471;C4019010
budesonide mmx $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
entocort ec n $nmbr$,C1170256
mean age years range,C1514721;C2348147;C3542016
uc history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
mean disease duration years,C0872146;C0439234
duration,C0449238;C2926735
duration $nmbr$ to,C0449238;C2926735
duration $nmbr$ years n,C0449238;C0439234;C2926735
disease extent n,C0012634;C0439792
proctosigmoiditis,C0033252
left sided colitis,C2887821
extensive pancolitis,C0205231;C0868908
mean baseline ucdai score,C3533236;C0168634;C1442488
mean baseline ei score,C3533236;C0022067;C1414370;C2348481
prior mesalazine use,C0042153;C0457083;C1947944
prior sulfasalazine use,C0042153;C0457083;C1947944
nerd,
eo,C0332120
gender male n,C0079399;C0086582;C1706180;C1706428;C1706429;C1522384
american indian alaskan native,C0886378
native hawaiian pacific islander,C0337920;C0242191
alcohol drinker n,C0001962;C0001975
caffeine user n,C3532939
h pylori status n,C0079488;C0449438
baseline los angeles grade of eo n,C0441800;C0919553;C3244287
figure $nmbr$ frequency of $nmbr$ h heartburn free days during treatment in a non erosive oesophageal reflux disease nerd and b erosive oesophagitis eo patients,C0376249;C0439603;C0871396;C1561548;C1705502;C3898838;C4321352;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0267055;C0030705
statistically significant differences among bmi categories within treatment group were determined using kruskal wallis test,C1705241;C1705242;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0521095;C1524063;C1708614
no psa n $nmbr$,C3810537;C3813209
psa n $nmbr$,C3810537;C3813209
mean age years $nmbr$ ci,C0008107;C3259781
mean bmi $nmbr$ ci,C0008107;C3259781
mean involved bsa $nmbr$ ci,C0008107;C3259781
mean pasi score $nmbr$ ci,C0008107;C3259781
mean dlqi score $nmbr$ ci,C0008107;C3259781
daily activities,C0871707
leisure,C0086542
personal relationships,C1552027
symptoms and feelings,C0683368;C1457887;C1527305
treatment satisfaction,C3476649
work and school,C0043227;C0036375
mean eq $nmbr$ d response $nmbr$ ci,C0205163;C0439185;C0008107;C3259781
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ t,C2603360
mean sf $nmbr$ score $nmbr$ ci,C0008107;C3259781
physical functioning,C0516981;C4049916
physical role,C0035820;C1705810;C3871154
bodily pain,C3890602
general health,C0424575;C4018875
vitality,C0424589
social functioning,C0037395
mental health,C0025353
emotional role,C0035820;C1705810;C3871154
physical component summary,C0031809;C0205485;C1509143
mental component summary,C0229992;C0449432;C1705248
mean ham d score $nmbr$ ci,C0008107;C3259781
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ tt,C1452561;C4554543
no of events per $nmbr$ patient years,C0441471;C3541888;C0030705;C0439234
no psa,C3810537;C3813209
placebo $nmbr$ $nmbr$ pt yrs,C0032743;C0699718
$nmbr$ mg qw $nmbr$ $nmbr$ pt yrs,C0032743;C0699718
$nmbr$ mg biw $nmbr$ $nmbr$ pt yrs,C0032743;C0699718
any event,C0441471;C4019010
arthritis,C0003864;C4552845
back pain,C0004604;C1963071;C4553945
bursitis,C0006444
muscle twitching,C0026845;C4083049;C0231530
musculoskeletal stiffness,C0497254;C0427008;C2707260
neck pain,C0007859;C1963180;C4553909
pain in extremity,C0030196;C4553007
psoriatic arthropathy,C0003872
shoulder pain,C0037011
tendonitis,C0039503
low feno subgroup $nmbr$ $nmbr$ ppb n $nmbr$,C0205251;C1079230;C1515021;C1550472;C3890211;C4048187;C4321351;C4522223
high feno subgroup $nmbr$ $nmbr$ ppb n $nmbr$,C0205250;C1079230;C1515021;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
low eosinophil subgroup $nmbr$ ml n $nmbr$,C0205251;C0014467;C1550472;C3890211;C4048187;C4321351;C4522223
high eosinophil subgroup $nmbr$ ml n $nmbr$,C0205250;C0014467;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
low periostin subgroup $nmbr$ ng ml n $nmbr$,C0205251;C0439275;C1550472;C3890211;C4048187;C4321351;C4522223
high periostin subgroup $nmbr$ ng ml n $nmbr$,C0205250;C0439275;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
mean sd age yr,C0001779;C0439234
mean body weight sd kg,C0022718;C0439209;C4054209
mean total serum ige sd iu ml,C0229671;C0439458;C1546774;C1550100
mean prebronchodilator fev $nmbr$ sd predicted,C0444504;C2699239;C2347634;C2348143;C0681842;C1882327
hospitalized for asthma n,C0701159;C0004096;C2984299
mean sd number of exacerbations,C0237753;C0449788
mean sd total asthma symptom scores,C3533236
mean sd number of albuterol per day puff,C0237753;C0449788;C1533107;C1882376
mean sd aqlq,C0444504;C4055434;C2347634;C2348143
mean sd feno ppb,C0444504;C1415800;C2347634;C2348143
mean eosinophil count per ml,C0200638;C0750879
mean sd periostin ng ml,C0219433;C0439275;C1424662;C3812270
concomitant asthma medications n,C0004096;C0013227;C0802604;C2598133;C4284232;C2984299
m $nmbr$ subgroup,C1079230;C1515021
total asthma symptom score,C3533163;C0004096;C2984299
albuterol use,C0042153;C0457083;C1947944
aqlq score,C0449820;C4050231
change from baseline in predicted fev $nmbr$,C0392747;C0443172;C1705241;C4319952;C0681842;C3714541;C1882327
low subgroup,C1079230;C1515021
high subgroup,C1079230;C1515021
feno placebo lsm,C0032042;C1696465;C1706408
omalizumab lsm,C0966225
lsm difference,C1705241;C1705242
eosinophils,C0014467;C0200638
placebo lsm,C0032042;C1696465;C1706408
periostin,C0219433;C1424662;C3812270
diagnosis at presentation no,C0011900;C1704338;C1704656
nste acs,C0742343;C4318612
other countries,C0454664
cardiac biomarker status no total no,C1999091;C2735302;C0439175;C0439810
abnormal,C0205161;C2347472;C2699333
clopidogrel $nmbr$ mg loading dose,C4086581
duration of pci min,C0449238;C2926735
drug eluting stent no,C1322815
bare metal stent no,C2825200
balloon angioplasty no,C0002996;C0002997
cangrelor clopidogrel no of events total no,C1121991;C0070166;C0439175;C0439810
diagnosis at presentation,C0011900;C1704338;C1704656
biomarker status,C0449442
insulin dependent diabetes,C0011854
previous tia or stroke,C0007787;C0917805;C1054154;C0038454;C4554100
history of pad,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
clopidogrel dose,C0178602;C0869039;C1114758
periprocedural anticoagulant,C0003280;C0848112;C3536711
bivalirudin only,C0168273
heparin only,C0019134;C0770546
arterial access,C0444454;C1554204
femoral,C0015811
radial,C0442038;C0920847
no of vessels,C0005847
stent type,C0332307;C1547052
drug eluting,C0013227;C1254351
bare metal,C0025552
aspirin dose,C4696290
timing of clopidogrel loading dose,C0449243;C1704250
before pci,C4049621
after pci,C4049621
duration of study drug infusion,C0489652
fibrinolysis n $nmbr$,C0016017;C1305868
p valuey,C0369773;C2603361
killip class no total no i,C1881332;C0439175;C0439810;C0021966;C0221138
infarct location no total no,C0450429;C1515974;C4284930;C4284931;C0439175;C0439810
previous coronary artery bypass grafting,C2144990
median time delay interquartile range min,C0702093;C1524029;C3813700
symptom onset to first medical contact ambulance or emergency department,C4086878;C0002422;C3846685;C0562508
randomization to arrival in catheterization laboratory,C0034656;C1555577;C1706079;C0007430;C0022877;C3244292;C4283904
randomization to arterial sheath insertion,C0034656;C0003842;C0221464
symptom onset to arrival in catheterization laboratory,C4086878;C1555577;C1706079;C0007430;C0022877;C3244292;C4283904
symptom onset to start of reperfusion treatment tenecteplase or arterial sheath insertion,C4086878;C0035124;C0684253;C0021107;C0441587;C1512796;C1883719
fibrinolysis primary pci n $nmbr$ n $nmbr$ no of patients total no,C0016017;C0205225;C0439612;C0439631;C1305868;C0030705;C0439175;C0439810
relative risk $nmbr$ ci ofprimary end point,C2349179;C2826544
overall event rate,C0871208;C1521828
ii iv,C0022326;C4265176
place of randomization,C0442504;C1533810;C1704765;C1882509
ambulance,C0002422;C3846685
community hospital,C0020003
time of randomization,C0040223;C3541383
before amendment,C0680532;C2346732
after amendment,C0680532;C2346732
ranolazine n $nmbr$ placebo n $nmbr$,C0073633;C0032042;C1696465;C1706408
prior angioplasty,C0162577;C1548817
prior bypass graft surgery,C0455610
duration of diabetes yrs,C0449238;C2926735
antianginal medications,C0013227;C0802604;C2598133;C4284232
on $nmbr$,
long acting nitrates,C0205166;C0028125;C1706317
ace l arbs,C1452534;C3888198;C4284014
baseline heart rate beats min,C0439385
baseline systolic blood pressure mm hg,C4274438;C0439475
baseline diastolic blood pressure mm hg,C4274392;C0439475
figure $nmbr$ subgroup analyses of the primary endpoint of weekly angina frequency,C2986480;C3695257
incidence density ratio or the relative difference in the incidence rates of weekly angina frequency according to the generalized linear model with nega tive binomial distribution within pre speci ed strati cations and categorical subgroups a b shows the exploratory analysis of subgroups of hba $nmbr$ c by var ious thresholds cabg coronary artery bypass graft surgery pci percuta neous coronary intervention,C0456603;C1547037;C1705241;C1705242;C0023732;C0332152;C0007447;C0740175;C2257086;C3669034;C1079231;C1547282;C2986480;C0397581
watchman n $nmbr$,C0335390
height inches,C0489786;C0439204
weight lbs,C0439219;C3161851
hawaiian pacific,C0337920
chads score,C0449820;C4050231
warfarin naive,C0043031
$nmbr$ days warfarin,C0439228;C0043031
experience,C0237607;C0596545
$nmbr$ yr warfarin experience,C0237607;C0596545
history of cad,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
mellitus,
clinical characteristics n,C0683325
egfr crcl ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
pervious cerebrovascular event,C0441471;C4019010
pad details n,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
peripheral arterial revascularization,C0003842;C0581603;C0221464
prior amputation,C0002688;C0332840;C1546539
prior carotid intervention,C0184661;C0886296;C1273869
abi,C1328319;C3888326
abi $nmbr$ $nmbr$,C1328319;C3888326
claudication fontaine class $nmbr$,C0456387;C1518526;C1705943
baseline medical therapy n,C0168634;C0418981;C1442488
no antiplatelet therapy,C1096021
aspirin and thienopyridine therapy,C0004057;C0039798;C0087111;C1363945
cilostazol,C0055729
vorapaxar n $nmbr$ n,C2974521
overall efficacy,C1280519;C1707887
cvd mi stroke,C0038454;C4554100
cvd mi stroke urgent coronary revascularization,C0007222;C0877341
cvd mi stroke urgent vascular hospitalization,C0005847;C0019993;C1558950;C1801960
cvd mi stroke revascularization urgent vascular hospitalization,C0005847;C0019993;C1558950;C1801960
peripheral limb vascular efficacy,C1280519;C1707887
hospitalization for acute limb ischemia,C0019993;C2945695
any peripheral revascularization,C0205100;C0581603
urgent peripheral revascularization,C0205100;C0581603
elective peripheral revascularization,C0205100;C0581603
any vascular efficacy,C1280519;C1707887
urgent vascular hospitalization,C0005847;C0019993;C1558950;C1801960
any revascularization,C0581603
bleeding,C0019080
gusto moderate severe bleed,C0205081;C0019080;C1881878;C4049705;C4049706;C4085643;C4321335
gusto severe bleed,C0205082;C0019080;C4050465;C4050466
fatal bleed,C1302234;C0019080;C1705232
nebivolol n $nmbr$,C0068475
age years a,C1510829
trough seated sbp mmhg a,C0085805;C0439475
trough seated dbp mmhg a,C0277814;C0439475;C1283233
trough seated hr bpm a,C0444506;C0277814;C1283233
all men,C0025266
all women,C0043210
ethnicity t,C0015031;C0243103
education y mean sd,C0013621;C2699239;C0013622;C0013658;C0039401
treatment n,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
blood pressure mm hg mean sd,C0428886;C2699239
dbp $nmbr$ $nmbr$ $nmbr$ $nmbr$ baseline lipid profile mg dl mean sd,C0439269;C2699239
total glucose mg dl,C0017725;C0439269
diabetes mellitus classification,C0008902;C0008903;C0678229
diabetes mellitust,C0011847;C0011849
normoglycemic^,C0580545
history of mi or stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0038454;C4554100
st t wavett,C0036056;C3272372
$nmbr$ $nmbr$ $nmbr$ continued,C0549178
estimated gfr ml min per $nmbr$ $nmbr$ m $nmbr$ mean sd,C0017654;C0439445;C1424601;C0444504;C2699239;C2347634;C2348143
atrial fibrillation flutter n,C0155709
outcomes,C1274040
$nmbr$ y rate per $nmbr$ persons se n,C0871208;C1521828
hazard ratio and $nmbr$ confidence interval,C2985465;C0009667
a c,
l c,C0439394;C1706495;C3642217
total randomized n,C0439175;C0034656;C3815594;C0439810
chd nonfatal mi fatal chd,C0280604;C1302234;C1705232;C3542407
secondary end points,C0027627;C2349179;C0175668;C0205436
mortality outcomes,C0026565;C1274040;C0026566
combined fatal nonfatal outcomes,C1548228
heart failure treated hospitalized fatal,C1302234;C1705232
hospitalized fatal heart failure,C0018801;C0018802;C4554158
hospitalized angina,C0701159;C0002962
insulin glargine n $nmbr$,C0907402
standard care n $nmbr$,C1442989;C1947933;C2828392
n $nmbr$ fatty acids n $nmbr$,C0369718;C0015684;C0441922
geographic distribution no,C0681686
history of cvd and of cv risk factors no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0035648;C1553898
prior cardiovascular event,C0332152;C1320716;C2826257
prior or new diabetes,C0332152;C2826257;C0011847;C0011849
impaired glucose tolerance or impaired fasting glucose,C0271650;C1272092
microalbuminuria or macroalbuminuria,C0730345
dietary epa dha intake mg day,C1286104;C0439422
heart rate beats per minute,C0439385
laboratory investigations,C0022877;C1261322;C3244292;C4283904
fasting plasma glucose mmol l,C0202042;C1532563;C0455280
$nmbr$ $nmbr$ l l,C3539687
l l $nmbr$ $nmbr$,C3539687
ldl cholesterol mmol,C0023824;C0439190;C0202117
serum creatinine gmol,C0201976;C0600061
estimated glomerular filtration rate ml min $nmbr$ $nmbr$ m $nmbr$,C3811844;C0439445
urinary albumin creatinine ratio,C0486293;C1318293
cardiovascular and oral hypoglycemic drugs no,C0007226;C3887460;C0359086
asa or antiplatelet agent,C0004057;C3853627;C0085826
other oral hypoglycemic drug s,C0359086
carotid imt,C0334121;C1704614;C4318736
average maximum cimt mm,C4330985;C4554674
average of maximum common carotid cimt mm,C1510992;C2825518
$nmbr$ $nmbr$ h $nmbr$ $nmbr$,C0033727;C0369286;C0441932;C0564385;C4528284
average maximum common and bifurcation cimt mm,C0205214;C1522138;C3245511;C4330985;C4554674
average of maximum far wall cimt mm,C1510992;C2825518
insulin glargin arm,C0446516;C3715044;C4553528
insulin glargine slope lsm se mm year,C0439234;C0439508
standard care slope lsm se mm year,C0439234;C0439508
difference glargine standard care lsm se mm year,C0439234;C0439508
p value for interaction by region,C1709380;C1704675;C0017446;C0205147
north america n $nmbr$,C0028405
south america n $nmbr$,C0037713
n $nmbr$ fatty acit,C0369718;C0441922
s arm,C0446516;C3715044;C4553528
n $nmbr$ fatty acids slope lsm se mm year,C0439234;C0439508
placebo slope lsm se mm year,C0439234;C0439508
difference n $nmbr$ fa placebo lsm se mm year,C0439234;C0439508
other europe n $nmbr$ australia n $nmbr$ and india n $nmbr$ the data from these regions were collapsed due to the small numbers,C0015176;C0004340;C0021201;C2700456;C1511726;C3245479;C3714741;C0344329;C0392748
n $nmbr$ fatty acids placebo lsm $nmbr$ cl,C0015684;C0596019
ageadj,
no previous cv event,C0441471;C4019010
previous cv event,C0441471;C4019010
maximum cimt median,C0549183;C0876920;C2347635;C2348144;C2939193
maximum cimt a med an,C0806909;C1552615;C2826546;C4321267
hbalc medan,
hbalca median,C0549183;C0876920;C2347635;C2348144;C2939193
tnglycendes median,C0549183;C0876920;C2347635;C2348144;C2939193
tngtycendes a median,C0549183;C0876920;C2347635;C2348144;C2939193
fastng plasma glucose median,C0549183;C0876920;C2347635;C2348144;C2939193
fascng plasma glucose a medan,C0202042;C0455280
no statin,C0360714
stalin,
interactior p value,C1709380
dabetes,
hbalc median,C0549183;C0876920;C2347635;C2348144;C2939193
tngtycerides median,C0549183;C0876920;C2347635;C2348144;C2939193
tngtycerides a median,C0549183;C0876920;C2347635;C2348144;C2939193
fasting plasma glucose median,C0549183;C0876920;C2347635;C2348144;C2939193
fasting plasma glucose $nmbr$ medan,C0202042;C0455280
no ststm,
llv wlalil $nmbr$ statin,C0360714
sita $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
cana $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
other i,C0021966;C0221138
a $nmbr$ c mmol mol,C3829066
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
duration of type $nmbr$ diabetes years,C0449238;C2926735
supplementary figure $nmbr$ change in a $nmbr$ c from baseline to week $nmbr$ by baseline a $nmbr$ c subgroup,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488;C1079230;C1515021
ls least squares se standard error sita sitagliptin cana canagliflozin a $nmbr$ c $nmbr$ $nmbr$ to $nmbr$ $nmbr$ sita $nmbr$ mg n $nmbr$ cana $nmbr$ mg n $nmbr$,C0023189;C1710181;C1319635;C1418845
covariate,
cluster $nmbr$ diuretic n $nmbr$,C1555715;C0012798;C1704332
cluster $nmbr$ reversible no diuretic n $nmbr$,C1555715;C0205343;C1704332;C0012798
cluster $nmbr$ not reversible no diuretic n $nmbr$,C1555715;C1704332;C1518422;C0205343;C0012798
age median years,C1510829;C0549183;C0876920;C2347635;C2348144;C2939193
iqr,
median m kg $nmbr$ iqr,C0549183;C0876920;C2347635;C2348144;C2939193;C0022718;C0439209;C4054209
smoking mean,C0444504;C2347634;C2348143
pack years iqr,C1277691
fev $nmbr$ predicted sd,C0681842;C2699239;C1882327
fev $nmbr$ reversibility sd,C0449261;C2699239
reversibility stratum,C0449261
[no yes],C1549445;C1705108;C1710701
exacerbations requiring hospitalisation past year,C4086268;C0019993;C0439234;C0439508
exacerbations requiring oral steroids antibiotics past year,C4086268;C0003232;C0003237;C3540704;C3540705;C3540706;C3540707;C3540708;C3540709;C3540710
baseline medications,C0013227;C0802604;C2598133;C4284232
anti thrombotics,C0087086
lipid modifiers,C0023779;C4284280
blockers,
psycholeptics,C3653516
anti histamines,C0019590
anti anaemics,C0857322
anti hypertensives,C0003364
glargine,C0907402
standard therapy,C2936643
$nmbr$ drinks week,C0332174;C0439230
$nmbr$ years education,C0013621;C0013622;C0013658;C0039401
depression,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827
$nmbr$ h pg mmol l,C2827798;C2827804
grip strength kg,C0022718;C0439209;C4054209
bm $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
waist to hip male,C0230097;C0019552;C0022122;C1505163;C3538851;C4284725
waist to hip female,C0230097;C0019552;C0022122;C1505163;C3538851;C4284725
urine acr mg g,C0042036;C1300563;C0042037;C2963137
egfr ml min,C1739039;C0439445;C3811844;C3812682
alt units l,C1266129;C0439339;C4553172
ldl mmol l,C1532563
hdl mmol l,C3715113;C1532563
tg mmol l,C0337445;C1532563
omega $nmbr$ fa,C1719844
or $nmbr$ cl,C0596019
age median,C0549183;C0876920;C2347635;C2348144;C2939193
alcohol,C0001962;C0001975
alcohol $nmbr$ wk,C0332174;C0439230
no depression,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827
a $nmbr$ c median,C0549183;C0876920;C2347635;C2348144;C2939193
waist hip median,C0549183;C0876920;C2347635;C2348144;C2939193
waisvhip median,C0549183;C0876920;C2347635;C2348144;C2939193
grip strength meidan,C0429271;C2598165
grip strength median,C0549183;C0876920;C2347635;C2348144;C2939193
urine acr median,C0549183;C0876920;C2347635;C2348144;C2939193
diabetic subjects n $nmbr$,C0241863;C0681850;C1550501;C1706203;C2349001;C2697811
non diabetic subjects n $nmbr$,C1518422;C0241863
alcohol usef n,C0001962;C0001975
serum urate mg dl n,C0455272;C0439269
years with gouty arthritis,C0439234;C0003868
presence of tophi n,C0150312;C0392148;C3854307
renal function n,C0232804
figure $nmbr$ achievement of sua,C0001072
vildagliptin n $nmbr$,C1570906
gfr mdrd ml min $nmbr$ $nmbr$ m $nmbr$,C0017654;C0439445;C1424601
normal $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
mild $nmbr$ to,C2945599
moderate $nmbr$ to,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
frailty status,C0424594;C0449438
hba $nmbr$ c levels,C0019016;C0441889;C1825777;C3538758
frail,C0871754
non frail,C1518422;C0871754
tiotropium n z $nmbr$,C0213771
control n z $nmbr$,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
copd duration y,C0024117;C0449238;C2926735;C1412502;C3714496
sabaa,
labaa,
saaca,
laaca,
icsa,
ocs,
mean sd change in pre bronchodilator fev $nmbr$ l,C0392747;C0443172;C1705241;C4319952
visits $nmbr$ e $nmbr$,C0545082;C1512346
univariate p value,C1709380
multivariate p value,C1709380
male n z $nmbr$,C0086582;C1706180;C1706428;C1706429
female n z $nmbr$,C0043210;C0086287;C1705497;C1705498
current smoker n z $nmbr$,C3173209;C3241966
ex smoker n z $nmbr$,C0337671;C4555205
treatment arm,C1522541
copd severity gold stage,C0205390;C1300072;C1306673
iorii n z $nmbr$,
iii n z $nmbr$,C0439070;C1705160
iv n z $nmbr$,C0022326;C4265176
bronchodilator response ml,C0439526;C1705224;C3887665
asia n $nmbr$,C0003980
eastern europe n $nmbr$,C0015177
latin america n $nmbr$,C0023122
western europe n $nmbr$,C0043129
higher target group n $nmbr$,C0441848
lower target group n $nmbr$,C0441848
blood pressure at entry mm hg,C0005823;C1271104;C1272641
ischaemic heart disease,C0010054;C0151744
previous clinical stroke or tia,C0038454;C4554100;C0007787;C0917805;C1054154
current tobacco smoker,C3173209;C3241966
ischaemic stroke,C0948008
number of antihypertensive medications at study entry,C1718138;C0557651;C1705654;C2603343
mean number of antihypertensive medications at $nmbr$ year,C0444504;C1718138;C2347634;C2348143;C0439234;C0439508
types of antihypertensive medications at $nmbr$ year,C0457591;C0439234;C0439508
ace inhibitor arb,C0003015;C3888198;C4541021
mean number of antihypertensive medication at last visit,C0444504;C0237753;C0449788;C2347634;C2348143;C0545082;C1512346;C2826704
types of antihypertensive medications at last visit,C0457591;C0545082;C1512346;C2826704
statins used during follow up,C0360714;C1273517;C0589120;C1522577;C1704685;C3274571
number of events annualised rate [ ],C4330837
$nmbr$ o i $nmbr$ mm hg,C0021966;C0439475;C0221138
age p o $nmbr$,C0001779
sex p $nmbr$,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
female n lll $nmbr$,C0043210;C1261077;C0086287;C1705497;C1705498
history of diabetes p $nmbr$ $nmbr$,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
non diabetic n $nmbr$,C1518422;C0241863
diabetes n $nmbr$,C0011847;C0011849
race p o $nmbr$,C0034510;C1706779;C3853635
hispanic n $nmbr$ l $nmbr$,C0086409
other mixed n $nmbr$,C0205430;C3160715
region of residence p $nmbr$ $nmbr$,C0017446;C0205147
spain n $nmbr$,C0037747
baseline sbp p o $nmbr$,C0168634;C0085805;C1442488
normotensive n $nmbr$,C2712122
sbp median n $nmbr$,C0085805;C0549183;C0876920;C2347635;C2348144;C2939193
$nmbr$ $nmbr$ $nmbr$ $nmbr$ i $nmbr$,C0021966;C0221138
ala carriers,C0523459;C0007294;C3888236
pro pro homozygotes,C1120626;C0019904
sex male n,C0086582
mmol mol,C3829066
map mmhg,C0024779;C0439475;C1706473;C4050322
uae p g min,C1519789;C0560021
acei vs non acei,C1518422
renal events,C0441471;C3541888
cvd events,C0441471;C3541888
composite events,C0441471;C3541888
$nmbr$ $nmbr$ mga n $nmbr$,C0065879
uc disease duration y,C0872146
limited to left side of colon,C0439801;C2674459;C3542948;C4050251
mayo score $nmbr$ $nmbr$,C0449820;C4050231
endoscopy subscore n,C0014245
moderate disease,C0205081;C0012634;C1881878;C4049705;C4049706;C4085643;C4321335
severe disease,C1836348
crp mg l n,C3890735;C0439268;C4048285
patients receiving any uc medication n,C0030705;C1514756;C0013227;C3244316;C4284232
corticosteroids excluding budesonide,C0001617;C3539185;C3540725;C3540726;C3540727
$nmbr$ mg d peq,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
immunomodulatory drugs,C0013227;C3687832
$nmbr$ mercaptopurine azathioprine,C0000618;C0004482
golimumab $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ne ne,C0027608;C0028219;C3538705
normonatremic $nmbr$ meq l at baseline,C0439375;C0168634;C1442488
hyponatremic,C0857122
p value placebo group p value hyponatremia normonatremic group tolvaptan vs hyponatremic vs placebo,C1709380;C1176308;C0857122;C0032042;C1696465;C1706408
placebo n $nmbr$ $nmbr$ $nmbr$,C0032042;C1696465;C1706408
placebo tolvaptan $nmbr$ mg n $nmbr$ $nmbr$ n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
age y sd,C0001779;C2699239
systolic blood pressure mm hg sd,C0488055;C2699239;C0871470;C1306620
diastolic blood pressure mm hg sd,C0428883;C2699239;C1305849
heart rate sd,C0018810;C2699239
history of htn,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
intravenous vasoactive drugs y,C0683092;C1980011
nesiritide z,C0054015
edema z,C0013604;C1717255
jvd $nmbr$ cm h $nmbr$ o,C0425687;C0455483
duration of hf y,C0449238;C2926735
prior hospitalization for hf,C0019993;C0018488;C1313497;C1538440;C3273279
nyha iv,C0022326;C4265176
blood urea nitrogen mg dl,C0005845;C0439269;C0600137
non asian n $nmbr$ $nmbr$,C1518422;C0078988
$nmbr$ n weight kg,C0022718;C0439209;C4054209
type of atrial fibrillation,C0332307;C1547052
paroxysmal n,C0205311
persistent n,C0205322;C0332996
permanent n,C0205355
$nmbr$ n chads $nmbr$ score,C0449820;C4050231
previous stroke yes n previous myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
heat failure,C0231174;C0680095
diabetes mellitus yes n hypertension,C0020538;C1963138
medication in use at the baseline,C0013227;C3244316;C4284232;C0150312;C0042153;C0457083;C1947944;C0332285;C1707101
arb n,C3888198
ace i n,C0021966;C0221138
blocker n,
verapamil n,C0042523
proton pump inhibitor n,C0358591;C3536754;C4521480
h $nmbr$ blocker n long term vka therapy,C0039798;C0087111;C1363945
experience n,C0237607;C0596545
non asian,C1518422;C0078988
event number,C0237753;C0449788
stroke or,C0038454;C4554100
systemic embolism,C0013922;C1704212
hemorrhagic,C0333275
death from,C0011065;C1306577;C4082313;C4552775
any cause,C0015127;C1524003
tcz $nmbr$ mg kg n $nmbr$,C0439272
positive hla b $nmbr$ status n,C1426226
as duration y mean sd,C0444504;C2699239;C2347634;C2348143
swollen joints $nmbr$ n,C0152031
basdai score mean sd,C0444504;C2699239;C2347634;C2348143
crp mg dl mean sd,C0439269;C2699239
crp mg dl median,C0549183;C0876920;C2347635;C2348144;C2939193
rvalue for interaction,C1704675
favors dabigatran,C0309049;C2348066
no heart failure,C0018801;C0018802;C4554158
prior stroke tia,C0007787;C0917805;C1054154
no prior stroke tia,C0007787;C0917805;C1054154
chadsa,
chadsj $nmbr$,
cha $nmbr$ ds $nmbr$ vasc $nmbr$ $nmbr$,C1420648;C3714751
chajdsa vasc $nmbr$ $nmbr$,
chajdsj vasc $nmbr$,
has bledo,C1019275
has bled $nmbr$ $nmbr$,C0019080
has bled $nmbr$,C0019080
sbp $nmbr$ mm hg,C0085805;C0439475
crcl,C1846718
crcl $nmbr$ ml min,C1846718;C0439445
history of cad mi,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
no cad mi,C1504769;C3810814;C2239547;C3813548;C4284121
chadsj,
chajdsrvasc $nmbr$ $nmbr$,
chajdsj vasc $nmbr$ $nmbr$,
sbp $nmbr$ mmhg,C0085805;C0439475
nocad mi,C3810814
age s $nmbr$,C0001779
$nmbr$ e h,C0033727;C0369286;C0441932;C0564385;C4528284
chad $nmbr$ $nmbr$,C0007928;C1413373
cha $nmbr$ ds $nmbr$ vasc $nmbr$,C1420648;C3714751
sbp $nmbr$ mnn hg,C0025424;C0428257;C2347108;C2347109;C2348272
intensified n $nmbr$,
history of nicotine use,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
history of alcohol use,C0551571;C0552479
chronic obstructive lung disease,C0024117
retinopathy stage $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0205390;C1300072;C1306673
peripheral artery occlusive disease,C1306889
peripheral artery occlusive disease stage $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0699749
cerebral vascular disease,C0007820
peripheral neuropathy,C0031117
control baseline n $nmbr$,C0243148;C0168634;C1442488;C1550141;C1882979;C2587213;C3274648;C4553389
intensified baseline n $nmbr$,C0168634;C1442488
control $nmbr$ months n $nmbr$,C0243148;C0439231;C1550141;C1882979;C2587213;C3274648;C4553389
intensified $nmbr$ months n $nmbr$,C0439231
blood pressure systolic mm hg,C0005823;C0439475;C1271104;C1272641
ras antagonist,C0034678;C0231491;C0525678
ras target dose,C0178602;C0869039;C1114758
beta blocker target dose,C0178602;C0869039;C1114758
oral antidiabetic drugs,C0029167;C0175795;C0304289
normal cognitive,C0205307;C0231683;C0439166;C2347086;C4553972;C1516691
impaired cognitive,C0221099;C1516691
status spmsq,C0449438
status spmsq $nmbr$,C0449438
female gender,C0086287
treatment arm zoledronate,C1522541;C0392938
bmi kg m $nmbr$ sd,C0022718;C0439209;C4054209;C2699239
total hip n $nmbr$ $nmbr$ bmd g cm $nmbr$ sd,C0019552;C2699239;C0022122;C1505163;C3538851;C4284725
femoral neck n $nmbr$ $nmbr$ bmd g cm $nmbr$ sd,C0015815;C2699239
fn t score,C0449820;C4050231
op concomitant medications,C0013227;C0802604;C2598133;C4284232
charlson index,C0600653;C0918012;C1552854;C1637833;C2986546
normal cognitive function spmsq,C4296962
impaired cognitive function spmsq $nmbr$ n $nmbr$ n participants with the event of interest,C0009240;C0679646;C0392335;C4050130
chi square p value,C1552646;C1709380
clinical fracture,C0205210;C0016658
zoledronic acid arm,C0446516;C3715044;C4553528
placebo arm,C0446516;C3715044;C4553528
sita $nmbr$,
pio $nmbr$,C0030800;C2347712
sita $nmbr$ pio $nmbr$,C0030800;C2347712
american indian or native alaskan,C0002460;C0682125
ethnicity hispanic or latino,C0015031;C0086409;C0243103;C0086528
a $nmbr$ c distribution,C0520511;C1704711
$nmbr$ $nmbr$ and $nmbr$ $nmbr$,
known duration of type $nmbr$ diabetes years,C0449238;C2926735
received an oral aha within $nmbr$ weeks prior to screening,C1514756;C0050451;C0772110;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
sita pio $nmbr$ $nmbr$,C0030800;C2347712
a $nmbr$ c at baseline,C0168634;C1442488
a $nmbr$ c at baseline $nmbr$ $nmbr$,C0168634;C1442488
empagliflozin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
o total randomized,C0439175;C0439810;C0034656;C3815594
pen label empagliflozin $nmbr$ mg baseline hba $nmbr$ c $nmbr$,C0024671;C0019016;C1825777;C3538758;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
time since diagnosis of type $nmbr$ diabetes,C0040223;C3541383
$nmbr$ year,C0439234;C0439508
mdg mmol l,C0024443;C1532563;C1417239;C2986643
egfr ml min $nmbr$ $nmbr$ m $nmbr$ [mdrdequation],C1739039;C0439445;C3811844;C3812682
patients with egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n,C0030705;C0439445;C0369718;C0441922
change from baseline in hba $nmbr$ c,C0392747;C0443172;C1705241;C4319952;C0019016;C1825777;C3538758
difference vs placebo,C1705241;C1705242;C0032042;C1696465;C1706408
patients with egfr $nmbr$ $nmbr$ to,C0030705;C1739039;C3811844;C3812682
vedolizumab,C2742797
cohort $nmbr$ n $nmbr$ f,C0009247;C0016327;C0599755
cohort $nmbr$ n $nmbr$,C0009247;C0599755
white race no,C0007457;C0043157
mayo clinic score,C0449820;C4050231
partial mayo clinic scored,C0002424;C0442592;C0449820
ibdq score,C0449820;C4050231
fecal calprotectin pg g,C0015733;C1638318
site of disease no,C2945843;C0012634
rectum and sigmoid colon only,C0034896;C0227391
left side of colon,C0227388
proximal to the splenic flexure,C0205107;C4489236
all of the colon,C0009368;C3888384
concomitant medications for ulcerative colitis no,C0013227;C0802604;C2598133;C4284232
immunosuppressants onlyff,C0021081
glucocorticoids and immunosuppressants,C0017710;C3540777;C3540778;C0021081
no glucocorticoids or immunosuppressants,C0017710;C3540777;C3540778;C0021081
prednisone equivalent dose mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
prior anti tnf therapy no,C1514463
prior failure of anti tnf therapy no,C0231174;C0680095;C0279936
$nmbr$ failure,C0231174;C0680095
inadequate response,C0871261;C1704632;C1706817;C2911692
loss of response,C1517945;C0871261;C1704632;C1706817;C2911692
unacceptable adverse events,C0877248;C1705413
hemoglobin concentration g liter,C1319312;C0475211
white cell count x $nmbr$ _ $nmbr$ liter,C0023508;C0475211;C0427512
veflonzumao,
estimated difference,C1705241;C1705242
duration of ulcerative colitis,C0449238;C2926735
extensive colitis,C0009319;C1963084
pancolitis,C0868908
baseline composite mayo clinic score,C4055211;C0002424;C0442592
baseline fecal caicrctectin,C0168634;C0015733;C1442488
$nmbr$ ug g,C0439272
z $nmbr$ $nmbr$,
prior treatment history $nmbr$,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
any prior anti tnf treatment failure,C1514463
prior immunnosupressive failure but no anti tnf failure,C0332152;C0231174;C0680095;C2826257
prior corticosteroid failure only,C0231174;C0680095
stratification variables,C1514983;C0439828
concomitant corticosteroid use,C0521115;C0239126
no concomitant cortcosteroid use,C0042153;C0457083;C1947944
concomitant immunosuppressive and or prior anti tnf use,C0521115;C0021081;C0332152;C2826257
no concomitant immunosuppressive and or prior anti tnf use,C0521115;C0021081;C0332152;C2826257
patients with deep vein thrombosis only,C0030705;C0149871
patients with pulmonary embolism,C0030705;C0034065
edoxaban n $nmbr$,C2975435
creatinine clearance $nmbr$ to,C0812399
patients receiving $nmbr$ mg of edoxaban at randomization no f,C0030705;C1514756;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0034656;C0016327
anatomical extent of qualifying event no t,C0220784;C0439792;C1514624;C0441471;C4019010;C2603360
limited,C0439801;C2674459;C3542948;C4050251
not assessable,C1883425
concomitant dvt no baseline nt probnp no,C0149871;C2926618;C3899446;C0669479;C0754710
patients with measurement,C0030705;C0242485
patients with level $nmbr$ pg ml,C0030705;C0439297
right ventricular dysfunction no total no,C0242707;C1556315;C0439175;C0439810
causes of dvt or pe no ^,C0015127;C1314792;C0070939;C1880476;C4284304
temporary risk factor,C0205374;C0035648;C1548539;C3245481
edoxaban,C2975435
presenting diagnosis,C0449450;C0011900;C1704338;C1704656
pe with without dvt,C0070939;C1880476;C4284304;C0149871;C2926618;C3899446
aga group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
gendar,
baseline risk factors,C0035648;C1553898
temporary factors,C1521761;C2827422
all others eteed for $nmbr$ mg edoxaban dose at,C1955473;C4086581;C3539125
ra ndosii zat ion,C0022023;C1700702
no body weight at randomization ixrs,C0005910;C1305866
$nmbr$ kg body weight at randomization,C0005910;C1305866
$nmbr$ is $nmbr$ $nmbr$,
creatinine clearance at randomization,C0812399;C0034656
fragile,
yaa,
fl $nmbr$ b,C1300812;C1708024
southern europe,C0037724
nordic,C0331873
china japan,C0008115;C0022341
south africa south america,C0037713
usa canada,C0041703;C0006823
$nmbr$ t $nmbr$ $nmbr$,C2603360
american indian or,C0002460
native hawaiian or,C0337920
other pacific islander,C0242191
medical history cancer,C0006826;C0998265;C1306459
no history of cancer,C0455471
active cancer at randomisation,C0006826;C0998265;C1306459
no active cancer center level inr percent time,C0040223;C3541383
in therapeutic range for warfarin subjects,C0460097;C0043031
$nmbr$ ^ initial heparin treatment duration,C0444921;C3259042
on or after e^andomization,
$nmbr$ day s initial heparin treatment duration,C0332173;C0439228;C0439505;C0444921;C3259042
medion $nmbr$ days,C0439228
initial type of heparin treatment received,C0019134;C0455708;C0770546;C1514756
concomitant aspirin use,C0042153;C0457083;C1947944
hazard ratio with,C2985465
n t,C0369718;C0441922
warfarin s $nmbr$ cl,C0043031;C0596019
all others,C1955473;C3539125
need for $nmbr$ ng edoxaban dose at,C0017887;C0028074
body weight at randonization ixrs,C0005910;C1305866
body weight at randomization,C0005910;C1305866
creatinine clearance at randomization ixrs,C0812399;C0034656
$nmbr$ $nmbr$ ml rain,C0439526;C0034640;C1705224;C3887665
ho,C0019905;C1832110;C3889614
hordic,
china tjapan,C0008115
fl $nmbr$ $nmbr$,C1300812;C1708024
active cancer at randomization,C0006826;C0998265;C1306459
ho active cancer,C0006826;C0998265;C1306459
center level ihr percent time in therapeutic range for warfarin subjects,C1554109;C0681850;C1550501;C1706203;C2349001;C2697811
initial heparin treatment duration on or after randomization,C0444921;C3259042;C0034656
initial heparin treatment duration,C0444921;C3259042
median $nmbr$ days,C0549183;C0439228;C0876920;C2347635;C2348144;C2939193
ib $nmbr$ $nmbr$,C2744579;C3890035;C4283819
saxagliptin n $nmbr$,C1611934
hispanic ethnic group no i,C0015031;C1879937;C0021966;C0221138
weight^,C0005910;C0043100;C1305866;C1705104
$nmbr$ kg no,C0022718;C0439209;C4054209
duration of diabetes yr^,C0449238;C2926735
established atherosclerotic disease no,C0333482;C0012634
dyslipidemia no,C0242339
prior heart failure no,C0018801;C0018802;C4554158
prior coronary revascularization no,C0332152;C0877341;C2826257
mean ml min,C0444504;C0439445;C2347634;C2348143
albumin to creatinine ratio i,C0021966;C0221138
$nmbr$ yr km rate,C0871208;C1521828
saxagliptin,C1611934
atherosclerosis,C0003850;C0004153
established,C0443211;C1272684
multiple risk factors,C0035648;C1553898
a $nmbr$ years,C0439234
region north america,C0017446;C0028405;C0205147
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ i,C0021966;C0221138
baseline glycated,C0168634;C1442488;C3666909
baseline insulin,C0021641;C1533581;C1579433;C3714501
baseline sulfonylurea yes,C1549445;C1705108;C1710701
baseline metformin,C0168634;C0025598;C1442488
baseline microalbumin,C0201838;C2362049
creatinine ratio,C0456603;C1547037
_ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
p vaiue interaction,C0369773;C1704675;C2603361
saxagiiptin,
piacebo,
non hishnic,C1518422
$nmbr$ $nmbr$ to $nmbr$ i iot,C0021966;C0006196;C0221138
prior hypertension,C0020538;C1963138
$nmbr$ $nmbr$ f $nmbr$ $nmbr$ $nmbr$ $nmbr$ h,C0016327;C0033727;C0369286;C0441932;C0564385;C4528284
baseiine aspirin,C0004057
baseiine statin,C0360714
baseiine acei arb,C3888198
$nmbr$ $nmbr$ ^ $nmbr$ $nmbr$ $nmbr$ t,C2603360
baseiine ccb,C0006684
baseiine diuretic,C0012798
overaii,
alogliptin n $nmbr$,C1958126
race or ethnic group no t,C0034510;C1706779;C3853635;C0015031;C1879937;C2603360
region of world no,C0017446;C0205147
united states and canada,C0041703;C0006823
western europe australia new zealand and middle east,C0027978;C0324547;C0026068
central and south america and mexico,C0205099;C1879652;C0037713;C0025885
eastern europe and africa,C0015177;C0001737
asia and pacific islands,C0003980;C0030168
cardiovascular risk factors and history no,C0850624;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
estimated glomerular filtration rate^,C3811844
median ml min $nmbr$ $nmbr$ m $nmbr$,C0549183;C0439445;C0876920;C2347635;C2348144;C2939193
$nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ no,C0439445
index acs no,C0742343;C4318612
unstable angina requiring hospitalization,C0002965;C0019993
time between index acs and randomization days,C0040223;C3541383;C0034656;C0439228
alogliptin,C1958126
hazard,C0598697
with treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
overall treatment effect,C0282416;C1518681;C1561607
history of ml before index event,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0441471;C4019010
history of pci or cabg before index event,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0010055;C0441471;C4019010
history of chf before index event,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0441471;C4019010
baseline bmi,C0168634;C0578022;C1442488
$nmbr$ and $nmbr$ years,C0439234
baseline glycemic control,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
hba $nmbr$ c $nmbr$ level,C0441889;C0456079;C1547707;C2946261
insulin use at baseline,C0240016;C0168634;C1442488
biguanide use at baseline,C0042153;C0457083;C1947944
thiazolidinedione use at baseline,C0042153;C0457083;C1947944
sulfonylurea use at baseline,C0042153;C0457083;C1947944
united states canada,C0041703;C0006823
mexico central south america,C0007674
western europe australia new zealand middle east,C0043128;C0026068
eastern europe africa,C0001741
renal function,C0232804
normalfunction or mild impairment,C0221099;C0684336
golimumab $nmbr$ mg kg mtx,C0025677;C1417487
randomised patients n,C0030705
median iq range,C1514721;C2348147;C3542016
total vdh s score $nmbr$ $nmbr$ n,C2964552
erosion score $nmbr$ $nmbr$,C0449820;C4050231
jsn score $nmbr$ $nmbr$,C0449820;C4050231
crp normal,C0205307;C0231683;C0439166;C2347086;C4553972
cdai $nmbr$ $nmbr$,C0683448;C1413248;C3273706
disease activity n,C1292728
low $nmbr$ $nmbr$ and,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
moderate $nmbr$ and,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
high $nmbr$,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
sdai $nmbr$ $nmbr$,C3871128
haq di $nmbr$ $nmbr$,C3826998;C4321476
direction of hr,C0449738
right,C0205090;C0444532
centre,C0205099;C3810851
causaslan,
left,C0205091;C0443246;C1552822
middle,C0444598;C0549183;C1552826
period i,C0021966;C0221138
e $nmbr$ a $nmbr$,
period ii,C1710602;C4082587
dapagliflozin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
northamerica,
bmi x $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
pre enrollment antihyperglycemic therapy,C1882440;C0020616
insulin based,C0021641;C1533581;C1579433;C3714501;C1527178;C1705938
sulfonylurea based,C0038766;C3536898;C1527178;C1705938
thiazolidinedione based,C0289779;C1257987;C3537039;C1527178;C1705938
chronic kidney disease stage egfr ml min per $nmbr$ $nmbr$ m $nmbr$,C1561643;C0439445;C4553188
stage $nmbr$ b $nmbr$ and,C0441781
stage $nmbr$ a $nmbr$ and,C0205390;C1300072;C1306673
stage $nmbr$ $nmbr$,C0205390;C1300072;C1306673
urinary albumin creatinine ratioa mg g,C0486293;C1300563;C4281686
urinary protein creatinine ratioa mg mg,C0369901;C1319635;C0428627
patients with diabetic nephropathy,C0030705;C0011881;C1442864
difference from placebo,C1705241;C1705242
this study,C0557651;C2603343
stage $nmbr$ b egfr $nmbr$ and,C1739039;C3811844;C3812682
stage $nmbr$ a egfr $nmbr$ and,C0205390;C1300072;C1306673;C1739039;C3811844;C3812682
age y median range,C1514721;C2348147;C3542016
weight kg median range,C1514721;C2348147;C3542016
uc duration y mean range,C1514721;C2348147;C3542016
partial mayo score mean sd,C0444504;C2699239;C2347634;C2348143
crp nmol l median range,C1514721;C2348147;C3542016
comorbidites n,
gastroesophageal reflux disease,C0017168;C4553201
asthma,C0004096;C2984299
oral corticosteroid,C0442027;C0001617;C3536709;C4521986
azathioprine $nmbr$ mercaptopurine,C0004482;C0000618
corticosteroid azathioprine $nmbr$ mercaptopurine,C0001617;C0000618;C3536709
corticosteroid or azathioprine $nmbr$ mercaptopurine,C0001617;C3536709;C0004482;C0000618
prior therapy with tnf antagonist n,C1514463
figure $nmbr$ patient based relative risk rr of hospi talization by study and for the combined studies a the rr and corresponding $nmbr$ ci of all cause hos pitalization was deter mined for adalimumab ada vs placebo pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both trials combined b the rr and corresponding $nmbr$ ci of uc related hospitalization was deter mined for ada vs pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both,C0242492;C4554402;C0557651;C2603343;C0205195;C0947630;C0008107;C3259781;C0026175;C0338297;C0032042;C0031962;C1696465;C1706408;C0030705;C3272598;C1448177;C1456820;C1522669;C0008976;C0205171;C0439044;C0679994
statin n $nmbr$,C0360714
$nmbr$ $nmbr$ y,
nste mi,C3537184;C4255010
active smoking,C0037369;C0453996;C1881674
total cholesterol $nmbr$ mg dl,C0201950;C0439269;C0543421
ecrcl,
egfr ml min m $nmbr$,C1739039;C0439445;C3811844;C3812682
previous pci or cabg,C0205156;C4049621;C1552607;C0010055
baseline lvef,C0428772;C0488728
high risk clinical features,C0035648
laboratory variables at baseline,C0022877;C0439828;C3244292;C4283904
haemoglobin mg dl,C0019046;C0439269
ctn i ng ml,C0021966;C0439275;C0221138
$nmbr$ $nmbr$ z,
ck mb ng ml,C0010290;C0439275
glycemia mg dl,C0005802;C0439269
time intervals h,C0033727;C0369286;C0441932;C0564385;C4528284
randomization to angiography,C0034656;C0002978
randomization to angiography distribution time,C0034656;C0681683
within $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
after $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
hospital stay days,C0587438
angiographic data and treatment,C1511726;C3245479;C3714741;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
contrast volume ml,C0439526;C1705224;C3887665
contrast volume $nmbr$ ml,C0439526;C1705224;C3887665
additional angiography,C1524062;C0002978
within $nmbr$ h after first procedure,C0033727;C0369286;C0441932;C0564385;C4528284
management distribution,C0520511;C1704711
pci data,C1511726;C3245479;C3714741
contrast nephropathy risk score,C0035647;C0449820;C4050231;C4552904
score distribution,C0520511;C1704711
medications at coronary angiography,C0013227;C0802604;C2598133;C4284232
gp llb llla inhibitors,C1705010;C0243077;C3811116
medications at discharge,C0806915
events statin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
events control group,C0441471;C0009932;C3541888
orc $nmbr$ cl,C1167125;C0596019
oradj $nmbr$ cl,C0596019
baseline ecrcl,C0168634;C1442488
contrast volume,C0449468;C1690016;C1705102;C2700258
$nmbr$ ml,C0439526;C1705224;C3887665
ci aki risk score,C0035647;C0449820;C4050231;C4552904
clopidogrel aspirin n $nmbr$,C0070166;C0004057
previous coronary angioplasty n,C2114427
multivessel disease n,C0012634
clinical indication at the index procedure n,C2315323;C2347896
discharge medication n,C0012621;C0013227;C3244316;C4284232;C0030685;C2926602
vessel treated n,C0005847;C1522326
left anterior descending artery n,C0226032
left circumflex artery n,C0226037
right coronary artery n,C1261316
left main coronary artery n,C1261082
graft n,C0181074;C0332835;C1961139
multivessel intervention n,C0184661;C0886296;C1273869
acc aha lesion class b $nmbr$ or c n,C4072694;C0221198;C1546698
bifurcation n,C0184906;C3146289
calcification n,C0006660;C0006663;C0175895;C1533591;C1879982;C2242558
total occlusion n,C0001168;C0011382;C0028778;C0441597;C1110554;C1947917
stents per lesion n,C0038257;C0221198;C1546698
stent length per lesion mm,C1444754;C1706316
type of drug eluting stent n,C0457591
sirolimus,C0072980
paclitaxel,C0144576
zotarolimus,C1700035
everolimus,C0541315
event rate of primary endpoints,C0871208;C1521828
aspirin alone n $nmbr$ $nmbr$ $nmbr$,C0004057;C0205171;C0439044;C0679994
aspirin clopidogrel n $nmbr$ $nmbr$ $nmbr$,C0004057;C0070166
cohort,C0009247;C0599755
first n $nmbr$,C0205435;C1279901
second n $nmbr$,C0205436;C0457385;C0565930;C1561503;C1705190
$nmbr$ mon n $nmbr$,
$nmbr$ yo n $nmbr$,C1413296
bifurcation,C0184906;C3146289
left main disease,C0205091;C0012634;C0443246;C1552822
long $nmbr$ mm stenting yes n $nmbr$,C0205166;C0038257;C2348535;C1706317
multivessel stenting,C0038257;C2348535
type of des,C0332307;C1547052
older des n $nmbr$,C0011702;C4551552
new des n $nmbr$,C0205314;C0011702;C4551552
predictive factor,C0683956
age yr range,C1514721;C2348147;C3542016
bmi no,C0578022
lifestyle behaviors,C0004927;C0677505
alcohol consumption no,C0001948
comorbidities concomitant medications,C0013227;C0802604;C2598133;C4284232
comorbidities no,C0009488
cardiovascular disorder,C0007222
cardiac disorder,C0018799
no antihypertensive medication,C0003364
one antihypertensive medication,C0205447;C0003364
two or more antihypertensive medications,C0205448;C0003364
statin s,C0360714
ed characteristics,C3538926;C1521970
ed $nmbr$ yr no,C3538926;C0439234
ed etiology no,C0015127;C1314792;C1524003
ed severity no a,C0439793;C0522510
mild iief ef $nmbr$ $nmbr$,C2945599;C3641331
moderate iief ef $nmbr$ $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
severe iief ef,C0205082;C3641331;C4050465;C4050466
previous pde $nmbr$ i therapy no,C0039798;C0087111;C1363945
tadalafil $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
tadalafil $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ls mean change,C0392747;C0443172;C1705241;C4319952
pbo adjusted ls mean change,C0392747;C0443172;C1705241;C4319952
overally,
alcohol consumption at baseline,C0001948;C0168634;C1442488
smoker at baseline,C0337664;C0168634;C1442488
antihypertensive use,C0042153;C0457083;C1947944
none at baseline,C0168634;C1442488
one at baseline,C0205447;C0168634;C1442488
two or more at baseline,C0205448;C0168634;C1442488
ed duration,C0449238;C2926735
pretreatment concomitant treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
copd severity,C0439793;C0522510
ics laba nz $nmbr$,C0815320;C0027978;C4551720
ics laba n z $nmbr$,C0815320;C4551720
$nmbr$ years n z $nmbr$,C0439234
current n z $nmbr$,C0521116;C1705970
former n z $nmbr$,C0205156;C0750523
moderate n z $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
severe n z $nmbr$,C0205082;C4050465;C4050466
very severe n z $nmbr$,C3641272;C4050419
north america n z $nmbr$,C0028405
europe n z $nmbr$,C0015176
rest of world n z $nmbr$,C0035253;C1622890
age mean,C0444504;C2347634;C2348143
years sd,C0439234;C2699239
very severe,C3641272;C4050419
lung function mean,C0444504;C2347634;C2348143
prebronchodilator fev $nmbr$ l,C2599602;C3714541
postbronchodilator fev $nmbr$ l,C2599594;C3714541
prebronchodilator fev $nmbr$ predicted,C0681842;C1882327
concomitant treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
with laba n pretreatment,C1550147;C2709094;C3539075;C3539076
with ics n,C0815320;C4551720
figure $nmbr$ least squares ls mean differences between ro umilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting b $nmbr$ agonist,C0444504;C2347634;C2348143;C0032042;C1696465;C1706408;C2599594;C3714541;C0032659;C1257890;C0016529;C1306036;C0162425;C1283828;C1550453
figure $nmbr$ rate ratios and $nmbr$ con dence intervals for reduction of moderate or severe copd exacerbations in the itt population and subpopulations copd chronic obstructive pulmonary disease ics inhaled corticosteroid itt intent to treat laba long acting b $nmbr$ agonist,C0871208;C0456603;C1610540;C1521828;C1272706;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0740304;C0032659;C1257890;C0162425;C1283828;C1550453
figure $nmbr$ least squares ls mean differences between roflumilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting $nmbr$ agonist,C0444504;C2347634;C2348143;C0032042;C1696465;C1706408;C2599594;C3714541;C0032659;C1257890;C0016529;C1306036;C0162425;C1283828;C1550453
risedronate n $nmbr$,C0246719
history of osteoporotic fracture n a,C4075937
serum $nmbr$ hydroxyvitamin d ng ml,C0020337;C0439275
duration of prior alendronate use months,C1881378;C2826775
$nmbr$ tob $nmbr$ months n,C1420851;C0439231
$nmbr$ months n,C0439231
time since prior alendronate use n,C1279919;C2362777
$nmbr$ tob $nmbr$ months,C1420851;C0439231
never took alendronate,C2003901;C1515187;C0102118
still taking alendronate at study entry n,C0102118;C0557651;C2603343
serum ctx $nmbr$ ng ml median iqr,C0010377;C0439275;C0631180;C3539598
lower tertile b $nmbr$ $nmbr$,C0441994;C1548802;C2003888
middle tertile $nmbr$ $nmbr$ to b $nmbr$ $nmbr$,C0444598;C0549183;C1552826
upper tertile $nmbr$ $nmbr$,C1282910
glycopyrronium $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
tiotropium $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
gender n male,C0086582;C1706180;C1706428;C1706429
mean sd body mass index kg m $nmbr$,C0022718;C0439209;C4054209
mean sd duration of copd years,C0449238;C2926735
severity of the disease gold $nmbr$ n,C0521117;C0018026;C1304897
copd exacerbation history n,C0740304;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
$nmbr$ exacerbations,C4086268
ics use at baseline n,C0042153;C0457083;C1947944
mean sd duration of smoking pack years,C0449238;C2926735
mean sd fev $nmbr$ l pre bronchodilator,C0444504;C2599602;C2347634;C2348143
mean sd fev $nmbr$ l post bronchodilator,C0444504;C2347634;C2348143;C2599594
mean sd post bronchodilator fev $nmbr$ percentage predicted,C0439165;C1549488;C1561533;C0681842;C1882327
mean sd post bronchodilator fev $nmbr$ reversibility,C2599594;C0449261
mean sd post bronchodilator fev $nmbr$ fvc,C2599594;C3714541
figure $nmbr$ subgroup analyses for the primary efficacy endpoint,C2986480;C2986535
ipst n $nmbr$,
no ipst n $nmbr$ $nmbr$,
prior ptca pci,C0332152;C4049621;C2826257
non u s,C1518422;C0041703
patient presentation,C0030705;C0449450
baseline cardiac biomarkers,C2735101;C2735102
periprocedural medications,C0013227;C0802604;C2598133;C4284232
clopidogrel loading dose $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
glycoprotein iib iiia inhibitor,C0016011;C1999216
catheter access site,C0449652
brachial,C0445456
length of stay randomization to discharge h,C0023303;C0034656;C0033727;C0369286;C0441932;C0564385;C4528284
ipst,
no ipst,
or [ $nmbr$ ci],C0008107;C3259781
p [int],C0369773;C3272375;C2603361
lm bifurcation treated,C0184906;C3146289;C1522326
lm bifurcation not treated,C0184906;C3146289;C1518422;C1522326
$nmbr$ vessel pci,C0005847;C4049621
$nmbr$ mg clopidogrel load,C1550025;C1704782;C1708715
losartan plus placebo n $nmbr$,C0126174;C0032042;C1696465;C1706408
losartan plus lisinopril n $nmbr$,C0126174;C0065374
hispanic ethnic group no f,C0015031;C1879937;C0016327
serum potassium mmol liter,C0302353;C0475211;C0543465
mean ml min $nmbr$ $nmbr$ m $nmbr$,C0444504;C0439445;C2347634;C2348143
category no total no,C0683312;C3889287;C0439175;C0439810
$nmbr$ $nmbr$ $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0439445
urinary albumin to creatinine ratio^,C0486293;C1318293
urinary protein to creatinine ratio,C0428627;C1318206
use of ace inhibitor arb or both no,C1524063;C0003015;C4541021
ace inhibitor monotherapy,C0003015;C4541021
arb monotherapy,C3888198
both ace inhibitor and arb,C0003015;C4541021;C3888198
neither ace inhibitor nor arb,C0003015;C4541021;C3888198
blood pressure medications at randomization no total no,C0849164;C0439175;C0439810
[ $nmbr$ cl],C0596019
losartan placebo,C0032042;C1696465;C1706408
losartan lisinopril,C0126174;C0065374
[ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
albuminuria $nmbr$ gram gram cr,C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
previously on acei arb,C3888198
age $nmbr$ years old,C1510829;C0580836
black and other,C0005680;C0027567;C0085756;C0439541
stenting plus medical therapy n $nmbr$,C0038257;C2348535
medical therapy only n $nmbr$,C0418981;C0369718;C0441922
blood pressure at target level,C0005823;C1271104;C1272641
estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$ ^,C0017654;C0439445;C1424601
stage $nmbr$ chronic kidney disease,C1561643;C4553188
method of identification ofstenosis,C1301921
angiography,C0002978
duplex ultrasonography,C3825392
computed tomographic angiography,C1441526;C0002978;C1880157
magnetic resonance angiography,C0243032
medical history and risk factors,C0262926;C1704706;C0035648;C1553898
history of heart failure,C0455531
smoking in past yr,C0037369;C0453996;C1881674;C0439234
angiographic findings,C2607943;C2926606;C3539655
stenosis as assessed by core laboratory,C0678234;C1261287;C2632116;C0022877;C3244292;C4283904
stenosis as assessed by investigator,C0678234;C1261287;C2632116;C0035173
global ischemia,C0205246;C0022116;C4321499;C2348867
bilateral disease j j,C1511113
stent plus medical therapy,C0038257;C0418981
medical therapy alone,C0418981;C0205171;C0439044;C0679994
no of patients total no,C0030705;C0439175;C0439810
creatinine level,C0428279
u s sites,C0041703;C0205145
maximal diameter stenosis,C0678234;C1261287;C2632116
characteristicsa,
varespladib n $nmbr$,C2713485
otherb,
western europe and lebanon,C0043129;C0023190
present smokerc,C0150312;C0449450
body mass index mean sd d,C0005893;C2699239;C0578022;C1305855
prior lipid modifying therapy,C1514463;C0023779
unstable angina biomarker negative,C0205160;C1513916;C2825415;C2825491;C3853545
index event to randomization median iqr h,C0441471;C4019010
pci or cabg surgery for index event,C4049621;C0038894;C0038895;C0543467;C1274039
medications at randomization,C0013227;C0802604;C2598133;C4284232
clopidogrel ticlopidine or prasugrel,C0070166;C0040207;C1620287
biochemical parameters at randomization mean,C0449381;C0034656
sd mg dl,C2699239;C0439269
c reactive protein median iqr mg l,C0006560;C0439268;C1413716;C4048285
concomitant atorvastatin dose mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
varespladib,C2713485
a primary composite outcome,C0205199;C1274040;C1547335
baseline lipid therapy,C0039798;C0087111;C1363945
primary indication,C1549995
pci postindex event,C0441471;C4019010
diabetes at baseline,C0011847;C0011849
hypertension at baseline,C0020538;C1963138
b myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
high dose edoxaban n $nmbr$,C0444956;C2975435
low dose edoxaban n $nmbr$,C0445550;C1708745
asia pacific region and south africa,C0017446;C0205147;C0037712
paroxysmal atrial fibrillation no,C0235480;C4050122
qualifying risk factor no,C1514624;C0035648
prior stroke or transient ischemic attack,C0038454;C4554100;C0007787;C0917805
hypertension requiring treatment,C0020538;C1963138;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
$nmbr$ $nmbr$ no,
dose reduction at randomization no i,C0301630;C0392756;C1293152;C4551656;C0021966;C0221138
use of verapamil or quinidine,C1524063;C0042523;C0034414
previous use of vitamin k antagonist for $nmbr$ days no,C1524063;C1096489;C2267235;C0439228
medication at time of randomization no,C0013227;C3244316;C4284232
digoxin or digitalis preparation,C0012265;C0304520
hazard ratio with high $nmbr$ cl,C2985465;C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
hazard ratio with low $nmbr$ cl,C2985465;C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
high dose edoxaban vs warfarin,C0444956;C2975435;C0043031
low dose edoxaban vs warfarin,C0445550;C2975435;C1708745;C0043031
hale,
af type,C0332307;C1547052
prior stroke or tza,C0038454;C4554100;C0039298
$nmbr$ p $nmbr$,C0369773;C2603361
congestive heart,C0742742;C0018787
failure,C0231174;C0680095
cha $nmbr$ s $nmbr$ score,C1420648;C0449820;C4050231
dose adjusted,C0178602;C0869039;C1114758;C0456081
vka naxve,
amiodarone use at baseline,C0042153;C0457083;C1947944
center level ttr,C0032923;C1421224
amiodarone ote at baseline,C0002598;C0168634;C1442488
$nmbr$ $nmbr$ ^,
ff $nmbr$ ig n $nmbr$,C0021027;C0305052;C0360506
ff vi $nmbr$ $nmbr$ ig n $nmbr$,C0205999;C0021027;C0305052;C0360506
never smoked n,C2003901;C0037366;C0439994;C1881674
former smoker n,C0337671
number of exacerbations in last $nmbr$ months,C0237753;C0449788;C0439231
screening prebronchodilator fev $nmbr$ l,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
screening predicted fev $nmbr$,C0220908;C3714541;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
screening reversibility fev $nmbr$,C0220908;C3714541;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
screening absolute reversibility fev $nmbr$ ml,C0439526;C1705224;C3887665
baseline acq $nmbr$ score,C0449820;C4050231
percentage of patients using ics or ics laba on entry,C0439165;C1549488;C1561533;C1524063;C0815320;C4551720;C1705654
ics only,C0815320;C4551720
ff $nmbr$ gg n $nmbr$ $nmbr$,C0017454;C0018370
ff vi $nmbr$ $nmbr$ gg n $nmbr$ $nmbr$,C0017454;C0018370
argentina,C0003761;C1504311
philippines,C0031529
japan,C0022341
baseline fev l,C0168634;C1442488
grouped region,C0017446;C0205147
australasia,C0282279;C1257882
values are mean sd median [quartile range] or ace indicates angiotensin converting enzyme arb angiotensin receptor blocker bnp b type natriuretic peptide bp blood pressure bun blood urea nitrogen lvef left ventricular ejection fraction and nt probnp n terminal pro b type natriuretic peptide,C0042295;C0549183;C0876920;C2347635;C2348144;C2939193;C1514721;C2348147;C3542016;C1452534;C4284014;C0005845;C0428772;C0600137;C0754710
alive n $nmbr$,C2584946;C4551704
dead n $nmbr$,C0011065
lvef within $nmbr$ mo,C0428772;C0488728
total intravenous loop diuretics mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
bun mmol l,C1532563
no readmission n $nmbr$,C1548168;C4489276
readmission n $nmbr$,C1548168;C4489276
increase creatinine,C0010294;C1561535
increase creatinine $nmbr$ $nmbr$ mg dl,C0010294;C0439269;C1561535
no hemoconcentration hemoconcentration,C0549409;C0854379
participants no,C0679646
gi bleed,C1708130;C0019080;C3539617;C4050121
no gi bleed,C1708130;C0019080;C3539617;C4050121
participants randomized,C0679646;C0034656;C3815594
no a,
black non black,C0005680;C0027567;C0085756;C0439541
hispanic non hispanic,C0086409;C1518422
women taking estrogen,C0014939;C2936882;C4542544
hdl mean sd mg dl,C0444504;C0439269;C2347634;C2348143
diabetes classificationa,C0011847;C0011849
nondiabetes,
mean sd mg kg $nmbr$,C0444504;C0439272;C2347634;C2348143
yes no,C1512698
history mi or stroke,C0019664;C3810814;C0019665;C0262512;C0262926;C1705255;C2004062;C0038454;C4554100
history coronary,C0019664;C0018787;C0019665;C0262512;C0262926;C1705255;C2004062
other atherosclerotic,C0333482
lvh by minnesota code,C0149721;C0009219;C0805701;C3889831
unadjusted hr $nmbr$ ci a,C0008107;C3259781
lisinopril vs chlorthalidone,C0065374;C0008294
lisinopril vs amlodipineb,C0065374
aspirin at baseline,C0004057;C0168634;C1442488
no aspirin at baseline,C0004057;C0168634;C1442488
asthma population n $nmbr$,C0004096;C0032659;C1257890;C2984299
copd population n $nmbr$,C0024117;C0032659;C1257890;C1412502;C3714496
duration of disease years,C0872146;C0439234
self reported disease severity $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
current inhaler,C0021461;C1881212;C4319647
diskus only n,C1553480;C0369718;C0441922
handihaler and diskus n,C1553480
handihaler only n,C0369718;C0441922
mdi hfa n,C0993596;C0015458;C1839839;C4049613
dpi other than diskus n,C1553480
qva $nmbr$ $nmbr$ pg once daily n $nmbr$,C0030827;C0072225;C1266240;C0332173
sfc $nmbr$ $nmbr$ pg twice daily n $nmbr$,C0030827;C0585361;C0072225;C1266240
ics users at baseline,C1706077;C0168634;C1442488
smoking history r,C0205090;C0684010;C2603358
ex smokers,C0337671;C4555205
estimated number of pack years,C0237753;C0449788
copd exacerbation history in the previous year n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
pre bronchodilator fev l,C2599602;C3714541
post bronchodilator fev l,C2599594;C3714541
pre bronchodilator fev predicted,C2599602;C3714541;C0681842;C1882327
post bronchodilator fev predicted,C2599594;C3714541;C0681842;C1882327
post bronchodilator fev reversibility,C2599594;C0449261
post bronchodilator fev fvc,C2599594;C3714541
lsm $nmbr$ cl,C0596019
overall qvai $nmbr$ sfc,C0282416;C4521536;C1561607
ex smokers qvai $nmbr$ sfc,C0337671;C4521536;C4555205
$nmbr$ o o $nmbr$ o $nmbr$,C0483204
smokers qva $nmbr$ $nmbr$ fc,C0337664;C2983605
moderate cord qva $nmbr$ sfc,C0205081;C4521536;C1881878;C4049705;C4049706;C4085643;C4321335
severe cord qvai $nmbr$ sfc,C0205082;C4521536;C4050465;C4050466
o $nmbr$ o oo $nmbr$ o $nmbr$ o,C0483204
men qvai $nmbr$ sfc,C0025266;C4521536
women qva $nmbr$ sfc,C0043210;C4521536
ics non users qvai $nmbr$ sfc,C0815320;C4521536;C4551720
$nmbr$ oo $nmbr$ o $nmbr$,
ics users qvai $nmbr$ sfc,C0815320;C4521536;C4551720
age $nmbr$ qvai $nmbr$ sfc,C0001779;C4521536
$nmbr$ ml min n $nmbr$,C0439445
median $nmbr$ th $nmbr$ th percentile,C0039725;C1264641;C0039738;C1420718;C4282123;C4285344
af duration n,C0344434;C0449238;C2926735;C4049859
$nmbr$ mo $nmbr$ y,C0026544;C0332177
chads $nmbr$ risk factors n,C0035648;C1553898
chads $nmbr$ score n,C0449820;C4050231
any anticoagulant,C0003280;C0848112;C3536711
events n y,C0441471;C3541888
dabigatran $nmbr$ mg bid vs warfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0043031
dabigatran $nmbr$ vs dabigatran $nmbr$ mg bid,C2348066;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
outcome according to renal function level in ml min,C1274040;C0232804;C0439445
dabigatran $nmbr$ mg bid events n y,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
warfarin events n y,C0043031;C0441471;C3541888
p value inter,C1709380;C0205103;C1548610
life threatening bleed,C1546953;C0019080;C2826244;C3537125
intracranial bleed,C0151699
net clinical benefit,C1456447;C4684590;C3853572;C3887809;C3890893
czp $nmbr$ mg every $nmbr$ weeks n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0439230
arthritis characteristics,C0003864;C1521970;C4552845
crp median range mg literl,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
esr median range mm hour,C0439227;C0564385
tender joint count range $nmbr$ $nmbr$ joints,C0451530;C1514721;C2348147;C3542016
swollen joint count range $nmbr$ $nmbr$ joints,C0451521;C1514721;C2348147;C3542016
modified total sharp score,C0392747;C2964552;C3889737
joint space narrowing score,C0449820;C4050231
physician s assessment of disease activity vas mm,C0031831;C0804815;C1261322;C1516048
enthesitis,C1282952
lei $nmbr$,C0023401;C0428209
dactylitis,C0239161
ldi $nmbr$,
psoriasis characteristics,C0033860;C1521970
$nmbr$ bsa psoriasis no,C0033860
pasi median range,C1514721;C2348147;C3542016
nail involvement,C0027342;C1314939;C1432728;C3538766
mnapsi,
patient reported outcomes,C2987124
patient assessment of disease activity mm,C0679830;C1292728
patient assessment of arthritis pain mm,C0679830
fatigue range $nmbr$ $nmbr$,C1514721;C2348147;C3542016
haq di range $nmbr$ $nmbr$,C1514721;C2348147;C3542016
sf $nmbr$ pcs,C1864389;C1882368
sf $nmbr$ mcs,C0037712
psaqol,
dlqi,C3899393
dlqi patients with $nmbr$ bsa psoriasis,C0030705;C0033860
prior tnf inhibitor exposure no,C0274281;C0332157
adalimumab,C1122087
no prior tnf inhibitor exposure,C0274281;C0332157
prior tnf inhibitor exposure,C0274281;C0332157
czp combined arms n $nmbr$,C0054841;C0205195;C1861828;C1872109
pain mm,C4330985;C4554674
haq di,C3826998;C4321476
indacaterol $nmbr$ ug n $nmbr$,C0041573;C0439211
indian indian subcontinent,C0454693
smokers,C0337664
fevi l,C0429706;C0849974;C1561566;C4528367
fevi predicted,C0849974;C1561566;C4528367;C0681842;C1882327
reversibility to salbutamol,C1271924
n indacaterol $nmbr$ ug indacaterol $nmbr$ ug placebo,C0032042;C1696465;C1706408
indacaterol $nmbr$ ug versus placebo,C0041573;C0439211;C0032042;C1696465;C1706408
indacaterol $nmbr$ ug versus indacaterol $nmbr$ ug,C0041573;C0439211
intent to treat population,C0087111;C0032659;C1257890;C1292734;C1522326
subgroup based on,C1079230;C1515021;C1527178;C1705938
theophylline use at screening,C0241361;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
saba reversibility,C0449261
figure $nmbr$ proportion of all and very high risk subjects achieving targets defined by european guidelines a all subjects b very high risk subjects with avd error bars standard error european guidelines on cardiovascular disease prevention in clinical practice version $nmbr$ [ $nmbr$ ] triple combination includes ldl c,C1709707;C0681850;C1550501;C1706203;C2349001;C2697811;C1521840;C2986546;C1704788;C3539106;C0332167;C0442804;C3272283;C4050568;C4319571;C4321397;C0596269;C0205210;C0205195;C1947911;C3811910;C0332257;C1552866;C2700399
abatacept $nmbr$ $nmbr$ n $nmbr$,C1619966
class iv glomerulonephritis,C0441888;C0017658;C2698970
duration of current flare median range months n $nmbr$ $nmbr$ $nmbr$,C0449238;C2926735
baseline creatinine median range mg dl,C0010294;C0439269;C1561535
baseline upgr mg mmole n $nmbr$ $nmbr$ $nmbr$,C0567349;C2348885
baseline upgr $nmbr$ gm gm $nmbr$ mg mmole,C0567349;C2348885
prestudy treatment status,C0749659
naive no treatment for current flare,C2827774;C1517205;C3540542
recent treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
inadequate response $nmbr$ months mmf ggs,C0205412;C0083765;C0209368;C3848524;C0439856
baseline prednisone or oral prednisone equivalent daily dose,C0168634;C0032952;C1442488;C2348070
mean sd mg n $nmbr$ $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
goncomitant treatment with age inhibitors angiotensin,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
receptor blockers,C0597357
premature discontinuation,C0457454;C1444662;C4552847
adverse event,C0877248
lack of efficacy,C0235828
withdrew consent,C2349954;C1511481;C1554192;C2923685
no longer met study criteria,C0428210;C0243161;C1550543;C4317104
poor compliance noncompliance,C0376405;C0457432
pregnancy,C0032961
ind gly n $nmbr$,C0017890;C0523677
ind pbo n $nmbr$,C4049864;C0031962
severity of airflow limitation gold $nmbr$ n,C0439793;C0522510
baseline copd exacerbation history n,C0740304;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
$nmbr$ exacerbation,C4086268
mean sd fev $nmbr$ postbronchodilator l,C0444504;C2347634;C2348143
mean sd postbronchodilator fev $nmbr$ predicted,C0681842;C1882327
mean sd postbronchodilator fev $nmbr$ reversibility,C0444504;C0449261;C2347634;C2348143
mean sd postbronchodilator fev $nmbr$ fvc,C0444504;C3714541;C2347634;C2348143
lsm $nmbr$ ci,C0008107;C3259781
moderate or less airflow limitation,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0231999;C0443288;C0449295
severe or worse airflow limitation,C0205082;C4050465;C4050466;C0443288;C0449295
smoking ex smoker,C0037369;C0337664;C0453996;C1881674
smoking current smoker,C3173209;C3241966
ics use at baseline no,C0042153;C0457083;C1947944
ics use at baseline yes,C0042153;C0457083;C1947944
reversibility $nmbr$,C0449261
bmi $nmbr$ $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
revive i,C0021966;C0221138
revive ii,
levosimendan n $nmbr$,C0246904
basal only,C0205112
$nmbr$ $nmbr$ lung fields,C0225759
legs only,C1140621
sacral and or lumbar,C0036037;C0024090
iv vasodilator,C0042402;C3537240
iv inotropic drug,C1971835
both iv vasodilator and inotrope,C0042402;C3537240
figure $nmbr$ hazard ratio for all cause mortality hazard ratio for all cause mortality levosimendan placebo at $nmbr$ days as a function of the systolic blood pressure at randomization,C2985465;C0015127;C1524003;C0032042;C1696465;C1706408;C0005811;C0034656
coenzyme q $nmbr$,C0041536
categorical variables,C0439828
continuous variables mean sd,C0439828;C2699239
age at onset y,C0206132;C3870509
age at diagnosis y,C1828181;C3173302
duration of pd y,C0449238;C2926735
diagnosed y,C0011900
updrs score,C0449820;C4050231
mental,C0229992
adl,C0001288;C1420005
motor,C1513492;C1705994
hoehn and yahr stage,C0205390;C1300072;C1306673
modified se adl scale,C0175659;C0349674;C1947916
pdqol scale,C0175659;C0349674;C1947916
modified rankin score,C0392747;C0449820;C4050231;C3889737
symbol digit score,C0449820;C4050231
$nmbr$ mg vs placebo,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C1696465;C1706408
p value lnteraction,C1709380
bl h y unilateral,C0005918;C0006413;C1552663;C2827109;C0205092
bl h y bilateral,C0005918;C0006413;C1552663;C2827109;C0238767
bl updrs low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
bl updrs high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
table $nmbr$ selected baseline characteristics of the study patients,C4684572
spironolactone n $nmbr$,C0037982
nyha functional classification no,C1275491;C0205245;C0542341;C2700217
eligibility stratum,C0013893;C1548635
hospitalization in previous year with management of heart failure as major component no,C0019993;C0205156;C1552607;C0001554;C0376636;C1273870;C3273539;C0449432;C1705248
elevated natriuretic peptides in previous $nmbr$ days no,C1144709;C0205156;C1552607
current smoker no blood pressure mm hg,C3173209;C3241966;C0005823;C0439475;C1271104;C1272641
region of enrollment no,C0017446;C0205147
russia and georgia,C0035970;C0017452;C0017454
no of events patients,C0441471;C0030705;C3541888
randomization stratum,C0034656
not hospitalized for heart failure in the year prior to study enrollment,C0701159;C0018801;C0018802;C4554158;C0332152;C3258203
hospitalized for heart failure during that time period,C0701159;C0018801;C0018802;C4554158;C1948053
ejection fraction based on local reading,C0489482;C2700378;C1527178;C1705938
less than the median,C0549183;C0876920;C2347635;C2348144;C2939193
at or above the median,C0549183;C0876920;C2347635;C2348144;C2939193
less than $nmbr$,
greater than or equal to $nmbr$,C0439093;C0205163
$nmbr$ years or older,C0439234;C0580836
yes insulin treated,C0021641;C1533581;C1579433;C3714501;C1522326
yes non insulin treated,C1549445;C1705108;C1710701;C1518422;C0021641;C1533581;C1579433;C3714501
new york heart association congestive heart failure class,C1882083
less than $nmbr$ mm hg,C0439475
greater than or equal to $nmbr$ mm hg,C0439093;C0205163;C0439475
use of statins,C1524063;C0360714
pulse pressure,C0949236
less than $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0439445
greater than or equal to $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0439093;C0205163;C0439445
racial category,C0683312;C3889287
use of cardiac medication,C1524063
use of blood pressure lowering medication,C1524063
quartiles of fgf $nmbr$ ru ml,C2828255;C0016026;C0919505
current tobacco use,C0040335;C0543414;C0841002;C3853727
prior pci or cabg,C0332152;C4049621;C2826257;C0010055
apo a $nmbr$ mg dl,C0003592;C0439269;C0523508;C4553344;C4553379
$nmbr$ year km,C0439234;C3887676;C0439508
t $nmbr$ $nmbr$,C2603360
hr $nmbr$ $nmbr$,
$nmbr$ ci $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0008107;C3259781
risk categories,C0035647;C0683312;C4552904
fgf $nmbr$ low egfr $nmbr$,C1739039;C3811844;C3812682
fgf $nmbr$ low egfr,C1739039;C3811844;C3812682
fgf $nmbr$ high egfr $nmbr$,C1739039;C3811844;C3812682
fgf $nmbr$ high egfr,C1739039;C3811844;C3812682
pinteraction $nmbr$ $nmbr$,
fgf $nmbr$ low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
fgf $nmbr$ low $nmbr$ elevated biomarkers,C0016026;C0005516;C0919505
fgf $nmbr$ high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
fgf $nmbr$ high $nmbr$ elevated biomarkers,C0016026;C0005516;C0919505
p interaction $nmbr$ $nmbr$,C0369773;C1704675;C2603361
$nmbr$ mw distance m,C0024548;C0012751;C0026385;C0556966
randomized treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
ischemic hf etiology,C0015127;C1314792;C1524003
ace i or arb,C0021966;C0221138;C3888198
$nmbr$ yr km mortality rate,C0026565;C0205848
icd vs placebo,C0021122;C0032042;C1696465;C1706408
amiodarone vs placebo,C0002598;C0032042;C1696465;C1706408
patients $nmbr$ y,C0030705
duration of diabetes y,C0449238;C2926735
patients with cardiac disorders n,C0741926
patients on antihypertensive medications n,C0030705;C0003364
number of patients randomized,C2360800;C0034656;C3815594
number of swollen joints $nmbr$ $nmbr$,C0449813
number of tender joints $nmbr$ $nmbr$,C0449813
psa modified shs of hands feet $nmbr$ $nmbr$ $nmbr$,C0018563;C0016504;C0347981;C1552914
all patients n,C0030705
patients receiving mtx n,C0030705;C1514756;C0025677;C1417487
patients not receiving mtx n,C0030705;C1518422;C1514756;C0025677;C1417487
patients with dactylitis,C0030705;C0239161
dactylitis score $nmbr$ $nmbr$,C0449820;C4050231
patients with enthesitis,C0030705;C1282952
psa modified mases score $nmbr$ $nmbr$,C0449820;C4050231
patients with $nmbr$ bsa,C0030705
haq di score $nmbr$ $nmbr$,C0449820;C4050231
patients with fingernail involvement,C0522476
napsi score $nmbr$ $nmbr$ of target fingernail,C0449820;C4050231;C1521840;C0222001;C2986546
sf $nmbr$ summary scores,C0037712;C0449820
pcs score,C0449820;C4050231
mcs score,C0449820;C4050231
patients receiving mtx,C0030705;C1514756;C0025677;C1417487
eplerenone n $nmbr$,C0961485
race no b,C0034510;C1706779;C3853635
estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$ of body surface area,C0017654;C0439445;C1424601;C0005902
serum potassium mmol l,C0302353;C1532563;C0543465
anterior mi,C3536746
concomitant treatments at randomization,C0087111;C0034656
acetylsalicylic acid,C0004057
p $nmbr$ y $nmbr$ antagonists,C0369773;C0243076;C2603361
heparins and fondaparinux,C0019134;C1098510
gp iib iiia inhibitors,C0016011;C0243077
fibrinolytics,C0040044
pci thrombolysis at randomization,C0520997;C0034656
thrombolysis,C0520997
no reperfusion,C0035124;C0684253
subgroup level,C0441889;C0456079;C1547707;C2946261
n participants,C0369718;C0679646;C0441922
age group $nmbr$,C0027362;C2348001
systolic blood pressure median $nmbr$ $nmbr$,C0549183;C0876920;C2347635;C2348144;C2939193
pulse pressure median $nmbr$ $nmbr$ ],C0549183;C0876920;C2347635;C2348144;C2939193
heart rate median $nmbr$ $nmbr$,C0549183;C0876920;C2347635;C2348144;C2939193
prior bb plus acbi plus arb use,C0004739;C0332297;C0042153;C0457083;C1947944
prior acbi or arb use,C0332152;C2826257;C0042153;C0457083;C1947944
anterior or non anterior ml,C0205094;C0439526;C1705224;C3887665
acute reperfusion,C0035124;C0684253
$nmbr$ $nmbr$ h,C0033727;C0369286;C0441932;C0564385;C4528284
not perfused,C1518422;C1549542
use of pci or thrombolysis within one day of randomization,C1524063;C4049621;C0520997;C3844320
first dose admin $nmbr$ $nmbr$ h $nmbr$ $nmbr$ h post onset of symptoms,C0178602;C0033727;C0369286;C0441932;C0564385;C4528284;C0869039;C1114758;C0687676;C4086878;C1704687;C3469826
$nmbr$ $nmbr$ hours,C0439227
cardiac enzyates raised,C0018787;C1522601;C0442818
figure $nmbr$ forrest plot on the primary composite endpoint with eplerenone vs placebo according to pre speci ed subgroups webplotdig,C2986535;C0205199;C1547335;C0961485;C0032042;C1696465;C1706408
zoledronic acid n $nmbr$,C0257685
age groups n,C0441848
baseline bmi kg m $nmbr$,C0022718;C0439209;C4054209
baseline t score at femoral neck n,C0449820;C4050231
entry hip fracture location n,C3260017
intertrochanteric,C0745355
subtrochanteric,
fracture history n,C0016658;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
hip fracture only,C0019557;C0149531;C4552776
hip other nonvertebral fractures,C0019552;C0022122;C1505163;C3538851;C4284725;C0016658
hip $nmbr$ vertebral fractures,C0019557
hip nonvertebral vertebral,C0019552;C0549207;C0022122;C1505163;C3538851;C4284725
fractures,C0016658
time to first infusion from hip surgery days n,C0040223;C3541383;C0596706;C0439228
$nmbr$ weeks,C0439230
baseline serum calcium level n,C0036785;C0728876
prior use of osteoporosis medications n,C1524063
bone mineral density g cm $nmbr$ mean sd,C0005938;C2699239;C0177804
eq $nmbr$ dprofile mobility n,C0205163;C0080078;C0425245;C0449580;C4318935;C0439185
walking,C0080331;C4283795;C4321241;C4321242
some walking,C0080331;C4283795;C4321241;C4321242
mental status baseline spmsq scores n,C0278060;C0168634;C1442488
charlson comobility score n,C0449820;C4050231
between treatment comparison of percentage change from baseline in total hip bmd,C1299575;C1707455;C0168634;C1442488
month $nmbr$ subgroup x treatment interaction p value,C0039798;C1709380;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
age groups,C0027362
t score at femoral neck,C3854607;C0015815
$nmbr$ $nmbr$ and,
hip fracture $nmbr$,C0019557;C0149531;C4552776
time to first infusion,C0040223;C3541383
calcium level,C0201925;C0428302
charlson,
mental status,C0278060
eq $nmbr$ d mobility,C0205163;C0439185;C0080078;C0425245;C0449580;C4318935
age mean sd years n,C1510829;C0444504;C2347634;C2348143
education mean sd years,C0013621;C0439234;C0013622;C0013658;C0039401
weight mean sd lbs,C0439219;C3161851
antihypertensive treatment n,C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
st t wave n,C0036056;C0429103;C3272372
lvh by ecg or echo n,C0232306;C0058928;C1655045
visit $nmbr$ blood pressures,C0545082;C1272641;C1512346;C2826704
bp,C0037623;C1415692;C1708288;C4318478
serum potassium mean sd mmol l,C0302353;C1532563;C0543465
fasting serum glucose mean sd mg dl,C0202041;C0439269;C3534430
serum cholesterol mean sd mg dl,C0587184;C0439269
treatment groups n,C0039798;C0441848;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
history of mi or stroke n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0038454;C4554100
amlodipine vs chlorthalidone normal,C0051696;C0205307;C0231683;C0439166;C2347086;C4553972
amlodipine vs chlorthalidone overweight,C0051696;C0008294;C0497406
amlodipine vs chlorthalidone obese,C0051696;C0008294;C0028754
favors amlodipine favors chlorthalidone,C0051696;C0008294
favors favors amlodipine chlorthalidone,C0051696;C0008294
lisinopril vs chlorthalidone normal,C0065374;C0205307;C0231683;C0439166;C2347086;C4553972
lisinopril vs chlorthalidone overweight,C0065374;C0008294;C0497406
lisinopril vs chlorthalidone obese,C0065374;C0008294;C0028754
favors lisinopril favors chlorthalidone,C0065374;C0008294
favors favors lisinopril chlorthalidone,C0065374;C0008294
dulaglutide $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
fsg mg dl,C0439269
prestudy treatment a,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
no oam,
$nmbr$ oam,
dulaglutide $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
oam,
overall population n $nmbr$,C0282416;C0032659;C1257890;C1561607
tnf antagonist failure population n $nmbr$,C0231174;C0032659;C1257890;C0680095
tnf antagonist naive subgroup n $nmbr$,C0231491;C1079230;C1515021
median age y range,C1514721;C2348147;C3542016
mean body weight kg range,C1514721;C2348147;C3542016
median body mass index kg m $nmbr$ range,C0022718;C0439209;C4054209;C1514721;C2348147;C3542016
median crohn s disease duration y range,C0549183;C0010346;C0876920;C2347635;C2348144;C2939193;C1514721;C2348147;C3542016
mean crp level mg l sd,C0439268;C2699239
mean fecal calprotectin level mg g stool sd,C1300563;C2699239
disease localization n,C0012634;C0475264;C1744691
ileocolonic both ileum and colon,C0020885;C0009368;C3888384
history of crohn s disease surgery n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0012634;C0038894;C0038895;C0543467;C1274039
history of fistulizing disease n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0012634
corticosteroid use n,C0239126
immunosuppressive use n,C0021081;C0042153;C0457083;C1947944
mesalamine use n a,C0127615;C0042153;C0457083;C1947944
prior immunosuppressive exposure n,C0021081;C0274281;C0332157
prior tnf antagonist failure n b,C3887647;C0231174;C0680095
$nmbr$ prior tnf antagonist failure n b,C3887647;C0231174;C0680095
$nmbr$ prior tnf antagonist failures n b,C3887647;C0231174;C0680095
overall n u $nmbr$,C0282416;C0439148;C1561607
insulin glargine n $nmbr$ ll,C0907402
omega $nmbr$ fatty acid n $nmbr$,C1719844;C0015684
placebo n $nmbr$ o,C0032042;C1696465;C1706408
previous cardiovascular disease,C0205156;C0007222;C1552607
present smoker,C0150312;C0337664;C0449450
laser or vitrectomy,C0023089;C0458142;C1023865;C1706315;C0042903
depression^,C0011570;C0011581;C0344315;C0460137;C4049644;C4084909;C4085311;C4553827
hba,C0019016;C1825777;C3538758
mini mental state examination,C0451306
digit symbol substitution,C1555721;C1706204
insulin glargine vs standard care least squares mean $nmbr$ cl,C0907402;C0023189;C0596019
p $nmbr$ interaction,C0369773;C1704675;C2603361
number insulin glargine,C0237753;C0907402;C0449788
number standard care,C1442989;C1947933;C2828392
a mini mental state examination insulin glargine vs standard care,C0451306;C0907402;C1442989;C1947933;C2828392
o oo $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$,C0483204
$nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$,
education $nmbr$ $nmbr$ years,C0013621;C0439234;C0013622;C0013658;C0039401
education $nmbr$ years,C0013621;C0439234;C0013622;C0013658;C0039401
hbak median,C0549183;C0876920;C2347635;C2348144;C2939193
o oi $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$,C0029118;C0029434
omega $nmbr$ fatty acid,C1719844;C0015684
b digit symbol substitution insulin glargine vs standard care,C0907402;C1442989;C1947933;C2828392
$nmbr$ $nmbr$ $nmbr$ $nmbr$ too $nmbr$,
hbak,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ l $nmbr$ to $nmbr$ $nmbr$,C0439394;C1706495;C3642217
omega $nmbr$ fatty acid vs placebo least squares mean $nmbr$ cl,C1719844;C0015684;C0023189;C0596019
number omega $nmbr$ number placeb fatty acid,C0237753;C0015684;C0449788
a mini mental state examination omega $nmbr$ fatty acids vs placebo,C0451306;C0015684;C0032042;C1696465;C1706408
b digit symbol substitution omega $nmbr$ fatty acids vs placebo,C0582802;C0015684;C3241971;C0032042;C1696465;C1706408
etn mtx n $nmbr$,C0014758;C0025677;C1417487;C0717758
csdmards mtx n $nmbr$,C0025677;C1417487
hcq mtx n $nmbr$,C0020336;C0025677;C1417487
ssz mtx n $nmbr$,C0025677;C1417487
lef mtx n $nmbr$,C0025677;C1417487
race n b,C0034510;C1706779;C3853635
african latin american,C0085756
mestizos,C0682082
sjc $nmbr$ joints,C0022417;C0392905
tjc $nmbr$ joints,C0022417;C0392905
cdai,C0683448;C1413248;C3273706
haq,C0102923;C0451208
supplementary figure s $nmbr$ das $nmbr$ early vs late disease appeal lara a $nmbr$ years disease duration population,C0051767;C1279919;C0057671;C0012634;C3900351;C0032659;C1257890
n $nmbr$ for etn mtx n $nmbr$ for dmards,C0369718;C0441922;C0014758;C0025677;C1417487;C0717758;C0242708
supplementary figure s $nmbr$ das $nmbr$ early vs late disease appeal lara b $nmbr$ years disease duration population,C0051767;C1279919;C0057671;C0032659;C1257890
bl baseline etn etanercept csdmards conventional synthetic dmards n $nmbr$ for etn mtx n $nmbr$ for dmards,C0005918;C0006413;C1552663;C2827109;C0014758;C0025677;C1417487;C0717758;C0242708
supplementary figure s $nmbr$ das $nmbr$ moderate vs severe disease appeal lara,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C1836348;C3900351
a das $nmbr$ moderate disease population n $nmbr$ for etn mtx n $nmbr$ for dmards,C0012634;C0032659;C1257890;C0014758;C0025677;C1417487;C0717758;C0242708
a das $nmbr$ severe disease population bl baseline etn etanercept csdmards conventional synthetic dmards n $nmbr$ for etn mtx n $nmbr$ for dmards,C1836348;C0005918;C0006413;C1552663;C2827109;C0014758;C0025677;C1417487;C0717758;C0242708
race n a,C0034510;C1706779;C3853635
region n a,C0017446;C0205147
central south america,C0007674
mean sd hba $nmbr$ c level,C0441889;C0456079;C1547707;C2946261
mean sd duration of t $nmbr$ dm y,C0449238;C2926735
patients with microvascular complications n,C0030705;C0009566;C1171258
patients with cardiac disorders n c,C0741926
mean treatment exposure wk,C0332174;C0439230
$nmbr$ st tertile,C0036056;C3272372
$nmbr$ nd tertile $nmbr$ to $nmbr$ $nmbr$ to,
$nmbr$ rd tertile $nmbr$ mg dl [ $nmbr$ $nmbr$ mmol l] d,C0439422
cana $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
baseline mg dl mmol l,C0439268
ls mean se,C0023668;C0036919
change mg dl mmol l,C0439268
difference vs pbo $nmbr$ ci,C1705241;C1705242;C0008107;C3259781
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
difference vs pbo,C1705241;C1705242;C0031962
tcz sc $nmbr$ mg every other week n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0332174;C0439230
pbo sc every other week n $nmbr$,C0031962;C0282380;C0332174;C0439230
weight group no,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
other dmards,C0242708
previous dmards mean sd,C0205156;C2699239;C1552607
previously failed anti tnf treatment no,C0231175;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
laboratory tests,C0022885
rf positive no,C0439178;C1446409;C1514241;C2825490;C3812269
acpa positive no,C0439178;C1446409;C1514241;C2825490;C3812269
crp level mean sd mg dl,C0441889;C0439269;C0456079;C1547707;C2946261
esr mean sd mg dl,C0444504;C0439269;C2347634;C2348143
disease activity,C1292728
duration of ra mean sd years,C0449238;C2926735
tender joints $nmbr$ joint count mean sd,C0451530;C2699239
swollen joints $nmbr$ joint count mean sd,C0451521;C2699239
das $nmbr$ mean sd,C0051767;C2699239;C0057671
shs mean sd,C0444504;C2699239;C2347634;C2348143
jsn mean sd,C0444504;C2699239;C2347634;C2348143
erosion mean sd,C0333307;C2699239;C1880549;C1959609;C3887524
haq di score range $nmbr$ $nmbr$ mean sd,C3826998;C2699239;C4321476
pain vas range $nmbr$ $nmbr$ mean sd,C0042815;C2699239
patient global assessment of disease,C4054229
activity range $nmbr$ $nmbr$ mean sd,C0205177;C2699239;C0439167;C0441655;C1561536;C3668946;C4049938;C4049939
physician global assessment of disease,C4050369
study $nmbr$ $nmbr$,C0557651;C2603343
olodaterol,C2934193
$nmbr$ g n $nmbr$,C0439267
pre bronchodilator mean sd fev $nmbr$ l,C2599602;C0444504;C2347634;C2348143
mean sd fev $nmbr$ l,C0444504;C2347634;C2348143
mean sd predicted normal fev $nmbr$,C0205307;C3714541;C0231683;C0439166;C2347086;C4553972
mean sd fev $nmbr$ fvc,C0444504;C3714541;C2347634;C2348143
mean sd change from pre to post bronchodilator fev $nmbr$ l,C0392747;C0443172;C1705241;C4319952
gold stage n,C0018026;C0205390;C1300072;C1306673;C1304897
baseline pulmonary medications,C0013227;C0802604;C2598133;C4284232
any pulmonary medication n,C0024109;C0013227;C3244316;C4284232;C2707265;C2709248;C4522268
sama b n,C1075468
lama tiotropium b n,C0999593;C0213771;C1416775
saba inhaled c n,C0004048
laba inhaled d n,C0004048;C0369718;C0441922
oral adrenergics n,C0442027;C0001637;C4521986
steroids n,C0038317
inhaledb,
oralb,
xanthines b n,C0043318;C3541955
mean se auc^p l,C0036919;C0376690
olodaterol $nmbr$ jig,C2934193
tiotropium n $nmbr$ non tiotropium n $nmbr$,C0213771;C1518422
non tiotropium,C1518422;C0213771
mean se trough l,C0444504;C0036919;C2347634;C2348143
tiotropium n $nmbr$ non tiotropium n $nmbr$ $nmbr$,C0213771;C1518422
n unless otherwise specified,C0369718;C0441922;C0205369
a vs c,
l vs c,C0439394;C1706495;C3642217
education years mean sd,C0013621;C2699239;C0013622;C0013658;C0039401
type ii diabetes,C0011860
hx cabg,C0262926;C0010055;C3814444
hx mi or stroke,C0262926;C3810814;C3814444;C0038454;C4554100
oascvd,
antihypertensive medication $nmbr$,C0003364
estrogen,C0014939;C2936882;C4542544
heart rate mean sd,C0018810;C2699239
lvh by ecg minnesota code,C0232306;C0009219;C0805701;C3889831
cholesterol mg dl mean sd,C0439269;C2699239
fasting glucose mg dl mean sd,C0439269;C2699239
egfr ml min per $nmbr$ $nmbr$ m $nmbr$ mean sd,C1739039;C0439445;C3811844;C3812682;C0444504;C2699239;C2347634;C2348143
blood pressure mmhg mean sd,C0428886;C2699239
systolic total,C0439175;C0439810
diastolic total,C0439175;C0439810
systolic treated at baseline,C0039155;C1522326;C0168634;C1442488
diastolic treated at baseline,C0012000;C1522326;C0168634;C1442488
interaction p values are as follows amlodipine vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ lisinopril vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ peripheral arterial disease refers to in trial hospitalization or lower extremity revascularization procedure,C1704675;C1709380;C0332283;C1719822;C4281991;C0051696;C0008294;C0001779;C0011847;C0065374;C0011849;C0085096;C1704436;C0008976;C0019993;C0184661;C2700391;C3274430;C3539779
$nmbr$ mg mtx,C0025677;C1417487
patients with prior dmard use n a,C0030705;C0042153;C0457083;C1947944
hydroxychloroquine,C0020336
sulfasalazine,C0036078
patients taking oral corticosteroids at baseline n,C0442027;C0001617;C3539185;C3540725;C3540726;C3540727;C4521986
prednisone or equivalent dose mg day,C0032952;C0178602;C0439422;C0869039;C1114758
anti ccp antibody positive n,C0432633
total vdh s score,C2964552
diuretics group n $nmbr$,C0012798;C0441848
no diuretics group n $nmbr$,C0012798;C0441848
on drug treatment,C0150270;C3469597
positive family history of type $nmbr$ diabetes,C1313937
history of peripheral arterial disease,C0683519;C0730226;C0850708;C0944983
pulse rate bpm,C0232117
uric acid mg dl,C0041980;C0439269
k mmol l,C0597277;C1532563;C1708601
na mmol l,C0597484;C1532563;C1272460;C1546968;C1879645;C4049872;C4552882
triglyceride mg dl,C0041004;C0439269
non diuretics,C1518422;C0012798
fbs $nmbr$ mg dl,C3812213;C0439269
fbs,C3812213
with beta blocker,C0001645
without beta blocker,C0001645
with acei arb,C3888198
without acei arb,C3888198
continuation n $nmbr$,
interruption n $nmbr$,C0332453;C1512900
age in years,C1510829
older than $nmbr$ years,C0580836;C0439234
body weight index kg m $nmbr$,C0022718;C0439209;C4054209
dyslipidaemia,C0242339
high on treatment platelet reactivity,C0039798;C0005821;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
prior percutaneous coronary intervention,C0332152;C1532338;C2826257
prior coronary artery bypass graft,C0010055;C1260596
calcium channel inhibitor,C0006685;C1999216
drug eluting stent implanted,C1322815;C0021102;C2828363
first generation stentt,C0205435;C0079411;C3146294;C1279901
second generation stent,C0079411;C0038257;C3146294
stented vessel,C0038257;C0005847
coronary artery bypass graft,C0010055;C1260596
continuation,
interruption,C0332453;C1512900
aqc,
woman,C0043210;C4281745
no smoking,C0037369;C0453996;C1881674
number stent $nmbr$,C0237753;C0038257;C0449788
full population,C0032659;C1257890
olodaterol $nmbr$ gg n $nmbr$,C0017454;C0018370
formoterol $nmbr$ gg n $nmbr$,C0017454;C0018370
pre bronchodilator screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
post bronchodilator screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
mean sd of predicted normal fev $nmbr$,C2699239;C0520835
baseline pulmonary medication b n,C0024109;C0013227;C3244316;C4284232;C2707265;C2709248;C4522268
samac,
lamad,
sabae,
icsf,
xanthinesg,
mean se auc $nmbr$ $nmbr$ l,C0036919;C0376690
placebo tiotropium n $nmbr$ non tiotropium n $nmbr$,C0032042;C0213771;C1696465;C1706408
olodaterol $nmbr$ ig tiotropium n $nmbr$ non tiotropium n $nmbr$,C4032878;C0021027;C0305052;C0360506
olodaterol $nmbr$ $nmbr$ ig tiotropium n $nmbr$ non tiotropium n $nmbr$,C4032878;C0021027;C0305052;C0360506
formoterol tiotropium n $nmbr$ non tiotropium n $nmbr$,C0060657;C0213771
omalizumab,C0966225
x $nmbr$ years,C0439234
o $nmbr$ kg n,C0022718;C0439209;C4054209
body mass index kgm _ $nmbr$,C0005893;C0578022;C1305855
time since diagnosis of ciu csu years $nmbr$,C0556970;C0011900;C1704338;C1704656
cu index test n $nmbr$,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
no of previous ciu csu medications,C0205156;C0013227;C0802604;C2598133;C4284232;C1552607
median range total ige level iuml $nmbr$,C0439175;C0439810
in clinic uas $nmbr$,C0150312;C0002424;C0442592;C0332285;C1707101
uas $nmbr$,
weekly iss $nmbr$,C1740819;C1845118
weekly number of hives score $nmbr$,C0237753;C0449788
overall dlqi score $nmbr$,C0282416;C3897059;C1561607
angioedema present n $nmbr$,C0002994;C0150312;C0449450
lsm difference $nmbr$ cl,C1705241;C0596019;C1705242
sia,C1225105;C1551538
sack,
non united states,C1518422;C0041703
baseline weekly iss,C1740819;C1845118
baseline uas $nmbr$,C0168634;C1442488
a median,C0549183;C0876920;C2347635;C2348144;C2939193
body weiqht,C0242821;C0460148;C1268086;C4082212
positive cu index test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
presence of angioedema at baseline,C0150312;C0392148;C3854307;C0168634;C1442488
previous use of systemic steroids for ciu csu,C0281991;C0578870
level of thyroperoxidase antibody at baseline,C0428536;C0168634;C1442488
high $nmbr$ $nmbr$ u ml,C0439340;C1880521;C2945590
duration of disease before baseline,C0872146;C0168634;C1442488
previous number of ciu csu medications,C0205156;C1718138;C1552607
figure $nmbr$,
b hazard ratios for serious infections cox proportional hazards model in tofacitinib treated patients in the pooled phase ii phase iii and long term extension study population values are the mean $nmbr$ confidence interval [ $nmbr$ ci] dmard disease modifying antirheumatic drug,C0018623;C0456603;C1610540;C0030705;C0441767;C1706317;C0009667;C0242708
lipoprotein a mg dl,C0065058;C0439269;C0125953;C1096202;C1439335
fasting blood glucose mg dl,C0428568;C0439269;C1261430
$nmbr$ a,
former or current smokers,C0205156;C0750523;C3173209;C3241966
baseline high density lipoprotein cholesterol mg dl,C0023822;C0439269
no of cardiovascular events cardiovascular events $nmbr$ person years,C1320716;C0027361;C2347489
pfor trend,C1521798;C4554533
chd plus cerebral infarction,C0280604;C3542407
total deaths,C0011065;C1306577
pharmaco invasive n $nmbr$,C0205281;C1334278
age $nmbr$ y n,C0001779
killip class ii iv n,C2697847
timi risk score $nmbr$ n,C0035647;C0449820;C4050231;C4552904
time to randomization from symptom onset,C0040223;C3541383;C4086878
$nmbr$ h n,C0033727;C0369286;C0441932;C0564385;C4528284
anterior n,C0205094
inferior n,C0542339;C0678975
ambulance n,C0002422;C3846685
community hospital n,C0020003
all cause mortality at $nmbr$ year,C0015127;C0026565;C0026566;C1524003
age [years] interaction p $nmbr$ $nmbr$,C0001779;C0439234;C1704675
time to randomisation [hours] interaction p $nmbr$ $nmbr$,C0040223;C3541383;C0439227;C1704675
previous ml interaction p $nmbr$ $nmbr$,C0205156;C0439526;C1705224;C3887665;C1552607
sex interaction p $nmbr$ $nmbr$,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
systolic blood pressure [mmhg] interaction p $nmbr$ $nmbr$,C0488055;C0871470;C1306620;C0439475;C1704675
killip class interaction p $nmbr$ $nmbr$,C1881332;C1704675
infarct location interactsn p $nmbr$ $nmbr$,C0021308;C0450429;C1515974;C4284930;C4284931
other diabetes interaction p $nmbr$ $nmbr$,C0011847;C0011849
yes weight [kg] interaction p $nmbr$ $nmbr$,C0005910;C0043100;C1305866;C1705104;C0022718;C0439209;C4054209;C1704675
p lace of randomization interaction p $nmbr$ $nmbr$,C0280109;C0453991
timi risk score interaction p $nmbr$ $nmbr$,C0035647;C0449820;C4050231;C4552904
time of randomization interaction p $nmbr$ $nmbr$,C0040223;C3541383
prehospital ticagrelor n $nmbr$,C1999375
in hospital ticagrelor n $nmbr$,C0019994;C1510665
bmi $nmbr$ no f,C0578022;C0016327
timi risk score no t,C0035647;C0449820;C4050231;C4552904;C2603360
killip class i no,C2697844
first medical contact no,C0332158;C0337611;C1705415;C3812666
in ambulance,C0002422;C3846685
in emergency department before ambulance transfer,C0562508;C0002422;C3846685
procedures for index event,C0025664;C0184661;C2700391;C3538935
coronary angiography no,C0085532;C1548829
femoral access no total no,C0444454;C1554204;C0439175;C0439810
radial access no total no,C0444454;C1554204;C0439175;C0439810
missing data no total no,C4684714;C0439175;C0439810
thromboaspiration no,
with stent^l,C0038257
no pci or cabg no,C4049621;C0010055
study medication no,C0013227;C3244316;C4284232
first loading dose,C0205435;C3714444;C1279901
second loading dose,C0205436;C3714444;C0457385;C0565930;C1561503;C1705190
maintenance dose,C3714445
any use,C0042153;C0457083;C1947944
other antithrombotic medication for index event no,C0013227;C3244316;C4284232
glycoprotein ilb iiia inhibitor before pci],C0017968;C1999216
intravenous anticoagulant during hospitalization,C0003280;C0848112;C3536711
combination therapy,C0009429;C0556895
total patients,C0439175;C0030705;C0439810
endpoint rate,C0871208;C1521828
p value int,C1709380;C3272375
pre h,C0033727;C0369286;C0441932;C0564385;C4528284
in h,C0033727;C0369286;C0441932;C0564385;C4528284
n nt,C0332126;C1449832;C3889152;C4050156;C4283901;C4284038
pnorpci,
pnorcabg,
so $nmbr$,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ j $nmbr$,
location of ml,C0450429;C1515974;C4284930;C4284931
tim $nmbr$ nsk score,C0449820;C4050231
highest killip classiciation pre pci,C1522410;C0332152;C0740175;C2257086;C3669034
$nmbr$ ix,C0015491
prior asa use,C0042153;C0457083;C1947944
gpifeellla inhibitor use before angography,C0042153;C0457083;C1947944
morphine use for index event pci,C0242000;C0441471;C4019010
heparin ondaparinux or brvalirudin use between rxjex event,C0019134;C0770546;C0042153;C0457083;C1947944
total atients,C0439175;C0439810
tlmi risk score,C0035647;C0449820;C4050231;C4552904
so,
gpifo llia inhibitor use before angography,C0042153;C0457083;C1947944
heparin fondaparinux or brvalirudin use between oex event,C0019134;C1098510;C0770546;C0042153;C0457083;C1947944
ivabradine n $nmbr$,C0257190
cardiovascular risk factors and medical history,C0850624;C0262926;C1704706
duration of coronary artery disease yr,C0872146
previous coronary revascularization no,C0205156;C0877341;C1552607
angina status no,C0002962;C0449438
no symptoms,C0683368;C1457887
ccs class,C1879987
previous stroke no,C0038454;C4554100
concomitant treatment no,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
antiplatelet agent or anticoagulant,C0085826;C0003280;C0848112;C3536711
angiotensin il receptor blocker,C0034787;C1622222
dihydropyridine calcium channel blocker,C2945601
diltiazem or verapamil,C0012373;C0042523
antidiabetic agent,C0935929
plus minus values are means sd there were no significant differences at,C0042295;C1704970;C2699239;C0237881;C0750502;C1546944
denotes angiotensin converting enzyme,C0022709;C1452534
j the body mass index is the weight in kilograms divided by the square of the,C0005893;C0578022;C1305855;C0005910;C0043100;C1305866;C1705104;C0332849;C0205120;C1552595
height in meters,C0489786;C0441074
race was determined by the investigator during the patient s interview,C0034510;C1706779;C3853635;C0521095;C0035173;C0030705;C0021822;C0935630
classes on the canadian cardiovascular society ccs scale range from i to iv,C0007226;C1879987;C3887460;C0022326;C4265176
with higher classes indicating greater limitations on physical activity owing to,C0456387;C1518526;C1705943;C4019422;C0449295;C0015259;C0026606
ivabradine,C0257190
no of events total no,C0439175;C0439810
angina class at baseline,C0456387;C1518526;C1705943
class i or no symptoms,C0441885;C1319793;C2698967;C0683368;C1457887
beta blocker use at randomization,C0042153;C0457083;C1947944
$nmbr$ beats min,C0439385
total by treatment,C0439175;C0439810
early,C1279919
delayed,C0205421;C1545665;C3272602
vka n $nmbr$,
creatinine clearance an,C0812399
prior non cns se,C0332152;C0036919;C2826257
prior tia,C0007787;C0917805;C1054154
nyha class iii iv,C0278962
vascular disease,C0042373
first diagnosed,C0205435;C1279901;C0011900
long standing persistent,C0205322;C0332996
cha $nmbr$ ds $nmbr$ vasc score n,C1420648;C0449820;C4050231
$nmbr$ or $nmbr$ if female only,C0043210;C0086287;C1705497;C1705498
$nmbr$ except for female alone,C0043210;C0086287;C1705497;C1705498;C0205171;C0439044;C0679994
oac experienced bn,C0005005;C0034700;C1706574;C4551963
antiarrhythmic drugs n,C0003195
dronedarone,C0766326
flecainide,C0016229
propafenone,C0033429
others classes i and iiic,C0441885;C1319793;C2698967
efficacy n a,C1280519;C1707887
safety n b,C0036043;C1705187
fatal,C1302234;C1705232
critical site,C0205145;C1515974;C2825164
ich,C0019191;C3272597;C3281105
hb decrease $nmbr$ g dl,C0439267
transfusion $nmbr$ units rbcs or whole blood,C0005841;C0014792;C0199960;C1879316;C0229664;C0370231;C1546552;C1608383
prior heart failure n $nmbr$ $nmbr$,C0018801;C0018802;C4554158
no prior heart failure n $nmbr$ $nmbr$,C0018801;C0018802;C4554158
age years median iqr,C1510829;C0549183;C0876920;C2347635;C2348144;C2939193
multiracial n,C1881928
weight kg median iqr,C0005910;C0022718;C0439209;C4054209;C0043100;C1305866;C1705104
weight $nmbr$ kg n,C0005910;C0022718;C0439209;C4054209;C0043100;C1305866;C1705104
body mass index kg m $nmbr$ median iqr,C0022718;C0439209;C4054209;C0549183;C0876920;C2347635;C2348144;C2939193
body mass index $nmbr$ n,C0005893;C0578022;C1305855
duration of diabetes median iqr,C0449238;C2926735
established atherosclerotic disease n,C0333482;C0012634
prior coronary revascularization n,C0332152;C0877341;C2826257
glycated hemoglobin median iqr,C0017853;C0549183;C0876920;C2347635;C2348144;C2939193
glycated hemoglobin n,C0062408
fasting serum glucose mg dl median iqr,C0202041;C0439269;C3534430
estimated glomerular filtration rate ml min median iqr,C3811844;C0439445
estimated glomerular filtration rate n,C3811844
albumin creatinine ratio mg mmol median iqr,C0486293;C1318293
albumin creatinine ratio n,C0486293;C1318293
$nmbr$ $nmbr$ mg mmol,C0567349;C2348885
$nmbr$ $nmbr$ $nmbr$ $nmbr$ mg mmol,C0567349;C2348885
baseline cardiovascular medications n,C0168634;C0007220;C1442488
baseline anti hyperglycemic medications n,C0432633;C0013227;C0802604;C2598133;C4284232
thiazolidinediones,C1257987;C3541957
state,C1301808;C1442792;C3148680
glomerular,C0022663;C0268731
filtration rate $nmbr$ $nmbr$,C0871208;C1521828
prior hypertension yes,C1549445;C1705108;C1710701
prior heart failure yes,C1549445;C1705108;C1710701
duration of,C0449238;C2926735
baseline albumin,C0168634;C0001924;C1442488
creatinine ratio $nmbr$ $nmbr$,C0456603;C1547037
pg mg,C1627892
acei arb,C3888198
baseline calcium yes,C1549445;C1705108;C1710701
antagonist,C0231491
mepolizumab,C0969324
intravenous n $nmbr$,C0348016
subcutaneous n $nmbr$,C0443315
mean age range yr,C0001779;C0439234
former smoker no,C0337671
duration of asthma yr,C0449238;C2926735
use of oral glucocorticoids,C1524063
maintenance use no,C0042153;C0457083;C1947944
mean daily dose range mg i,C0024671;C0021966;C0221138;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
allergic rhinitis no,C1334103;C2607914;C4552864
fev $nmbr$,C3714541
before bronchodilation liters,C1371299;C0475211;C3537072
percent of predicted value before bronchodilation^,C1882327;C1371299;C3537072
fevt fvc ratio,C0456603;C1547037
morning peak expiratory flow liters min,C0702093;C1524029;C3813700
score on asthma control questionnaire,C4706265
score on st george s respiratory questionnaire^^,C0449820;C4050231;C0521346;C0034394;C1546767
geometric mean ige on loge scale u ml,C0439340;C1880521;C2945590
geometric mean blood eosinophil count on loge scale cells ^ljj,C2986759;C0200638
asthma exacerbations,C0349790
severe episodes in previous year no patient,C0205082;C0332189;C4050465;C4050466;C0030705
necessitating hospitalization in previous year no,C0019993;C0205156;C1552607
history of asthma related intubation no,C0455544;C0021925
p $nmbr$ z $nmbr$ n $nmbr$,C0369773;C2603361
$nmbr$ to $nmbr$ n,C0369718;C0441922
north america oceania,C0282279;C4085681
femoral neck t score mean sd,C0015815;C2699239
$nmbr$ $nmbr$ to $nmbr$ $nmbr$ n,C0369718;C0441922
mean bmd sd g cm $nmbr$,C0444504;C0439267;C2347634;C2348143
lumbar,C0024090
prior medication use n,C0332152;C0240320;C2826257
calcitonin,C0006668;C0770558;C1704385;C2825090;C4520796
serms,C0732611
other osteoporosis medication,C0013227;C3244316;C4284232
mean sd days since,C0444504;C0439228;C2347634;C2348143
last infusion in the horizon pft,C0574032;C1827465
core study to first infusion,C0557651;C2603343
in extension study,C0557651;C2603343
with ckd intensive n $nmbr$,C1561643
with ckd standard n $nmbr$,C1561643;C1442989;C2828392
no ckd intensive n $nmbr$,C1561643
no ckd standard n $nmbr$,C1561643;C1442989;C2828392
o $nmbr$ $nmbr$,C0483204
uacr mg g,C1300563
no ckd,C1561643
ckd stage $nmbr$,C0205390;C1300072;C1306673
serum glucose mg dl,C0202041;C0439269;C3534430
duration of dm years,C0449238;C2926735
history of cvd,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
merformin,
any anti hypertensive agent,C0003364
dihydropyridine ccbs,C0012315;C0006684;C0220821
non dihydropyridine ccbs,C0012315;C0006684;C0220821
fibrate,
hdl female,C0043210;C0086287;C1705497;C1705498
hdl male,C0086582;C1706180;C1706428;C1706429
ohs graduate,C0588053;C1547183
hs graduate ged,C0588053;C1880947;C1547183
some college tech,C0557806;C1826596
college graduate or more,C0682187
network,C0150775;C1513822;C1705739;C1882071
fp sal $nmbr$ $nmbr$ pg n $nmbr$,C0016704;C0030827;C0072225;C1266240;C1419068;C1419906;C3541238;C3541412
sal $nmbr$ pg n $nmbr$,C0030827;C0072225;C1266240
copd type,C0332307;C1547052
chronic bronchitis,C0008677
emphysema,C0013990;C0034067
smoking pack years,C0037369;C1277691;C0453996;C1881674
baseline pre bronchodilator fev $nmbr$ l,C0168634;C2599602;C1442488
baseline predicted fev $nmbr$,C0168634;C3714541;C1442488
fev $nmbr$ reversibility,C3714541;C0449261
non reversible,C1518422;C0205343
reversible,C0205343
ratio fp sal sal $nmbr$ ci,C0008107;C3259781
severe exacerbations itt population n,C0205082;C0032659;C1257890;C4050465;C4050466
patients having exacerbation,C0030705;C4086268
number of exacerbations,C0237753;C0449788
mean annualized exacerbation rate,C0871208;C1521828
moderate severe exacerbations itt population n,C0205081;C0032659;C1257890;C1881878;C4049705;C4049706;C4085643;C4321335
moderate severe exacerbations patient subgroups n,C0205081;C0030705;C1881878;C4049705;C4049706;C4085643;C4321335
baseline post bronchodilator predicted fev $nmbr$ and prior ics use,C2599594;C3714541;C0042153;C0457083;C1947944
baseline post bronchodilator predicted fev $nmbr$ and no prior ics use,C2599594;C3714541;C0042153;C0457083;C1947944
baseline post bronchodilator predicted fev $nmbr$ and concurrent tiotropium use,C2599594;C3714541;C0042153;C0457083;C1947944
exacerbations,C4086268
baseline post bronchodilator predicted fev $nmbr$ and no concurrent tiotropium,C2599594;C3714541;C0205420;C0213771
baseline post bronchodilator predicted fev $nmbr$,C2599594;C3714541
patients using concurrent tiotropium,C0030705;C1524063;C0205420;C0213771
$nmbr$ mg empagliflozin,C0024671;C3490348;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
egfr ml min $nmbr$ $nmbr$ m $nmbr$ mdrd,C1739039;C0439445;C3811844;C3812682;C3839656
hba $nmbr$ c [mmol mol],C0019016;C1825777;C3538758;C3829066
$nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ ],
years since diagnosis of type $nmbr$ diabetes n,C0439234;C1320657
sbp office measurement mmhg,C0085805;C0439475
sbp mean over $nmbr$ h mmhg,C0444504;C2347634;C2348143
dbp office measurement mmhg,C0242485;C0439475
dbp mean over $nmbr$ h mmhg,C0444504;C2347634;C2348143
pulse rate mean $nmbr$ h bpm,C0232117;C0033727;C0369286;C0441932;C0564385;C4528284
number of antihypertensive medications n,C1718138
daytime mean sbp abpm at week $nmbr$ mmhg,C0332169;C0085805
change from baseline mmhg,C0392747;C0443172;C1705241;C4319952
nighttime mean sbp abpm at week $nmbr$ mmhg,C0240526;C0085805
daytime mean dbp abpm at week $nmbr$ mmhg,C0332169;C0332174;C0439230
nighttime mean dbp abpm at week $nmbr$ mmhg,C0240526;C0332174;C0439230
mean $nmbr$ h sbp,C0033727;C0085805;C0369286;C0441932;C0564385;C4528284
patients with bp $nmbr$ $nmbr$ mmhg abpm at baseline nt,C0030705;C0037623;C1415692;C1708288;C4318478;C0332126;C1449832;C3889152;C4050156;C4283901;C4284038
change from baseline in mean $nmbr$ h sbp mmhg,C0392747;C0443172;C1705241;C4319952;C0033727;C0439475;C0369286;C0441932;C0564385;C4528284
patientswith bp $nmbr$ $nmbr$ mmhg abpm at baseline n,C0037623;C0168634;C1442488;C1415692;C1708288;C4318478
mean $nmbr$ h dbp,C0536221;C3813197;C4281799
patientswith bp $nmbr$ $nmbr$ mmhg abpm at baseline nt,C0037623;C0168634;C1442488;C1415692;C1708288;C4318478
change from baseline in mean $nmbr$ h dbp mmhg,C0392747;C0443172;C1705241;C4319952;C0033727;C0439475;C0369286;C0441932;C0564385;C4528284
fish oil n $nmbr$,C0016157
demographic and medical variables,C0011298;C0199168;C0439828;C0205476
coronary disease,C0010068;C1956346
class l ll heart failure,C0456387;C1518526;C1705943;C0018801;C0018802;C4554158
cardiac and echocardiography parameters,C0018787;C1522601;C0013516;C0449381
sinus rhythm at baseline,C0232201;C0168634;C1442488
$nmbr$ lead ecg heart rate beats min,C0439385
left atrial dimension cm,C2950135
left ventricular hypertrophy on echo,C0149721;C3484363
left ventricular ejection fraction af history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
paroxysmal af,C0235480
persistent af,C0344434;C4049859
time since first af diagnosis yrs,C0040223;C3541383
class i or iii aad use in $nmbr$ months before enrollment,C0441885;C1319793;C2698967;C0042153;C0457083;C1947944;C1516879;C1696073;C3888021
acei or arb,C3888198
figure $nmbr$ occurrence of primary endpoint in pre speci ed subgroups,C0243132;C1554210;C2745955;C0332152;C1079230;C0740175;C2257086;C3669034
placebo every $nmbr$ weeks n $nmbr$,C0032042;C1696465;C1706408;C0439230
evolocumab $nmbr$ mg every $nmbr$ weeks n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0439230
placebo monthly n $nmbr$,C0032042;C0332177;C1696465;C1706408
evolocumab $nmbr$ mg monthly n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ldl cholesterol at baseline mmol l ldl cholesterol at screening,C0023824;C0202117;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
other lipid parameters,C0023779;C0449381
apolipoprotein b g l,C1447574;C4319541
apolipoprotein a $nmbr$ g l,C1447574;C4319541
$nmbr$ $nmbr$ o $nmbr$ $nmbr$ $nmbr$,C0483204
lipoprotein a nmol l,C0065058;C0439282;C0125953;C1096202;C1439335
hscrp nmol l,C0439282
unbound pcsk $nmbr$ nmol l,C0439282
figure $nmbr$ treatment di erences between evolocumab and placebo in mean percentage changes from baseline in ldl cholesterol at week $nmbr$ and the associations with sex age bmi lipid lowering therapy and baseline ldl cholesterol concentrations a doses administered every $nmbr$ weeks b doses administered monthly error bars are $nmbr$ ci bmi body mass index na not available,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0032042;C1696465;C1706408;C0168634;C1442488;C0332174;C0439230;C0871236;C0023824;C0086045;C0202117;C0178602;C1521801;C0743559;C1608199;C0597484;C1272460;C1546968;C1879645;C4049872;C4552882;C0686905
black or african,C0005680;C0027567;C0085756;C0439541
american,C0596070
region no c,C0017446;C0205147
central south,C0205099;C1710133;C1879652
america,C0002454
otherd,
duration of t $nmbr$ dm y,C0449238;C2926735
taking antihypertensive medication at baseline no e,C0003364
dbp $nmbr$ mmhg,C0536221;C0439475;C3813197;C4281799
on antihypertensive medication at baseline n,C0003364;C0168634;C1442488
saxa dapa met n $nmbr$,C0428210;C1550543;C4317104
saxa met n $nmbr$,C0428210;C1550543;C4317104
dapa met n $nmbr$,C0428210;C1550543;C4317104
hba $nmbr$ c category,C0683312;C3889287
$nmbr$ and $nmbr$ and,
$nmbr$ $nmbr$ mmol mol,C3829066
ppg mg dl,C1418888;C0439269
baseline hba $nmbr$ c subgroup,C1079230;C1515021
baseline mean sd [mmol mol],C0168634;C2699239;C1442488;C3829066
adjusted mean change from baseline $nmbr$ ci [mmol mol],C0392747;C0443172;C1705241;C4319952;C3829066
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
mean $nmbr$ ci difference vs saxa dapa met,C1705241;C1705242;C0428210;C1550543;C4317104
$nmbr$ to $nmbr$ to,
age subgroup y,C0001779;C1079230;C1515021
x n,
proportion $nmbr$ ci adjusted for baseline hba $nmbr$ c,C0008107;C3259781;C0456081;C0019016;C1825777;C3538758
$nmbr$ to $nmbr$ to $nmbr$ mmol mol,C3829066
secukinumab $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
age years $nmbr$,C1510829
weight kg $nmbr$,C0022718;C0439209;C4054209
time since psoriasis diagnosis years $nmbr$,C0556970;C0011900;C1704338;C1704656
pasi score $nmbr$,C0449820;C4050231
bsa involved $nmbr$,C1314939
iga mod $nmbr$ score n,C0011860;C0449820;C4050231
$nmbr$ moderate disease,C0205081;C0012634;C1881878;C4049705;C4049706;C4085643;C4321335
$nmbr$ severe disease,C1836348
psa reported n,C0684224;C0700287;C4319718
conventional agents,C0450442;C1254351;C1521826
topical,C0332237
phototherapy previous systemic treatment n,C0031765;C0678812
biologic,C0005515;C0205460
anti p $nmbr$,
anti tnf,C1448177
efficacy endpoints,C1280519;C2349179;C1707887
visit,C0545082;C1512346;C2826704
japanese subpopulation,C0376247;C1257890;C1556094
week,C0332174;C0439230
secukinumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
pasi $nmbr$,C4528685
iga $nmbr$ $nmbr$,C2825347
abatacept plus mtx n $nmbr$,C1619966;C0025677;C1417487
abatacept monotherapy n $nmbr$,C1619966
mtx n $nmbr$,C0025677;C1417487
age year median,C0549183;C0876920;C2347635;C2348144;C2939193
weight kg median,C0549183;C0876920;C2347635;C2348144;C2939193
female sex number,C0237753;C0449788
white race number,C0237753;C0449788
geographic region number,C0237753;C0449788
row,C1552840;C1552846
ra symptom duration year,C0439234;C0439508
ra symptom duration,C0449238;C2926735
rf positive number,C0035448;C3812269;C0201660;C0748398;C1547111
tender joint count $nmbr$ joints,C0451530
swollen joint count $nmbr$ joints,C0451521
patient global assessment $nmbr$ $nmbr$ mm vas,C0042815;C3536884;C3827561
physician global assessment $nmbr$ $nmbr$ mm vas,C0042815;C3536884;C3827561
pain $nmbr$ $nmbr$ mm vas,C0042815;C4330985;C4554674
physical function $nmbr$ $nmbr$ short form $nmbr$ subscale,C0597240;C0700329
missing number n,C0237753;C0449788
median $nmbr$ $nmbr$ number n,C0237753;C0449788
haq di number,C0237753;C0449788
symptom duration,C0449238;C2926735
median $nmbr$ $nmbr$ years number n,C0439234;C0237753;C0449788
$nmbr$ months number n,C0439231;C0237753;C0449788
pain $nmbr$ mm vas,C0042815;C4330985;C4554674
median $nmbr$ number n,C0237753;C0449788
erosion,C0333307;C1880549;C1959609;C3887524
q $nmbr$ $nmbr$ $nmbr$ q $nmbr$ $nmbr$ $nmbr$ number n,C0237753;C0449788
q $nmbr$ $nmbr$ $nmbr$ number n,C0237753;C0449788
osteitis,C0029400
q $nmbr$ $nmbr$ q $nmbr$ $nmbr$ $nmbr$ number n,C0237753;C0449788
q $nmbr$ $nmbr$ $nmbr$ q $nmbr$ $nmbr$ number n,C0237753;C0449788
q $nmbr$ $nmbr$ number n,C0237753;C0449788
synovitis,C0039103
device group n $nmbr$,C0441848
age mean sd [range] y,C0001779;C2699239;C1514721;C2348147;C3542016
$nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ ],
heart rate mean sd [range] beats min,C0018810;C2699239;C1514721;C2348147;C3542016;C0439385
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$ ],
blood pressure mean sd [range] mm hg,C0428886;C2699239;C1514721;C2348147;C3542016;C0439475
body mass index mean sd [range]a,C0005893;C2699239;C0578022;C1305855;C1514721;C2348147;C3542016
chads $nmbr$ scoreb,C0007928;C1413373
mean sd [range],C0444504;C2699239;C2347634;C2348143;C1514721;C2348147;C3542016
risk factors for stroke no,C0035648;C1553898
previous ischemic stroke ortia,C0205156;C0948008;C1552607
lv ejection fraction mean sd [range],C0489482;C2699239;C2700378;C1514721;C2348147;C3542016
classification of af no,C0008902;C0008903;C0678229
onsetofaf no,
previous warfarin use no,C0042153;C0457083;C1947944
source,C0449416;C1705919;C4521696
device group,C1706365
history of tia or stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0038454;C4554100
prior years taking warfarin,C0332152;C0043031;C2826257
median $nmbr$ mm,C4330985;C4554674
continued thienopyridine n $nmbr$ subjects,C0681850;C1550501;C1706203;C2349001;C2697811
placebo n $nmbr$ subjects,C0681850;C1550501;C1706203;C2349001;C2697811
subject characteristics,C0681884;C1519021;C1706465
current cigarette smoker or within past year,C3173209;C3241966;C0439234;C0439508
positive stress test,C0015260;C3494508
indication for pci,C0392360;C3146298
treatment characteristics,C0039798;C1521970;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
des type at index procedure,C0011702;C0455713;C4551552
everolimus eluting,C0541315
paclitaxel eluting,C0144576
zotarolimus eluting,C1700035
sirolimus eluting,C0072980
$nmbr$ des type,C0332307;C1547052
number of treated lesions,C0449791;C1522326
number of treated vessels,C0237753;C0449788
number of stents,C0237753;C0449788
minimum stent diameter,C4054490;C0038257
total stent length,C1444754;C1706316
lesion characteristics,C1286326
n $nmbr$ lesions,C0369718;C0221198;C0441922
treated vessel s,C1522326;C0005847
native coronary,C0302891;C0018787
lad,
rca,
venous graft,C0181074;C0332835;C1961139
arterial graft,C0450140
modified acc aha lesion class b $nmbr$ or cj,C4072694;C0221198;C1546698;C0007481
continued thienopyridine n,C0549178;C1120149
hr $nmbr$ and $nmbr$ cl,C0596019
no current tobacco use,C0040335;C0543414;C0841002;C3853727
no prior pci,C0332152;C4049621;C2826257
no prior cabg,C0332152;C0010055;C2826257
clinical or lesion rf for st,C0205210;C0035448;C0201660;C0748398;C1547111
no clinical or lesion rfs for st,C0205210;C0341703;C0036056;C3272372
any clinical or lesion rf for st,C0205210;C0035448;C0201660;C0748398;C1547111
european union,C0015179
aspirin dose at randomization,C4696290;C0034656
thienopyridine type,C0332307;C1547052
clopiodogrel,
des type,C0332307;C1547052
zotarolimust,
americas n $nmbr$,C0002454;C0596070
russia georgia n $nmbr$,C0017452;C0017454
ejection fraction nyha class n,C0489482;C1882083;C2700378
stratum n,
any cardiovascular disease history n,C1880008
insulin treated,C0021641;C1533581;C1579433;C3714501;C1522326
percutaneous coronary intervention or coronary artery bypass graft surgery n,C1532338;C0010055
angina n,C0002962
sodium,C0037473;C0597484;C3541959;C3714642
estimated glomerular filtration rate ml min per $nmbr$ $nmbr$ m $nmbr$,C3811844;C0439445
bnp pg mlt,C0030827;C4553833;C0072225;C1266240
nt probnp pg mlt,C0669479;C4553833;C0754710
angiotensin converting enzyme or angiotensin receptor blocker,C0022709;C1452534;C0034787;C1622222
long acting nitrate,C0028125;C0699857;C3848573
bnp indicates brain natriuretic peptide and nyha new york heart association,C0054015;C1095989;C1417808;C2982014;C0459867
tcomparison of proportion of patients with nyha class lll iv heart failure,C1709707;C0030705;C0018801;C0018802;C4554158
data reported as n or median quartiles $nmbr$ $nmbr$,C1511726;C3245479;C3714741;C0684224;C0700287;C4319718;C0549183;C2828255;C0876920;C2347635;C2348144;C2939193
tamong those enrolling via bnp stratum the study qualifying bnp or,C0054015;C1095989;C1417808;C2982014;C0557651;C2603343;C1514624
nt probnp values were reported in $nmbr$ of $nmbr$ patients enrolled in this stratum,C0669479;C0042295;C0754710;C0588446;C4684790
$nmbr$ $nmbr$ values were not collected for $nmbr$ patients $nmbr$ $nmbr$ who were enrolled,C0042295;C1516695;C1516698;C4684790
before a change to the enrollment form was implemented in august $nmbr$ bnp,C0392747;C0443172;C1705241;C4319952;C4520547;C0054015;C1095989;C1417808;C2982014
values were reported for $nmbr$ patients in the spironolactone group and $nmbr$,C0042295;C0588446;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
patients in the placebo group nt probnp values were reported for $nmbr$ patients,C0030705;C0669479;C0754710;C0588446
in the spironolactone group and $nmbr$ patients in the placebo group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C0030705;C0032042;C1696465;C1706408
p regional difference,C0369773;C0682132;C2603361
p treatment by region interaction,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
no with event [incidence rate per $nmbr$ patient y],C0441471;C4019010;C1708485;C0030705
hr $nmbr$ ci p value,C0008107;C1709380;C3259781
$nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ ],
aborted cardiac arrest,C0018790;C4553105
hospitalization for heart failure,C3898876
recurrent heart failure,C0018801;C0018802;C4554158
$nmbr$ events[ $nmbr$ $nmbr$ ],C0441471;C3541888
irr $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C4082285
all cause hospitalization,C0015127;C0019993;C1524003
doubling of creatinine,C0205173;C1705764
creatinine $nmbr$ $nmbr$ mg dl,C0010294;C0439269;C1561535
hyperkalemia potassium $nmbr$ $nmbr$ mmol l,C0020461;C1532563;C4552983
or $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
or $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
hypokalemia potassium,C0032821;C0202194;C0304475;C0597277;C3714637
figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use,C1274040;C1546471;C2825142;C0021641;C0008976;C1533581;C1579433;C3714501;C0392747;C0443172;C1709707;C0030705;C0019016;C2825507;C1825777;C3538758;C0005910;C1305866;C0007222;C0679831;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C3538987;C0035648;C4048877;C4318503;C0020538;C1963138;C0360714;C0042153;C0457083;C1947944
abbreviations cv cardiovascular cvd cardiovascular disease glip glipizide hba $nmbr$ c glycated hemoglobin met metformin saxa saxagliptin se standard error,C0019045;C1710181
amlodipine lisinopril chlorthalidone comparison,C0008294;C1707455
no in trial stroke n $nmbr$ $nmbr$,C0008976;C0038454;C4554100
in trial nonfatal or fatal stroke n $nmbr$ $nmbr$,C0150312;C0008976;C0332285;C1707101;C1302234;C0038454;C4554100;C1705232
education in years mean sd,C0013621;C0013622;C0013658;C0039401
lipids medications,C0013227;C0802604;C2598133;C4284232
blood pressure in mm hg mean sd,C0428886;C0488053
sbp at visit $nmbr$,C0085805;C0545082;C1512346;C2826704
dbp at visit $nmbr$,C0536221;C3813197;C4281799
pulse in beats minute mean sd,C0232117;C0391850;C1947910
eligibility risk factors n,C0035648;C1553898
history coronary revascularization,C0019664;C0877341;C0019665;C0262512;C0262926;C1705255;C2004062
major st depression or t wave inversion,C0041696;C1269683;C0520888
hdl c $nmbr$ mg dl,C3715113;C0439269
lvh by echo or ecg,C0149721;C0058928;C1655045;C1623258
history chd,C0280604;C3542407
atrial fibrillation on baseline ecg n,C0344434;C0168634;C1442488
baseline gfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n,C0017654;C0439445;C1424601;C0369718;C0441922
biochemical measures mean sd,C0079809;C2699239;C1879489
in trial $nmbr$ year rates per $nmbr$ se total events number at risk,C1264674;C1444641
in trial and post trial $nmbr$ year rates per $nmbr$ se total events number at risk,C0150312;C0008976;C0332285;C1707101;C1264674;C1444641
chlor,C0308648
$nmbr$ fe black,C0005680;C0027567;C0085756;C0439541
ment,C0084844;C1538994
women t,C0043210
no atrial fibrillation,C0004238;C0344434;C1963067
chd at baseline,C0280604;C3542407
no chd at baseline,C0280604;C3542407
crcl at baseline,C1846718;C0168634;C1442488
prior stemi,C1536220;C3538872
baseline medical therapy,C0168634;C0418981;C1442488
vorapaxar $nmbr$ y,C2974521
placebo r,C0205090;C0684010;C2603358
hx stroke tia,C0007787;C0917805;C1054154
no stroke tia,C0007787;C0917805;C1054154
no prior stemi,C1536220;C3538872
mi $nmbr$ months,C3810814;C0439231
rando in na,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882
not rando in na,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882
asa $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
des,C0011702;C4551552
no des,C0011702;C4551552
carotid revascularization,C0741968;C0581603
all ischemic stroke,C0948008
ischemic stroke with hemnrrhnaic cnnversinn,C0948008
ischemic stroke without hemorrhagic conversior,C0948008
table $nmbr$ baseline characteristics of randomized participants using insulin $nmbr$ iu day at baseline,C4684572;C0034656;C3815594;C1524063;C0021641;C0439465;C1533581;C1579433;C3714501
acr albumin to creatinine ratio dbp diastolic blood pressure fpg fasting plasma glucose sbp systolic blood pressure percentages may not total $nmbr$ due to rounding including american indian or alaskan native native hawaiian or other paci c islander multiple other and unknown data on dosing regimen are missing for $nmbr$ $nmbr$ of individuals some participants had more than one type of atherosclerotic disease at baseline,C0439165;C1549488;C1561533;C0439175;C0439810;C0332490;C0002460;C0238611;C0337920;C1165245;C0439064;C1511726;C3245479;C3714741;C1551393;C1705492;C3272743;C0679646;C0205447;C0457464;C0168634;C1442488
canagliflozin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
duration of diabetes years mean sd,C0449238;C2926735
insulin dose iu day median,C0549183;C0876920;C2347635;C2348144;C2939193
insulin therapy n,C0021641;C0039798;C0087111;C1363945;C1533581;C1579433;C3714501
basal plus bolus,C0205112;C1186706;C1511237;C1705509;C3812160
basal alone,C0205112;C0205171;C0439044;C0679994
bolus alone,C1186706;C1511237;C1705509;C3812160;C0205171;C0439044;C0679994
other drug therapy n,C0013216;C0013217
antithrombotic,
microvascular disease n,C0443258;C0012634
nephropathy,C0022658
atherosclerotic vascular disease n,C0004153
cerebrovascular,C1880018
peripheral,C0205100
dbp mmhg mean sd,C0439475;C2699239
total cholesterol mmol l mean sd,C0201950;C2699239;C0543421
triglycerides mmol l mean sd,C1532563;C2699239
hdl cholesterol mmol l mean sd,C0023822;C2699239;C0392885
ldl cholesterol mmol l mean sd,C0023824;C2699239;C0202117
ldl to hdl cholesterol ratio mean sd,C0428621;C1171408
egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n,C1739039;C0439445;C3811844;C3812682;C0369718;C0441922
acr mg g mean sd,C1300563;C2699239
figure $nmbr$ supplement effects of each dose of canagliflozin compared to placebo on hba $nmbr$ c in patient subgroups at $nmbr$ weeks,C1280500;C0178602;C0869039;C1114758;C1707455;C0032042;C1696465;C1706408;C0019016;C1079232;C1825777;C3538758
total study population n $nmbr$ $nmbr$,C3258257
$nmbr$ predicted arr n $nmbr$,C0681842;C1882327
caucasian ethnicity,C0015031;C0243103
past smoking,C0037369;C0453996;C1881674
never smoking,C0037369;C0453996;C1881674
alcohol use $nmbr$ drink wk,C0332174;C0439230
peri or postmenopausal,C0347985;C0232970
hormone replacement therapy use,C0042153;C0457083;C1947944
high density lipoprotein mg dl,C0023821;C0439269
high sensitivity c reactive protein mg l,C0006560;C0439268;C1413716;C4048285
blood pressure lowering medication use,C0240320
lipid lowering medication use,C0023779;C0441994;C2003888;C0240320
family history of cancera,C0241889
history of dyspepsia,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
randomized to aspirin use,C0034656;C3815594
$nmbr$ year predicted risk of,C0035647;C4552904
colorectal cancer,C0009402;C0346629;C1527249;C2984278;C3542412
non colorectal cancer,C0009402;C0346629;C1527249;C2984278;C3542412
major gastro intestinal bleeding,C0205082;C0017181;C0205164;C4318856;C4521762
total study population,C3258257
women $nmbr$ years,C0043210;C0439234
arr $nmbr$ ci,C0008107;C3259781
annt or bnnh $nmbr$ ci,C0008107;C3259781
$nmbr$ $nmbr$ to $nmbr$ a,
$nmbr$ b $nmbr$ b to $nmbr$ a,
$nmbr$ $nmbr$ to $nmbr$ b,
total adjusted weight of $nmbr$ $nmbr$ for gastrointestinal bleeding,C0005910;C0043100;C1305866;C1705104;C0017181
vi $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ff vi $nmbr$ mg $nmbr$ mg n $nmbr$,C0205999;C1319635
smoking status n former,C0205156;C0750523
total pack years mean sd,C1277691;C2699239
baseline fev $nmbr$ predicted,C0681842;C1882327
post bronchodilator reversibility fev $nmbr$ mean sd,C2599594;C2699239
previous pneumonia,C0205156;C0032285;C1552607
i ii fev $nmbr$ $nmbr$ predicted,C0681842;C1882327
iii fev $nmbr$ $nmbr$,C0439070;C3714541;C1705160
iv fev $nmbr$,C0022326;C3714541;C4265176
leukocytes $nmbr$ nl,C0027778;C0560008;C3892223
neutrophils $nmbr$ nl,C0027778;C0560008;C3892223
monocytes $nmbr$ nl,C0027778;C0560008;C3892223
lymphocytes $nmbr$ il,C0020898;C0021764;C0022271
hemoglobin mg dl,C0019046;C0439269
ctn l ng ml,C0917591;C0439275
angiographic data,C1511726;C3245479;C3714741
pci revascularization,C4049621;C0581603
odds ratio adj $nmbr$ cl,C0028873;C0596019
baseline hs crp tertiles mg i],C0024671;C0021966;C0221138;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ st $nmbr$ $nmbr$,C0036056;C3272372
$nmbr$ nd $nmbr$ $nmbr$,
$nmbr$ rd $nmbr$ $nmbr$,C0694666;C4553350
egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n $nmbr$ $nmbr$,C1739039;C0439445;C3811844;C3812682;C0369718;C0441922
egfr $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n $nmbr$ $nmbr$,C1739039;C0439445;C3811844;C3812682;C0369718;C0441922
egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n $nmbr$,C1739039;C0439445;C3811844;C3812682;C0369718;C0441922
established atherosclerotic disease,C0333482;C0012634
clinical and laboratory measurements,C0205210;C0681902
acr mg mmol,C0567349;C2348885
acr,C1412134;C1515941
$nmbr$ $nmbr$ to $nmbr$ $nmbr$ mg mmol,C0567349;C2348885
baseline cv medications,C0013227;C0802604;C2598133;C4284232
b blockers,
baseline anti hyperglycemic medications,C0013227;C0802604;C2598133;C4284232
egfr $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
saxagliptin $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
saxagliptin $nmbr$ $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
saxagliptin $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
cv death mi ischemic stroke,C0011065;C0948008;C1306577;C4082313;C4552775
cv death mi ischemic stroke hospitalization for hf coronary revascularization ua,C0019993;C0877341
hospitalization for hf,C0019993;C0018488;C1313497;C1538440;C3273279
$nmbr$ yr km n,C0439234;C3887676
s,
egfr $nmbr$ $nmbr$,C1739039;C3811844;C3812682
cv death ml ischemic stroke hosp for hf cor revasc ua,C0011065;C0948008;C1306577;C4082313;C4552775
hosp for hf,C0018488;C1313497;C1538440;C3273279
primary renal endpoint,C2986535;C0022646
primary renal endpoint or death,C2986535;C0022646;C0011065;C1306577;C4082313;C4552775
hosji fcrhypoglycemia,
major hypoglycemia,C0020615;C4553659
ebria,C1917247
initiation of insulin,C0589507;C1158830;C1704686
any new anti hyperglycemic rx,C1425688;C1521941;C2709207
worsened,C1457868;C4084902
no change,C0392747;C0443172;C1705241;C4319952
improved,C0184511;C0332272;C1561611;C4084203
olodaterol $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
tiotropium $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
tiotropium $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
tiotropium olodaterol $nmbr$ $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
tiotropium olodaterol $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
participants n,C0679646
$nmbr$ $nmbr$ i $nmbr$,C0021966;C0221138
$nmbr$ i $nmbr$ $nmbr$,C0021966;C0221138
$nmbr$ $nmbr$ i i,C0021966;C0221138
$nmbr$ i $nmbr$ $nmbr$ $nmbr$,C0021966;C0221138
$nmbr$ i $nmbr$ $nmbr$ i $nmbr$,C0021966;C0221138
$nmbr$ ii $nmbr$ $nmbr$,C1710602;C4082587
pre bronchodilator screening fev $nmbr$ ml,C0439526;C1705224;C3887665
i $nmbr$ $nmbr$,C0021966;C0221138
i $nmbr$ i $nmbr$ $nmbr$,C0021966;C0221138
ii $nmbr$ $nmbr$,C1710602;C4082587
post bronchodilator screening fev $nmbr$ ml,C0439526;C1705224;C3887665
i $nmbr$ $nmbr$ ii,C1710602;C4082587
i $nmbr$ $nmbr$ i,C0021966;C0221138
change from pre to,C0392747;C0443172;C1705241;C4319952
i $nmbr$ i $nmbr$,C0021966;C0221138
i $nmbr$ i i $nmbr$,C0021966;C0221138
post bronchodilator fev $nmbr$ ml,C0439526;C1705224;C3887665
$nmbr$ $nmbr$ ii $nmbr$,C1710602;C4082587
$nmbr$ i ii $nmbr$,C1710602;C4082587
fev $nmbr$ pred,C0032952;C0044955
$nmbr$ fevi ^ $nmbr$ pred,C0032952;C0044955
i $nmbr$ i,C0021966;C0221138
$nmbr$ fevi $nmbr$,C0849974;C1561566;C4528367
$nmbr$ fev $nmbr$,C3714541
ii $nmbr$ ii $nmbr$,C1710602;C4082587
baseline pulmonary medication,C0013227;C3244316;C4284232
sama $nmbr$,C1075468
i $nmbr$ i i $nmbr$ $nmbr$,C0021966;C0221138
i $nmbr$ i $nmbr$ i,C0021966;C0221138
lama,C0999593;C1416775
saba,
xanthines $nmbr$,C0043318;C3541955
baseline cardiovascular medication,C0168634;C0007220;C1442488
i $nmbr$ $nmbr$ $nmbr$,C0021966;C0221138
ii $nmbr$ i $nmbr$ $nmbr$,C0021966;C0221138
treatment comparison,C0039798;C1707455;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
ics usage,C0815320;C0457083;C4551720
adjusted mean se $nmbr$ ci,C0008107;C3259781
fevi auc $nmbr$ $nmbr$ l,C0429706;C0376690;C0849974;C1561566;C4528367
common study baseline,C0168634;C1442488
tiotropium olodaterol $nmbr$ $nmbr$ pg,C0030827;C0072225;C1266240
versus olodaterol $nmbr$ pg,C0030827;C0072225;C1266240
versus tiotropium $nmbr$ pg,C0030827;C0072225;C1266240
tiotropium olodaterol $nmbr$ $nmbr$ $nmbr$ pg,C0030827;C0072225;C1266240
versus tiotropium $nmbr$ $nmbr$ pg,C0030827;C0072225;C1266240
versus tiotropium olodaterol $nmbr$ $nmbr$ $nmbr$ pg,C0030827;C0072225;C1266240
trough fevi l,C0444506;C0429706;C0849974;C1561566;C4528367
dapagliflozin $nmbr$ mg day n $nmbr$,C2353951;C0439422
type $nmbr$ diabetes duration mean sd years,C1320657;C0439234
hba $nmbr$ c mean sd [mmol mol],C0019016;C2699239;C1825777;C3538758;C3829066
fpg mean sd mg dl [mmol l],C0444504;C0439269;C2347634;C2348143;C1532563
$nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
prior history of cardiovascular disease n,C0332152;C0455539;C2826257
concomitant medications n,C0521115;C0013227;C0802604;C2598133;C4284232
antihypertensives,C0003364
angiotensin receptor blocker and or ace,C0034787;C1622222;C1452534;C4284014
dapagliflozin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
hba $nmbr$ c in patients with baseline hba $nmbr$ c,C0019016;C0030705;C1825777;C3538758
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ ] $nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ ],
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ ] $nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ ] $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
hba $nmbr$ c in patients with baseline hba $nmbr$ c $nmbr$ to $nmbr$ to,C0019016;C0030705;C1825777;C3538758
hba $nmbr$ c in patients with baseline hba $nmbr$ c $nmbr$ $nmbr$ mmol mol [mmol mol] la n baseline sd adjusted mean change $nmbr$ ci placebo subtracted change se,C0030705;C3829066;C0008107;C0036919;C3259781
open label phase baseline week $nmbr$,C0332174;C0439230
randomized double blind reversal phase baseline week $nmbr$,C0332174;C0439230
total cohort,C0009247;C0599755
azl ma,C0024443;C3887485
azl m cldb,
azl m,
race no c,C0034510;C1706779;C3853635
baseline dbp mean sd mm hg,C0168634;C0439475;C1442488
baseline sbp mean sd mm hg,C0085805;C0439475
table $nmbr$ baseline demographics and clinical characteristics,C0011298;C1704791;C0683325
all patients who were treated with $nmbr$ dose of study medication yall patients who had a baseline and $nmbr$ on treatment hba $nmbr$ c measurement egfr estimated glomerular filtration rate fpg fasting plasma glucose hba $nmbr$ c glycated hemoglobin mdrd modification of diet in renal disease nph neutral protamine hagedorn oads oral antidiabetes drugs sd standard deviation,C0030705;C3272598;C0332293;C0013175;C0168634;C1442488;C1299575;C0457987;C0871420
linagliptin,C2746078
patients treated set n,C0030705;C0036849;C1442518;C1705195
males n,C0086582
renal function egfr according to mdrd n,C1739039;C3811844;C3812682
normal $nmbr$ ml min,C0205307;C0439445;C0231683;C0439166;C2347086;C4553972
mild impairment $nmbr$ to $nmbr$ ml min,C0221099;C0684336;C0439445
moderate impairment $nmbr$ to $nmbr$ ml min,C0221099;C0684336;C0439445
severe to end stage impairment $nmbr$ ml min,C0205082;C4050465;C4050466
patients full analysis sety n,C0030705;C0002778;C0936012;C1524024
hba $nmbr$ c mmol mol mean sd,C3829066;C2699239
time since diagnosis of diabetes mean sd,C0040223;C3541383
type of basal insulin n,C0457592
insulin detemir,C0537270
nph,C0020258;C0027442
concomitant oads n,C0521115
pioglitazone only,C0071097
metformin pioglitazone,C1635037
figure $nmbr$ mean hba $nmbr$ c change from baseline at week $nmbr$ by type of basal insulin a by age b and by renal impairment stage c fas locf egfr estimated glomerular filtration rate fas full analysis set hba $nmbr$ c glycated hemoglobin locf last observation carried forward nph neutral protamine hagedorn qd once daily,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230;C0457592;C0001779;C2986798;C0020258;C0332173;C0027442
baseline cardiovascular disease,C0168634;C0007222;C1442488
dilated cardiomyopathy,C0007193;C2984282
haemodynamics and lv function,C0019010;C4281788;C0031843;C0542341;C0700205;C1705273
lvdd mm,C4330985;C4554674
laboratory findings,C0587081
haemoglobin g dl,C0439267
albumin mg dl,C0001924;C0439269
baseline medication,C0013227;C3244316;C4284232
event total,C0439175;C0439810
lower,C0441994;C1548802;C2003888
upper,C1282910
age y o,C0001779
taci n $nmbr$,C0666480;C1425349;C4284230
paci n $nmbr$,C1165245
poci n $nmbr$,
laci n $nmbr$,C1420705;C3273314;C4281721
sss score,C0449820;C4050231
duration of symptoms h,C0436359;C0033727;C0369286;C0441932;C0564385;C4528284
treatment with candesartan,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
current or previous atrial fibrillation,C0521116;C1705970;C0004238;C0344434;C1963067
current use of an ace inhibitor,C1524063;C0003015;C4541021
thrombolytic treatment before randomization,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
composite vascular endpoint,C2349179;C2826544
functional outcome mrs $nmbr$ $nmbr$,C1522706;C2349188;C3714939;C3854213
taci,C0666480;C1425349;C4284230
candesartan $nmbr$ $nmbr$,C0717550
paci,C1165245
poci,
laci,C1420705;C3273314;C4281721
prespecified subgroups,C1079230
anacetrapib $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
fc ldl c mg dl,C2983605;C0439269
use of concomitant lipid modifying therapy,C1524063;C1707479
statin only n,C0360714;C0369718;C0441922
statin ezetimibe n,C0360714;C1142985
statin fibrate or,C0360714
niacin n,C0027996;C1142562
type of concomitant statin,C0332307;C1547052
simvastatin n,C0074554
atorvastatin n,C0286651
rosuvastatin n,C0965129
fc ldl c friedewald calculated,C2983605;C0444686;C1441506
low density lipoprotein choles,C0023823
terol hdl c high density lipoprotein cholesterol,C0023822
sd standard,C1442989;C2828392
deviation tg triglyceride,C0012727;C0041004;C0205419;C1705236
percent change from baseline at week $nmbr$,C3272907;C0332174;C0439230
difference in ls means $nmbr$ ci,C1705241;C1705242
ls mean $nmbr$ ci,C0008107;C3259781
vs placebo,C0032042;C1696465;C1706408
anacetrapib $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
baseline hdl c,C0168634;C3715113;C1442488
baseline fc ldl c,C0168634;C1442488
baseline tg,C0168634;C0337445;C1442488
statin only,C0360714
statin ezetimibe,C0360714;C1142985
statin fibrate or niacin,C0360714;C0027996;C1142562
dm n $nmbr$,C0011816;C3250443
no dm n $nmbr$,C0011816;C3250443
median age $nmbr$ $nmbr$ y,C0549183;C0001779;C0876920;C2347635;C2348144;C2939193
hyperlipidemia n,C0020473;C0428465;C4555212
current tobacco abuse n,C0521116;C0040336;C1705970
peripheral arterial disease n,C0085096;C1704436
history of heart failure n,C0455531
previous pci cabg n,C0205156;C0010055;C1552607
baseline gfr,C0017654;C1424601
baseline medications n,C0168634;C0013227;C0802604;C2598133;C4284232;C1442488
baseline diabetes mellitus therapy n,C0168634;C0948092;C1442488
lifestyle modifications,C0870811;C2960841
noninsulin therapy,C0039798;C0087111;C1363945
insulin therapy,C0021641;C0039798;C0087111;C1363945;C1533581;C1579433;C3714501
vorapaxar event rate n $nmbr$,C0441471;C0871208;C1521828;C4019010
placebo event rate n $nmbr$,C0032042;C0441471;C4019010;C1696465;C1706408
cvd mi or stroke,C0007222;C3810814;C0038454;C4554100
cvd or mi,C0007222;C3810814
cvd mi stroke or recurrent ischemia urgent revascularization,C0038454;C4554100;C0022116;C0581603;C4321499
cvd mi stroke or recurrent ischemia urgent revascularization or hospitalization for unstable angina,C0038454;C4554100;C0022116;C0581603;C4321499;C0019993;C0002965
recurrent ischemia urgent revascularization,C0022116;C0581603;C4321499
hospitalization for unstable angina,C0019993;C0002965
patients treated with statins n $nmbr$,C0030705;C0332293;C0360714
patients not treated with statins n $nmbr$,C0030705;C0332293;C0360714
mean bmi kg m $nmbr$,C0022718;C0439209;C4054209
creatinine clearance n,C0812399
planned treatment duration n,C4528394
index event n,C0600653;C0441471;C4019010;C0918012;C1552854;C1637833;C2986546
only dvt,C0149871;C2926618;C3899446
pe dvt,C0149871;C2926618;C3899446
index event not confirmed,C0441471;C4019010;C0521093;C0750484
immobilization at randomization n,C0020944;C4048292
active cancer at randomization n,C0006826;C0998265;C1306459
ischemic heart disease n,C0010054;C0151744
ischemic cerebrovascular disease n,C0475224;C0007820
asa use at baseline n,C0042153;C0457083;C1947944
asastoppedat randomization n,C0034656
recurrent vte statin use vs non use,C0042153;C0457083;C1947944
asa use at baseline,C0042153;C0457083;C1947944
no asa use at baseline,C0042153;C0457083;C1947944
no cardiac disease,C0018799
major bleeding statin use vs non use,C0042153;C0457083;C1947944
included in this study n $nmbr$,C0332257;C0557651;C2603343
patients with early cd n $nmbr$,C0030705;C0007928;C0034283;C4552032
disease duration year median,C0549183;C0876920;C2347635;C2348144;C2939193
crp median mg dl,C0549183;C0439269;C0876920;C2347635;C2348144;C2939193
crp $nmbr$ $nmbr$ mg dl n,C3890735;C0439269;C4048285
cdai score mean s d,C0449820;C0444504;C2347634;C2348143;C4050231
gastrointestinal area involved n total n,C0017446;C0205146
upper gastrointestinal tract,C3203348
baseline crohn s disease medications,C0168634;C0010346;C1442488;C0013227;C0802604;C2598133;C4284232
systemic corticosteroids n,C4053960
budesonide n,C0054201
$nmbr$ asa compounds n,C0004057;C3853627
history of bowel resections n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
early crohn s disease,C1279919;C0010346;C0012634
non early crohn s disease,C1279919;C0010346;C0012634
remission component of variable,C0449432;C1705248
azathioprine monotherapy,C0004482
infliximab monotherapy,C0666743
infliximab combination therapy,C4076075
p valuer,C0369773;C0401806;C2603361
crj,
mhi,
crpnonr,
cr mh,C0026514;C2930980
cr crpnorr,C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
mh crpnorr,C0026514;C2930980
cr mh crpnorr,C0201975;C0026514;C2930980;C3539604;C3711669;C4084730;C4553336;C4553337
[ $nmbr$ ci],C0008107;C3259781
a aza treatment ref,C0004482;C1425988
ifx treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
combination treatment ifx aza,C0020823;C0004482
previous cd related surgery ref a,C0007928;C1425988;C0034283;C4552032
no previous cd related surgery $nmbr$,C0038894;C0038895;C0543467;C1274039
b aza treatment ref,C0004482;C1425988
history of bowel resection ref,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
no history of bowel resections,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
c kza treatment ref,C0039798;C1425988;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
no hospitalization in the past $nmbr$ months prior to baseline ref,C0019993;C0439231;C0168634;C1425988;C1442488
hospitalization in the past $nmbr$ months prior to baseline,C0019993;C0439231;C0168634;C1442488
no history of extra intestinal manifestations of ibd ref,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
history of extra intestinal manifestations of ibd,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
d aza treatment ref,C0004482;C1425988
no steroid use at baseline ref,C0281991;C0168634;C1442488
on steroid at baseline,C0038317;C0168634;C1442488
e aza treatment ref,C0004482;C1425988
reslizumab n $nmbr$,C1869620
median age years iqr,C0549183;C1510829;C0876920;C2347635;C2348144;C2939193
mean body mass index kg mq,C0005893;C0024853;C0578022;C1305855
$nmbr$ $nmbr$ $nmbr$ i,C0021966;C0221138
mean time since diagnosis years,C0556970;C0011900;C1704338;C1704656
mean ics use at enrolment pg,C0042153;C0457083;C1947944
oral corticosteroid use at enrolmentt,C0239126
laba use at enrolment,C0042153;C0457083;C1947944
mean prebronchodilation l,C0444504;C2347634;C2348143
mean predicted value prebronchodilation,C0444504;C0681842;C1882327;C2347634;C2348143
mean reversibility,C0444504;C0449261;C2347634;C2348143
mean aqlq total score t,C3533236
mean acq $nmbr$ scores,C3533236;C2919686
mean asui scored,C0444504;C2347634;C2348143;C0449820
saba use in past $nmbr$ days,C0042153;C0457083;C1947944;C0439228
mean number of puffs per day,C0444504;C0237753;C0449788;C2347634;C2348143;C0332173;C0439228;C0439505
mean blood eosinophil count cells per pl,C0444504;C0200638;C2347634;C2348143
mean number of caes in past $nmbr$ months number per patient ],C0444504;C0237753;C0449788;C2347634;C2348143;C0439231;C0030705
reslizumab,C1869620
place,C0442504;C1533810;C1704765;C1882509
rate ratio $nmbr$ cl,C0456603;C0596019;C1547037
ocs at baseline,C0168634;C1442488
$nmbr$ $nmbr$ o $nmbr$ o $nmbr$,C0483204
ics plus laba,C0815320;C4551720
ics no laba,C0815320;C4551720
body mass index kg mj previous diagnosis,C0005893;C0332132;C0578022;C1305855
use of concomitant lipid lowering treatment,C1524063;C0023779
statin with ezetimibe,C0360714;C1142985
type of concomitant statin by daily dose,C0332307;C1547052;C2348070
simvastatin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
atorvastatin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
pravastatin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
fluvastatin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
baseline lipid and lipoprotein values,C0168634;C0023779;C1442488;C0023820;C0042295
apo a $nmbr$ g l,C1447574;C4521365
lp a pmol l,C0065058;C0439284;C1439335;C4553379
age s $nmbr$ years n $nmbr$ $nmbr$,C1510829
baseline tg level n $nmbr$ $nmbr$,C0168634;C0337445;C1442488
baseline tg level n $nmbr$ $nmbr$ $nmbr$ $nmbr$ mg dl,C0168634;C0439269;C1442488
statin only n $nmbr$ $nmbr$,C0360714;C0369718;C0441922
statin ezetimibe n $nmbr$ $nmbr$,C0360714;C1142985
other n $nmbr$ $nmbr$ ],C0369718;C0441922
simvastatin n $nmbr$ $nmbr$,C0074554
atorvastatin n $nmbr$ $nmbr$,C0286651
rosuvastatin n $nmbr$ $nmbr$,C0965129
diabetics yes n $nmbr$ $nmbr$,C0241863;C1549445;C1705108;C1710701
diabetics no n $nmbr$ $nmbr$,C0241863;C0369718;C0441922
baseline ldlc level n $nmbr$ $nmbr$ ^ $nmbr$ $nmbr$ mg dl,C0168634;C0439269;C1442488
baseline ldlc level n $nmbr$ $nmbr$ $nmbr$ $nmbr$ mgzdl,C0168634;C0441889;C0456079;C1547707;C2946261;C1442488
baseline hdl c level n s $nmbr$ $nmbr$,C0168634;C0441889;C0456079;C1547707;C2946261;C1442488
baseline hdl c level n $nmbr$ $nmbr$ $nmbr$ $nmbr$ mg dl,C0168634;C0439269;C1442488
baseline tg level n $nmbr$ $nmbr$ s $nmbr$ $nmbr$ mg dl,C0168634;C0337445;C1442488;C0439269
other n $nmbr$ $nmbr$,C0369718;C0441922
baseline ldlc level n $nmbr$ $nmbr$ s $nmbr$ $nmbr$ mg dl,C0168634;C0441889;C0456079;C1547707;C2946261;C1442488;C0439269
baseline ldlc level n $nmbr$ $nmbr$ $nmbr$ $nmbr$ mg dl,C0168634;C0439269;C1442488
baseline hdl c level n $nmbr$ $nmbr$ s $nmbr$ $nmbr$ mg dl,C0168634;C0441889;C0456079;C1547707;C2946261;C1442488;C0439269
p value $nmbr$ years,C1709380;C0439234
saxagliptin n $nmbr$ $nmbr$,C1611934
pharmacotherapy,C0013216;C0013217
$nmbr$ years placebo n $nmbr$ $nmbr$ saxagliptin n $nmbr$ $nmbr$,C0439234;C0032042;C1696465;C1706408
km event rate,C0871208;C1521828
interaction p value $nmbr$ $nmbr$,C1704675;C1709380
secondary,C0027627;C0175668;C0205436
nonfatal ischemic stroke,C0948008
hospitalization for due to,C0019993
doubling of creatinine level,C0205173;C1705764
initiation of dialysis renal transplantation or creatinine $nmbr$ $nmbr$ mg dl $nmbr$ mmol l,C0589507;C1158830;C1704686;C0439268
history of heart failure at baseline,C0455531;C0168634;C1442488
no history of heart failure at baseline,C0455531;C0168634;C1442488
baseline hba $nmbr$ c concentration,C0086045;C1446561;C3827302
bodyweight kg,C0022718;C0439209;C4054209
cardiovascular risk factors and history,C0850624;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
egfr ml min per $nmbr$ ^ $nmbr$ m,C1739039;C0439445;C3811844;C3812682
egfr $nmbr$ ml min per $nmbr$ ^ $nmbr$ m,C1739039;C0439445;C3811844;C3812682
time from index acs event to randomisation days,C0040223;C3541383;C0034656;C0439228
nyha chf class,C1882083;C0018802
baseline bnp concentration pg ml,C0054015;C0439297;C1095989;C1417808;C2982014
baseline concomitant cardiovascular medications,C0168634;C0007220;C1442488
ace inhibitor arb or both,C0003015;C3888198;C4541021
mras,C1335594;C1367476
primary mace endpoint,C2986535;C0349381;C0949745;C1445339
non fatal myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
$nmbr$ $nmbr$ s $nmbr$ $nmbr$ t,C2603360
pinteraction for treatment and history of heart failure,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0455531
secondary mace endpoint,C4528314;C0349381;C0949745;C1445339
urgent revascularisation due to unstable angina,C0581603;C0002965
cardiovascular death and hospital admission for heart failure,C0011065;C1306577;C4082313;C4552775;C0184666;C0018801;C0018802;C4554158
hospital admission for heart failure,C0184666;C0018801;C0018802;C4554158
normal responder n $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
sensitive responder n $nmbr$,C0020517;C0332324;C1522640
highly sensitive responder n $nmbr$,C0439822
median age [interquartile range] yr,C0549183;C0001779;C0876920;C2347635;C2348144;C2939193;C1711350;C0439234
atrial fibrillation no,C0004238;C0344434;C1963067
qualifying risk factors no,C1514624;C0035648;C1553898
chads $nmbr$ score mean sd,C0444504;C2699239;C2347634;C2348143
previous exposure to a vitamin k antagonist no current or former never,C0332157;C1096489;C2267235;C0521116;C1705970;C0205156;C0750523
medications at time of randomization no,C0013227;C0802604;C2598133;C4284232
digoxin or digitalis preparations,C0012265;C0304520
asia pacific and south africa,C0003980;C0037712
edoxaban higher dose vs warfarin,C2975435;C0444956;C0043031
edoxaban lower dose vs warfarin,C2975435;C0445550;C1708745;C0043031
higher dose,C0444956
lower dose,C0445550;C1708745
pinteraction,
any overt bleed,C0019080
normal responder,C0205307;C0231683;C0439166;C2347086;C4553972
sensitive,C0020517;C0332324;C1522640
highly sensitive,C0439822
major or clinically relevant non major bleed,C0205082;C0205164;C4318856;C4521762;C0019080
clinically relevant non,C2347946;C1518422
background therapy,C0039798;C0087111;C1363945
su,C0038642;C1705534
biguanide,C0005382;C3537187;C4317165
agi,C1299007
dpp $nmbr$ inhibitor,C1414174;C1999216
study drug,C0013175
empagliflozin,C3490348
metformin open label,C0025598;C1709323
time since diagnosis of t $nmbr$ dm,C0040223;C3541383
figure must be in supplement is not in paper,C0242295;C1947943;C2348609;C1518422;C0030351;C1547566
ticagrelor $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
multivessel coronary artery disease no total no,C0010054;C0010068;C1956346;C0439175;C0439810
history of pci no total no t,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0439175;C0439810;C2603360
$nmbr$ prior myocardial infarction no,C0027051;C0428953;C2926063;C3810814;C4552959
qualifying events,C1514624;C0441471;C3541888
years since myocardial infarction,C0439234;C0027051;C0428953;C2926063;C3810814;C4552959
type of myocardial infarction no,C0332307;C1547052
unknown type,C0332307;C1547052
medication at enrollment no,C0013227;C3244316;C4284232
aspirin at any dose,C4696290
ticagrelor $nmbr$ mg $nmbr$ year km,C0024671;C3887676;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
placebo $nmbr$ year km,C0032042;C3887676;C1696465;C1706408
age at randomization,C0001779;C0034656
median $nmbr$ kg,C0022718;C0439209;C4054209
second prior mi,C0205436;C3810814;C0457385;C0565930;C1561503;C1705190
second mi,C0205436;C3810814;C0457385;C0565930;C1561503;C1705190
no second mi,C0205436;C3810814;C0457385;C0565930;C1561503;C1705190
no multivessel disease,C0012634
non endstage renal dysfunction,C1565489;C3279454
no renal dysfunction,C1565489;C3279454
heparin alone n $nmbr$,C0019134;C0205171;C0439044;C0679994;C0770546
heparin plus tirofiban n $nmbr$,C0019134;C0770546
type of ml no,C0332307;C1547052
symptom onset to hospital arrival median iqr h,C4086878;C0019994;C1510665
killip class $nmbr$ no,C1881332
anemia no total,C0002871;C1000483;C4554633;C0439175;C0439810
crusade bleeding score mean sd ^,C0019080;C2699239
$nmbr$ moderate or high bleeding risk no total,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0332167;C3272283;C4050568;C4319571;C0439175;C0439810
heparin tirofiban n $nmbr$,C0019134;C0247025;C0770546
no of events total no $nmbr$,C0439175;C0439810
$nmbr$ years old,C0439234;C0580836
class ll iv,C0456387;C1518526;C1705943;C0022326;C4265176
transradial,
transfemoral,
previous cv events,C0441471;C3541888
crusade score,C0449820;C4050231
lad artery,C0003842;C0226004
non lad artery,C0003842;C0226004
killip ciass,
ciass ll iv,C0022326;C4265176
ciass i,C0021966;C0221138
creatinine ciearance,C0010294;C1561535
$nmbr$ mi min,C0702093;C1524029;C3813700
arteriai access,C0444454;C1554204
no of events totol no,C0441471;C3541888
placebo golimumab $nmbr$ mg $nmbr$ mga b,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ mg $nmbr$ mgc,C0024671;C3888239;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ mg $nmbr$ mgb,C0024671;C0373680;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
randomized patients,C0034656;C0030705;C3815594
psa modified shs $nmbr$ $nmbr$,C3810537;C0392747;C3889737;C3813209
ptga $nmbr$ $nmbr$ cm vas,C0042815;C3536884;C3827561
pasi score $nmbr$ $nmbr$ d,C0449820;C4050231
methotrexate use at baseline,C0042153;C0457083;C1947944
placebofigolimumab $nmbr$ mg $nmbr$ mgt,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
golimumab $nmbr$ mg $nmbr$ mgt,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mtx use at baseline,C0042153;C0457083;C1947944
no mtx use at baseline,C0042153;C0457083;C1947944
no patients with,C0030705
available data,C1511726;C3245479;C3714741
myocardial infarction at presentation n $nmbr$,C0027051;C0428953;C2926063;C3810814;C4552959
no myocardial infarction at presentation n $nmbr$,C0027051;C0428953;C2926063;C3810814;C4552959
thienopyridine n $nmbr$,C1120149
non white race,C0007457;C0043157
any risk factor for stent thrombosis,C0035648;C3897493
renal insufficiency or failure,C0035078;C1565489;C0231174;C0680095
more than $nmbr$ vessels stented,C0005847;C0038257
more than $nmbr$ lesions per vessel,C0221198;C0005847
lesion length $nmbr$ mm,C4330985;C4554674
bifurcation lesion,C0221198;C1546698
in stent restenosis of des,C3272317;C0011702;C4551552
vein graft stented,C0042449;C0181074;C0332835;C1961139;C0038257
unprotected left main stented,C0205091;C0038257;C0443246;C1552822
thrombus containing lesion,C0087086;C0302148;C3146237;C0332256;C2700400;C0221198;C1546698
prior brachytherapy,C0332152;C0006098;C2826257
thienopyridine at randomization,C1120149;C0034656
type of des at index procedure,C0332307;C1547052;C0184661;C2700391;C3274430;C3539779
$nmbr$ type,C0332307;C1547052
no of treated lesions,C1522326;C0221198
no of treated vessels,C1522326;C0005847
no of stents,C0038257
total stent length mm,C4330985;C4554674
lesions,C0221198
native coronary artery lesions,C0205042;C0221198
in stent restenosis,C3272317
extreme tortuosity,C0205403;C0333076;C3641272;C4085555
heavy calcification,C0006660;C0006663;C0175895;C1533591;C1879982;C2242558
modified acc or aha lesion class b $nmbr$ or c,C0175754;C0282160;C3541413;C0050451;C0221198;C1546698;C0772110
figure $nmbr$ cumulative incidence of stent thrombosis according to randomization arm for patients with panel a and without panel b acute myocardial infarction,C0021149;C0220856;C0446516;C3715044;C4553528;C0441833;C1706365;C1999270;C0155626;C3541950
age y median $nmbr$ th to $nmbr$ th percentiles,C0001779;C0039725;C0039738;C1420718;C4282123;C4285344
qualifying type of atherosclerosis n,C1514624;C0332307;C1547052
selected clinical characteristics n,C1707391;C0683325
peripheral revascularization,C0205100;C0581603
any established coronary artery disease,C0010054;C0010068;C1956346
any established peripheral arterial disease,C0085096;C1704436
ace inhibitors or arb,C0003015;C3888198
lipid lowering medications,C0023779;C0441994;C2003888;C0013227;C0802604;C2598133;C4284232
vorapaxar placebo $nmbr$ yr km rate,C0871208;C1521828
planned thienopyridine at baseline,C1120149;C0168634;C1442488
mitt population n $nmbr$,C0032659;C1257890
bmi $nmbr$ kg m $nmbr$ population n $nmbr$,C0022718;C0439209;C4054209;C0032659;C1257890
canagliflozin $nmbr$ mg vs sitagliptin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
hba $nmbr$ c $nmbr$ $nmbr$ bp $nmbr$ $nmbr$ mm hg ldl c $nmbr$ mg dl,C0967300;C0439269
dapagliflozin $nmbr$ mg group n $nmbr$,C0024671;C0441848;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
subjects $nmbr$ years of age n,C1510829
bw mean sd kg,C0022718;C0439209;C4054209
qualifying cv event n,C1514624;C3538987;C0441471;C4019010;C4048877;C4318503
not reported,C0684224;C0700287;C4319718
time from most recent qualifying,C0040223;C3541383;C1514624
cv event years,C0441471;C0439234;C4019010
duration of hypertension n,C0449238;C2926735
seated sbp mean sd mmhg,C0085805;C0439475
seated dbp mean sd mmhg,C0277814;C0439475;C1283233
type $nmbr$ diabetes duration years,C1320657;C0439234
fpg mean sd mmol l,C0444504;C1532563;C2347634;C2348143
type of treatment n,C0455708
oad,
oad plus insulin,C0021641;C1533581;C1579433;C3714501
daily insulin dose mean sd iu,C0049272;C0439453;C0694756
oads n,
aceis arbs,C3888198
full analysis set,C0002778;C0036849;C1442518;C1705195;C0936012;C1524024
hba $nmbr$ c at $nmbr$ weeks,C0019016;C0439230;C1825777;C3538758
change from baseline adjusted mean $nmbr$ ci,C0392747;C0443172;C1705241;C4319952
responders of three item end point at $nmbr$ weeks,C2349179;C2826544;C0439230
seated sbp at $nmbr$ weeks mmhg,C0277814;C0085805;C1283233
bw at $nmbr$ weeks kg,C0005910;C0006041;C2986891
patients with bw decrease of $nmbr$ in patients with baseline bmi of $nmbr$ kg m $nmbr$,C0030705;C0005910;C0006041;C2986891;C0022718;C0439209;C4054209
fpg mmol lt,C0023376;C0230426;C3887647;C4521399
insulin lispro mix $nmbr$,C0205430;C1421951;C1720722;C4553942
caucasians n $nmbr$,C0007457;C0043157
asians n $nmbr$,C0078988
mg dl fpg mmol l,C0439268
phg,
fhg,
fig $nmbr$ responses at baseline and endpoint to insulin glargine and insulin lispro mix $nmbr$ by baseline hba $nmbr$ c quartiles a fasting hyperglycaemia fhg area under the curve auc and b postprandial hyperglycaemia phg auc,C0871261;C0168634;C1442488;C2349179;C2826544;C0205430;C1421951;C1720722;C4553942;C0019016;C2828255;C1825777;C3538758;C0015663;C0020456;C0376690;C4552833;C1855520
all patients on maximally tolerated statin other llt,C0030705;C0360714;C2347090
aiirocumab n $nmbr$,
any cv history risk factors n,C0035648;C1553898
chd history n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
chd risk equivalents n,C1282512;C0439185;C4049980
lipid medication n,C0023779;C0013227;C3244316;C4284232
any statin,C0360714
high dose statin use at screening,C0042153;C0457083;C1947944
other llt use,C0042153;C0457083;C1947944
ezetimibe use,C0042153;C0457083;C1947944
lipid parameters mg dl mean sd,C0439269;C2699239
ldl c calculated,C0444686;C1441506
ldl c measured,C0444706;C3541902
lp a,C0065058;C1439335;C4553379
fasting tgs,C0015663;C1156212;C1537574
aiirocumab,
placebo estimated mean,C0444504;C2347634;C2348143
consistency of effect,C0332529;C1547017
estimated mean,C0444504;C2347634;C2348143
not hispanic latino,C1518424;C0086528
statin treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
high intensity statin,C4081854;C0360714
no high intensity statin,C4081854;C0360714
other llt at randomization,C2347090;C0034656
statin with other llt,C0360714;C2347090
statin without other llt,C0360714;C2347090
history of ml or ischemic stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0948008
prior history ml or stroke,C0439526;C1705224;C3887665;C0038454;C4554100
no prior ml or stroke,C0439526;C1705224;C3887665;C0038454;C4554100
moderate ckd at randomization,C1561643;C0034656
no moderate ckd,C0205081;C1561643;C1881878;C4049705;C4049706;C4085643;C4321335
diabetes at randomization,C0011847;C0011849
estimated mean $nmbr$ cl,C0444504;C0596019;C2347634;C2348143
age years mean $nmbr$ sd,C1510829;C2699239
weight kg mean $nmbr$ sd,C0005910;C2699239;C0043100;C1305866;C1705104
bmi kg m $nmbr$ mean $nmbr$ sd,C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
hba $nmbr$ c mean $nmbr$ sd,C0019016;C2699239;C1825777;C3538758
hba $nmbr$ c mmol mol mean,C0444504;C2347634;C2348143
fsg mg dl mean sd,C0439269;C2699239
diabetes duration years mean sd,C0011847;C2699239;C0011849
took prior antihyperglycemic agent any,C1515187;C0450442;C1254351;C1521826
sulfonylureas,C0038766;C3653359
concomitant lipid lowering therapy any,C0585943
fibrates,C1449704;C3540783
niacin,C0027996;C1142562
duration of diabetes years t,C0449238;C2926735
qualifying hba $nmbr$ c,C1514624;C0019016;C1825777;C3538758
urinary albumin creatinine ratio mg g,C0486293;C1300563;C1318293
prior cardiovascular disease,C0332152;C0007222;C2826257
$nmbr$ coronary stenosis,C0242231
prior cerebrovascular disease,C0332152;C0007820;C2826257
prior peripheral arterial disease,C0085096;C1704436
nyha class $nmbr$ or higher,C1882083;C0205250
antihyperglycemic,C0020616
ezetimibe,C1142985
age subgroups,C0001779;C1079230
^median,C0549183;C0876920;C2347635;C2348144;C2939193
asia pacific and other,C0003980
diabetes duration subgroups,C0011847;C1079230;C0011849
diabetes therapy at baseline alone or in combination,C3274787;C3539002;C0205171;C0439044;C0679994;C0205195;C1947911;C3811910
thiazolidinedione includes pioglitazone,C0289779;C1257987;C3537039;C0332257;C1552866;C2700399;C0071097
hba $nmbr$ c subgroups,C0019016;C1079230;C1825777;C3538758
renal function subgroups,C0232804;C1079230
systolic blood pressure subgroups,C0488055;C1079230;C0871470;C1306620
diastolic blood pressure subgroups,C0428883;C1079230;C1305849
body mass index subgroups,C0005893;C1079230;C0578022;C1305855
^median median,C0549183;C0876920;C2347635;C2348144;C2939193
a $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
medications taken at time of randomization statins,C0013227;C0802604;C2598133;C4284232;C1883727;C0034656
asteria i ii,C1710602;C4082587
glacial $nmbr$,
placebo n [ $nmbr$,C0032042;C1696465;C1706408
omalizumab $nmbr$ mg n [ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
time since diagnosis of ciu csuf y,C0040223;C3541383
positive cu index test z n,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
no of previous ciu csu medications mean median,C0205156;C0013227;C0802604;C2598133;C4284232;C1552607
previous use of systemic steroids n,C0281991
total ige levelx iu ml median range,C1514721;C2348147;C3542016
in clinic uask,C0150312;C0002424;C0442592;C0332285;C1707101
weekly iss,C1740819;C1845118
weekly number of hives score,C0237753;C0449788
weekly size of largest hives score,C0456389;C0042109
overall dlqi score,C0282416;C3897059;C1561607
angioedema present n,C0002994;C0150312;C0449450
primary key efficacy endpoint,C2986535
change from baseline to week $nmbr$ in weekly iss,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230;C1740819;C1845118
additional endpoints,C1524062;C2349179
change from baseline to week $nmbr$ in uas $nmbr$,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230
change from baseline to week $nmbr$ in weekly no of hives score,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230;C0042109;C0449820;C4050231
median $nmbr$ ci time to weekly iss mid response up to week $nmbr$ wk f,C0040223;C3541383;C0871261;C1704632;C1706817;C2911692
$nmbr$ $nmbr$ ne ne,C0027608;C0028219;C3538705
hr vs placebo $nmbr$ ci,C0008107;C3259781
patients with weekly iss mid response n v,C0030705;C0332174;C0871261;C1704632;C1706817;C2911692
change from baseline to week $nmbr$ in weekly size of largest hive score,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230;C0456389;C0042109;C0221232
change from baseline to week $nmbr$ in dlqi scorez,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230;C3899393
proportion of angioedema free days from week $nmbr$ to week $nmbr$ x,C1709707;C0002994;C0332174;C0439230
lvef $nmbr$ n $nmbr$ $nmbr$ a,C0428772;C0488728
prior angiography showing stenosis $nmbr$ n $nmbr$ $nmbr$ a,C0332152;C0002978;C2826257;C1547282;C0678234;C1261287;C2632116
bnp $nmbr$ pg ml n $nmbr$ $nmbr$,C0054015;C0439297;C1095989;C1417808;C2982014
tni ultrapositive $nmbr$ $nmbr$ g l n $nmbr$ $nmbr$,C0439294;C0456615
medications during hospitalization or at discharge,C0013227;C0802604;C2598133;C4284232;C0012621;C0030685;C2926602
ranotazine vs placebo km failure rate,C0231174;C0680095
hr $nmbr$ s ci,C0008107;C3259781
primary ep cvd mi ri,C0035487;C1826843
$nmbr$ $nmbr$ vs $nmbr$ $nmbr$,
$nmbr$ $nmbr$ $nmbr$ s $nmbr$ $nmbr$ $nmbr$,
no pci,C4049621
$nmbr$ $nmbr$ vi $nmbr$ $nmbr$,C0205999
ranolazine vs placebo km failure rate,C0073633;C0231174;C0680095
hr $nmbr$ s a,
rec ischemia requiring revasc,C0022116;C4321499;C0378365
rec ischemia leading to hosp,C0022116;C4321499;C0332152;C1522538
rec ischemia,C0022116;C4321499
due to ecg changes,C0855329
due worsening angina,C0678226;C3146286;C0332271;C1457868;C1546960;C0002962
no po,C0032729;C0442027
pa,C0030428;C3541314
no pa,C0030428;C3541314
rec ischemia leading to hasp,C0022116;C4321499;C0332152;C1522538
rec ischemia due to ecg changes,C0022116;C4321499
rec ischemia due worsening angina,C0678226;C3146286;C0332271;C1457868;C1546960;C0002962
de $nmbr$ mg bid n $nmbr$ $nmbr$,C0011198;C0017480;C3541240
warfarin n $nmbr$ $nmbr$,C0043031
gfr ckd epi,C1561643;C0162734;C4281721
ckd stages,C1561643;C1306673
$nmbr$ $nmbr$ to $nmbr$ ml min,C0439445
history of stroke see tia,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
hypertension requiring medical treatment,C0020538;C1963138;C0679624
previous vka use stratified randomization,C0042153;C4687737;C0457083;C1947944
naive,
experienced,
duration of previous use of vka months,C1881378;C2826775
q $nmbr$ q $nmbr$,
normal study termination,C1549081;C1692758
concomitant medication $nmbr$,C0013227;C3244316;C4284232
p gp inhibitor,C3898062
vitamins,C0042890;C3540032;C3714649
oral hypoglycemic,C0359086
alpha blocker other vasodilator,C0001641;C0042402;C3537240
previous vka use,C0042153;C0457083;C1947944
$nmbr$ $nmbr$ _ $nmbr$ $nmbr$,
adjusted mean se change from baseline,C0392747;C0443172;C1705241;C4319952
p value vs previous time point,C1709380;C0205156;C2348792;C1552607
calculated annual decline mean se,C0332181;C0036919
adjusted mean _ se change from baseline,C0392747;C0443172;C1705241;C4319952
elderly patients n $nmbr$,C0870602
very elderly patients n $nmbr$,C0442824;C0870602;C2984081
p between age groups,C0441849;C1959644
olmesartan along with ccb n $nmbr$,C1098320;C0006684
olmesartan along with diuretic n $nmbr$,C1098320;C0012798
grade of hypertension,C0441800;C0919553;C3244287
grade $nmbr$,C0441800;C0919553;C3244287
previous history of cardiovascular events,C2004062
drinking,C0001948;C0684271
number of visits median,C1549755;C0549183;C0876920;C2347635;C2348144;C2939193
number of visits mean sd,C1549755;C0444504;C2347634;C2348143
sbp during the follow up period mmhg,C0085805;C0589120;C1522577;C1704685;C3274571
dbp during the follow up period mmhg,C0536221;C3813197;C4281799
uncover $nmbr$,
ixekizumab every $nmbr$ weeks n $nmbr$,C3489764;C0439230
nx,C0445085
bmi kg per m $nmbr$,C0022718;C0439209;C4054209
psoriasis duration years,C0033860;C0439234
percentage of bsa involved,C0439165;C1549488;C1561533;C1314939
spga $nmbr$,
pasi,C4528685
qids sr $nmbr$,C4331197
napsit,
itch nrs,C2240043;C4050142
previous therapy,C0039798;C0087111;C1363945
topical prescription,C0033080;C1521941
topical non prescription,C0332237;C1518422;C0033080;C1521941
phototherapy,C0031765
non biological systemic,C0445097;C0205373
biological,C0005532;C0205460
qva $nmbr$ $nmbr$ $nmbr$ ig od n $nmbr$,C0021027;C0229089;C0439164;C1512019;C3273373;C3665488;C0305052;C0360506
sfc $nmbr$ $nmbr$ ig bid n $nmbr$,C0021027;C0305052;C0360506
copd severity n a,C0024117;C0439793;C0522510;C1412502;C3714496
gold $nmbr$ groups,C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429
gold b,C0018026;C1304897
gold d,C0018026;C1304897
patients with prior copd related,C0030705;C0332152;C2826257;C0024117;C0439849;C0445223;C1412502;C3714496
ics users at baseline n,C1706077;C0168634;C1442488
postbronchodilator fev $nmbr$ reversibility,C2599594;C0449261
postbronchodilator fev $nmbr$ fvc,C2599594;C3714541
cat score,C0449820;C4050231
cat score category,C0683312;C3889287
$nmbr$ $nmbr$ mild,C2945599
$nmbr$ $nmbr$ moderate,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
$nmbr$ $nmbr$ severe,C0205082;C4050465;C4050466
$nmbr$ $nmbr$ very severe,C3641272;C4050419
bdi focal score,C0449820;C4050231
mmrc grade,C0441800;C0919553;C3244287
smoking history current smoker,C3173209;C3241966
smoking history ex smoker,C1519384;C0337664
copd severity mild moderate,C0439793;C0522510;C1299392
copd severity severe very severe,C0024117;C0205082;C4050465;C4050466;C1412502;C3714496
baseline ics use yes,C1549445;C1705108;C1710701
baseline ics use no,C0042153;C0457083;C1947944
copd exacerbation yes,C1549445;C1705108;C1710701
copd exacerbation no,C0740304
diabetics n $nmbr$,C0241863
non diabetics n $nmbr$,C1518422;C0241863
patients with dm n $nmbr$,C0030705;C0011816;C3250443
patients without dm n $nmbr$,C0030705;C0011816;C3250443
patients with dm vs patients without dm,C0030705;C0011816;C3250443
age\\yr,C0001779;C0439234
b $nmbr$ $nmbr$,
year,C0439234;C0439508
male sex \ no,C0086582
body mass index \ kg m $nmbr$,C0022718;C0439209;C4054209
ischemic stroke incl uncertain,C0948008;C0087130;C4085655
hba $nmbr$ c \n,C0019016;C1825777;C3538758
\mean sd,C0444504;C2699239;C2347634;C2348143
af type no,C0332307;C1547052
median crcl ml min,C0549183;C0439445;C0876920;C2347635;C2348144;C2939193
peripheral arterial disease no,C0085096;C1704436
baseline chads $nmbr$ a c,C0168634;C1442488
baseline cha $nmbr$ ds $nmbr$ vascb c,C0168634;C1420648;C1442488
patients without dm n $nmbr$ $nmbr$,C0030705;C0011816;C3250443
stroke or systemic,C0038454;C4554100;C0205373
embolism,C0013922;C1704212
incl uncertain,C0087130;C4085655
ustekinumab $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
psoriasis,C0033860
patients with psoriasis $nmbr$ of body surface area,C0030705;C0005902
pasi score,C0449820;C4050231
dlqi score,C3897059
swollen joint count,C0451521
tender joint count,C0451530
haq di score,C0449820;C4050231
dactylitis in $nmbr$ digit,C0239161;C0582802;C3241971
dactylitis score,C0449820;C4050231
enthesitis score,C0449820;C4050231
dose mg week,C0332174;C0439230
mean dose sd mg week,C0332174;C0439230
dose mg day,C0178602;C0439422;C0869039;C1114758
mean dose sd mg day,C0178602;C0439422;C0869039;C1114758
non steroidal anti inflammatory drugs,C0003211
placebo to ustekinumab $nmbr$ mgt,C0032042;C1696465;C1706408
ustekinumab,C1608841
patients randomized no,C0030705;C0034656;C3815594
clinical efficacy at week $nmbr$,C0087113;C0332174;C0439230
patients no,C0030705
acr response by baseline weight,C0871261;C1704632;C1706817;C2911692
no total no,C0439175;C0439810
acr response by baseline mtx use no total no acr $nmbr$,C0871261;C1704632;C1706817;C2911692;C0439175;C0439810;C1412134;C1515941
good moderate response,C0205170;C4085643
change from baseline median iqr,C0392747;C0443172;C1705241;C4319952
patients with improvement $nmbr$ $nmbr$,C0030705;C2986411
patients with $nmbr$ bsa at baseline no,C0030705;C0168634;C1442488
pasi $nmbr$ at week $nmbr$,C4528685;C0332174;C0439230
no total no t,C0439175;C0439810;C2603360
pasi $nmbr$ no total no $nmbr$,C4528685;C0439175;C0439810
pasi response by baseline weight no total no pasi $nmbr$,C0871261;C1704632;C1706817;C2911692;C0439175;C0439810;C4528685
pasi response by baseline mtx use no total no pasi $nmbr$,C0871261;C1704632;C1706817;C2911692;C0439175;C0439810;C4528685
$nmbr$ $nmbr$ $nmbr$ $nmbr$ continued,C0549178
patients with dactylitis at baseline no,C0030705;C0239161;C0168634;C1442488
dactylitis score at baseline median iqr week $nmbr$,C0449820;C4050231
score improvement baseline to week $nmbr$ median iqr,C0168634;C1442488
percent improvement baseline to week $nmbr$ median iqr,C0168634;C1442488
patients with $nmbr$ dactylitis digit at week $nmbr$ enthesitis,C0030705;C0239161;C0332174;C1282952;C0439230
patients with enthesitis at baseline no,C0030705;C1282952;C0168634;C1442488
enthesitis score at baseline median iqr week $nmbr$,C0449820;C4050231
patients with enthesitis at week $nmbr$ radiographic progression change from baseline to week $nmbr$ in psa modified total shs score,C0030705;C1282952;C0392747;C0443172;C1705241;C4319952;C0332174;C0439230;C2964552;C3889737
mean $nmbr$ sd,C0444504;C2699239;C2347634;C2348143
median iqr change from baseline to week $nmbr$ in psa modified total shs score,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230;C2964552;C3889737
median iqr mean $nmbr$ sdchange from baseline to week $nmbr$ by weight group and mtx use weight,C0444504;C0168634;C1442488;C2347634;C2348143;C0332174;C0439230;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C0005910;C0043100;C1305866;C1705104
$nmbr$ kg mtx use,C0042153;C0457083;C1947944
patients with change from baseline in psa modified total shs score $nmbr$,C0030705;C0392747;C0443172;C1705241;C4319952;C0168634;C1442488
low risk n $nmbr$ $nmbr$,C3272281;C3538919
high risk n $nmbr$ $nmbr$,C0332167;C3272283;C4050568;C4319571
time since diagnosis of copd years,C0556970;C0011900;C1704338;C1704656
spirometry,C0037981
respiratory medication taken at baseline n,C0418986;C1883727;C0168634;C1442488
other steroids,C0038317
ics laba free or fdc,C0332296;C1880497;C1996904;C0340427;C1413520;C3539652
patient classification,C0008902;C0008903;C0678229
salmeterol,C0073992
tiotropium vs salmeterol,C0213771;C0073992
number of patients with events,C2360800;C0441471;C3541888
low risk,C3272281;C3538919
infrequent exacerbator,C0521114
frequent exacerbator,C0332183
low risk ics,C0815320;C4551720
high risk ics,C0815320;C4551720
olodaterol $nmbr$ pg,C0030827;C0072225;C1266240
tiotropium $nmbr$ $nmbr$ pg,C0030827;C0072225;C1266240
tiotropium $nmbr$ pg,C0030827;C0072225;C1266240
gold $nmbr$ $nmbr$,C0018026;C1304897
current smoker n post bronchodilator screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
mean sd fevi ml,C0439526;C1705224;C3887665
mean sd change from pre to post bronchodilator fevi ml,C2599594;C3481639
mean sd fevi fvc,C0802741;C3815113
mean sd of predicted normal fevi,C2699239;C0205307;C0231683;C0439166;C2347086;C4553972
gold $nmbr$ $nmbr$ n $nmbr$,C0018026;C1304897
olodaterol sgg,C2934193
tiotropium olodaterol $nmbr$ $nmbr$,C4032878
mean sd change from pre to post bronchodilator fevi nil,C2599594;C3481639
gold $nmbr$ $nmbr$ $nmbr$,C0018026;C1304897
mean sd eevi ml,C0439526;C1705224;C3887665
mean sd fevi evc,C0013903;C0429711;C1414479
mean sd of predicted normal eevi,C2699239;C0205307;C0231683;C0439166;C2347086;C4553972
adjusted mean se fevi auco_ $nmbr$ ml,C0439526;C1705224;C3887665
adjusted mean se trough fevi ml,C0439526;C1705224;C3887665
gold $nmbr$,C0018026;C1304897
versus tiotropium $nmbr$ pg tiotropium olodaterol $nmbr$ $nmbr$ $nmbr$ pg,C4032878;C0030827;C0072225;C1266240
median interquartile range,C0549183;C1711350;C0876920;C2347635;C2348144;C2939193
saudi arabia,C0036243
time from pah diagnosis months,C0011900;C0556969;C1704338;C1704656
aetiology of pah,C0015127;C1314792;C1524003
familial,C0015576;C0241888
repaired congenital shunts,C0232180;C0542331;C1442858
drugs and toxins,C0013227;C3687832;C0040549
$nmbr$ min walk distance m,C0702093;C0429886;C1524029;C3813700
who functional class,C0205245;C0456387;C1518526;C1705943;C0542341;C2700217
nt probnp $nmbr$ pmol l $nmbr$,C0669479;C0439284;C0754710
baseline sildenafil dose mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ $nmbr$ $nmbr$ y,
body weight mean sd kg,C0022718;C0439209;C4054209
egfr mean sd ml min $nmbr$ $nmbr$ m $nmbr$,C0444504;C0439445;C2347634;C2348143
hdl cy,C0010622;C0332298;C2239193
baseline mean _ sd mg dl,C0168634;C0439269;C1442488
ls mean change from baseline _ se,C0392747;C0443172;C1705241;C4319952
ldl cz,C0206578
ldl c hdl cx,C3715113
baseline mean _ sd mg mg,C0168634;C1319635;C1442488
liraglutide n $nmbr$,C1456408
hispanic or latino ethnic groupf,C0086409;C0086528;C0015031;C0680174
body mass index categories no c,C0005893;C0683312;C0578022;C1305855
$nmbr$ $nmbr$ $nmbr$ overweight,C0497406
$nmbr$ $nmbr$ $nmbr$ obese class i,C3853264
$nmbr$ $nmbr$ $nmbr$ obese class ii,C3853263
$nmbr$ obese class iii,C1319441
fasting insulin tiu ml,C0015663;C0439526;C1705224;C3887665
free fatty acids mmol liter,C0015688;C0475211
prediabetes no $nmbr$,C0362046
estimated means and difference,C0750572;C1704970;C1705241;C1705242
mean baseline bmi,C0168634;C0578022;C1442488
liraglutide $nmbr$ $nmbr$ mg mean n,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
placebo mean n,C0032042;C0444504;C2347634;C2348143;C1696465;C1706408
pooled analysis,C0002778;C0936012;C1524024
bmi $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0578022
estimated response rate and odds ratio,C0750572;C0237629;C0028873
estimated odds ratio,C0750572;C0028873
number of previous anti tnf treatments for psoriatic arthritis,C0237753;C0449788;C0087111;C0003872
methotrexate use at randomisation,C0042153;C0457083;C1947944
systemic glucocorticoid use at randomisation,C0042153;C0457083;C1947944
patients with specific disease characteristics,C0683521;C0815172
psoriasis body surface area $nmbr$,C0033860;C0005902
dactylitis count,C0750480;C1705566
enthesitis count,C0750480;C1705566
baseline disease and quality of life scores,C0168634;C0012634;C1442488;C3476431
physician s global assessment vas,C0031831;C0804815;C0042815;C3536884;C3827561
pain vas,C0042815
patient s global assessment vas,C0030705;C0042815;C3536884;C3827561
odds ratio versus placebo $nmbr$ ci,C0028873;C0008107;C3259781
p value versus placebo,C1709380;C0032042;C1696465;C1706408
anti tnf naive patients,C1448177;C0030705
acr $nmbr$ response,C0871261;C1704632;C1706817;C2911692
pasi $nmbr$ response,C0871261;C1704632;C1706817;C2911692
anti tnf ir patients,C0022065;C0030705;C0022071;C1448132
czp mtx n $nmbr$,C0054841;C0025677;C1417487;C1861828;C1872109
pbo mtx n $nmbr$,C0031962;C0025677;C1417487
ra duration months,C0449238;C0439231;C2926735
$nmbr$ $nmbr$ months n,C0439231
previous dmards use n,C0205156;C0042153;C0457083;C1947944;C1552607
steroid use at baseline n,C0281991;C0168634;C1442488
high titre $nmbr$ times of uln n,C0040223;C1632851
titre u ml t,C0439340;C1880521;C2945590
rf positive n,C0035448;C0201660;C0748398;C1547111
bone erosion judged by physician n,C0587240;C0221191;C0031831;C0804815
ptgada mm,C4330985;C4554674
phgada mm,C4330985;C4554674
esr mm h,C3811131;C0456680
mmp $nmbr$ ng ml,C0623362;C0439275;C0919336
sdai,C3871128
mtss,
average weekly mtx dose mg week,C0332174;C0439230
parameter at baseline,C0549193;C1704769;C2350001
czp mtx,C0025677;C1417487
pbo mtx,C0025677;C1417487
mtss cfb mean sd,C0009002;C2699239;C1824728
anti ccp antibody u,C0003242;C0439148
rf iu ml,C0035448;C0439458;C0201660;C0748398;C1547111
concomitant mtx,C0025677;C1417487
average dose mg week,C0332174;C0439230
creatinine clearance category ml min no b,C0812399;C0439445
medical conditions no,C0012634;C0348080;C1705253;C3864998
previous cancerc,C0205156;C1552607
previousdistaldeep veinthrombosisorsuperficial vein thrombosis,C0042487
method used to diagnose the incident pulmonary embolism no,C0025663;C0449851;C0871511;C1273517;C0011900;C1551358;C0034065
high probability ventilation perfusion lung scanning,C0560738
spiralcomputedtomographyangiography,
associatedproximaldeep veinthrombosisatdiagnosis no,
characteristics of pulmonary embolism at inclusion,C1521970;C0034065;C0007637;C1512693
residual perfusion defect $nmbr$ on lung scan no,C0031001;C1457869;C4281794;C0203683
residual deep vein thrombosis no,C1609982;C0149871
systolic pulmonary arterial pressure mean sd mm hg,C0871470;C0439475
d dimer level mean sd ng mld,C0023522;C1539265;C3539688;C3539689
thrombophilia no e,C0398623
minor,C0026193;C0205165
major,C0205082;C0205164;C4318856;C4521762
treatmentofpulmonary embolismpriorto randomization,C0034656
warfarin no,C0043031
fluindione no,C0117899
acecoumarol no,
duration of initial anticoagulation mean sd mo,C0449238;C2926735
percentage of time in therapeutic inr range mean sd,C0439165;C1549488;C1561533;C0460097;C2699239
use of compression stockings no,C1524063;C0038348
main concomitant treatments no,C0205225;C0087111;C1542147
accp bleeding risk at inclusion no f,C3251812;C0007637;C1512693;C0016327
low no risk factor,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223;C0035648
moderate $nmbr$ risk factor,C0205081;C0035648;C1881878;C4049705;C4049706;C4085643;C4321335
high $nmbr$ risk factor,C0035648
p for i,C0369773;C2603361
previous cancer,C0006826;C0998265;C1306459
pe associated with dvt at diagnosis,C0070939;C1880476;C4284304;C0332281;C0149871;C2926618;C3899446;C0011900;C1704338;C1704656
time in therapeutic range before inclusion,C1554109;C0007637;C1512693
perfusion defectsatinclusion,C0031001;C4281794
right ventriculardysfunction atinclusion,C0205090;C0444532
d dimer levelsatinclusion,C0060323
$nmbr$ microg l,
accp score,C0449820;C4050231
compression stockings,C0038348
liraglutide $nmbr$ $nmbr$ mg day n $nmbr$,C1456408;C0439422
mean s d duration of diabetes years,C0449238;C2926735
women men,C0043210;C0025266
mean s d weight kg,C0022718;C0439209;C4054209
mean s d bmi kg m $nmbr$,C0022718;C0439209;C4054209
mean s d hba $nmbr$ c,C0444504;C0019016;C1825777;C3538758;C2347634;C2348143
mean s d fpg,C0444504;C2347634;C2348143
metformin no yes,C0025598;C1549445;C1705108;C1710701
basal insulin analogue insulin,C0650607;C2825028
detemir insulin glargine,C0537270;C0907402
basal insulin analogue dose coefficient,C0366513;C1707429
of variation iu,C0049272;C0439453;C0694756
liraglutide $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
baseline hba $nmbr$ c $nmbr$ $nmbr$,C0168634;C0019016;C1825777;C3538758;C1442488
east asian,C1707877;C0078988
non east asian,C1518422;C0078988
p value for east asian versus non east asian,C1709380;C0078988;C1518422
age years mean _ sd,C1510829;C2699239
weight of $nmbr$ kg n,C0005910;C0043100;C1305866;C1705104
crcl of $nmbr$ $nmbr$ ml min n,C1846718;C0439445
patients meeting the criteria to receive $nmbr$ mg of,C0030705;C0556656;C0243161;C1514756;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
edoxaban at randomization n,C2975435;C0034656
anatomic extent of qualifying event n x,C0220784;C0439792;C1514624;C0441471;C4019010
concomitant dvt n,C0521115;C0149871;C2926618;C3899446
right ventricular dysfunction n n j,C0242707;C1556315
causes of dvt or pe n,C0015127;C1314792;C0070939;C1880476;C4284304
non east asianf,C1518422;C1707877
edoxaban n $nmbr$ n n,C2975435
warfarin n $nmbr$ n n,C0043031
hr with edoxaban $nmbr$ ci,C2975435;C0008107;C3259781
event during overall,C0441471;C4019010
study period fatal pe,C0070939;C1880476;C4284304
death with pe not,C0011065;C1306577;C4082313;C4552775;C1518422
ruled out non fatal pe with or,C1446409;C0070939;C1880476;C4284304
without dvt dvt alone,C0149871;C2926618;C3899446;C0205171;C0439044;C0679994
event during on,C0441471;C4019010
treatment period index dvt event,C0441471;C4019010
during overall study period,C0439531;C1948053
index pe event during,C0441471;C4019010
overall study period,C0439531;C1948053
gaviscon da n $nmbr$,C0061146;C0011318;C3668815
bmi kg m $nmbr$ median range,C0022718;C0439209;C4054209;C1514721;C2348147;C3542016
erd n,
la grade a n f,C0441800;C0919553;C3244287;C0369718;C0016327;C0441922
la grade b n f,C1881342;C0016327
fdc $nmbr$ $nmbr$ g n $nmbr$,C0340427;C0439267;C1413520;C3539652
aclidinium $nmbr$ g n $nmbr$,C2699757;C0439267
formoterol $nmbr$ g n $nmbr$,C0060657;C0439267
number of exacerbations in previous $nmbr$ months,C0237753;C0449788;C0205156;C0439231;C1552607
prior copd medicationa n,C0332152;C0024117;C1412502;C3714496;C2826257
any copd medication,C0013227;C3244316;C4284232
e rs total scoreb,C0035970;C0439175;C0439810;C3714753;C3813325
overall night time copd symptom severity scorec,C0240526;C1319166
overall early morning copd symptom severity scorec,C0024117;C1319166;C1412502;C3714496
gold group n,C0018026;C0441848;C1304897
gold group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
fdc $nmbr$ $nmbr$ pg vs placebo,C0030827;C0072225;C1266240;C0032042;C1696465;C1706408
fdc $nmbr$ $nmbr$ pg vs aclidinium $nmbr$ pg,C0030827;C0072225;C1266240
fdc $nmbr$ $nmbr$ pg vs formoterol $nmbr$ pg,C0030827;C0072225;C1266240
aclidinium $nmbr$ pg vs placebo,C0030827;C0072225;C1266240;C0032042;C1696465;C1706408
formoterol $nmbr$ pg vs placebo,C0030827;C0072225;C1266240;C0032042;C1696465;C1706408
hcru a,
fdc $nmbr$ $nmbr$ pg,C0030827;C0072225;C1266240
rr $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C4554402
rro $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
aclidinium $nmbr$ pg,C0030827;C0072225;C1266240
formoterol $nmbr$ pg,C0030827;C0072225;C1266240
exact b,C2828393;C4050514
outcome type,C0332307;C1547052
outcome severity,C0439793;C0522510
any severity,C0439793;C0522510
moderate severity,C0439793;C0522510
baseline ics,C0815320;C4551720
with concomitant ics,C0815320;C4551720
without concomitant ics,C0815320;C4551720
rr $nmbr$ $nmbr$,C4554402
mtx sio mg week,C0332174;C0439230
mtx $nmbr$ and si $nmbr$ mg week,C0025677;C1417487;C0332174;C0439230
mtx $nmbr$ mg week,C0332174;C0439230
czp $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
czp $nmbr$ mg n lll,C0024671;C1261077;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
acr response acr $nmbr$,C1412134;C0871261;C1704632;C1706817;C2911692;C1515941
change from baseline in,C0392747;C0443172;C1705241;C4319952
das $nmbr$ esr mean sd das $nmbr$ esr remission,C0544452;C0687702
eda,C0162359;C1539327;C3539920;C3887494
mean change in radiographic end points shs mean sd,C0392747;C0443172;C1705241;C4319952
erosion score mean sd,C0333307;C2699239;C1880549;C1959609;C3887524
fsn score mean sd,C0444504;C2699239;C2347634;C2348143
teaes cases per $nmbr$ patient years ci,C0868928;C1533148
mtx $nmbr$ $nmbr$ mg week,C0332174;C0439230
czp $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
related to study druga,C0439849;C0445223
leading to study withdrawal,C0332152;C0557651;C2603343;C1522538
leading to death,C0332152;C0011065;C1306577;C4082313;C4552775;C1522538
gastrointestinal gi disorders,C0017178;C1708130;C3539617;C4050121
infections,C3714514
serious teaes,C0205404
most frequent gi disorders,C0332183;C0012634
most frequent infections,C0239998
most frequent non infectious teaesb,C0332183;C1518422
pyrexia,C0015967
rash,C0015230
contusion,C0009938
most frequent serious teaes,C0332183;C0205404
serious infections,C0205404;C3714514
serious gi disorder,C0205404;C0012634
pneumonia,C0032285
erysipelas,C0014733
disseminated tuberculosis,C0152915
investigations,C1261322
alanine aminotransferase increased,C0001899;C0057041;C1415274;C3887708;C0205217;C0442805
aspartate aminotransferase increased,C0004002;C0205217;C0442805
c group n $nmbr$,C0441848
nc group n $nmbr$,C0027964;C0441848;C0028407;C0067895;C0265987
systolic blood pressure mmhg mean sd,C0428886;C2699239
diastolic blood pressure mmhg mean sd,C0428886;C2699239
left ventricular systolic dysfunction n,C1277187;C1963159;C4553199
serum creatinine mg dl mean sd,C0201976;C2699239;C0600061
ldl cholesterol mg dl mean sd,C0023824;C2699239;C0202117
hdl cholesterol mg dl mean sd,C0023822;C2699239;C0392885
triglyceride mg dl mean sd,C0439269;C2699239
concomitant medications after randomization,C0013227;C0802604;C2598133;C4284232
aceis n,
b blockers n,
ca channel blockers n,C3887642;C0870261
statins n,C0360714
number of diseased vessels mean sd,C0237753;C0449788
left main disease n,C0205091;C0012634;C0443246;C1552822
type b $nmbr$ c lesions n,C4264484;C0221198
des implantation for restenosis n,C0021107;C0029976
sirolimus eluting stent use n,C0038257;C0042153;C0457083;C1947944
paclitaxel eluting stent use n,C0038257;C0042153;C0457083;C1947944
number of implanted stents n mean sd,C0237753;C0449788
total length of implanted stents mm mean sd,C0439175;C0449462;C0439810
rotablator use n,C0042153;C0457083;C1947944
aceis angiotensin converting enzyme inhibitors c candesartan des drug eluting stent egfr estimated glomerular filtration rate hdl high density lipoprotein ldl low density lipoprotein nc non candesartan,C0003015;C0151691;C2757044
aspirin only n $nmbr$ $nmbr$,C0004057;C0369718;C0441922
aspirin i clopidogrel n $nmbr$ $nmbr$,C0004057;C0021966;C0221138
history of hf,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
hf or lvef,C0018488;C1313497;C1538440;C3273279;C0428772;C0488728
type of event,C1561488
elevated cardiac markers,C0205250;C1271630;C3163633
use of parenteral antithrombotic,C1524063;C0030547;C4522267
selected baseline medications,C0013227;C0802604;C2598133;C4284232
aspirin $nmbr$ clopidogrel,C0004057;C0070166
apixaban vs placebo,C1831808;C0032042;C1696465;C1706408
rate n,C0871208;C1521828
cv death mi or ischemic stroke,C0011065;C3810814;C1306577;C4082313;C4552775;C0948008
stent thrombosis,C3897493
timi major bleeding,C0205082;C0019080;C0205164;C4318856;C4521762
timi major or minor bleeding,C0205082;C0205164;C4318856;C4521762;C0026193;C0019080;C0205165
bdmard naive,
bdmard ir,C0022065;C0022071;C1448132
tofacitinib $nmbr$ mg twice daily n $nmbr$,C0024671;C0585361;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
mean sd weight kg,C0022718;C0439209;C4054209
europe and canada,C0015176;C0006823
mean sd disease duration years,C0872146;C0439234
mean sd bmi,C0444504;C0578022;C2347634;C2348143
rf,C0035448;C0201660;C0748398;C1547111
anti ccp $nmbr$ units,C0439148;C1519795;C3853603
mean sd das $nmbr$ $nmbr$ esr,C0051767;C3811131;C0057671
mean sd sdai,C0444504;C3871128;C2347634;C2348143
mean sd cdai,C0683448;C1413248;C3273706
mean sd tender joint count,C0444504;C0451530;C2347634;C2348143
mean sd swollen joint count,C0444504;C0451521;C2347634;C2348143
mean sd pain vas,C0444504;C0042815;C2347634;C2348143
mean sd ptga vas,C0042815;C3536884;C3827561
mean sd pga vas,C0042815;C3536884;C3827561
mean sd crp mg l,C0444504;C0439268;C2347634;C2348143
mean sd esr mm h,C0444504;C0456680;C2347634;C2348143
previously taken methotrexate,C1883727;C0025677
previously taken dmards other than methotrexate,C0242708;C0025677
previously taken tnfi,C1883727
previously taken any other dmards n,C1883727;C0242708
abatacept,C1619966
anakinra,C0245109
rituximab,C0393022
tocilizumab,C1609165
tnfi no other bdmard taken t n,C1883727
one tnfi,C0205447
multiple tnfi,C0439064
other bdmards no tnfi taken t n,C1883727
tnfi and other bdmardst n,
one tnfi and,C0205447
other bdmard,
multiple tnfi and other bdmards,C0439064
parameter $nmbr$ ci,C0008107;C3259781
das $nmbr$ $nmbr$ esr,C0051767;C3811131;C0057671
haq di improvement $nmbr$ $nmbr$,C3826998;C2986411;C4321476
total ipss,C1019118;C1998280;C2827405;C3811063
age category n $nmbr$ years,C1510829;C0683312;C3889287
baseline sd,C0168634;C2699239;C1442488
end point sd,C2349179;C2699239;C2826544
ls mean change se,C0023668;C0036919
pbo adjusted ls mean change se,C0023668;C0036919
luts severity,C0439793;C0522510
mild moderate ipss $nmbr$,C1019118;C1998280;C2827405;C3811063
mean age sd,C0001779;C2699239
severe ipss $nmbr$ age group,C0027362;C2348001
lifestyle behaviours,C0004927;C0677505
body mass index bmi kg m $nmbr$ n $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
$nmbr$ years bmi,C0439234;C0578022
mean bmi sd,C0444504;C2699239;C2347634;C2348143
comorbidities and concomitant medications,C0009488;C0013227;C0802604;C2598133;C4284232
diabetes mellitus n yes,C1549445;C1705108;C1710701
$nmbr$ kg m $nmbr$ smokers,C0022718;C0439209;C4054209;C0337664
glycaemic control hba $nmbr$ c n,C0243148;C0019016;C1825777;C3538758;C1550141;C1882979;C2587213;C3274648;C4553389
diabetic therapy use n no therapy,C0039798;C0042153;C0457083;C1947944;C0087111;C1363945
oral agent,C0450442;C1254351;C1521826
glycaemic control group,C0009932
oral agent and or insulin therapy,C0450442;C1254351;C1521826;C0021641;C0039798;C0087111;C1363945;C1533581;C1579433;C3714501
hba $nmbr$ c $nmbr$ $nmbr$,C0019016;C1825777;C3538758
hyperlipidaemia n yes,C1549445;C1705108;C1710701
hyperlipidaemia therapy use n no lipid lowering agent therapy,C0020473;C0039798;C0087111;C1363945;C0428465;C4555212;C0585943
combined insulin oral hypoglycaemic agent use,C0240016
statin medication,C0013227;C3244316;C4284232
other lipid lowering medication,C0023779;C0441994;C2003888;C0013227;C3244316;C4284232
statin and or other lipid lowering agent therapy,C0360714;C0585943
hypertension n yes,C1549445;C1705108;C1710701
antihypertensive medication use n,C0003364;C0240320
number of antihypertensive medications used n no antihypertensive therapy,C1718138;C0585941
combined statin and other lipid lowering agent use,C0205195;C0360714;C0042153;C0457083;C1947944
type of antihypertensive medication use among patients using antihypertensive medications n,C0457591;C0030705;C1524063;C0003364
antihypertensive agent use,C0042153;C0457083;C1947944
centrally acting sympathomimetics,C3653511
number of antihypertensive agent reported,C0237753;C0449788;C0684224;C0700287;C4319718
$nmbr$ med at baseline,C4321267;C0168634;C1442488
$nmbr$ med at baseline cardiac disorder,C4321267;C0018799
cardiac disorder n,C0018799
cardiovascular disorder n,C0007222
no cardiovascular disorder $nmbr$,C0007222
ischaemic heart disease or cerebrovascular disorder n,C0010054;C0151744;C0007820
cardiac arrhythmia n,C0003811;C0264886;C1560249
luts bph characteristics,C0005001;C1521970;C1704272
combined cardiac failure cardiomyopathy or other cardiac disorder n luts severity n,C0018801;C0878544;C0018802;C0521117;C1292730
combined ischaemic heart disease and or cerebrovascular disorder,C0010054;C0151744;C0007820
mild to moderate ipss $nmbr$,C1019118;C1998280;C2827405;C3811063
mean total ipss sd,C0439175;C2699239;C0439810
mean ipss voiding subscore sd,C0042034;C2699239;C4067975
mean ipss storage sub score sd,C3533236;C2699239
mean ipss qol sd,C0444504;C2699239;C2347634;C2348143
combined cardiac failure cardiomyopathy or other cardiac disorders,C0018801;C0878544;C0018802;C0018799
$nmbr$ uln,C1519815
pi,C0122626;C0429863;C3537219;C3539772
ppci,
prior chf,C0332152;C0018802;C2826257
to $nmbr$,
killip class i,C2697844
timi risk score $nmbr$,C0035647;C0449820;C4050231;C4552904
inferior mi,C0340305;C3542426
baseline rst segment elevation mm,C4330985;C4554674
baseline rst segment,C0168634;C0441635;C1442488
deviation mm,C4330985;C4554674
q waves in the infarct territory at baseline,C0429089;C1305738;C0168634;C1442488
figure $nmbr$ relative risk plot of the $nmbr$ day composite endpoint of shock chf,C0242492;C0018802
upper panel infarct size groups and $nmbr$ day shock chf by treatment strategy lower panel infarct size groups and $nmbr$ day shock chf by treatment strategy and pre speci ed $nmbr$ hour time from symptom onset to treatment randomization cut off adjusted for thrombolysis in myocardial infarction risk score chf indicates congestive heart failure pi pharmacoinvasive ppci primary percutaneous coronary intervention uln upper limit normal,C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429;C0013806;C0018802;C0449244;C0034656;C1442160;C0456081;C0027051;C0428953;C2926063;C3810814;C4552959;C0205307;C0231683;C0439166;C2347086;C4553972
cyclosporine n $nmbr$,C0010592;C0010594
killip class at admission no total no,C1881332;C0184666;C0809949;C0439175;C0439810
previous ischemic heart disease no,C0010054;C0151744
treated with cabg no total no,C0332293;C0010055;C0439175;C0439810
treated with pci no total no,C0332293;C4049621;C0439175;C0439810
managed medically no total no,C1273870;C0439175;C0439810
previous heart failure no,C0018801;C0018802;C4554158
subgroup sex,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
cyclo,C1172566
p value for interaction $nmbr$ $nmbr$,C1709380;C1704675
no of events total,C0439175;C0439810
initial timi flow,C0205265;C3272266;C1279901;C1555582;C1705685
final timi flow,C0205088;C3272266;C1546485;C3853528
symptom onset,C4086878
$nmbr$ $nmbr$ s $nmbr$,
rentrop score,C0449820;C4050231
killip at baseline,C0168634;C1442488
proximal mainleft,C0205107;C4489236
medial distal diag,C0205098;C0348026
thrombus aspiration,C0220787;C0349707;C0700198;C2712334;C2827071
fh $nmbr$,
fh ii,C1854107
alirocumab n $nmbr$,C3491162
diagnosis of heterozygous familial hypercholester,C0011900;C1704338;C1704656
olaemia n,
genotyping,C1285573
clinical criteria $nmbr$,C0205210;C0243161
coronary heart disease n b,C0010054;C0010068;C1956346
coronary heart disease risk equivalents n c,C1277690;C0439185;C4049980
type $nmbr$ diabetes n d,C1320657
statin use n,C0360714;C0042153;C0457083;C1947944
high dose statin use n e,C0444956;C0042153;C0457083;C1947944
change from baseline ls means se,C0392747;C0443172;C1705241;C4319952
alirocumab,C3491162
prior history of ml or ischemic stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0948008
high intensity,C4081854
lowzmedium intensity,C0522510
dose of atorvastatin,C0178602;C0869039;C1114758
dose of rosuvastatin,C0178602;C0869039;C1114758
llt other than statin at randomization,C2347090;C0360714;C0034656
no thienopyridine,C1120149
tp vs no tp,C0036183;C3541334
weight $nmbr$ kg,C0022718;C0439209;C4054209
vascular history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
any coronary revascularization,C0877341
previous cabg total,C0439175;C0439810
previous pci total,C0439175;C0439810
previous stenting previous pci,C0038257;C4049621;C2348535
des previous stenting,C0038257;C2348535
time from qualifying mi,C0040223;C3541383;C1514624;C3810814
$nmbr$ $nmbr$ mo,C0026544;C0332177
n $nmbr$ yr km event rate,C0871208;C1521828
vora,
plac,C0048838
p int,C0369773;C3272375;C2603361
cv death mi stroke,C0038454;C4554100
cv death mi stroke ucr,C0011065;C0038454;C4554100;C1306577;C4082313;C4552775
ucr,
fracture during follow up,C0016658;C0589120;C1522577;C1704685;C3274571
no n $nmbr$ $nmbr$,C0369718;C0441922
age median iqr years,C1510829;C0549183;C0876920;C2347635;C2348144;C2939193
all others n,C1955473;C3539125
hispanic latino ethnicity n,C0086409;C0015031;C0243103
weight median sd kg,C0022718;C0439209;C4054209
bmi median sd kg m $nmbr$,C0022718;C0439209;C4054209
diabetes duration median iqr years,C0011847;C0439234;C0011849
prior heart failure n,C0018801;C0018802;C4554158
baseline measurements,C0168634;C0242485;C1442488
egfr median sd ml min,C0549183;C0439445;C0876920;C2347635;C2348144;C2939193
albumin to creatinine ratio,C0486293;C1318293
median sd mg mmol,C0567349;C2348885
hba $nmbr$ c median sd,C0019016;C2699239;C1825777;C3538758
fasting serum glucose median sd mg dl,C0202041;C0439269;C3534430
baseline cv medications n,C0168634;C0013227;C0802604;C2598133;C4284232;C1442488
baseline antihyperglycemic medications n,C0020616;C0013227;C0802604;C2598133;C4284232
cl $nmbr$,C0596019
oretal,
$nmbr$ m,
cvd subjects,C0681850;C1550501;C1706203;C2349001;C2697811
m $nmbr$ s,C0439493;C1513009
mrf subjects,C0681850;C1550501;C1706203;C2349001;C2697811
renal function normal mild,C0205307;C0231683;C0439166;C2347086;C4553972;C2945599
renal function moderate,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
renal function severe,C0232804;C0205082;C4050465;C4050466
race while,C0034510;C1706779;C3853635
region latin america,C0017446;C0023122;C0205147
region asia paafic,C0017446;C0003980;C0205147
region europe,C0017446;C0015176;C0205147
region europe union,C0015176;C2825217
race n y,C0034510;C1706779;C3853635
known duration of t $nmbr$ dm y,C0449238;C2926735
history of cvd n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
goal,C0018017;C1571704
baseline n,C0168634;C1442488
week $nmbr$ n,C0332174;C0439230
or for cana vs pbo $nmbr$ ci,C1418845;C0008107;C3259781
p value nominal,C1709380
body weight reduction $nmbr$,C1262477
week $nmbr$ n $nmbr$ or for cana vs pbo $nmbr$ ci,C0332174;C0439230;C1418845;C0008107;C3259781
week $nmbr$ n or for cana vs pbo $nmbr$ ci,C0332174;C0439230;C1418845;C0008107;C3259781
hdl c $nmbr$ mg dl $nmbr$ $nmbr$ mmol l,C0439268
composite endpoint a $nmbr$ c,C0205199;C1547335
[ $nmbr$ $nmbr$ mmol l],C1532563
week $nmbr$ n ^,C0332174;C0439230
male patients,C0150904
female patients^,C0150905
week $nmbr$ n j,C0332174;C0439230
week $nmbr$ n $nmbr$,C0332174;C0439230
ef $nmbr$ $nmbr$ $nmbr$ n $nmbr$ $nmbr$,
black race,C0005680
russia georgia,C0017452;C0017454
history of hf hospitalization,C0551577;C0018488;C1313497;C1538440;C3273279
history of diabetes nyha class,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
heart rate b p m,C0018810
body mass index mg m $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ace arb,C1452534;C3888198;C4284014
all patients n $nmbr$ $nmbr$,C0030705
ejection fraction group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
continuous lvef $nmbr$ treatment interaction,C0039798;C1704675;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
event rate per $nmbr$,C0871208;C1521828
patient years hr unadjusted,C0030705;C0439234;C1439367
referent,C1706462
hr adjusteda,
treatment effect hr,C1518681
empagliflozin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
pooled empagliflozin n $nmbr$,C1709595;C2349200;C4522255
other missing,C1551393;C1705492;C3272743
north america plus australia and new zealand,C0028405;C0004340;C0027978;C0324547
africa,C0001737
body mass index kg m $nmbr$ t,C0005893;C1532718;C0578022;C1305855
cv risk factor no,C3538987;C0035648;C4048877;C4318503
multi vessel coronary artery disease,C1299432
history of stroke $nmbr$,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
single vessel coronary artery disease $nmbr$,C0581374
cardiac failure,C0018801;C0018802
time since diagnosis of type $nmbr$ diabetes no,C0040223;C3541383
glucose lowering therapy no,C0017725;C0441994;C2003888;C0039798;C0087111;C1363945
medication taken alone or in combination,C0205171;C0439044;C0679994;C0205195;C1947911;C3811910
median daily dose iu,C0049272;C0439453;C0694756
dipeptidyl peptidase $nmbr$ inhibitor,C0003015;C2757044;C3536837
glucagon like peptide $nmbr$ agonist,C0014361;C2987634
anti hypertensive therapy no,C0585941
angiotensin converting enzyme inhibitors angiotensin receptor blockers,C0521942;C0815017
mineralocorticoid receptor antagonists,C1373021;C1579268
renin inhibitors,C2917241;C3653375
anti coagulants no,C0848112
low density lipoprotein cholesterol mg dltt,C0023824;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
estimated glomerular filtration rate ml min $nmbr$ $nmbr$ m $nmbr$ tt,C3811844;C0439445;C1452561;C4554543
urine albumin to creatinine ratio no,C0455271;C1318330
$nmbr$ to $nmbr$ mg g,C1300563
patients with event patients analyzed,C0030705;C0441471;C4019010;C0936012
sbp $nmbr$ mmhg and or dbp $nmbr$ mmhg,C0085805;C0439475;C0536221;C3813197;C4281799
urine albumin to creatinine ratio,C0455271;C1318330
cardiovascular risk,C0007226;C0035647;C4552904;C3887460
only cerebrovascular disease,C0007820
only coronary artery disease,C0010054;C0010068;C1956346
only peripheral artery disease,C1704436;C4025272
$nmbr$ or $nmbr$ high cardiovascular risk categories,C0332167;C0683312;C3272283;C4050568;C4319571
statins ezetimibe,C0360714;C1142985
prior ptca or pci,C0332152;C2936173;C2826257;C4049621
primary endpoint death mi idr st,C0036056;C3272372
ischemia driven revascularization,C0022116;C0581603;C4321499
gusto bleeding severe moderate,C0019080;C1299393
timi bleeding major minor,C0019080;C4441842
acuity bleeding major minor,C0019080;C4441842
no of previous anti tnf drugs no,C0205156;C1552607;C0013227;C3687832
use of methotrexate at randomization,C1524063;C0025677;C0034656
use of systemic glucocorticoid at random,C1524063;C0017710;C0034656;C0439605
ization no,
patients with specific disease characteris,C0683521;C0205369;C1552740
tics no,C0040188;C0278076;C2169806;C3889970
psoriasis affecting $nmbr$ of body surface,C0033860;C0392760;C1314939;C0489451
area,C0017446;C0205146
disease and quality of life scores,C0012634;C3476431
tender joint count of $nmbr$ joints,C0451530
swollen joint count of $nmbr$ joints,C0451521
pasi^i,C0021966;C0221138
physician s global assessment of dis,C0031831;C0804815;C0281858;C0451119;C1444662;C1970187
ease activity],C0205177;C0439167;C0441655;C1561536;C3668946;C4049938;C4049939
haq di scoreff,C3826998;C4321476
psoriatic arthritis pain],C4317006
patient s global assessment of,C0030705;C0281858
disease activity],C1292728
sf $nmbr$ physical component summaryjj,C0037712;C0031809;C0205485;C1509143
efficacy endpoint,C2349179;C2826544
secukinumab,C3179547
iv $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
anti tnf naive patients $nmbr$,C1448177;C0030705
acr $nmbr$ response n n,C1412134;C0871261;C1704632;C1706817;C2911692;C1515941
das $nmbr$ crp ls mean change from baseline se,C0392747;C0443172;C1705241;C4319952
anti tnf experienced patients,C1448177;C0030705
no of hospitalised patients,C0030705
aplxaban $nmbr$ $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
apixaban $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
apixaban $nmbr$ $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
table $nmbr$ baseline characteristics of total study sample and stratified by treatment assignment and testosterone levela,C4684572;C0205363;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0039601
main effect baseline hormone,C0019932;C4521914
baseline total ipss,C1019118;C1998280;C2827405;C3811063
unadjusteda beta se,C0330390;C0036919;C0439096;C2004068
adjustedb c beta se,C0330390;C0036919;C0439096;C2004068
stratified by,C0205363
linear regression,C0023733;C2346679
treatment randomization,C0039798;C0034656;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
testosterone level nmol l,C0428412;C0439282;C0523912
testosterone nmol l,C0039601;C0439282
continuous,C0549178
low tt,C1452561;C4554543
high tt $nmbr$ $nmbr$ n $nmbr$,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
estradiol pmol l,C0014912;C0439284
baseline outcomes,C0168634;C1274040;C1442488
logistic regression,C0206031
odds ratios $nmbr$ ci,C0008107;C3259781
ipss v,C1019118;C1998280;C2827405;C3811063
moderate $nmbr$ $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
ipss s,C1019118;C1998280;C2827405;C3811063
severe $nmbr$,C0205082;C4050465;C4050466
ipss categories,C1019118;C0683312;C1998280;C2827405;C3811063
hormones,C0019932
testosterone tt nmol l,C0039601;C0439282
estradiol e $nmbr$ pmol l,C0014912;C0439284
estradiol quartiles,C0014912;C2828255
$nmbr$ st $nmbr$ $nmbr$ $nmbr$ pmol l,C0036056;C0439284;C3272372
$nmbr$ nd $nmbr$ $nmbr$ $nmbr$ $nmbr$ pmol l,C0439284
$nmbr$ rd $nmbr$ $nmbr$ $nmbr$ $nmbr$ pmol l,C0694666;C0439284;C4553350
$nmbr$ th $nmbr$ $nmbr$ $nmbr$ pmol l,C0039725;C0439284;C0039738;C1420718;C4282123;C4285344
american indian or alaskan,C0002460;C0238611
alcohol useb,C0001962;C0001975
smokingb,
obese $nmbr$ kg m $nmbr$ b,C0028754;C1532718
comorbid conditionsb,
cardiac diseasec,C0018787;C1522601
medication useb,C0013227;C3244316;C4284232
psychoactivesd,
diabetese,
other lipid lowering drugs,C0086440
alpha blockers,C0001641
angiotensin receptive blocker,C0003018;C4521302
other antihypertensive medications,C0003364
cyp $nmbr$ a $nmbr$ inhibitors,C1418793;C0243077;C2634343
alpha reductase inhibitors,C0597153;C1655741
previous pde $nmbr$ inhibitors,C0205156;C0031638;C1552607
hemoglobin a $nmbr$ c,C0019020;C3889898
good control,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
fair control $nmbr$ $nmbr$ $nmbr$,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
cholesterol nmol l,C0008377;C0439282
glucose non fasting or random nmol l,C0017725;C1518422;C0015663;C0034656;C0439282;C0439605
standard bp lowering,C1442989;C2828392;C0037623;C0441994;C2003888;C1415692;C1708288;C4318478
intensive bp lowering,C0037623;C0441994;C2003888;C1415692;C1708288;C4318478
latino,C0086528
intensive glycemia lowering,C0005802;C0441994;C2003888
cornell index pv,C0030840;C0032463
safety population,C0032659;C1257890
brv $nmbr$ mg day n $nmbr$,C0155502;C0439422
brv $nmbr$ mg day n,C0155502;C0439422
gender female n,C0079399;C0043210;C0086287;C1705497;C1705498;C1522384
europe eu,C0015179;C3665627
asia pacific other,C0003980
europe non eu,C0015179;C3665627
duration of epilepsy years mean sd,C0449238;C2926735
age at first seizure years mean sd,C1510829;C0036572;C1959629;C4553401
baseline pos frequency per $nmbr$ days,C0168634;C0585290;C1442488
number of prior aeds n,C0237753;C0449788
number of concomitant aeds n,C0237753;C0449788
concomitant aedsa,C0521115
carbamazepine,C0006949;C0006950;C0682993
lamotrigine,C0064636;C0524166
valproate,C0080356
oxcarbazepine,C0069751
topiramate,C0076829
lacosamide,C0893761
lev status n,C0023556;C0449438
never used lev,C1273517;C0023556
prior lev use,C0042153;C0457083;C1947944
subgroup analysis itt population percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period in prior lev and lev naive patients a $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period in prior lev and lev naive patients b percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to reason for prior discontinuation of lev c $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to reason for prior discontinuation of lev d percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to number of prior aeds e $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to number of prior aeds f analysis by reason for prior discontinuation of lev excluded one patient who was previously treated with either levetiracetam or pregabalin in a blinded study aeds antiepileptic drugs brv brivaracetam itt intention to treat lev levetiracetam pbo placebo pos partial onset seizure,C2986480;C0032664;C0149775;C0332152;C0023556;C2826257;C0030705;C0871208;C1521828;C0168634;C1442488;C0301630;C0392756;C1293152;C4551656;C0392360;C0444930;C2746065;C1264674;C0237753;C0449788;C0332293;C0377265;C3693636;C0657912;C0003299;C0751495;C0206132;C0332162
spirono n $nmbr$,
enrollment strata prior hospitalization,C0332152;C0019993;C2826257
physical characteristics,C0031809;C1521970;C0205485;C1509143
hematocrit,C0018935;C0518014
prior hf hospitalization n $nmbr$,C0018488;C0019993;C1313497;C1538440;C3273279
elevated natriuretic peptide level n $nmbr$,C1144709;C2709270;C3537020
p for inter act,C0369773;C2603361;C0205103;C1548610;C0079613;C1704930;C1869853;C3890007;C4048375
lv heart structure,C0023128;C0018787;C0731033;C1881413
lvedv ml,C0439526;C1705224;C3887665
lvesv ml,C0439526;C1705224;C3887665
mean wall thickness cm,C4054557;C0677535
lv mass index mg m $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
relative wall thickness,C0080103;C0205345;C1547039
lav ml,C0439526;C1705224;C3887665
la diameter,C0023031;C1301886;C0023749;C0230347;C2346906;C4553351
lv function,C0031843;C0542341;C0700205;C1705273
e a ratio,C0456603;C1547037
tdi e septal cm sec,C0205976;C0439392;C2674784;C3714807
e e septal,C0442004
rv and pulmonary vascular,C0035190;C3889272;C0459963;C1508661
tr jet velocity m sec,C0439830;C1547053;C0565930
rvfac,
enrolled in the americas,C4684790;C0002454;C0596070
enrolled in russia or georgia,C4684790;C0035970;C0017452;C0017454
baseline adjusted hr,C0168634;C0456081;C1442488
alvedv per ml,C0439526;C1705224;C3887665
alvesv per ml,C0439526;C1705224;C3887665
alvmi per g m $nmbr$,C0439267
alvef per $nmbr$,
ae a ratio per $nmbr$ $nmbr$ unit,C3887670;C0456603;C1547037
ae per cm s,C3887670
ae e ratio per $nmbr$ unit,C0456603;C1547037
alav per ml,C0439526;C1705224;C3887665
apasp per mmhg,C0439475
arvfac per $nmbr$,
sbp at baseline,C0085805;C0168634;C1442488
sd of sbp,C2699239;C0085805
range of sbp,C1514721;C2348147;C3542016
change in sbp,C0392747;C0443172;C1705241;C4319952
bp lowering treatment n $nmbr$,C0037623;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C1415692;C1708288;C4318478
r tpa,C0032143
time to treatment h,C3494202;C0033727;C0369286;C0441932;C0564385;C4528284
nihss score,C0449820;C4050231
stroke subtype,C0038454;C0449560;C4554100
infarct size,C0021308;C0456389
no infarct visible,C0021308;C0205379
small medium,C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283
large very large,C0549177;C0442824;C2984081
symptomatic infarct swelling,C0013604;C0038999
symptomatic ich,C0019191;C3272597;C3281105
nd not due to swelling or ich,C0678226;C0013604;C0038999;C0019191;C3272597;C3281105
early ichaem ic stroke,C0038454;C4554100
any early adverse event,C1279919;C0877248
early death,C1836407
poor outcome at $nmbr$ months,C3806166;C0439231
numbers of events,C4330837
ors $nmbr$ cis,C1504308;C1742862
$nmbr$ days to $nmbr$ year n $nmbr$,C0556972
age median iqr,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
caucasiana,
bmi median iqr,C0578022;C0549183;C0876920;C2347635;C2348144;C2939193
multivessel cad,C1504769;C2239547;C3813548;C4284121
pci for index mi,C4049621;C0600653;C0918012;C1552854;C1637833;C2986546
history of more than $nmbr$ prior mi,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
egfr at baseline $nmbr$ ml min b,C1739039;C3811844;C3812682
months from mi median iqr,C0439231;C0549183;C0876920;C2347635;C2348144;C2939193
mi type unknown,C0439673;C3541433;C4050014
figure $nmbr$ cardiovascular death myocardial infarction or stroke at $nmbr$ years with ticagrelor doses pooled purple compared with placebo in patients withdrawn from p $nmbr$ y $nmbr$ inhibitor therapy within $nmbr$ days of randomization strati ed by a qualifying myocardial infarction $nmbr$ months prior to randomization left and $nmbr$ months prior to randomization right,C0027051;C0428953;C2926063;C3810814;C4552959;C0038454;C4554100;C0178602;C0439542;C1707455;C0032042;C1696465;C1706408;C0030705;C0424092;C2349954;C2825032;C3853865;C0439228;C0034656;C1514624;C0439231;C0332152
age mean sd yrs,C0001779;C0444504;C2347634;C2348143
history myocardial infarction,C0155668;C1275835
history pci,C0019664;C4049621;C0019665;C0262512;C0262926;C1705255;C2004062
anti platelet therapy,C0039798;C0087111;C1363945
time to end of study ivus median iqr days,C3698632
cardiovascular events,C1320716
hospitalization for acs,C0019993;C0742343;C4318612
arterial revascularization,C0003842;C0581603;C0221464
first mace,C0349381;C0949745;C1445339
biochemical events,C0441471;C3541888
hyperkalemia $nmbr$ $nmbr$ meq l,C0020461;C0439375;C4552983
elevated creatinine $nmbr$ pmol l,C0151578;C0439284;C0700225
elevated bun $nmbr$ $nmbr$ meq l,C0151539;C0439375
aliskiren dm vs dm,C0011816;C3250443
placebo dm vs dm,C0011816;C3250443
dm aliskiren vs placebo,C0011816;C1120110;C3250443;C0032042;C1696465;C1706408
hard mace,C0349381;C0949745;C1445339
hba $nmbr$ c $nmbr$,C0019016;C1825777;C3538758
hbalc $nmbr$ n $nmbr$,
established cardiovascular disease,C0443211;C0007222;C1272684
egfr $nmbr$ ml min,C1739039;C0439445;C3811844;C3812682
urine albumin creatinine ratio mg g,C0455271;C1300563;C1318330
antihyperglycemic medications,C0013227;C0802604;C2598133;C4284232
cardiovascular medications,C0007220
adp antagonist,C0523452;C0231491
cvdeath ml or ischemic stroke,C0439526;C1705224;C3887665;C0948008
cv death ml ischemic stroke hospitalization for unstable angina revascularization or heart failure,C0019993;C0002965;C0018801;C0018802;C4554158
risk score category points,C1552961;C2347617;C3714763
western europe and other,C0043129
creatinine mmol,C0010294;C0439190;C1561535
hemoglobin g l,C0635222
nyha functional class i,C1882084;C0205245;C0542341;C2700217
kccq score,C0449820;C4050231
coronary artery bypass surgery,C0010055
diuretic agent,C0450442;C1254351;C1521826
mineralocorticoid receptor antagonist,C1579268
oral anticoagulant agent,C0354604
cardiac resynchronization therapy,C1167956
risk category points,C1552961;C2347617;C3714763
enalapril lcz $nmbr$ n $nmbr$ n $nmbr$,C0014025
enalapril n $nmbr$,C0014025
lcz $nmbr$ n $nmbr$,
cv death or hf hospitalization n,C0011065;C1306577;C4082313;C4552775;C0018488;C0019993;C1313497;C1538440;C3273279
ratet $nmbr$ cl,C0596019
cv death n,C0011065;C1306577;C4082313;C4552775
hf hospitalization n,C0018488;C0019993;C1313497;C1538440;C3273279
all cause death n,C0015127;C0011065;C1306577;C4082313;C4552775;C1524003
hr bpm,
creatinine mol l,C0010294;C0347982;C1561535
median bnp iqr pg ml,C0054015;C0439297;C1095989;C1417808;C2982014
median nt probnp iqr pg ml,C0669479;C0439297;C0754710
ischaemic etiology n,C0475224;C0015127;C1314792;C1524003
nyha,C1275491
hospitalization for heart failure n,C3898876
coronary artery bypass grafting n,C0010055
percutaneous coronary intervention n,C1532338
diuretic n,C0012798
beta blocker n,C0001645
mineralocorticoid receptor antagonist n,C1579268
oral anticoagulant n,C0354604
antiplatelet agent n,C0085826
lipid lowering agent n,C0086440
implantable cardioverter defibrillator n,C0162589;C2825184
cardiac resynchronization therapy n,C1167956
enalapril,C0014025
lcz $nmbr$,
cv death or hf hosp,C0011065;C1306577;C4082313;C4552775;C0018488;C1313497;C1538440;C3273279
hf hosp,C0018488;C1313497;C1538440;C3273279
acd,C4554601
bmi body mass index bnp brain natriuretic peptide dbp diastolic blood pressure gfr glomerular filtration rate hr heart rate iqr interquartile range kccq kansas city cardiomyopathy questionnaire n number nt n terminal nyha new york heart association sbp systolic blood pressure,C0488055;C0871470;C1306620
psoriasis duration mean sd years,C0033860;C0439234
bsa affected mean sd,C0392760;C2699239;C1314939
pasi score mean sd,C0444504;C2699239;C2347634;C2348143
fig $nmbr$ pasi $nmbr$ pasi $nmbr$ and pasi $nmbr$ response rates at week $nmbr$ overall and by type of prior failed systemic therapy,C0349966;C1337208;C0237629;C1515119
tiotropium $nmbr$ g n $nmbr$,C0213771;C0439267
tiotropium $nmbr$ $nmbr$ g n $nmbr$,C0213771;C0439267
median range duration of asthma y,C0449238;C2926735
fev $nmbr$ at screening,C3714541;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
actual l,C0237400
of predicted,C0681842;C1882327
fev $nmbr$ at baseline randomization,C3714541;C0168634;C0034656;C1442488
fvc,C3714541
fev $nmbr$ fvc at baseline randomization,C3714541;C0034656
pefam l min,C0702093;C1524029;C3813700
pefpm l min,C0702093;C1524029;C3813700
acq $nmbr$ total score,C2919686;C2964552
ics dose of stable maintenance treatment g,C3714445
treatment and parameter,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0549193;C1704769;C2350001
adjusted mean se ml,C0439526;C1705224;C3887665
active vs placebo,C0205177;C3853793;C3888249;C0032042;C1696465;C1706408
adjusted mean of difference se ml,C0444504;C2347634;C2348143
peak fev $nmbr$ $nmbr$ $nmbr$ h response,C0871261;C1704632;C1706817;C2911692
trough fev $nmbr$ response,C0871261;C1704632;C1706817;C2911692
fev $nmbr$ of predicted normal post bronchodilator,C3714541;C0205307;C0231683;C0439166;C2347086;C4553972;C2599594
dabigatran $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
enoxaparin $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
number of treated patients,C2360800;C1522326
females n,C0086287
body mass indexa,C0518010
previous vte n,C0205156;C0630906;C1552607
creatinine clearanceb ml min,C0010294;C0439445;C1561535
racec n,C4287599
australia new zealand south africa,C0027978;C0037712;C0324547
patients treated and operated n,C0030705;C1522326;C3242339
anesthesiad n,
general alone,C0205246;C3812897;C3891294;C4521767;C0205171;C0439044;C0679994
neuraxial alonee,
combinationf,
mean duration of surgery sd min,C0449238;C2926735
study treatment,C1521826
mean time to first subcutaneous injectiong h in relation to surgery hr,C0040223;C3541383;C0038894;C0038895;C0543467;C1274039
mean time to first oral dose postsurgeryh hr,C0040223;C3541383
median range duration of hospital stayi d,C0449238;C2926735
median range treatment duration d,C0444921;C3259042
enoxaparn $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
risk difference,C0035647;C1705241;C1705242;C4552904
estimate,C0750572
$nmbr$ cl $nmbr$,C0596019
i i i,C0021966;C0221138
t,C2603360
_ $nmbr$ _,
weight [kg],C0005910;C0043100;C1305866;C1705104;C0022718;C0439209;C4054209
creatinine clearance [ml min],C0812399;C0439445
n c,C2349138
bmi [kg m $nmbr$ ],C0578022;C0022718;C0439209;C4054209
mr $nmbr$,C0024485;C1417249;C2347167;C3254418;C4050513
age [years],C0001779;C0439234
$nmbr$ $nmbr$ f $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0016327
monotherapy $nmbr$,
add on to met $nmbr$,C1883712;C0428210;C1550543;C4317104
add on to met su $nmbr$,C1883712;C0038642;C1705534
mean sd age y race n,C0001779;C0034510;C1706779;C3853635
othery ethnicity n,C0015031;C0243103
mean sd hba $nmbr$ c,C0444504;C0019016;C1825777;C3538758;C2347634;C2348143
latin american subgroup,C1079230;C1515021
add on to met,C1883712;C0428210;C1550543;C4317104
add on to met su,C1883712;C0038642;C1705534
cana,C1418845
figure $nmbr$ changes in systolic bp for the overall populations and latin american subgroups of the a pbo controlled studies at week $nmbr$ and b active controlled studies at week $nmbr$,C1268766;C0032659;C1257890;C1553378;C1079230;C0031962;C0681867;C1706449
bp blood pressure pbo placebo met metformin su sulfonylurea ls least squares se standard error ci confidence interval cana canagliflozin sita sitagliptin glim glimepiride ns not significant p $nmbr$ $nmbr$ versus pbo sita ystatistical comparisons were not performed in the post hoc analysis of patients from latin america zp ns versus pbo xstatistical comparisons were not performed not prespecified,C0038944;C1112705;C1705982;C1273937;C0031962;C1707455;C0884358;C0002778;C0936012;C1524024;C1518422
pooled non canvas studies n $nmbr$ non cana n $nmbr$ cana $nmbr$ mg n $nmbr$ cana $nmbr$ mg n $nmbr$,C0947630;C1319635
canvas n $nmbr$ placebo n $nmbr$ cana $nmbr$ mg n $nmbr$ cana $nmbr$ mg n $nmbr$,C0032042;C1319635;C1696465;C1706408
overall population n $nmbr$ $nmbr$ non cana n $nmbr$ cana $nmbr$ mg n $nmbr$ cana $nmbr$ mg n $nmbr$,C0032659;C1319635;C1257890
othera,
fpg mg dl mmol l,C0439268
microvascular complicationsb,C0443258
use of loop diuretics,C1524063;C0354100
prior cv history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
all cana,C1418845
$nmbr$ years of age,C1510829
duration of t $nmbr$ dm $nmbr$ years,C0449238;C2926735
egfr $nmbr$ ml min $nmbr$ $nmbr$ mz,C0026655;C1705291
no fracture history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
fracture history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
microvascular complications n,C0443258;C0009566;C1171258
use of loop diuretics n,C1524063;C0354100
prior cv history n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
continued thienopyridine n $nmbr$ $nmbr$,C0549178;C1120149
non white raceb,C0007457;C0043157;C0220938
hispanic or latino ethnic groupb,C0086409;C0086528;C0015031;C0680174
body mass indexc,C0518010
renal insufficiency failure,C0035078;C1963154
prior cancer,C0006826;C0998265;C1306459
indication for index pci,C0392360;C3146298
unstable anginad,C0443343;C1883468
type of stent at index procedure,C0332307;C1547052;C0184661;C2700391;C3274430;C3539779
continued thienopyridine,C0549178;C1120149
p value for interactiont,C1709380
no mi,C3810814
bp and fasting glucose results,C0037623;C1415692;C1708288;C4318478;C1274040;C1546471;C2825142
ethnicity $nmbr$,C0015031;C0243103
mean change in sbp from baseline mmhg mean sd,C0392747;C0443172;C1705241;C4319952;C0168634;C2699239;C1442488
education yrs mean sd,C0013621;C2699239;C0013622;C0013658;C0039401
receiving antihypertensive treatment n blood pressure mm hg mean sd,C1514756;C0428886;C2699239
mean change in dbp from baseline mg dl mean sd,C0392747;C0443172;C1705241;C4319952;C0439269;C2699239
baseline lipid profile mg dl mean sd,C0439269;C2699239
participants at baseline n,C0679646;C0168634;C1442488
fasting glucose mg dl diabetes classification,C0008902;C0008903;C0678229
diabetesz,
mean sd baseline,C0168634;C1442488
impaired fasting glucosex,C0221099;C0015663
baseline if have $nmbr$ yr follow up,C0168634;C1442488;C0589120;C1522577;C1704685;C3274571
lipid trial participantsk,C0023779;C0008976
change from baseline mg dl mean sd,C0392747;C0443172;C1705241;C4319952
fasting glucose $nmbr$ mg dl n,C0015663;C0439269
st t waveft,C0036056;C3272372
history of lvh on electrocardiogram,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0013798;C1547122;C1623258
history of lvh on echocardiogram,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0013516;C2243117
estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$ mean sd,C0017654;C0439445;C1424601;C0444504;C2699239;C2347634;C2348143
additional antihypertensive subgroup,C1079230;C1515021
dapagliflozin n $nmbr$,C2353951
women ethnic origin,C0043210;C0015031
$nmbr$ $nmbr$ l,C0439394;C1706495;C3642217
hbaj mmol mol,C3829066
participants taking insulin,C0679646;C3842788
selective vascular history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
carotid artery disease,C0007273
history of dyslipidaemia,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
recent cardiovascular eventf,C0332185;C0007226;C3887460
egfr ml min per $nmbr$ $nmbr$ m,C1739039;C0439445;C3811844;C3812682
seated sbp n,C0277814;C0085805;C1283233
baseline mean seated sbp mm hg sd,C0439475;C2699239
sbp difference vs placebo $nmbr$ cl,C1705241;C1705242;C0032042;C0596019;C1696465;C1706408
hba $nmbr$ c n,C0019016;C1825777;C3538758
hba $nmbr$ c baseline mean hba $nmbr$ c sd,C0019016;C2699239;C1825777;C3538758
hba $nmbr$ c difference vs placebo $nmbr$ cl,C1705241;C1705242;C0032042;C0596019;C1696465;C1706408
ambulatory sbp n,C0439841;C0085805
baseline mean ambulatory sbp mm hg sd,C0439475;C2699239
ambulatory sbp difference vs placebo $nmbr$ cl,C1705241;C1705242;C0032042;C0596019;C1696465;C1706408
serum uric acid n,C0455272;C0700634
baseline mean serum uric acid pmol l sd,C0455272;C2699239;C0700634
serum uric acid difference vs placebo $nmbr$ cl,C1705241;C1705242;C0032042;C0596019;C1696465;C1706408
dapagliflozin,C2353951
p blockersubgroup,C0369773;C2603361
o $nmbr$ o $nmbr$ loto $nmbr$ $nmbr$,C0483204
calcium channel blockersubgroup,C0006685
diuretic subgroup,C1079230;C1515021
laa closure n $nmbr$,C0185003;C1521802
long term warfarin n $nmbr$,C0443252;C0043031
previous myocardiaunfarction,C0205156;C1552607
previous major bleeding,C0205082;C0019080;C0205164;C4318856;C4521762
$nmbr$ _ $nmbr$ $nmbr$ $nmbr$,
cha $nmbr$ ds $nmbr$ vasc,C1420648;C3714751
$nmbr$ _ $nmbr$ l $nmbr$,C0439394;C1706495;C3642217
modified has bled,C0392747;C3889737;C0019080
laa closure,C0185003;C1521802
hazard ratio $nmbr$ confi dence interval,C1272706;C1552654;C1552713
modified has bled $nmbr$,C0392747;C3889737;C0019080
no history of tia stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
history of tia stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
lixisenatide n $nmbr$,C2973895
retinopathy no,C0035309;C1962966
neuropathy no,C0442874
race no t,C0034510;C1706779;C3853635;C2603360
hispanic ethnic group no t,C0015031;C1879937;C2603360
geographic region no,C0017446
africa or near east,C0001737;C1707877
south or central america,C1710133;C0007674
myocardial infarction before index acs no,C0027051;C0428953;C2926063;C3810814;C4552959
medical history at randomization no,C0262926;C1704706
qualifying acs event no,C1514624;C0441471;C4019010
unclassified,C0205426;C1546437;C2347854;C4085229
days from acs to randomization,C0439228;C0742343;C4318612;C0034656
urinary albumin creatinine ratio^,C0486293;C1318293
less than $nmbr$ y ears,C0013443;C0521421
not hispanic,C1518424
africa near east,C0001741
south central america,C0037713
days between acs and rand,C0439228;C0742343;C4318612;C1555436
$nmbr$ to less than $nmbr$,
$nmbr$ or greater,C1704243
region us,C0815353;C3889164
non us,C0815353;C3889164
dm duration,C0449238;C2926735
$nmbr$ years or more,C0439234
less than $nmbr$ $nmbr$,
$nmbr$ $nmbr$ or more,
less than $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
$nmbr$ kg m $nmbr$ or more,C0022718;C0439209;C4054209
acs event,C0441471;C4019010
pcr after acs,C0032520;C3853643;C4050242
ace arb use,C0042153;C0457083;C1947944
uacr,
stent n $nmbr$,C0038257
medical therapy n $nmbr$,C0418981
stenosis core lab,C0678234;C4684837;C1261287;C2632116
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ ],
stenosis investigator,C0678234;C0035173;C1261287;C2632116
peak systolic pressure gradient,C4687747
mean systolic pressure gradient,C4687744
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ ] $nmbr$ $nmbr$,
stent,C0038257
percent stenosis [core lab],C0678234;C1261287;C2632116;C4684837
percent stenosis [investigator],C0678234;C1261287;C2632116;C0035173
$nmbr$ o,C0483204
any albuminuria,C0001925
ankle brachial index $nmbr$ $nmbr$,C1328319;C3888326
diabetes with use of oral diabetes drugs,C0020616;C1524063
diabetes with no use of diabetes drugs,C0020616;C1524063
new diabetes,C0011847;C0011849
igt or ifg,C1334085;C1708411
fasting glucose mmol l,C0015663;C1532563
hbalc mmol mol,C3829066
nonglycemic cardiovascular risk factors,C0850624
creatinine p mol l,C0010294;C0347982;C1561535
urine acr mg mmol,C0567349;C2348885
other antihypertensive drug,C0003364
insulin glargine n x,C0907402
standard care n,C1442989;C1947933;C2828392
first co primary outcome,C0205225;C1274040;C0439612;C0439631
s $nmbr$ $nmbr$ s,C0565930;C2603362
alc $nmbr$ $nmbr$,C1424945;C3811058
no metformin use,C0042153;C0457083;C1947944
metformin use,C0042153;C0457083;C1947944
neither ace i nor arb use,C0021966;C0221138;C0042153;C0457083;C1947944
ace i or arb use,C0021966;C0221138;C0042153;C0457083;C1947944
new om,C0028971;C1705272
prior om,C0028971;C1705272
second co primary outcome,C0205225;C1274040;C0439612;C0439631
s $nmbr$ $nmbr$ $nmbr$,
standard care allocation,C1442989;C1706778;C2828392
insulin glargine allocation,C0907402;C1706778
heart rate $nmbr$ bpm,C0018810
no betablocker use,C0042153;C0457083;C1947944
betablocker use,C0042153;C0457083;C1947944
omega $nmbr$ fa intake $nmbr$ st third,C0036056;C3272372
omega $nmbr$ fa intake $nmbr$ nd third,C1512806;C0205437
omega $nmbr$ fa intake $nmbr$ d third,C1719844;C1512806;C0205437
triglycerides $nmbr$ st third,C0036056;C3272372
triglycerides $nmbr$ nd third,C0041004;C0205437
triglycerides $nmbr$ d third,C0041004;C0205437
selexipag n $nmbr$,C2000145
western europe and australia,C0043129;C0004340
time since diagnosis of pah yrf,C0040223;C3541383
pah classification no,C0008902;C0008903;C0678229
heritable,C0439660
associated with connective tissue disease,C0332281
associated with corrected congenital shunts,C0332281;C0009678;C1744681
associated with hiv infection,C0332281;C0019693
associated with drug or toxin exposure,C0332281;C0013227;C1254351;C0040537
who functional class no c,C0205245;C0456387;C1518526;C1705943;C0542341;C2700217
$nmbr$ minute walk distance m,C0439232;C0429886;C0700321;C0702093;C1282918;C2347166
use of medications for pah no,C1524063;C0030123;C3203102;C4284467
endothelin receptor antagonists,C1134681;C2266875
phosphodiesterase type $nmbr$ inhibitors,C0031638;C1656262;C3539996
endothelin receptor antagonists plus phosphodiesterase type $nmbr$ inhibitors,C1134681;C2266875
selexipag,C2000145
no of patients no of events,C0030705;C0441471;C3541888
pah therapy at baseline,C0039798;C0087111;C1363945
era and pde $nmbr$ inhibitors,C1521863;C3495919;C0031638
era monotherapy,C1521863;C3495919
pde $nmbr$ inhibitor monotherapy,C0031638
no pah therapy,C0039798;C0087111;C1363945
l ll,C0439394;C1706495;C3642217
age at screening,C0001779;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
ipah hpah hiv drug or toxin induced,C0013227;C1254351;C0040549;C0205263;C4522020
assoc with connective tissue disease,C0009782
assoc with corrected congenital shunts,C0205202;C0009678;C1744681
western europe australia,C0043128
japan n $nmbr$,C0022341
not japan n $nmbr$ $nmbr$,C1518422;C0022341
overall n $nmbr$ $nmbr$,C0282416;C1561607
range min max,C1514721;C0702093;C1524029;C3813700;C2348147;C3542016
screening and baseline lung function characteristics,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C4684572;C0035245
screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
predicted pre bronchodilator fev $nmbr$,C2599602;C3714541
absolute reversibility in fev $nmbr$ ml,C0205344;C0449261
baseline fev $nmbr$ l,C0168634;C1442488
predicted fev at baseline,C3714541;C0168634;C1442488
ff vi $nmbr$ $nmbr$ pg od,C0229089;C0439164;C1512019;C3273373;C3665488
ff $nmbr$ pgod,C4554348
ls mean change from baseline se,C0392747;C0443172;C1705241;C4319952
difference vs placebo $nmbr$ ci,C1705241;C1705242;C0008107;C3259781
difference vs ff $nmbr$ pg $nmbr$ ci,C1705241;C1705242;C0008107;C3259781
not japan,C1518422;C0022341
white $nmbr$ $nmbr$,C0007457;C0043157;C0220938
black african american $nmbr$ $nmbr$,C0085756
asian $nmbr$ $nmbr$,C0078988
other $nmbr$ $nmbr$ t,C2603360
pooled trials n $nmbr$,C1709595;C2349200;C4522255
wc cm,C0013123;C2825512
insulin pmol l t vital signs,C0150404;C0518766
pulse beats min cholesterol mmol l,C2827896
ffa mmol l,C0015688;C1532563
prediabetes n,C0362046
dyslipidaemia n,C0242339
dyslipidaemia and hypertension n,C0242339;C0020538;C1963138
individuals with normoglycaemia,C0027361;C0237401
individuals with prediabetes,C0027361;C0237401
individuals with t $nmbr$ dm scale diabetes,C0027361;C0237401
estimated treatment difference,C1705241;C1705242
test for interaction between treatment and race,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0034510;C1706779;C3853635
liraglutide $nmbr$ $nmbr$ mg ls means n,C0024671;C0023668;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
placebo ls means n,C0032042;C0023668;C1696465;C1706408
etd [ $nmbr$ ci],C0008107;C3259781
number of individuals,C1549735
current weekly alcohol use,C0332174;C0001948
age at completion of highest level of,C0001779;C4321237
exercise times per week minimum,C0456698
$nmbr$ min time,C0040223;C3541383
ace arb medication,C0013227;C3244316;C4284232
any blood pressure medications,C0849164
lipid lowering medication,C0023779;C0441994;C2003888;C0013227;C3244316;C4284232
aspirin or thienopyridines,C0004057;C1120149;C2936588
no of events women men,C0043210;C0025266
ratio of hrs $nmbr$ ci p for sex interaction,C0456603;C1547037;C0009253;C1704675;C0036864;C0079399;C0804628;C1314687;C1522384
primary outcomes,C0205225;C1274040;C0439612;C0439631
major cardiovascular,C0007226;C3887460
all cardiovascular,C0007226;C3887460
major coronary,C0205082;C0018787;C0205164;C4318856;C4521762
major cerebrovascular,C0205082;C0205164;C4318856;C4521762;C1880018
all cancer,C0006826;C0998265;C1306459
no of events womenmen,C0441471;C3541888
ratio of hrs $nmbr$ cl p for sex interaction,C0456603;C1547037;C0009253;C1704675;C0036864;C0079399;C0804628;C1314687;C1522384
no previous diagnosis of diabetes mellitus,C0332132;C0011849
previous diabetes mellitus,C0205156;C0011849;C1552607
hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0019016;C1825777;C3538758
any hba $nmbr$ c,C0019016;C1825777;C3538758
lcz $nmbr$ treatment n,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
hba $nmbr$ c median q $nmbr$ q $nmbr$,C0019016;C0549183;C0876920;C2347635;C2348144;C2939193;C1825777;C3538758
hf duration y n,C0018488;C0449238;C2926735;C1313497;C1538440;C3273279
jugular venous distension n,C0425687
edema n,C0013604;C1717255
rales n,C0034642;C0240859
ckd egfr,C1739039;C3811844;C3812682
icd crt d n,C0021122
crt p d n,C0369718;C0441922
ischemic cause,C0015127;C1524003
previous af,C0344434;C4049859
mra,C0243032;C1609165;C3891069
antiplatelets any,
hypoglycemic agent,C0020616
normoglycemia,
pre diabetes mellitus,C0362046
undiagnosed diabetes mellitus,C1408353;C0011849
p values for interaction,C1709380;C1704675
hf hospitalization or cardiovascular death,C0018488;C0019993;C1313497;C1538440;C3273279;C0011065;C1306577;C4082313;C4552775
significant worsening in kccq clinical score $nmbr$ at $nmbr$ mo,C0237881;C0750502;C1546944;C0332271;C0205210;C1457868;C1546960;C0026544;C0332177
normal hba $nmbr$ c n $nmbr$,C0205307;C0019016;C1825777;C3538758;C0231683;C0439166;C2347086;C4553972
pre diabetes mellitus n $nmbr$,C0011849;C0362046
undiagnosed diabetes mellitus n $nmbr$,C1408353;C0011849
diabetes mellitus n $nmbr$,C0011849
p values of interaction,C1709380;C1704675
hypotension n,C0020649;C3163620
symptomatic hypotension,C0020649;C3163620
symptomatic hypotension with sbp,C0020649;C3163620
leading to study drug discontinuation,C0332152;C0013175;C1522538
serum creatinine $nmbr$ $nmbr$ mg dl,C0201976;C0439269;C0600061
hyperkalemia n,C0020461;C4552983
serum potassium $nmbr$ $nmbr$ mmol l,C0302353;C1532563;C0543465
cough n,C0010200;C1961131;C3274924;C4084725;C4084726;C4084727
any cough,C0010200;C1961131;C3274924;C4084725;C4084726;C4084727
angioedema adjudicated n,C0002994
no treatment or antihistamines only,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0019590
catecholamines or corticosteroids without hospitalization,C0007412;C0001617;C3539185;C3540725;C3540726;C3540727
hospitalized without airway compromise,C0701159;C4055482
airway compromise,C4055482
any adverse event leading to study drug discontinuation n,C0877248;C0332152;C0013175;C1522538
female subgroup,C1079230;C1515021
body mass kg,C0022718;C0439209;C4054209
type of mi,C0332307;C1547052
symptom onset to hospital arrival hours,C4086878;C0019994;C1510665
killip class ii,C2697845
crusade bleeding score,C0449820;C4050231
$nmbr$ $nmbr$ _ $nmbr$,
nace primary endpoint,C2986535
cardiac death,C0376297
reinfarction,
ischemic tvr,C0475224
all bleeding,C0019080
barc $nmbr$ $nmbr$,
thrombocytopenia,C0040034;C0392386
definite,C0439544;C1704787
probable,C0033204;C0332148
acute,C0205178
subacute $nmbr$ $nmbr$ days,C0205365;C0439228
p value cangrelor versus clopidogrel in women,C1709380;C1121991;C0070166;C0043210
p value cangrelor versus clopidogrel in men,C1709380;C1121991;C0070166;C0025266
p value men versus women,C1709380;C0025266;C0043210
age y median iqr,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
dx at presentation n,C3538936;C0449450
nsteacs,
cardiac biomarker n,C1271630
previous heart failure,C0018801;C0018802;C4554158
baseline hemoglobin median iqr g dl,C0439267
baseline hematocrit median iqr,C0168634;C0018935;C0518014;C1442488
periprocedural medications n clopidogrel $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
clopidogrel $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
duration of pci min median n iqr,C0449238;C2926735
poba n,
access site,C0589360
p interaction rx arm sex,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
cangrelor n $nmbr$ n n,C1121991
clopidogrel n $nmbr$ n n,C0070166
unadjusted or $nmbr$ ci p value,C1439367;C0008107;C1709380;C3259781
adjusted or $nmbr$ ci p value,C0456081;C0008107;C1709380;C3259781
q wave mi,C0861151
death or stent thrombosis,C0011065;C1306577;C4082313;C4552775;C3897493
death q wave mi or ischemia driven revasc,C0011065;C0861151;C1306577;C4082313;C4552775;C0022116;C0378365;C4321499
primary gusto severe bleeding,C0205082;C0019080;C4050465;C4050466
primary gusto moderate or severe bleeding,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0205082;C0019080;C4050465;C4050466
gusto severe or,C0205082;C4050465;C4050466
life threatening,C1546953;C2826244;C3537125
gusto moderate,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
or severe,C0205082;C4050465;C4050466
timi major,C0205082;C0205164;C4318856;C4521762
timi major or,C0205082;C0205164;C4318856;C4521762
any blood,C0005767;C0005768;C0229664
transfusion,C0005841;C0199960;C1879316
acuity major,C0205082;C0205164;C4318856;C4521762
acuity minor,C0026193;C0205165
acuity major or,C0205082;C0205164;C4318856;C4521762
renal parameters,C0022646;C0449381
egfr ml min $nmbr$ $nmbr$ mz,C0026655;C1705291
u c mg g,C1532633;C2608091
haemoglobin mmol l,C0635222
calcium mmol l,C0006675;C1532563;C0006726;C2936886;C3540037;C3714611
phosphate mmol l,C0031603;C1532563;C0031701;C1601799
other risk factors,C0035648;C1553898
hba]c mmol mol,C0019016;C1825777;C3538758;C3829066
concomitant drug treatment,C0150270;C3469597
event rate,C0871208;C1521828
cardiovascu lar subg roup,C1419115;C0276828;C3814448
renal subgroup,C1079230;C1515021
albuminuria,C0001925
normoalbuminuria or microalbuminuria,C0730345
egfr and albuminuria,C1739039;C3811844;C3812682;C0001925
number of e,C0237753;C0449788
vents patients,C0030705
pfor heterogeneity,C0019409;C0242960
sulfonylurea derivatives,C0038766
$nmbr$ $nmbr$ mm,C4330985;C4554674
$nmbr$ $nmbr$ $nmbr$ $nmbr$ mm,C4330985;C4554674
$nmbr$ $nmbr$ $nmbr$ mm,C4330985;C4554674
baseline ^ste mm,C4330985;C4554674
baseline ste in worst lead mm,C1420459;C3811127
baseline std mm,C4330985;C4554674
q wave in the infarct territory at baseline,C0429089;C1305738;C0168634;C1442488
time from sx onset to baseline ecg min,C1519428;C0449244;C3539997;C3815196;C0702093;C1524029;C3813700
cana $nmbr$ met n $nmbr$,C1418845;C0428210;C1550543;C4317104
cana $nmbr$ n $nmbr$,C1418845
race n t,C0034510;C1706779;C3853635
$nmbr$ $nmbr$ $nmbr$ mmol mol,C3829066
figure $nmbr$ effects on ef cacy parameters,C1280500;C0449381
c change from baseline in hba $nmbr$ c in subgroups with baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ mmol mol or $nmbr$ $nmbr$ $nmbr$ mmol mol at week $nmbr$,C0392747;C0443172;C1705241;C4319952;C1079230;C3829066;C0332174;C0439230
apremilast,C1678805
$nmbr$ mg twice daily n $nmbr$,C0024671;C0585361;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
duration mean sd years,C0444504;C0439234;C2347634;C2348143
prior use of conventional dmards only biologic nai ve n,C1524063;C0242708;C0005515;C3537218;C0205460;C0369718;C0441922
prior use of biologics n,C1524063;C0005515;C0005522;C4553887
prior biologic therapeutic failures n,C0005515;C0087111;C0302350;C0205460
baseline dmard use n,C0168634;C0042153;C0457083;C1947944;C1442488
mtx mean dose $nmbr$ $nmbr$ mg wk,C0366550;C1881833
leflunomide mean dose $nmbr$ $nmbr$ mg day,C0063041;C0439422
sulfasalazine mean dose $nmbr$ $nmbr$ g day,C0036078;C0439417
baseline corticosteroidst mean dose $nmbr$ $nmbr$ mg day n,C0168634;C0439422;C1442488
sjc $nmbr$ $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
tjc $nmbr$ $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
haq di $nmbr$ $nmbr$ mean sd,C3826998;C2699239;C4321476
crp normal range $nmbr$ $nmbr$ $nmbr$ mg dl mean sd,C0086715;C2699239
patient s global assessment of disease activity $nmbr$ $nmbr$ mm vas mean sd,C0030705;C0281858;C1292728
physician s global assessment of disease activity $nmbr$ $nmbr$ mm vas mean sd,C0031831;C0804815;C0281858;C1292728
das $nmbr$ crp mean sd,C0051767;C2699239;C0057671
bsa $nmbr$ n t,
pasi score $nmbr$ $nmbr$ t mean sd,C0444504;C2699239;C2347634;C2348143
presence of enthesitis n,C0150312;C0392148;C3854307
mases $nmbr$ $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
presence of dactylitis n,C0150312;C0392148;C3854307
dactylitis count $nmbr$ $nmbr$ mean sd,C0239161;C2699239
week $nmbr$ itt population,C0032659;C1257890
apremilast $nmbr$ mg bid n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
concomitant conventional dmard use,C0042153;C0457083;C1947944
prior biologic exposure,C0274281;C0332157
biologic naive,C0005515;C0205460
prior biologic use,C0042153;C0457083;C1947944
biologic therapeutic failure,C0231174;C0680095
trial,C0008976
trial $nmbr$,C0008976
scale obesity and prediabetes,C0028754;C1963185;C0362046
scale diabetes,C0011847;C0011849
phase $nmbr$ dose finding trial,C0037088;C0008976;C0243095;C2825141
biometric parameters,C0449381
[sd],C2699239
[ $nmbr$ ],
glycaemic parameters,C0449381
mean hba $nmbr$ c,C0444504;C0019016;C1825777;C3538758;C2347634;C2348143
mean hba $nmbr$ c mmol mol,C0019016;C3829066;C1825777;C3538758
individuals with pre diabetes n,C0027361;C0237401
individuals with type $nmbr$ diabetes n,C0027361;C0237401
normoglycaemic individuals n,C0580545;C0027361;C0237401
figure $nmbr$ liraglutide exposure and body weight loss in men and women,C0274281;C0332157;C2911645;C0025266;C0043210
liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial,C0274281;C0332157;C0017446;C0205146;C0376690;C0678587;C0005911;C0025266;C0043210;C0042295;C1180280;C0444504;C2347634;C2348143;C0205120;C0205119;C1552595;C1882932;C0549183;C0876920;C2347635;C2348144;C2939193;C1514721;C0178602;C0205132;C0750572;C0032659;C1257890;C0205452;C0032042;C1696465;C1706408;C1456408;C0023693;C1306462;C1570446;C1881376;C3842678;C4050248;C4521367;C0028754;C1963185;C0008976;C0011847;C0011849;C0282460
figure $nmbr$ liraglutide exposure and glycated haemoglobin hba $nmbr$ c,C0274281;C0332157;C0019020;C3889898
exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes,C0274281;C0332157;C0017446;C0205146;C0376690;C0678587;C0392747;C0443172;C1705241;C4319952;C0027361;C0237401;C0497406;C0028754;C1963185;C1320657;C0205363;C0008976;C0444504;C0042295;C2347634;C2348143;C0205423;C0032042;C0205132;C1696465;C1706408;C1882932;C0750572;C0057717;C0549183;C0876920;C2347635;C2348144;C2939193;C1514721;C0178602
demographic feature,C0683970
black race no total no f,C0005680;C0439175;C0439810;C0016327
hispanic ethnic group no total no j,C0015031;C1879937;C0439175;C0439810
stroke no total no,C0038454;C4554100;C0439175;C0439810
at entry,C1705654
coronary artery disease no total no,C0010054;C0010068;C1956346;C0439175;C0439810
atrial fibrillation no total no,C0004238;C0344434;C1963067;C0439175;C0439810
physical and cognitive examination,C0031809;C0205485;C1509143;C1516691;C4321457
score on modified mini mental state examination median iqr,C4304091;C0549183;C0876920;C2347635;C2348144;C2939193
score on nih stroke scale median iqr,C4049715
score on modified rankin scale median iqr,C4049715
median fasting insulin iqr pu per milliliter,C0549183;C0876920;C2347635;C2348144;C2939193;C0015663;C0021641;C0018387;C1533581;C1579433;C3714501
homa ir index median iqr,C0022065;C0022071;C1448132
fasting cholesterol mg dl,C0015663;C0008377;C0439269
statin no total no,C0360714;C0439175;C0439810
antiplatelet no total no,C0439175;C0439810
oral anticoagulant no total no,C0354604;C0439175;C0439810
ace inhibitor or angiotensin receptor blocker no total no,C0003015;C4541021;C0034787;C1622222;C0439175;C0439810
diuretic no total no,C0012798;C0439175;C0439810
beta blocker no total no,C0001645;C0439175;C0439810
interval after index event,C1272706;C1552654;C1552713
no of days to homa ir testing median iqr,C0439228;C0022065;C0022071;C1448132
no of days to randomization median iqr,C0439228;C0034656;C0549183;C0876920;C2347635;C2348144;C2939193
homa ir index,C0600653;C0918012;C1552854;C1637833;C2986546
medication adherence,C2364172
$nmbr$ $nmbr$ to $nmbr$ $nmbr$ n $nmbr$,C0369718;C0441922
mean lvef,C0428772;C0488728
prior hf hospitalization,C0018488;C0019993;C1313497;C1538440;C3273279
ischemic cardiomyopathy,C0349782
history of af,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
icd or crt d,C0021122
hf hospitalisation,C0018488;C0019993;C1313497;C1538440;C3273279
breakfastb,
lunchb,
evening mealb,C0587117
lm $nmbr$ bid n $nmbr$,C1261082;C1551056
igl n $nmbr$,C0021037;C0314619;C2247518
glycemic variability mmol lc,C2827666;C0439190
insulin glargine dose at screening visit iu,C0366513
figure $nmbr$ change in glycosylated hemoglobin hba $nmbr$ c from baseline to $nmbr$ weeks in patients with type $nmbr$ diabetes treated with insulin lispro protamine suspension $nmbr$ insulin lispro solution $nmbr$ lm $nmbr$ or basal insulin glargine once daily plus prandial insulin lispro once daily igl grouped according to main meal the meal with the highest $nmbr$ hour postprandial blood glucose level as determined from three separate $nmbr$ point self monitoring of blood glucose profiles all changes significant versus baseline p $nmbr$ $nmbr$,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488;C1550335;C0332293;C0982221;C0907402;C0332173;C0293359;C0021037;C0314619;C2247518;C0439745;C4319846;C1998602;C0020456;C0521095;C0205449;C0005803;C1979963;C2003903;C0237881;C0750502;C1546944
data are presented as box plots which allow presentation of multiple statistical endpoints diamonds mean horizontal lines median end margins of boxes $nmbr$ th and $nmbr$ th percentile values,C1511726;C3245479;C3714741;C0449450;C1706992;C0683607;C0444504;C0039725;C1532337;C0039738;C1420718;C4282123;C4285344
table $nmbr$ characteristics of the patients at baseline,C0039224;C0815172;C1706074;C0168634;C1442488
fluticasone salmeterol n $nmbr$,C0939232
fluticasone alone n $nmbr$,C0082607;C0205171;C0439044;C0679994
patients with diabetes mellitus n $nmbr$,C0030705;C0011849
patients without diabetes mellitus n $nmbr$,C0030705;C0011849
patients with diabetes mellitus,C0030705;C0011849
continued thienopyridine n $nmbr$,C0549178;C1120149
hispanic or latino ethnic group,C0086409;C0015031;C1879937
oral medications,C0304289
without insulin or insulin modifying therapy,C0021641;C1533581;C1579433;C3714501;C0392747;C0039798;C0087111;C1363945
lesion s,C0221198;C1546698
modified acc aha lesion class b $nmbr$ or c,C4072694;C0221198;C1546698
figure $nmbr$ ischemic and bleeding outcomes by randomized treatment arm according to diabetes mellitus status treatment effect according to diabetes status at $nmbr$ to $nmbr$ months in all randomly assigned patients n $nmbr$ $nmbr$ for the outcomes of stent thrombosis major adverse cardiovascular and cerebrovascular events and severe or moderate bleeding,C0475224;C0085415;C1518681;C0749659;C0439231;C0030705;C1274040;C3897493;C0441471;C3541888;C0205082;C4050465;C4050466;C0205081;C0019080;C1881878;C4049705;C4049706;C4085643;C4321335
reslizumab $nmbr$ $nmbr$ mg kg n $nmbr$,C1869620;C0439272
bmi mean kg m $nmbr$,C0022718;C0439209;C4054209
years since diagnosis mean,C0439234;C0011900;C1704338;C1704656
ics use at enrollment mean mg d,C0042153;C0457083;C1947944
exacerbation within previous $nmbr$ mo no,C4086268;C0026544;C0332177
acq score mean,C0444504;C2347634;C2348143
airway reversibility,C0178987;C0449261;C0458827
fev $nmbr$ mean l,C0444504;C2347634;C2348143
rescue medication use mean inhalations previous $nmbr$ d,C0004048;C0354922;C0205156;C1552607
blood eosinophils mean range cells ml,C2699156
treated with laba,C0332293
baricitinib $nmbr$ mg daily n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
positive for anti cyclic citrullinated peptide antibody no f,C0741132;C1320283;C0016327
positive for rheumatoid factor no t,C0439178;C1446409;C1514241;C2825490;C3812269;C2603360
no of previous biologic dmards no,C0205156;C4055380;C1552607
tnf inhibitors,C1448177;C0243077
non tnf inhibitors,C1448177;C0243077
swollen joint count of $nmbr$ joints examined,C0451521;C0332128
tender joint count of $nmbr$ joints examined,C0451530;C0332128
scores for global and pain assessments,C0449820;C0205246;C2348867;C0030198
physician s global assessment,C0031831;C0804815;C0281858
patient s global assessment,C0030705;C0281858
patient s assessment of pain,C0030705;C0030198
haq di scored,C3826998;C4321476;C0449820
high sensitivity crp mg liter,C1441604;C0475211
esr mm hr,C3811131;C4330985;C4554674
simplified disease activity index score,C4706353
baricitinib $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
of prior bdmards,C0332152;C2826257
of prior tnfi among non tnfi naive,C0332152;C1518422;C2826257
of prior non tnfi bdmards,C0332152;C1518422;C2826257
characteristica,
ukpds $nmbr$ year risk score $nmbr$,C0035647;C0449820;C4050231;C4552904
ukpds $nmbr$ year risk score,C0035647;C0449820;C4050231;C4552904
saxagliptin $nmbr$ $nmbr$ mg n z $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
saxagliptin $nmbr$ mg n z $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
t $nmbr$ dm duration y,C0011816;C0449238;C2926735;C3250443
baseline fpg,C0168634;C1442488
baseline $nmbr$ h ppg,C0033727;C1418888;C0369286;C0441932;C0564385;C4528284
$nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ ],
mmol l [n],C1532563;C0369718;C0441922
saxagliptin $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
saxagliptin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
baseline mean se,C0168634;C0036919;C1442488
week $nmbr$ mean se,C0332174;C0036919;C0439230
adjusted mean change,C0392747;C0443172;C1705241;C4319952
from baseline $nmbr$ ci,C0008107;C3259781
treatment by subgroup interaction p $nmbr$ $nmbr$,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
ppg mmol l,C1418888;C1532563
white race no y left ventricular ejection fraction,C0007457;C0043157;C0428772;C0488728
nyha functional classification no i,C1275491;C0205245;C0542341;C2700217;C0021966;C0221138
hospitalization in previous year with management of heart failure,C0019993;C0205156;C1552607;C0001554;C0376636;C1273870;C3273539
as major component no,C0449432;C1705248
qrs $nmbr$ ms $nmbr$ cl n $nmbr$,C2349943;C0596019;C3539704;C3713294
hr $nmbr$ cl pvalue,C0596019
adjusted hr $nmbr$ cl pvalue,C0456081;C0596019
$nmbr$ events,C0441471;C3541888
$nmbr$ $nmbr$ per $nmbr$ py,C0030428;C3538810
$nmbr$ events $nmbr$ $nmbr$ per $nmbr$ py $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0441471;C3541888;C0030428;C3538810
$nmbr$ event $nmbr$ $nmbr$ per $nmbr$ py $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0441471;C4019010;C0030428;C3538810
heart failure hospitalizations,C3898876
persistent faol n [ $nmbr$,C0205322;C0332996
persistent faod n [ $nmbr$,C0205322;C0332996
inconsistent fao n [ $nmbr$,C0442809;C0016457
total n [ $nmbr$,C0439175;C0439810
duration of asthma y,C0449238;C2926735
predose fev $nmbr$ l,C0439565;C3714541;C3812758
fevj predicted t,C0681842;C1882327
fvc predicted t,C0681842;C1882327
baseline ics dose n,C0168634;C0178602;C0869039;C1114758;C1442488
moderatex,
highjj,
rescue medication use inh d,C0240320;C0022209
asthma control days,C0004096;C0439228;C2984299
figure $nmbr$ predose fev $nmbr$ improvements in l by treatment and fao status,C0439565;C2986411;C3812758;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0016457;C0449438
baseline was defined as the predose fev $nmbr$ value measured on the day of randomization visit $nmbr$ or the screening predose value if no value was available at visit $nmbr$ bid twice daily bud budesonide fao fixed airflow obstruction fev $nmbr$ forced expiratory volume l in $nmbr$ second fm formoterol,C0168634;C1442488;C1704788;C3539106;C0444706;C3541902;C0220908;C1522609;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164;C1551351;C0205436;C0060657;C0457385;C0565930;C1561503;C1705190
losmapimod n $nmbr$,C3272847
body mass index median iqr b,C0005893;C0578022;C1305855
baseline egfr,C1739039;C3811844;C3812682
prior coronary artery bypass graft surgery,C0010055
prior peripheralarterialdisease,C0332152;C2826257
prior ischemic stroke,C0332152;C0948008;C2826257
baseline laboratory values median iqr d,C0022877;C0042295;C3244292;C4283904
high sensitivityc reactive protein mg l,C0033684;C0439268
n terminal pro brain natriuretic peptide pg ml,C3272900;C0439297
index events,C0441471;C3541888
non st elevation myocardial infarction,C1536221;C1536222;C3537184;C4255010
st elevation myocardial infarction,C1536220;C3538872
catheterization performed for qualifying event,C0007430;C0884358;C1514624;C0441471;C4019010
pciperformed for qualifying event,C1514624;C0441471;C4019010
fibrinolytic for qualifying event,C0040044;C1514624;C0441471;C4019010
time from study drug administration to coronary revascularization median iqr h,C0040227;C0206209;C2349982;C0033727;C0369286;C0441932;C0564385;C4528284
useofmedical therapyathospitaldischarge,
p $nmbr$ y $nmbr$ inhibitor,C0369773;C1999216;C2603361
ace inhibitor or angiotensin receptor blocker,C0003015;C4541021;C0034787;C1622222
events no,C0441471;C3541888
$nmbr$ wk kaplan meier rate,C0871208;C1521828
losmapimod,C3272847
qualifying diagnosis,C1514624;C0011900;C1704338;C1704656
non st elevation mi,C0520886;C3810814
st elevation mi,C0520886;C3810814
chronic kidney disease,C1561643;C4553188
prior pci or cabg surgery,C0332152;C4049621;C2826257;C0038894;C0038895;C0543467;C1274039
planned treatment strategy,C0599880;C0679199
invasive,C0205281;C1334278
conservative,
actual treatment strategy,C0039798;C0679199;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
medical management only,C0199168;C0001554;C0376636;C1273870;C3273539;C0205476
time from randomization to pci st elevation mi min,C0040223;C3541383;C0702093;C1524029;C3813700
time from randomization to pci non st elevation mi h,C0040223;C3541383;C0033727;C0369286;C0441932;C0564385;C4528284
no of predictors of cardiovascular risk,C0007226;C0035647;C4552904;C3887460
index mi n $nmbr$ $nmbr$,C0600653;C0918012;C1552854;C1637833;C2986546
any mi n $nmbr$ $nmbr$,C3810814
no mi n $nmbr$ $nmbr$,C3810814
pvaluefor any mi versus no mi,C3810814
race nonwhitet,C0034510;C1706779;C3853635
diet controlled or no,C0743195
history of major bleeding,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
indication for index procedure,C2315323;C0600653;C0918012;C1552854;C1637833;C2986546
unstable anginat,C0443343;C1883468
any mi,C3810814
ischemic outcomes,C0475224;C1274040
continue thienopyridine n $nmbr$,C0549178;C1120149
stratified hazard ratio $nmbr$ ci,C0008107;C3259781
stratified log rank p value,C0205363;C1709380
stent thrombosis arc definite probable,C0033204;C0332148
macce death mi stroke,C0038454;C4554100
stent thrombosis related mi,C3897493;C3810814
non stent thrombosis related mi,C3897493;C3810814
bleeding outcomes,C0019080;C1274040
log rank p value,C0667477;C1709380;C0699794
gusto severe moderate,C1299393
barc types $nmbr$ $nmbr$ or $nmbr$,C0332307
log rank,C0667477;C0699794
no diabetes n $nmbr$ $nmbr$,C0011847;C0011849
diabetes n $nmbr$ $nmbr$,C0011847;C0011849
qualifying mi type,C1514624;C0332307;C1547052
qualifying mi,C1514624;C3810814
history of second prior mi,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
non end stage renal dysfunction,C1565489;C3279454
multivessel coronary artery disease,C0010054;C0010068;C1956346
history of hypercholesterolemia,C1533076
history of stroke or transient ischemic attack,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0007787;C0917805
prior coronary artery bypass grafting,C0332152;C0010055;C2826257
history of percutaneous coronary intervention,C1320647;C4554713
ace i or angiotensin receptor blocker,C0021966;C0221138;C0034787;C1622222
history of diabetes requiring drugs,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0013227;C3687832
figure $nmbr$ rates of mace in the pooled ticagrelor versus placebo arms for patients with and without diabetes,C0871208;C1521828;C1709595;C1999375;C2349200;C4522255;C0206655;C0446516;C2681631;C3715044;C4553528;C0011847;C0011849
no pad n $nmbr$ $nmbr$,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
pad n $nmbr$ $nmbr$,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
history of copd,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
history of stroke or tia,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0007787;C0917805;C1054154
history of pci with stenting,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0038257;C2348535
history of claudication,C2315493
western europe including south africa,C0043129
asia australia new zealand,C0027978;C0324547
time from qualifying mi yrs,C0040223;C3541383;C1514624;C3810814
qualifying mi $nmbr$ yrs prior,C1514624;C0332152;C2826257
time from last dose of p $nmbr$ y $nmbr$ inhibitor days,C0946444
beta blocker use at baseline,C0042153;C0457083;C1947944
ace i or arb use at baseline,C0021966;C0221138;C0042153;C0457083;C1947944
central illustration ticagrelor in patients with pad and prior mi $nmbr$ year results,C1999375;C0030705;C0182158;C0332568;C3540603;C3669270;C3814046;C4319657;C1274040;C1546471;C2825142
peripheral artery disease pad,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
adolescents aged $nmbr$ $nmbr$ y no,C0001779;C0001792;C1999167
adults aged $nmbr$ y no,C0001675;C0001779;C0001792;C1999167
non hispanic non latino,C1518424;C0086528
mean time since diagnosis y,C0040223;C3541383
exacerbation within $nmbr$ mo,C4086268;C0026544;C0332177
aqlq score mean,C0444504;C2347634;C2348143
asui score mean,C0444504;C2347634;C2348143
airway reversibility mean,C0444504;C2347634;C2348143
fev $nmbr$ mean predicted,C0444504;C2347634;C2348143;C0681842;C1882327
rescue use mean no of inhalations d,C0444504;C2347634;C2348143;C0004048;C0354922
blood eosinophils mean range cells mlb,C0005773
total daily dose of ics mean gc,C2348070;C0444504;C2347634;C2348143
a reslizumab $nmbr$ $nmbr$ mg kg n n,C1869620;C0439272
b reslizumab $nmbr$ $nmbr$ mg kg n n,C1869620;C0439272
eos count cells pl,C3897966;C4049765
mensa,
sirius,
prior oma use,C0042153;C0457083;C1947944
no prior oma use,C0042153;C0457083;C1947944
mepo n $nmbr$,
prior oma use n $nmbr$,C0332152;C0042153;C0457083;C1947944;C2826257
no prior oma use n $nmbr$,C0332152;C0042153;C0457083;C1947944;C2826257
annual exacerbation rate,C0871208;C1521828
age mean range years,C1510829;C0444504;C2347634;C2348143
rate ratio mepo pbo $nmbr$ ci,C0008107;C3259781
female n race n,C0043210;C0034510;C1706779;C3853635;C0086287;C1705497;C1705498
change from baseline in acq $nmbr$,C0392747;C0443172;C1705241;C4319952;C2919686
score at week $nmbr$ mean se difference mepo pbo $nmbr$ ci,C3533236;C0008107;C3259781
change from baseline in sgrq,C0392747;C0443172;C1705241;C4319952
change from baseline in morning pef during weeks $nmbr$ $nmbr$ mean l min se,C0392747;C0443172;C1705241;C4319952;C0030771;C1518922;C1542834
hispanic ethnicity n,C0086409;C0015031;C0243103
difference mepo pbo $nmbr$ ci,C0008107;C3259781
change from baseline in pre bd,C0392747;C0443172;C1705241;C4319952;C0005126;C2344255;C4050145
fev $nmbr$ at week $nmbr$ mean ml se difference mepo pbo $nmbr$ ci,C3714541;C0008107;C3259781
duration of asthma,C0449238;C2926735
change from baseline in post bd,C0392747;C0443172;C1705241;C4319952;C0005126;C2344255;C4050145
mean sd years daily ocs use n,C0332173;C0042153;C0457083;C1947944
ocs dose mean sd,C0178602;C2699239;C0869039;C1114758
ratio to baseline in eosinophil count at week $nmbr$ geometric mean se on loge scale cells ll,C0456603;C1547037;C0200638;C0750879;C0007584;C0007634
mg day,C0439422
ratio mepo pbo $nmbr$ ci,C0008107;C3259781
eosinophils cells ll inclusion criteria n,C0007584;C0007634;C1512693
ratio to baseline in total ige at week $nmbr$ geometric mean se on loge scale u ml,C0456603;C1547037;C0806481;C2986759;C0439340;C1880521;C2945590
$nmbr$ in previous,C0205156;C1552607
$nmbr$ at screening,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
predicted pre bd,C0005126;C2344255;C4050145
fev $nmbr$ mean sd pre bd fev $nmbr$ fvc,C0005126;C3714541;C2344255;C4050145
mean sd reversibility fev $nmbr$ at,C0444504;C3714541;C2347634;C2348143
screening mean sd morning pef mean,C0220908;C0030771;C1518922;C1542834;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
sd l min acq $nmbr$ score mean sd,C0449820;C0444504;C2347634;C2348143;C4050231
sgrq score mean sd,C0444504;C2699239;C2347634;C2348143
total ige geometric,C0439175;C0439810
mean sd on loge scale u ml,C2699239;C0439340;C1880521;C2945590
blood eosinophil count geometric mean sd loge scale cells ll,C0005773
severe exacerbations,C0205082;C4086268;C4050465;C4050466
in previous year mean sd,C0205156;C2699239;C1552607
exacerbations in previous year requiring hospitalization and or ed visit n,C4086268;C0205156;C1552607;C0019993;C0545082;C1512346;C2826704
exacerbations in previous year requiring hospitalization n,C4086268;C0205156;C1552607;C0019993
spondylitis,C0038012
non spondylitis,C1518422;C0038012
ustekinumab combined,C1608841;C0205195
randomised patients with spondylitis at baseline n,C0030705;C0038012;C0168634;C1442488
patients randomised n,C0030705
randomised patients with basdai assessment at baseline and week $nmbr$ n,C1998004;C0679830;C0168634;C1442488;C0332174;C0439230
mean sd improvement from baseline to week $nmbr$ in basdai,C2986411;C0168634;C1442488;C0332174;C0439230;C1998004
number of swollen joints $nmbr$ $nmbr$ mean sd,C0449813
mean sd improvement from baseline to week $nmbr$ in basdai questions,C2986411;C0168634;C1442488;C0332174;C0439230;C1998004;C1522634
number of tender joints $nmbr$ $nmbr$ mean sd,C0449813
question $nmbr$ fatigue tiredness,C0015672;C4553152
haq di score $nmbr$ $nmbr$ mean sd,C3826998;C2699239;C4321476
question $nmbr$ neck back hip pain,C0007859;C1963180;C4553909
crp mg l mean sd,C0439268;C2699239
question $nmbr$ pain swelling in joints other than neck back hips,C0152031;C0004600;C0019552;C0205095;C0460009;C1995000
psa subtypes n,C3810537;C0449560;C3813209
question $nmbr$ discomfort from any areas tender to touch pressure,C2364135;C0205146;C4319729;C0033095;C0460139;C1306345;C4284008
dip joint arthritis,C0003864;C4552845
question $nmbr$ morning stiffness since arising,C1522634;C0457086;C0332284;C4019053;C4318616
arthritis mutilans,C0702102
question $nmbr$ length of morning stiffness since arising,C1444754;C1706316;C0332284;C4019053;C4318616
asymmetric peripheral arthritis,C0332514;C0238694
basdai responses at week $nmbr$,C0871261;C0332174;C0439230
polyarticular arthritis no rheumatoid nodules,C0162323;C0035450
basdai $nmbr$ n,C1998004
spondylitis with peripheral arthritis,C0038012;C0238694
psa duration years mean sd,C0439234;C2699239
psoriasis duration years mean sd,C0033860;C2699239
patients taking mtx n,C0030705;C0025677;C1417487
patients with digits with dactylitis n,C0030705;C0582802;C0239161
haq di improvement from baseline to week $nmbr$,C3826998;C2986411;C4321476;C0332174;C0439230
dactylitis score $nmbr$ $nmbr$ mean sd,C0239161;C2699239
patients with enthesitis n,C0030705;C1282952
enthesitis score mases $nmbr$ $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
patients with radiographic erosion n n,C0030705;C0333307;C1880549;C1959609;C3887524
randomised patients with $nmbr$ bsa psoriasis skin involvement at baseline,C0522476;C0168634;C1442488
basdai score $nmbr$ $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
dlqi improvement from baseline to week $nmbr$,C2986411;C0168634;C1442488;C0332174;C0439230
basdai question $nmbr$ score $nmbr$ $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
patients with $nmbr$ bsa psoriasis skin involvement n,C0522476
bsa mean sd,C0444504;C2699239;C2347634;C2348143
pasi score $nmbr$ $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
randomised patients with dactylitis at baseline,C0030705;C0239161;C0168634;C1442488
dlqi $nmbr$ $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
improvement in dactylitis score at week $nmbr$ n,C2986411;C0239161;C0332174;C0439230
patients with dactylitis at week $nmbr$ n,C0030705;C0239161;C0332174;C0439230
randomised patients with enthesitis at baselinet,C0030705;C1282952
improvement in enthesitis score at week $nmbr$ n,C2986411;C0449820;C4050231;C0332174;C0439230
patients with enthesitis at week $nmbr$ n,C0030705;C1282952;C0332174;C0439230
standard treatment n $nmbr$,C4684780
mra regimen n $nmbr$,C0243032;C0040808;C2945654;C1609165;C3891069
risk factors and medical history,C0035648;C1553898;C0262926;C1704706
presentation,C0449450
creatinine clearance ml min $nmbr$,C0812399;C0439445
potassium at admission mmol l $nmbr$,C0032821;C0202194;C0304475;C0597277;C3714637
admission grace score,C0449820;C4050231
in hospital medication,C0013227;C3244316;C4284232
p $nmbr$ y $nmbr$ antagonist,C0369773;C0231491;C2603361
fibrinolysist,
glycoprotein iib iiia inhibitort,C0016011
interventional or surgical procedures,C0184661;C3274035;C0543467
primary pcit,C0205225;C0439612;C0439631
demographic characteristic,C0011298;C1521970
umec $nmbr$ $nmbr$ ig n $nmbr$,C0021027;C0305052;C0360506
tio $nmbr$ ig n $nmbr$,C0021027;C0305052;C0360506
umec $nmbr$ $nmbr$ mcg n $nmbr$,C0439211;C3463985
tio i $nmbr$ mcg n $nmbr$,C0021966;C0221138
treatment diff vs tio $nmbr$ ci,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0008107;C3259781
gold grade $nmbr$,C0441800;C0919553;C3244287
ls mean change from baseline ml se a,C0392747;C0443172;C1705241;C4319952
$nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0369773;C2603361
current smoker at screening n,C3173209;C3241966
smoking pack yearsa,C0037369;C0453996;C1881674
post salbutamol fev $nmbr$ l b mean sd,C0001927;C2699239
gold group b,C0018026;C4522078;C1304897
post salbutamol fev $nmbr$ fvcb mean sd,C0001927;C2699239
reversibility to salbutamolc d mean sd,C0449261;C0444504;C2699239;C2347634;C2348143
gold group d,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
nonreversible,
ics users at screening,C1706077;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
gold grades $nmbr$ $nmbr$ percent predicted fev n,C0018026;C0439165;C1304897
grade $nmbr$ moderate copd n,C0205081;C0024117;C1412502;C3714496;C1881878;C4049705;C4049706;C4085643;C4321335
ics non users at screening,C1518422;C1706077
grade $nmbr$ severe copd n,C0205082;C0024117;C1412502;C3714496;C4050465;C4050466
gold groups a d using mmrcb,C0441838;C1524063
gold grade $nmbr$ and ics users at screening,C0441800;C0919553;C3244287;C1706077;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
group b low risk more symptoms n,C3272281;C3538919;C0683368;C1457887
group d high risk more symptoms n,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C0332167;C3272283;C4050568;C4319571;C0683368;C1457887
gold grade $nmbr$ and ics non users at screening,C0441800;C0919553;C3244287;C1518422;C1706077
ics use at screening,C0042153;C0457083;C1947944
ics nonusers n,C0815320;C4551720
proportion of patients with trough fevi $nmbr$ ml above baseline n,C1709707;C0030705;C0439526;C1705224;C3887665
or $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0369773;C2603361
heterogeneity test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
y $nmbr$,
previous statin use,C0042153;C0457083;C1947944
troponin $nmbr$ at baseline,C0041199;C0168634;C1442488
$nmbr$ $nmbr$ ng ml,C0439275
duration of assigned regimen before surgery,C0449238;C2926735;C0038894;C0038895;C0543467;C1274039
surgical technique,C0683469
on pump,C3842462
off pump,C1518543;C0182537
procedure,C0184661;C2700391;C3274430;C3539779
aortic valve replacement,C0003506
postoperative glucocorticoid use,C0042153;C0457083;C1947944
postoperative nsaid or glucocorticoid use,C0003211;C3536840;C0042153;C0457083;C1947944
trend het test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
duration of assigned regimen before surgery post randomisation characteristic,C0449238;C2926735;C0034656;C1521970
xi $nmbr$ $nmbr$,C1720296
xi $nmbr$,C1720296
percentage difference $nmbr$ cl,C0439165;C0596019;C1549488;C1561533
surgical technique post randomisation characteristic,C0683469;C1521970
avr,C0449217
postoperative glucocorticoid use post randomisation characteristic,C0017710;C1521970
postoperative nsaid or glucocorticoid use post randomisation characteristic,C0003211;C3536840;C0017710;C1521970
x $nmbr$ $nmbr$,
dulaglutide $nmbr$ $nmbr$ mgf,C1366394;C3712803;C3887684
age $nmbr$ vears n $nmbr$,C0001779
previous oral antidiabetic medication use n,C1527415
no oral antidiabetic medication,C0175795
$nmbr$ oral antidiabetic medication,C0175795
insulin oral antidiabetic medication s,C0175795
figure $nmbr$ glycated haemoglobin hba $nmbr$ c change from baseline to $nmbr$ weeks by individual study,C0392747;C0443172;C1705241;C4319952;C0439230;C0027361;C0237401
data presented as ls means and $nmbr$ cis award assessment of weekly administration of ly $nmbr$ dulaglutide in diabetes bl baseline hbalc glycated haemoglobin met metformin su sulphonylurea tzd thiazolidinedione yrs years,C1511726;C3245479;C3714741;C0449450;C0023668;C2708217;C2708218;C0017853;C0439234
europe and australia,C0015176;C0004340
latin and north america,C0028405
systemic corticosteroids n a,C4053960
das $nmbr$ esr mean sd,C0051767;C2699239;C0057671
moderate disease activity $nmbr$ $nmbr$ to,C1513375;C3833417
high disease activity $nmbr$ $nmbr$ n,C4699623
sdai mean sd,C0444504;C2699239;C2347634;C2348143
cdai mean sd,C0444504;C2699239;C2347634;C2348143
haq di mean sd,C3826998;C2699239;C4321476
tjc $nmbr$ joints mean sd,C0022417;C2699239;C0392905
sjc $nmbr$ joints mean sd,C0022417;C2699239;C0392905
esr mm h median min max,C3642211
crp mg l median min max,C0439420
months since ra was first diagnosed mean sd,C0439231;C3538806;C4048756;C0011900;C2699239
$nmbr$ months mean sd,C0439231;C2699239
months since first ra symptom mean sd f,C0439231;C0016327
rf positive $nmbr$ iu ml n,C0035448;C0439458;C0201660;C0748398;C1547111
acpa positive $nmbr$ iu ml n,C0439178;C0439458;C1446409;C1514241;C2825490;C3812269
mtss median min max,C0549183;C0702093;C1524029;C3813700;C0876920;C2347635;C2348144;C2939193
$nmbr$ months median min max,C0439231;C0549183;C0876920;C2347635;C2348144;C2939193
$nmbr$ $nmbr$ $nmbr$ $nmbr$ l,C0439394;C1706495;C3642217
erosion score median min max,C0333307;C0449820;C4050231;C1880549;C1959609;C3887524
jsn median min max,C0549183;C0702093;C1524029;C3813700;C0876920;C2347635;C2348144;C2939193
presence of erosions n,C0150312;C0392148;C3854307
supplementary figure $nmbr$ subgroup analysis stratified by time since ra diagnosis for week $nmbr$ outcomes in the a pbo mtx and b czp mtx groups c odds ratios for week $nmbr$ outcomes stratified by time since ra diagnosis forest plot,C2986480;C0205363;C0040223;C3541383;C0011900;C1704338;C1704656;C0025677;C1417487;C0441837;C0028873;C0086312
indacaterol glycopyrronium group n $nmbr$,C1722260;C0441848
salmeterol fluticasone group n $nmbr$,C0939232;C0441848
use of inhaled glucocorticoids at screening no,C1524063;C0004048;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
severity of copd no f,C0439793;C0522510;C0016327
group a,C0441835;C4522145
group b,C4522078
group c,C0441837
group d,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
post bronchodilator fev $nmbr$ liters,C2599594;C0475211
post bronchodilator fev $nmbr$ of predicted value,C2599594;C3714541;C0681842;C1522609;C1882327
post bronchodilator ratio of fev $nmbr$ to fvc,C0456603;C1547037;C3714541
total score on the sgrq c i,C2964552;C3826872
indacaterol glycopyrronium group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
salmeterol fluticasone group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
smoking status at screening,C1519386
severity of airflow limitation,C0439793;C0522510
severity of copd,C0439793;C0522510
copd exacerbations during the previous year,C0740304;C0205156;C1552607
inhaled glucocorticoid use at screening,C0042153;C0457083;C1947944
no use,C0042153;C0457083;C1947944
laba use at screening,C0042153;C0457083;C1947944
laba inhaled glucocorticoid use at screening,C0042153;C0457083;C1947944
lama use at screening,C0042153;C0457083;C1947944
included in analysis,C0332257;C0002778;C0936012;C1524024
total sample $nmbr$,C0370003;C2347026
age at baseline in years mean sd,C0001779;C0168634;C1442488;C0439234;C2699239
$nmbr$ $nmbr$ lo i,C0021966;C0221138
time from parkinson s disease diagnosis in months mean sd,C0040223;C3541383;C0439231;C2699239
total updrs score baseline mean sd,C2964552;C2699239
activities of daily living updrs subscore baseline mean sd,C0001288;C4050548
motor updrs subscore baseline mean sd,C0168634;C2699239;C1442488
mental activities updrs subscore baseline mean sd,C0168634;C2699239;C1442488
hoehn and yahr stage baseline mean sd,C0168634;C2699239;C1442488
initial treatment randomization,C0039798;C0034656;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
$nmbr$ mg $nmbr$ $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
placebo $nmbr$ $nmbr$ $nmbr$,C0032042;C1696465;C1706408
gentype,
weeks,C0439230
weeks_measured,C0444706;C3541902
mean change in total updrs scores adjusted according to baseline updrs,C0392747;C0443172;C1705241;C4319952;C0456081;C0168634;C1442488
$nmbr$ to $nmbr$ y n $nmbr$ $nmbr$ $nmbr$,
$nmbr$ y n $nmbr$ $nmbr$ $nmbr$,
event rate vr,C0441471;C3476815;C4019010
edoxaban vs warfarin,C2975435;C0043031
$nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
edo,
stroke see,C0042789;C1947903
type of af,C0332307;C1547052
persisent,
fatal stroke,C0038454;C4554100
crcl ml min at randomization,C0439445;C0034656
cha $nmbr$ ds $nmbr$ vasc score,C0449820;C4050231
has bled score $nmbr$,C0449820;C4050231
major gl bleeding,C0018229;C0019080;C1423073;C1427674
time in therapeutic range,C1554109
dose reduction at randomization,C0301630;C0392756;C1293152;C4551656
prior vka experience,C0237607;C0596545
medication at time of randomization,C0013227;C3244316;C4284232
gly $nmbr$ $nmbr$ mg b i d n $nmbr$,C0439422
ind $nmbr$ mg q d n $nmbr$,C4049864;C0439422
number of pack years,C0237753;C0449788
severity of copd airflow limitation n,C0439793;C0522510
moderate gold $nmbr$,C0018026;C1304897
severe gold $nmbr$,C0018026;C1304897
very severe gold $nmbr$,C0018026;C1304897
severity of copd combined assessment n,C0439793;C0522510
mmrc dyspnea scale n,C0013404;C0175659;C0349674;C1947916;C1963100
copd assessment test cat score,C0237855;C0237856
post bronchodilator fev $nmbr$ reversibility a,C2599594;C0449261
ccv history condition,C0683519
gly $nmbr$ $nmbr$ gg b i d n n,C1415124;C0152277
ind $nmbr$ gg q d n n,C0017454;C0018370
severity of airflow obstruction,C0439793;C0522510
mild or moderate copd,C2945599;C0024117;C1412502;C3714496
severe or very severe copd,C0205082;C4050465;C4050466;C0024117;C1412502;C3714496
ics use at baseline,C0042153;C0457083;C1947944
ccv history condition at baseline,C0683519;C0168634;C1442488
history of atrial fibrillation flutter,C0729790
history of cardiac arrhythmia,C3494593
long acting bronchodilator use at screening,C0042153;C0457083;C1947944
attain,
augment copd,C0205217;C0024117;C1412502;C3714496
pooled analysis sample,C1709595
aclidinium $nmbr$ g n $nmbr$ a,C2699757;C0439267
placebo n $nmbr$ a,C0032042;C1696465;C1706408
aclidinium $nmbr$ g n $nmbr$ b,C2699757;C0439267
placebo n $nmbr$ b,C0032042;C1696465;C1706408
all patients n $nmbr$ b,C0030705
post bronchodilator fev $nmbr$ l mean sd c,C2599594;C0444504;C2347634;C2348143
post bronchodilator fev $nmbr$ predicted mean sd c,C2599594;C0444504;C2347634;C2348143
bronchial reversibility sd,C0205039;C2699239;C1442216
number of exacerbations in previous year mean sd,C0237753;C0449788;C0205156;C2699239;C1552607
rs breathlessnessb,C0035970;C3714753;C3813325
rs cough sputumc,C0035970;C0010200;C1961131;C3274924;C4084725;C4084726;C4084727;C3714753;C3813325
rs chest symptomsd,C0035970;C0817096;C1527391;C3714753;C3813325
rs totala,C0035970;C3714753;C3813325
aclidinium $nmbr$ g bid n $nmbr$,C2699757;C0439267
gold group a,C0441835;C4522145
gold group c,C0018026;C0441837;C1304897
fig $nmbr$ change from baseline in e rs scores and proportion of e rs responders at week $nmbr$ overall and by gold group a and b rs total score c and d rs breathlessness domain e and f,C0392747;C0443172;C1705241;C4319952;C0035970;C0449820;C3714753;C3813325;C1709707;C0282416;C1561607;C0441835;C4522145;C2964552;C0013404;C0119082;C0016327
rs cough sputum domain g and h rs chest symptoms domain p,C0370205;C0119082;C0150618;C0035970;C3714753;C3813325
lixisenatide,C2973895
high i $nmbr$ baseline hba $nmbr$ c,C0021966;C0019016;C1825777;C3538758;C0221138
high i $nmbr$ kg m $nmbr$ baseline bmi,C0022718;C0439209;C4054209;C0168634;C0578022;C1442488
short,C1282927;C1806781;C2350002
long i $nmbr$ years duration of diabetes,C0439591;C0011847;C0011849
i $nmbr$ years of age,C0021966;C1510829;C0221138
getgoal l asia,C0003980
getgoal s,
high $nmbr$ baseline hbalc,C0205250;C0168634;C1442488;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
high $nmbr$ kg m^ baseline bmi,C0022718;C0439209;C4054209;C0168634;C0578022;C1442488
long $nmbr$ years duration of diabetes,C0439591;C0011847;C0011849
suit quartile $nmbr$ b $nmbr$ $nmbr$ nmol mmol n $nmbr$,C1532564;C1533073
suit quartile $nmbr$ $nmbr$ $nmbr$,C2828255
suit quartile $nmbr$ $nmbr$ $nmbr$ nmol mmol n $nmbr$,C1532564;C1533073
t $nmbr$ d duration years,C2603360;C0449238;C0439234;C2926735
oad use n,C0042153;C0457083;C1947944
oad history years,C0019664;C0439234;C0019665;C0262512;C0262926;C1705255;C2004062
ppg post meal test mmol l,C0376674;C1532563
suit index nmol mmol,C1532564;C1533073
no cv event n $nmbr$ $nmbr$,C3538987;C0441471;C4019010;C4048877;C4318503
nonfatal mi n $nmbr$,C3810814
hhf n $nmbr$,
nonfatal stroke n $nmbr$,C0038454;C4554100
ua n $nmbr$,C0041580;C0042014
baseline glycated hemoglobin,C0168634;C0017853;C1442488
cv risk factors and history,C0035648;C1553898;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
alogliptin n,C1958126
$nmbr$ kg ma $nmbr$,C0024443;C3887485
$nmbr$ years and $nmbr$ years,C0439234
western europe australia new zealand middle eai,C0043128;C0027978;C0324547
normal function or mild impairment,C4296962;C0221099;C0684336
liraglutide n $nmbr$ $nmbr$,C1456408
heart failurea,C0018787
established cvd age $nmbr$,C0007222;C0001779
$nmbr$ stenosis of coronary carotid or lower extremity arteries,C0007282;C0242231;C0226415
documented symptomatic chdb,C1301725;C0231220;C1609436
documented asymptomatic cardiac ischemiac,C0231221;C0018787;C1522601
heart failure nyha ii iii,C0439070;C1705160
chronic kidney diseased,C0022646;C0227665
cvd risk factors age $nmbr$,C0001783
microalbuminuria or proteinuria,C0730345;C0033687;C1962972;C4554346
hypertension and left ventricular hypertrophy,C0020538;C1963138;C0149721;C3484363
left ventricular systolic or diastolic dysfunction,C0225897;C0039155;C0520863
normal egfr $nmbr$,C1739039;C3811844;C3812682
mild impairment egfr $nmbr$ $nmbr$,C1739039;C3811844;C3812682
moderate impairment egfr $nmbr$ $nmbr$,C1739039;C3811844;C3812682
severe impairment egfr,C1739039;C3811844;C3812682
liraglutide,C1456408
table $nmbr$ characteristics of the patients at baseline according,C0039224;C0815172;C1706074;C0168634;C1442488;C0680240
to the estimated glomerular filtration r,C0205090;C0684010;C2603358
ate egfr,C1739039;C3811844;C3812682
p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition,C1709380;C1704970;C2699239;C0017654;C1424601;C0750572;C3839656;C1739039;C3811844;C3812682;C0686905;C0030705;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C0237881;C0750502;C1546944;C0041420;C0681848;C0023822;C1704436;C4025272;C0439232;C0700321;C0702093;C1282918;C2347166;C0042295;C0008377;C1532563;C1719797;C2911648;C0041004;C0005893;C0578022;C1305855;C0005910;C0043100;C1305866;C1705104;C0332849;C0205120;C1552595;C0017853;C1522609;C1551393;C1705492;C3272743;C0456603;C1547037;C0444706;C3541902;C0439208;C0065055;C0032042;C1696465;C1706408;C0017351;C0021034;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0205447;C0439526;C1705224;C3887665;C0231174;C0680095;C0521095;C1140263;C0012634;C0348080;C1705253;C3864998
patients with egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less,C0030705;C0439526;C1705224;C3887665;C0439232;C0700321;C0702093;C1282918;C2347166
patients with minute per,C0030705;C0439232;C0700321;C0702093;C1282918;C2347166
egfr of $nmbr$ ml per $nmbr$ $nmbr$ m $nmbr$ or more,C1739039;C3811844;C3812682
empagliflozin n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C3490348
interval of $nmbr$ yr since diagnosis of type $nmbr$ diabetes no,C1272706;C1552654;C1552713;C1550351
urinary albumin to creatinine ratio no,C0486293;C1318293
low density lipoprotein^,C0023823
high density lipoprotein],C0023821
angiotensin converting enzyme inhibitor or angiotensin,C0003015;C2757044;C3536837;C4541021;C0003018;C4521302
receptor blocker,C0597357
statin and or ezetimibe,C0360714;C1142985
anti hypertensive therapy,C0585941
ace inhibitor and or arb,C0003015;C4541021;C3888198
us n $nmbr$,C0815353;C3889164
non us n $nmbr$,C1518422;C0815353;C3889164
mean sd n,C0444504;C2347634;C2348143
cardiac biomarker status,C1999091;C2735302
number of vessels treated index pci,C0237753;C0449788
time from hospital admission to pci h median q $nmbr$ q $nmbr$,C3854258;C3854259;C0033727;C0369286;C0441932;C0564385;C4528284
efficacy,C1280519;C1707887
primary end point death mi idr st,C0036056;C3272372
key secondary end point st,C0036056;C3272372
idr,
death from cardiovascular causes,C0007465;C0007226;C3887460
death q wave mi idr,C0011065;C0861151;C1306577;C4082313;C4552775
death st,C0036056;C3272372
safety non cabg related bleeding,C0010055;C0019080
gusto defined bleeding,C1704788;C0019080;C3539106
primary safety end point severe life threatening,C1546953;C2826244;C3537125
timi defined bleeding,C1704788;C0019080;C3539106
acuity defined bleeding,C0750509;C0019080
any blood transfusion,C0005841;C0281867
efficacy and safety net adverse clinical events,C1280519;C1707887;C0877248;C1705413
death mi idr st gusto defined moderate or severe bleeding,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0205082;C0019080;C4050465;C4050466
gold a,C0018026;C1304897
gold c,C0018026;C1304897
naive no,
naive yes,C1549445;C1705108;C1710701
ics no,C0815320;C4551720
ics yes,C1549445;C1705108;C1710701
mean sd pre bronchodilator,C0444504;C2599602;C2347634;C2348143
mean sd post bronchodilator,C0444504;C2699239;C2347634;C2348143;C2599594
fev $nmbr$ fvc ratio sd,C0456603;C2699239;C1547037
baseline pulmonary medication n,C0024109;C0013227;C3244316;C4284232;C2707265;C2709248;C4522268
sama,C1075468
fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold $nmbr$ and $nmbr$ disease,C0349966;C1337208;C3714541;C0376690;C0444506;C2964552;C0449820;C4050231;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C2603360;C0439267;C0032042;C1696465;C1706408;C0018026;C1304897;C0012634
fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold a d disease,C0349966;C1337208;C3714541;C0376690;C0444506;C2964552;C0449820;C4050231;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C2603360;C0439267;C0032042;C1696465;C1706408;C0018026;C0012634;C1304897
fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were treatment naive not treatment naive at baseline,C0349966;C1337208;C3714541;C0376690;C0444506;C2964552;C0039798;C1707455;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C2603360;C0439267;C0032042;C1696465;C1706408
fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were receiving not receiving ics treatment at baseline,C0349966;C1337208;C3714541;C0376690;C0444506;C2964552;C0039798;C1707455;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C2603360;C0439267;C0032042;C1696465;C1706408;C1514756;C1518422
rotigotine n $nmbr$,C1700683;C4318637
stage of pda,C0205390;C1300072;C1306673
early n,C1279919
advanced n,C0205179
time since pd diagnosis mean sd,C0040223;C3541383
years modified hoehn and yahr stage n,C0439234;C0679846
brv dosage mg d,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
racial group n,C0441848
whitea,C1021495
baseline focal seizure frequency $nmbr$ days median q $nmbr$ q $nmbr$,C0149775;C0751495
seizure types reported during baseline b n,C0036572;C0332307;C1959629;C4553401;C0684224;C0700287;C4319718
simple partial ia,C0020980;C0694634;C1947960
complex partial ib,C2744579;C3890035;C4283819
partial evolving to secondarily generalized ic,C0728938;C1550516;C0205246;C0020750;C4554818
no of prior aeds c n,C0332152;C0180309;C2826257
most common concomitant aeds d n,C0205214;C0180309;C1522138;C3245511;C0369718;C0441922
prior lev treatment,C1514463;C0023556
lev naive,C0023556
central eastern europe russia,C0682369;C0035970
syst bp mmhg,C0037623;C0439475;C1415692;C1708288;C4318478
nt probnp pg mla iqr,C0669479;C0754710
ckd egfr $nmbr$ b,C1561643;C1739039;C3811844;C3812682
north,C1709269
western,C1705493
central eastern,C0205099;C1879652;C1707877
latin,
europe and russia,C0015176;C0035970
event rates per $nmbr$ patient years $nmbr$ ci,C0871208;C1521828
$nmbr$ $nmbr$ ref,C1425988
adjustedahr,
all cause mortality no of events,C0015127;C0026565;C0026566;C1524003;C0441471;C3541888
significant worsening in kccq clinical,C0237881;C0750502;C1546944;C0332271;C0205210;C1457868;C1546960
score $nmbr$ at $nmbr$ monthsb unadjusted or,C0449820;C4050231;C1439367
adjustedaor,
overall hr $nmbr$ cl,C0282416;C0596019;C1561607
north america hr $nmbr$ cl,C0028405;C0596019
western europe hr $nmbr$ cl,C0043129;C0596019
central eastern europe and russia hr $nmbr$ cl,C0682369;C0035970;C0596019
latin america hr $nmbr$ cl,C0023122;C0596019
asia pacific hr $nmbr$ cl,C0003980;C0596019
significant worsening in kccq clinical score $nmbr$ at $nmbr$ months $nmbr$,C0237881;C0750502;C1546944;C0332271;C0205210;C1457868;C1546960;C0439231
renal function at randomization,C0232804;C0034656
moderate dysfunction crcl $nmbr$ $nmbr$ ml min n $nmbr$ [ $nmbr$ $nmbr$ ],C3274776;C0439445
mild or no dysfunction crcl $nmbr$ ml min n $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ ],C2945599;C0031847;C0439445;C0277785;C3887504;C3887505
mild dysfunction crcl $nmbr$ $nmbr$ ml min n $nmbr$ [ $nmbr$ $nmbr$ ],C3274775;C0439445
normal function crcl $nmbr$ ml min n $nmbr$ [ $nmbr$ $nmbr$ ],C4296962;C0439445
bmi median iqr kg m $nmbr$,C0022718;C0439209;C4054209
crcl median iqr ml min,C0549183;C0439445;C0876920;C2347635;C2348144;C2939193
current or prior smoking,C0521116;C1705970;C0037369;C0453996;C1881674
other vascular disease cvd or pad,C0042373;C0007222;C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
asia pacific and africa,C0003980;C0001737
chads $nmbr$ mean sd,C0444504;C2699239;C2347634;C2348143
cha $nmbr$ ds $nmbr$ vasc mean sd,C0444504;C2699239;C2347634;C2348143
modified has bled score mean sd,C0392747;C3889737;C0444504;C2699239;C2347634;C2348143
intermediate $nmbr$,C0205103;C1550465;C2827755;C3889971
potent phosphorylated glycoprotein inhibitor use,C0042153;C0457083;C1947944
prior vka use for $nmbr$ d,C0042153;C0457083;C1947944
medication at randomization,C0013227;C3244316;C4284232
time in therapeutic range median iqr,C1554109
n n yr,C0369718;C0439234;C0441922
warf,C0043031
hder,C3898895
stroke or se s se,C0038454;C4554100;C0036919
crcl $nmbr$ $nmbr$,C1846718
crci $nmbr$,
major bleeding mb,C0019080;C0024853
s se mb or death,C0036919;C0024853;C0011065;C1306577;C4082313;C4552775
previous ischemic stroke tia n $nmbr$ $nmbr$ $nmbr$,C0948008;C0007787;C0917805;C1054154
no previous ischemic stroke tia n $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0948008;C0007787;C0917805;C1054154
warfarin n $nmbr$ n y,C0043031
higher dose edoxaban n $nmbr$ n y,C0444956;C2975435
higher dose edoxaban vs warfarin,C0444956;C2975435;C0043031
ard per $nmbr$ $nmbr$ patient years $nmbr$ ci,C1817569;C1826411
previous stroke tia,C0007787;C0917805;C1054154
no previous stroke tia,C0007787;C0917805;C1054154
cvd stroke see,C0042789;C1947903
all cause death stroke see,C0042789;C1947903
atrial fibrillation type n,C0004238;C0344434;C1963067
permanent af,C0344434;C4049859
qualifying risk factor n,C1514624;C0035648
chads $nmbr$ score $nmbr$ $nmbr$ n,C0449820;C4050231
dose reduction n,C0178602;C0301630;C0392756;C1293152;C4551656;C0869039;C1114758
renal impairment crcl,C1565489;C1846718
low body weight,C0041667
nondisabling nonfatal stroke,C0038454;C4554100
vka naive n,
medication at randomization n,C0013227;C3244316;C4284232
disabling stroke,C0038454;C4554100
disabling or fatal stroke,C0038454;C4554100
primary hemorrhagic stroke,C0205225;C0553692;C0439612;C0439631
primary ischemic stroke,C0205225;C0948008;C0439612;C0439631
no prior hf hospitalization n $nmbr$ $nmbr$,C0018488;C0019993;C1313497;C1538440;C3273279
nyha functional class at randomization,C1882083;C0205245;C0542341;C2700217
western europe plus other,C0043129
ace,C1452534;C4284014
[ $nmbr$ $nmbr$ $nmbr$ ],
figure $nmbr$ treatment effect of sacubitril valsartan therapy,C1518681
note have already got interaction values from the paper itself,C1316572;C1317574;C0042295;C0030351;C1547566
elevated serum creatinine $nmbr$ $nmbr$ mg dl,C0700225;C0439269
elevated serum potassium $nmbr$ $nmbr$ mmol l,C0553704;C1532563
drug discontinuation not due to death,C0457454;C1444662;C4552847;C0678226;C0011065;C1306577;C4082313;C4552775
any dose reduction,C0301630;C0392756;C1293152;C4551656
average daily dose,C1510992;C2348070;C2825518
of target,C1521840;C2986546
sacubitril valsartan,C4033631
no prior hf hospitalization,C0018488;C0019993;C1313497;C1538440;C3273279
vildagliptin metformin vldm,C1570906;C0025598
metformin hdm,C0025598
age distribution n,C0001782
bmi distribution n,C0578022;C0520511;C1704711
mean s d duration of t $nmbr$ dm years,C0449238;C2926735
mean s d baseline hba $nmbr$ c,C0168634;C0019016;C1825777;C3538758;C1442488
mean s d baseline fpg mmol l,C0168634;C1532563;C1442488
mean s d metformin dose mg day,C0025598;C0439422
age $nmbr$ years and bmi,C1510829;C0578022
age $nmbr$ years and bmi $nmbr$ kg m $nmbr$,C1510829;C0022718;C0439209;C4054209
vldm n $nmbr$,
hdm n $nmbr$,
hba $nmbr$ c $nmbr$ weeks,C0019016;C0439230;C1825777;C3538758
hba $nmbr$ c $nmbr$ $nmbr$ without gi adverse reactions,C0019016;C1825777;C3538758;C1708130;C0559546;C3539617;C4050121
reduction of hba $nmbr$ c from baseline $nmbr$ $nmbr$,C0301630;C0392756;C1293152;C4551656;C0168634;C1442488
mean age y median range,C1514721;C2348147;C3542016
systolic blood pressure mm hg median range,C1514721;C2348147;C3542016
diastolic blood pressure mm hg median range,C1514721;C2348147;C3542016
previous ischemic stroke n,C0205156;C0948008;C1552607
previous coronary artery disease n,C0010054;C0010068;C1956346
history of diabetes mellitus n,C0455488
history of hypercholesterolemia n,C1533076
baseline scales median range,C1514721;C2348147;C3542016
nihss at randomization,C1697238;C0034656
stroke subtype n,C0038454;C0449560;C4554100
laa,
soe or sue,
extracranial carotid stenosis n,C0580586;C0007282
medications at timing of randomization n,C2359859;C0034656
antiplatelet within $nmbr$ mo before randomization,C0026544;C0332177;C0034656
antidiabetic agents,C0935929
time from onset to randomization h mean sd,C0449244;C0033727;C2699239;C0369286;C0441932;C0564385;C4528284
time from onset to medication h mean sd,C0449244;C0013227;C2699239;C3244316;C4284232
event rates,C0871208;C1521828
p value for variance,C1709380;C1711260;C2348152
clopidogrel plus aspirin,C0070166;C0004057
placebo plus aspirin,C0032042;C1696465;C1706408
history of ischemic stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
time to treatment,C3494202
hospital factor $nmbr$,C1521761;C2827422
$nmbr$ enroll,
$nmbr$ beds,C0004916
lesion location,C0450429;C1515974;C4284930;C4284931
cortical only,C0001613;C0007776;C0022655
non cortical,C0001613;C0007776;C0022655
vascular territory $nmbr$,C1301808;C2983136
anterior circulation,C0005775;C1516559
posterior circulation,C0005775;C1516559
mca,C0149566
with n $nmbr$,C0369718;C0441922
without n $nmbr$ $nmbr$,C0369718;C0441922
asia pacific or other,C0003980
diabetesduration mean sd y,C0444504;C2347634;C2348143
glycated hemoglobin mean sd,C0017853;C2699239
glycatedhemoglobin category,C0683312;C3889287
priorvascular disease,C0012634
peripheral artery,C0489868
priorheartfailure,
baseline heart failure severity amongthose with priorheartfailure,C0018801;C0018802;C4554158
nyha class iii,C1882086
nyha class iv,C1882087
nyha class not reported,C1882083;C0684224;C0700287;C4319718
bloodpressure mean sd m m hg,C0025424;C0428257;C2347108;C2347109;C2348272
body massindex mean sd a,C0242821;C2699239;C0460148;C1268086;C4082212
cigarettesmoking,
antihyperglycemictherapies,
nonaspirin antiplatelet agent,C0722138;C0085826
sitagliptin no total no,C1565750;C0439175;C0439810
placebo no total no,C0032042;C1696465;C1706408;C0439175;C0439810
p value fo interactio,C1709380
sexa male,C0086582;C1706180;C1706428;C1706429
region latin american,C0017446;C1553378;C0205147
racea white,C0007457;C0043157;C0220938
ethnicitya hispanic or latino,C0086409;C0086528
diabetes durationa,C0011847;C0011849
prior congestive heart failure yes,C1549445;C1705108;C1710701
baseline heart failure severity nyha class i,C0018801;C1882084;C0018802;C4554158
prior myocardial infarction yes,C1549445;C1705108;C1710701
prior coronary artery disease yes,C1549445;C1705108;C1710701
prior hypertensiona yes,C1549445;C1705108;C1710701
$nmbr$ egfr ml min $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
$nmbr$ egfr ml min $nmbr$ $nmbr$ m $nmbr$ a,C0369637;C0441923
insulin yes,C1549445;C1705108;C1710701
thiazolidinedione yes,C1549445;C1705108;C1710701
ace inhibitor yes,C1549445;C1705108;C1710701
angiotensin receptor blocker yes,C1549445;C1705108;C1710701
p blocker yes,C1549445;C1705108;C1710701
diuretic thiazide,C0012802
lvef median iqr,C0428772;C0488728
hfpef ef n $nmbr$,
systolic bp mmhg mean sd,C0488053;C2699239
diastolic bp mmhg mean sd,C0488053;C2699239
mitral regurgitation,C0026266
heart failure hf,C0018488;C1313497;C1538440;C3273279
hospitalization for hf previous year,C0019993;C0018488;C1313497;C1538440;C3273279
hf hospitalizations median iqr,C0018488;C0019993;C1313497;C1538440;C3273279
stroke or pvd,C0038454;C4554100;C0085096;C4521226
aicd,C0972395;C2611803;C3537205;C3546309
medication prior to admission,C0013227;C3244316;C4284232
ccbs,C0006684
presenting signs and symptoms,C0449450;C0220912;C0220913;C0311392;C0683368;C1457887
orthopnea,C0085619
dyspnea at rest nyha iv,C0743330;C0022326;C4265176
edema,C0013604;C1717255
jvp,
n $nmbr$ yrs,C0369718;C0441922
inflammation,C0021368
crp ng ml,C3890735;C0439275;C4048285
d dimer ng ml,C0060323;C0439275
gdf $nmbr$ ng ml,C1418244;C0439275
interleukin $nmbr$ pg ml,C0021764;C0439297;C1527200
pentraxin $nmbr$ ng ml,C0439275
procalcitonin ng ml,C0072027;C0439275
pigr ng ml,C1418569;C0439275
psap b ng ml,C1418975;C0439275;C1420002;C1425004
rage ng ml,C0034634;C0439275;C3539760;C3815186
tnf r $nmbr$ a ng ml,C1363984;C1706001;C0439275
wap $nmbr$ c ng ml,C0439275
oxidative stress,C0242606
mpo ng ml,C0439275
remodeling,
syndecan $nmbr$ ng ml,C0075691;C0439275;C1419891
periostin ng ml,C0219433;C0439275;C1424662;C3812270
galectin $nmbr$ ng ml,C0607430;C0439275
osteopontin ng ml,C0069676;C0439275;C1420369;C1505427;C4084879
cardiac stretch,C0018787;C0600080;C1522601
st $nmbr$ ng ml,C0036056;C0439275;C3272372
troponin i pg ml,C0077401;C0439297
angiogenesis,C0302600;C1519670
vegfr ng ml,C1568520;C0439275
angiogenin ng ml,C0051844;C0439275;C1367482
mesothelin ng ml,C0380162;C0439275;C1334533
neuropilin ng ml,C0287275;C0439275
proadm ng ml,C0439275
ntpro cnp ng ml,C3889729;C0439275
endothelin $nmbr$ pg ml,C0079284;C0439297
troy ng ml,C1420811;C0439275;C1883402
arteriosclerosis,C0003850
esam ng ml,C1424976;C0439275
ltbr ng ml,C1416931;C0439275
ngal ng ml,C0215955;C0439275;C1416806;C2346625
kim $nmbr$ pg ml,C0439297
pioglitazone n $nmbr$ $nmbr$,C0071097
laboratory data mean sd,C0022877;C2699239;C3244292;C4283904
insulin mu ml,C0021641;C0439339;C1533581;C1579433;C3714501
dysglycemic categories n,C0683312
ada ifg,C1334085;C1708411
$nmbr$ mg dl [ $nmbr$ $nmbr$ mmol l],C0439268
who idf ifg,C1334085;C1708411
hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ mmol mol,C0019016;C3829066;C1825777;C3538758
hba $nmbr$ c $nmbr$ $nmbr$ to,C0019016;C1825777;C3538758
ncep atp iii metabolic syndrome features n,C1864620
antihypertensive medication or,C0003364
sbp dbp $nmbr$ $nmbr$ mmhg,C0085805;C0439475
abdominal obesity,C0311277
number s of features present,C0237753;C0449788;C0150312;C0449450
pioglitazone events n,C0071097;C0441471;C3541888
placebo events n,C0032042;C0441471;C3541888;C1696465;C1706408
hispanic ethnicity,C0015031;C0243103
hypertension history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
coronary artery disease history,C0683519
aerobic activity,C0001701
not at goal,C1518422;C0018017;C1571704
at goal,C0018017;C1571704
ada impaired fasting glucose,C1060325;C1272092;C3811629
present $nmbr$ mg dl,C0150312;C0439269;C0449450
who idf impaired fasting glucose,C3272598;C1272092
homa,
$nmbr$ men $nmbr$ women,C0025266;C0043210
linagliptin n z $nmbr$,C2746078
presence of mets a,C0150312;C0392148;C3854307
$nmbr$ e $nmbr$ years,C0439234
homa ir mean sd mu l mmol l b,C0022065;C0439342;C0022071;C1448132
homa ir b,C0022065;C0022071;C1448132
$nmbr$ $nmbr$ mu l mmol l,C0439342;C0439190
fasting c peptide nmol l c,C0015663;C0607868
previous oad,C0205156;C1552607
placebo adjusted mean difference in hba $nmbr$ c $nmbr$ ci [ p value],C0444504;C1705241;C1705242;C2347634;C2348143;C1709380
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ ],
homa ir mu l^mmol l,C0022065;C0439342;C0022071;C1448132
presence of mets,C0150312;C0392148;C3854307
aclidinium formoterol $nmbr$ $nmbr$ pg twice daily,C0030827;C0072225;C1266240
salmeterol fluticasone $nmbr$ $nmbr$ pg twice daily,C0030827;C0072225;C1266240
gold classification,C0008902;C0008903;C0678229
smoking consumption pack years,C0425291;C1277691
exacerbation in previous year,C4086268;C0205156;C1552607
prior copd medication,C0013227;C3244316;C4284232
laba lama,C0999593;C1416775
laba lama ics,C0815320;C4551720
fevi $nmbr$ l,C0429706;C0849974;C1561566;C4528367
post bronchodilator fevi $nmbr$ predicted,C0681842;C1882327
bronchial reversibility,C0205039;C0449261;C1442216
bdi focal score $nmbr$,C0449820;C4050231
cat total score $nmbr$,C0007450;C2964552;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
sgrq total score $nmbr$,C2964552
duration of ra,C0449238;C2926735
tofacitinib $nmbr$ mg two times a day,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1948050;C0332173;C0439228;C0439505
early n $nmbr$,C1279919
established n $nmbr$,C0443211;C1272684
tjc,
sjc,
vdhmtss,
hscrp mg dl,C0439269
acpa positive,C0439178;C1446409;C1514241;C2825490;C3812269
figure $nmbr$ clinical response in patients with early and established ra at month $nmbr$ p,C4055223;C0030705;C1279919;C3538806;C4048756
acr american college of rheumatology response criteria das $nmbr$ $nmbr$ esr disease activity score in $nmbr$ joints erythrocyte sedimentation rate haq di health assessment questionnaire disability index ls least squares mtx methotrexate ra rheumatoid arthritis,C0035452;C4706353;C0014779;C0003873
a no vhd n $nmbr$ $nmbr$,
b vhd n $nmbr$,
c right sided vhd n $nmbr$,C0205090;C0444532
d mitral stenosis vhd n $nmbr$,C0026269;C0264766
bonferroni adjusted p value b vs a,C0456081;C1709380
bonferroni adjusted p value c vs a,C0456081;C1709380
bonferroni adjusted p value d vs a,C0456081;C1709380
vhd event rate year n,C0439234;C0439508
no vhd event rate year n,C0439234;C0439508
adiusted hazard ratio,C2985465
persistent af n,C0205322;C0332996
strokezsee,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
crcl at baseline ml min,C1846718;C0439445
moderate renal impairment n,C0205081;C1565489;C1881878;C4049705;C4049706;C4085643;C4321335
coronary artery disease n,C0010054;C0010068;C1956346
vitamin k antagonist experienced n,C1096489;C2267235
history of stroke see tia n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
on sulfonylurea,C0038766;C3536898
alone,C0205171;C0439044;C0679994
plus metformin,C0025598
hba $nmbr$ c distribution,C0520511;C1704711
$nmbr$ h pmg mg dl,C0033727;C0439269;C0369286;C0441932;C0564385;C4528284
fasting insulin giu ml,C0015663;C0439526;C1705224;C3887665
homa p,
efficacy parameter,C0549193;C1704769;C2350001
subset of patients on metformin,C1515021;C0030705;C0025598
subset of patients not on metformin,C1515021;C0030705;C1518422;C0025598
ls mean change from baseline $nmbr$,C0392747;C0443172;C1705241;C4319952
difference in ls means $nmbr$ ci $nmbr$,C1705241;C1705242
total n $nmbr$ n,C0439175;C0439810
min max age,C0702093;C0001779;C1524029;C3813700
duration of ra years,C0449238;C2926735
ara functional class,C0205245;C0456387;C1518526;C1705943;C0542341;C2700217
biologics user,C1548600;C1706077
methotrexate user,C1548600;C1706077
low dose corticosteroid user,C1548600;C1706077
dmard user,C1548600;C1706077
dmard or corticosteroid,C0242708;C0001617;C3536709
fig $nmbr$ treatment differences by baseline median subgroups $nmbr$ mg vs $nmbr$ mg for time weighted change from baseline in efficacy endpoints over $nmbr$ weeks in part i,C1705241;C1705242;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0168634;C1442488;C0439230;C0021966;C0221138
colchicine n $nmbr$,C0009262
no colchicine n $nmbr$,C0009262
age y mean range,C1514721;C2348147;C3542016
creatinine mg dl mean sd,C0439269;C2699239
ef mean sd,C0444504;C2699239;C2347634;C2348143
ef b $nmbr$,
valvular heart disease,C0018824;C1963123
$nmbr$ $nmbr$ range $nmbr$ $nmbr$,C1514721;C2348147;C3542016
age y n $nmbr$,C0001779
age $nmbr$ $nmbr$ y n $nmbr$,C0001779
$nmbr$ y kaplan meier rate $nmbr$ ci,C0008107;C3259781
female race white,C0007457;C0043157;C0220938
vorapaxar,C2974521
cv death mi stroke recurrent ischemia,C0022116;C4321499
with rehospitalization urgent coronary revascularization,C0439609;C0877341;C3272275
age b $nmbr$ y n $nmbr$,C0001779
bmi kg m $nmbr$ median q $nmbr$ q $nmbr$,C0022718;C0439209;C4054209;C0549183;C0876920;C2347635;C2348144;C2939193
gusto moderate severe bleeding,C0205081;C0019080;C1881878;C4049705;C4049706;C4085643;C4321335
gusto moderate bleeding ich,C0019191;C3272597;C3281105
hyperlipidmemia,
net clinical benefit cv death mi stroke gusto moderate severe bleeding,C4684590;C0019080
thienopyridine at baseline,C1120149;C0168634;C1442488
aspirin dose at baseline mg,C4696290
secukinumab $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
range race n,C1514721;C0034510;C1706779;C3853635;C2348147;C3542016
height cm mean sd a,C0444504;C2699239;C2347634;C2348143
bmi kg m $nmbr$ mean sd a,C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
range iga modified $nmbr$ score n,C0392747;C0449820;C4050231;C3889737
time since first psoriasis diagnosis y mean sd,C0040223;C3541383
previous exposure to systemic psoriasis therapyb yes n,C0332157;C0033860
previous exposure to biologic systemic psoriasis therapyb yes n,C0332157;C0005515;C0205460
previous exposure to non biologic systemic psoriasis therapyb yes n,C0332157;C0005515;C0205460
tpasi $nmbr$,
ulpasi $nmbr$,
llpasi $nmbr$,
patient characteristic,C0030705;C1521970
on omt,
off omt,
on omt n $nmbr$,
off omt n $nmbr$,
p value on vs off omt,C1709380
reduced ef,C0392756
thienopyridine drug at start of open label period,C0013191;C1705425
number of treated lesions per patient,C0449791;C1522326;C0030705
number of treated vessels per patient,C0237753;C0449788;C0030705
number of stents per patient,C0237753;C0449788;C0030705
total stent length mm mean sd,C0038257;C2699239
treated vessel native coronary,C0005847;C0018787
modified acc aha lesion class b $nmbr$ c,C0101856
unadjusted p value for interaction,C1439367;C1709380
adjusted hr $nmbr$ ci,C0008107;C3259781
p value for adjusted hr,C1709380;C0456081
adjusted p value for interaction,C0456081;C1709380
gusto moderate or severe bleeding,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0205082;C0019080;C4050465;C4050466
no stroke n $nmbr$ $nmbr$,C0038454;C4554100
stroke n $nmbr$,C0038454;C4554100
weight in kg median iqr,C0005910;C0043100;C1305866;C1705104
sbp mm hg median iqr,C0085805;C0439475
dbp mm hg median iqr,C0536221;C0439475;C3813197;C4281799
cardiovascular history,C1880008
history of second prior mi n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
multivessel cad n,C1504769;C2239547;C3813548;C4284121
history of cabg n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
history of pci n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
qualifying nstemi n,C1514624;C3537184;C4255010
history of chf n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
history of atrial fibrillation n,C0729790
history of tia n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
medical therapies,C0418981
ace inhibitor n,C0003015;C4541021
ticagrelor $nmbr$ mg $nmbr$ yr km,C0024671;C3887676;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
placebo $nmbr$ yr km,C0032042;C3887676;C1696465;C1706408
ticagrelor $nmbr$ mg vs placebo hr $nmbr$ ci,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0008107;C3259781
p interactio n,C0369773;C2603361
no history of chf,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
no history of af,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
low dose,C0445550;C1708745
high dose,C0444956
budesonide formoterol $nmbr$ $nmbr$ $nmbr$ ^g n $nmbr$,C1276807;C0439267
budesonide $nmbr$ ^g n $nmbr$,C0054201;C0439267
budesonide formoterol $nmbr$ ^g $nmbr$ $nmbr$ ^g n $nmbr$,C1276807
budesonide formoterol n $nmbr$,C1276807
budesonide n $nmbr$,C0054201
age yr age group no,C0027362;C2348001
female sex no race no f,C0086287;C0034510;C1706779;C3853635;C0016327
mean time since asthma,C0040223;C3541383
diagnosis yr,C0011900;C0439234;C1704338;C1704656
mean acq $nmbr$ score at randomization,C3533236;C0034656
asthma control status at randomization no,C0004096;C0449438;C2984299
controlled acq $nmbr$,C2587213;C2919686;C2911690
uncontrolled acq $nmbr$ $nmbr$ $nmbr$,C0205318;C2919686
exacerbations in past $nmbr$ mo no,C4086268;C0026544;C0332177
daily dose of inhaled glucocorticoid no,C2348070;C0004048
medium,C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283
monitoring group n $nmbr$,C0150369;C0441848;C1283169
body mass index kg m,C0022718;C0439209;C4054209
inflammatory disease,C1290884
previous cardiovascular events,C0205156;C1320716;C1552607
concomitant medication after randomisation,C0013227;C3244316;C4284232
mra spironolactone or eplerenone,C0243032;C0037982;C1609165;C3891069;C0961485
secondary pci,C0027627;C4049621;C0175668;C0205436
coronary angiography and intervention,C0085532;C1548829;C0184661;C0886296;C1273869
radial access,C0444454;C1554204
one vessel disease,C3275121
two vessel disease,C0581375
three vessel disease,C3272265
multivessel two vessel three vessel or left main,C0205448;C0005847;C0205091;C0205225;C1542147;C0443246;C1552822
number of stents implanted,C0237753;C0449788;C0021102;C2828363
drug eluting stent implanted at least one,C1322815;C0205447
stented vessels,C0038257;C0005847
coronary bypass graft,C1260596
creatinine clearance at admission ml min,C0184666;C0151280;C0809949
monitoring treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
t $nmbr$,C2603360
no hypertension,C0020538;C1963138
no current smoking,C0037369;C0453996;C1881674
st,C0036056;C3272372
creat clearance,C0449297;C1382187;C2825073;C4554548
creat clearance $nmbr$ ml min,C0201975;C0439445
no prior cancer,C0006826;C0998265;C1306459
no prior heart failure,C0018801;C0018802;C4554158
one vessel,C0205447;C0005847
multi vessel or left main,C0439064;C0005847;C3266262;C0205091;C0205225;C1542147;C0443246;C1552822
bms,
length of stent median,C0449462;C0549183;C0876920;C2347635;C2348144;C2939193
number of stent l or $nmbr$ or $nmbr$,C0237753;C0449788
roflumilast n $nmbr$ $nmbr$,C0965618
age mean sd yr,C0001779;C0439234
total cigarette pack years mean sd,C1303175;C2699239
copd duration mean sd yr,C0024117;C0439234;C1412502;C3714496
prebronchodilator fev $nmbr$ mean sd l,C0444504;C2347634;C2348143
post bronchodilator fev $nmbr$ mean sd l,C2599594;C0444504;C2347634;C2348143
predicted prebronchodilator fev $nmbr$ mean sd l,C0681842;C0444504;C2347634;C2348143;C1882327
predicted post bronchodilator fev $nmbr$ mean sd l,C2599594;C0444504;C2347634;C2348143
post bronchodilator fev $nmbr$ fvc ratio mean sd,C2599594;C2699239
no of moderate or severe exacerbations in previous,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0205082;C4086268;C4050465;C4050466
$nmbr$ mo mean sd x,C0026544;C0332177
year n,C0439234;C0439508
prior hospitalizations n,C0332152;C0019993;C2826257
cat score mean sd,C0007450;C2699239;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
exact pro total score mean sd,C2964552;C2699239
ics laba therapy n,C0039798;C0087111;C1363945
fluticasone propionate salmeterol fdc,C0340427;C1413520;C3539652
budesonide formoterol fdc,C0340427;C1413520;C3539652
lama use n,C0042153;C0457083;C1947944
brv $nmbr$ mg day,C0155502;C0439422
brv overall,C0155502;C0282416;C1561607
etiology n,C0015127;C1314792;C1524003
cryptogenic,C0332240
$nmbr$ b,
mean sd [range] duration of epilepsy years,C0444504;C2699239;C2347634;C2348143;C1514721;C2348147;C3542016;C0449238;C2926735
median minimum maximum focal seizure frequency $nmbr$ days at baseline,C0149775;C0439228
prior lev treatment n,C1514463;C0023556
concomitant aedsb n,C0521115
$nmbr$ teae,
teaes leading to discontinuation of study drug,C0332152;C0013175;C1522538
saes,C1519255;C1622657;C4553214
drug related saes,C1519255;C1622657;C4553214
teaes reported by $nmbr$ patients in the overall brv group n,C1709908;C0155502;C0441848
paresthesia,C0030554;C4553220
somnolence,C0013144;C2830004;C4553740
cataract,C0086543;C4555209
constipation,C0009806;C1963087;C3641755;C4084722;C4084723;C4084724
convulsion,C0036572;C4048158
cystitis,C0010692;C0600041;C1963088
hyponatremia,C0020625;C4553967
hot climate subset,C0178683;C1515021
other climate subset,C0008946;C1515021
sex n b,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
otherc,
high dosage ics plus laba with baseline blood eosinophils a $nmbr$ cells per pl n $nmbr$,C0815320;C4551720;C0005773
high dosage ics plus laba with baseline blood eosinophils,C0815320;C4551720;C0168634;C0014467;C1442488
benralizumab $nmbr$ mg q $nmbr$ w n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
local eosinophil count cells per pl t,C0007584
central eosinophil count cells per pl t,C0007584
prebronchodilator fev $nmbr$ l t,C2599602;C3714541
prebronchodilator fev $nmbr$ predicted normal t,C0520835;C0681842;C1882327
fev $nmbr$ fvc prebronchodilatort,C3714541
reversibility t,C0449261
time since asthma diagnosis years,C0556970;C0004096;C2984299
number of exacerbations in the past $nmbr$ months,C0237753;C0449788;C0439231
number resulting in emergency department visit,C0237753;C0449788;C0332294;C0562508
patients with $nmbr$ exacerbations resulting in emergency department visit,C0030705;C4086268;C0332294;C0562508
number resulting in hospital admission,C0237753;C0449788;C0184666
patients with $nmbr$ exacerbations resulting in hospital admission,C0030705;C4086268;C0184666
diagnosis of allergic rhinitis,C0011900;C1704338;C1704656
nasal polyps,C0027430
atopic based on phadiatop test,C0392707;C1527178;C1705938
history of omalizumab treatment,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
aqlq s $nmbr$ scorets,C4055434
smoking pack year years fl,C1300812;C1708024
empty,C1880497
a beuralizuinab $nmbr$ ing q $nmbr$ w,
b benralizumab $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
estimate $nmbr$ ci,C0008107;C3259781
baseline ocs use yes,C1549445;C1705108;C1710701
age groiro,C0001779
geo graphic region asia,C0017446;C0003980;C0205147
$nmbr$ kg nr,C0027496;C3844738
exacerbations in the prev year $nmbr$,C4086268;C0439234;C0439508
nasal polyps at baseline yes,C0027430;C0168634;C1442488
iee at baseline,C0168634;C1442488
$nmbr$ iu l,C0439457
atopic at baseline yes,C0392707;C0168634;C1442488
$nmbr$ $nmbr$ fo $nmbr$ $nmbr$ $nmbr$,
prior therapy with omalizumab yes,C1514463;C0966225
high dosage ics plus laba with baseline blood eosinophils $nmbr$ cells per pl n $nmbr$,C0815320;C4551720;C0005773
eosinophil count cells per pl,C0007584
central eosinophil count cells per pl,C0007584
predicted normal,C0205307;C0231683;C0439166;C2347086;C4553972
prebronchodilator fev $nmbr$ fvc,C2599602;C3714541
acq $nmbr$ scoret,C2919686
number resulting in ed visit,C0237753;C0449788;C0332294
patients with $nmbr$ exacerbations resulting in ed visit,C0030705;C4086268;C0332294
aqlq s $nmbr$ scored,C4055434;C0449820
nicotine pack years,C0028040;C1277691
appendix $nmbr$ figure $nmbr$ annual asthma exacerbation rate ratio at $nmbr$ weeks by subgroup for a benralizumab q $nmbr$ w vs placebo and b benralizumab q $nmbr$ w vs placebo for patients receiving high dosage ics laba with blood eosinophils $nmbr$ cells l,C0871208;C0456603;C1547037;C1521828;C1079230;C1515021;C0032042;C1696465;C1706408;C2982078;C1514756;C0014467;C0347983
at increased fall risk n $nmbr$,C4699158
notatincreased fall risk n $nmbr$ $nmbr$,C1268740
randomization group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
higher dose edoxaban regimen,C2348331
lower dose edoxaban regimen,C2348331
has bled score,C0449820;C4050231
crcl at randomization ml min,C1846718;C0439445
aspirin use at randomization,C0042153;C0457083;C1947944
dose reduced at randomization,C0178602;C0869039;C1114758;C0392756;C0034656
ttr warfarin arm only,C0446516;C3715044;C4553528
charlson comorbidity index,C4546361
increased risk for falls,C4699158
no increased risk for falls,C4699158
univariable,
multivariable,
bone fracture,C0016658
bone fracture due to fall,C0016658;C0678226
malignancy death,C0011065;C1306577;C4082313;C4552775
net ep $nmbr$,C1880476;C4321526
major crnm bleed,C0205082;C0019080;C0205164;C4318856;C4521762
death or ich,C0011065;C1306577;C4082313;C4552775;C0019191;C3272597;C3281105
abaloparatide sc n,C4042342;C0282380
all participantsa,
t score categories lumbar spineb,C3854607
total hipc,C0439175;C0439810
femoral neckc,C0015811
fracture status prevalent vertebral fractured,C0016658;C0549207;C4554413
prior nonvertebral fracture,C0332152;C0016658;C2826257
age categories,C2916832
abl sc n n,C0023139;C0282380;C1704928;C3890208
\bl sc n n,C0439394;C0282380;C1706495;C3642217
interaction j $nmbr$ valuet,C1704675
lumbar spine bmd t,C0024091;C3887615
total hip bmi t score,C2964552;C0019552;C0022122;C1505163;C3538851;C4284725
placebo mean,C0444504;C2347634;C2348143
abl sc mean,C0444504;C2347634;C2348143
least squares mean difference $nmbr$ ci,C0008107;C3259781
interaction p valuef,C1704675
o os,C2673162
lavolta $nmbr$,
lavolta ii,C1710602;C4082587
lebrikizumab $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
lebrikizumab $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
body mass index kg mq,C0005893;C0024853;C0578022;C1305855
median range duration of asthma years,C0449238;C2926735
baseline ics $nmbr$ pg per day fluticasone propionate dpi or equivalent and laba,C2827928;C0117996;C0205163;C0439185
mean ics fluticasone propionate dpi or equivalent pg per day,C0444504;C0117996;C2347634;C2348143;C0205163;C2827928;C0439185
pre bronchodilator fevj,C2599602
absolute l,C0205344
t jj $nmbr$ $nmbr$,C2603360
median serum periostin ng ml t,C0219433;C0439275;C1424662;C3812270
median feno ppb f,C0549183;C0016327;C0876920;C2347635;C2348144;C2939193
tj $nmbr$ $nmbr$,C0039247
median blood eosinophil count cells per pl t,C0549183;C0200638;C0876920;C2347635;C2348144;C2939193
biomarker high periostin $nmbr$ ng ml or blood eosinophils $nmbr$ cells per pl t,C0005516;C0439275;C0005773
patients with $nmbr$ exacerbation in previous $nmbr$ months,C0030705;C4086268;C0205156;C0439231;C1552607
adjusted exacerbation rate per patient peryear,C0871208;C1521828
rate difference lebrikizumab placebo,C0032042;C1696465;C1706408
rate reduction,C0301630;C0392756;C1293152;C4551656
rate ratio lebrikizumab vs placebo $nmbr$ cl,C0456603;C2981360;C1547037;C0032042;C0596019;C1696465;C1706408
biomarker high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
lebrikizumab $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
lebrikizumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
biomarker low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
periostin high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
periostin low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
eosinophil high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
eosinophil low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
change from baseline in fevj mb,C0392747;C0443172;C1705241;C4319952;C0024853
adjusted mean se,C0444504;C0036919;C2347634;C2348143
difference in means $nmbr$ cl,C1705241;C1705242
time to first exacerbation,C0040223;C3541383
patients with event n,C0030705;C0441471;C4019010
median time to event weeks,C0040223;C3541383
asthma related health,C0004096;C0018684;C2984299
care use,C0042153;C0457083;C1947944
health care use rate peryear,C0814514;C0871208;C1521828
rate difference events year,C0439234;C0439508
oil,C0028908;C0032085;C1517288;C3541397
change from baseline in aqlq s score,C0392747;C0443172;C1705241;C4319952;C0449820;C4050231
change from baseline in rescue medication use puffs per day,C0392747;C0443172;C1705241;C4319952;C0240320;C1533107
change from baseline in acq $nmbr$ score,C0392747;C0443172;C1705241;C4319952;C0449820;C4050231
difference in means,C1705241;C1705242
ifg,C1334085;C1708411
no dysglycaemia or mets,C1960636;C0812270;C1705694;C2939420
evomab n $nmbr$,
cerebrovascular or peripheral arterial disease n,C1880018;C0085096;C1704436
current cigarette use n,C0521116;C0694535;C1705970
statin use at study entry n,C0360714;C0869040
other lipid modifying drug use at study entry n,C0023779;C0392747;C0242510
ncep risk category at study entry n,C2983287;C2983669
moderately high risk,C0332167;C3272283;C4050568;C4319571
moderate risk,C0035647;C4552904
waist circumference mean sd cm,C0455829;C0444504;C2347634;C2348143
fpg median q $nmbr$ q $nmbr$ mmol l,C0549183;C1532563;C0876920;C2347635;C2348144;C2939193
insulin median q $nmbr$ q $nmbr$ pmol l,C0021641;C0439284;C1533581;C1579433;C3714501
c peptide median q $nmbr$ q $nmbr$ nmol l,C0607868
homa_ b median q $nmbr$ q $nmbr$,C0549183;C0876920;C2347635;C2348144;C2939193
homa_ir median q $nmbr$ q $nmbr$ $nmbr$,C0022065;C0022071;C1448132
lipid parameters,C0023779;C0449381
low density lipoprotein cholesterol mean sd mmol l,C0023824;C1532563
lipoprotein a median qi q $nmbr$ nmol l,C0065058;C0439282;C0125953;C1096202;C1439335
triglycerides median qi q $nmbr$ mmol l,C0041004;C1532563
high density lipoprotein cholesterol mean sd mmol l,C0023822;C1532563
apolipoprotein b mean sd g l,C1447574;C4319541
type $nmbr$ diabetes pbo n $nmbr$ vs evomab n $nmbr$,C1320657;C0031962
ifg pbo n $nmbr$ vs evomab n $nmbr$,C1334085;C0031962;C1708411
mets pbo n $nmbr$ vs evomab n $nmbr$,C0812270;C0031962;C1705694;C2939420
no dysglycaemia or mets pbo n $nmbr$ vs evomab n $nmbr$,C1960636;C0812270;C0031962;C1705694;C2939420
hba $nmbr$ c tx difference vs pbo median change from baseline se $nmbr$,C1705241;C1705242;C0392747;C0443172;C4319952
fpg tx difference vs pbo median change from baseline se $nmbr$,C1705241;C1705242;C0392747;C0443172;C4319952
insulin tx difference vs pbo median change from baseline se $nmbr$,C1705241;C1705242;C0392747;C0443172;C4319952
c peptide tx difference vs pbo median change from baseline se $nmbr$,C1705241;C1705242;C0392747;C0443172;C4319952
homa_ b tx difference vs pbo median change from baseline se $nmbr$,C1705241;C1705242;C0392747;C0443172;C4319952
homa_ir tx difference vs pbo median change from baseline se $nmbr$,C1705241;C1705242;C0392747;C0443172;C4319952
low density lipoprotein cholesterol tx difference vs pbo ls mean change from baseline se,C1705241;C1705242;C0392747;C0443172;C4319952
lipoprotein a tx difference vs pbo ls mean change from baseline se,C1705241;C1705242;C0392747;C0443172;C4319952
triglycerides tx difference vs pbo ls mean change from baseline se,C1705241;C1705242;C0392747;C0443172;C4319952
high density lipoprotein cholesterol tx difference vs pbo ls mean change from baseline se,C1705241;C1705242;C0392747;C0443172;C4319952
apolipoprotein b tx difference vs pbo ls mean change from baseline se,C1705241;C1705242;C0392747;C0443172;C4319952
evolocumab,C3529352
safety,C0036043;C1705187
dysglycaemia or mets,C1960636;C0812270;C1705694;C2939420
all subjects n,C0681850;C1550501;C1706203;C2349001;C2697811
postbaseline new onset diabetes n,C0746890;C0011847;C0011849
any adverse event ae,C0877248;C3887670
baseline normoglycaemia fpg $nmbr$ $nmbr$ mmol l n,C0168634;C1532563;C1442488
most common aes in any group,C1412268;C2699274
baseline ifg fpg $nmbr$ $nmbr$ $nmbr$ $nmbr$ mmol l n,C0168634;C1532563;C1442488
influenza,C0021400;C0021403
serious,C0205404
leading to discontinuation,C0332152;C0457454;C1444662;C4552847;C1522538
ck $nmbr$ x uln $nmbr$,C0009212;C1519815;C0010287;C1872855
alt or ast $nmbr$ x uln $nmbr$,C1266129;C4553172;C1415181;C1519815;C3891303
total bilirubin $nmbr$ x uln $nmbr$,C0005437;C1519815;C0368753
potential injection site reactions,C3245505;C0151735
postbaseline binding antibodies,C1145667;C0003241;C1167622
semaglutide n $nmbr$,C3885068
low density lipoprotein cholesterol mg dlf,C0023824;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
never smoked no,C0037366;C0439994;C1881674
tnf naive patientsa,C1448177
tnf failure patientsa,C0231174;C0680095
vedolizumab cohort $nmbr$ n $nmbr$,C0009247;C0599755
disease duration y mean sd,C0872146;C2699239
mayo clinic score mean sd,C0002424;C2699239;C0442592
fcal mg g mean sd,C1300563;C2699239
cs only,C0010182;C0271160;C3540510;C4085345
is only,
cs and is,C0010182;C0271160;C3540510;C4085345
no cs and is,C0010182;C0271160;C3540510;C4085345
type of tnf failure n b,C0332307;C1547052
intolerance,C0231199;C1744706;C2355652
tnf naivea,C1448177
tnf failurea,C1448177
all patientsb,
point difference $nmbr$ ci c,C1552961;C0008107;C3259781;C2347617;C3714763
rr $nmbr$ ci c,C0008107;C3259781
clinical responsed,C0205210
clinical remissione,C0205210
mucosal healingf,C0026724
durable clinical responseg,C0205210
durable clinical remissionh,C0205210
corticosteroid free remissioni,C0001617;C0332296;C1880497;C1996904;C3536709
patients not receiving statin,C0030705;C1518422;C1514756;C0360714
patients receiving statin,C0030705;C1514756;C0360714
$nmbr$ q $nmbr$ w n $nmbr$,
race black or african american n,C0005680;C0027567;C0085756;C0439541
ethnicity hispanic latino n,C0015031;C0086409;C0243103
diagnosis of hefh n,C0011900;C1704338;C1704656
by genotyping,C1285573
by who simon broome criteria,C0443058;C0243161
diabetes mellitus type $nmbr$ n,C1320657
cardiovascular risk n,C0007226;C0035647;C4552904;C3887460
very high,C0442804;C4321397
lipid treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
patients on atorvastatin rosuvastatin or simvastatin at,C0030705;C0286651;C0074554
randomization n,C0034656
any llt other than statins n b,C2347090;C0360714
any llt other than nutraceuticals n,C2347090;C1518478
ezetimibe n,C1142985
nutraceuticals n,C1518478
baseline lipid parameters mg dl mmol l or g l,C0439268;C0439294;C0456615
ldl c calculated mean sd,C0444504;C2699239;C2347634;C2348143
ldl c measured mean sd,C0444504;C2699239;C2347634;C2348143
non hdl c mean sd,C0444504;C2699239;C2347634;C2348143
total cholesterol mean sd,C0201950;C2699239;C0543421
apo b mean sd,C0003593;C2699239;C3252643
lp a median q $nmbr$ q $nmbr$,C0065058;C1439335;C4553379
fasting tgs median q $nmbr$ q $nmbr$,C0015663;C0549183;C0876920;C2347635;C2348144;C2939193
apo a $nmbr$ mean sd,C0003592;C2699239;C0523508;C4553344;C4553379
change from baseline to week $nmbr$,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230
no statin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
statin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
$nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
moderate chronic kidney disease,C1561643;C4553188
baseline total pcsk $nmbr$ level,C0441889;C0456079;C1547707;C2946261
below median,C0549183;C0876920;C2347635;C2348144;C2939193
baseline free pcsk $nmbr$ level,C0441889;C0456079;C1547707;C2946261
statin intolerant,C0360714;C0231200
baseline ldl c mg dl,C0168634;C0439269;C1442488
baseline hdl c mg dl,C0168634;C0439269;C1442488
baseline fasting tgs mg dl,C0168634;C1442488;C0015663;C1156212;C0439269;C1537574
baseline lp a mg dl,C0065058;C0439269;C1439335;C4553379
cohort $nmbr$ uacr,C0009247;C0599755
cohort $nmbr$ uacr $nmbr$ $nmbr$ mg g,C0009247;C1300563;C0599755
uacr not available,C0686905
statin usage,C0360714;C0457083
cigarette smoking in the past year,C0239059;C0700219
albumin creatinine ratio,C0486293;C1318293
core laboratory percent stenosis,C0678234;C1261287;C2632116
acr deciles,C1412134;C1515941
stable angina n $nmbr$ $nmbr$,C0340288
acs n $nmbr$ $nmbr$,C0742343;C4318612
u s site,C0205145;C1515974;C2825164
inter p value,C0205103;C1548610;C1709380
d mi idr st,C0036056;C3272372
qmi,
any gusto bleeding,C0019080
severe life ttireatening,C0205082;C0376558;C4050465;C4050466
sa acs,C0742343;C4318612
severe moderate,C1299393
any timi bleeding,C0019080
any acuity bleeding,C0750509;C0019080
any blood product transfusion,C0005841;C0281867
fvc $nmbr$ predicted,C0681842;C1882327
nintedanib n $nmbr$,C2930789
time since diagnosis years,C0556970;C0011900;C1704338;C1704656
centrilobular emphysema,C0221227
fvc ml,C0439526;C1705224;C3887665
fev $nmbr$ fvc ratio,C0456603;C1547037
diffusion capacity of the lung for carbon monoxide predicted,C0231971;C0007018;C4520712;C0681842;C1882327
st george s respiratory questionnaire total score,C1553316;C0034394;C2964552
composite physiologic index,C0600653;C0918012;C1552854;C1637833;C2986546
absolute decline in fvc $nmbr$ predicted or death n,C0205344;C0681842;C1882327;C0011065;C1306577;C4082313;C4552775
treatment by subgroup interaction,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
criterion reached first n,C0243161;C0205435;C1279901
absolute decline in fvc $nmbr$ predicted,C0205344;C0681842;C1882327
linagliptin metformin,C3264599
age n,C0001779
native american alaskan,C0682125
diabetes duration n,C0011847;C0011849
hba $nmbr$ c mean sd b,C0019016;C0444504;C2347634;C2348143;C1825777;C3538758
hba $nmbr$ c n b,C0019016;C1825777;C3538758
fasting plasma glucose mg dl mean sd b,C0202042;C0439269;C0455280
number of antidiabetes drugs at screening n,C0237753;C0449788;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
renal function egfr ml min $nmbr$ $nmbr$ m $nmbr$ according to mdrd n,C0232804;C0439445;C3839656
moderate impairment $nmbr$ to,C0221099;C0684336
severe impairment,C0221099;C0684336
macrovascular disease n,C0012634
difference $nmbr$ cl,C1705241;C0596019;C1705242
baricitinib $nmbr$ mg qd n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
duration of rheumatoid arthritis year,C0449238;C2926735
anticyclic citrullinated peptide positive^ n,C1320283;C0439178;C1446409;C1514241;C2825490;C3812269
rheumatoid factor positive n,C0035448;C0201660
$nmbr$ erosion n,C0333307;C1880549;C1959609;C3887524
mtss units,C0439148;C1519795;C3853603
prior conventional synthetic dmards n,C0332152;C0242708;C2826257
swollen joint count of $nmbr$,C0451521
tender joint count of $nmbr$,C0451530
high sensitivity c reactive protein mg ltt,C0006560;C1413716;C4048285
erythrocyte sedimentation rate mm hour,C0439227;C0564385
simplified disease activity index,C3869582
a acr $nmbr$,C1412134;C1515941
week $nmbr$ overall population,C0032659;C1257890
background csdmard category,C0683312;C3889287
mtx only,C0025677;C1417487
non mtx csdmards,C0025677;C1417487
mtx other csdmards,C0025677;C1417487
b acr $nmbr$,C1412134;C1515941
nteraction p value,C1709380
c das $nmbr$ crp,C3890735;C4048285
statin users n $nmbr$,C0360714;C1706077
statin non users n $nmbr$,C0360714;C1518422
mean predicted fvc sd,C0444504;C2699239;C2347634;C2348143
mean predicted dlco sd,C0444504;C2699239;C2347634;C2348143
mean $nmbr$ mwd m sd,C0444504;C2347634;C2348143;C2699239
mean ucsd sobq score sd,C3533236;C2699239
chronic renal failure,C0022661;C1561643;C2316810
cardiovascular risk factors n,C0850624
hypercholesterolaemia,C0020443;C1522133
smoker current former,C0205156;C0750523
obesity t,C0028754;C1963185
crude analysis n,C0002778;C0936012;C1524024
bivariate frailty model statin users vs non users,C0360714;C1706077;C1518422
disease progression composite outcome,C0679250;C3542417
first disease progression outcome to occur,C0679250;C3542417;C1709305;C2745955;C4284875
absolute fvc decrease $nmbr$,C0392756;C0547047
$nmbr$ mwd decrease $nmbr$ m,C0392756;C0547047
mortality,C0026565;C0026566
ipf related,C0034069;C1800706;C0439849;C0445223
fvc change,C0392747;C0443172;C1705241;C4319952
absolute decrease $nmbr$,C0392756;C0547047
relative decrease $nmbr$,C0392756;C0547047
death or absolute fvc decrease $nmbr$,C0011065;C1306577;C4082313;C4552775;C0392756;C0547047
death or $nmbr$ mwd decrease $nmbr$ m,C0011065;C1306577;C4082313;C4552775;C0392756;C0547047
hospitalisation,C0019993
respiratory related^,C0439849;C0445223
ind gly $nmbr$ $nmbr$ pg o d n $nmbr$,C0017890;C2827928;C0523677
sfc $nmbr$ $nmbr$ pg b i d n $nmbr$,C2827928
gold $nmbr$ groups n,C0018026;C0441848;C1304897
icsusers atbaseline n,
catscorecategory n,
mmrc grade n,C0441800;C0919553;C3244287
post bronchodilator fev $nmbr$ reversibility,C2599594;C0449261
post bronchodilator fev $nmbr$ fvc,C2599594;C3714541
figure forest plot of the treatment di erence in trough fev l at week across di erent subgroups of the lantern study ind gly indacaterol glycopyrronium sfc salmeterol uticasone,C0086312;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0332174;C0439230;C1079230
stage $nmbr$ a,C0205390;C1300072;C1306673
stage $nmbr$ b,C0441781
egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n $nmbr$ $nmbr$ $nmbr$ $nmbr$,C1739039;C0439445;C3811844;C3812682;C0369718;C0441922
egfr $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n $nmbr$ $nmbr$ $nmbr$ $nmbr$,C1739039;C0439445;C3811844;C3812682;C0369718;C0441922
egfr $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n $nmbr$ $nmbr$ $nmbr$,C1739039;C0439445;C3811844;C3812682;C0369718;C0441922
glucose lowering therapies,C0017725;C0441994;C2003888;C0087111
treatment by egfr stage,C0815181;C1739039;C3811844;C3812682
cv endpoints n,C3538987;C2349179;C4048877;C4318503
$nmbr$ point mace,C0349381;C0949745;C1445339
tocilizumab n $nmbr$,C1609165
white ethnicity,C0015031;C0243103
das $nmbr$,C0051767;C0057671
number of previous dmards,C0237753;C0449788
baseline diabetes,C0011847;C0011849
il $nmbr$ pg ml,C0020898;C0439297;C0021764;C0022271
tender joint count n $nmbr$,C0451530
swollen joint count n $nmbr$,C0451521
haemoglobin g l,C0635222
troponin t pg ml,C0077404;C0439297;C1420827
fig $nmbr$ relative effect of tocilizumab on hstnt and nt probnp strati ed by key baseline variables with p values for test for interaction,C1280500;C1518681;C2348382;C0669479;C3538926;C0754710;C1709380;C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744;C1704675
no peripheral revascularization n $nmbr$ $nmbr$,C0205100;C0581603
peripheral revascularization n $nmbr$,C0205100;C0581603
never smoker,C0425293
history of atrial fibrillation or fl utter,C0729790;C1300812;C1708024
egfr crcl,C1739039;C1846718;C3811844;C3812682
peripheral artery disease details,C1704436;C1522508;C4025272
peripheral artery revascularization without amputation,C0489868;C0581603
statin therapy,C1278454
figure $nmbr$ rates of peripheral revascularization during follow up by history of revascularization or amputation at baseline,C0871208;C1521828;C0589120;C1522577;C1704685;C3274571;C0002688;C0332840;C1546539
mod sev exacerbation rate,C0871208;C1521828
ff vi $nmbr$ $nmbr$,C4554348;C0205999
current smoker n $nmbr$ $nmbr$,C3173209;C3241966
former smoker n $nmbr$ $nmbr$,C0337671
cv entry criteria,C1705654;C0243161
$nmbr$ $nmbr$ cv disease n $nmbr$ $nmbr$,C0007222
$nmbr$ $nmbr$ risk not disease n $nmbr$ $nmbr$,C0035647;C4552904;C1518422;C0012634
hispanic latino n $nmbr$,C0086409;C0086528
not hispanic latino n $nmbr$ $nmbr$,C1518424;C0086528
asian n $nmbr$ $nmbr$,C0078988
african american african heritage n $nmbr$,C0085756;C2986513
usa n $nmbr$ $nmbr$,C0041703
asia n $nmbr$ $nmbr$,C0003980
europe $nmbr$ n $nmbr$ $nmbr$,C0015176
rest of world n $nmbr$,C0035253;C1622890
moderate severe exacerbation,C0205081;C4086268;C1881878;C4049705;C4049706;C4085643;C4321335
hospitalized for an exacerbation,C0701159;C4086268
hospitalized exacerbation rates,C0871208;C1521828
mod sev exacerbation rates,C0871208;C1521828
favors ffa i favors placebo,C0032042;C1696465;C1706408
ff vi,C4554348;C0205999
b_ $nmbr$,
h $nmbr$ $nmbr$,C0033727;C0369286;C0441932;C0564385;C4528284
$nmbr$ t i,C0021966;C0221138
predicted fev,C0681842;C3714541;C1882327
t n $nmbr$ $nmbr$,C2986835
favors ff vi favors placebo,C0032042;C1696465;C1706408
current smoker n $nmbr$ $nmbr$ former smoker n $nmbr$ $nmbr$,C3173209;C3241966
ijb^,
$nmbr$ bh i,C0021966;C0221138
i ^w i $nmbr$,C0021966;C0221138
predicted fev^,C0681842;C3714541;C1882327
mn population,C0032659;C1257890
umec vi $nmbr$ $nmbr$ $nmbr$ n $nmbr$ $nmbr$,C0205999
tio n $nmbr$ $nmbr$,
current smoker at screeninga n,C3173209;C3241966
smoking pack yearsb n,C0037369;C0453996;C1881674
reversible to albuterolc d n,C0205343;C0369718;C0441922
post albuterol predicted fev $nmbr$ mean sd e,C0001927;C0444504;C2347634;C2348143
gold stage nf,C0018026;C0205390;C1300072;C1306673;C1304897
ics use at screeningg n,C0042153;C0457083;C1947944
exacerbation historyh n,C4086268
required corticosteroid and or antibiotic without hospitalization,C0001617;C3536709;C0003232;C0019993
required hospitalization,C1708385
components of the first cid,C0449432;C0205435;C1279901
umec vi $nmbr$ $nmbr$ $nmbr$,C0205999
tio,
hazard ratio umec vi vs tio $nmbr$ ci,C2985465;C0205999;C0008107;C3259781
itt population n,C0032659;C1257890
c $nmbr$ ml decrease in trough fev $nmbr$,C0392756;C0547047
c $nmbr$ unit sgrq total score increase,C2964552;C0442805
moderate to severe copd exacerbation,C1299393;C0740304
mn population n,C0026327;C0026405;C4285072
re cover re cover ii,C0556581;C0180153;C1999244;C3888055;C2986904
re medy,
not tested,C1518422;C0392366
de n $nmbr$,C0011198;C0017480;C3541240
bmi mean kg m $nmbr$ sd,C0022718;C0439209;C4054209;C2699239
crcl mean ml min sd,C0439445;C2699239
qualifying symptomatic event n a,C1514624;C0231220;C0441471;C4019010
pe and dvt,C0070939;C1880476;C4284304;C0149871;C2926618;C3899446
pe only,C0070939;C1880476;C4284304
neither pe nor dvt,C0070939;C1880476;C4284304;C0149871;C2926618;C3899446
non transient risk factors for recurrent vte n,C0035648;C1553898
active cancer at any timeb,C0006826;C0998265;C1306459
concomitant anticoagulant antithrombotic or nsaid n,C0521115;C0003280;C0848112;C3536711;C0003211;C3536840
vte vte related deathsa n n,C0439849;C0445223
pulmonary embolisma n n,C0024109;C2707265;C2709248;C4522268
vte vte related deathsb n n,C0439849;C0445223
pulmonary embolismb n n,C0024109;C2707265;C2709248;C4522268
de,C0011198;C0017480;C3541240
treatment de vs warfarin by thrombophilia interaction,C0011198;C0017480;C3541240;C0043031;C0398623
mbesc n n,
mbes crbesc,
mbesb n n,
mbes crbesb n n,
p value for mra vs no mra,C1709380;C0243032;C1609165;C3891069
no mra at baseline,C0243032;C1609165;C3891069
mra at baseline,C0243032;C1609165;C3891069
sacubitril valsartan n $nmbr$,C4033631
heart rate mean sd beats min,C0439385
creatinine mean sd mg dl,C0010294;C0439269;C1561535
potassium mean sd meq l,C0032821;C0439375;C0202194;C0304475;C0597277;C3714637
clinical features of hf,C0683325;C0018488;C1313497;C1538440;C3273279
left ventricular ef mean sd,C0225897;C2699239
nt probnp median iqr pg ml,C0669479;C0439297;C0754710
treatment at randomization,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
mra use,C0042153;C0457083;C1947944
patients receiving enl no,C0030705;C1514756
incidence^,C0021149;C0220856
patients receiving lcz no,C0030705;C1514756
hr enl vs lcz $nmbr$ cl,C0596019
adjusted hr enl vs lcz $nmbr$ cl,C0456081;C0596019
hyperkalemia,C0020461;C4552983
severe hyperkalemia s,C0020461;C4552983
evolocumab n $nmbr$,C3529352
bmi mean sd b,C0578022;C0444504;C2347634;C2348143
baseline statin usec,C0168634;C0439224;C1442488
lntensityd,
baseline ezetimibe usec,C0168634;C0439224;C1442488
characteristic at baseline,C1521970;C0168634;C1442488
pav mean $nmbr$ ci,C0008107;C3259781
evolocumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
on treatment,C4684449
age years median n $nmbr$ $nmbr$,C1510829;C0549183;C0876920;C2347635;C2348144;C2939193
race non white n $nmbr$ $nmbr$,C0034510;C0007457;C0043157;C0220938;C1706779;C3853635
race white n $nmbr$ $nmbr$,C0034510;C0007457;C0043157;C0220938;C1706779;C3853635
no history of mi n $nmbr$ $nmbr$,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
history of mi n $nmbr$ $nmbr$,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
non smoker n $nmbr$ $nmbr$,C0337672;C0425293;C4554605
baseline pav median n $nmbr$ $nmbr$,C0168634;C0058890;C1442488
baseline tav median n $nmbr$ $nmbr$,C0168634;C0279686;C1442488
non high density lipoprotein mg dl baseline median n $nmbr$ $nmbr$,C1535899;C0439269
proprotein convertase subtil kexin typ $nmbr$ ng ml baseline median n $nmbr$ $nmbr$,C1100660;C0439275
no family history of chd n $nmbr$ $nmbr$,C0241889;C0280604;C3542407
family history of chd n $nmbr$ $nmbr$,C0241889;C0280604;C3542407
no type $nmbr$ diabetes n $nmbr$ $nmbr$,C1320657
type $nmbr$ diabetes n $nmbr$ $nmbr$,C1320657
no prior statin n $nmbr$ $nmbr$,C0332152;C0360714;C2826257
prior statin n $nmbr$ $nmbr$,C0332152;C0360714;C2826257
non high dose statin n $nmbr$ $nmbr$,C0444956;C0360714
high dose statin n $nmbr$ $nmbr$,C0444956;C0360714
change in pav mean $nmbr$ cl,C0392747;C0443172;C1705241;C4319952
agea,
current cigarette use,C0521116;C0694535;C1705970
baseline pava,C0168634;C0135567;C1442488
baseline tava,C0168634;C1442488
baseline non hdl ca,C1518422;C3715113
baseline pcsi,C0168634;C1442488
prior statin use,C0042153;C0457083;C1947944
statin intensity per acc ahac,C0522510;C0175754;C0282160;C3541413
moderate low,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
chlorthalidone $nmbr$,C0008294
amlodipine lisinopril $nmbr$,C0051696;C0065374
total $nmbr$,C0439175;C0439810
white non hispanic n,C1533020;C1533021
black non hispanic n,C1533017;C1533018
white hispanic n,C1533020;C1533021
black hispanic n,C1533017;C1533018
receiving antihypertensive treatment,C1514756;C0003364;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
n blood pressure mean sd mm hg,C0428886;C0439475
major st depression or t wave,C0041696;C1269683;C0429103
inversion,C0021943;C0021945;C1705687;C2349984
diabetes t,C0011847;C0011849
medication use at baseline n,C0240320;C0168634;C1442488
females only,C0086287
atenolol use at $nmbr$ month,C0042153;C0457083;C1947944
cholesterol mean sd n,C0008377;C0444504;C2347634;C2348143
serum creatinine mean sd n,C0201976;C0600061
egfr mean sd n,C1739039;C0444504;C2347634;C2348143;C3811844;C3812682
baseline mdrd,C0168634;C3839656;C1442488
baseline ckd epi,C1561643;C0162734;C4281721
lipid trial participants n,C1997894;C2242969
baseline mdrd egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0168634;C0439445;C1442488
baseline mdrd egfr,C1739039;C3811844;C3812682
baseline ckd egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0168634;C0439445;C1442488
baseline ckd egfr,C1739039;C3811844;C3812682
no cvd,C0007222
prevalent cvd,C0007222
healthy weight,C0005910;C0043100;C1305866;C1705104
overweight,C0497406
no estrogen,C0014939;C2936882;C4542544
budesonide symptom days a week,C0054201;C0439228;C0332174;C0439230
placebo symptom days a week,C0032042;C0439228;C1696465;C1706408;C0332174;C0439230
$nmbr$ tol n $nmbr$,
lto,
$nmbr$ n $nmbr$ l $nmbr$,C0369718;C0441922
age mean age years sex,C0009253;C0036864;C0079399;C0804628;C1314687;C1522384
$nmbr$ u,C0439148
passive smoker,C0425309
prebronchodilator fevj predicted,C2599602;C0681842;C1882327
postbronchodilator fevj predicted,C2599594;C0681842;C1882327
controllertreatment before entry,C1705654
inhaled corticosteroid,C0004048;C0001617;C3536709
oral or other systemic corticosteroid,C0442027;C4521986;C4053960
xanthine,C0043314;C0043318
cromoglicate,C0010347
leukotriene modifier,C0205349;C1514623;C1516451;C3542952
time to first sare,C0040223;C3541383
cumulative incidence lyear,C0021149;C0220856
cumulative incidence $nmbr$ years,C0021149;C0439234;C0220856
rate of sares,C0871208;C1521828
rate per $nmbr$ patient years,C0871208;C1521828
$nmbr$ year mean change from baseline,C0392747;C0443172;C1705241;C4319952
$nmbr$ to $nmbr$ $nmbr$,
prebronchodilator fevi predicted,C0849974;C1561566;C4528367;C0681842;C1882327
lyear mean change from baseline,C0392747;C0443172;C1705241;C4319952
time to first inhaled corticosteroid,C0040223;C3541383
time to first oral or systemic corticosteroid,C0040223;C3541383;C4053960
rate of oral or systemic corticosteroid,C0871208;C1521828;C4053960
asthma symptoms in the past $nmbr$ weeks,C0683368;C1457887
mean proportion,C0444504;C1709707;C2347634;C2348143
restriction in normal activities in the past $nmbr$ weeks,C0443288;C4697852;C0439230
sleeping problems in the past $nmbr$ weeks,C0037313;C0424522;C4050403;C1546466;C0439230
symptom free days in the past $nmbr$ weeks,C0332296;C0677547;C1880497;C1996904
$nmbr$ to $nmbr$ symptom days per week,C1457887;C0677547;C3854129
lto $nmbr$ symptom days per week,C1457887;C0677547;C3854129
$nmbr$ symptom days per week,C1457887;C0677547;C3854129
hr $nmbr$ $nmbr$ $nmbr$ cl $nmbr$ $nmbr$ $nmbr$,C0596019
hr $nmbr$ $nmbr$ $nmbr$ cl $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0596019
a prebronchodilator fevl predicted,C2599602;C0681842;C1882327
baseline symptom days perweek,C0168634;C0439228;C1442488
mean difference $nmbr$ cl,C0444504;C0596019;C2347634;C2348143
yearl,
b postbronchodilator fevl predicted,C2599594;C0681842;C1882327
baseline feature,C1521970;C1706388;C2346469;C2348519
lived alone,C0205171;C0439044;C0679994
stroke at entry,C0038454;C4554100
nih stroke scale,C1697238;C3484372
health practices,C0018684;C0237607
$nmbr$ $nmbr$ drinks day if male female,C0332173;C0439228;C0439505;C0043210;C0086287;C1705497;C1705498
aerobic exercise,C0001701
cognitive,C1516691
and physical examination,C0031809;C1744699
$nmbr$ ms score,C0449820;C4050231
antidepressant,C0003289
benzodiazepine or bzra,C0005064;C3536850;C4048284
epilepsy drug,C0013227;C1254351
osteoporosis drug,C0013227;C1254351
vitamin d,C0014695;C0042866;C2936842;C3537249;C3714503
risk at,C0035647;C4552904
fxs,C0016667
any site,C0205145;C1515974;C2825164
upper limb,C1140618
distal lower,C0441994;C1548802;C2003888
limb,C0015385
hip femur,C0019552;C0015811;C0022122;C1505163;C3538851;C4284725
rib,C0035561
black or african america,C0005680;C0027567;C0085756;C0439541;C0002454
chd risk no,C1282512
very high risk,C0332167;C0442804;C3272283;C4050568;C4319571;C4321397
lower risk,C3272281;C3538919
at ldl c bq goal at baseline no,C0018017;C1571704
prior diagnosis no,C0332132
use of concomitant lipid lowering therapy no,C1524063;C0585943
statin with niacin,C0360714;C0027996;C1142562
statin with fibrate,C0360714
other $nmbr$,
type of concomitant statin by daily dose no,C0332307;C1547052;C2348070
lovastatin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
pitavastatin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
baseline lipid lipoprotein values,C0443602;C0042295
ldl c bq mg dl mean sd,C0439269;C2699239
non hdl c mg dl mean sd,C0439269;C2699239
apo b mg dl mean sd,C0003593;C2699239;C3252643
apo a l mg dl mean sd,C1447574;C2699239;C4521365
figure $nmbr$ least square mean difference of percent change from baseline $nmbr$ ci at week $nmbr$ presented by patient subgroup for a ldl c b quanti cation and b hdl c for anacetrapib $nmbr$ mg versus placebo comparison,C1705241;C1705242;C0008107;C3259781;C1079231;C1079232;C3715113;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C1707455;C1696465;C1706408
the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebc group,C0205132;C0700221;C1550648;C1552960;C0282416;C1518681;C1561607;C2360800;C0024671;C0441848;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebo group,C0205132;C0700221;C1550648;C1552960;C0282416;C1518681;C1561607;C2360800;C0024671;C0441848;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1696465;C1706408
uniti $nmbr$,
im uniti,
ustekinu,
mab,C0003250;C0369637
usteki,
numab,
$nmbr$ mg kgf n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ mg $nmbr$ wk n $nmbr$,C1881833
duration of disease yr t,C0872146;C0439234
median c reactive protein mg liter,C0006560;C0475211;C1413716;C4048285
median fecal calprotectin mg kg gi areas involved no,C0205146;C4319729;C1314939
proximal gi tract,C0205107;C0017189;C4489236
perianal gi tract,C0442158;C0017189
medications for crohn s disease taken at baseline no,C0013227;C0802604;C2598133;C4284232;C0012634;C1883727;C0168634;C1442488
one or more medications,C0205447;C0013227;C0802604;C2598133;C4284232
immunosuppressant^,C0021081
aminosalicylate,C0368663;C2825094
glucocorticoid],C0017710
history of disease refractory to treatment with tnf antagonist no,C0683519;C0730226;C0850708;C0944983;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
no history of tnf antagonist treatment no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
history of tnf antagonist treatment failure no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
patients who received $nmbr$ drug,C0013227;C1254351
patients who received $nmbr$ or $nmbr$ drugs,C0030705;C3272598;C1514756;C0013227;C3687832
primary nonresponse,C0205225;C0439612;C0439631
secondary nonresponse,C0027627;C0175668;C0205436
unacceptable side effects,C0001688;C0877248;C0879626
uistekinumab,
$nmbr$ mq kq,C0024853
while,
weight at baseline,C1303013
$nmbr$ st quartile,C0036056;C2828255;C3272372
$nmbr$ st and $nmbr$ nd quartile,C0036056;C3272372;C2828255
$nmbr$ nd and $nmbr$ rd quartile,C0694666;C2828255;C4553350
$nmbr$ rd quartile,C0694666;C2828255;C4553350
crohn s disease duration,C0010346;C0872146
s $nmbr$ yrs,
$nmbr$ to s $nmbr$ yrs,
involved gastrointestinal,C1314939;C0521362
areas,C0205146;C4319729
secukinumab intravenous $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
time since as diagnosis mean sd years,C0040223;C3541383;C0011900;C0439234;C1704338;C1704656
hla b $nmbr$ positive n,C1426226
anti tnf naive n,C1448177
hscrp median min max mg l,C0549183;C2827895;C0876920;C2347635;C2348144;C2939193
elevated hscrp $nmbr$ mg l n,C0205250;C0439268;C3163633
total basdai mean sd,C0439175;C2699239;C0439810
basfi mean sd,C0444504;C2699239;C2347634;C2348143
basmi linear mean sd,C0205132;C2699239
msasss mean sd,C0444504;C2699239;C2347634;C2348143
syndesmophyte present n,C0221690;C0150312;C0449450
total back pain mean sd,C0004604;C2699239;C1963071;C4553945
patient s global assessment of disease activity mean sd,C0030705;C0281858;C1292728
placebo secukinumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
placebo secukinumab pooled,C0032042;C3179547;C1696465;C1706408;C1709595;C2349200;C4522255
change at week $nmbr$,C0392747;C0443172;C1705241;C4319952
patients with syndesmophytes at baseline,C0030705;C0221690;C0168634;C1442488
patients without syndesmophytes at baseline,C0030705;C0221690;C0168634;C1442488
elevated hscrp,C0205250;C3163633
normal hscrp,C0205307;C0231683;C0439166;C2347086;C4553972
smokers at baseline,C0337664;C0168634;C1442488
non smokers at baseline,C0337672;C4554605
egfr ml min $nmbr$ $nmbr$ m $nmbr$ mdrd mean sd,C1739039;C0439445;C3811844;C3812682;C0444504;C2699239;C2347634;C2348143
sbp mm hg office measurement mean sd,C0439475;C2699239
sbp mm hg mean $nmbr$ h mean sd,C0456680;C2699239
dbp mm hg office measurement mean sd,C0439475;C2699239
dbp mm hg mean $nmbr$ h mean sd,C0456680;C2699239
pulse rate bpm mean $nmbr$ h mean sd,C0232117;C2699239
time since diagnosis of t $nmbr$ dm y n,C0040223;C3541383
use of diuretics n,C1524063;C0012798
use of ace inhibitors arbs n,C1524063;C0003015
$nmbr$ antihypertensive medication,C0003364
$nmbr$ antihypertensive medications,C0003364
$nmbr$ aes,C1412268;C2699274
$nmbr$ drug related aes,C1412268;C2699274
$nmbr$ aes leading to discontinuation,C1412268;C2699274;C0332152;C0457454;C1444662;C4552847;C1522538
$nmbr$ serious aes,C1412268;C2699274
special interest categories,C0205555;C0683312
hypoglycemiat,
events requiring assistance,C0441471;C3541888;C0018896;C1269765
events consistent with uti,C0441471;C3541888;C0332290;C0042029;C0077906;C1412376
events consistent with genital infection,C0441471;C3541888;C0332290;C0729552
events consistent with volume depletion,C0441471;C3541888;C0332290;C0546884
positive orthostatic test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
no diuretic therapy,C0948575
diuretic therapy,C0948575
no ace inhibitor arb,C0003015;C3888198;C4541021
ace inhibitor arb therapy,C1444755;C3888198
therapy,C0039798;C0087111;C1363945
empa,C2699863
$nmbr$ drug related,C0013227;C0439849;C0445223;C1254351
aes,C1412268;C2699274
hypoglycemia^,C0020615;C4553659
requiring assistance,C0018896;C1269765
orthostatic test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
non cana n $nmbr$,C1518422;C1418845
baseline hbalc,C0168634;C1442488
baseline hbalc $nmbr$ to,C0168634;C1442488
baseline hbalc $nmbr$,C0168634;C1442488
genital mycotic infections male $nmbr$,C0564768
utis,C0042029
osmotic diuresis related aes,C1412268;C2699274
volume depletion related aes,C1412268;C2699274
olodaterol $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
tiotropium olodaterol $nmbr$ $nmbr$ mg n $nmbr$,C4032878;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
co morbidities a n,C0009488;C0369718;C0441922
cardiac rhythm disorders,C0264886
vascular disordersb,C0005847;C1558950;C1801960
gold n,C0018026;C1304897
$nmbr$ $nmbr$ e,
baseline cardiovascular medication c n,C0168634;C0007220;C1442488
mean sd extent of exposure days,C0439792;C0274281;C0332157
cardiac rhythm disorder at baseline no,C0264886;C0168634;C1442488
cardiac rhythm disorder at baseline yes,C0264886;C0168634;C1442488
meddra smq,C1140263
olodaterol $nmbr$ m g,C2934193;C0439267
tiotropium $nmbr$ m g,C0213771;C0439267
total patients n,C0439175;C0030705;C0439810
any aes n,C1412268;C2699274
tachyarrhythmias n,C0080203
supraventricular tachyarrhythmias incl atrial,C1698480;C3853833
fibrillation flutter,C0016385;C2242390
ventricular tachyarrhythmias,C3827656
ischaemic heart disease n,C0010054;C0151744
other ischaemic heart disease non infarction,C0027051;C1518422
cardiac failure n,C0018801;C0018802
cerebrovascular disorders n,C0007820
haemorrhagic,C0333275
racea,
copd disease severity,C0024117;C0521117;C1412502;C3714496
chinese subgroup,C1079230;C1515021
korea republic of,C0022773
malaysia,C0024552
body weighta kg,C0022718;C0439209;C4054209
belimumab $nmbr$ mg sc n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
age mean $nmbr$ sd years,C1510829;C0444504;C2347634;C2348143
weight mean $nmbr$ sd kg,C0022718;C0439209;C4054209
enrollment by region no,C1516879;C1696073;C3888021
americas excluding us,C0002454;C0596070
western europe australia israel,C0043128;C0022271
disease duration median range years,C0872146;C0439234
selena sledai range u $nmbr$ u $nmbr$ t,C0451528;C0439148
score of $nmbr$ no,C0449820;C4050231
organ system involvement no,C0460002;C1314939
mucocutaneous,
musculoskeletal,C0497254;C2707260
immunologic,C0152036;C0205470
renal,C0022646
hematologic,C0018943;C0205488
cardiovascular and respiratory,C0007226;C3887460;C0521346;C1546767
constitutional,C1511487
central nervous system,C3540014;C3714787
disease hare no i,C0242372;C1425660;C0021966;C0221138
at least $nmbr$ flare,C1517205;C3540542
at least $nmbr$ severe flare,C1517205;C3540542
physician s global assessment mean $nmbr$ sd,C0031831;C0804815;C0281858;C2699239
$nmbr$ $nmbr$ cm vas,C0042815;C3536884;C3827561
facit fatigue mean $nmbr$ sd range $nmbr$ $nmbr$,C1514721;C2348147;C3542016
corticosteroids only,C0001617;C3539185;C3540725;C3540726;C3540727
immunosuppressants only,C0021081
antimalarials only,C0003374
corticosteroids and immunosuppressants only,C0001617;C3539185;C3540725;C3540726;C3540727;C0021081
corticosteroids and antimalarials only,C0001617;C3539185;C3540725;C3540726;C3540727;C0003374
immunosuppressants and antimalarials only,C0021081;C0003374
corticosteroids immunosuppressants and antimalarials,C0001617;C0021081;C3539185;C3540725;C3540726;C3540727;C0003374
mycophenolate mofetil,C0209368
sri response,C0871261;C1704632;C1706817;C2911692
overall n $nmbr$ vs $nmbr$,C0282416;C1561607
ss at baseline,C2699257;C3891295;C4551874
ss $nmbr$ n $nmbr$ vs $nmbr$,C2699257;C3891295;C4551874
ss,C2699257;C3891295;C4551874
black race n $nmbr$ vs $nmbr$,C0005680
non black race n $nmbr$ vs $nmbr$,C1518422;C0005680
race and ss at baseline,C0034510;C1706779;C3853635;C2699257;C3891295;C4551874
black race and ss,C0005680;C2699257;C3891295;C4551874
black race and ss $nmbr$ n $nmbr$ vs $nmbr$,C0005680;C2699257;C3891295;C4551874
i $nmbr$ $nmbr$ vs $nmbr$ $nmbr$,C0021966;C0221138
non black race and ss,C1518422;C0005680;C2699257;C3891295;C4551874
non black race and ss $nmbr$ n $nmbr$ vs $nmbr$,C1518422;C0005680;C2699257;C3891295;C4551874
baseline body weight quartile,C1303013;C2828255
q $nmbr$,
q $nmbr$ $nmbr$ $nmbr$ to,
q $nmbr$ $nmbr$ $nmbr$ kg n $nmbr$ vs $nmbr$,C0022718;C0439209;C4054209
steroid use at baseline,C0281991;C0168634;C1442488
steroids n $nmbr$ vs $nmbr$,C0038317
no steroids n $nmbr$ vs $nmbr$,C0038317
vonoprazan $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
aget y,
bmit,
previous smoker,C0337671
every day,C0332173;C0439228;C0439505
$nmbr$ or $nmbr$ d wk,C0332174;C0439230
$nmbr$ or $nmbr$ d mo,C0026544;C0332177
never drink,C2003901;C0452428
caffeine consumption,C0948365
modi fied la grade,C0441800;C0919553;C3244287
heartburn severity during the run in periodt,C0439793;C0522510
esophageal hiatal hernia,C3489393
yes z $nmbr$ cm,C1549445;C1705108;C1710701
yes o $nmbr$ cm,C1549445;C1705108;C1710701
h pylori serology,C0036745;C0220911;C0455278
history of h pylori eradication,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
yes r $nmbr$ y,C1549445;C1705108;C1710701;C0205090;C0684010;C2603358
yes $nmbr$ $nmbr$ y,C1549445;C1705108;C1710701
serum gastrint pg ml,C0229671;C0439297;C1546774;C1550100
serum pepsinogen i iit,C0077923;C0523816
czp mtx^mtx,C0054841;C0025677;C1417487;C1861828;C1872109
pbo mtx^mtx,C0031962;C0025677;C1417487
total patients n $nmbr$,C0439175;C0030705;C0439810
patients entering pt period n $nmbr$,C0030705;C1522196;C0032743;C0439531;C1948053;C0699718
db baseline week $nmbr$,C0332174;C0439230
pt baseline week $nmbr$,C0332174;C0439230
average weekly mtx dose mg week t,C0366550;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
czp mtx to mtx,C0054841;C0025677;C1417487;C1861828;C1872109
pbo mtx to mtx,C0031962;C0025677;C1417487
mtss cfb,C0009002;C1824728
baseline factor,C1521761;C2827422
baseline erosion,C0333307;C1880549;C1959609;C3887524
tnf alpha pg ml,C1448177;C0439297;C1456820;C1522669
baseline steroids,C0168634;C0038317;C1442488
mtx exposure mg week,C0332174;C0439230
age of onset,C0206132;C3175530
age of onset $nmbr$ years n $nmbr$,C0206132;C3175530
icsa plus laba n,
geographical location n,C4545686
ocs n,
fev $nmbr$ l mean sd,C0444504;C2699239;C2347634;C2348143
fev $nmbr$ predicted mean sd,C0444504;C2699239;C2347634;C2348143
acq $nmbr$ score mean sd,C0444504;C2699239;C2347634;C2348143
aqlq score mean sd,C0444504;C2699239;C2347634;C2348143
asui score mean sd,C0444504;C2699239;C2347634;C2348143
blood eosinophils cells ml,C2699156
allergic disease by historyb n,C0020517;C0851444
atopy specific ige c n,C0392707;C0205369;C1552740;C3539705
chronic sinusitis nasal polypsd n,C0149516;C0028429;C4520890
age of asthma onset years,C0206132;C3175530
resllzumab,
demographic data,C4684639
alprostadil n $nmbr$,C0002335
gender male female number,C0237753;C0449788
risk factors and diabetes status,C0035648;C1553898;C1317301
caffeine,C0006644;C0236734
complete healinga,C0205197;C0725685;C3853530;C4283785
major amputationsb,C0205082;C0205164;C4318856;C4521762
alprostadil n n,C0002335
interim analysis,C4684691
overall analysis,C0002778;C0936012;C1524024
cochranemantelehaenszel repeated $nmbr$ $nmbr$ ci c,C0205341;C0008107;C3259781
statistic,C2348149;C2828391
statisticd,
interim analysis all patients,C4684691;C0030705
e $nmbr$ $nmbr$ to $nmbr$ $nmbr$,
final analysis all patients,C0002778;C0936012;C1524024;C0030705
duration of paod years mean sd,C0449238;C2926735
intensity of rest pain mmvas mean sd,C1320357;C4085211
systolic pressure at ankle level mmhg mean sd,C0871470
analgesic medication n,C0002771
past treatment for paod,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
medical treatment n,C0679624
revascularisation n,C0581603
amputations n,C0002688
ischaemic skin lesions,C0475224;C0037284
number of lesions n a,C0449791
size cm $nmbr$ mean standard deviation,C1828170
type,C0332307;C1547052
ulcer n a,C0041582;C3887532
necrosis n a,C0027540;C1334928
base,C0002055;C0178499;C1880279
clean n a,C1947930
granulating n a,C1272460
infected n a,C0439663
missing n a,C1551393;C1705492;C3272743
serum mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
serum mg $nmbr$ $nmbr$ mmol l normal mg hvpermagnesemia,C2827881
pbo n $nmbr$ $nmbr$,C0031962
cana $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ethnicity n b,C0015031;C0243103
hba $nmbr$ c mmol mole,C0019016;C3829066;C1825777;C3538758
baseline serum mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
baseline serum mg $nmbr$ $nmbr$ mmol l,C0439268
baseline mmol l,C0168634;C1532563;C1442488
week $nmbr$ mmol l,C0332174;C1532563;C0439230
total number of patients,C2360800
egfr mean sd,C0444504;C2699239;C2347634;C2348143
egfr $nmbr$ to,C1739039;C3811844;C3812682
egfr $nmbr$ ml min n,C1739039;C0439445;C3811844;C3812682
af first diagnosis $nmbr$ years n,C0205435;C0011900;C1704338;C1704656;C1279901
af on baseline ecg n,C0344434;C4049859
$nmbr$ or $nmbr$ n,C0369718;C0441922
cha $nmbr$ ds $nmbr$ vasc score mean sd,C0444504;C2699239;C2347634;C2348143
risk factors for stroke,C0035648;C1553898
previous stroke or tia n,C0038454;C4554100;C0007787;C0917805;C1054154
heart failure n,C0018801;C0018802;C4554158
hypertension receiving treatment n,C0020538;C1963138;C1514756;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
valvular heart disease n,C0018824;C1963123
concomitant medications at baseline,C0013227;C0802604;C2598133;C4284232
arb or ace inhibitor n,C3888198;C0003015;C4541021
ppi or h $nmbr$ receptor antagonist n,C0358591;C0871125;C3811894;C0033727;C4543207;C0369286;C0441932;C0564385;C4528284
on oac at time of randomisation n,C0040223;C0034656;C3541383
dabigatran $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
dabigatran $nmbr$ mg versus warfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0043031
dabigatran $nmbr$ mg versu swarfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
clinical outcome,C0205210;C1274040
number of events,C4330837
event rate year,C0439234;C0439508
p value for interaction age groups,C1709380
p value for interaction age continuous,C1709380;C0001779;C0549178
stroke non,C0038454;C1518422;C4554100
cns systemic embolism,C0013922;C1704212
$nmbr$ mg sirukumab every $nmbr$ weeks n $nmbr$,C0024671;C3254570;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0439230
duration of rheumatoid arthritis years,C0449238;C2926735
anti ccp antibody positive,C0741132
das $nmbr$ c reactive protein,C0006560;C1413716;C4048285
clinical disease activity index score $nmbr$ $nmbr$,C4706353
simplified disease activity index score $nmbr$ $nmbr$,C4706353
duration of morning,C0449238;C2926735
stiffness min,C0702093;C1524029;C3813700
conventional synthetic dmard use at baseline,C0042153;C0457083;C1947944
methotrexate dose at baseline,C0178602;C0869039;C1114758
$nmbr$ $nmbr$ mg week,C0332174;C0439230
sirukumab $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
evaluable for acr $nmbr$ at week $nmbr$ n,C1516986;C1412134;C1515941;C0332174;C0439230
acr $nmbr$ response at week $nmbr$ n,C0871261;C1704632;C1706817;C2911692
prior anti tnf therapy,C1514463
received $nmbr$ prior anti tnf therapy n,C1514463
received $nmbr$ prior anti tnf therapies n,C1514463
prior biologic therapy including anti tnfs,C0278947;C1448177
received $nmbr$ prior biologic therapy n,C1514756;C0278947
received $nmbr$ prior biologic therapies n,C1514756;C0278947
low $nmbr$ $nmbr$ n $nmbr$ $nmbr$ $nmbr$,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
intermediate $nmbr$ n $nmbr$ $nmbr$ $nmbr$,C0205103;C1550465;C2827755;C3889971
high $nmbr$ n $nmbr$ $nmbr$ $nmbr$,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
coexisting conditions,C0012634;C0348080;C1705253;C3864998
previous ml before index acs,C0439526;C1705224;C3887665
previous pci before index acs,C0205156;C4049621;C1552607
previous cabg before index acs,C0205156;C0010055;C1552607
before index acs event,C0441471;C4019010
at index acs event,C0441471;C4019010
ml with st segment elevation,C0439526;C1705224;C3887665
ml without st segment elevation,C0439526;C1705224;C3887665
pre randomization pci,C0034656;C4049621
time from acs to randomization,C0040223;C3541383;C0034656
$nmbr$ $nmbr$ $nmbr$ o $nmbr$ o,C0483204
low risk ri $nmbr$ $nmbr$,C0035487;C1826843
intermediate risk ri $nmbr$,C0035487;C1826843
high risk ri $nmbr$,C0035487;C1826843
ez simva,C0206578
arr,C2170357;C4084934
risk model endpoint,C2349179;C2826544
pre specified trial endpoints,C2826245;C2349179
secondary $nmbr$,C0027627;C0175668;C0205436
individual endpoints,C0027361;C2349179;C0237401
cor revasc,C0018787;C0378365;C0056331
urgent cor revasc,C0018787;C0378365;C0056331
acm,C0001143;C1549040
pooled,C1709595;C2349200;C4522255
seizure types reported during baseline n a,C0036572;C0332307;C1959629;C4553401;C0684224;C0700287;C4319718
number of prior aeds n b,C0237753;C0449788
most common concomitant aeds n,C0205214;C0180309;C1522138;C3245511
phenytoin,C0031507;C0202454
levetiracetam,C0377265;C3693636
patients with minimal important change in qolie $nmbr$ p,C0030705;C3845594
minimal important change threshold improvement a,C3845594;C2986411
$nmbr$ focal seizure frequency responders,C0149775;C0751495
cognitive functioning,C1516691;C0205245;C0542341;C4552744
emotional well being,C2984554;C3641833
energy fatigue,C0015672;C3463815;C4050243;C4554645
medication effects,C1319171
overall quality of life,C3641830
seizure worry,C0036572;C0233481;C1959629;C4553401
daily activities social functioning,C0871707;C0037395
$nmbr$ $nmbr$ $nmbr$ obesity class $nmbr$,C0456387;C1518526;C1705943
$nmbr$ obesity class $nmbr$,C0456387;C1518526;C1705943
glycated haemoglobin,C0017853
$nmbr$ h plasma glucose during ogtt mmol l,C0202042;C0455280
women n $nmbr$ vs $nmbr$,C0043210
men n $nmbr$ vs $nmbr$,C0025266
vldl cholesterol,C0023826;C0523560
non hdl cholesterol,C0729627;C1535899
free fatty acids mmol l,C0015688;C1532563
dyslipidaemiat,
hypertensiont,
dyslipidaemia and hypertensiont,C0242339
estimated proportions and odds ratios,C0750572;C1709707;C0028873
interaction between treatment and baseline bmi category,C1704675;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0683312;C3889287
bmi a $nmbr$,C0578022
estimated means and treatment differences,C0750572;C1704970;C1705241;C1705242
llraglutide $nmbr$ $nmbr$ mg mean n,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
baseline hstni,C0168634;C1442488
$nmbr$ ng l n $nmbr$,C0439297
p value trend,C1521798;C4554533
glycohemoglobin,C0202054;C0696092
prior coronary intervention or coronary artery bypass grafting,C0184661;C0886296;C1273869;C0010055
index inclusion acute coronary syndrome,C0007637;C0948089;C1512693
time from acute coronary syndrome to randomization days,C0040223;C3541383;C0034656;C0439228
median egfr interquartile range,C0549183;C1711350;C0876920;C2347635;C2348144;C2939193
$nmbr$ ng l n $nmbr$ n,C0439297
cardiovascular death nonfatal myocardial infarction nonfatal stroke,C0027051;C0428953;C2926063;C3810814;C4552959
nonfatal myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
cardiovascular death or hospitalization for heart failure,C0011065;C1306577;C4082313;C4552775;C3898876
cardiovascular death or nonfatal myocardial infarction,C0011065;C1306577;C4082313;C4552775;C0027051;C0428953;C2926063;C3810814;C4552959
demographic features,C0683970
black race n,C0005680
hispanic ethnic group n,C0441848
clinical history n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
stroke at entry vs transient ischemic attack,C0038454;C4554100;C0007787;C0917805
prior stroke before index event,C0332152;C0456712;C2826257
coronary angioplasty or stenting,C0002997;C0190211;C0038257;C2348535
carotid artery intervention,C0397581
fasting glucose mmol l mean sd,C1532563;C2699239
insulin iu ml median q $nmbr$ q $nmbr$,C0021641;C0439458;C1533581;C1579433;C3714501
homa ir median q $nmbr$ q $nmbr$,C0022065;C0022071;C1448132
hdl cholesterol mmol l men mean sd,C0023822;C2699239;C0392885
hdl cholesterol mmol l women mean sd,C0023822;C2699239;C0392885
c reactive protein median q $nmbr$ q $nmbr$,C0006560;C1413716;C4048285
other antihypertensive,C0003364
aspirin and other antiplatelet,C0004057
nonaspirin antiplatelet,C0722138
coumadin,C0699129
other anticoagulant,C0003280;C0848112;C3536711
pioglitazone pts n,C0071097;C1419129;C2698747
placebo pts n,C0032042;C1419129;C2698747;C1696465;C1706408
$nmbr$ z $nmbr$,
fema le,C0023190;C0439090;C1423767;C2697858
white other,C0007457;C0043157;C0220938
homa median,C0549183;C0876920;C2347635;C2348144;C2939193
arb ace,C1452534;C4284014
$nmbr$ $nmbr$ o,C0483204
copd n $nmbr$,C0024117;C1412502;C3714496
copd placebo n $nmbr$,C0024117;C0032042;C1696465;C1706408;C1412502;C3714496
copd rosuvastatin n $nmbr$,C0024117;C0965129;C1412502;C3714496
copd placebo $nmbr$ pt n,C0024117;C0032042;C1696465;C1706408;C1412502;C3714496
copd rosuvastatin $nmbr$ pt n,C0024117;C0032743;C0699718;C1412502;C3714496
model $nmbr$,C3161035;C3274659;C3714583;C3853906
symptoms,C0683368;C1457887
nyha ii n,C1275491;C1710602;C4082587
nyha iii n,C1275491;C0439070;C1705160
nyha iv n,C1275491;C0022326;C4265176
former current smoker n,C0337671
previous hf hospitalization n,C0018488;C0019993;C1313497;C1538440;C3273279
previous cabg n,C0205156;C0010055;C1552607
previous pci n,C0205156;C1552607
pm n,C0030266;C4049155
history of atrial arrhythmia n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
previous cancer n,C0205156;C0006826;C0998265;C1306459;C1552607
ischaemic n,C0475224
dilatative n,
hypertensive n,C0857121
other cause n,C0015127;C1524003
non detectable unknown n,C1518422;C0439673;C3541433;C4050014
s $nmbr$ gallop n,
mitral regurgitation n,C0026266
ecg,C1623258
pathologic q waves n,C0429089;C1305738
lv hypertrophy n,C0149721
qrs duration $nmbr$ ms n,C2349943;C3539704;C3713294
diuretics n,C0012798
calcium channel blockers n,C0006684;C2757014
beta blockers all n,C0001645;C0369718;C0441922
other antiplatelet agents n,C0085826
$nmbr$ blood eosinophils at baseline,C0014467;C0168634;C1442488
ind gly $nmbr$ $nmbr$ mg once daily n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0332173
sfc $nmbr$ $nmbr$ mg twice daily n $nmbr$,C0024671;C0585361;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ind gly $nmbr$ $nmbr$ mg once daily n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0332173
sfc $nmbr$ $nmbr$ mg twice daily n $nmbr$ $nmbr$,C0024671;C0585361;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ics use at screening n,C0042153;C0457083;C1947944
laba use at screening n,C0042153;C0457083;C1947944
lama use at screening n,C0042153;C0457083;C1947944
laba ics use at screening n,C0042153;C0457083;C1947944
triple therapy use at screening n,C0042153;C0457083;C1947944
smoking status at screening n,C1519386
severity ofcopd gold $nmbr$ n,C0439793;C0018026;C1304897;C0522510
low risk and fewer symptoms group a,C3272281;C3538919;C0441835;C4522145
low risk and more symptoms group b,C3272281;C3538919;C0683368;C4522078;C1457887
high risk and fewer symptoms group c,C0332167;C3272283;C4050568;C4319571;C0683368;C0441837;C1457887
high risk and more symptoms group d,C0332167;C3272283;C4050568;C4319571;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
severity of airflow limitation gold $nmbr$ $nmbr$ n,C0439793;C0522510
mild gold $nmbr$,C0018026;C1304897
post bronchodilator fev $nmbr$ reversibility percentage of baseline value,C0439165;C1549488;C1561533
number of copd exacerbations in the previous year n,C0237753;C0449788;C0205156;C0439234;C0439508;C1552607
no of patients ind gly sfc,C0030705;C0017890;C0523677
annualized rate ind gly sfc,C0017890;C4521536;C0523677
rate ratio $nmbr$ ci,C0008107;C3259781
blood eosinophils count,C0200638;C0750879
$nmbr$ cells ul $nmbr$ $nmbr$,C0439378
$nmbr$ to $nmbr$ cel,C0208736;C0346421;C0439237;C1413336
ls ul $nmbr$ $nmbr$,C0023668;C1300557
$nmbr$ cells ul,C0439378
$nmbr$ cells pl,C3897966;C4049765
$nmbr$ to $nmbr$ cells,C0007584;C0007634
pl $nmbr$ $nmbr$,C3897966;C4049765
exposed n $nmbr$,C0332157
naive n $nmbr$,
no of prior aeds n,C0332152;C0180309;C2826257
$nmbr$ $nmbr$ a $nmbr$ $nmbr$ $nmbr$ $nmbr$,
$nmbr$ $nmbr$ b $nmbr$ $nmbr$ $nmbr$ $nmbr$,
$nmbr$ $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$,
number of prior aeds,C0237753;C0449788
lev exposed,C0023556;C0332157
$nmbr$ responder rate n,C0871208;C1521828
cbz exposed,C0006949;C0332157
cbz naive,C0006949
tpm exposed,C0076829;C0332157
tpm naive,C0076829
ltg exposed,C1420817;C4521367;C4521846;C0332157
ltg naive,C1420817;C4521367;C4521846
placebo no diabetes n $nmbr$,C0032042;C1696465;C1706408;C0011847;C0011849
placebo diabetes n $nmbr$,C0011847;C0011849
ticagrelor $nmbr$ mg no diabetes n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0011847;C0011849
ticagrelor $nmbr$ mg diabetes n $nmbr$,C0011847;C0011849
caucasian race,C0007457
body mass index median,C0549183;C0876920;C2347635;C2348144;C2939193
kg m $nmbr$,C0022718;C0439209;C4054209
prior mi diagnosis,C0332132;C3810814
years since mi median,C0439234;C0549183;C0876920;C2347635;C2348144;C2939193
prior transient ischaemic,C0040704;C0475224;C0205374
attack,C0277793;C1261512;C1304680
time since last dose of,C0946444
study medication pre dose,C0801821;C3174092
median h,C0033727;C0369286;C0441932;C0564385;C4528284
beta blocker use,C0042153;C0457083;C1947944
hypoglycaemic therapy,C0039798;C0087111;C1363945
diet controlled,C0743195
ticagrelor $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
lta max response to $nmbr$ pm adp defined hpr patients,C2611142;C0030266;C4049155
pre dose,C0439565;C3812758
p value for dm vs no dm,C1709380;C0011816;C3250443
post dose,C0439568
verifynow pru defined hpr patients,C1337105;C0030705
vasp pri defined hpr patients,C0034044;C0030705;C1826843;C3539761;C3539762
vhd,
no vhd,
aspirin use at randomization n,C0042153;C0457083;C1947944
history of coronary artery disease n,C1881055
history of carotid disease n,C0683519;C0730226;C0850708;C0944983
history of diabetes n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
history of stroke or tia n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0007787;C0917805;C1054154
itt cohort overall study period,C0439531;C1948053
hd n $nmbr$,
ld,C0694649
hd edoxaban vs warfarin,C2975435;C0043031
ld edoxaban vs warfarin,C0694649;C2975435;C0043031
stroke or see,C0038454;C4554100;C0042789;C1947903
ischemic stroke or see,C0948008;C0042789;C1947903
disabling or fatal,C1302234;C1705232
key secondary end points,C0027627;C2349179;C0175668;C0205436
stroke see or cv death,C0042789;C1947903;C0011065;C1306577;C4082313;C4552775
stroke see or death,C0042789;C1947903;C0011065;C1306577;C4082313;C4552775
other end points,C2349179
death or disabling stroke,C0011065;C1306577;C4082313;C4552775;C0038454;C4554100
cv,C3538987;C4048877;C4318503
aspirin $nmbr$ mg n $nmbr$,C0004057;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
weight no,C0005910;C0043100;C1305866;C1705104
index event no,C0441471;C4019010
isolated deep vein thrombosis,C0205409;C0149871;C1548221
isolated pulmonary embolism,C0205409;C0034065;C1548221
index event asymptomatic or unconfirmed,C0441471;C0231221;C4019010;C1547326
classification of index venous thromboembolism no,C0008902;C0008903;C0678229
provoked,C1444748
hormonal therapy no,C0279025
estrogens,C0014939;C3537250;C3541386;C3714615
progestins,C0033306
median duration of study drug administration iqr days,C0920470;C2348354
individual intended study duration no,C0027361;C0489652;C0237401
rivaroxaban $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
aspirin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
presentation of index event,C0449450;C0441471;C4019010
pulmonary embolism deep vein thrombosis,C0392108;C0852030
extent of index event,C0439792;C0441471;C4019010
history of recurrent venous thromboembolism,C0455533
risk factor profile index event,C0441471;C4019010
duration of pre randomization anticoagulant therapy,C2711563
s $nmbr$ months,C0439231
s $nmbr$ ml min,C0439445
known thrombophilia,C0205309;C0398623
history of cv disease,C0683519;C0730226;C0850708;C0944983
any ae,C3887670
aes leading to,C1412268;C2699274;C0332152;C1522538
discontinu ation,
aes related to,C1412268;C2699274;C0439849;C0445223
study druga,C0557651;C2603343
serious aes,C1412268;C2699274
baseline statin use,C0042153;C0457083;C1947944
cv risk factors,C0035648;C1553898
uncontrolled on oad s,C0205318
uncontrolled on basal insulin,C0205318;C0650607
dual i extension,C0231448;C1880641
dual iv,C0022326;C4265176
dual ii,C1710602;C4082587
global trial population,C0032659;C1257890
indian subpopulation,C1524069;C1257890
ideglira,C4308663
ideg,
lira,C1555441
number of people n,C0237753;C0449788
oad at screening n,C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
metformin su,C0038642;C1705534
np tercile $nmbr$ bnp,C0054015;C1095989;C1417808;C2982014
nptercile $nmbr$ bnp $nmbr$ $nmbr$ pg ml nt probnp $nmbr$ $nmbr$ $nmbr$ pg ml n $nmbr$,C4284038
np tercile $nmbr$ bnp $nmbr$ pg ml nt probnp $nmbr$ $nmbr$ pg ml n $nmbr$,C4284038
pvaluefor trend,C1521798;C4554533
nt probnp median pg ml,C0669479;C0439297;C0754710
i or ii,C0021966;C0221138
hf symptoms and signs,C0683368;C1457887;C0220912;C0220913;C0311392
pnd,C1417807;C1956415;C4552608
dyspnea t,C0013404;C1963100
jvp $nmbr$ cm h $nmbr$ o,C0455483
ankle edema,C0235439
pulmonary congestion cxr,C0006888;C0039985
sodium meq l,C0037473;C0439375;C0597484;C3541959;C3714642
microalbuminuria mg g cr,C0201975;C3539604;C3711669;C4084730;C4553336;C4553337
total bilirubin mg dl,C0005437;C0439269;C0368753
albumin g dl,C0001924;C0439267
lvh on ecg,C0232306
diuretic agents,C0450442;C1254351;C1521826
long acting nitrate agents,C0450442;C1254351;C1521826
bnp ntbnp n $nmbr$,C0054015;C1095989;C1417808;C2982014
terlile $nmbr$,
bnp n $nmbr$,C0054015;C1095989;C1417808;C2982014
ntbnp n $nmbr$,
dyspnoea n $nmbr$,C0013404;C1963100
no dyspnoea n $nmbr$,C0013404;C1963100
non usa,C1518422;C0041703
with dyspnoea,C0013404;C1963100
without dyspnoea,C0013404;C1963100
cangrelor dyspnoea vs no dyspnoea,C0013404;C1963100
clopidogrel dyspnoea vs no dyspnoea,C0013404;C1963100
death mi idr st,C0036056;C3272372
p inter action,C0205103;C0441472;C3266814;C1548610
non cabg related bleeding at $nmbr$ h,C0010055;C0019080
severe life threatening,C1546953;C2826244;C3537125
fixed triple n $nmbr$,C0443218;C0205174;C2827483;C3714578
open triple n $nmbr$,C0175566;C0205174
blood leucocyte concentration $nmbr$ cells per l,C0005773;C0347983
blood eosinophil concentration $nmbr$ cells per l,C0005773;C0347983
blood eosinophil proportion,C0014467;C1709707
time since first copd diagnosis years,C0556970;C0011900;C1704338;C1704656
of predicted normal value,C0681842;C0086715;C1882327
inspiratory capacity l,C0021610;C0802663
chronic bronchitist,C0205191
exacerbation rate in the previous year range,C0871208;C1521828
cat total score,C0007450;C2964552;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
copd medication at study entry,C0024117;C0013175;C1412502;C3714496
ics lama,C0999593;C1416775
spacer use during the study,C0221874;C0869040
patients with at least one concomitant disease,C0683521
myocardial ischaemia,C0010054;C0151744
ischaemic cardiomyopathy,C0349782
coronary artery osteochondrosis,C0029376;C0029429;C0729346
cholecystitis chronic,C0008325;C0205191;C1963083;C4553186
subgroup levels,C1079230;C0441889;C1515021
overall itt n $nmbr$,C0282416;C1561607
mar imputation random n $nmbr$,C0034656;C0439605
cr imputation random n $nmbr$,C0201975;C0034656;C0439605;C3539604;C3711669;C4084730;C4553336;C4553337
very severe itt n $nmbr$,C3641272;C4050419
severe itt n $nmbr$,C0205082;C4050465;C4050466
ex smokers itt n $nmbr$,C0337671;C4555205
current smokers itt n $nmbr$,C3173209;C3241966
males itt n $nmbr$,C0086582
females itt n $nmbr$,C0086287
reversibility s $nmbr$ itt n $nmbr$,C0449261
reversibility $nmbr$ itt n $nmbr$,C0449261
chronic bronchitis itt n $nmbr$,C0008677
emphysema itt n $nmbr$,C0013990;C0034067
mixed itt n $nmbr$,C0205430;C3160715
$nmbr$ exacerbation in prev $nmbr$ m n $nmbr$,C4086268;C1552852;C0369718;C0441922
cardiovascular disease n $nmbr$,C0007222
no cardiovascular disease n $nmbr$,C0007222
eosinophils $nmbr$ n $nmbr$,C0014467;C0200638
eosinophils $nmbr$ $nmbr$ x $nmbr$ $nmbr$ n $nmbr$,C0014467;C0200638
age $nmbr$ $nmbr$ years n $nmbr$,C1510829
age $nmbr$ years n $nmbr$,C1510829
overall per protocol n $nmbr$,C0282416;C1698058;C1561607
bocf iike imputation random n $nmbr$,C0034656;C0439605
eosinophils $nmbr$ itt n $nmbr$,C0014467;C0200638
eosinophils $nmbr$ $nmbr$ x $nmbr$ ^ itt n $nmbr$,C0014467;C0200638
age $nmbr$ $nmbr$ years itt n $nmbr$,C1510829
age $nmbr$ years itt n $nmbr$,C1510829
eosinophils $nmbr$ $nmbr$ x $nmbr$ ^^ itt n $nmbr$,C0014467;C0200638
eosinophils $nmbr$ $nmbr$ x $nmbr$ $nmbr$ itt n $nmbr$,C0014467;C0200638
rate $nmbr$ patient years,C0030705;C0439234
$nmbr$ or $nmbr$ high risk categories,C0332167;C0683312;C3272283;C4050568;C4319571
statin or ezetimibe,C0360714;C1142985
antihypertensive therapy,C0585941
vitamin k antagonist,C1096489;C2267235
patients with event analyzed,C0030705;C0441471;C4019010;C0936012
lue for interaction,C1704675
$nmbr$ ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$,C0439445
sbp $nmbr$ mm hg and or dbp $nmbr$ mm hg $nmbr$ $nmbr$,C0085805;C0439475;C0536221;C3813197;C4281799
subpopulation analyses according to baseline hba $nmbr$ c,C1514228
iglarlixi fixed ratio combination,C0205195;C1947911;C3811910
iglar insulin glargine l $nmbr$ u,C0907402;C0439148
hbalc $nmbr$,
mean change at week $nmbr$,C0392747;C0443172;C1705241;C4319952
mean difference seb,C0059386;C1309881;C1423585;C3815268
daily iglar dose at week $nmbr$ u,C2348070;C0560588
l $nmbr$ years,C0439394;C0439234;C1706495;C3642217
t $nmbr$ dm duration years,C0011816;C0439234;C3250443
pool of fh i and ii studies,C0337051;C1509144;C2349200;C1710602;C0947630;C4082587
pool of long term hefh patients only and high fh,C0337051;C1509144;C2349200;C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
alirocumab $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
alirocumab $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
q $nmbr$ w n $nmbr$ $nmbr$,
race n white,C0007457;C0043157;C0220938
diabetes type ii n,C0011860
coronary heart disease n cardiovascular risk per protocol n very high,C0442804;C4321397
patients with no prior cvd primary,C0030705;C1335497
prevention n patients on llt other than statin n,C0199176;C0030705;C1706420;C2700409;C0360714
ldl c calculated mg dl mean sd,C0439269;C2699239
total cholesterol mg dl mean sd,C0201950;C2699239;C0543421
lp a mg dl median q $nmbr$ q $nmbr$,C0065058;C0439269;C1439335;C4553379
triglycerides mg dl median q $nmbr$ q $nmbr$,C0041004;C0439269
apo a $nmbr$ mg dl mean sd,C0003592;C2699239;C0523508;C4553344;C4553379
factor at baseline,C1521761;C2827422
percentage of patients receiving dose adjustment,C0439165;C1549488;C1561533;C1514756;C2826232
distance to ldl c goal,C0012751;C0018017;C1571704
$nmbr$ $nmbr$ s $nmbr$ $nmbr$ $nmbr$,
$nmbr$ i,C0021966;C0221138
ltt other than statin,C0360714
no reference,C1514811;C1706462
$nmbr$ $nmbr$ $nmbr$ $nmbr$ o $nmbr$,C0483204
mepolizumab $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
number of exacerbations in the $nmbr$ months before screening,C0237753;C0449788;C0439231;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
patients with $nmbr$ exacerbation requiring er visit or admission to hospital in the $nmbr$ months before screening,C0030705;C4086268;C0545082;C1512346;C2826704;C0184666;C0439231;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
patients with $nmbr$ exacerbation requiring admission to hospital in the $nmbr$ months before screening,C0030705;C4086268;C0184666;C0439231;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
current oral corticosteroid use,C1527415
oral corticosteroid dose mg day,C0001617;C0439422;C3536709
current inhaled corticosteroid use,C0004048;C0239126
th $nmbr$,C0039725;C0039738;C1420718;C4282123;C4285344
current laba use,C0042153;C0457083;C1947944
current lra use,C0042153;C0457083;C1947944
current xanthine derivative use,C0042153;C0457083;C1947944
current lama use,C0042153;C0457083;C1947944
measures of lung function,C0079809;C1879489
pre bronchodilator fev^ l,C2599602;C3714541
percentage of predicted pre bronchodilator fev^,C0439165;C1549488;C1561533
percentage of fevj reversibility,C0439165;C1549488;C1561533
pre bronchodilator fef $nmbr$ $nmbr$ ml s baseline blood eosinophil count,C0200638;C0750879
baseline geometric mean $nmbr$ l,C0168634;C2986759;C1442488
$nmbr$ per pl at screening,C3897966;C4049765
$nmbr$ per pl in $nmbr$ months before screening,C3897966;C4049765;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
total sgrq score,C2964552
baseline presence of nasal polyps,C0150312;C0392148;C3854307
positive atopic status,C0392707;C0449438
eosinophil count,C0200638;C0750879
mean change in sgrq,C0392747;C0443172;C1705241;C4319952
$nmbr$ $nmbr$ $nmbr$ cl $nmbr$ $nmbr$ to $nmbr$ $nmbr$,C0596019
mean change in fev $nmbr$,C0392747;C0443172;C1705241;C4319952
$nmbr$ $nmbr$ cl $nmbr$ to $nmbr$,C0596019
mean change in acq score,C0392747;C0443172;C1705241;C4319952
exacerbation rate per year,C0871208;C1521828
ularitide n $nmbr$,C0077910
group no,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
nonblack race no j,C0034510;C1706779;C3853635
left ventricular ejection fraction no total no,C0428772;C0488728;C0439175;C0439810
interval between clinical evaluation and initiation oftreatment no,C2826267;C0589507;C1158830;C1704686
previous episode of heart failure,C0332189;C0018801;C0018802;C4554158
nyha class within past month no total no,C1882083;C0332177;C0439231;C0439175;C0439810
median n terminal probnp iqr pg ml,C0669479;C0439297
median cardiac troponin t iqr pg ml,C3538889;C0439297
treatment at randomization no,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
intravenous nitrates,C0348016;C0028125
intravenous dobutamine,C0348016;C0012963
ularitide n n,C0077910
white caucasian,C0043157
baseline systolic bp,C0168634;C0871470;C1442488
$nmbr$ mmhq,
time from first eval,C0040223;C3541383
^ $nmbr$ hrs,C1568891
$nmbr$ hrs,C1568891
coronarv arterv disease,C0012634
reported in ecrf,C0684224;C0700287;C4319718
not reported in ecrf,C0684224;C0700287;C4319718
gfr as assessed by mdrd,C0017654;C1424601;C3839656
^ $nmbr$ ml min,C0439445
history of chronic hf,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
troponin t,C0077404;C1420827
baricitinib $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
female patients n,C0150905
duration of ra time from symptom onset years,C0449238;C2926735;C4086878;C0439234
concomitant corticosteroid use n,C0521115;C0239126
concomitant mtx use n,C0025677;C0042153;C0457083;C1947944;C1417487
mean sd mtx dose mg week,C0332174;C0439230
number of prior csdmards n,C0237753;C0449788
number of concomitant csdmards n,C0237753;C0449788
non mtx,C0025677;C1417487
mtx non mtx,C0025677;C1417487
$nmbr$ non mtx,C0025677;C1417487
das $nmbr$ hscrp,C0051767;C0057671
patient reported outcome measures,C4277735
health assessment questionnaire disability index,C4321476
patient s global assessment of disease,C0030705;C0281858
activity $nmbr$ $nmbr$ vas,C0042815;C3536884;C3827561
patient s assessment of pain $nmbr$ $nmbr$ vas,C0030705;C0030198
functional assessment of chronic illness,C0278372;C0008679
therapy fatigue facit f $nmbr$ $nmbr$,C0015672;C3272505;C3463815;C4050243;C4554645
short form $nmbr$ sf $nmbr$,C2964478;C0037712
physical component score pcs,C1864389;C1882368
mental component score mcs,C0229992;C0449432;C1705248
european quality of life $nmbr$ dimensions $nmbr$ level eq $nmbr$ d,C0205163;C0439185
health state index score uk algorithm,C0002045;C1553907
vas $nmbr$ $nmbr$,C0042815;C3536884;C3827561
mtx other csomards,C0025677;C1417487
mtx othetcsdmards,C0025677;C1417487
fluticasone furoate n $nmbr$,C1948374
vilanterol n $nmbr$,C2935023
cardiovascular inclusion criteriat,C0007226;C0007637;C1512693;C3887460
diabetes with target organ disease,C0011847;C0011849
high risk receiving treatment for,C0332167;C3272283;C4050568;C4319571;C1514756;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
concomitant cardiovascular therapy taken $nmbr$ days,C1707479;C0439228
antithrombotic coagulant,C0009117
ras aldosterone inhibitor^,C1514727
beta $nmbr$ selective,C0330390;C0439096;C2004068
dihydropyridine,C0012315;C0220821
long acting or short acting nitrates,C0205166;C1706317;C1282927;C0028125;C1806781;C2350002
current smoker n $nmbr$,C3173209;C3241966
former smoker n $nmbr$,C0337671
$nmbr$ years to,C0439234
$nmbr$ $nmbr$ with cv disease n $nmbr$,C0007222
$nmbr$ $nmbr$ with cv risk but not disease n $nmbr$,C0035647;C4552904;C1518422;C0012634
europe $nmbr$ n $nmbr$,C0015176
ischemic heart disease indicator no n $nmbr$ l,C0021212;C1235732;C1522602;C0369718;C0441922
vascular disease indicator no n $nmbr$,C0021212;C1235732;C1522602;C0369718;C0441922
iglarlixi,
iglar,
lixi,
week $nmbr$ changea,C0332174;C4349366;C0439230
$nmbr$ hour ppg mmol l,C0439227;C1532563;C0564385
hypoglycaemiad,
events patient year n,C0030705;C0439234;C0439508
mean baseline n,C0444504;C0168634;C1442488;C2347634;C2348143
$nmbr$ $nmbr$ f $nmbr$,C0016327
subpopulation analyses according to bmi,C1514228;C0578022
octave induction $nmbr$,C0205263;C0857127
octave sustain,C0443318;C2732140
male sex no f,C0086582;C0016327
induction trial group assignment no,C1320290;C1516050
tofacitinib $nmbr$ mg twice daily,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
remission at maintenance trial entry no,C0544452;C0687702
extent of disease no total no ^,C0449279;C4553144;C0439175;C0439810
extensive colitis or pancolitis,C0009319;C1963084;C0868908
total mayo score,C2964552;C0454788;C1077578
partial mayo score,C0449820;C4050231
c reactive protein mg literj,C0006560;C1413716;C4048285
oral glucocorticoid use at baseline no t,C1527415;C0017710;C2603360
previous treatment with tnf antagonist no,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
previous treatment failure no,C0162643;C0235828;C0521983;C1547544
tnf antagonist,C1448177;C0231491
immunosuppressant^^,C0021081
tofacitinib $nmbr$ mg bid,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
prior tnf antagonist treatment yes,C1549445;C1705108;C1710701
prior tnf antagonist treatment no,C1514463;C0231491
prior tnf antagonist failure yes,C1549445;C1705108;C1710701
prior tnf antagonist failure no,C0231174;C0680095
corticosteroid use at baseline yes,C0239126;C0168634;C1442488
corticosteroid use at baseline no,C0239126;C0168634;C1442488
geographic region europe,C0017446;C0015176
geographic region north america,C0017446;C0028405
geographic region other,C0017446
abatacept n $nmbr$,C1619966
dip involvement n,C3539618;C1314939
patient global assessment of disease activity vas $nmbr$ $nmbr$ mm,C4054228;C0042815;C3536884;C3827561
physician global assessment of disease activity vas $nmbr$ $nmbr$ mm,C4050369;C0042815;C3536884;C3827561
patient global assessment of pain vas $nmbr$ $nmbr$ mm,C4054229
elevated crp ulnt n,C0742906
psa modified total shs,C0392747;C0439175;C0439810;C3889737
psoriasis covering $nmbr$ bsa n,C0033860;C0180153;C0439844
enthesitis n,C1282952
dactylitis n,C0239161
anti ccp positive $nmbr$ u ml n,C0432633;C0439340;C1880521;C2945590
prior tnfi n,C0332152;C2826257
concomitant methotrexate n,C0521115;C0025677
concomitant csdmards other than methotrexate n,C0521115;C0025677
concomitant oral corticosteroids n,C0442027;C0001617;C3539185;C3540725;C3540726;C3540727;C4521986
estimated difference $nmbr$ ci,C0008107;C3259781
abatacept open label abatacept,C1619966;C1709323
placebo open label abatacept,C1709323;C1619966
tnfi naive,
tnfi exposed,C0332157
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ $nmbr$,
lvh n $nmbr$,C0149721
non cns embolism,C0013922;C1704212
medication use at entry,C0240320;C1705654
antiplateletsa,
arbs or ace inhibitors,C3888198;C0003015
_ $nmbr$,
electrocardiography,C0013798;C1623258
r wave in avl mm,C0429091;C0449216
s wave in v $nmbr$ mm,C0429094;C4330985;C4554674
strain,C0080194;C0456178;C1518614;C2987481
lv ejection fractionb,C0023128;C0302131;C0336969;C0812388;C0731033;C1881413
p value d $nmbr$ mg vs warfarin,C1709380;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0043031
yr,C0439234
d $nmbr$ mg vs warfarin,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0043031
pravastatin sodium,C0700474
medication use no total no,C0240320;C0439175;C0439810
current cigarette smoking no,C0239059;C0700219
lipid values,C0023779;C0042295
antihypertensive randomization no a,C0003364;C0034656
years of follow up mean sd [maximum],C0439234;C0589120;C1522577;C1704685;C3274571;C0806909;C1552615;C2826546
cumulative events,C0441471;C3541888
$nmbr$ y incidence rate se per $nmbr$ participants,C1708485;C0036919
pravastatin vs usual care,C0085542;C3538928;C1947933
cvd deaths,C0011065;C1306577
chd deaths,C0011065;C1306577
stroke deaths,C0011065;C1306577
non cvd deaths,C0011065;C1306577
cause of death unknown,C0277589
fatal chd and nonfatal mia,C0280604;C3542407;C1417154
stroke fatal and nonfatal,C0038454;C4554100;C1302234;C1705232
heart failure hospitalized or fatal,C0018801;C0018802;C4554158;C0701159;C1302234;C1705232
cancer fatal and nonfatal,C0006826;C0998265;C1306459;C1302234;C1705232
secukinumab pooled n $nmbr$,C1709595;C2349200;C4522255
current smoker at baseline n,C3173209;C3241966
methotrexate use at randomization n,C0042153;C0457083;C1947944
sulfasalazine use at randomization n,C0042153;C0457083;C1947944
corticosteroid use at randomization n,C0239126;C0034656
total back pain $nmbr$ $nmbr$ mm vas mean sd,C0042815;C2699239
nocturnal back pain $nmbr$ $nmbr$ mm vas mean sd,C1970122;C2699239
basdai total mean sd,C0439175;C2699239;C0439810
hscrp mg l median min max,C0439420
mean time since as diagnosis years mean sd,C0040223;C3541383;C0011900;C2699239;C1704338;C1704656
anti tnf na ve n,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882;C0369718;C0441922
endpoints,C2349179
hscrp exp ls mean change se,C0023668;C0036919
asas $nmbr$ $nmbr$ n,C0004057;C3853627
sf $nmbr$ pcs ls mean change se,C0023668;C0036919
asqol ls mean change se,C0023668;C0036919
asas partial remission n,C1521726;C4552913;C4552914
criterion,C0243161
placebo controlled period,C0439531;C1948053
any secukinumab n $nmbr$,C3179547
no of patients with events,C0030705;C0441471;C3541888
any sae,C1519255;C1622657;C4553214
infections and infestations,C3714514;C0851341
most common aes,C1412268;C2699274
mouth ulceration,C0149745
leukopenia,C0023530;C0750394
pharyngitis,C0031350;C4553308
osteoprotegerin decreased,C0538161;C1308614;C1336645;C0205216;C0392756;C0442797
oropharyngeal pain,C2363731;C4554669
lymphadenopathy,C0497156;C4282165
rhinitis,C0035455
neutropenia,C0023530;C0027947;C0853697
gastroenteritis,C0017160
includes patients originally randomized to placebo who were switched to secukinumab per the study designs aes that occurred in at least $nmbr$ $nmbr$ of the patients in the any secukinumab group during the $nmbr$ week placebo controlled period and events with an eair of at least $nmbr$ $nmbr$ cases per $nmbr$ patient years in the any secukinumab group during the entire treatment period events listed according to preferred term in the medical dictionary for regulatory activities meddra version $nmbr$ $nmbr$ sorted in descending order of eair in the any secukinumab group for the entire treatment period the entire treatment period for safety data was from baseline to week $nmbr$ visit of the last patient enrolled in these studies ae adverse event as ankylosing spondylitis eair exposure adjusted incidence rates n number of randomized patients sae serious adverse event urti upper respiratory tract infection,C0332257;C1552866;C2700399;C0030705;C0034656;C3815594;C1707719;C3179547;C1412268;C2699274;C1709305;C0009932;C0441471;C3541888;C0439234;C0374505;C0439531;C1948053;C0745732;C3272378;C0237886;C0700314;C1947906;C0205386;C1547177;C1705175;C1705176;C1705177;C1705178;C1882348;C3889825;C4284072;C0168634;C1442488;C0545082;C1512346;C2826704;C4684790;C0877248;C0038013;C1264674;C1519255;C0041912
ab ff $nmbr$ $nmbr$ pg n $nmbr$,C0030827;C0072225;C1266240
ab $nmbr$ pg n $nmbr$,C0030827;C0072225;C1266240
ff $nmbr$ pg n $nmbr$,C0030827;C0072225;C1266240
cigarette smoking mean pack years sd,C1303175;C2699239
mean fev $nmbr$ l sd,C0444504;C2699239;C2347634;C2348143
post bronchodilator percent of predicted fev $nmbr$ sd,C2599594;C1882327
moderate n a,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
severe n b,C0205082;C4050465;C4050466
mean number of exacerbations in previous $nmbr$ months sd,C0444504;C0237753;C0449788;C2347634;C2348143;C0205156;C2699239;C1552607
mean bdi focal score sd,C3533236;C2699239
mean sgrq total score sd,C3533236;C2699239
previous treatment with a laba and or lama n c,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0999593;C1416775
baseline ics use n,C0168634;C0042153;C0457083;C1947944;C1442488
fig $nmbr$ analysis of time to first cid event in patients who a received treatment with a laba and or lama and b did not receive treatment with a laba and or lama prior to the study,C0349966;C1718396;C1337208;C0441471;C4019010;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0999593;C1416775;C1518422;C1514756
fig $nmbr$ analysis of time to first cid event in patients with a moderate and b severe copd at baseline itt population,C0349966;C1718396;C1337208;C0441471;C4019010;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0024117;C1412502;C3714496
tnt and ideal pooled,C1512612;C1709595;C2349200;C4522255
without psoriasis n $nmbr$,C0033860
with psoriasis n $nmbr$,C0033860
without psoriasis n $nmbr$ $nmbr$,C0033860
p valueb,C0369773;C2603361
\ $nmbr$ $nmbr$,
duration of psoriasis years,C0449238;C2926735
$nmbr$ $nmbr$ $nmbr$ $nmbr$ [n $nmbr$ ],C0369718;C0441922
cerebrovascular disease n,C0007820
nd,
baseline concomitant therapies,C0168634;C1707479;C1442488
calcium channel antagonists n,C0006684;C2757014
ace inhibitors or angiotensin ii,C0003015;C0003009;C1366631;C3714928
receptor blockers n,C0597357
baseline lipid and apolipoprotein levels,C0168634;C0023779;C1442488;C0003591;C0441889
total cholesterol hdl c ratio,C0523558
apoa $nmbr$ mg dl,C0003592;C0439269;C0523508;C4553344;C4553379
patients without psoriasis n $nmbr$,C0030705;C0033860
patients with psoriasis n $nmbr$,C0030705;C0033860
interaction treatment by psoriasis p value $nmbr$,C3258078;C1709380
atorvastatin ls means difference $nmbr$ mg $nmbr$ ci a n $nmbr$,C0008107;C3259781;C0369718;C0441922
ls means difference $nmbr$ ci $nmbr$,C0008107;C3259781
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$,
apob apoal,C0003593;C3252643
ato $nmbr$ mg and sim $nmbr$ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ato $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
lsms difference $nmbr$ ci $nmbr$,C0008107;C3259781
ato $nmbr$ mg and sim $nmbr$ ^ $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
incidence rate of cv events n,C1708485;C0441471;C3541888
hazard ratio $nmbr$ ci $nmbr$ with vs without psoriasis,C0008107;C3259781;C0033860
total v $nmbr$ $nmbr$,C0439175;C0439810
all treatments,C0087111
atorvastatin $nmbr$ mg and simvastatin $nmbr$ $nmbr$ mg zi $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0043476
atorvastatin $nmbr$ mg zi $nmbr$,C0024671;C0043476;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
canagliflozin n $nmbr$,C2974540
history of heart failure no,C0455531
history of microvascular disease no,C0683519;C0730226;C0850708;C0944983
history of atherosclerotic vascular disease no,C0683519;C0730226;C0850708;C0944983
history of cardiovascular disease no ^,C0455539
history of amputation no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
ratio of ldl to hdl,C0456603;C1547037;C3715113
egfr ml min $nmbr$ $nmbr$ m,C1739039;C0439445;C3811844;C3812682
albumin measurements^^,C0201838
median albumin to creatinine ratio interquartile range,C0486293;C1711350;C1318293
normoalbuminuria no total no,C0439175;C0439810
microalbuminuria no total no,C0730345;C0439175;C0439810
macroalbuminuria no total no,C0439175;C0439810
canagliflozin,C2974540
no of participants per $nmbr$ patient yr,C0679646;C0030705;C0439234
canvas,C3281223
canvas r,C0205090;C0684010;C2603358
central america and south america,C0007674;C0037713
systolic blood pressure $nmbr$ mm hg or diastolic blood pressure $nmbr$ mm hg,C0488055;C0439475;C0871470;C1306620;C0428883;C1305849
history of amputation,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
insulin use,C0240016
antithrombotic use,C0042153;C0457083;C1947944
raas inhibitor use,C0042153;C0457083;C1947944
diuretic use,C0042153;C0457083;C1947944
hba $nmbr$ ca mmol mol,C0019016;C1825777;C3538758;C3829066
time since diagnosis of diabetesa n,C0040223;C3541383
systolic blood pressurea mm hg,C0005767;C0439475;C0005768;C0229664
diastolic blood pressurea mmhg,C0005767;C0439475;C0005768;C0229664
egfr mdrd ml min $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
egfr ckd epi cystatin c ml min $nmbr$ $nmbr$ m $nmbr$,C0071744;C0439445;C1413772
egfr ckd epi cystatinc ml min $nmbr$ $nmbr$ m $nmbr$ n,C0162734;C0439445;C4281721;C0369718;C0441922
uacra mg g gmean gcv,C1300563;C0017066
uacra mg g n,C1300563
oral antidiabetes monotherapya n,C0442027;C4521986
oral antidiabetes combination therapy without insulina n,C0009429;C0556895
insulina n,
antihypertensive therapy n,C0585941
^ blockers,
number of participants,C0237753;C0449788
baseline hbalc $nmbr$ $nmbr$ $nmbr$ mmol mol $nmbr$,C0168634;C3829066;C1442488
baseline uacr,C0168634;C1442488
baseline uacr $nmbr$ mg g,C0168634;C1300563;C1442488
normoalbuminuria at baseline $nmbr$ of patients treated,C0168634;C0030705;C1442488;C1522326
microalbuminuria at baseline $nmbr$ of patients treated,C0730345;C0030705;C1522326
macroalbuminuria at baseline $nmbr$ of patients treated,C0168634;C0030705;C1442488;C1522326
empagliflozin n $nmbr$,C3490348
other or missing data,C4684714
ldl cholesterolt,
egfr ml min per $nmbr$ $nmbr$ m $nmbr$ t,C0439445;C0369637;C0441923
medical history of diabetic retinopathy,C0262926;C0011884
supplementary table $nmbr$ change from baseline in urine albumin to creatinine ratio by hba $nmbr$ c at baseline in patients with normoalbuminuria microalbuminuria and macroalbuminuria,C0392747;C0443172;C1705241;C4319952;C0455271;C1318330;C0168634;C1442488;C0730345
patients with normoalbuminuria at baseline,C0030705;C0168634;C1442488
patients with microalbuminuria at baseline,C0030705;C0730345;C0168634;C1442488
patients with macroalbuminuria at baseline,C0030705;C0168634;C1442488
n analysed,C0369718;C0441922
uric acid tertile $nmbr$,C0041980
uric acid tertile $nmbr$ $nmbr$ $nmbr$ to,C0041980
uric acid fertile $nmbr$ $nmbr$ $nmbr$ mg dl,C0041980;C0439269
uric acid tertile $nmbr$ $nmbr$ $nmbr$ mg dl,C0041980;C0439269
characteristic no,C1521970
digoxin n $nmbr$ $nmbr$,C0012265
no digoxin n $nmbr$ $nmbr$ $nmbr$,C0012265
white race n $nmbr$ $nmbr$,C0007457;C0043157
type of atrial fibrillation n $nmbr$ $nmbr$,C0332307;C1547052
qualifying risk factor,C1514624;C0035648
coronary artery disease n $nmbr$ $nmbr$,C0010054;C0010068;C1956346
nyha iii or iv n $nmbr$ $nmbr$,C0439070;C1705160;C0022326;C4265176
peripheral arterial disease n $nmbr$ $nmbr$,C0085096;C1704436
former current smoker n $nmbr$ $nmbr$,C0337671
mitral valve disease n $nmbr$ $nmbr$,C0026265;C4553832
aortic valve disease n $nmbr$ $nmbr$,C1260873;C4553103
prior electrical cardioversion for af n $nmbr$ $nmbr$,C0013778;C0542380
charlson comorbidity index mean sd,C4546361;C2699239
heart rate mean sd bpm n $nmbr$ $nmbr$,C0018810;C0444504;C2347634;C2348143
hypertrophy per ecg n $nmbr$ $nmbr$,C0020564;C1623258
vitamin k antagonist experiencedk n $nmbr$ $nmbr$,C1096489;C2267235
antiarrhythmics,C0003195
class ii b blockers,C0441886;C2698968
raas inhibitor,C1999216
high dose edoxaban,C0444956;C2975435
low dose edoxaban,C0445550;C2975435;C1708745
digoxin scd no y,C0012265
no digoxin scd no y,C0012265
persistent permanent,C0205322;C0205355;C0332996
lv hypertrophy per ecg,C0232306
b blockers at baseline,C0168634;C1442488
diuretic use at baseline,C0042153;C0457083;C1947944
normal responders n $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
sensitive responders n $nmbr$,C0020517;C0332324;C1522640
highly sensitive responders n $nmbr$,C0439822
age year mean sd,C0001779;C2699239
creatinine clearance ml min mean sd,C0439445;C2699239
edoxaban dose adjusted at randomisation n,C0178602;C0869039;C1114758;C0456081;C0034656
bleeding events during first $nmbr$ days of treatmen,C0441471;C3541888
bleeding events during the entire study,C0441471;C3541888
adj hr $nmbr$ cl a,C0001552;C0596019;C2826286
p b int,C1539794;C3272375
edoxaban warfarin,C2975435;C0043031
total bleeds,C0232100
major and crnm bleeds,C0205082;C0205164;C4318856;C4521762;C0019080
laba ics n $nmbr$,C0815320;C4551720
laba or lamab n $nmbr$,
ind glyb n $nmbr$,C4049864;C1415124
post bronchodilator fev $nmbr$ predicted of normal value,C0681842;C1882327
dyspnoea mmrc grade n,C0013404;C0441800;C0919553;C3244287;C1963100
number of exacerbation in the previous $nmbr$ months n,C0237753;C0449788;C0205156;C0439231;C1552607
baseline treatments n a,C0168634;C0087111;C1442488
lama only monotherapy,C0999593;C1416775
laba only monotherapy,
laba ics free or fixed dose combination,C0332296;C1880497;C1996904;C0178602;C0205195;C1947911;C3811910;C0869039;C1114758
othersc,
laba ics versus indzgly lsm difference $nmbr$ cl,C0815320;C4551720;C1705241;C0596019;C1705242
indzgly,
exacerbations in the previous year,C4086268;C0205156;C1552607
fev $nmbr$ at baseline,C3714541;C0168634;C1442488
mmrc at baseline,C3826977;C0168634;C1442488
form bud,C2700462;C2945744
sfc,C4521536
laba or lama versus ind gly lsm difference $nmbr$ cl,C0999593;C1416775;C0017890;C0596019;C0523677
laba or lama,C0999593;C1416775
ind gly,C0017890;C0523677
ex smokers $nmbr$,C0337671;C4555205
fev at baseline,C3714541;C0168634;C1442488
pooled itt,C1709595;C2349200;C4522255
cat $nmbr$ n $nmbr$ $nmbr$,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
median y range,C1514721;C2348147;C3542016
mean mmrc grade units sd,C0439148;C2699239;C1519795;C3853603
mean sgrq total score,C3533236
use of ics at baseline,C1524063;C0815320;C4551720;C0168634;C1442488
mean copd duration y sd,C0024117;C2699239;C1412502;C3714496
mean number of exacerbations in previous y sd,C0444504;C0237753;C0449788;C2347634;C2348143;C0205156;C2699239;C1552607
mean postbronchodilatora fev $nmbr$ predicted sd,C0444504;C2699239;C2347634;C2348143
reversible to bronchodilator b,C0205343;C0006280
favors comparator,C1707454;C4553389;C4553390
gff mdi,C0993596;C1839839;C4049613
gp mdi,C0993596;C1839839;C4049613
ff mdi,C0993596;C1839839;C4049613
placebo mdi,C0993596;C1839839;C4049613
cat $nmbr$,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ^,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ f,C0016327
empagliflozin $nmbr$ mg day n $nmbr$,C3490348;C0439422
parameters at baseline,C0449381;C0168634;C1442488
a bmi subgroups,C0578022;C1079230
b age subgroups,C1304659;C0001779
empagiiflozin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
fpg,
n $nmbr$ l $nmbr$,C0369718;C0441922
n l $nmbr$,C0369718;C0441922
baseline cardiac biomarkers elevated,C2735101;C2735102;C0205250;C3163633
tobacco abuse,C0040336
radial access site,C0442038;C0589360;C0920847
$nmbr$ vessels with $nmbr$ stenosis,C0679403
$nmbr$ vessels treated,C0005847;C1522326
treatment with drugeluting stent,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
baseline aspirin dose,C0168634;C4696290;C1442488
intended clopidogrel dose $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
clopidogrel dose on before pci,C0178602;C0869039;C1114758;C4049621
bivalirudin used during pci,C0168273;C1273517;C4049621
gpi used during pci,C1415351;C1273517;C4049621
duration from hospital admission to pci h median iqr,C0449238;C2926735;C0033727;C0369286;C0441932;C0564385;C4528284
duration from clopidogrel placebo to pci min median iqr,C0449238;C2926735;C0702093;C0549183;C0876920;C2347635;C2348144;C2939193;C1524029;C3813700
pci duration in min median iqr,C0449238;C2926735
death mi idr or st,C0011065;C1306577;C4082313;C4552775;C0036056;C3272372
st arc definite only,C0036056;C3272372;C0439544;C1704787
gusto moderate severe,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0205082;C4050465;C4050466
timi major minor,C4441842
death mi idr st or gusto severe bleeding,C0036056;C3272372;C0205082;C0019080;C4050465;C4050466
death mi idr st or gusto moderate severe bleeding,C0036056;C3272372;C0205081;C0019080;C1881878;C4049705;C4049706;C4085643;C4321335
death mi idr st or any timi bleeding,C0036056;C3272372;C0019080
p value nt,C0332126;C1449832;C3889152;C4050156;C4283901;C4284038
net composite,C0205199;C1547335
death mi idr st or gusto mod sev bleeding,C0036056;C3272372;C0011860;C0019080
pah ctd,C1335071;C1442905
pah ssc,C0030123;C3897657;C3203102;C4284467
pah sle,C0030123;C0024141;C3203102;C4284467
pah mctd ctd other,C1335071;C1442905
age years geographic region,C1510829;C0017446
time since diagnosis of pah years,C0556970;C0011900;C1704338;C1704656
use of medication for pah,C1524063;C0030123;C3203102;C4284467
era,C1521863;C3495919
pde $nmbr$ i,C0021966;C0221138
era and pde $nmbr$ i,C1521863;C3495919;C0021966;C0221138
other medications,C0013227;C0802604;C2598133;C4284232
corticosteroids $nmbr$,C0001617;C3539185;C3540725;C3540726;C3540727
placebo patients events n,C0032042;C0030705;C1696465;C1706408
selexipag patients events n,C0030705;C0441471;C3541888
overall study population,C0282416;C2348561;C1561607
overall ctd,C1335071;C1442905
pde $nmbr$ i monotherapy,C0021966;C0221138
no pah specific therapy,C0039798;C0087111;C1363945
ctd population subgroup,C1079230;C1515021
pooled pah mctd and pah,C0030123;C0026272;C3203102;C4284467
years since pd diagnosis mean sd,C0439234;C0011900;C1704338;C1704656
duration of disease n,C0872146
hoehn yahr stage on n,C0205390;C1300072;C1306673
hoehn yahr stage off n,C0205390;C1300072;C1306673
levodopa dose mean sd mg day,C0023570;C0439422
concomitant pd medications at baseline n c d,C0013227;C0802604;C2598133;C4284232
tertiary amines,C3653356
dopa and dopa derivativese,C0013023
adamantane derivatives,C3653470
entacapone,C0165921
monoamine oxidase b inhibitors,C2917290;C3653412
daily off time mean sd h dayf,C0332173;C0033727;C0369286;C0441932;C0564385;C4528284
mean sd baseline score,C3533236;C0168634;C1442488
mean sd change from,C0392747;C0443172;C1705241;C4319952
ls mean [ $nmbr$ ci] treatment difference vs placebo,C0444504;C2347634;C2348143;C0008107;C3259781;C1705241;C1705242;C0032042;C1696465;C1706408
p value ancova treatment difference a,C1705241;C1705242
baseline to eom placebo n $nmbr$,C0168634;C1442488
number of off periods,C0237753;C0449788;C0439531;C1948053
absolute time spent on h day,C0439546;C0680968;C0033727;C0369286;C0441932;C0564385;C4528284
absolute time spent on without troublesome dyskinesia h day,C0439546;C0680968;C0332173;C0439228;C0439505
absolute time spent on with troublesome dyskinesia h day,C0439546;C0680968;C0332173;C0439228;C0439505
patient status after wake up of days patient woke,C0449437;C1170730;C0442696;C0585034
off,
on without troublesome dyskinesia,C0013384
on with troublesome dyskinesia,C0013384
updrs iii motor,C1513492;C1705994
overall $nmbr$ $nmbr$,C0282416;C1561607
with ckd $nmbr$,C1561643
without ckd $nmbr$,C1561643
mean or n,C0444504;C2347634;C2348143;C0369718;C0441922
sd or,C2699239
median urine acr mg g iqr,C0042036;C1300563;C0042037;C2963137
median fasting serum glucose mg dl iqr,C0202041;C0439269;C3534430
glycemic status,C0449438
igt ifg,C1334085;C1708411
other glucose status,C0017725;C0449438
dcct a $nmbr$ c,
duration dm in dm years,C0011816;C0439234;C3250443
pulse pressure mm hg,C0949236;C0439475
median pulse pressure mm hg iqr,C0949236;C0439475
n $nmbr$ fatty acids,C0369718;C0015684;C0441922
no glucose lowering drugs,C0017725;C0441994;C2003888;C0013227;C3687832
other bp drug,C0013227;C1254351
median tg iqr,C0549183;C0337445;C0876920;C2347635;C2348144;C2939193
ckd rate events,C0441471;C3541888
no ckd rate events,C0441471;C3541888
cv death non fatal mi or non fatal stroke,C0011065;C3810814;C1306577;C4082313;C4552775;C0038454;C4554100
secondary outcome,C0027627;C1274040;C0175668;C0205436
stroke any,C0038454;C4554100
stroke non fatal,C0038454;C4554100;C1518422;C1302234;C1705232
primary outcome plus revascularization or nonfatal hf,C0205225;C1274040;C0439612;C0439631;C0018488;C1313497;C1538440;C3273279
major coronary disease event fatal non fatal mi,C0741923;C3810814
ckd n,C1561643
no ckd n,C1561643
$nmbr$ yrs or more,
diabetes melitus,C0011847;C0011849
treatment glargine,C0039798;C0907402;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
rivaroxaban plus aspirin n $nmbr$,C1739768;C0004057
rivaroxaban alone n $nmbr$,C0205171;C0439044;C0679994
tobacco use no,C0040335;C0543414;C0841002;C3853727
heart failure no,C0018801;C0018802;C4554158
estimated gfr no $nmbr$,C0017654;C1424601
western europe israel australia or south africa,C0043128;C0037712
nontrial ppi,C0358591;C0871125;C3811894
rivaroxaban aspirin,C1739768;C0004057
hazard ratio for cardiovascular death stroke or myocardial infarction $nmbr$ ci,C2985465;C0027051;C0008107;C3259781
baseline tobacco use,C0040335;C0543414;C0841002;C3853727
baseline dyslipidemia,C0168634;C0242339;C1442488
socalone n $nmbr$,
evolocumab soc n $nmbr$,C3529352
type $nmbr$ diabetes mellitus $nmbr$,C1320657
high risk of diabetes,C0332167
cerebrovascular or peripheral arterial disease,C1880018;C0085096;C1704436
fasting plasma glucose mmol l $nmbr$,C0202042;C1532563;C0455280
fasting plasma glucose mg dl $nmbr$,C0202042;C0439269;C0455280
ldl c in mmol l baseline mean sd [n] wk $nmbr$ and change mean se [n],C1532563;C0168634;C1442488;C0369718;C0441922;C0332174;C0439230;C0392747;C0036919;C0443172;C1705241;C4319952
fasting plasma glucose in mmol l median q $nmbr$ q $nmbr$ [n],C0583513;C1532563
hba $nmbr$ c in median q $nmbr$ q $nmbr$ [n],C0019016;C0549183;C0876920;C2347635;C2348144;C2939193;C1825777;C3538758
weight in kg baseline mean sd [n] wk $nmbr$ and change mean se [n],C0022718;C1303013;C0439209;C4054209;C0369718;C0441922;C0332174;C0439230;C0392747;C0036919;C0443172;C1705241;C4319952
soc,
evomab soc,
change to week $nmbr$,C0392747;C0443172;C1705241;C4319952
[ $nmbr$ [,
ldl c in mmol l mean sd for baseline [n] mean se for week $nmbr$ [n],C1532563;C0444504;C2347634;C2348143;C0168634;C1442488;C0369718;C0441922;C0036919;C0332174;C0439230
any placebo,C0032042;C1696465;C1706408
evomab,
[ $nmbr$,
high risk for diabetes,C0332167;C3272283;C4050568;C4319571
enrolled into osler,C4684790
did not enrol into osler,C1518422
phi n $nmbr$,C1333690;C1704947;C1706536;C2975867;C4084801
ppci n $nmbr$,
previous angina pectoris,C0205156;C0002962;C1552607
previous coronary intervention,C0184661;C0886296;C1273869
family history of coronary disease,C0850707
high risk $nmbr$ $nmbr$,C0332167;C3272283;C4050568;C4319571
red blood cell counting $nmbr$ l,C0014792;C0750480;C1705566;C0439394;C1706495;C3642217
platelet $nmbr$ l,C0456525
mean platelet volume fl,C1300812;C1708024
scr gmol l,C1539487;C4050416
ppci in $nmbr$,
no of panents total no $nmbr$,C0439175;C0439810
overal event rate,C0871208;C1521828
$nmbr$ $nmbr$ hr,
$nmbr$ l $nmbr$ mmhg,C0439394;C0439475;C1706495;C3642217
iiiv,
anacetrapib n $nmbr$ $nmbr$,C2604745
previous disease no f,C0205156;C0012634;C1552607;C0016327
mean mm hg,C0444504;C0439475;C2347634;C2348143
level no,C0441889;C0456079;C1547707;C2946261
glomerular filtration rate,C0017654;C1561549
lipid difference mg dl,C0023779;C0439269
no of participants with events,C0679646;C0441471;C3541888
anacetrapib n $nmbr$,C2604745
rate ratio,C0871208;C0456603;C1547037;C1521828
age at randomization years,C1510829;C0034656
prior disease,C0332152;C0012634;C2826257
time since qualifying event,C0040223;C3541383;C1514624;C0441471;C4019010
waisthip ratio,C0456603;C1547037
current drinker,C0556297
former non drinker,C0205156;C0457801;C0750523
medication,C0013227;C3244316;C4284232
apolipoprotein a $nmbr$ mg dl,C0003592;C0439269;C0523508
glomerular filtration rate ml min $nmbr$ $nmbr$ ma,C0024443;C3887485
urinary albumimcreatinine ratio,C0456603;C1547037
micro albuminuria,C0085672;C0001925;C1553035;C3811161;C4049106
macro albuminuria,C2984010;C0001925
gly $nmbr$ $nmbr$ pg b i d n $nmbr$,C2827928
severity of copda airflow limitation n,C0439793;C0522510
severity of copda combined assessment of copd n,C0439793;C0522510
discontinuation of lama prior to baseline n,C0457454;C1444662;C4552847;C0168634;C1442488
discontinuation of ics laba prior to baseline n,C0457454;C1444662;C4552847;C0168634;C1442488
pre bronchodilator fev i l,C2599602;C0021966;C0221138
post bronchodilator fevx l,C2599594
post bronchodilator fev i reversibility b,C2599594;C0021966;C0221138
fev auc i $nmbr$ h,C0021966;C0033727;C0369286;C0441932;C0564385;C4528284;C0221138
ics use yes,C1549445;C1705108;C1710701
ics use no,C0042153;C0457083;C1947944
$nmbr$ bmi kg m,C0022718;C0439209;C4054209
renal function egfr ml min $nmbr$ $nmbr$ m $nmbr$,C0232804;C0439445
ace inhibitors and arb,C0003015;C3888198
insulin na ive,C3435805;C4554334
not treated,C1518422;C1522326
insulin oad,C0021641;C1533581;C1579433;C3714501
subgroup no,C1079230;C1515021
combined estimated gfr and albuminuria status,C0017654;C1424601;C0001925;C0449438
and microalbuminuria or macroalbuminuria,C0730345
estimated gfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0017654;C0439445;C1424601
or no microalbuminuria or macroalbuminuria,C0730345
tiotropium group n $nmbr$,C0213771;C0441848
former smoking,C0037369;C0453996;C1881674
smoking index pack yr,C0037369;C0439234;C0453996;C1881674
duration of copd days^,C0449238;C2926735
previous respiratory disease other than copd no,C0035204;C0035242
previous medication for respiratory disease no,C0418986
traditional chinese medicine for respiratory disease no,C0025124;C1515884
spirometric values at baseline,C0042295;C0168634;C1442488
before bronchodilator use,C0042153;C0457083;C1947944
after bronchodilator use,C0042153;C0457083;C1947944
airflow reversibility no,C0231999;C0449261
gold stage no,C0205390;C1300072;C1306673
cat scoreff,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
mmrc dyspnea scale score t t,C0013404;C4049715;C1963100
ccq score,C0449820;C4050231
follow up,C0589120;C1522577;C1704685;C3274571
cat,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
difference tiotropium placebo ml $nmbr$ ci,C0008107;C3259781
pre bronchodilation fev $nmbr$,C0439566;C3714541
month $nmbr$,C0332177;C0439231
post bronchodilation fev $nmbr$,C0439576;C3714541
pre bronchodilation fvc,C0439566;C3714541
post bronchodilation fvc,C0439576;C3714541
table $nmbr$ baseline characteristics of early dmard naive patients with ra participating in the swefot trial,C4684572;C3538806;C4048756;C0679823;C0008976
patients with available bmi for univariate analyses or with all data available for the multivariate model did not differ from the original swefot trial population proportions n were compared with pearson s $nmbr$ continuous variables medians iqr were compared with independent samples mann whitney u tests all patients who originally participated in the swefot missing data were as follows in number n bmi $nmbr$ smoking status $nmbr$ rf status $nmbr$ anti acpa status $nmbr$ concurrent prednisolone use $nmbr$ haq $nmbr$ univariate model where the das $nmbr$ at $nmbr$ months and baseline bmi were required missing data n were as follows smoking status $nmbr$ rf status $nmbr$ acpa status $nmbr$ concurrent prednisolone use $nmbr$ and haq $nmbr$ multivariate model shown in table $nmbr$ and gure $nmbr$ a missing data points n were as follows rf status $nmbr$ acpa status $nmbr$ concurrent prednisolone use $nmbr$ acpa anticitrullinated protein antibody bmi body mass index das $nmbr$ $nmbr$ joint count disease activity score dmard disease modifying rheumatic drug haq health assessment questionnaire ra rheumatoid arthritis rf rheumatoid factor swefot swedish pharmacotherapy trial,C0030705;C0470187;C0683962;C1511726;C3245479;C3714741;C3161035;C3274659;C3714583;C3853906;C1518422;C0008976;C0032659;C1257890;C1707455;C0549178;C0439828;C0242927;C3272598;C4684714;C1519386;C0035448;C0201660;C0748398;C1547111;C0051767;C0057671;C0439231;C0168634;C0578022;C1442488;C1514873;C0332283;C1719822;C4281991;C0042153;C0457083;C1947944;C1547282;C0039224;C1706074;C1552961;C2347617;C3714763;C1537044;C1954799;C0392747;C0304229
swefot n $nmbr$,
univariatet n $nmbr$,
multivariate^ n $nmbr$,
proportions n,C1709707
obese bmi $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
overweight bmi $nmbr$ $nmbr$ $nmbr$,C0497406;C0578022
normal bmi,C4229017
concurrent prednisolone,C0205420;C0032950
medians iqr,C0549183
symptom duration months,C0449238;C0439231;C2926735
haq score,C0449820;C4050231
year from randomization,C0439234;C0439508
first year,C0439234;C0439508
second year,C0439234;C0439508
third yeart,C0205437
chd disease death,C0011065;C1306577;C4082313;C4552775
placebo km,C0032042;C3887676;C1696465;C1706408
ticagrelor $nmbr$ mg km,C0024671;C3887676;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
cv death myocardial infarction stroke,C0038454;C4554100
metrex modified intention to treat population with an eosinophilic phenotypey,C0087111;C0032659;C1257890;C1292734;C1522326
metrex overall modified intention to treat population,C0087111;C0032659;C1257890;C1292734;C1522326
metreo modified intention to treat population,C0087111;C0032659;C1257890;C1292734;C1522326
smoking history no,C1519384
moderate or severe copd exacerbations,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0205082;C0740304;C4050465;C4050466
no in the $nmbr$ mo before screening,C0026544;C0332177
one or more requiring hospitalization in $nmbr$ mo before screening no $nmbr$,C0205447;C0019993;C0026544;C0332177;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
gold group d no,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
postbronchodilator lung function at screening,C0035245;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
percent of predicted fev $nmbr$,C1882327;C3714541
blood eosinophil count $nmbr$ mm $nmbr$ at screening no,C4330985;C4554674;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
geometric mean blood eosinophil count sd on a loge scale cells mm $nmbr$,C0200638;C2699239
blood eosinophil count $nmbr$ mm $nmbr$ in $nmbr$ months before screening no,C4330985;C4554674;C0439231;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
blood eosinophil count cells mm $nmbr$ no,C4330985;C4554674
mepolizumab group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
of patients meeting criterion total no of patients,C0439175;C0439810;C0030705
sotagliflozin n $nmbr$,C3896939
race or ethnic group no white,C0034510;C1706779;C3853635;C0015031;C1879937;C0007457;C0043157;C0220938
native american or alaska native,C0282204;C1515945;C0682125
bmij,
bmi $nmbr$ no,C0578022
systolic blood pressure $nmbr$ mm hg no,C0488055;C0439475;C0871470;C1306620
daily total dose of insulin lu kg,C2348070
insulin dose lu day,C0332173;C0439228;C0439505
basal,C0205112
bolus and corrections,C1186706;C1511237;C1705509;C3812160;C1705565;C1947976
type of insulin therapy no $nmbr$,C0457592;C0039798;C0087111;C1363945
subcutaneous injections,C0021499
sotagliflozin,C3896939
no totalno,
percentage points,C1552961;C2347617;C3714763
patients with glycated hemoglobin,C0030705;C0017853
patients who used insulin pump,C0030705;C1140609
patients who did not use insulin pump,C0030705;C3272598;C1140609
patients with glycated hemoglobin $nmbr$ $nmbr$ and $nmbr$ episode of severe hypoglycemia,C0030705;C0017853;C0332189;C0020615;C4553659
patients with glycated hemoglobin $nmbr$ $nmbr$ and $nmbr$ episode ofdiabetic ketoacidosis,C0030705;C0017853;C0022638;C0220982
randomization groups $nmbr$ and $nmbr$,C0441833;C0687744;C1257890;C1519504;C1552839;C1705428;C1705429
pfo closure group n $nmbr$,C0185003;C0441848;C1521802
antiplatelet only group n $nmbr$,C0441848
anticoagulant group n $nmbr$,C0003280;C0441848;C0848112;C3536711
antiplatelet onl group n $nmbr$,C0441848
body mass index $nmbr$ no f,C0005893;C0578022;C1305855;C0016327
oral contraceptive pills no total no,C0009905;C0009906;C0029151;C0439175;C0439810
migraine no,C0149931
stroke no,C0038454;C4554100
deep vein thrombosis or pulmonary embolism no,C0149871;C0034065
qualifying event no,C1514624;C0441471;C4019010
carotid infarct,C0741968;C0021308
vertebrobasilar infarct,C0545733;C0021308
modified rankin scale no,C2984908;C3854213
rope score,C0449820;C4050231
septal anomaly no,C0332447;C1704258
pfo with large shunt without atrial septal aneurysm,C0232180;C0542331;C1442858;C0521533
pfo with large shunt and atrial septal aneurysm,C0232180;C0542331;C1442858;C0521533
pfo with mild to moderate shunt and atrial septal aneurysm,C1299392;C0232180;C0542331;C1442858;C0521533
pfo closure,C0185003;C1521802
no of strokes,C0038454
age at randomisation,C0001779;C0034656
patent foramen ovale,C0016522;C0344724
large shunt,C0232180;C0542331;C1442858
pfo asa,C0004057;C3853627
fluticasone furoate and vilanterol n $nmbr$,C1948374;C2935023
body mass index $nmbr$ kg nrn,C0005893;C1425210;C0578022;C1305855
asthma control test score at baseline,C2733224;C0168634;C1442488
duration of asthma $nmbr$ years,C0449238;C2926735
daytime symptoms more than twice per week,C0683368;C1457887;C1720725;C1948050;C0332174;C0439230
nocturnal symptoms in past week,C0683368;C1457887;C0332174;C0439230
number of exacerbations $nmbr$ months before randomisation,C0237753;C0449788;C0034656
figure s $nmbr$ baseline subgroups and act scores at week $nmbr$ pea population,C0168634;C1079230;C1442488;C0449820;C0030738;C0069964;C0070939;C1262903;C3257529
patients with prevalent kidney disease at baseline,C0683521;C0168634;C1442488
patients without prevalent kidney disease at baseline,C0683521;C0168634;C1442488
cv risk factor,C3538987;C0035648;C4048877;C4318503
peripheral artery diseasef,C0489868
single vessel coronary artery disease,C0581374
glucose lowering therapy,C0017725;C0441994;C2003888;C0039798;C0087111;C1363945
anti coagulants,C0848112
total cholesterol mg dl^,C0201950;C0439269;C0543421
low density lipoprotein cholesterol mg dl,C0023824;C0439269
high density lipoprotein cholesterol mg dl^,C0023822;C0439269
triglycerides mg dl^,C0041004;C0439269
estimated glomerular filtration rate mdrd ml min $nmbr$ $nmbr$ m $nmbr$,C3811844;C0439445
patients with egfr,C0030705;C1739039;C3811844;C3812682
patients with egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ at baseline,C0030705;C0439445;C0168634;C1442488
change from baseline at week $nmbr$,C0392747;C0443172;C1705241;C4319952;C0332174;C0439230
serum uric acid mg dl,C0455272;C0439269;C0700634
asian oriental,C0078988;C0699027
not reported unknown,C0439673;C3541433;C4050014
mean s d hbalc,C0444504;C2347634;C2348143
mean s d hbalc mmol mol,C0444504;C3829066;C2347634;C2348143
chda,
no ascvd additional cv risk factors n,C0035648;C1553898
micro macro albuminuria ckd and or retinopathy,C0001925;C1561643;C0035309;C1962966
$nmbr$ additional cv risk factors $nmbr$,C0035648;C1553898
median q $nmbr$ q $nmbr$ duration of diabetes years,C0449238;C2926735
median q $nmbr$ q $nmbr$ duration of insulin use years,C1881378;C2826775
mean s d systolic blood pressure mm hg,C0428886;C0439475;C0488053
mean s d diastolic blood pressure mm hg,C0428886;C0439475;C0488053
mean s d egfr ml min $nmbr$ $nmbr$ m $nmbr$,C0444504;C0439445;C2347634;C2348143
ckdc n,
baseline lipids,C0168634;C0023779;C1442488
mean s d calculated ldl cholesterol,C0023824;C0202117
mean s d measured ldl cholesterol,C0023824;C0202117
mean s d apob mg dl,C0003593;C0439269;C3252643
mean s d non hdl cholesterol,C0729627;C1535899
median q $nmbr$ q $nmbr$ tgs,C1156212;C1537574
mean s d hdl cholesterol,C0023822;C0392885
median q $nmbr$ q $nmbr$ lp a mg dl,C0065058;C0439269;C1439335;C4553379
mean s d apoc ll $nmbr$ mg dl,C0444504;C0003594;C2347634;C2348143;C0439269
median q $nmbr$ q $nmbr$ tg rich lipoprotein cholesterol,C0337445;C0065055
mean s d ldl particle number nmol l,C2612459;C0439282
mean s d ldl particle size nm,C0203634;C0312860;C3890923
mean s d free pcsk $nmbr$ ng ml,C0332296;C0439275;C1880497;C1996904
mean s d total pcsk $nmbr$ ng ml,C0439175;C0439275;C0439810
concomitant lipid lowering therapy n,C0585943
statin intensity $nmbr$ $nmbr$,C0360714;C0522510
statin monotherapy,C0360714
any other llts other than statin,C2347090;C0360714
cholesterol absorption inhibitor ezetimibe,C0003277;C1142985
statin intolerance $nmbr$ n,C0360714;C0231199;C1744706;C2355652
concomitant antihyperglycaemic drugs n,C0020616;C0013227;C3687832
any other antihyperglycaemic drugs,C0013227;C3687832
biguanides metformin,C0005382;C0025598;C0360396;C3540012
median q $nmbr$ q $nmbr$ total daily insulin dose $nmbr$,C2348070
iu,C0049272;C0439453;C0694756
lu kg,C0022718;C0439209;C4054209
t $nmbr$ d,C2603360
difference vs placebo [ $nmbr$ cl] p,C1705241;C1705242;C0032042;C1696465;C1706408;C0596019;C0369773;C2603361
ls mean s e primary endpoint change from baseline to week $nmbr$,C0444504;C2347634;C2348143;C0392747;C0443172;C1705241;C4319952;C0332174;C0439230
$nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ ],
selected key secondary efficacy endpoints,C4528314;C1280519;C1707887
change from baseline mean s e,C0392747;C0443172;C1705241;C4319952
calculated ldl cholesterol week $nmbr$,C0332174;C0439230
non hdl cholesterol week $nmbr$,C0332174;C0439230
apob week $nmbr$,C0332174;C0439230
total cholesterol week $nmbr$,C0332174;C0439230
lp a week $nmbr$,C0332174;C0439230
$nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ ] $nmbr$,
hdl cholesterol week $nmbr$ a,C0332174;C0439230
$nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ ] $nmbr$ b,
triglycerides week $nmbr$ a,C0332174;C0439230
ldl particle numbers week $nmbr$,C0332174;C0439230
ldl particle size week $nmbr$,C0332174;C0439230
ls mean difference se vs placebo,C0023668;C0036919;C0032042;C1696465;C1706408
ali,
age in $nmbr$ classes,C0001779;C0456387;C1518526;C1705943;C4019422
duration of diabetes by tertiles,C0449238;C2926735
ascvd as per protocol,C3665365;C1698058
ascvd including tia,C3665365;C0007787;C0917805;C1054154
any statin versus no statin at randomization,C0360714;C0034656
any statin with without llt,C0360714;C2347090
no statin vs statin alone vs any statin plus other llt,C0360714;C0205171;C0439044;C0679994;C2347090
no statin llt,C0360714;C2347090
statin alone,C0360714;C0205171;C0439044;C0679994
any statin other llt,C0360714;C2347090
high intensity statin vs medium or low intensity statin at randomization,C4081854;C0360714;C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283;C0596836
medium or low intensity statin,C0009458;C0439536;C1705217;C3244283;C4085196;C4522282;C4522283;C0596836;C0360714
prior history of mi or ischaemic stroke,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0948008
egfr in $nmbr$ classes,C1739039;C3811844;C3812682
baseline albumin creatinine ratio in $nmbr$ classes,C0486293;C1318293
diabetic kidney disease,C0011881
category $nmbr$,C0683312;C3889287
category $nmbr$ and $nmbr$,C0683312;C3889287
calculated ldl c in $nmbr$ classes,C0444686;C0456387;C1518526;C1705943;C4019422;C1441506
non hdl c in $nmbr$ classes,C1518422;C3715113
baseline trl c in $nmbr$ classes,C0456387;C1518526;C1705943;C4019422
baseline trl c by quintiles,C0168634;C1442488
baseline hdl c in $nmbr$ classes,C0168634;C3715113;C1442488
low hdl c for men,C0151691;C0025266
high hdl c for men $nmbr$ mg dl for women $nmbr$ mg dl,C3715113;C0439269;C0043210
baseline triglycerides in $nmbr$ classes,C0168634;C0041004;C1442488
baseline triglycerides by quintiles,C0168634;C0041004;C1442488
baseline lp a in $nmbr$ classes,C0065058;C1439335;C4553379
baseline total pcsk $nmbr$ level by median,C0441889;C0456079;C1547707;C2946261
$nmbr$ ng ml,C0439275
baseline free pcsk $nmbr$ level by median,C0441889;C0456079;C1547707;C2946261
baseline hba $nmbr$ c in $nmbr$ classes,C0456387;C1518526;C1705943;C4019422
diabetes mellitus status,C1317301
controlled,C2587213;C2911690
baseline insulin daily dose kg,C0022718;C0439209;C4054209
$nmbr$ u kg day,C1532634
exenatide n $nmbr$,C0167117
indian american or alaska native,C1524069;C0596070;C0682125
european subcategories,C0239307;C1515010;C1535514
prior cv event at randomization,C0441471;C4019010
history of congestive heart failure,C0455531
egfr via mdrd ml min $nmbr$ $nmbr$ m $nmbr$,C1739039;C3811844;C3812682
antihyperglycemic medication usage,C0013227;C0457083;C3244316;C4284232
oral agents use,C1527415;C0450442;C1254351;C1521826
$nmbr$ oral agents,C0450442;C1254351;C1521826
insulin alone,C0021641;C1533581;C1579433;C3714501;C0205171;C0439044;C0679994
insulin plus $nmbr$ oral agent,C0021641;C1533581;C1579433;C3714501
pramlintide,C0537551
non sulfonylurea secretagogues,C0038766;C4704833;C3536898
alpha glucosidase inhibitors,C1299007;C2756986;C3539108
glp $nmbr$ receptor agonist other than study drug,C4543206
exenatide lar,C1419115;C3814448
other glp $nmbr$ receptor agonist,C0018301;C4543206;C1422069;C1425391;C1539338;C2350813
dpp $nmbr$ inhibitor therapy,C0039798;C0087111;C1363945
vildagliptin,C1570906
allogliptin,
sglt $nmbr$ inhibitors^,C3665045
dapagliflozint,
other sglt $nmbr$ inhibitor,C1999216
other antihyperglycemic agents not listed,C0020616;C0745732;C3272378
cardiovascular medication usage,C0007220;C0457083
antihypertensive antianginal and other cardiovascular medications,C1874267;C3537168;C0007220
aldosterone antagonists e g spironolactone,C0002007;C2757004;C0037982
alpha $nmbr$ blockers,C0001641
renin inhibitor e g aliskerin,C1960108;C3537174;C4521920
digoxin digitalis glycoside,C0012265;C0012253
antithrombotic and anticoagulant medications,C0003280
vitamin k antagonist e g warfarin coumarol,C1096489;C2267235;C0043031
factor xa inhibitor,C2825027;C4553708
direct thrombin inhibitors,C0003440;C3541936
other anti platelet agents,C0040616;C0005821
clopidogrel ticlopidine,C0070166;C0040207
lipid lowering medications^,C0023779;C0441994;C2003888;C0013227;C0802604;C2598133;C4284232
statini,
niacini,
other medication usage,C0013227;C0457083;C3244316;C4284232
hormone replacement therapy,C0282402
chronic non steroidal antiinflammatory drugs,C0205191;C0003211
chronic cox $nmbr$ inhibitors,C0205191;C0085387
fish oil,C0016157
exenatide no of events total no,C0167117;C0439175;C0439810
placebo no of events total no,C0032042;C1696465;C1706408;C0439175;C0439810
indian american or alaskan native,C1524069;C0596070;C0238611;C0302891
antihyperglycemic oral agent therapy,C0039798;C0087111;C1363945
glycated hemoglobin level,C0202054
estimated gfr renal function stage,C0205390;C1300072;C1306673
stage $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0205390;C0439445;C1300072;C1306673
stage $nmbr$ $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0205390;C0439445;C1300072;C1306673
stage $nmbr$ a $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0205390;C1300072;C1306673;C0439445
stage $nmbr$ b $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0441781;C0439445
previous cardiovascular event at randomization,C1320716;C0034656
ertugliflozin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
background aha therapy at screening n,C0039798;C0087111;C1363945
dpp $nmbr$ inhibitors,C1414174;C0243077
sulphonylureas,C0038766
two agents,C0450442;C1254351;C1521826
three or more agents,C0205449;C0450442;C1254351;C1521826
one or more blood pressure medications n,C0205447;C0849164
ras agents,C0450442;C1254351;C1521826
other anti hypertensives,C0003364
c peptide,C0006558
ertugliflozin $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
subgroup analysis change from baseline in hba $nmbr$ c at week $nmbr$ per baseline hba $nmbr$ c category,C0392747;C0443172;C1705241;C4319952;C0019016;C0332174;C0439230;C1825777;C3538758;C0683312;C3889287
baseline hba $nmbr$ c median $nmbr$ $nmbr$ $nmbr$ mmol mol,C0019016;C3829066;C1825777;C3538758
ls mean $nmbr$ ci mmol mol,C0008107;C3829066;C3259781
difference in ls mean vs placebo $nmbr$ ci,C1705241;C1705242;C0008107;C3259781
difference in ls mean vs placebo $nmbr$ ci mmol mol,C1705241;C1705242;C0008107;C3829066;C3259781
baseline hba $nmbr$ c $nmbr$ $nmbr$ to,C0168634;C0019016;C1825777;C3538758;C1442488
baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ mmol mol,C0019016;C3829066;C1825777;C3538758
pravastatin n $nmbr$,C0085542
$nmbr$ month n $nmbr$,C0332177;C0439231
ischemic stroke subtype,C0948008;C0449560
atherothrombotic stroke n,C0038454;C4554100
lacunar infarction n,C0333559
undetermined etiology n,C0478157
use of antiplatelet agents n,C1524063;C0085826
use of anti hypertensive agents n,C1524063;C0003364
incidence of each outcome,C0021149;C0220856
stroke and tia n,C0038454;C4554100;C0007787;C0917805;C1054154
incidence $nmbr$ person year,C0027361;C0439234;C0439508;C2347489
all strokes n,C0038454
atherothrombotic infarction n,C0021308
cardioembolic infarction n,C0021308
intracranial hemorrhage n,C0151699;C4554169
tia n,C0007787;C0917805;C1054154
vascular accidents n,C0005847;C0000924;C1558950;C1801960
death n,C0011065;C1306577;C4082313;C4552775
hospitalization n,C0019993
bmi kg m $nmbr$ median iqr,C0022718;C0439209;C4054209;C0549183;C0876920;C2347635;C2348144;C2939193
patient s history of,C0030705;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
prior non haemorrhagic stroke,C0332152;C0553692;C2826257
chronic renal disease,C0022661;C1561643
index event information,C0441471;C1533716;C4019010
first medical contact in ambulance,C0332158;C0337611;C1705415;C3812666
minutes from symptom onset to prehospital ecg median iqr,C0439232;C0700321;C0702093;C1282918;C2347166;C0549183;C0876920;C2347635;C2348144;C2939193
minutes from prehospital ecg to pci median iqr,C0439232;C0700321;C0702093;C1282918;C2347166;C0549183;C0876920;C2347635;C2348144;C2939193
minutes from pre pci angiography to post pci angiography median iqr,C0439232;C0700321;C0702093;C1282918;C2347166;C0002978;C0549183;C0876920;C2347635;C2348144;C2939193
received first loading dose,C0205435;C3714444;C1279901
risk level at admission,C2923839;C0184666;C0809949
culprit vessel,C0005847
no culprit vessel identified,C0005847;C0205396;C1550043
normal coronary angiography,C0853522
femoral access,C0444454;C1554204
thromboaspiration,
with any stent,C0038257
with des,C0011702;C4551552
no revascularisation,C0581603
any glycoprotein iib iiia inhibitor use,C0042153;C0457083;C1947944
glycoprotein iib iiia inhibitor use before angiography,C0042153;C0457083;C1947944
intravenous anticoagulant prior to pre pci angiography,C0003280;C0848112;C3536711
intravenous anticoagulant during hospitalisation,C0003280;C0848112;C3536711
pre hospital ticagrelor n $nmbr$,C0332152;C0019994;C1510665;C0740175;C2257086;C3669034
model n,C3161035;C3274659;C3714583;C3853906
patients with endpoin t n,C0030705
composite of death mi stro ke urgent revasc definit e acute stent thrombosis,C0205199;C1547335
composite of death mi urg ent revasc,C0205199;C1547335
nt estimated,C0332126;C1449832;C3889152;C4050156;C4283901;C4284038;C0750572
urgent revascularizati on,C0439609;C3272275
definite acute stent thrombosis,C0205178;C3897493
acute stent thrombosis definite or probable,C0205178;C3897493;C0439544;C1704787;C0033204;C0332148
enalapril aliskiren dm $nmbr$ non dm $nmbr$,C0011816;C1518422;C3250443
aliskiren dm $nmbr$ non dm $nmbr$,C0011816;C1518422;C3250443
enalapril dm $nmbr$ non dm $nmbr$,C0011816;C1518422;C3250443
hazard ratio or difference $nmbr$ $nmbr$ cl p value,C2985465;C0596019;C1709380
enalapril aliskiren n $nmbr$,C0014025;C1120110
cv death or first hhf,C0011065;C1306577;C4082313;C4552775;C0205435;C1279901
race $nmbr$,C0034510;C1706779;C3853635
non diabetes,C0011847;C0011849
first hhf,C0205435;C1279901
non ischaemic cardiomyopathy,C1518422;C0349782
time since diagnosis of heart failure,C0040223;C3541383
kccq $nmbr$ months,C3476798;C0439231
nyha functional class at screening,C1882083;C0205245;C0542341;C2700217
physiological measures,C0079809;C1879489
other outcomes,C1274040
laboratory measures,C0079809;C1879489
nt probnp pg ml q $nmbr$ q $nmbr$,C0669479;C0439297;C0754710
change in nt probnp at $nmbr$,C0392747;C0443172;C1705241;C4319952
months log transformed,C1708728;C2986775;C1510411
beta adrenergic blocker,C0001645;C2757061;C3536830
devices for heart failure at screening visit,C0025078;C2024216;C0545082;C1512346;C2826704
crt p,
crt d,
change in nt probnp at $nmbr$ months log transformed,C0392747;C0443172;C1705241;C4319952;C1708728;C2986775;C1510411
change in sbp $nmbr$ months,C0392747;C0443172;C1705241;C4319952
hyperkalaemia investigator reported,C0020461;C0035173;C4552983;C0684224;C0700287;C4319718
hyperkalaemia serum potassium $nmbr$ $nmbr$ mmol l,C0302353;C1532563;C0543465
symptomatic hypotension sbp,C0020649;C0085805;C3163620
deterioration in renal function investigator reported,C0868945;C0232804;C0684224;C0700287;C4319718
elevated serum creatinine $nmbr$ $nmbr$ mg dl_,C0700225;C0439269
cough investigator reported,C0010200;C0035173;C1961131;C3274924;C4084725;C4084726;C4084727;C0684224;C0700287;C4319718
cough leading to study drug discontinuation,C0010200;C1961131;C3274924;C4084725;C4084726;C4084727;C0332152;C0013175;C1522538
fig $nmbr$ acr $nmbr$ $nmbr$ and $nmbr$ response rates by baseline tnf status at weeks $nmbr$ $nmbr$ and $nmbr$,C1412134;C1515941;C0237629;C0168634;C1442488;C0439230
fig $nmbr$ acr $nmbr$ acr $nmbr$ and acr $nmbr$ response rates by baseline mtx use at weeks $nmbr$ $nmbr$ and $nmbr$,C0349966;C1337208;C0237629;C0025677;C1417487;C0439230
no stroke n $nmbr$,C0038454;C4554100
any stroke n $nmbr$,C0038454;C4554100
prior ml before index acs,C0439526;C1705224;C3887665
prior cabg before index acs,C0332152;C0010055;C2826257
cha $nmbr$ ds $nmbr$ vasc score median iqr,C0449820;C0549183;C0876920;C2347635;C2348144;C2939193;C4050231
labs at the index acs event,C0587081;C0441471;C4019010
total cholesterol median iqr mg dl,C0201950;C0439269;C0543421
ldl c median iqr mg dl,C0549183;C0439269;C0876920;C2347635;C2348144;C2939193
hdl c median iqr mg dl,C0549183;C0439269;C0876920;C2347635;C2348144;C2939193
time from acs to randomization median iqr,C0040223;C3541383;C0034656;C0549183;C0876920;C2347635;C2348144;C2939193
labs at randomization,C0587081;C0034656
hs crp median iqr mg l,C0549183;C0439268;C0876920;C2347635;C2348144;C2939193
egfr median iqr ml min $nmbr$ $nmbr$ m $nmbr$,C0549183;C0439445;C0876920;C2347635;C2348144;C2939193
no prior stroke,C0038454;C4554100
htn,C0020538
no htn,C0020538
crcl $nmbr$,C1846718
prior llt,C0332152;C2347090;C2826257
no prior llt,C0332152;C2347090;C2826257
ldl csmedian,
ldl c median,C0549183;C0876920;C2347635;C2348144;C2939193
simva n $nmbr$ n,
ez simva n $nmbr$ n,C0206578
arr $nmbr$ cl,C2170357;C0596019;C4084934
stroke of any etiology,C0038454;C4554100
primary trial end point,C2986535;C0008976
other individual and exploratory end points,C0027361;C0237401;C2349179
coronary heart disease death,C0376297
cv death ml or stroke,C0439526;C1705224;C3887665;C0038454;C4554100
patients no total no,C0030705;C0439175;C0439810
stroke vs tia,C0038454;C4554100;C0007787;C0917805;C1054154
index event subtype,C0441471;C0449560;C4019010
large vessel atherosclerosis,C0225990;C0003850;C0004153
lacunar,
cardioembolic,
other defined,C1704788;C3539106
motor weakness,C1513492;C3714552;C1705994
aphasia,C0003537
modified rankin scale score,C2984908;C3854213
systolic blood pressure mean sd mm hga,C0428886;C0488055;C0871470;C1306620
hemoglobin a $nmbr$ c mean sd b,C0062248
feature,C1521970;C1706388;C2346469;C2348519
p int f,C0369773;C0016327;C2603361
htn hx,C0262926;C3814444
placebo [n $nmbr$ ],C0032042;C1696465;C1706408;C0369718;C0441922
tofacitinib $nmbr$ mg bid [n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0369718;C0441922
placebo [n $nmbr$,C0032042;C1696465;C1706408;C0369718;C0441922
age mean years [sd],C1510829;C0444504;C2347634;C2348143;C2699239
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$,
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$ a,
gender n [ ] male,C0079399;C1522384;C0086582;C1706180;C1706428;C1706429
duration of disease median,C0872146;C0549183;C0876920;C2347635;C2348144;C2939193
years [range],C0439234;C1514721;C2348147;C3542016
previous anti tnf therapy n [ ],C0205156;C1552607
$nmbr$ [ $nmbr$ $nmbr$ a,
concomitant aminosalicylates n [ ] concomitant corticosteroids n [ ] mayo score mean [sd],C0521115;C0368663;C0001617;C3539185;C3540725;C3540726;C3540727;C0444504;C2347634;C2348143;C2699239
$nmbr$ _ $nmbr$ s,
ibdq total score mean [sd],C0444504;C2347634;C2348143;C2699239
ibdq domain scores mean [sd],C0444504;C2347634;C2348143;C2699239
bowel function,C0011135
systemic symptoms,C0683368;C1457887
emotional status,C0013987;C0449438;C0849912
social function,C0037395
sf $nmbr$ v $nmbr$ pcs mean [sd],C0037712;C0444504;C2347634;C2348143;C2699239
sf $nmbr$ v $nmbr$ mcs mean [sd],C0037712;C0444504;C2347634;C2348143;C2699239
sf $nmbr$ v $nmbr$ domain scores mean [sd],C0037712;C0444504;C2347634;C2348143;C2699239
physical function,C0516981;C4049916
role physical,C0035820;C0031809;C0205485;C1509143;C1705810;C3871154
role emotional,C0035820;C0013987;C0849912;C1705810;C3871154
octave induction $nmbr$ and $nmbr$,C0205263;C0857127
ls mean change from baseline,C0392747;C0443172;C1705241;C4319952
in ibdq total score at week $nmbr$ mean [se],C2964552;C0036919
corticosteroid use at baseline,C0239126;C0168634;C1442488
placebo n $nmbr$ i,C0021966;C0221138
patient demographics age yr,C4698447;C0439234
disease characteristics duration of psoriatic arthritis yr,C0872146;C0003872
$nmbr$ $nmbr$ o $nmbr$,C0483204
leeds enthesitis index^ score $nmbr$ no,C0449820;C4050231
dactylitis severity score score $nmbr$ no,C0239161;C0457451
swollen joint count of $nmbr$ joints assessed no,C0451521;C1516048
tender or painful joint count of $nmbr$ joints assessed no,C0234234;C0750480;C1705566;C1516048
elevated high sensitivity crp no,C0742906;C1441604
affected body surface area $nmbr$ no,C0005902;C1879646
median pasi score range i i,C0021966;C0221138
day $nmbr$ oral glucocorticoid use no,C1527415;C0017710
concomitant use of conventional synthetic dmard up to $nmbr$ mo no methotrexate,C1524063;C0242708;C0026544;C0332177;C0025677
leflunomide,C0063041
otherj^,
methotrexate dose on day $nmbr$ mg per wl,C4086581
no of previous tne inhibitors,C0205156;C0243077;C1552607
previous use of other biologic agents in addition to tne,C1524063;C0005515;C3896585
inhibitors no se $nmbr$ physical functioning score^^,C0243077;C4483112
eacit e total score,C2964552
figure s $nmbr$ american college of rheumatology $nmbr$ response rate and change from baseline in health assessment questionnaire disability index at month $nmbr$ by number of prior tnfi inadequate responses,C0035452;C0237629;C0392747;C0443172;C1705241;C4319952;C4321476;C0332177;C0439231;C0237753;C0449788
high sensitivity c reactive protein stratification,C0006560;C1514983;C1413716;C4048285
$nmbr$ to $nmbr$ mg l n $nmbr$,C0439268
$nmbr$ mg l n $nmbr$,C0439268
coronary bypass surgery,C0010055
index acs,C0742343;C4318612
major adverse cardiovascular events,C0877248;C1705413
urgent revascularization because of unstable angina,C0581603;C0002965
complex anatomy n $nmbr$ $nmbr$,C0439855;C0002808;C0700276;C1384516;C1704241
noncomplex anatomy n $nmbr$ $nmbr$,C0002808;C0700276;C1384516
$nmbr$ $nmbr$ _ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
stroke transient ischemic attack,C0007787;C0917805
anatomic complexity characteristics,C0220784;C1521970
$nmbr$ lesions per vessel,C0221198;C0005847
bifurcation lesion with side branch $nmbr$ $nmbr$ mm stented,C0221198;C1546698;C0038257
vein bypass graft stented,C0398147;C0038257
stent diameter $nmbr$ mm,C4330985;C4554674
central illustration dual antiplatelet therapy with complex lesions cumulative incidence of endpoint events from $nmbr$ to $nmbr$ months after randomization,C0205173;C1096021;C1554184;C0439231;C0034656
the endpoint events were strati ed by randomized treatment arm and number of anatomical complexity characteristics outcomes were analyzed comparing randomized treatments among subgroups of subjects with $nmbr$ n $nmbr$ $nmbr$ $nmbr$ n $nmbr$ $nmbr$ or $nmbr$ or more n $nmbr$ anatomic complexity characteristics to assess whether treatment effects differed depending on the number of complexity factors,C0441471;C3541888;C3538926;C1522541;C0237753;C0449788;C0936012;C1707455;C0034656;C0087111;C3815594;C0369718;C0441922;C0220784;C1521970;C1516048;C1518681
ischemic stroke vs tia,C0948008;C0007787;C0917805;C1054154
modified rankin scale at screening $nmbr$ $nmbr$,C2984908;C3854213
nihss at randomization $nmbr$ $nmbr$,C1697238;C0034656
int p,C3272375
carotid stenosis,C0007282
canagliflozin dose,C0178602;C0869039;C1114758
aged $nmbr$ y or older n,C0001779;C0001792;C1999167;C0580836
bmi o $nmbr$ kg m $nmbr$ n,C0022718;C0439209;C4054209;C0369718;C0441922
bmi $nmbr$ kg m $nmbr$ n,C0022718;C0439209;C4054209;C0369718;C0441922
duration of diabetes y mean sd,C0449238;C2926735
duration of oral antidiabetic treatment y mean sd,C0444921
egfr category n,C1739039;C0683312;C3889287;C3811844;C3812682
$nmbr$ to o $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0483204;C0439445
serum creatinine gmol l mean sd,C0201976;C2699239;C0600061
subgroup treatment,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
baseline value,C0168634;C1522609;C1442488
difference a vs placebo $nmbr$ cl,C1705241;C1705242;C0032042;C0596019;C1696465;C1706408
baseline bmi $nmbr$ kg m $nmbr$,C0022718;C0439209;C4054209
baseline egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$,C0168634;C0439445;C1442488
duration of diabetes $nmbr$ years,C0449238;C2926735
baseline su dose $nmbr$ $nmbr$ maximal,C0205289;C0806909;C4049713
calima japandhigh dosage ics laba and baseline blood eosinophils $nmbr$ cells ml n $nmbr$ y,C0178602;C0815320;C4551720;C2986497;C0005773
calima overalldhigh dosage ics laba and baseline blood eosinophils $nmbr$ cells ml n $nmbr$,C0178602;C0815320;C4551720;C2986497;C0005773
benralizumab q $nmbr$ w n $nmbr$,C2982078
age [years] median range,C0001779;C0439234;C1514721;C2348147;C3542016
body mass index [kg m $nmbr$ ] mean sd,C0005893;C0578022;C1305855;C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
time since asthma diagnosis [years] median range,C0040223;C3541383;C0439234;C1514721;C2348147;C3542016
oral corticosteroid use n,C1527415
number of exacerbations in the last $nmbr$ months,C0237753;C0449788;C0439231
ed visit related to exacerbation n,C0545082;C1512346;C2826704;C0439849;C0445223
hospitalisation related to exacerbation n,C0019993;C0439849;C0445223
fev $nmbr$ prebronchodilator [l] mean sd,C3714541;C2599602;C0439394;C1706495;C3642217;C0444504;C2699239;C2347634;C2348143
fev $nmbr$ prebronchodilator [ pn] mean sd,C3714541;C2599602;C0219433;C1549735;C3541307;C4049640;C4049767;C0444504;C2699239;C2347634;C2348143
fev $nmbr$ fvc prebronchodilator mean sd,C0444504;C2699239;C2347634;C2348143
reversibility [ ] median range,C0449261;C1514721;C2348147;C3542016
total asthma symptom score mean sdz,C3533163;C0004096;C2984299
local eosinophil count [cells ml] median range,C0200638;C0750879;C2699156;C1514721;C2348147;C3542016
calima japan n $nmbr$,C0022341
calima overall n $nmbr$,C0282416;C1561607
benralizumab,C2982078
q $nmbr$ w n $nmbr$,
number of exacerbations in the last $nmbr$ months mean sd,C0237753;C0449788;C0439231;C2699239
total asthma symptom score mean sd,C3533163;C2699239
local eosinophil count [cells l] median range,C0200638;C0750879;C0347983;C1514721;C2348147;C3542016
japanese subgroup n $nmbr$,C0376247;C1079230;C1515021;C1556094
any ae n,C3887670
aes in $nmbr$ japanese patients in a study arm n,C1412268;C2699274;C0557651;C0446516;C3715044;C4553528;C2603343
allergic rhinitis,C1334103;C2607914;C4552864
eczema,C0013595;C4553957
bacterial pneumonia,C0004626
urticaria,C0042109;C1559188
upper respiratory tract inflammation,C0877266
epistaxis,C0014591;C4554627
dermatitis atopic,C0011603;C0392707
injection site reaction n,C0151735;C4551923
hypersensitivity n,C0020517;C0520946
any drug related ae n,C0013227;C0439849;C0445223;C1254351
any ae leading to discontinuation n,C3887670;C0332152;C0457454;C1444662;C4552847;C1522538
any serious ae n,C0205404;C3887670
deaths n,C0011065;C1306577
low dose rivaroxaban plus aspirin n $nmbr$,C2608320;C1739768
body mass index kq nrn,C0005893;C1425210;C0578022;C1305855
systolic blood pressure mm hq,C0488055;C0871470;C1306620
diastolic blood pressure mm hq,C0428883;C1305849
smokinq status,C0449438
lipid lowerinq druq,C0023779
e blocker,
reqion,
north american,C0425358;C2700615
south american,C0425359
western european includinq australia israel and south africa,C0043128;C0022271;C0037712
eastern european,C0239309
low dose rivaroxaban aspirin n n,C2608320;C1739768
aspirin alone n n,C0004057;C0205171;C0439044;C0679994
$nmbr$ $nmbr$ o $nmbr$ $nmbr$ oo,C0483204
w est europe,C3811127;C0015176;C3890902
east europe,C1707877;C0015176
y es,C0013754;C0205944
n o,C0369718;C0441922
no previous myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
history of pci ptca,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
history of cabg,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
myocardial infarction cabg pci,C0027051;C4049621;C0428953;C2926063;C3810814;C4552959
$nmbr$ mmol l,C1532563
non smokers receiving lipid lowering drugs p blockers and either an ace inhibitor or angiotension receptor blocker,C0337672;C4554605;C1514756;C0086440;C0003015;C4541021;C0597357
west europe,C1705493;C0015176
no previous myocardial infarction $nmbr$ $nmbr$,C0027051;C0428953;C2926063;C3810814;C4552959
non smokers receiving lipid lowering drugs $nmbr$ blockers and either an ace inhibitor or angiotension receptor blocker,C0337672;C4554605;C1514756;C0086440;C0003015;C4541021;C0597357
w hite,
mean systolic blood pressure mm hg,C0428886;C0439475;C0488053
mean diastolic blood pressure mm hg,C0428886;C0439475;C0488053
risk factors for pad,C0035648;C1553898
median total cholesterol mmol l,C0201950;C1532563;C0543421
previous aorta femoral or lower extremity bypass surgery pta of iliac or infrainguinal artery,C0003483;C0015811;C0187763;C3274435;C0003842;C0226004
history of intermittent claudication and abi $nmbr$,C2315493;C1328319;C3888326
previous limb or foot amputation,C0205156;C0015385;C1552607;C0188605
symptomatic pad of lower extremities,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
carotid artery diseaset,C0007272;C0162859
symptomatic padt,C0231220
cad and abi,C1504769;C2239547;C3813548;C4284121;C1328319;C3888326
normal $nmbr$ $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
non study ppi use,C0869040;C0358591;C0871125;C3811894
low dose rivaroxaban aspirin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
aspirin alone group no of events total n,C0004057;C2826346;C0439175;C0439810
no of events total n,C0439175;C0439810
former or never,C0205156;C0750523;C2003901
symptomatic pad,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
pad lower extremities,C0182158;C0023216;C0332568;C3540603;C3669270;C3814046;C4319657
overall pad,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
demographics and clinical characteristics,C0011298;C1704791;C0683325
all completers n $nmbr$ $nmbr$,
$nmbr$ hba $nmbr$ c,C0019016;C1825777;C3538758
hba $nmbr$ c $nmbr$ n $nmbr$ $nmbr$,C0019016;C1825777;C3538758
duration of t $nmbr$ d years,C0449238;C2926735;C0439234
screening bmi kg m $nmbr$,C0022718;C0439209;C4054209
screening hba $nmbr$ c,C0220908;C0019016;C1825777;C3538758;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
basal insulin dose at run in u day,C0366513;C0456683
iglar dose at randomization u day,C0178602;C0869039;C1114758
all completers,
ls mean change sea,C0023668;C0036493
ls mean difference seb,C0059386;C1309881;C1423585;C3815268
$nmbr$ confidence interval,C0009667
dose n,C0178602;C0869039;C1114758
$nmbr$ c,
mean iglar dose sd u day,C0178602;C0456683;C0869039;C1114758
mean lixi dose sd lg day,C0332173;C0439228;C0439505
age categories n,C2916832
bmi categories n,C0578022;C0683312
duration of type $nmbr$ diabetes categories n,C1547660;C1320657
hba $nmbr$ c categories n,C0019016;C0683312;C1825777;C3538758
fasting plasma glucose categories n,C0202042;C0455280
metformin use n,C0025598;C0042153;C0457083;C1947944
total daily insulin dose u,C2348070;C0439148
insulin type n,C0457592
intermediate acting,C0205103;C1550465;C2827755;C3889971
intermediate long acting fast acting,C0015663;C0456962;C2985769
long acting intermediate long acting fast acting,C0015663;C0456962;C2985769
individuals without diabetes n $nmbr$ $nmbr$,C0027361;C0237401
baseline bmi $nmbr$ to,C0168634;C0578022;C1442488
baseline bmi $nmbr$ kg m $nmbr$ n $nmbr$ $nmbr$,C0022718;C0439209;C4054209;C0369718;C0441922
liraglutide $nmbr$ $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
prediabetes,C0362046
individuals with diabetes n $nmbr$,C0027361;C0237401
baseline bmi $nmbr$ kg m $nmbr$ n $nmbr$,C0022718;C0439209;C4054209;C0369718;C0441922
baseline bmi $nmbr$ kg m $nmbr$ n $nmbr$ $nmbr$ change from baseline to $nmbr$ weeks,C0022718;C0439209;C4054209;C0392747;C0443172;C1705241;C4319952;C0439230
liraglutide $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
etd $nmbr$ ci,C0008107;C3259781
iwqol lite total score arbitrary units,C1264693;C0439148;C1519795;C3853603
iwqol lite physical score arbitrary units,C1264693;C0439148;C1519795;C3853603
baseline bmi $nmbr$ kg m $nmbr$ n $nmbr$ change from baseline to $nmbr$ weeks,C0022718;C0439209;C4054209;C0392747;C0443172;C1705241;C4319952;C0439230
canakinumab hscrp $nmbr$ $nmbr$ mg l at $nmbr$ months n $nmbr$,C0439268;C0439231
canakinumab hscrp,C2718773
unknown or missing,C0439673;C3541433;C4050014;C1551393;C1705492;C3272743
renin angiotensin inhibitors,C2917241;C3653375
anti ischaemia agents,C0450442;C1254351;C1521826
interleukin $nmbr$ ng l,C0021764;C0439297;C1527200
randomised to canakinumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
primary cardiovascular endpoint,C2986535;C0007226;C3887460
incidence rate per $nmbr$ person years,C1708485;C0027361;C2347489
canakinumab,C2718773
ldl cholesterol $nmbr$ $nmbr$ mmol l,C0023824;C1532563;C0202117
hscrp $nmbr$ to,
hscrp $nmbr$ mg l,C0439268
hdl cholesterol $nmbr$ $nmbr$ mmol l,C0023822;C1532563;C0392885
triglycerides $nmbr$ $nmbr$ mmol l,C0041004;C1532563
secondary cardiovascular endpoint,C4528314;C0007226;C3887460
sbp $nmbr$ mmhg n $nmbr$,C0085805;C0439475
$nmbr$ sbp $nmbr$ mmhg n $nmbr$,C0085805;C0439475
pulse pressure mmhg,C0949236;C0439475
randomization to,C0034656
nyha class iii or iv n,C1882086;C0022326;C4265176
enrolment through hf,C1516879;C1696073;C3888021
hospitalization stratum n,C0019993
co morbidities n,C0009488
acei and or arb,C3888198
other anti hypertensive,C0003364
anti hypertensive,C0003364
laboratory testing,C0022885
rate ml min $nmbr$ $nmbr$ m $nmbr$,C0871208;C0439445;C1521828
ecg and imaging data,C1623258;C1511726;C3245479;C3714741
ecg left ventricular,C1623258;C0225897
hypertrophy n,C0020564
ecg atrial fibrillation n,C0004238;C0344434;C1963067
composite endpoint,C2349179;C2826544
event rate per $nmbr$ person years,C0871208;C1521828
crude model hr $nmbr$ ci,C0008107;C3259781
multivariable adjusted model hr $nmbr$ ci,C0008107;C3259781
recurrent hf hospitalization,C0018488;C0019993;C1313497;C1538440;C3273279
hyperkalaemia,C0020461;C4552983
hypokalaemia,C0020621;C4553966
men n $nmbr$ $nmbr$,C0025266
prior lipid lowering agent use,C0042153;C0457083;C1947944
at qualifying event,C1514624;C0441471;C4019010
dual antiplatelet,C0205173;C1554184
pbo simva $nmbr$ yr km rale,C0031962;C0034642
eze simva $nmbr$ yr km rale,C0439234;C0034642
any death,C0011065;C1306577;C4082313;C4552775
coronary revascularization $nmbr$ days after randomization,C0877341;C0439228
cardiovascular death myocardial infarction stroke,C0027051;C0428953;C2926063;C3810814;C4552959
pint,C0560012;C3811619;C3890014;C3890556
cardiovasculardeath,
cardiovasculardeath myocardial infarction stroke,C0038454;C4554100
placebo simvastatin,C0032042;C0074554;C1696465;C1706408
ezetimibe simvastatin,C1532737
pin,C0175718;C1168556;C1704584
permanently stopped study drug because of adverse events,C0041755
alt ast or both $nmbr$ x uln,C3831581;C1519815
gallbladder related aes,C1412268;C2699274
rhabdomyolysis or myopathy,C0035410;C4552660;C0026848
rhabdomyolysis myopathy or myalgia with ck elevation $nmbr$ x uln,C0035410;C0026848;C4552660;C0231528;C4552646
myopathy,C0026848
ertugliflozin $nmbr$ mg n $nmbr$ $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
medical history of cv disease or heart failure n,C0262926;C0018801;C0018802;C4554158
currently on aha therapy,C0050451;C0039798;C0087111;C1363945;C0772110
glp $nmbr$ receptor agonists,C0018301;C4543206;C1422069;C1425391;C1539338;C2350813
insulins and analogs,C0021641;C3537244;C4049919;C0243071
overall cohort primary analysis,C0086027;C0205225;C0439612;C0439631
difference in ls means $nmbr$ ci versus placebo,C1705241;C1705242;C0032042;C1696465;C1706408
stage $nmbr$ a ckd cohort secondary analysis,C0205390;C1300072;C1306673;C0086027;C0027627;C0175668;C0205436
overall cohort post hoc analysis excluding metformin users,C0086027;C0025598
stage $nmbr$ a ckd cohort post hoc analysis excluding metformin users,C0205390;C1300072;C1306673;C0086027;C0025598
week $nmbr$ a,C0332174;C0439230
table $nmbr$ baseline characteristics in america between patients w wo resistant htn,C4684572;C0002454;C0030705;C1980014
abbreviations ace angiotensin converting enzyme arb angiotensin receptor blocker bb beta blocker bmi body mass index bnp brain natriuretic peptide ccb calcium channel blocker dbp diastolic blood pressure egfr estimated glomerular ltration rate hr heart rate sbp systolic blood pressure w wo with or without,C4528226;C1980014
america all patients,C0002454;C0030705
america rhtn only,C0002454
no resistant htn n $nmbr$ $nmbr$,C0332325;C0020538;C1514892;C1550464;C2827757
resistant htn n $nmbr$,C0332325;C0020538;C1514892;C1550464;C2827757
resistant htn placebo n $nmbr$,C0020538;C0032042;C1696465;C1706408
resistant htn spiro n $nmbr$,C0332325;C0020538;C1514892;C1550464;C2827757
race_white,C0007457;C0043157;C0220938
nyha_class,C1882083
eligibility strata,C0013893;C1548635
elevated bnp,C0054015;C1095989;C1417808;C2982014
ace or arb,C1452534;C4284014;C3888198
bb,C0004739;C0332297
hb g dl,C0439267
table $nmbr$ outcom,C0039224;C1706074
es in americas according to the presence absence of rhtn,C0013754;C0205944;C0332197;C1689985
abbreviations ace angiotensin converting enzyme arb angiotensin receptor blocker ci con dence interval cvd cardiovascular death hf heart failure hr hazard ratio rhtn resistant hypertension afrom unadjusted model bstrati ed by eligibility strata cfurther adjusted for age ace arb diabetes,C0596525;C3538926;C0013893;C1548635;C4300468
rhtn,
no rhtn,
number and of participants with events and incidence rate per $nmbr$ person year,C0237753;C0449788;C0679646;C0441471;C3541888;C1708485;C0027361;C2347489
unadjusted model hr $nmbr$ ci p value,C0008107;C1709380;C3259781
strata modelb hr $nmbr$ ci p value,C0008107;C1709380;C3259781
adjusted modelc hr $nmbr$ ci p value,C0008107;C1709380;C3259781
p for interaction between rhtn and no rhtn and treatmenta,C0369773;C2603361
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ per $nmbr$ pyr,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ per $nmbr$ $nmbr$ per $nmbr$ pyr $nmbr$ pyr,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ per $nmbr$ $nmbr$ $nmbr$ per pyr $nmbr$ pyr,
recurrent hf,C0018488;C1313497;C1538440;C3273279
$nmbr$ $nmbr$ per $nmbr$ pyr,
$nmbr$ $nmbr$ per $nmbr$ $nmbr$ $nmbr$ per $nmbr$ pyr pyr,
itca $nmbr$ $nmbr$ mg day n $nmbr$,C0165330;C0439422
femalesex,
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ t,C2603360
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ],
egfr ml min bsa,C1739039;C0439445;C3811844;C3812682
medications at baselinet,C0013227;C0802604;C2598133;C4284232
metforminmonotherapy,
metformin su tzd,C0025598;C0038642;C1705534
tah n $nmbr$,C0404079
ta n $nmbr$,C0039297;C1506978;C1705538;C3272501;C4553364
anthropometrics mean sd,C0444504;C2699239;C2347634;C2348143
vital signs mean sd,C0150404;C2699239;C0518766
baseline sitting sbp $nmbr$ mm hg,C0085805;C0439475
baseline sitting dbp mm hg,C0168634;C0439475;C1442488
comorbidity no,C0009488
dm or ckd,C0011816;C3250443;C1561643
female gender n,C0086287
crcl ml min mean sd,C0439445;C2699239
prespecified medical conditions n f,C0199168;C0016327;C0205476
cardiovascular disease n,C0007222
cancer n,C0006826;C0998265;C1306459
number of medications n,C1718138
aspirin use n,C0004057;C0042153;C0457083;C1947944
dose adjustment n,C2826232
dose adjustment reason $nmbr$ kg,C0022718;C0439209;C4054209
crcl $nmbr$ $nmbr$ ml min,C1846718;C0439445
p gp use,C0042153;C0457083;C1947944
two or more,C0205448
treatment duration mean sd,C0444921;C2699239;C3259042
unprovoked vte n,C0630906
index events dvt n,C0441471;C0149871;C2926618;C3899446;C3541888
extent of index dvt n of dvt patients,C0439792;C0030705
index events pe dvt n,C0070939;C0149871;C2926618;C3899446;C1880476;C4284304
extent of index pe n of pe patients,C0439792;C0030705
nt probnp $nmbr$ ng ml n,C4284038;C0439275
edoxaban n n rate,C0871208;C1521828
warfarin n n rate,C0871208;C1521828
primary efficacy outcome,C0205225;C1274040;C0439612;C0439631
recurrent vte during overall study period,C0630906;C0282416;C1561607
primary safety outcome,C0036043;C1274040;C1705187
major or clinically relevant non major bleeding,C0205082;C0205164;C4318856;C4521762;C0019080
net clinical benefit on treatment vte or major bleeding,C1516635;C0630906;C0205082;C0019080;C0205164;C4318856;C4521762
diabetes absent $nmbr$ $nmbr$ $nmbr$,C0011847;C0011849;C0332197;C4285062
diabetes present $nmbr$ $nmbr$ $nmbr$,C0150312;C0449450
median weight kg iqr,C0005910;C0022718;C0439209;C4054209;C0043100;C1305866;C1705104
median body mass index kg m $nmbr$ iqr,C0022718;C0439209;C4054209
medications before admission,C0013227;C0802604;C2598133;C4284232
at index event,C0441471;C4019010
diagnostic angiography,C0002978
laboratory values at admission median and iqr,C0022877;C0042295;C3244292;C4283904
no prior statin use,C0042153;C0457083;C1947944
high density lipoprotein cholesterol mg l,C0023822;C0439268
triglycerides mg l,C0041004;C0439268
creatine clearance ml min,C0373595;C0439445
laboratory values at randomization median and iqr,C0022877;C0042295;C3244292;C4283904
statin during admission,C0360714;C0184666;C0809949
no statin during admission,C0360714;C0184666;C0809949
km event at $nmbr$ y,C0441471;C4019010
primary end points,C0205225;C2349179;C0439612;C0439631
secondary end points $nmbr$,C0027627;C2349179;C0175668;C0205436
secondary end points ii,C1710602;C4082587
secondary end points iii,C0439070;C1705160
tertiary end points,C0205372;C2349179
alanine aminotransferase or aspartate aminotransferase $nmbr$ x upper limit of normal n $nmbr$,C0001899;C0057041;C1415274;C3887708;C0004002;C1519815
dm absent,C0011816;C3250443;C0332197;C4285062
dm present,C0150312;C0449450
cholecystectomy n $nmbr$,C0008320
gall bladder adverse event n $nmbr$,C0016976;C0877248
rhabdomyolysis n $nmbr$,C0035410;C4552660
rhabdomyolysis myopathy or elevated creatine phosphokinase $nmbr$ x upper limit of normal n $nmbr$,C0035410;C0026848;C4552660;C1519815
hemorrhagic stroke n $nmbr$,C0553692
cancer n $nmbr$,C0006826;C0998265;C1306459
e $nmbr$ n $nmbr$,
s $nmbr$ n $nmbr$,C2986823
e $nmbr$ s $nmbr$ n $nmbr$,C3846405
testing order,C1705175;C1705176;C1705177;C1705178;C1882348;C3889825;C4284072
hba $nmbr$ c change from baseline,C0392747;C0443172;C1705241;C4319952
e $nmbr$ s $nmbr$ vs s $nmbr$,C3846405
e $nmbr$ s $nmbr$ vs e $nmbr$,C3846405
body weight change from baseline,C0005911
fasting plasma glucose change from baseline,C0392747;C0443172;C1705241;C4319952
systolic blood pressure change from baseline,C1268766
hba $nmbr$ c patients,C0019016;C0030705;C1825777;C3538758
dynamic measure of cell function s change from baseline assessed for mmtt subset only,C0079809;C0242485;C0392747;C0443172;C1705241;C4319952;C1516048;C1515021
liraglutide $nmbr$,C1456408
hbaie mean sd,C0444504;C2699239;C2347634;C2348143
hbajc mmol mol mean sd,C3829066;C2699239
diabetes duration mean sd,C0011847;C2699239;C0011849
caleitonin ng l males mean sd,C0439297;C2699239
$nmbr$ $nmbr$ lo $nmbr$ $nmbr$,C0206579;C1232424
caleitonin ng l females mean sd,C0439297;C2699239
lo lo lo,C0206579;C1232424
egfr n normal egfr $nmbr$ ml min em^,C0205307;C0439445;C0231683;C0439166;C2347086;C4553972
mild impairment egfr $nmbr$ $nmbr$ ml min m^,C0221099;C0439445;C0684336
moderate impairment egfr $nmbr$ $nmbr$ ml min m^,C0205081;C0439445;C1881878;C4049705;C4049706;C4085643;C4321335
patients with established cv disease aged $nmbr$ years,C0683521
n patients with risk faetors for cv disease aged $nmbr$,C0030705;C0035647;C4552904;C0007222;C0001779;C0001792;C1999167
years n smoking n current,C0521116;C1705970
use of proton inhibitors n,C1524063;C0033727
use of h $nmbr$ bloekers n,C1524063;C0033727;C0369286;C0441932;C0564385;C4528284
history of thyroid disease n,C0683519;C0730226;C0850708;C0944983
ct calcitonin cv cardiovascular egfr estimated glomerular filtration rate hbalc glycated hemoglobin h $nmbr$ histamine $nmbr$ iqr interquartile range n number of patients sd standard deviation,C2986735;C0030705;C0871420
high uln,C0205250;C1519815;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
$nmbr$ ng l,C0439297
ulnand,
cdmard,
none cdmard naive or past use at baseline,C0042153;C0457083;C1947944;C0168634;C1442488
ixeq $nmbr$ w n $nmbr$,C0369718;C0441922
time since psa diagnosis years mean sd,C0556970;C0011900;C1704338;C1704656
tender joint count $nmbr$ joints mean sd,C0451530;C2699239
swollen joint count $nmbr$ joints mean sd,C0451521;C2699239
haq di total score mean sd,C2964552;C2699239
van der heijde mtss mean sd,C0444504;C2699239;C2347634;C2348143
figure $nmbr$ acr response rates at $nmbr$ weeks in patients treated with pbo ixeq $nmbr$ w or ixeq $nmbr$ w alone or in combination with cdmards or mtx the proportions of patients achieving acr $nmbr$ a acr $nmbr$ b and acr $nmbr$ c are shown,C0237629;C0439230;C0030705;C0332293;C0031962;C0205171;C0439044;C0679994;C0205195;C1947911;C3811910;C0025677;C1417487;C1709707;C1412134;C1515941;C1547282
overallb,
who fc ii symptoms at baseline,C0683368;C1457887
who fc iii symptoms at baseline,C0683368;C1457887
time since pah diagnosisc years,C0556970;C0030123;C3203102;C4284467
pah classification,C0008902;C0008903;C0678229
associated with ctd,C0332281;C1335071;C1442905
associated with corrected,C0332281;C0205202
congenital shunts,C0232180;C0542331;C1442858
associated with drug toxin,C0332281;C0013227;C1254351
exposure,C0274281;C0332157
p value for interaction $nmbr$,C1709380;C1704675
patients events n,C0030705;C0441471;C3541888
selexipag vs placebo hazard ratio $nmbr$ cl,C2000145;C2985465;C0596019
time to first morbidity mortality event up to the end of the treatment periodd,C0040223;C3541383;C0444930;C2746065
time to death due to pah or hospitalization due to pah up to the end of the treatment periodd,C1301931;C0030123;C3203102;C4284467;C0019993;C0678226;C0444930;C2746065
who fc ii symptoms at baselinef,C0683368;C1457887
time to all cause death up to end of the study,C1301931;C0444930;C2746065
who fc ii symptoms at baseline $nmbr$,C0683368;C1457887
open label population,C0032659;C1257890
randomize,
d population,C0032659;C1257890
demographic disease characteristics at baseline,C0599878
etn $nmbr$ mg mtx n $nmbr$,C0014758;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0717758
prior tobacco use n,C0040335;C0543414;C0841002;C3853727
acpa positive n,C0439178;C1446409;C1514241;C2825490;C3812269
clinical and patient reported characteristics at baseline and randomization,C0205210;C0815172;C4684572;C0034656
tjc $nmbr$ $nmbr$,
sjc $nmbr$ $nmbr$,
esr $nmbr$ $nmbr$ mm hour,C0439227;C0564385
pga $nmbr$ $nmbr$,C0016410;C3541266;C4050369
ptga $nmbr$ $nmbr$,
general health vas $nmbr$ $nmbr$ mm,C4330985;C4554674
pain vas $nmbr$ $nmbr$ mm,C4330985;C4554674
total haq $nmbr$ $nmbr$,C0102923;C0451208
radiographic characteristics at baseline and randomization,C0444708;C4684572;C0034656
mtss $nmbr$ $nmbr$,
fig $nmbr$ continuous and categorical baseline predictors of disease activity score based on $nmbr$ joints das $nmbr$ a simplified disease activity index sdai b and clinical disease activity index cdai c remission using univariate logistic regression unadjusted if the $nmbr$ ci does not contain the value $nmbr$ $nmbr$ the predictor is statistically significant at $nmbr$ $nmbr$ non significant predictors black significant predictors gray,C0349966;C1337208;C0549178;C0035648;C1527178;C1705938;C3869582;C3871128;C0544452;C1524063;C0206031;C1439367;C0008107;C3259781;C1518422;C0332256;C2700400;C1522609;C2698872;C0237881;C0005680;C0027567;C0085756;C0439541
mvd n $nmbr$ $nmbr$,C1417507;C3272839
no mvd n $nmbr$ $nmbr$,C1417507;C3272839
qualifying mi stemi,C1514624;C1536220;C3538872
figure $nmbr$ ef cacy of ticagrelor,C1419788;C3274822
supplementary figure s $nmbr$ mda response through $nmbr$ weeks by disease duration,C0871261;C1704632;C1706817;C2911692;C0872146
met atopy and ige $nmbr$ $nmbr$ ku l criteria n $nmbr$,C0392707;C3539705;C0439340;C0243161
did not meet atopy and ige $nmbr$ $nmbr$ ku lcriteriaa n $nmbr$ $nmbr$,C0392707;C3539705;C0022804;C1337080;C1532717;C1881335
ige high $nmbr$ ku l n $nmbr$ $nmbr$,C0205250;C0439340;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
igelow n $nmbr$ $nmbr$,
atopy n $nmbr$ $nmbr$,C0392707;C3539705
no atopy n $nmbr$,C0392707;C3539705
body mass index kg m $nmbr$ mean sd c,C0022718;C0439209;C4054209;C0444504;C2347634;C2348143
eosinophil count cells pl median range c,C0200638;C0750879
fev $nmbr$ pre bronchodilator l mean sd c,C2599602;C0444504;C2347634;C2348143
fev $nmbr$ pre bronchodilator predicted normal mean sd c d,C0520835;C2599602
reversibility median range c,C0449261;C0549183;C0876920;C2347635;C2348144;C2939193
exacerbations in previous $nmbr$ mo n mean sd,C4086268;C0026544;C0332177
acq $nmbr$ score mean sd e,C0449820;C0444504;C2347634;C2348143;C4050231
aqlq s $nmbr$ score mean sd c f,C0444504;C0016327;C2347634;C2348143
atopy by phadiatop test n,C0392707;C3539705
ige ku l median range c,C0439340;C0549183;C0876920;C2347635;C2348144;C2939193
nasal polyps n,C0027430
maintenance ocs use n,C0024501;C0042153;C0457083;C1947944
igehigh i $nmbr$ ku l n i $nmbr$,C0021966;C0439340;C0221138
igelow,
placebo n $nmbr$ i $nmbr$,C0021966;C0221138
annual asthma exacerbation rates,C0871208;C1521828
patients analyzed n,C0030705;C0936012
rate estimate $nmbr$ ci,C0008107;C3259781
i $nmbr$ $nmbr$ $nmbr$ i $nmbr$,C0021966;C0221138
i $nmbr$ i $nmbr$ $nmbr$ i $nmbr$,C0021966;C0221138
absolute difference estimate vs placebo $nmbr$ ci,C1549031;C0750572;C0008107;C3259781
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ i $nmbr$,C0021966;C0221138
rate ratio vs placebo $nmbr$ ci,C0871208;C0456603;C1547037;C1521828;C0008107;C3259781
$nmbr$ $nmbr$ $nmbr$ $nmbr$ i $nmbr$ $nmbr$,C0021966;C0221138
nominal p vs placebo,C0032042;C1696465;C1706408
pre bronchodilator fevi change,C2599602;C3481639
patients in analysis n,C0030705;C0002778;C0936012;C1524024
patients with eot data n,C2707520
ls mean difference vs placebo $nmbr$ ci,C0444504;C1705241;C1705242;C2347634;C2348143;C0008107;C3259781
$nmbr$ i $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0021966;C0221138
$nmbr$ i $nmbr$ $nmbr$ $nmbr$ i $nmbr$ $nmbr$,C0021966;C0221138
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ i $nmbr$ i,C0021966;C0221138
absolutedifferenceestimate vs placebo $nmbr$ ci,C0008107;C3259781
montelukast n $nmbr$,C0298130
lebrikizumab n $nmbr$,C2981360
pre bronchodilator fev $nmbr$,C2599602;C3714541
absolute litres,C0205344;C0475211
aqlq s score,C0449820;C4050231
median serum periostin ng mla,C0017887;C0599973;C0028074
median feno ppba,C0549183;C0876920;C2347635;C2348144;C2939193
median blood eosinophil count cells per pla,C0200638;C0456170
biomarker high periostin $nmbr$ ng ml or blood eosinophils $nmbr$ cells per pl na,C0005516;C0439275;C0005773
biomarker low periostin $nmbr$ ng ml or blood eosinophils $nmbr$ cells per pl na,C0005516;C0439275;C0005773
saba puffs per day at baseline,C1533107;C0332173;C0439228;C0439505;C0168634;C1442488
fig $nmbr$ absolute change in fev $nmbr$ from baseline at week $nmbr$ mitt patients top biomarker high group middle biomarker low group bottom,C0349966;C1549031;C1337208;C0168634;C1442488
ltg subgroup n $nmbr$,C1420817;C1079230;C1515021;C4521367;C4521846
tpm subgroup n $nmbr$,C0076829;C1079230;C1515021
brv overalla n $nmbr$,C0155502
whiteb,
regions n,C0017446;C0205147
age at time of first seizure,C0001779;C0036572;C1959629;C4553401
lev status,C0023556;C0449438
previous lev only,C0205156;C0023556;C1552607
number of concomitant aedsc,C0237753;C0449788
aed inducer status,C0887457;C0449438
no inducer at core study entry,C3898767;C0444669;C1167518;C1706352;C1882467;C3274653
no of prior aedsd,C0332152;C2826257
seizure types reported during baselinee,C0036572;C0332307;C1959629;C4553401;C0684224;C0700287;C4319718
type ia,C0020980;C0694634;C1947960
type ib,C2744579;C3890035;C4283819
type ic,C0020750;C4554818
$nmbr$ baricitinib $nmbr$ mg baricitinib $nmbr$ mg,C4044947;C1319635
baseline weight kg,C0022718;C0439209;C4054209
region pooled,C0017446;C0205147;C1709595;C2349200;C4522255
usa and canada,C0041703;C0006823
seropositivity,
rf or acpa positive,C0035448;C0201660;C0748398;C1547111;C0439178;C1446409;C1514241;C2825490;C3812269
rf and acpa negative $nmbr$,C0035448;C0201660;C0748398;C1547111;C0205160;C1513916;C2825415;C2825491;C3853545
no of prior bdmards,C0332152;C2826257
no of prior tnfi,C0332152;C2826257
prior tnfi treatment,C1514463
etn yes,C1549445;C1705108;C1710701
etn no,C0014758;C0717758
ada yes,C1549445;C1705108;C1710701
ada no,C1060325;C3811629
inflix yes,C1549445;C1705108;C1710701
inflix no,C0666743
no of non tnfi,C1518422
no of tnfi among non tnfi naive,C1518422
bdp ff g n $nmbr$,C0004906;C0439267;C1422585;C1538710
blood leukocyte count $nmbr$ cells per l,C0005771;C0009555
blood eosinophil count $nmbr$ cells per l,C0200638
blood eosinophil,C0014467
fev_ l,C3714541
proportion of predicted normal fev $nmbr$ value,C1709707;C0086715
clinical copd phenotype^,C0031437;C1285572
mixed chronic bronchitis and emphysema,C0205430;C0008677;C3160715;C0013990;C0034067
moderate or severe exacerbations in the previous year range,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C0205082;C4086268;C4050465;C4050466
copd medication taken for at least $nmbr$ months before st,C0013227;C3244316;C4284232;C1883727;C0439231;C0036056;C3272372
udy entry,C1705654
benign prostatic hyperplasia,C1704272
overall pp n $nmbr$,C0030375;C0063017;C4319755
sensitivity analyses,C0020517;C0036667;C0312418;C0427965;C1511883;C1522640;C2346484;C2349185
mar itt n $nmbr$,C3829202;C4255469
or itt n $nmbr$,
post bronchodilator fev $nmbr$ at screening,C2599594;C3714541;C0220908;C0220909;C1698960;C1710031;C1710032;C1710477;C2348164
males n $nmbr$,C0086582
females n $nmbr$,C0086287
ex smokers n $nmbr$,C0337671;C4555205
current smokers n $nmbr$,C3173209;C3241966
reversibility $nmbr$ n $nmbr$,C0449261
chronic bronchitis n $nmbr$,C0008677
emphysema n $nmbr$,C0013990;C0034067
mixed n $nmbr$,C0205430;C3160715
eosinophils $nmbr$ $nmbr$ x $nmbr$ $nmbr$ $nmbr$ n $nmbr$,C0014467;C0200638
prediabetese,
prior admb,C0332152;C2826257
no prior admc,C0332152;C2826257
all diabetesd,
dmab n $nmbr$,C0012411
white or caucasian n,C0007457;C0043157;C0220938
serum ctx i ng ml,C0631180;C0439275
$nmbr$ oh vitamin d ng ml,C0014695;C0439275;C0042866;C2936842;C3537249;C3714503
baseline use of adm n,C0168634;C1524063;C1442488
insulins,C0021641;C3537244;C4049919
a glucosidase inhibitors,C1512211
meglitinides glinides,C0065880;C3537178;C1579432
baseline numberf of adm classes n,C0168634;C0215825;C4521767;C1442488
all dulaglutide $nmbr$ $nmbr$ mg insulin lispro insulin glargine n $nmbr$,C0907402
insulin glargine insulin lispro award $nmbr$ n $nmbr$,C0293359
placebo insulin glargine award $nmbr$ n $nmbr$,C0907402;C0004446
ef $nmbr$ $nmbr$ hfmref n $nmbr$ $nmbr$,
ef $nmbr$ hfpef n $nmbr$ $nmbr$,
candesartan,C0717550
physical exam oedema,C0013604;C1717255
creatinine mg dl_,C0010294;C0439269;C1561535
hf cause,C0015127;C1524003
previous hf,C0018488;C1313497;C1538440;C3273279
af,C0344434;C4049859
other vasodilator,C0042402;C3537240
anti arrhythmic,C0003195;C3537142
ef $nmbr$ $nmbr$,
ef $nmbr$,
cv death hf hospitalization,C0011065;C0019993;C1306577;C4082313;C4552775
incidence rate,C1708485
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$ $nmbr$,
unadjusted irr,C1439367;C4082285
azl m $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
age mean sd yearsa,C0001779;C0444504;C2347634;C2348143
weight mean sd kgb,C0005910;C0043100;C1305866;C1705104
bmi mean sd kg m $nmbr$ c,C0444504;C1532718;C2347634;C2348143
concomitant medication n d,C0521115;C0013227;C3244316;C4284232
medication continued into double blind treatment period,C0013227;C3244316;C4284232;C0549178;C0013072
initiated use during double blind treatment period,C0042153;C0457083;C1947944
smoking classification n,C0008902;C0008903;C0678229
scsbp mean sd mmhge,C0444504;C2347634;C2348143
scdbp mean sd mmhgf,C0444504;C2347634;C2348143
prior stroke n $nmbr$,C0332152;C0038454;C4554100;C2826257
no prior stroke n $nmbr$,C0332152;C0038454;C4554100;C2826257
age median $nmbr$ th $nmbr$ th y,C0001779;C0039725;C0039738;C1420718;C4282123;C4285344
history of diabetes mellitus no,C0455488
prior mi within $nmbr$ y no,C0332152;C3810814;C2826257
history of pvd no,C4534349
history of hf or lvef b $nmbr$ with index event no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0428772;C0441471;C4019010;C0488728
history of impaired renal function no,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
no revascularization for index acs event no,C0581603;C0441471;C4019010
hf,C0018488;C1313497;C1538440;C3273279
revascularization history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
pci history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
cabg history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
acs management no,C0001554;C0376636;C1273870;C3273539
dual antiplatelet therapy,C0205173;C1096021;C1554184
cardiovascular death mi or stroke,C0007226;C3810814;C3887460;C0038454;C4554100
timi major minor bleeding,C4441842;C0019080
any bleeding,C0019080
all death,C0011065;C1306577;C4082313;C4552775
six study placebo controlled set,C0036849;C1442518;C1705195
ra beam,C0338248;C2347880;C4521565
all baricitinib ra n $nmbr$,C4044947;C3538806;C4048756
$nmbr$ years of age n,C1510829
tobacco use yes n,C0040335;C0543414;C0841002;C3853727
duration of rat years,C0449238;C2926735
central south america and mexico,C0007674;C0025885
asia excluding japan,C0003980;C0022341
hscrp mg l median first third quartiles,C0439268;C2828255
baricitinib $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
non statin n $nmbr$,C1518422;C0360714
patients with draining fistulae at baseline[n $nmbr$ ],C0030705;C0013103;C0180499;C4265177;C0016169;C0168634;C1442488;C0369718;C0441922
patients without draining fistulae at baseline[n $nmbr$ ],C0030705;C0013103;C0180499;C4265177;C0016169;C0168634;C1442488;C0369718;C0441922
vdz pbo [n $nmbr$ ],C0031962;C0369718;C0441922
vdz vdz [n $nmbr$ ],C0369718;C0441922
age [year] mean sda,C0001779;C0439234;C0439508;C0276477;C1428349;C1553165
male sex n [ ],C0086582
current smoker n [ ],C3173209;C3241966
disease duration [year] mean sda,C0872146;C0439234;C0439508;C0276477;C1428349;C1553165
cdai score mean sda,C0276477;C1428349;C1553165
crp [mg l] median,C3890735;C4048285;C0439268;C0549183;C0876920;C2347635;C2348144;C2939193
disease site n [ ],C0012634;C0205145;C1515974;C2825164
prior surgery for cd n [ ],C0455610;C0007928;C0034283;C4552032
prior tnf antagonist failure n [ ],C0231491;C0231174;C0680095
concomitant medication n [ ],C0521115;C0013227;C3244316;C4284232
cs,C0010182;C0271160;C3540510;C4085345
imm,C0205470
cs and imm,C0010182;C0271160;C3540510;C4085345;C0205470
neither cs nor imm,C0010182;C0271160;C3540510;C4085345;C0205470
history of fistulising disease n [ ],C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0012634
concomitant antibiotic use n [ ],C0003232;C0042153;C0457083;C1947944
number of draining fistulae per patient n,C0237753;C0449788;C0013103;C0180499;C4265177;C0016169;C0030705
[ ],
patients with perianal fistulae n [ ],C0030705;C0267561
psa ng ml,C3810537;C0439275;C3813209
drinker n,C0556338
ex drinker,C0337679
underlying disease,C4067746;C0012634
erectile dysfunction,C0242350;C1961100
pde $nmbr$ inhibitors,C0031638
irritative subscore,
obstructive subscore,C0549186
qol,C0518214
voided volume ml,C0439526;C1705224;C3887665
pvr ml,C0439526;C1705224;C3887665
tamsulosin $nmbr$ $nmbr$ mg vs placebo,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C1696465;C1706408
tamsulosin $nmbr$ $nmbr$ mg vs $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
t $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
week $nmbr$ baseline,C0168634;C1442488
ancova result,C1274040;C1546471;C2825142
ls mean difference se,C0023668;C0036919
participants with heart failure,C0679646;C0018801;C0018802;C4554158
participants without heart failure,C0679646;C0018801;C0018802;C4554158
p value heart failure vs no heart failure,C0018801;C0018802;C4554158
duration of diabetes mellitus y mean sd,C0449238;C2926735
microvascular disease history n,C0443258;C0683519
atherosclerotic vascular disease history n t,C0004153
cardiovascular disease history n,C1880008
history of amputation n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
ldl hdl cholesterol ratio mean sd,C0428621;C2699239
estimated glomerular filtration rate ml min $nmbr$ $nmbr$ m $nmbr$ mean sd,C3811844;C0439445;C0444504;C2699239;C2347634;C2348143
micro or macroalbuminuria n,C0085672;C1553035;C3811161;C4049106
concomitant drug therapies n,C0013216
renin angiotensin aldosterone system blocker,C0086907
glucagon like peptide $nmbr$ receptor agonist,C0014361;C4543206
patients per $nmbr$ patient years,C0030705;C0439234
ard $nmbr$ cl per $nmbr$ patient years,C0596019;C0030705
cardiovascular death or hospitalized hf,C0011065;C1306577;C4082313;C4552775;C0018488;C1313497;C1538440;C3273279
no history of hf,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
fatal or nonlatal myocardial inlarctlon,C1302234;C1705232;C0027061;C1522564
fatal or nonlatal stroke,C1302234;C1705232;C0038454;C4554100
serious decline in kidney function $nmbr$,C0205404;C0232804
number of previous anti tnf treatments for psa n,C0237753;C0449788;C1448177;C0087111
time since diagnosis of psa years mean sd,C0556970;C0011900;C1704338;C1704656
mtx use at randomization n,C0042153;C0457083;C1947944
systemic glucocorticoid use at randomization n,C0042153;C0457083;C1947944
patients with specific disease characteristics n,C0683521;C0815172
psoriasis $nmbr$ of bsa,C0033860
presence of dactylitis,C0150312;C0392148;C3854307
presence of enthesitis,C0150312;C0392148;C3854307
disease and quality of life scores mean sd,C0012634;C3476431;C2699239
pasia,
psa pain vas,C3810537;C0042815;C3813209
all doses n $nmbr$,C0178602
alcohol use $nmbr$ day,C0332173;C0439228;C0439505
daily exercise,C0015259;C1522704
impaired fasting glucose $nmbr$ mg dl,C1272092;C0439269
canakinumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
all canakinumab,C2718773
n events n at risk,C0369718;C0441471;C3541888;C0441922;C1444641
hazard ratio $nmbr$ ci vs placebo,C0008107;C3259781;C0032042;C1696465;C1706408
p value vs placebo,C1709380;C0032042;C1696465;C1706408
baseline prediabetes,C0168634;C0362046;C1442488
baseline normoglycemia,C0168634;C1442488
hazard ratio vs placebo,C2985465;C0032042;C1696465;C1706408
p heterogeneity,C0019409;C0242960
hazard ratio $nmbr$ ci for adjudicated type $nmbr$ diabetes,C0008107;C3259781
risk marker and model,C1519104;C3161035;C3274659;C3714583;C3853906
hscrp range mg l,C1514721;C0439268;C2348147;C3542016
model $nmbr$ t,C3161035;C3274659;C3714583;C3853906
il $nmbr$ range ng l,C0020898;C0439297;C0021764;C0022271
czp $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
week $nmbr$ czp $nmbr$ mg q $nmbr$ w n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
pbo czp $nmbr$ mg q $nmbr$ w week $nmbr$ n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
demographic characteristics mean sd unless otherwise indicated,C0683970;C2699239;C1444656
mean sd unless otherwise indicated,C0444504;C2699239;C2347634;C2348143;C1444656
time from psoriatic arthritis diagnosis [a] years,C0040223;C3541383;C0439234
crp mg l [b] median min max,C3890735;C0439268;C4048285;C0549183;C0702093;C1524029;C3813700;C0876920;C2347635;C2348144;C2939193
tender joint count $nmbr$ $nmbr$ joints,C0451530
swollen joint count $nmbr$ $nmbr$ joints,C0451521
psoriasis bsa $nmbr$ n,C0033860
pasi [c] median min max,C4528685;C0549183;C0702093;C1524029;C3813700;C0876920;C2347635;C2348144;C2939193
prior use of synthetic dmards n,C1524063;C0242708
concomitant use of nsaids to week $nmbr$,C1524063;C0003211;C0332174;C0439230
prior anti tnf exposure,C0332152;C2826257
concomitant use of mtx to week $nmbr$,C1524063;C0025677;C1417487;C0332174;C0439230
week $nmbr$ czp $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
week $nmbr$ czp dose combined,C0178602;C0869039;C1114758;C0205195
pbo to czp week $nmbr$ dose combined,C0031962;C0054841;C1861828;C1872109;C0205195
baseline mtss subgroup,C1079230;C1515021
mtss at baseline observed case,C0168634;C0868928;C1706255;C1706256;C1442488
n observed,C0369718;C0441922;C1441672
[min max],C0702093;C1524029;C3813700
mmrm estimates ls mean se [ $nmbr$ ci],C0008107;C3259781
mtss at,
czp baseline,C0168634;C1442488
cfb at week $nmbr$,C0009002;C1824728
observed case,C0868928;C1706255;C1706256
rate of non progression defined as cfb in mtss $nmbr$ $nmbr$ n n,C0871208;C1521828;C1704788;C3539106
rate of non progression defined as cfb in mtss $nmbr$ n n,C0871208;C1521828;C1704788;C3539106
blisibimod n $nmbr$,C3713826
gender female male,C0086582;C1706180;C1706428;C1706429
central and south america,C0205099;C1879652;C0037713
selena sledai mean score sd,C3533236;C2699239
selena sledai activity n,C0205177;C0439167;C0441655;C1561536;C3668946;C4049938;C4049939
total score $nmbr$,C2964552
dermal,C0221928;C1522447
bilag a b or c domain score n,C1880389;C0449820;C4050231;C1883221;C3541951
haematological,
pga score mean sd,C0016410;C2699239;C3541266;C4050369
pga score range,C1514721;C2348147;C3542016
corticosteroid dose prednisone,C0001617;C0032952;C3536709
dose equivalent mg sd,C0024671;C2699239;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
smedian prednisone dose n,C0032952;C0178602;C0869039;C1114758
systemic sle medications n,C0024141;C0013227;C0802604;C2598133;C4284232
any including corticosteroid,C0001617;C3536709
antimalarial,C0003374;C3536844;C4552582
mycophenolate any derivative,C0883242;C1527240
sle markers n,C0024141;C0005516
anti dsdna positive,C0439178;C1446409;C1514241;C2825490;C3812269
low c $nmbr$ c $nmbr$ and anti dsdna,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223;C0012854;C0311474
upcr n,
s $nmbr$ $nmbr$ mg mmol,C0567349;C2348885
s $nmbr$ mg mmol,C0567349;C2348885
patients without diabetes,C0030705;C0011847;C0011849
patients with diabetes,C0030705;C0011847;C0011849
previous hospital admission for heart failure,C0184666;C0018801;C0018802;C4554158
ntprobnp pg ml,C0669479;C0439297;C0754710
treatments at randomisation,C0087111;C0034656
difference $nmbr$ ci p value,C0008107;C1709380;C3259781
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ p,C0369773;C2603361
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ p $nmbr$ $nmbr$,C0369773;C2603361
characteristic outcome,C1521970;C1274040
nonblack n $nmbr$,
standardized mean difference,C0444504;C1705241;C1705242;C2347634;C2348143
bnp nt probnp,C0669479;C0754710
qrs duration ms,C2349943;C3539704;C3713294
egfr ml kg per $nmbr$ $nmbr$ m $nmbr$,C1739039;C1300574;C3811844;C3812682
hf signs and symptoms,C0220912;C0220913;C0311392;C0683368;C1457887
paroxysmal nocturnal dyspnea,C1956415
not present at screening but within previous year,C0150312;C0449450;C0205156;C0439234;C0439508;C1552607
present at screening,C0150312;C0449450
chest x ray,C0039985
comorbid illnesses,C0221423
any cvd history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
insulin treated dm,C0011816;C3250443
non insulin treated dm,C0011816;C3250443
adjusted hazard ratio,C0456081;C2985465
outcomes by treatment spironolactone vs placebo,C0085415;C0037982;C0032042;C1696465;C1706408
black n $nmbr$ adjusted hazard ratio,C0456081;C2985465
nonblack n $nmbr$ adjusted hazard ratio,C0456081;C2985465
sc belimumab $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
sri $nmbr$ response rate,C1420401;C0237629
$nmbr$ point reduction in selena sledai score,C0301630;C0392756;C1293152;C4551656
no worsening in pga,C0332271;C0016410;C3541266;C4050369;C1457868;C1546960
no new a or and no more than $nmbr$ new bilag b domain score,C0205314;C0449820;C4050231
baricitinib $nmbr$ mg qd,C0024671;C0332173;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
us w $nmbr$,C0815353;C3889164
row n $nmbr$,C1552840;C1552846
body mass index kg m^ mean sd,C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
time from symptom onset of ra years median,C1320528
time from ra diagnosis years median,C0556970;C0011900;C1704338;C1704656
seropositivity status n,C0449438
rf and acpa positive n,C0035448;C0201660;C0748398;C1547111;C0439178;C1446409;C1514241;C2825490;C3812269
rf negative and acpa positive n,C0205160;C1513916;C2825415;C2825491;C3853545;C0439178;C1446409;C1514241;C2825490;C3812269
rf positive and acpa negative n,C0439178;C1446409;C1514241;C2825490;C3812269;C0205160;C1513916;C2825415;C2825491;C3853545
rf and acpa negative n,C0035448;C0201660;C0748398;C1547111;C0205160;C1513916;C2825415;C2825491;C3853545
no of previous csdmards n,C0205156;C1552607
current corticosteroid use n,C0521116;C0239126;C1705970
mtx average weekly dose mg week mean sd,C0366550;C2699239
tender joint count $nmbr$ mean sd,C0451530;C2699239
swollen joint count $nmbr$ mean sd,C0451521;C2699239
patient global assessment of disease activity mean sd,C4054228;C0444504;C2347634;C2348143
patient assessment of pain $nmbr$ $nmbr$ mm mean sd,C0679830
physician global assessment of disease activity mean sd,C4050369;C0444504;C2347634;C2348143
hscrp mean sd,C0444504;C2699239;C2347634;C2348143
das $nmbr$ hscrp mean sd,C0051767;C2699239;C0057671
esr mm h mean sd,C0456680;C2699239
bone erosion score mean sd,C0587240;C2699239
joint space narrowing score mean sd,C1859695;C2699239
table baseline characteristics by study and blood pressure intervention in participants with baseline egfr $nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$ or higher,C4684572;C0184661;C0886296;C1273869;C0168634;C0439445;C1442488;C0205250
data are number of patients mean sd or median iqr accord action to control cardiovascular risk in diabetes acr albumin creatinine ratio egfr estimated glomerular filtration rate mdrd modification of diet in renal disease n a not applicable n r not reported sprint systolic blood pressure intervention trial defined in the accord trial as one or more of myocardial infarction stroke angina coronary artery bypass graft percutaneous transluminal coronary intervention or other revascularisation procedure defined in sprint as one or more of myocardial infarction acute coronary syndrome coronary revascularisation carotid revascularisation peripheral arterial disease with revascularisation greater than $nmbr$ stenosis of coronary carotid or lower extremity artery or abdominal aortic aneurysm $nmbr$ mm or larger $nmbr$ participants assigned the standard intervention and $nmbr$ allocated the intensive intervention had a fasting plasma glucose greater than $nmbr$ $nmbr$ mmol l at baseline estimated by four variable mdrd equation,C1511726;C3245479;C3714741;C2360800;C0444504;C2347634;C2348143;C0441472;C3266814;C0086153;C3671772;C0022658;C0205090;C0684010;C2603358;C0814861;C1704788;C3539106;C0205447;C0010055;C1260596;C0184661;C2700391;C3274430;C3539779;C0948089;C0085096;C1704436;C0581603;C0439093;C0007282;C0226415;C4330985;C4554674;C0549177;C0679646;C1704243;C1516050;C1552601;C0886296;C1273869;C0202042;C0455280;C1532563;C0168634;C1442488;C0750572;C0205450
accord trial,C0680240;C0008976
sprint,
intensive n $nmbr$,
clinical atherosclerotic disease,C0205210;C0012634
antihypertensive agents n per patient,C0003364
n r,C0205090;C0684010;C2603358
urinary acr mg mmol,C0567349;C2348885
sprint acr,C1412134;C1515941
sprint acr $nmbr$ $nmbr$,C1412134;C1515941
accord acr,C1412134;C1515941
accord acr $nmbr$ $nmbr$,C1412134;C1515941
absolute risk difference $nmbr$ cl,C1549031;C0596019
sustain $nmbr$,C0443318;C2732140
pooled analysis of sustain $nmbr$ $nmbr$ trials,C0002778;C0936012;C1524024;C0443318;C2732140;C0008976
semaglutide,C3885068
semaglutide $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
exenatide er,C3810541;C3811131
placebo add on to basal insulin,C1883712;C0650607
elderly,C0001792;C1999167
bw kg,C0022718;C0439209;C4054209
mdrd egfr ml min $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
blood pressure mmhg systolic,C0005823;C0039155;C1271104;C1272641
dyspnea mmrc grade n,C0013404;C0441800;C0919553;C3244287;C1963100
number of patients with exacerbations in the previous $nmbr$ months n,C2360800;C4086268;C0205156;C1552607
ccq total score,C2964552
tofacitinib $nmbr$ mg bid n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
induction study treatment,C4049995
in remission at maintenance study baseline,C0544452;C0687702
ibdq total score,C2964552
baseline crp category mg l,C0168634;C0439268;C1442488
prior anti tnf treatment,C1514463;C1448177
prior anti tnf failure,C0332152;C2826257
prior immunosuppressant failure,C0231174;C0680095
prior corticosteroid treatment,C1514463;C0001617;C3536709
steroid use at baseline mg day,C0281991;C0439422
subsets,C1515021
dose mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
semaglutide exposure nmol l,C0274281;C0439282;C0332157
mean change from baseline points,C0392747;C0443172;C1705241;C4319952
mean $nmbr$ ci change from $nmbr$ $nmbr$ to $nmbr$ $nmbr$ mg points,C0392747;C0443172;C1705241;C4319952;C1552961;C2347617;C3714763
mean change from baseline,C0392747;C0443172;C1705241;C4319952
mean $nmbr$ ci change from $nmbr$ $nmbr$ to $nmbr$ $nmbr$ mg,C0392747;C0443172;C1705241;C4319952;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
$nmbr$ participants,C0679646
with highest bwa,C1522410;C0006041
with lowest bwb,C1708760
with highest hba $nmbr$ cc,C0008318;C3538933
with lowest hba $nmbr$ cd,C0007928;C0034283;C4552032
sustain $nmbr$ semaglutide vs placebo,C0443318;C2732140;C3885068;C0032042;C1696465;C1706408
sustain $nmbr$ semaglutide vs sitagliptin $nmbr$ mg,C0443318;C2732140;C3885068;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
sustain $nmbr$ semaglutide vs exenatide er $nmbr$ $nmbr$ mg,C0443318;C2732140;C3885068;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
sustain $nmbr$ semaglutide vs iglar,C0443318;C2732140;C3885068
sustain $nmbr$ semaglutide add on to insulin vs placebo,C0443318;C2732140;C1883712;C0021641;C1533581;C1579433;C3714501;C0032042;C1696465;C1706408
$nmbr$ wk,C0332174;C0439230
baseline characteristics mean sd a,C4684572;C2699239
subject disposition n,C0681850;C0743223;C1705555;C1550501;C1706203;C2349001;C2697811
exposed,C0332157
trial completers,C0008976
premature treatment discontinuation,C0457454;C1444662;C4552847
subjects with imputed value for end of treatment body weight,C0681850;C1550501;C1706203;C2349001;C2697811;C2983672;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
adverse events any grade,C0877248;C1705413;C0441800;C0919553;C3244287
gastrointestinal disorders,C0017178
adverse events leading to premature treatment discontinuation,C0877248;C1705413;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
nausea and or vomiting adverse events,C0027497;C1963179;C2984057;C3829611;C4084796;C4085222;C4085661;C4085862;C4255480;C4552888;C4552889;C4553767;C0877248;C1705413
participants with a history of cabg,C0679646;C0010055
participants without a history of cabg,C0679646;C0010055
time since cabg,C0040223;C3541383
cv disease,C0007222
history of strokea,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
peripheral artery diseaseb,C0489868
single vessel coronary artery diseasea,C0265903;C0005847
cardiac failurec,C0018787;C1522601
hba $nmbr$ c mmol mold,C0019016;C0369241;C1825777;C3538758
hba $nmbr$ c d,C0019016;C1825777;C3538758
angiotensin converting enzyme inhibitor angiotensin receptor blocker,C0034787;C1622222
renin inhibitor,C1960108;C3537174;C4521920
total cholesterol mmol le,C0023190;C0439090;C1423767;C2697858
ldl cholesterol mmol lf,C1416933;C2986618;C4554443
hdl cholesterol mmol le,C0023190;C0439090;C1423767;C2697858
triacylglycerol mmol le,C0023190;C0439090;C1423767;C2697858
egfr mdrd ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
empagliflozin n with event n,C3490348;C0441471;C4019010
placebo analysed,C0032042;C1696465;C1706408
all participants history of cabg,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
three point mace,C0349381;C0949745;C1445339
fatal or non fatal myocardial infarction,C1302234;C1705232;C0027051;C0428953;C2926063;C3810814;C4552959
fatal or non fatal stroke,C1302234;C1705232;C0038454;C4554100
hospitalisation for heart failure,C3898876
heart failure hospitalisation or cv death,C3898876;C0011065;C1306577;C4082313;C4552775
incident or worsening nephropathy,C1551358;C0332271;C1457868;C1546960;C0022658
placebo $nmbr$ $nmbr$ ml n $nmbr$,C0032042;C0439526;C1705224;C3887665;C1696465;C1706408
dupiiumab $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
prebronchodilator fevi liters,C0429706;C0475211;C0849974;C1561566;C4528367
percent of predicted normal value,C1882327
fevi reversibility,C3830088
no of exacerbations in past year,C4086268;C0439234;C0439508
use of high dose inhaled glucocorticoid no,C1524063;C0444956
ongoing atopic or allergic condition no,C0549178;C0392707;C0851444
nasal polyposis or chronic rhinosinusitis no,C0027430;C0149516
no of pack yr,C1968515;C0439234;C2825051;C2828395
biomarker levels,C0005516;C0441889
blood eosinophil count cells mm,C4330985;C4554674
feno ppb,C1415800
total ige lu ml,C0439175;C2697941;C0439810
relative risk vs placebo $nmbr$ cl,C0242492;C0032042;C0596019;C1696465;C1706408
dupilumab $nmbr$,C3660996
$nmbr$ cells mm^,C4330985;C4554674
$nmbr$ ppb,C1415800
eosinoohil count,C0750480;C1705566
gene,C0017337
snp,C0752046;C1527094
short term n $nmbr$,C0443303
long term n $nmbr$,C0443252
p $nmbr$ cl,C0369773;C0596019;C2603361
octi,
rs $nmbr$,C0035970;C3714753;C3813325
atm locus,C3711796;C1708726
atm locm,C3711796
ocn,C1412791;C2347392
octi mate $nmbr$,C0682323;C1260875
short term^,C0443303
long term,C0443252
rs $nmbr$ rs $nmbr$,C0035970;C3714753;C3813325
rs $nmbr$ aa rs $nmbr$,C0035970;C0282379;C1235746;C1882141;C4554792;C3714753;C3813325
rs $nmbr$ ac rs $nmbr$,C0001246;C0003354;C1412573;C2000891;C3539770
rs $nmbr$ cc rs $nmbr$,C0035970;C0008318;C3538933;C3714753;C3813325
active canakinumab n $nmbr$ $nmbr$,C0205177;C2718773;C3853793;C3888249
serum creatinine mol l,C0201976;C0347982;C0600061
serum albumin g l,C0439294;C0456615
serum calcium mmol l,C0036785;C1532563;C0728876
serum phosphate mmol l,C0036820;C1532563
protein in urine $nmbr$,C0033687
glucose in urine $nmbr$,C0004076
urine albumin creatinine ratio mg mmol,C0567349;C2348885
canakinumab dose,C0178602;C0869039;C1114758
ptrend across doses,C0178602
all doses,C0178602
incidence rate n,C1708485
uacr $nmbr$ mg mmol,C0567349;C2348885
figure $nmbr$ clinical remission from week $nmbr$ through week $nmbr$ of treatment among a all randomised patients entering the long term extension and b by induction study subgroups sc subcutaneous tnf tumour necrosis factor q $nmbr$ w every $nmbr$ weeks q $nmbr$ w every $nmbr$ weeks,C0205210;C0544452;C0687702;C0332174;C0439230;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0030705;C1522196;C0443252;C0231448;C1880641;C0033453;C0046774;C1824728
tnf antagonist naive,C1448177;C0231491
tnf antagonist exposed,C1448177;C0231491;C0332157
vedolizumab n $nmbr$,C2742797
age y median min max,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
weight kg median min max,C0005910;C1532757;C0043100;C1305866;C1705104
duration of disease y median min max,C0872146;C0549183;C0876920;C2347635;C2348144;C2939193
complete mayo clinic score median min max,C0205197;C0002424;C0442592;C0725685;C3853530;C4283785
history of elms n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
elms n,C0330531;C2980688
concomitant medications yes n,C0521115;C0013227;C0802604;C2598133;C4284232
imm only,C0205470
no cs and imm,C0010182;C0271160;C3540510;C4085345;C0205470
type of tnf antagonist failure n o,C0332307;C1547052
weight kg median m n max,C0549183;C0876920;C2347635;C2348144;C2939193;C0369718;C0441922
disease duration y median m n max,C0549183;C0876920;C2347635;C2348144;C2939193;C0369718;C0441922
cdai score median min max,C0449820;C0549183;C0876920;C2347635;C2348144;C2939193;C4050231
prior surgery for cd n,C0455610;C0007928;C0034283;C4552032
history of fistullzing disease n,C0683519;C0730226;C0850708;C0944983
draining fistulae n,C0013103;C0180499;C4265177;C0016169
type of tnf antagonist failure n,C0332307;C1547052
inadequate response ^,C0871261;C1704632;C1706817;C2911692
loss of response s,C1517945;C0871261;C1704632;C1706817;C2911692
figure $nmbr$ rbs and sfs in patients with uc percentage change from baseline in rbs in the overall itt a tnf antagonist naive b and tnf antagonist exposed c populations and in sfs in the overall itt d tnf antagonist naive e and tnf antagonist exposed f populations after vdz or pbo administration adata points represent adjusted change from bl mean where adjustment is for subscore bl value and treatment error bars represent se bdifference adjusted o f c $nmbr$ h $nmbr$ a ngcei[vd $nmbr$ z i npdibcoat]e s asdtajutisstteicdalmseiagnni change from bl for vdz adjusted mean change from bl for pbo upper limit cance at a nominal signi cance level of $nmbr$ $nmbr$ statistical signi cance and non signi cance patients with baseline rbs $nmbr$ or sfs $nmbr$ were excluded from this analysis of note the number of patients varies per study population at weeks $nmbr$ $nmbr$ and $nmbr$ and is reported below the x axis bl baseline ci con dence interval itt intent to treat ns nonsigni cance pbo placebo rbs rectal bleeding subscore sfs stool frequency subscore vdz vedolizumab,C0392475;C0030705;C0392747;C0443172;C1705241;C4319952;C0282416;C1561607;C3887647;C0231491;C2348484;C1448177;C0016327;C1552961;C2347617;C3714763;C1882932;C0376209;C0456081;C0683269;C0005918;C0006413;C1552663;C2827109;C0679862;C1707156;C3274014;C3541345;C0033727;C0369286;C0441932;C0564385;C4528284;C0036916;C0021966;C0221138;C0031962;C0557837;C0038215;C1829939;C0168634;C1442488;C0332196;C1554077;C2828389;C2360800;C1548673;C2348561;C0439230;C0684224;C0700287;C4319718;C0018932;C2742797;C0267596
figure $nmbr$ proportion of patients with uc who achieved the composite score rbs $nmbr$ and sfs $nmbr$ indicate statistical significance at a nominal significance level of $nmbr$ $nmbr$ statistical significance and nonsignificance cl confidence interval ns nonsignificance pbo placebo rbs rectal bleeding subscore sfs stool frequency subscore vdz vedolizumab,C1709707;C0030705;C3272598;C4055211;C0392475;C0814896;C0237881;C1709380;C0009667;C2742797
figure $nmbr$ abdominal pain subscores in patients with cd percentage change from baseline in aps in overall itt a tnf antagonist naive s and tnf antagonist exposed c populations and percentage change from baseline in lsfs in overall itt d tnf antagonist naive and tnf antagonist exposed f populations after vdz or pbo administration data points represent adjusted change from bl mean where adjustment is for subscore bl value and treatment error bars represent se difference adjusted change [vdz pbo] adjusted mean change from bl for vdz adjusted mean change from bl for pbo upper limit of $nmbr$ cl,C0000737;C4554323;C0392747;C0443172;C1705241;C4319952;C0001468;C1706670;C1448177;C0231491;C2348484;C0243902;C1456377;C3538776;C0016327;C1552961;C2347617;C3714763;C1882932;C0376209;C0456081;C0683269;C0005918;C0006413;C1552663;C2827109;C0679862;C1707156;C3274014;C3541345;C0031962;C1282910;C0439801;C1549649;C2349209
figure $nmbr$ combined score of abdominal pain and loose stool frequency in patients with cd percentage change from baseline in aps and lsfs in the overall itt a tnf antagonist naive s and tnf antagonist exposed c populations after vdz or pbo administration data points represent adjusted change from bl mean where adjustment is for subscore bl value and treatment error bars represent se difference adjusted change [vdz pbo] adjusted mean change from bl for vdz adjusted mean change from bl for pbo upper limit of $nmbr$ cl,C0582148;C0376249;C0439603;C0871396;C1561548;C1705502;C3898838;C4321352;C0392747;C0443172;C1705241;C4319952;C0001468;C1706670;C0243902;C1456377;C3538776;C1448177;C0231491;C2348484;C1552961;C2347617;C3714763;C1882932;C0376209;C0456081;C0683269;C0005918;C0006413;C1552663;C2827109;C0679862;C1707156;C3274014;C3541345;C0031962;C1282910;C0439801;C1549649;C2349209
figure $nmbr$ proportion of patients with cd gemini $nmbr$ and $nmbr$ who achieved the average daily composite score of aps $nmbr$ indicate statistical significance at a nominal significance level of $nmbr$ $nmbr$ statistical significance and nonsignificance aps abdominal pain subscore cl confidence interval lsfs loose stool frequency subscore ns nonsignificance pbo placebo vdz vedolizumab,C1709707;C0030705;C0007928;C0034283;C4552032;C3272598;C4055211;C0001468;C1706670;C0814896;C0237881;C1709380;C0518090;C2742797;C4082250
tnf na ve,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882
pain vas mean change from baselinea,C0392747;C0443172;C1705241;C4319952
sf $nmbr$ bodily pain mean change from baselineb,C0392747;C0443172;C1705241;C4319952
eq $nmbr$ d $nmbr$ l no pain or discomfortc,C0205163;C0439185;C0439394;C1706495;C3642217;C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
tnf ir,C0022065;C0022071;C1448132
pain vas mean change from baselined,C0392747;C0443172;C1705241;C4319952
sf $nmbr$ bodily pain mean change from baselinee,C0392747;C0443172;C1705241;C4319952
eq $nmbr$ d $nmbr$ l no pain or discomfortf,C0205163;C0439185;C0439394;C1706495;C3642217;C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132
low nfs nfs,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223
indeterminate nfs $nmbr$ $nmbr$ nfs,C0205258;C1555018
high nfs nfs $nmbr$ $nmbr$ n $nmbr$,C0205250;C1513839;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
p value low vs high nfs^,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223;C0205250;C1555018;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
p j $nmbr$ trend,C1521798;C4554533
body mass index kg m^^,C0022718;C0439209;C4054209
ezetimibe simvastatin group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
past cardiovascular history no,C1880008
any lipid lowering agent use,C0042153;C0457083;C1947944
at index event no,C0441471;C4019010
diagnostic catheterization,C0596429
prerandomization pci,C4049621
laboratory parameters median iqr,C0022877;C0449381;C3244292;C4283904
alanine aminotransferase u l,C0001899;C0439339;C0057041;C1415274;C3887708
aspartate aminotransferase u l,C0004002;C0439339
gamma glutamyltransferase u l,C0017040;C0439339
c reactive protein u l,C0006560;C0439339;C1413716;C4048285
platelets xlooo mm^,C4330985;C4554674
total cholesterol mg dl ^,C0201950;C0439269;C0543421
hemoglobin ale,C0678386;C2632076
outcome n,C1274040
high nafld fibrosis score nfs $nmbr$ $nmbr$,C1954436;C1555018;C1954437
low nafld fibrosis score nfs $nmbr$ $nmbr$,C1954436;C1555018;C1954437
placebo simva,C0032042;C1696465;C1706408
death from cv causes major coronary event or nonfatal stroke,C0376297;C0038454;C4554100
secondary endpoints,C4528314
$nmbr$ death from any cause major coronary event or nonfatal stroke,C0007465;C0376297;C0038454;C4554100
ii death from coronary heart disease nonfatal mi coronary revascularization $nmbr$ days,C0376297
iii death from cv causes nonfatal mi hospitalization for ua all revascularization $nmbr$ days nonfatal stroke,C0007465;C0019993;C0041580;C0042014;C0038454;C4554100
tertiary endpoints,C0205372;C2349179
death from coronary heart disease,C0376297
urgent coronaiy revascularization $nmbr$ days,C0439609;C0439228;C3272275
clinical endpoint,C2347784
km rates p s,C0234833;C0722388
km rates e s,C3887676;C0871208;C1521828
hr $nmbr$ c,
primary endpoint^,C2986535
nfs,C1555018
nfs $nmbr$ $nmbr$ high,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
secondary p,C0027627;C0175668;C0205436
secondary ip,C1308226;C4049997
secondary iii,C0439070;C1705160
p inte faction,C0369773;C2603361
upa $nmbr$ mg qd,C0024671;C0332173;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
characteristic_name,C0027365;C1547383;C4522128
characteristic_level,C0441889;C0456079;C1547707;C2946261
n america,C0369718;C0002454;C0441922
placebo n l $nmbr$,C0032042;C1696465;C1706408
upadacitinib $nmbr$ mg n l $nmbr$,C0439268
time since rheumatoid arthritis diagnosis years,C0556970;C0003873
u $nmbr$ $nmbr$ $nmbr$,C0439148
tj $nmbr$,C0039247
age years geographical distribution of patients,C0001782
previous bdmard received,C0205156;C1552607;C1514756
stratum $nmbr$ inadequate response or intolerance to $nmbr$ $nmbr$ bdmards of same moa,C0871261;C1704632;C1706817;C2911692;C0231199;C1744706;C2355652
stratum $nmbr$ inadequate response or intolerance to $nmbr$ bdmards of same moa or $nmbr$ of multiple moa,C0871261;C1704632;C1706817;C2911692;C0231199;C1744706;C2355652;C0439064;C4551881
inadequate response or intolerance to $nmbr$ anti tnfdrug,C0871261;C1704632;C1706817;C2911692;C0231199;C1744706;C2355652
lack of efficacy with $nmbr$ bdmard,C0235828
lack of efficacy with $nmbr$ anti interleukin $nmbr$,C0235828;C0021764;C1527200
t] $nmbr$,C2603360
csdmard use at baseline^,C0042153;C0457083;C1947944
methotrexate alone^,C0025677;C0205171;C0439044;C0679994
methotrexate plus other csdmardfl,C0025677
methotrexate dose mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
csdmard otherthan methotrexate,C0025677
chloroquine,C0008269
oral glucocorticoid use,C1527415;C0017710
oral glucocorticoid dose mg prednisone equivalent,C0205163;C0439185
rheumatoid factor and acpa positive,C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269
rheumatoid factor or acpa positive or both,C0035448;C0201660;C0439178;C1446409;C1514241;C2825490;C3812269
patient s ga $nmbr$ $nmbr$ mm vas,C0030705;C0042815;C3536884;C3827561
physician s ga $nmbr$ $nmbr$ mmvas,C0031831;C0804815;C0016993
clinical disease activity index,C3869583
morning stiffness severity $nmbr$ $nmbr$ scale,C0175659;C0349674;C1947916
morning stiffness duration min,C0702093;C1524029;C3813700
uniti $nmbr$ and uniti $nmbr$ im uniti,
ustekinumab n $nmbr$,C1608841
cd duration y,C0007928;C0034283;C4552032
involved gl areas,C1879646;C0018229;C1423073;C1427674
ileum only n,C0020885;C0369718;C0441922
colon only n,C0009368;C3888384;C0369718;C0441922
ileum and colon n,C0020885;C0009368;C3888384
proximal gl tract n,C0205107;C0018229;C1423073;C1427674;C4489236
perianal n,C0442158
cd complications,C0009566;C1171258
intra abdominal abscess past,C0243001
sinus tracts perforation ^ n,C0854572
fistula n,C0016169
bowel stricturing n,C0021853;C4083257;C1261287;C0369718;C0441922
patients with evaluable endoscopy,C2986511;C0014245
data n,C1511726;C3245479;C3714741
patients with eligible ses cd score,C0030705;C0007928;C0034283;C4552032
or ulcerations n,C0041582
ses cd mean sd,C0007928;C2699239;C0034283;C4552032
endoscopic disease severity,C0014245;C0521117;C0442418
total ses cd score at,C2964552;C0007928;C0034283;C4552032
baseline of induction n,C0168634;C1442488
mild $nmbr$ $nmbr$,C2945599
patients who had ulcerations at,C0030705;C3272598;C0041582
baseline of induction,C0168634;C1442488
lieum only n,C0369718;C0441922
ileum ses cd score mean sd,C0007928;C2699239;C0034283;C4552032
colon ses cd score mean sd,C0007928;C2699239;C0034283;C4552032
figure $nmbr$ endoscopy as sessments at week $nmbr$ pooled ustekinumab vs placebo a by induction study b randomized pa tients with eligible ses cd score or ulcerations at in duction baseline note $nmbr$ pooled ustekinumab group comprises patients receiving ustekinumab $nmbr$ mg and tiered ustekinu mab doses approximating $nmbr$ mg kg combined for analyses patients who prior to the designated analysis timepoint had a cd related surgery due to lack of ef cacy or had an initiation of speci ed prohibited medication had their baseline value carried forward or were considered to not have mucosal healing patients with missing segments at the designated analysis timepoint had their base line score or ulceration status at baseline for the missing segment s carried forward $nmbr$ clinically meaningful endoscopic improvement ses cd reduction $nmbr$ from induction baseline endoscopic response ses cd reduc tion $nmbr$ from induction baseline endoscopic remission ses cd total score $nmbr$ mucosal healing complete absence of ul cers in patients with ulcers at baseline cd crohn s disease ses simpli ed endoscopic disease severity score,C0014245;C0332174;C1608841;C0439230;C0032042;C1696465;C1706408;C0034656;C0030428;C3541314;C3815594;C0449820;C4050231;C0041582;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C2700400;C0030705;C1514756;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0003250;C0178602;C0369637;C0332232;C0439272;C0205195;C0002778;C2348792;C0936012;C1524024;C0038894;C0038895;C0543467;C1274039;C0138547;C4288398;C0168634;C0439780;C1442488;C0750591;C1518422;C0026724;C0449438;C1963256;C3887532;C1551393;C0441635;C1705492;C3272743;C0301630;C0392756;C1293152;C4551656;C0007928;C0034283;C4552032;C0442418;C0332197;C1689985;C0010346;C0521117
sex women men,C0009253;C0025266;C0036864;C0079399;C0804628;C1314687;C1522384
race or ethnic origin,C0034510;C1706779;C3853635;C0015031
native american or alaskan native,C0282204;C1515945;C0238611;C0302891
hba $nmbr$ c mmol mol [se],C0019016;C3829066;C1825777;C3538758;C0036919
sitting systolic blood pressure mm hg,C1319893;C0439475
sitting diastolic blood pressure mm hg,C1319894;C0439475
total daily insulin dose u day,C2348070;C0456683
duration of chronic kidney disease years,C0872146
egfr by creatinine ml min per $nmbr$ $nmbr$ m $nmbr$,C1739039;C3811844;C3812682
egfr by creatinine ml min per $nmbr$ $nmbr$ m $nmbr$ geometric mean [se],C1739039;C3811844;C3812682;C2986759;C0036919
baseline egfr $nmbr$ to,C1739039;C3811844;C3812682
egfr by cystatin c ml min per $nmbr$ $nmbr$ m $nmbr$ mean [se],C1739039;C3811844;C3812682;C0444504;C2347634;C2348143;C0036919
egfr by cystatin c ml min per $nmbr$ $nmbr$ m $nmbr$ geometric mean [se],C1739039;C3811844;C3812682;C2986759;C0036919
uacr mg g median [iqr],C0549183;C0876920;C2347635;C2348144;C2939193
normal albuminuria uacr,C0205307;C0001925;C0231683;C0439166;C2347086;C4553972
microalbuminuria uacr $nmbr$ $nmbr$,C0730345
macroalbuminuria uacr $nmbr$,
angiotensin converting enzyme inhibitor or angiotensin receptor blocker use mitt population,C0003015;C2757044;C3536837;C4541021;C0032659;C1257890
indacaterol glycopyrronium $nmbr$ $nmbr$ g o d,C1722260;C0439267
salmeterol fluticasone $nmbr$ $nmbr$ g b i d,C0439417
copd severitya n,C0024117;C1412502;C3714496
sgrq c total scoreb,C3826872;C0439175;C0439810
data presented as mean sd unless otherwise specified acopd severity is based on the gold $nmbr$ criteria [ $nmbr$ ] gold $nmbr$ [ $nmbr$ ] bon a scale of $nmbr$ $nmbr$ with higher scores indicating worse health status the mcid is a change of $nmbr$ units on a scale of $nmbr$ $nmbr$ with higher scores indicating more severe dyspnea on a scale of $nmbr$ $nmbr$ with higher scores indicating worse health status,C1511726;C3245479;C3714741;C0449450;C0444504;C2347634;C2348143;C0439793;C0522510;C1527178;C1705938;C0018026;C1304897;C1552041;C2986536;C0175659;C0349674;C1947916;C0205250;C0449820;C0332271;C0018759;C1279889;C1457868;C0392747;C0443172;C1705241;C4319952;C2080700
b i d twice daily cat copd assessment test copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s fvc forced vital capacity gold global initiative for chronic obstructive lung disease ics inhaled corticosteroid mcid minimum clinically important difference mmrc modified medical research council o d once daily sd standard deviation sgrq c st george s respiratory questionnaire for copd,C0016529;C1306036;C0205246;C0424093;C2348867;C0024117;C0079816;C0871420;C1553316;C0034394;C1412502;C3714496
baseline eosinophil $nmbr$ cells pl,C3897966;C4049765
baseline eosinophil,C0168634;C0014467;C1442488
very severe copd,C0024117;C1412502;C3714496
severe copd,C0024117;C1412502;C3714496
moderate copd,C0024117;C1412502;C3714496
egfr $nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$,C1739039;C0439445;C3811844;C3812682
drug therapy,C0013216;C0013217
renin angiotensin system inhibitor,C1960108;C3537174;C4521920
microvascular disease history,C0443258;C0683519
atherosclerotic vascular disease history,C0683519
ratio of ldl to hdl cholesterol,C0456603;C1547037;C0023822;C0392885
urinary albumin to creatinine ratio,C0486293;C1318293
mg g,C1300563
mg mmol,C0567349;C2348885
normoalbuminuria,
composite of doubling of serum creatinine end stage kidney disease or death from renal causes,C0205199;C1547335;C0007465;C0022646
composite of $nmbr$ reduction in egfr end stage kidney disease or death from renal causes,C0205199;C1547335;C0022661;C2316810;C0007465;C0022646
pvaluefor interaction $nmbr$ $nmbr$,C1704675
$nmbr$ $nmbr$ o $nmbr$ s o $nmbr$,C0483204
central or south america,C0205099;C1879652;C0037713
rest ofthe world,C0035253;C2700280;C1622890
$nmbr$ $nmbr$ o $nmbr$ i $nmbr$,C0021966;C0221138
$nmbr$ $nmbr$ o $nmbr$ i o $nmbr$,C0021966;C0221138
systolic blood pressure $nmbr$ mm hg or diastolic,C0488055;C0439475;C0871470;C1306620;C0012000
blood pressure $nmbr$ mm hg,C0005823;C0439475;C1271104;C1272641
$nmbr$ o $nmbr$ o $nmbr$,C0483204
hbai,
ecfr ml min per $nmbr$ $nmbr$ m,C0439445
baseline albuminuria,C0168634;C0001925;C1442488
renin angiotensin system inhibitor use,C0042153;C0457083;C1947944
loop diuretic use,C0042153;C0457083;C1947944
sotagliflozin $nmbr$ mg n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
race or ethnic group n,C0034510;C1706779;C3853635;C0441848
hispanic latino ethnicity,C0015031;C0243103
alc mmol mol,C1424945;C3829066;C3811058
mg dl sd,C0439269;C2699239
body mass index $nmbr$ kg m n,C0022718;C0439209;C4054209;C0369718;C0441922
systolic blood pressure $nmbr$ mm hg n,C0488055;C0871470;C1306620
total daily insulin dose lu kg,C0022718;C0439209;C4054209
mdi,C0993596;C1839839;C4049613
csii,
figure $nmbr$ lsm percent a and absolute b change from baseline in insulin dose at $nmbr$ and $nmbr$ weeks baseline values are iu day,C0439165;C1549031;C0168634;C1442488;C0366513;C0042295;C0439465
drug therapy no,C0013216;C0013217
glp $nmbr$ receptor agonist,C0018301;C4543206;C1422069;C1425391;C1539338;C2350813
microvascular disease history no,C0443258;C0683519
atherosclerotic vascular disease history no,C0683519
cv disease history no,C0683519
systolic bp mm hg mean sd,C0488053;C2699239
diastolic bp mm hg mean sd,C0488053;C2699239
glycohemoglobin mean sd,C0202054;C2699239;C0696092
hdl c mmol l mean sd,C1532563;C2699239
ldl c mmol l mean sd,C1532563;C2699239
ldl c hdl c ratio mean sd,C0428621;C2699239
uacr mg g median iqr,C1300563;C0549183;C0876920;C2347635;C2348144;C2939193
normoalbuminuria no,
micro or macroalbuminuria no,C0085672;C1553035;C3811161;C4049106
patients with an event per $nmbr$ patient years,C0030705;C0441471;C4019010;C0439234
number of participants with an event,C0237753;C0449788;C0441471;C4019010
canagiiflozin,
interaction p vaiue,C1704675
fatal nonfatal ml,C0439526;C1705224;C3887665
fatal nonfatal stroke,C0038454;C4554100
renal composite,C0205199;C1547335
geometric mean uacr,C2986759
dabigatran $nmbr$ mg b i d,C0439422
nsaid at least once,C0003211;C3536840
never nsaid,C0003211;C3536840
hr vs warfarin $nmbr$ ci,C0008107;C3259781
gi major bleeding,C0017181;C0205082;C0205164;C4318856;C4521762
stroke se,C0038454;C0036919;C4554100
duration of disease y,C0872146
daily bowel movements,C0332173;C0011135
$nmbr$ mg l,C0439268
oral corticosteroid use at baseline,C0239126
mean dose,C0444504;C0178602;C0869039;C1114758;C2347634;C2348143
median dose range,C0178602;C0869039;C1114758
dapagliflozin $nmbr$ mg insulin n $nmbr$,C0024671;C0021641;C1533581;C1579433;C3714501;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
placebo insulin n $nmbr$,C0032042;C0021641;C1533581;C1579433;C3714501;C1696465;C1706408
total baseline insulin dose,C2986497
dose iu,C0049272;C0439453;C0694756
dose weight iu kg,C0005910;C0439463;C0043100;C1305866;C1705104
method of insulin administration,C0087111;C1547585
use of cgm yes,C1524063;C1549445;C1705108;C1710701
hba $nmbr$ c at randomization,C0019016;C0034656;C1825777;C3538758
subgroup statistics,C0038215;C0600673
for patients using personal cgm,C0030705;C1524063;C1519021
adjusted mean change from baseline,C0392747;C0443172;C1705241;C4319952
difference from placebo $nmbr$ cl,C1705241;C1705242
for patients not using personal cgm,C0030705;C1518422;C1524063;C1519021
use of cgm interaction test p value^,C1524063;C1709380
adjusted mean change from baseline se,C0392747;C0443172;C1705241;C4319952
patients n n a,C0030705
overall pea population,C0032659;C1257890
ics subset,C0815320;C1515021;C4551720
ics laba subset,C0815320;C1515021;C4551720
ff vi n $nmbr$,C4554348;C0205999
uc n $nmbr$,
adjusted or $nmbr$ ci b,C0456081;C0008107;C3259781
adjusted or $nmbr$ ci c,C0456081;C0008107;C3259781
act total score $nmbr$ and or improvement from baseline $nmbr$,C0079613;C2964552;C1704930;C1869853;C3890007;C4048375;C2986411;C0168634;C1442488
act total score $nmbr$,C0079613;C2964552;C1704930;C1869853;C3890007;C4048375
improvement from baseline $nmbr$,C2986411;C0168634;C1442488
difference ff vi versus uc,C1705241;C0205999;C1705242
$nmbr$ ci b,C0008107;C3259781
$nmbr$ ci c,C0008107;C3259781
percent work time missed due to asthma,C0043227;C0040223;C3541383;C1705492;C0678226
percent impairment while working due to asthma,C0221099;C0684336;C0043227;C0678226
percent overall work impairment due to asthma,C0221099;C0684336
percent activity impairment due to asthma,C0221099;C0684336
proportion of responders n n,C1709707
ffa i,C0021966;C0221138
uc,
environmental stimuli,C0450025
activity limitation,C0443288;C0449295
emotional function,C0031843;C0542341;C0700205;C1705273
secukinumab $nmbr$ mg no load n $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1550025;C1704782;C1708715
time since as diagnosis years mean sd,C0040223;C3541383;C0011900;C2699239;C1704338;C1704656
hla b $nmbr$ positive at baseline n,C0439178;C1446409;C1514241;C2825490;C3812269
tnfi na ve n,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882;C0369718;C0441922
total basdai score mean sd,C2964552;C2699239
total back pain score $nmbr$ $nmbr$ mm scale mean sd,C1504479;C2699239
previous systemic treatment n,C0205156;C0678812;C1552607
methotrexate use at randomization,C0042153;C0457083;C1947944
sulfasalazine use at randomization,C0042153;C0457083;C1947944
corticosteroid use at randomization,C0239126;C0034656
cumulative nsaid score mean sd,C0003211;C2699239;C3536840
uveitis,C0042164;C1963266
tnfi ir,C0022065;C0022071;C1448132
asas $nmbr$,C0004057;C3853627
hscrp post baseline baseline ratio ls mean se,C0023668;C0036919
asas $nmbr$ $nmbr$,C0004057;C3853627
basdai ls mean change from baseline se,C0392747;C0443172;C1705241;C4319952
sf $nmbr$ pcs ls mean change from baseline se,C0392747;C0443172;C1705241;C4319952
asqol ls mean change from baseline se,C0392747;C0443172;C1705241;C4319952
benralizumab $nmbr$ mg q $nmbr$ w,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
a $nmbr$ $nmbr$ $nmbr$ a $nmbr$,
a $nmbr$ $nmbr$,
$nmbr$ nil,C0442734
other^,
bmp kg m $nmbr$,C0022718;C0439209;C4054209
eosinophil counf cells pl,C3897966;C4049765
pre bronchodilator fevr l,C2599602;C1708033
pre bronchodilator fevr pred,C0032952;C0044955
$nmbr$ $nmbr$ $nmbr$ a $nmbr$,
pre bronchodilator fevi fvc,C0802741;C3815113
$nmbr$ i $nmbr$ $nmbr$ ai,C0003504;C4551710
pre bronchodilator fvc pred,C0032952;C0044955
age at asthma diagnosis years,C1828181;C3173302
exacerbations in the past $nmbr$ months n,C4086268;C0439231
tass,C0559483
aqlq si $nmbr$ score,C0449820;C4050231
atopic,C0392707
ocs use,C0042153;C0457083;C1947944
subgroup name level,C0441889;C0456079;C1547707;C2946261
estimate $nmbr$ cl,C0750572;C0596019
no ocs,
no nasal polyps,C0027430
pre bd fvc,C0005126;C3714541;C2344255;C4050145
pre bd fvc s $nmbr$ of predicted,C0005126;C3714541;C2344255;C4050145;C0681842;C1882327
s $nmbr$ exacerbations,C4086268
age at diagnosis s $nmbr$ years,C1828181;C3173302;C0439234
age at diagnosis,C1828181;C3173302
either ocs use nasal polyps pre bd fvc,C0027430;C3714541
no ocs use no nasal polyps pre bd fvc s $nmbr$ of predicted and age at diagnosis,C0042153;C0457083;C1947944;C0027430;C3714541;C0681842;C1882327;C1828181;C3173302
aspirin group n $nmbr$,C0004057;C0441848
white race no i,C0007457;C0043157;C0021966;C0221138
participant reported hypertension no,C0020538;C1963138
aspirin use before screening no,C0042153;C0457083;C1947944
statin use no,C0042153;C0457083;C1947944
median interquartile range yr,C1711350;C0439234
vascular risk score no ^,C0449820;C4050231
aspirin n $nmbr$ no of participants with events,C0004057;C0679646;C0441471;C3541888
piacebo n $nmbr$ no of participants with events,C0679646;C0441471;C3541888
heterogeneity or trend p vaiue,C0019409;C0242960;C1521798;C4554533
body mass index kg m ^,C0022718;C0439209;C4054209
weight at randomization kg,C2985844;C0022718;C0439209;C4054209
prior aspirin use,C0042153;C0457083;C1947944
vascular risk score,C0449820;C4050231
other treatment assignment,C0039798;C1516050;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
omega $nmbr$ fatty acids,C1719844;C0015684
moderate s $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
fatty acid group n $nmbr$,C0015684;C0441848
unknown no,C0439673;C3541433;C4050014
patient reported hypertension no,C0020538;C1963138
medication use no,C0240320
median iqr yr,C0549183;C0439234;C0876920;C2347635;C2348144;C2939193
systolic blood pressure^,C0488055;C0871470;C1306620
$nmbr$ mm hg no,C0439475
omega $nmbr$ fa n $nmbr$,C1719844
heterogeneity or trend p value,C0019409;C0242960;C1521798;C1709380;C4554533
percentage,C0439165;C1549488;C1561533
body mass index kg m^ ^,C0022718;C0439209;C4054209
canakinumab $nmbr$ month on treatment il $nmbr$ above the median value $nmbr$ $nmbr$ ng l n $nmbr$,C0020898;C0021764;C0022271;C0549183;C0439297;C0876920;C2347635;C2348144;C2939193
canakinumab $nmbr$ month on treatment il $nmbr$ below the median value,C0020898;C0021764;C0022271;C0549183;C0876920;C2347635;C2348144;C2939193
unknown missing,C0439673;C3541433;C4050014;C1551393;C1705492;C3272743
randomized to canakinumab $nmbr$ mg,C0034656;C3815594
treatment group on treatment il $nmbr$ threshold,C0020898;C0449864;C0021764;C0022271
incidence rate n a,C1708485
hradjusted $nmbr$ ci b,C0008107;C3259781
$nmbr$ ref,C1425988
canakinumab il $nmbr$ top tertilec,C0020898;C0021764;C0022271
canakinumab il $nmbr$ middle tertile,C0020898;C0021764;C0022271
canakinumab il $nmbr$ lowest tertile,C0020898;C0021764;C0022271
p value for trend across categories,C1709380;C1521798;C4554533;C0683312
experimental intervention group n $nmbr$,C0441848
mean body mass index kg m $nmbr$ sd,C0022718;C0439209;C4054209;C2699239
insulin dependent diabetes mellitus,C0011854
stable coronary artery disease,C0010054;C0010068;C1956346
percutaneous coronary intervention done,C1532338;C1272695
vascular access site,C0589360
lesions treated per patient,C0221198;C1522326;C0030705
one lesion,C0221198;C1546698
two lesions,C0205448;C0221198
three or more lesions,C0205449;C0221198
treated lesions,C1522326;C0221198
n lesions,C0369718;C0221198;C0441922
stented lesions,C0038257;C0221198
index percutaneous coronary intervention,C0600653;C1532338;C0918012;C1552854;C1637833;C2986546
n stented lesions,C0038257;C0221198
mean stents per lesion sd,C0038257;C0221198;C1546698
biolimus a $nmbr$ eluting stent,C0038257
other stent,C0038257
mean total stent length per lesion mm sd,C1444754;C1706316
mean stent diameter per lesion mm sd,C0038257;C0552409
direct stenting per lesion,C0038257;C2348535
bifurcation per lesion,C0184906;C3146289
thrombus aspiration done per lesion,C0220787;C0349707;C0700198;C2712334;C2827071;C1272695;C0221198;C1546698
timi flow,C3272266
pre procedure,C3272300
post procedure,C3272301
experimental treatment group,C0949266;C2585119
control group,C0009932
indication,C0392360;C3146298
s $nmbr$ years,C0439234
renal failure,C0035078;C1963154
left main treated,C0205091;C1522326;C0443246;C1552822
type of reference treatment strategy,C0455708;C0679199
use of ticagrelor,C1524063;C1999375
use of clopidogrel,C1524063;C0070166
$nmbr$ $nmbr$ o $nmbr$ $nmbr$ o $nmbr$,C0483204
cld $nmbr$ mg n l $nmbr$,C0439268
azl m $nmbr$ mg $nmbr$ cld $nmbr$ mg n l $nmbr$,C2827881
$nmbr$ $nmbr$ $nmbr$ l l,C3539687
non hispanic and latino,C1518424;C0086528
not collected^,C1516695;C1516698
bmi kg m^ mean sd,C0022718;C0439209;C4054209;C0444504;C2699239;C2347634;C2348143
anti hypertensive treatment history n,C0432633
raas inhibitors,C0243077
change from baseline to final apbm,C0392747;C0443172;C1705241;C4319952;C0205088;C1546485;C3853528
cld $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
azl m $nmbr$ mg cld $nmbr$ mg,C1319635
p value overall,C1709380;C0282416;C1561607
baseline $nmbr$ hour mean sbp mm hg,C0085805;C0439475
cgfr ml min $nmbr$ $nmbr$ m $nmbr$,C0439445
people with diabetes n $nmbr$,C0027361;C0011847;C0011849
people without diabetes n $nmbr$,C0027361;C0011847;C0011849
atherosclerotic coronary heart disease ischaemic stroke or peripheral arterial disease n n number of people in phase $nmbr$ studies only high intensity statins were defined as atorvastatin $nmbr$ to $nmbr$ mg rosuvastatin $nmbr$ to $nmbr$ mg or simvastatin $nmbr$ mg daily,C0010054;C0948008;C0237753;C0449788;C0205390;C0947630;C1710475;C4081854;C0360714;C1704788;C3539106;C0024671;C0965129;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0332173
heterozygous familial hypercholesterolemia,C0020445;C0745103;C1366529
high intensity statins,C4081854;C0360714
any other lipid lowering therapy n,C0585943
anti hyperglycaemic agent n,C0432633;C1321567
injectable anti hyperglycaemic n,C1272883;C0432633
insulin n,C0021641;C1533581;C1579433;C3714501
triglycerides median q $nmbr$ q $nmbr$,C0041004;C0549183;C0876920;C2347635;C2348144;C2939193
duration of total exposure to study treatment weeks,C0439175;C2826870;C0439810;C1521826;C0439230
teaes of special interest,C0205555;C0543488
study population,C2348561
proportion of individuals a alirocumab placebo,C1709707;C0027361;C0237401;C0032042;C1696465;C1706408
rate per $nmbr$ patient years control vs alirocumab i,C0489879;C0030705;C0021966;C0221138
hr vs control $nmbr$ cl,C0243148;C0596019;C1550141;C1882979;C2587213;C3274648;C4553389
lisrs,
neurocognitive disorders,C0029227;C4041080
neurologicai events,C0441471;C3541888
hepatic disorders,C0023895
general allergic events,C0441471;C3541888
ophthalmologic events,C0441471;C3541888
dm or diabetic complications,C0011816;C3250443;C0342257
adjudicated mace $nmbr$,C0349381;C0949745;C1445339
teaes in a $nmbr$ of individuals,C0027361;C0237401
proportion of individuals control alirocumab,C1709707;C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
rate per $nmbr$ patient years control vs alirocumab,C0489879;C0030705;C3491162
diarrhoea,C0011991;C1963091;C3641756;C4084784;C4084802;C4085317
at,
ta,C0039297;C1506978;C1705538;C3272501;C4553364
tk,C0041405;C0220928;C4050092
week $nmbr$ czp dose combined n $nmbr$,C0054841;C0178602;C0869039;C1114758;C1861828;C1872109
dmard n $nmbr$,C0242708
demographic characteristics mean sd unless otherwise stated,C0683970;C2699239;C1301808;C1442792
disease characteristics n unless otherwise stated,C0599878;C1301808;C1442792
prior use of synthetic dmards,C1524063;C0242708
concomitant use of corticosteroids,C1524063
tender joint count $nmbr$ $nmbr$ joints mean sd,C0451530;C2699239
swollen joint count $nmbr$ $nmbr$ joints mean sd,C0451521;C2699239
patients with psoriasis bsa $nmbr$,C0030705;C0033860
pasi mean sd,C0444504;C2699239;C2347634;C2348143
patients with enthesitis lei $nmbr$,C0030705;C1282952
lei mean sd,C0444504;C2699239;C2347634;C2348143
patients with dactylitisa,C0030705
ldi mean sd a,C0444504;C2699239;C2347634;C2348143
patients with nail psoriasis mnapsi $nmbr$,C0030705;C0406322
mnapsi mean sd,C0444504;C2699239;C2347634;C2348143
observed,C1441672
imputed,C2699638
clinical and patient reported outcomes observed n unless otherwise indicated,C0205210;C2987124;C1441672;C1444656
pasi $nmbr$ a,C4528685
ldi mean [sd]b,C0444504;C2347634;C2348143;C2699239
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$ ] n $nmbr$,C0369718;C0441922
total resolution of dactylitisb,C1514893;C1706463;C2699488
lei mean [sd]c,C0444504;C2347634;C2348143;C2699239
total resolution of enthesitisc,C1514893;C1706463;C2699488
mnapsi mean [sd]d,C0444504;C2347634;C2348143;C2699239
total resolution of nail psoriasisd,C1514893;C1706463;C2699488
haq di mean [sd],C0444504;C2347634;C2348143;C2699239
haq di mcide,C3826998;C4321476
uc [gemini $nmbr$ ],
cd [gemini $nmbr$ ],C0007928;C0034283;C4552032
vdz n \ $nmbr$,
vdz pla n $nmbr$,C0456170
pla n $nmbr$,C0456170
vdz n $nmbr$,
pla $nmbr$,C0456170
disease duration mean [sd] years,C0444504;C2347634;C2348143;C2699239;C0439234
disease duration $nmbr$ years $nmbr$ [ ] disease activity s,C0872146;C0439234;C1292728
cdai mean [sd],C0444504;C2347634;C2348143;C2699239
cdai $nmbr$ n [ ],C0683448;C1413248;C3273706
ms mean [sd],C0444504;C2347634;C2348143;C2699239
ms,C2349943;C3539704;C3713294
ms $nmbr$ $nmbr$ n [ ],C2349943;C3539704;C3713294
crp mean [sd] mg $nmbr$,C0444504;C2347634;C2348143;C2699239;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
crp $nmbr$ mg $nmbr$ n [ ],C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
concomitant therapy n [ ],C1707479
cs and im,C0010182;C0271160;C3540510;C4085345
im on]y,
prior tnf antagonist n [ ],C0332152;C0231491;C2826257
smoking status n [ ],C1519386
supplementary figure $nmbr$ incidence of arthritis arthralgia in patients receiving corticosteroids at baseline according to tapering of corticosteroids in the previous $nmbr$ weeks in a patients with crohn s disease n $nmbr$ and b patients with ulcerative colitis n $nmbr$ this analysis includes patients who received $nmbr$ mg prednisone equivalent per day at baseline,C0021149;C0220856;C0030705;C1514756;C0001617;C3539185;C3540725;C3540726;C3540727;C0441640;C1548969;C0439230;C0010346;C0012634;C0009324;C0002778;C0936012;C1524024;C0332257;C1552866;C2700399;C0205163;C0439185;C0168634;C1442488
aii participants n $nmbr$,C1424250;C0679646;C2698414
anti gad positive n $nmbr$,C0270549;C0439178;C1446409;C1514241;C2825490;C3812269;C1414925
anti gad negative n $nmbr$,C0270549;C0205160;C1513916;C2825415;C2825491;C3853545;C1414925
prior cvd,C0332152;C0007222;C2826257
thyroid disease,C0040128
ethnic background,C0015031
prior gestational diabetes,C0332152;C0085207;C2826257
alcohol $nmbr$ drinks per week,C0556297;C0332174;C0439230
education level,C0013621;C0013658
education $nmbr$ to $nmbr$ y,C0013621;C0013622;C0013658;C0039401
education $nmbr$ y,C0013621;C0013622;C0013658;C0039401
creatinine pmol l,C0010294;C0439284;C1561535
acr $nmbr$ mg g,C1412134;C1300563;C1515941
f plasma glucose mmol l,C0202042;C1532563;C0455280
statin users,C0360714;C1706077
ace arb users,C1452534;C1706077;C4284014
beta blocker users,C0001645;C1706077
thiazide users,C0541746;C1706077
c peptide nmol l,C0607868
overall n n loopy,C0282416;C1561607
glargine n n loopy,C0907402
std n n loopy,
person years,C0027361;C0439234;C2347489
first co primary,C0205225;C0439612;C0439631
anti gad positive,C0439178;C1446409;C1514241;C2825490;C3812269
anti gad negative,C0205160;C1513916;C2825415;C2825491;C3853545
second co primary,C0205225;C0439612;C0439631
microvascular outcome,C0443258;C1274040
non severe hypoglycaemia,C0020615;C4553659
hbalc $nmbr$ $nmbr$ mmol mol,C3829066
iglarlixi n $nmbr$,
iglar n $nmbr$,
beam values mg dl mean sd,C0439269;C2699239
beam,C0338248;C2347880;C4521565
sample statistics,C2348149
nilvadipine,C0132512
years since diagnosis,C0439234;C0011900;C1704338;C1704656
years since symptom onset,C0439234;C4086878
apoe $nmbr$ carrier,C0007294;C0560175;C1325398;C1706209;C3273162
smmse,
smmse $nmbr$,
baseline adas cog $nmbr$,C0168634;C3539026;C1442488
baseline cdr sb n $nmbr$ $nmbr$,C0168634;C0038111;C3811240;C1442488
baseline dad n $nmbr$ $nmbr$,C0168634;C1442488
d $nmbr$ ci,C0008107;C3259781
group difference,C1705241;C1705242
non carrier n $nmbr$,C2986416
carrier n $nmbr$,C0007294;C0560175;C1325398;C1706209;C3273162
mild n $nmbr$,C2945599
moderate n $nmbr$,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
ease $nmbr$,C1331418
empaglifiozin $nmbr$ mg w $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
placebo w $nmbr$,C0032042;C1696465;C1706408
empaglifiozin $nmbr$ $nmbr$ mg w $nmbr$,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
femaie,
pacific,
egfr ml min $nmbr$ $nmbr$ m^,C1739039;C0439445;C3811844;C3812682
total daily insulin dose units kgt,C2348070
basal insulin doset,C0650607
bolus insulin doseh,C1186706;C0021641;C1533581;C1579433;C3714501;C1511237;C1705509;C3812160
type of insulin,C0457592
figure $nmbr$ hba $nmbr$ c ef cacy analysis data are from patients treated with $nmbr$ dose of study drug who had a baseline and $nmbr$ on treatment hba $nmbr$ c measurement c placebo corrected change from baseline in hba $nmbr$ c with empagli ozin at week $nmbr$ in subgroups by baseline hba $nmbr$ c $nmbr$ and $nmbr$ data are based on mixed model repeated measures analysis p $nmbr$ $nmbr$ for difference vs placebo p $nmbr$ $nmbr$ for difference vs placebo,C1511726;C3245479;C3714741;C0030705;C0332293;C0013175;C0168634;C1442488;C1299575;C0019016;C1825777;C3538758;C0332174;C0439230;C1079232;C1527178;C1705938;C1705241;C1705242;C0032042;C1696465;C1706408
permanent users,C0205355;C1706077
fp,C0016704;C1419068;C1419906;C3541238;C3541412
other ics,C0815320;C4551720
no ics,C0815320;C4551720
non inhaled steroid use n,C1518422;C0586793
anticholinergic use n,C0242896;C0042153;C0457083;C1947944;C3537004
fvc l mean sd,C0444504;C2699239;C2347634;C2348143
fvc predicted mean sd,C0444504;C2699239;C2347634;C2348143
fev $nmbr$ fvc mean sd,C0444504;C2699239;C2347634;C2348143
post bronchodilator fev $nmbr$ l mean sd,C2599594;C2699239
post bronchodilator fev $nmbr$ predicted mean sd,C2599594;C2699239
treatment throughout study,C1521826;C3161471
fp versus other ics,C0016704;C1419068;C1419906;C3541238;C3541412;C0815320;C4551720
fp versus no ics,C0016704;C1419068;C1419906;C3541238;C3541412;C0815320;C4551720
other ics versus no ics,C0815320;C4551720
hr or rr $nmbr$ ci,C0008107;C3259781
permanent users n,C0205355;C1706077
patients with pneumonia events n,C0030705;C0032285
pneumonia events n,C0032285;C0441471;C3541888
adjusted rate of pneumonia events per patient year mean $nmbr$ ci,C0456081;C0871208;C1521828;C0008107;C3259781
patients with hospitalized pneumonia events n,C0870668;C0032285
hospitalized pneumonia events n,C0032285;C0441471;C3541888
adjusted rate of hospitalized pneumonia events per patient year mean $nmbr$ ci,C0456081;C0871208;C1521828;C0008107;C3259781
patients with pneumonia resulting in death n,C0030705;C0032285;C0332294;C0011065;C1306577;C4082313;C4552775
treatment at baseline,C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
hr or rr,
use at baseline n,C0042153;C0457083;C1947944
patients with pneumonia event n,C0030705;C0032285
albiglutide n $nmbr$,C2607479
race or ethnicity,C0034510;C1706779;C3853635;C0015031;C0243103
non hispanic black or african american,C0005680;C0027567;C0085756;C0439541
eastern and central europe,C1707877;C0682369
diabetic eye disease,C0342245
peripheral sensory neuropathy,C0151313;C4554142
autonomic neuropathy,C0259749
glucose lowering medications,C0017725;C0441994;C2003888;C0013227;C0802604;C2598133;C4284232
none or diet,C0012155;C0012159;C1519433;C2983588;C3668949
sodium glucose cotransporter $nmbr$ inhibitor,C0017725;C1999216
glucosidase inhibitor,C1512211
albiglutide events patients,C0441471;C0030705;C3541888
non hispanicwhite,C1518422
$nmbr$ $nmbr$ o $nmbr$ s i $nmbr$,C0021966;C0221138
$nmbr$ $nmbr$ o $nmbr$ o i i $nmbr$,C0021966;C0221138
$nmbr$ o $nmbr$ o $nmbr$ $nmbr$ $nmbr$,C0483204
$nmbr$ $nmbr$ fo $nmbr$ $nmbr$ $nmbr$ ^,
number of arterial beds involved,C0237753;C0449788;C1314939
heart failure history,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
baseline egfr ml min per $nmbr$ $nmbr$ m,C0168634;C0439445;C1442488
baseline bmi kg m^,C0022718;C0439209;C4054209
baseline hba^c,C0168634;C0019016;C1825777;C3538758;C1442488
baseline dipeptidyl peptidase $nmbr$,C0168634;C0022709;C1442488
baseline statin,C0168634;C0360714;C1442488
normoalbuminuria uacr,
lixisenatide n $nmbr$ o,C2973895
$nmbr$ tq fi i,C0021966;C0221138
$nmbr$ f $nmbr$ q,C0016327
$nmbr$ f $nmbr$ l $nmbr$,C0016327
egfr ml min per $nmbr$ $nmbr$ m^,C1739039;C0439445;C3811844;C3812682
$nmbr$ $nmbr$ $nmbr$ $nmbr$ ^,
$nmbr$ ^ f $nmbr$ $nmbr$,C0016327
therapies,C0087111
angiotensin converting enzyme inhibitors,C0003015;C2757044
other blood pressure lowering drugs,C0003364
amann whitney u test wilcoxon sum rank test,C0439148;C0683443
age group $nmbr$ no,C0027362;C2348001
bpearson s chi square test,C0008041
body mass index group kg m $nmbr$ $nmbr$ kg m $nmbr$ no,C0022718;C0439209;C4054209
dyslipidaemia including hypercholesterol no,C0242339
chronic renal disease no,C0022661;C1561643
cfisher s exact test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
mi no,C3810814
coronary artery bypass graft no,C0010055;C1260596
chronic obstructive pulmonary disease no,C0024117
transient ischaemic attack no,C0007787;C0917805
haemorrhagic stroke no,C0553692
non haemorrhagic stroke no,C1518422;C0553692
timi risk score category no,C0683312;C3889287
gp iib iiia inhibitor before pci no,C0016011;C1999216
ticagrelor in hosp n $nmbr$,C1999375
ticagrelor pre hosp n $nmbr$,C0332152;C0740175;C2257086;C3669034
atwo sample t test,C0370003;C0871472;C2347026
age group $nmbr$ years no,C1510829
cmann whitney u test wilcoxon sum rank test,C0439148;C0683443
body mass index group $nmbr$ kg m $nmbr$ no,C0022718;C0439209;C4054209
dyslipidaemia no,C0242339
$nmbr$ $nmbr$ d,
dfisher s exact test,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
univariate logistic modela,C0242415
multivariate logistic modelb,C0242415
aunivariate logistic regression,C0206031
bmultivariate logistic regression with variables forced in the modela,C0206031;C0439828;C0441722;C0443221
mi previous pci and chronic obstructive pulmonary disease,C0205156;C4049621;C1552607;C0024117
pre hospital ticagrelor,C0019994;C1999375;C1510665
in hospital ticagrelor,C0019994;C1999375;C1510665
the p value is from the test statistic for testing the interaction between the treatment group and diabetes group,C1709380;C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744;C1704675;C0374505;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
$nmbr$ days composite of death new mi urgent revascularization and definite st,C0205199;C1547335;C0036056;C3272372
$nmbr$ days new mi or definite acute st,C0205314;C3810814;C0036056;C3272372
$nmbr$ days new mi,C0205314;C3810814
$nmbr$ days definite st,C0036056;C3272372
$nmbr$ days urgent revascularization,C0439228;C0581603
$nmbr$ days stroke ischemic,C0038454;C0475224;C4554100
timi flow grade $nmbr$ of mi culprit vessel pre pci,C0441800;C0919553;C3244287;C3810814;C0005847;C0332152;C0740175;C2257086;C3669034
st str $nmbr$ pre ci,C0008107;C3259781
timi flow grade $nmbr$ of mi culprit vessel post pci,C0441800;C0919553;C3244287;C0856742;C4049621
st str $nmbr$ post pci,C0036056;C4049621;C3272372
bail out use of glycoprotein iib iiia inhibitors,C1524063;C0016011
timi minor bleeding,C0026193;C0019080;C0205165
antiplatelet use,C0042153;C0457083;C1947944
high intensity statin use,C0042153;C0457083;C1947944
moderate intensity statin use,C0042153;C0457083;C1947944
imaged artery,C0003842;C0226004
ramus,C3538818
p value between groups,C1709380
normalized volume measures,C0079809;C1879489
necrotic core mm^,C4330985;C4554674
nominal change,C0392747;C0443172;C1705241;C4319952
fibrofatty mm^,C4330985;C4554674
fibrous mm,C4330985;C4554674
dense calcium mm,C4330985;C4554674
necrotic core,C0027540;C0444669;C1167518;C1706352;C1882467;C3274653
volume change mm^,C4330985;C4554674
fibrofatty,
fibrous,C0016059;C0439709
dense calcium,C0006675;C0006726;C2936886;C3540037;C3714611
fig $nmbr$ proportion of patients achieving das de ned remission over time by symptom duration in each treatment arm a abatacept mtx b abatacept monotherapy c mtx monotherapy error bars represent $nmbr$ ci das de ned remission is de ned as das $nmbr$ crp $nmbr$ $nmbr$ das $nmbr$ crp disease activity score in $nmbr$ joints with c reactive pro tein das $nmbr$ crp mtx methotrexate,C1709707;C0030705;C0544452;C0687702;C0444921;C3259042;C0743559;C1608199;C1882932;C1518340;C4706353;C0022417;C0392905
fig $nmbr$ proportion of patients achieving haq response over time by baseline symptom duration in each treatment arm a abata cept mtx b abatacept monotherapy c mtx monotherapy error bars represent $nmbr$ ci haq response is de ned as a reduction of at least $nmbr$ $nmbr$ units from baseline haq h ealth assessment question naire mtx methotrexate,C1709707;C0030705;C0102923;C0034746;C0451208;C0444921;C3259042;C0743559;C1608199;C1882932;C0871261;C1704632;C1706817;C2911692;C0011198;C1518340;C0017480;C3541240;C4684571;C0025677
dapaglifloiin n,
[ ifrerence vs placebo $nmbr$ cl,C0032042;C0596019;C1696465;C1706408
baseline hbalc^,C0168634;C1442488
s $nmbr$ $nmbr$ s $nmbr$ $nmbr$,C0565930;C2603362
s $nmbr$ $nmbr$ ^ $nmbr$ $nmbr$,
insulin administration,C0199782
cgm use,C0042153;C0457083;C1947944
dapaglifloz in n,
difference vs placebo $nmbr$ cl,C1705241;C1705242;C0032042;C0596019;C1696465;C1706408
baseline hba $nmbr$ c^,C0168634;C0019016;C1825777;C3538758;C1442488
difference vs placebo kg $nmbr$ cl,C1705241;C1705242;C0022718;C0596019;C0439209;C4054209
s $nmbr$ kg m^,C0022718;C0439209;C4054209
$nmbr$ ^ $nmbr$ kg m,C0022718;C0439209;C4054209
$nmbr$ kg m,C0022718;C0439209;C4054209
dapagliflozin n,C2353951
$nmbr$ s $nmbr$ kg m,C0022718;C0439209;C4054209
n liraglutide $nmbr$ placebo,C0032042;C1696465;C1706408
ldl c $nmbr$ $nmbr$ mg dl,C0439269
ldl c $nmbr$ mg dl,C0439269
non fatal ml,C0439526;C1705224;C3887665
expanded mace,C0349381;C0949745;C1445339
pci indication,C0392360;C3146298
thienopyridine at discharge,C1120149;C0012621;C0030685;C2926602
vein bypass stented,C0042449;C0741847;C0038257
stent thrombosis or mi,C3897493;C3810814
definite probable stent thrombosis,C0033204;C3897493;C0332148
definite stent thrombosis,C0439544;C3897493;C1704787
probable stent thrombosis,C0033204;C3897493;C0332148
noncardiac death,C0011065;C1306577;C4082313;C4552775
genetic subgroup,C1079230;C1515021
total aim high study,C0557651;C2603343
statin placebo n $nmbr$,C0360714;C0032042;C1696465;C1706408
statin er niacin n $nmbr$,C0360714;C0027996;C1142562
baseline tc mg dl,C0039411;C0439269;C0040642;C0041405;C0041698;C1824670;C3272447;C4522122
baseline tg mg dl median iqr,C0168634;C0439269;C1442488
baseline lipoprotein a nmol l median iqr,C0065058;C0125953;C1096202;C1439335
change in ldl c,C0392747;C0443172;C1705241;C4319952
$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ a,
change in hdl c,C0392747;C0443172;C1705241;C4319952
$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ b,
change in tc,C0392747;C0443172;C1705241;C4319952
change in tg,C0392747;C0443172;C1705241;C4319952
change in lp a,C0392747;C0443172;C1705241;C4319952
gene chr snp,C0752046;C1527094
alleles,C0002085
placebo statin,C0032042;C0360714;C1696465;C1706408
niacin statin,C0027996;C0360714;C1142562
maf,
minor major,C0205082;C0205164;C4318856;C4521762
trait,C0599883
frequency of events,C0376249;C0439603;C0871396;C1561548;C1705502;C3898838;C4321352
freqency of events,C0441471;C3541888
lipc,C1416867
aa g,C0282379;C0439267;C1235746;C1882141;C4554792
cad death,C0011065;C1306577;C4082313;C4552775
p value by gt,C1709380;C1435727;C1704693;C2697657
ampd $nmbr$,
ga a,C0016993
cyp $nmbr$ a $nmbr$,C1418793;C2634343
a ga,C0016993
ga,C0016993
male sex^,C0086582
diabetes duration years^,C0011847;C0439234;C0011849
geographic region^,C0017446
hbau,
body weight kg^,C0022718;C0439209;C4054209
systolic blood pressure mm hg^,C0488055;C0439475;C0871470;C1306620
diastolic blood pressure mm hg^,C0428883;C0439475;C1305849
established cvd chronic kidney disease age $nmbr$ ^,C1561643;C0001779;C4553188
cvd risk factors age $nmbr$ ^ ^,C0001783
antihyperglycaemic medication at baseline,C0013227;C3244316;C4284232
$nmbr$ oad,
$nmbr$ oads,
insulin dose u,C0366513;C0439148
per body weight u kg,C0005910;C1300561;C1305866
fig s $nmbr$ change in hba $nmbr$ c from baseline stratified by hba $nmbr$ c at baseline i first quartile hba $nmbr$ c,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488;C0205363;C0019016;C1825777;C3538758;C0021966;C0221138
table $nmbr$ baseline characteristics of the liraglutide and placebo groups including concomitant antihyperglycaemic treatment,C0039224;C4684572;C1706074;C0032042;C0374505;C1696465;C1706408
full analysis set data are the mean standard deviation or the number of patients percentage of either liraglutide or placebo group percentage data refer to the proportion of patients a data rst published in the leader primary publication marso et al [ $nmbr$ ] b established cvd was de ned as prior myocardial infarction or prior stroke or transient ischaemic attack or prior revascularisation or [ $nmbr$ stenosis of coronary carotid or lower extremity arteries or documented symptomatic coronary heart disease or documented asymptomatic cardiac ischaemia or heart failure or chronic kidney disease c cvd risk factors included microalbuminuria or proteinuria hypertension and left ventricular hypertrophy left ven tricular systolic or diastolic dysfunction or ankle brachial index \ $nmbr$ $nmbr$ bmi body mass index cvd cardiovascular disease hba $nmbr$ c glycated haemoglobin oad oral antihyperglycaemic drug,C1511726;C3245479;C3714741;C1828170;C2360800;C0439165;C1549488;C1561533;C0205543;C0030705;C1425219;C0034037;C1704324;C0443211;C0007222;C1272684;C1518340;C0027051;C0428953;C2926063;C3810814;C4552959;C0038454;C4554100;C0007787;C0917805;C0332152;C0581603;C2826257;C0007282;C0242231;C0226415;C0010054;C0010068;C1956346;C1279369;C2062869;C0018801;C0018802;C4554158;C0679238;C0730345;C0020538;C1963138;C0149721;C0039155;C3484363;C0520863;C0007220
age years^,C1510829
diabetes duration ycars,C0011847;C0011849
no polyvascular disease n $nmbr$ $nmbr$,C0012634
polyvascular disease n $nmbr$,C0012634
cardiac catheterisation or pci for index event,C0018795;C4049621;C0441471;C4019010
medications at enrolment,C0013227;C0802604;C2598133;C4284232
aspirin any dose,C0004057;C0178602;C0869039;C1114758
polyvascular disease status,C3176928
polyvascular disease and type $nmbr$ diabetes status,C0012634;C1317301
polyvascular disease and type $nmbr$ diabetes n $nmbr$,C0012634;C1320657
polyvascular disease and no type $nmbr$ diabetes n $nmbr$,C0012634;C1320657
cardiovascular death myocardial infarction or stroke,C0027051;C0428953;C2926063;C3810814;C4552959;C0038454;C4554100
cardiovascular hospitalisation,C0007226;C0019993;C3887460
peripheral revascularisation,C0205100;C0581603
central and eastern europe,C0205099;C1879652;C0015177
canada or united states,C0006823;C0041703
rest ofworld,C0035253;C1622890
medical history before index acute coronary syndrome no,C0262926;C1704706
family history of premature coronary heart disease,C0260520;C1313980;C2317524
index acute coronary syndrome no,C0600653;C0948089;C0918012;C1552854;C1637833;C2986546
percutaneous coronary intervention or coronary artery bypass grafting for index acute coronary syndrome no,C1532338;C0010055
median time from index acute coronary syndrome to randomization iqr mo,C0040223;C3541383;C0026544;C0332177
median duration oftype $nmbr$ diabetes iqr yr,C0011847;C0439234;C0011849
estimated glomerular filtration rate ml min $nmbr$ $nmbr$ m^,C3811844;C0439445
established atherosclerotic cardiovascular disease no,C0443211;C0004153;C1272684
history of coronary artery disease no,C1881055
history of peripheral artery disease no,C0683519;C0730226;C0850708;C0944983
history of cerebrovascular disease no,C0585890
glucose lowering therapies no,C0017725;C0441994;C2003888;C0087111
dpp $nmbr$,C1414174
cardiovascular therapies no,C0587038
dapagliflozin placebo no of events no of patients,C0032042;C1696465;C1706408;C0441471;C3541888;C0030705
hazard ratio $nmbr$ c,C2985465
a cardiovascular death or hospitalization for heart failure,C0011065;C1306577;C4082313;C4552775;C3898876
[,
mrf,C0312443;C1412879
$nmbr$ em,
i h,C0021966;C0033727;C0369286;C0441932;C0564385;C4528284;C0221138
$nmbr$ ml min $nmbr$ $nmbr$ m^,C0439445
b mace,C0349381;C0949745;C1445339
$nmbr$ ml min $nmbr$ $nmbr$,C0439445
icosapent ethyl events n,C0058978;C0441471;C3541888
risk stratum,C0035647;C4552904
secondary prevention cohort,C0009247;C0599755
primary prevention cohort,C0009247;C0599755
the netherlands australia new zealand and south africa,C0027978;C0324547;C0037712
$nmbr$ yr from the united states,C0439234;C0041703
baseline estimated gfr,C0017654;C1424601
baseline triglycerides $nmbr$ mg dl and,C0041004;C0439269
h dl cholesterol,C0033727;C0008377;C0369286;C0441932;C0564385;C4528284
baseline statin intensity,C0168634;C0522510;C1442488
baseline ldl cholesterol derived,C0023824;C0202117;C1441547;C3245521
in thirds,C0205437
$nmbr$ mg dl baseline high sensitivity crp,C3890735;C4048285
$nmbr$ mg liter,C0024671;C0475211;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
black af rican american,C0085756;C0344434;C4049859
europe plus south africa,C0015176;C0037712
ischemic heart disease no,C0010054;C0151744
egfr mdrd ml min $nmbr$ $nmbr$ m,C1739039;C0439445;C3811844;C3812682
uacr median iqr mg g,C0549183;C1300563;C0876920;C2347635;C2348144;C2939193
hemoglobin a^c,C0019020;C3889898
heart rate min,C0702093;C1524029;C3813700
$nmbr$ glucose lowering medication no,C0017725;C0441994;C2003888;C0013227;C3244316;C4284232
no of background glucose lowering therapies no,C1706907;C0017725;C0441994;C2003888;C0087111
$nmbr$ antihypertensive medication no,C0003364
incidence rate difference linagliptin placebo $nmbr$ cl,C1708485;C0596019
primary outcome $nmbr$ point mace,C0349381;C0949745;C1445339
cardiovascular death nonfatal myocardial infarction or nonfatal stroke,C0027051;C0428953;C2926063;C3810814;C4552959;C0038454;C4554100
secondary kidney composite outcome,C0022646;C1274040;C0227665
sustained esrd death due to kidney failure or sustained decrease of $nmbr$ in egfr from baseline,C0011065;C1306577;C4082313;C4552775;C0392756;C0547047;C1739039;C3811844;C3812682
death due to renal failure,C0011065;C1306577;C4082313;C4552775
sustained decrease of $nmbr$ in egfr,C0392756;C0547047;C1739039;C3811844;C3812682
exploratory cardiovascular and death outcomes,C0007226;C3887460;C0011065;C1274040;C1306577;C4082313;C4552775
noncardiovascular death,C0011065;C1306577;C4082313;C4552775
fatal myocardial infarction,C0027051;C0428953;C2926063;C3810814;C4552959
fatal or nonfatal myocardial infarction,C1302234;C1705232;C0027051;C0428953;C2926063;C3810814;C4552959
fatal or nonfatal stroke,C1302234;C1705232;C0038454;C4554100
$nmbr$ point mace $nmbr$ point mace plus hospitalization for unstable angina,C0349381;C0019993;C0949745;C1445339;C0002965
exploratory kidney and microvascular outcomes,C0022646;C0227665;C0443258;C1274040
death due to renal failure or sustained esrd,C0011065;C1306577;C4082313;C4552775;C0022661;C0035078;C2316810
albuminuria progression,C0242656;C0449258
composite microvascular end point,C2349179;C2826544
composite ocular end point^,C2349179;C2826544
severe hypoglycemia,C0205082;C0020615;C4553659;C4050465;C4050466
no severe hypoglycemia,C0205082;C0020615;C4553659;C4050465;C4050466
previous cvd^,C0205156;C0007222;C1552607
alcohol^,C0001962;C0001975
previous dm,C0011816;C3250443
dm duration years,C0011816;C0439234;C3250443
mean alc,C1424945;C3811058
mean fpg mmol l,C0444504;C1532563;C2347634;C2348143
glargine allocation,C0907402;C1706778
standard allocation,C1442989;C1706778;C2828392
n $nmbr$ allocation,C0369718;C1706778;C0441922
other glucose lowering drugs,C0017725;C0441994;C2003888;C0013227;C3687832
mean mmse score,C3533236;C0451306
nonsevere hypoglycemia,C0020615;C4553659
no nonsevere hypoglycemia,C0020615;C4553659
a severe hypoglycemia,C0205082;C0020615;C4553659;C4050465;C4050466
b nonsevere hypoglycemia,C0020615;C4553659
no prior dm,C0011816;C3250443
no prior cvd,C0332152;C0007222;C2826257
educ ssy,
educ $nmbr$ $nmbr$ y,
educ $nmbr$ y,
giargine,
standard,C1442989;C2828392
itch nrs $nmbr$ v $nmbr$,C2240043;C4050142
itch nrs $nmbr$ $nmbr$ at $nmbr$,C2240043;C4050142
itch nrs $nmbr$ $nmbr$ v $nmbr$,C2240043;C4050142
itch nrs $nmbr$ $nmbr$ \ $nmbr$,C2240043;C4050142
itch nrs $nmbr$ $nmbr$ a $nmbr$,C2240043;C4050142
geographic region n,C0017446
baseline pssi score mean sd,C0168634;C2699239;C1442488
baseline ppasi score mean sd,C0168634;C2699239;C1442488
baseline skin pain vas mean sd,C0042815;C2699239
baseline bsa mean sd,C0168634;C2699239;C1442488
baseline spga mean sd,C0168634;C2699239;C1442488
baseline pasi mean sd,C0168634;C2699239;C1442488
baseline dlqi mean sd,C0168634;C2699239;C1442488
age at enrollment years mean sd,C1510829;C0444504;C2347634;C2348143
duration of psoriasis years mean sd,C0449238;C2926735
previous use of nonbiologic systemic therapy n,C1524063;C1515119
previous use of biologic systemic therapy n,C1524063;C1515119
facial psoriasis n,C1276112
scalp psoriasis n,C0406326
fig $nmbr$ impact of baseline psoriasis associated itch severity on the itch numeric rating scale changes from baseline during the induction period pooled data from uncover $nmbr$ and $nmbr$ lsm in patients with psoriasis associated itch nrs c $nmbr$ at baseline the lsm difference $nmbr$ con dence interval and p values were derived from a mixed effects model for repeated measures analysis including the xed effects treatment study visit and treatment $nmbr$ visit with the variance covariance structure set to unstructured intent to treat population itch nrs $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ indicate the itch nrs scores at baseline etn etanercept ixe ixekizumab lsm least squares mean nrs numeric rating scale pbo placebo q $nmbr$ w every $nmbr$ weeks,C1825598;C4049986;C0392747;C0443172;C1511726;C3245479;C3714741;C0030705;C0033860;C0033774;C1422257;C0168634;C1442488;C1272706;C1552654;C1552713;C1709380;C1441547;C3245521;C0002778;C0936012;C1524024;C2359836;C0036849;C1442518;C1705195;C2240043;C4050142;C0449820;C0023189;C0439230
fig $nmbr$ impact of baseline itch numeric rating scale severity on the response rate for a clinically meaningful improvement in itch i e c $nmbr$ point reduction in itch nrs at week $nmbr$ in patients with psoriasis associated itch nrs c $nmbr$ at baseline intent to treat population treat ment p \ $nmbr$ $nmbr$ baseline itch nrs category p \ $nmbr$ $nmbr$ treatment $nmbr$ baseline itch nrs category p $nmbr$ $nmbr$ itch nrs $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ indicate the itch nrs score at baseline etn etanercept ixe ixekizumab nrs numeric rating scale pbo placebo q $nmbr$ w every $nmbr$ weeks p \ $nmbr$ $nmbr$ versus etn and pbo,C1825598;C4049986;C0237629;C2986411;C0033774;C1422257;C0301630;C0392756;C1293152;C4551656;C0332174;C0439230;C0030705;C0332281;C0032659;C1257890;C4049715;C0014758;C0717758;C0031962
fig $nmbr$ impact of baseline itch numeric rating scale severity on the response rate for complete itch resolution i e itch nrs $nmbr$ at week $nmbr$ in patients with psoriasis associated itch nrs c $nmbr$ at baseline intent to treat population treatment p \ $nmbr$ $nmbr$ baseline itch nrs category p \ $nmbr$ $nmbr$ treatment $nmbr$ baseline itch nrs category p $nmbr$ $nmbr$ at the end of the induction period pooled data from uncover $nmbr$ and $nmbr$ nri itch nrs $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ indicate the itch nrs score at baseline etn etanercept ixe ixekizumab nri nonre sponder imputation nrs numeric rating scale pbo placebo q $nmbr$ w every $nmbr$ weeks p \ $nmbr$ $nmbr$ versus etn and pbo,C1825598;C4049986;C0237629;C2240043;C4050142;C0332174;C0439230;C0030705;C0332281;C0032659;C0033774;C1422257;C1257890;C0444930;C2746065;C0449820;C4050231;C0014758;C0717758;C0031962
fig $nmbr$ impact of baseline psoriasis associated itch severity on the response rate for c $nmbr$ improvement in psoriasis area and severity index from baseline at the end of the induction period week $nmbr$ in patients with itch numeric rating scale c $nmbr$ at baseline intent to treat population pooled data from uncover $nmbr$ and $nmbr$ nri treatment p \ $nmbr$ $nmbr$ baseline itch nrs category p $nmbr$ $nmbr$ treatment $nmbr$ baseline itch nrs category p $nmbr$ $nmbr$ itch nrs $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ indicate the itch nrs score at baseline etn etanercept ixe ixekizumab nri nonre sponder imputation nrs numeric rating scale pasi psoriasis area and severity index pasi $nmbr$ c $nmbr$ improvement in pasi from baseline pbo placebo q $nmbr$ w every $nmbr$ weeks p \ $nmbr$ $nmbr$ versus etn and pbo,C1825598;C4049986;C0237629;C2986411;C0033860;C0017446;C0205146;C0444930;C2746065;C0336604;C1511726;C3245479;C3714741;C0039798;C0033774;C1422257;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0449820;C4050231;C4050142;C4528685;C0031962;C0439230;C0014758;C0717758
fig $nmbr$ impact of baseline psoriasis associated itch severity on the response rate for absolute psoriasis area and severity index score b $nmbr$ at week $nmbr$ in patients with itch numeric rating scale c $nmbr$ at baseline intent to treat population treatment p \ $nmbr$ $nmbr$ baseline itch nrs category p $nmbr$ $nmbr$ treatment $nmbr$ baseline itch nrs category p $nmbr$ $nmbr$ at the end of the induction period pooled data from uncover $nmbr$ and $nmbr$ nri itch nrs $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ indicate the itch nrs score at baseline etn etanercept ixe ixekizumab nri nonre sponder imputation nrs numeric rating scale pasi psoriasis area and severity index pbo placebo q $nmbr$ w every $nmbr$ weeks p \ $nmbr$ $nmbr$ versus etn and pbo,C1825598;C4049986;C0237629;C0457451;C0332174;C0439230;C0336604;C0032659;C0033774;C1422257;C1257890;C0444930;C2746065;C2240043;C4050142;C0449820;C4050231;C0014758;C0717758;C0031962
normal uln n $nmbr$,C0205307;C0231683;C0439166;C2347086;C4553972
high uln and $nmbr$ xuln n $nmbr$,C0205250;C1519815;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
very high $nmbr$ xuln n $nmbr$,C0442804;C4321397
age at disease onset years,C0206132;C3870509
age at disease onset n,C0206132;C3870509
duration of as years,C0449238;C2926735;C0439234
duration of as n,C0449238;C2926735;C0369718;C0441922
prior nsaid n a,C0332152;C0003211;C3536840;C2826257
hla b $nmbr$ n,C1426226
ptga,
asdas crp,C3890735;C4048285
basdai,C1998004
basfi,
nbp,
tbp,
comparison cat $nmbr$ vs cat $nmbr$,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
week $nmbr$ outcomes,C0332174;C1274040;C0439230
asdas crp $nmbr$ $nmbr$,C3890735;C4048285
cat $nmbr$ n n,C0007450;C0325090;C0524517;C1443200;C3665481;C4050461;C4284282
or $nmbr$ ci a,C0008107;C3259781
pb,C1415801;C3819255
high vs normalc,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
very high vs normal,C0442804;C4321397;C0205307;C0231683;C0439166;C2347086;C4553972
week $nmbr$ crp,C3890735;C4048285
elevated vs normalc,C0205250;C3163633
baseline asdas crp,C3890735;C4048285
$nmbr$ $nmbr$ vs $nmbr$ $nmbr$ and $nmbr$ $nmbr$,
male vs female,C0086582;C1706180;C1706428;C1706429;C0043210;C0086287;C1705497;C1705498
$nmbr$ years vs $nmbr$ years,C0439234
$nmbr$ to $nmbr$ years vs $nmbr$ years,C0439234
prior nsaid use,C0042153;C0457083;C1947944
yes vs no,C1549445;C1705108;C1710701
hla b $nmbr$,C0019737;C0550853;C1415561
positive vs negative,C0439178;C1446409;C1514241;C2825490;C3812269;C0205160;C1513916;C2825415;C2825491;C3853545
baseline ptga,C0168634;C1442488
$nmbr$ and $nmbr$ vs $nmbr$,
$nmbr$ vs $nmbr$,
baseline basdai,C0168634;C1998004;C1442488
baseline basfi,C0168634;C1442488
$nmbr$ to $nmbr$ vs $nmbr$,
baseline nbp,C0168634;C1442488
baseline tbp,C0168634;C1442488
week $nmbr$ outcome,C0332174;C1274040;C0439230
potential predictor,C3245505;C2698872
high vs normalb,C0205250;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209
very high vs normalb,C0442804;C4321397
elevated vs normalb,C0205250;C3163633
$nmbr$ $nmbr$ vs $nmbr$ $nmbr$ to $nmbr$ $nmbr$,
boost intensify premix i global patient population,C1511253;C1874596;C0032659;C1257890
boost intensify all pan asian patient population,C1511253;C1874596;C0032659;C1257890
total included in combined analysis,C0439175;C0439810;C0332257;C0002778;C0936012;C1524024
idegasp bid,
biasp $nmbr$ bid,
full analysis set n,C0002778;C0036849;C1442518;C1705195;C0936012;C1524024
idegasp biasp $nmbr$,
etd $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ] $nmbr$ ci p $nmbr$ $nmbr$,C1180255;C0008107;C3259781
end of trial,C0444930;C2746065
etd $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ] $nmbr$ ci p,C1180255;C0008107;C3259781
etr $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ] $nmbr$ ci p $nmbr$ $nmbr$,C0008107;C3259781
subpopulation,C1257890
week $nmbr$ before ee,C0332174;C0439230
week $nmbr$ non ee responders,C0332174;C0439230
crp uln,C3890735;C1519815;C4048285
adjusted mean difference $nmbr$ ci,C0008107;C3259781
facit f,C3272505
tnfi na ve,C0597484;C1272460;C1546968;C1879645;C4049872;C4552882
lev n $nmbr$,C0023556
duration of epilepsy mean sd years,C0449238;C2926735
seizure history n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
focal,C0205234
generalized,C0205246
absence,C0332197;C1689985
atypical absence,C0595948
myoclonic,
clonic,
tonic,C3543842
tonic clonic,C3543842
atonic,
cluster seizures,C1555715;C0036572;C1704332
classification of epilepsy type n,C0008902;C0008903;C0678229
idiopathica,
juvenile myoclonic epilepsy,C0270853
epilepsy with grand mal seizures on awakening,C0014549;C1720052
symptomaticb,
specific syndromes,C0039082;C1558916
undeterminedc,
seizure frequency during $nmbr$ week baseline median range,C0149775;C0168634;C1442488
prior aeds $nmbr$ n,C0332152;C0180309;C2826257
concomitant aeds n,C0521115;C0180309
phenobarbital,C0031412
freedom from gtc seizures n,C0016694;C0036572
figure $nmbr$ a median percent reduction from combined baseline in generalized tonic clonic seizures week during the $nmbr$ week treatment period full analysis set p values versus placebo calculated using ancova b median percent reduction from combined baseline in generalized tonic clonic seizures week for patients with idiopathic and symptomatic generalized epilepsy during the $nmbr$ week treatment period ancova analysis of covariance gtc generalized tonic clonic iqr interquartile range lev levetiracetam,C0301630;C0392756;C1293152;C4551656;C0494475;C0032042;C1696465;C1706408;C0444686;C1441506;C1524063;C0332174;C0439230;C0332240;C0270854;C0377265;C3693636
figure $nmbr$ a median percent reduction from combined baseline in generalized tonic clonic seizures week during the $nmbr$ week evaluation period p values versus placebo calculated using ancova b generalized tonic clonic seizure $nmbr$ responder rates during the $nmbr$ week treatment and $nmbr$ week evaluation periods full analysis set p values versus placebo calculated using logistic regression ancova analysis of covariance gtc generalized tonic clonic iqr interquartile range lev levetiracetam,C0301630;C0392756;C1293152;C4551656;C0494475;C0042295;C0032042;C1696465;C1706408;C0444686;C1441506;C1524063;C0871208;C1521828;C0814908
onset $nmbr$ [ $nmbr$ ],C0206132;C0332162
faster aspart mealtime,C0123677;C0587119
insulin aspart mealtime,C0123677;C0587119;C1708521
faster aspart,C0015663;C0123677;C0456962;C2985769
insulin aspart,C0123677;C1708521
faster aspart basal,C0123677;C0205112
basal insulin,C0650607
gender n men,C0079399;C0025266;C1522384
lb,
$nmbr$ mmol mol $nmbr$ $nmbr$ n,C3829066
change in hbalc after $nmbr$ weeks etd $nmbr$ cl,C0392747;C0443172;C1705241;C4319952;C0439230;C0596019
all participants n $nmbr$ $nmbr$,C0679646
bmi $nmbr$ kg m^ n $nmbr$ $nmbr$,C0022718;C0439209;C4054209;C0369718;C0441922
hbalc $nmbr$ $nmbr$ $nmbr$,
hbalc $nmbr$ mmol mol $nmbr$ $nmbr$ n $nmbr$ $nmbr$,C3829066
all participantst n $nmbr$ $nmbr$,
bmi $nmbr$ kg m $nmbr$ n $nmbr$ $nmbr$,C0022718;C0439209;C4054209;C0369718;C0441922
bmi $nmbr$ kg m n $nmbr$ $nmbr$,C0022718;C0439209;C4054209;C0369718;C0441922
hbalc a $nmbr$ mmol mol $nmbr$ $nmbr$ n $nmbr$ $nmbr$,C3829066
all participants^^ n $nmbr$ $nmbr$,C0679646
dose ratio at week $nmbr$ $nmbr$ cl,C0178602;C0456603;C1547037;C0869039;C1114758
hbalc $nmbr$ mmol mol,C3829066
normal baseline crp,C3890735;C4048285
elevated baseline crp,C0742906;C0168634;C1442488
pooled secukinumab,C1709595;C3179547;C2349200;C4522255
pooled placebo,C0032042;C1696465;C1706408
positive for hla b $nmbr$ n,C0439178;C1446409;C1514241;C2825490;C3812269
concomitant methotrexate use n,C0025677;C0042153;C0457083;C1947944
hscrp mg l median minimum maximum,C0806909;C1552615;C2826546
ptga of disease activity $nmbr$ $nmbr$ mm mean sd,C1292728;C0444504;C2347634;C2348143
baseline crp levels,C3890735;C0441889;C4048285
baseline crp levels $nmbr$ mg l,C0168634;C0439268;C1442488
basdai mean change from baseline,C0392747;C0443172;C1705241;C4319952
basdai $nmbr$,C1998004
asdas inactive disease,C0544452
asas partial remission,C1521726;C4552913;C4552914
with prior mi stroke n $nmbr$,C0332152;C0038454;C4554100;C2826257
cvd without mi or stroke n $nmbr$,C0007222;C3810814;C0038454;C4554100
cardiovascular risk factors alone n $nmbr$,C0850624;C0205171;C0439044;C0679994
age sd y,C0001779;C2699239
bmi sd kg m $nmbr$,C0022718;C0439209;C4054209
diabetes mellitus duration sd y,C0011849;C0449238;C2926735
hba $nmbr$ c sd mmol mol,C0019016;C3829066;C1825777;C3538758
sbp sd mm hg,C0085805;C0439475
dbp sd mm hg,C0536221;C0439475;C3813197;C4281799
heart rate sd bpm,C0018810;C2699239
egfr from the mdrd equation sd ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$,C1739039;C3811844;C3812682
moderate $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$ n,C0205081;C0439445;C1881878;C4049705;C4049706;C4085643;C4321335;C0369718;C0441922
mild $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$ n,C2945599;C0439445;C0369718;C0441922
normal $nmbr$ ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$ n,C0205307;C0439445;C0231683;C0439166;C2347086;C4553972;C0369718;C0441922
total cholesterol sd mg dl,C0201950;C0439269;C0543421
ldl cholesterol sd mg dl,C0023824;C0439269;C0202117
hdl cholesterol sd mg dl,C0023822;C0439269;C0392885
triglycerides sd mg dl,C0041004;C0439269
lipid lowering drugs n,C0086440
platelet aggregation inhibitors n,C0032177
antithrombotic medications n,C0013227;C0802604;C2598133;C4284232
blood glucose lowering drugs excluding insulin n,C0005802;C0441994;C2003888;C0013227;C3687832
insulin treatment n,C0745343
insulin naive n,C0021641;C1533581;C1579433;C3714501
rate $nmbr$ pyo,C0871208;C0033809;C1521828
hzard ratio,C0456603;C1547037
prior ml stroke,C0038454;C4554100
cvd without ml stroke,C0007222;C0038454;C4554100
all mis,C0687670;C1333208;C1412384;C3538735
all strokes,C0038454
cvd without miatroke,C0007222
cvd without ml^troke,C0007222;C0439526;C1705224;C3887665
micro macroalbuminuria,C0085672;C1553035;C3811161;C4049106
smoking n,C0037369;C0453996;C1881674
prior stroke mi n,C0332152;C0038454;C4554100;C2826257
diabetes mellitus duration y sd,C0011849;C2699239
body weight kg sd,C0005910;C2699239;C1305866
creatinine mg dl sd,C0439269;C2699239
egfr ml min $nmbr$ $nmbr$ m $nmbr$ sd,C1739039;C0439445;C3811844;C3812682;C2699239
normal egfr $nmbr$ n,C0205307;C0231683;C0439166;C2347086;C4553972
mild impairment egfr $nmbr$ $nmbr$ n,C0221099;C0684336
moderate impairment egfr $nmbr$ $nmbr$ n,C0205081;C0221099;C0684336;C1881878;C4049705;C4049706;C4085643;C4321335
uacr mg g q $nmbr$ q $nmbr$,C1300563
total cholesterol mmol l sd,C0201950;C2699239;C0543421
ldl c mmol l sd,C1532563;C2699239
sbp mm hg sd,C0439475;C2699239
dbp mm hg sd,C0439475;C2699239
hr bpm sd,C2699239
liraglutide n,C1456408
hazard ratio [ $nmbr$ ci],C2985465;C0008107;C3259781
$nmbr$ $nmbr$ [ $nmbr$ $nmbr$ $nmbr$ ],
egfr $nmbr$ ml min $nmbr$ $nmbr$,C1739039;C0439445;C3811844;C3812682
outcome_subgroup,C1079230;C1515021
egfr_p_interaction,C1739039;C1704675;C3811844;C3812682
albuminuria_p_interaction,C0001925;C1704675
primary cv endpoint,C2986535;C3538987;C4048877;C4318503
egfr s $nmbr$ ml min $nmbr$ $nmbr$ m^,C1739039;C0439445;C3811844;C3812682
micro macroaibuminuria,C0085672;C1553035;C3811161;C4049106
expanded cv endpoint,C2349179;C2826544
egfr s $nmbr$ o ml min $nmbr$ $nmbr$ m^,C1739039;C0439445;C3811844;C3812682
egfr $nmbr$ ml min $nmbr$ $nmbr$ m^,C1739039;C0439445;C3811844;C3812682
hospitalization for unstable ap,C0019993;C0002680;C3887950
acute increase in serum creatinine,C0442805;C0201976;C0600061
demographic factors,C0011292;C0011298
residence in asia n,C0237096;C0003980
medical and lifestyle history,C0199168;C0205476;C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
history of macrovascular disease at baseline n,C0683519;C0730226;C0850708;C0944983;C0168634;C1442488
current alcohol drinking n,C0001962;C0001975;C0001948;C0684271;C0369718;C0441922
hemoglobin a,C0019016
ecfr ml min per $nmbr$ $nmbr$ m $nmbr$,C0439445
uacr pg mg,C1627892
$nmbr$ $nmbr$ $nmbr$ $nmbr$ ^ $nmbr$ $nmbr$,
randomized treatments n,C0034656;C0087111;C3815594
perindopril indapamide,C1273169
intensive blood glucose control,C3267174
blood glucose lowering treatments n,C0005802;C0441994;C2003888;C0087111
oral hypoglycemic agentsj,C0359086
bp lowering treatments n,C0037623;C0087111;C1415692;C1708288;C4318478
diuretics^,C0012798
angiotensin converting enzyme inhibitors^,C0003015;C2757044
angiotensin ii receptor blockers,C0521942;C2757003
any bp lowering agents^,C0450442;C1254351;C1521826
changes in serum creatinine pmol l,C0392747;C0443172
first serum creatinine,C0201976;C0600061
second serum creatinine,C0201976;C0600061
increase in serum creatinine,C0442805;C0201976;C0600061
n events n subjects,C0681850;C1550501;C1706203;C2349001;C2697811
combined major macrovascular events neohrodathv and all cause mortalitv,C0205082;C0205164;C4318856;C4521762;C0015127;C1524003
major macrovascular events,C0441471;C3541888
new or worsenina neohrodathv,C0205314
all cause mortalitv,C0015127;C1524003
n events,C0441471;C3541888
combined major macrovascular events,C0441471;C3541888
neohrodathv and all cause mortalitv,C0015127;C1524003
new or worsentna neohrodathv,C0205314
golden $nmbr$ and $nmbr$,
golden $nmbr$,
glycopyrrolate glycopyrrolate eflow cs $nmbr$ meg eflow cs $nmbr$ meg n $nmbr$ n $nmbr$,C0017970;C0010182;C0271160;C3540510;C4085345
tiotropium $nmbr$ meg n $nmbr$,C0024489;C0025175;C0072225
glycopyrrolate eflow cs $nmbr$ meg n $nmbr$,C0017970;C0010182;C0271160;C3540510;C4085345
black or african heritage,C0005680;C0027567;C0085756;C0439541;C2986513
body mass index kg rn \ mean sd,C0005893;C2699239;C0578022;C1305855
number of copd exacerbations within $nmbr$ months mean sd,C0237753;C0449788;C0439231;C2699239
history of oxygen use yes n,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
high cardiovascular risk n ^,C0332167;C3272283;C4050568;C4319571
background laba use yes n,C0042153;C0457083;C1947944
inhaled corticosteroid yes n,C0004048;C0001617;C3536709
pulmonary function tests post bronchodilator mean sd,C0024119;C2699239;C2598152
fevi fvc,C0802741;C3815113
fevi percent predicted,C0429706;C0439165;C0849974;C1561566;C4528367;C0681842;C1882327
post bronchodilator fevi n,C2599594;C0429706;C0849974;C1561566;C4528367
$nmbr$ predicted to,C0681842;C1882327
$nmbr$ predicted,C0681842;C1882327
baseline in check pifr l min,C0702093;C1524029;C3813700
sgrq scores mean sd,C0444504;C2699239;C2347634;C2348143
activity,C0205177;C0439167;C0441655;C1561536;C3668946;C4049938;C4049939
impacts,C1825598;C4049986
sgrq responder,
odds ratio and $nmbr$ cl,C0028873;C0596019
sun $nmbr$ $nmbr$,C0038817;C0376223
lcl,C3658298
ucl,
background laba use,C0042153;C0457083;C1947944
fev predicted,C3714541;C0681842;C1882327
pifr l min,C0702093;C1524029;C3813700
$nmbr$ l min,C0439393
$nmbr$ l_ min,C0439393
participants with hf at baseline,C0679646;C0018488;C1313497;C1538440;C3273279;C0168634;C1442488
participants without hf at baseline,C0679646;C0018488;C1313497;C1538440;C3273279;C0168634;C1442488
total carmelina population,C3258257
europe including south africa,C0015176;C0037712
egfr mdrd n,C1739039;C3811844;C3812682
uacr mg g median $nmbr$ th $nmbr$ th percentile,C1300563;C1264641
uacr n,
diabetes mellitus duration y,C0011849;C0449238;C2926735
heart rate bpm mean sd,C0018810;C2699239
glucose lowering therapy n,C0017725;C0441994;C2003888;C0039798;C0087111;C1363945
antihypertensives n,C0003364
asa n,C0004057;C3853627
patients with event patients analysed,C0030705;C0441471;C4019010
p for interaetion,C0369773;C2603361
plaeebo,
raee,
blaek afriean ameriean,
ethnieity,
hispanie latino,C0086528
not hispanie latino,C1518422;C0086528
regiont,
enrope sonth afriea,
north ameriea,C1709269
latin ameriea,
glyeated haemoglobin,C0019046
$nmbr$ ky nr,C0027496;C3844738
blood pressure eontrolt,C0005823;C1271104;C1272641
$nmbr$ ml niin l $nmbr$ ni,C0028075;C2348274;C3869926;C3869927
urine albumin to ereatinine ratio,C0042038;C0587185;C2362049
not on metformin,C1518422;C0025598
angiotensin eonverting enzyme inhibitors angiotensin reeeptor bloekers,C0014432;C1152555;C2756995
angiotensin eonverting enzyme inhibitors,C0014432;C1152555;C2756995
caleium ehannel bloekers ccb,C0006684
beta bloekers,C0330390;C0439096;C2004068
diureties,
loop diureties,C0445022
isehemie heart disease,C0018799
duration of type $nmbr$ diabetes,C0449238;C2926735
ckd prognosis by kdigo,C0033325;C3854082
cardio renal risk,C0035647;C4552904
albuminuria and previous maerovaseular disease without established renal disease,C0001925;C0012634;C0022658
established renal disease egfr $nmbr$ $nmbr$ $nmbr$ ml inin l $nmbr$ m $nmbr$ with an uacr $nmbr$ mg g without previous maerovaseular and albuminuria disease,C0439268;C0439294;C0456615;C0205156;C1552607;C0001925;C0012634
albuminuria and previous maerovaseular disease plus established renal disease egfr $nmbr$ $nmbr$ ml min l $nmbr$ in with an uacr $nmbr$ mg g or egfr $nmbr$,C0001925;C0022658;C0439445;C1300563;C1739039;C3811844;C3812682
established renal disease,C0443211;C0022658;C1272684
established maerovaseular disease and albuminuria,C0443211;C0012634;C1272684;C0001925
prevalent kidney disease egfr $nmbr$ ml min usm^ or maeroalbuminuria uacr $nmbr$ mg g,C0022658;C0439445;C1300563
patients with a prior mi or stroke at baseline,C0030705;C0332152;C2826257;C0038454;C4554100
patients without a prior mi or stroke at baseline,C0030705;C0332152;C2826257;C0038454;C4554100
empagliflozin pooled n $nmbr$,C1709595;C2349200;C4522255
north america plus america and new zealand,C0028405;C0027978;C0324547
estimated glomerular filtration rate mdrd ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$,C3811844;C0439445
time since diagnosis of type $nmbr$ diabetes mellitus,C0040223;C3541383
$nmbr$ to $nmbr$ y,
ldl cholesterol lowering therapy,C0023824;C0202117;C0441994;C2003888;C0039798;C0087111;C1363945
glucose lowering medication,C0017725;C0441994;C2003888;C0013227;C3244316;C4284232
highest,C1522410
empagllflozin,
randomized group by subgroup interaction,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
rvw,
prior ml or stroke at baseline,C0439526;C1705224;C3887665;C0038454;C4554100
all causa mortality,C0026565;C0026566
hospitalization for heart failure or cv death,C3898876;C0011065;C1306577;C4082313;C4552775
empagllflozln,
history of ml at baseline,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0168634;C1442488
history of stroke at baseline,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062;C0168634;C1442488
$nmbr$ n n,C0369718;C0441922
estimated cv risk at baseline,C1519101;C0168634;C1442488
lowest,C1708760
$nmbr$ polnt mace,C0349381;C0949745;C1445339
hospitalization for heart failure or cv,C3898876;C3538987;C4048877;C4318503
gly $nmbr$ g bid,C0017890;C0439267;C0523677
baseline fev $nmbr$ median range l,C0168634;C0549183;C0876920;C2347635;C2348144;C2939193;C1442488
high cv risk,C0332167;C3272283;C4050568;C4319571
$nmbr$ yearsa,
$nmbr$ a n $nmbr$,C0369718;C0441922
post bronchodilator fev $nmbr$ predictedb,C2599594;C3714541
preferred term,C1709637;C2347664
fev $nmbr$ predicted $nmbr$,C0681842;C1882327
gly,C0017890;C0523677
$nmbr$ g bid n $nmbr$,C0439267
any teae,
copd worsening,C0024117;C1412502;C3714496;C0332271;C1457868;C1546960
chest discomfort,C0235710
any serious teaes,C0205404
age $nmbr$ yearsa,C0001779
any teaes,
notes,C1317574
^ $nmbr$ incidence in any treatment group in the overall safety population,C0021149;C0220856;C0032659;C1257890
asubset of the $nmbr$ years subgroup,C0439234;C1079230;C1515021
abbreviations teae treatment emergent adverse event gly glycopyrrolate inhalation solution bid twice daily,C4684800;C0585361
mace category n [ir],C0349381;C0683312;C3889287;C0949745;C1445339;C0022065;C0022071;C1448132
chlorthalidone n $nmbr$,C0008294
lisinopril n $nmbr$,C0065374
incident dm or change in,C0011816;C3250443;C0392747;C0443172;C1705241;C4319952
no incident dm or change in fg $nmbr$,C0011816;C3250443;C0392747;C0443172;C1705241;C4319952
fg $nmbr$,C0016703;C0439214;C2348814
lvh by ecg echo,C0232306;C0058928;C1655045
visit $nmbr$ sbp mm hg,C0085805;C0439475
visit $nmbr$ dbp mm hg,C0536221;C0439475;C3813197;C4281799
serum fg mg dl,C0439269
quintile range mg dl,C1508496;C0439269
serum cholesterol mg dl,C0587184;C0439269
mean score min max range,C1514721;C2348147;C3542016
grs,C1412761;C3539564
q $nmbr$ n $nmbr$,
test for trend,C0022885;C0039593;C0392366;C0456984;C1515976;C3831328;C4318744
with cerebrovascular disease,C0007820
without cerebrovascular disease,C0007820
p value w,C1709380
ith vs without,
age y meantsd,C0001779
other region no,C0017446;C0205147
duration of diabetes microvascular disease no,C0011847;C0872146;C0011849
atherosclerotic vascular disease no,C0004153
amputation no,C0002688;C0332840;C1546539
body mass index blood pressure mmhg,C0005893;C0439475;C0578022;C1305855
hba $nmbr$ c cholesterol mmol l,C0008377;C1532563
microalbuminuria no,C0730345
macroalbuminuria no drug therapy no,C0013216;C0013217
antithrombotic i,C0021966;C0221138
participants with an event per $nmbr$ patient years,C0679646;C0441471;C4019010;C0030705;C0439234
rvalue,
$nmbr$ kg m^,C0022718;C0439209;C4054209
bp control,C0243148;C1550141;C1882979;C2587213;C3274648;C4553389
sbp $nmbr$ mmhg or dbp $nmbr$ mmhg,C0085805;C0439475;C0536221;C3813197;C4281799
duration of diabetes mellitus,C0449238;C2926735
$nmbr$ ml min per $nmbr$ $nmbr$ m^,C0439445
history of pvd,C4534349
hospitalized heart failure,C0018801;C0018802;C4554158
progression of albuminuria,C0242656;C0449258
serious decline in kidney function,C0205404;C0232804
duration of t $nmbr$ d y,C0449238;C2926735
baseline hba $nmbr$ c $nmbr$ mmol mol $nmbr$ $nmbr$ n,C0019016;C3829066;C1825777;C3538758
fpg mmol la,C0023031;C0023749;C0230347;C2346906;C4553351
aha status at screeningb n,C0050451;C0449438;C0772110
not on an aha,C0050451;C0772110
on non metformin aha,C0050451;C0772110
on metformin ir or metformin xr $nmbr$ mg d,C0022065;C0022071;C1448132;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
supplemental figure $nmbr$ point estimates and $nmbr$ confidence intervals for differences in hba $nmbr$ c mean response variable in selected subgroups at week $nmbr$ for each subgroup n is given for sitagliptin placebo treatment groups,C1552961;C0750572;C2347617;C3714763;C0009667;C0439828;C4553760;C0332174;C0439230;C1079230;C1515021;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
$nmbr$ parameter,C0549193;C1704769;C2350001
baseline hbalc $nmbr$ mmol mol $nmbr$ $nmbr$,C0168634;C3829066;C1442488
glimepiride,C0061323
stratification factor menopausal status n,C1514984;C1513126
female premenopausal,C0043210;C0086287;C1705497;C1705498;C0279752
female perimenopausal or,C0043210;C0086287;C1705497;C1705498;C0849668;C3839366
female $nmbr$ years postmenopausal,C0043210;C0232970;C0086287;C1705497;C1705498
dipeptidyl peptidase $nmbr$ inhibitors,C0003015
other blood glucose lowering agents,C0005802;C0441994;C2003888;C0450442;C1254351;C1521826
sulphonamides urea derivatives,C0038760;C0243072
ertugliflozin $nmbr$ mg vs placebo glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C0061323;C1696465;C1706408
female participants who are $nmbr$ years postmenopausal,C0043210;C3272598;C0086287;C1705497;C1705498;C0439234;C0232970
ertugliflozin $nmbr$ mg vs placebo glinepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C1696465;C1706408
ertugliflozin $nmbr$ mg vs placebo glirneplride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C1696465;C1706408
eduglinozin $nmbr$ mg vs placebo glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C0061323;C1696465;C1706408
ertuglifldzin $nmbr$ mg vs placebo glinepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C1696465;C1706408
erlugliflozin $nmbr$ mg vs placebo glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C0061323;C1696465;C1706408
distal forearm,C0588203
ertugliflozin $nmbr$ mg vs placebo giimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C1696465;C1706408
ertuglrflozin $nmbr$ mg vs placebo glimepiride,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C0061323;C1696465;C1706408
rivaroxaban $nmbr$ $nmbr$ mg bid aspirin $nmbr$ mg od,C0229089;C0439164;C1512019;C3273373;C3665488
peri operative cabg participants,C0010055;C0679646
teriparatide n $nmbr$,C0070093
number of patients with available data,C2360800;C1511726;C3245479;C3714741
daily dose of vitamin d iu day,C2348070;C0014695;C0042866;C2936842;C3537249;C3714503
number of patients with dose available,C2360800;C0178602;C0869039;C1114758;C0470187
patients with supplemental vitamin d dose of $nmbr$ iu day starting at screeningc n,C0030705;C0014695;C0042866;C2936842;C3537249;C3714503;C0439659
serum $nmbr$ oh d concentrations ng ml mean sd,C0229671;C0220853;C1546774;C1550100;C0439275;C2699239
patients with serum $nmbr$ oh d $nmbr$ $nmbr$ and,C0030705;C0220853
teriparatide n n,C0070093
risedronate n n,C0246719
risk ratio [ $nmbr$ cl],C0028873;C0242492;C0596019
a new vertebral fractures mfas,C1549796;C1549980
baseline vitamin d,C0014695;C0042866;C2936842;C3537249;C3714503
sufficient,C0205410
insufficient,C0205412;C0231180;C0439856
overall vero population,C0032659;C1257890
b pooled new and worsened vertebral fractures mfas,C1709595;C0205314;C2349200;C4522255;C1549796;C1549980
hazard ratio [ $nmbr$ cl],C2985465;C0596019
c clinical fractures fas,C0205210;C0016658
d non vertebral fragility fractures fas,C0080179;C0302113
hazard ratio $nmbr$ cl],C2985465;C0596019
e major non vertebral fragility fractures fas,C0205082;C0080179;C0205164;C4318856;C4521762
rivaroxaban plus,C1739768
rivaroxaban plus aspirin $nmbr$ cl,C1739768;C0004057
no of events patients yr,C0030705;C0439234
$nmbr$ to $nmbr$ yr,C0439234
$nmbr$ to $nmbr$ mm hg,C0439475
lei $nmbr$ n $nmbr$,C0023401;C0428209
ldi b $nmbr$ n $nmbr$,
integrated analysis set n $nmbr$,C0002778;C0036849;C1442518;C1705195;C0936012;C1524024
age mean years sd gender n,C1510829;C0079399;C1522384
other multiple,C0439064
cdmard experience n,C0237607;C0596545
mtx at baseline n,C0025677;C1417487
time since psa onset mean years sd,C0449244
active pso wi $nmbr$ bsa $nmbr$ n y,C0205177;C0043193;C1520135;C3853793;C3888249
current enthesitis n,C0521116;C1282952;C1705970
current dactylitis n,C0521116;C0239161;C1705970
leeds enthesitis index mean sd,C0451148;C2699239
leeds dactylitis index basic mean sd ^,C0239161;C2699239
fig $nmbr$ patients reporting no enthesitis a and no dactylitis b at week $nmbr$ integrated analysis set with baseline enthesitis and dactylitis are shown as the percentages of responders $nmbr$ cl nri p vs pbo $nmbr$ $nmbr$ p vs pbo $nmbr$ $nmbr$ abbreviations achill tend insert achilles tendon insertion cl confidence interval ixeq $nmbr$ w ixekizumab $nmbr$ mg every $nmbr$ weeks ixeq $nmbr$ w ixekizumab $nmbr$ mg every $nmbr$ weeks lat epicond lateral epicondyle lei leeds enthesitis index ldi b leeds dactylitis index basic med fern cond medial femoral condyle nri nonresponder imputation pbo placebo,C0030705;C0700287;C1282952;C0002778;C0036849;C1442518;C1705195;C0936012;C1524024;C0168634;C1442488;C0239161;C1547282;C0596019;C0031962;C0000723;C0001074;C0009667;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0439230;C0064678;C0331729;C1856054;C2826243;C0032042;C1696465;C1706408
currently smoker,C0521116;C0337664
time since ipf diagnosisa mean years sd,C0556970;C0034069;C1800706
mean ml sd,C0439526;C2699239;C1705224;C3887665
median ml,C0439526;C1705224;C3887665
predicted value sd,C0681842;C2699239;C1882327
total sgrq mean total score sd,C2964552;C2699239
any aes,C1412268;C2699274
most frequent aesa,C0332183
lung infection,C0876973;C4552950
ipf,C0034069;C1800706
upper abdominal pain,C0232492
alt increased,C1266129;C4553172;C0205217;C0442805
ast increased,C1415181;C3891303;C0205217;C0442805
ggt increased,C1415053;C0205217;C0442805
aes leading to dose reduction of study drugb,C1412268;C2699274;C0861063;C0178602;C0869039;C1114758
transaminases increased,C0002594;C0919834;C0205217;C0442805
aes leading to discontinuation of study drugb,C1412268;C2699274;C0332152;C0457454;C1444662;C4552847;C1522538
blood bilirubin increased,C0005767;C0005437;C0005768;C0229664;C0205217;C0442805
liver disorder,C0023895
lung neoplasm malignant,C0024121;C0205282
investigator defined drug related aes,C1412268;C2699274
severe aes,C1412268;C2699274
fatal aes,C1412268;C2699274
risk factor,C0035648
pioglitazone group n $nmbr$,C0071097;C0441848
continuous variables mean sd ^,C0439828;C2699239
fasting glucose level mg dl,C0202045;C0439269
hemoglobin level,C0019029;C1314664
homa ir score,C0449820;C4050231
diastolic pressure mm hg,C0428883;C0439475
total cholesterol level mg dl,C0878805;C0439269;C1445957
triglycerides level mg dl,C0428475;C0439269
hdl c level mg dl,C0441889;C0439269;C0456079;C1547707;C2946261
ldl c level mg dl,C0441889;C0439269;C0456079;C1547707;C2946261
categorical variables no,C0439828
adherence $nmbr$,C1510802
stroke m $nmbr$,C0038454;C4554100
stroke m l hf hospitalization,C0456616;C0019993
no previous copd medication,C0013227;C3244316;C4284232
previous ics only,C0815320;C4551720
previous labd only,C0205156;C0396059;C1552607
previous ics labd,C0205156;C0396059;C1552607
subjects,C0681850;C1550501;C1706203;C2349001;C2697811
former smokers,C0337671
screening fev $nmbr$ predicted,C0681842;C1882327
one or more exacerbations,C0205447;C4086268
ff $nmbr$ g,C4554348;C0439267
vi $nmbr$ g,C0205999;C0439267
ff vi $nmbr$ $nmbr$ g,C0205999;C0439267
total subjects,C0681850;C1550501;C1706203;C2349001;C2697811
subjects who did not receive labd prior to the study,C0681850;C3272598;C1550501;C1706203;C2349001;C2697811;C1518422;C1514756;C0396059;C0332152
active versus placebo,C0205177;C3853793;C3888249;C0032042;C1696465;C1706408
reduction in risk $nmbr$ ci,C0520870;C1137094
subjects who did receive labd prior to the study,C0681850;C3272598;C1550501;C1706203;C2349001;C2697811;C1514756;C0396059;C0332152
labd alone,C0396059;C0205171;C0439044;C0679994
ics labd,C0815320;C0396059;C4551720
a those receiving no inhaled pre treatment maintenance medication,C1514756;C2347660
b those on inhaled corticosteroids and long acting bronchodilators as previous treatment use,C0004048;C0001617;C3539185;C3540725;C3540726;C3540727;C0006280;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704
previous ics alone,C0815320;C4551720;C0205171;C0439044;C0679994
previous labd alone,C0205156;C0396059;C1552607;C0205171;C0439044;C0679994
overall mortality,C0026565;C0026566
ff vi $nmbr$ $nmbr$ ci $nmbr$ $nmbr$,C0008107;C3259781
ff vi $nmbr$ $nmbr$ $nmbr$,C4554348;C0205999
ff $nmbr$ $nmbr$ ci $nmbr$ $nmbr$,C0008107;C3259781
ff $nmbr$ $nmbr$ $nmbr$,C4554348
vi $nmbr$ $nmbr$ ci $nmbr$ $nmbr$,C0008107;C3259781
vi $nmbr$ $nmbr$ $nmbr$,C0205999
risk of moderate severe exacerbations,C0332166
distribution of metformin dose at randomization n,C0520511;C1704711;C0034656
background aha therapy at screening a n,C0039798;C0087111;C1363945;C0369718;C0441922
number of agents,C0237753;C0449788
hong kong,C0019907;C2987742
baseline fpg mg dl,C0168634;C0439269;C1442488
baseline egfr ml min $nmbr$ $nmbr$ m $nmbr$,C0168634;C0439445;C1442488
ertugliflozin,C4079805
background aha therapy at screening a,C0039798;C0087111;C1363945
ls mean $nmbr$ ci a,C0008107;C3259781
pairwise comparison,C1707455
difference in ls means $nmbr$ ci a,C1705241;C1705242
week $nmbr$ ertugliflozin $nmbr$ mg vs placebo,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C0032042;C1696465;C1706408
$nmbr$ ci a,C0008107;C3259781
$nmbr$ ae,C3887670
drug relateda,C0013227;C1254351
$nmbr$ sae,C1519255;C1622657;C4553214
because of ae,C3887670
because of drug relateda ae,C0013227;C3887670;C1254351
because of sae,C1519255;C1622657;C4553214
because of drug relateda sae,C1519255;C1622657;C4553214
deathsb,
tier $nmbr$ aes,C1412268;C2699274
gmi women,C0043210
gmi men,C0025266
symptomatic hypoglycaemia,C0020615;C4553659
hypovolaemia,C0546884
other selected aes,C1412268;C2699274
documented hypoglycaemiac,C1301725;C1609436
due to ae,C3887670
due to drug relateda ae,C0013227;C3887670;C1254351
due to sae,C1519255;C1622657;C4553214
due to drug relateda sae,C1519255;C1622657;C4553214
characteristic a,C1521970
leader,
cv historya,C3538987;C4048877;C4318503
heart failure nyha ii iii n,C0018801;C0018802;C4554158
coronary artery bypass graft n,C0010055;C1260596
ischaemic stroke n,C0948008
carotid artery stenosis n,C0007282
$nmbr$ stenosis of major artery n,C0038449
lv systolic dysfunction n,C0023128;C0749225;C0731033;C1881413
lv diastolic dysfunction n,C0023128;C0520863;C0731033;C1881413
diabetes medication,C0013227;C3244316;C4284232
oral antihyperglycaemic n,C0359086
metformin n,C0025598
su n,C0038642;C1705534
moderate or severe renal disease n,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C1836348
cv medication,C0013227;C3244316;C4284232
acei n,
lipid lowering therapies n,C0585943
anti platelet agents n,C0432633
sustain,C0443318;C2732140
moderate or severe renal disease b n,C0205081;C1881878;C4049705;C4049706;C4085643;C4321335;C1836348
diabetes duration at baseline,C0449238;C2926735
hazard ratio glp $nmbr$ analogue vs placebo [ $nmbr$ cl],C2985465;C0243071;C0032042;C1696465;C1706408;C0596019
glp $nmbr$ analogue,C0018301;C0243071;C1422069;C1425391;C1539338;C2350813
bempedoic acid n $nmbr$,C3659310
cardiovascular risk factor no,C0850624
lipid measures at baseline mg dl,C0079809;C1879489
total cholesterol^,C0201950;C0543421
ldl cholesterol^,C0023824;C0202117
non hdl cholesterol j,C0729627;C1535899
hdl cholesterol^,C0023822;C0392885
apolipoprotein,C0003591
high sensitivity c reactive protein mg liter,C0006560;C0475211;C1413716;C4048285
concomitant lipid modifying therapy no,C1707479;C0023779
intensity of statin therapy at baseline no,C0522510;C1278454;C0168634;C1442488
bempedoic,
least squares mean difference $nmbr$ cl,C0023189;C0596019
cardiovascular disease risk category,C3699655
background lipid lowering therapy,C1706907;C0585943
intensity of statin therapy,C0522510;C1278454
low or moderate,C0205251;C1550472;C3890211;C4048187;C4321351;C4522223;C0205081;C1881878;C4049705;C4049706;C4085643;C4321335
el n,C1416870;C1447747;C1823249;C3811107;C3811848;C3815598
ll n,C0369718;C0441922
age y median q $nmbr$ q $nmbr$,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
acs presentation,C0742343;C0449450;C4318612
$nmbr$ mg ld,C0024671;C0694649;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
us site,C0205145;C1515974;C2825164
time from ld to pci min median q $nmbr$ q $nmbr$,C0040223;C3541383;C0702093;C0549183;C0876920;C2347635;C2348144;C2939193;C1524029;C3813700
catheter site femoral,C0449652;C0015811
bivalirudin used,C0168273;C1273517
gp iib iiia inhibitor used,C0016011;C1999216;C1273517
no of vessels with $nmbr$ stenosis,C0005847;C0678234;C1261287;C2632116
no of vessels treated,C0005847;C1522326
received drug eluting stent,C1514756;C1322815
left main coronary artery bifurcation,C3898614
pci duration,C0449238;C2926735
dosing,
cangrelor n n,C1121991
clopidogrel n n,C0070166
adjusted $nmbr$ or $nmbr$ cl,C0456081;C0596019
d mi idfvst,C3810814
early load,C1550025;C1704782;C1708715
late load,C1550025;C1704782;C1708715
adjusted or $nmbr$ cl,C0456081;C0596019
severe lite threatening,C0205082;C4050465;C4050466
transfusions,C0005841;C0199960;C1879316
hfref n $nmbr$,
hf without known reduced ef n $nmbr$,C0018488;C1313497;C1538440;C3273279
no hx of hf n $nmbr$,C0262926;C3814444
age yrs median iqr,C0001779;C0549183;C0876920;C2347635;C2348144;C2939193
hemoglobin ale median iqr,C0019046;C0549183;C0876920;C2347635;C2348144;C2939193
duration of diabetes years median iqr,C0449238;C2926735
history of dyslipidemia,C0019664;C0019665;C0262512;C0262926;C1705255;C2004062
main etiology of heart failure,C0015127;C1314792;C1524003
non ischemic,C1518422;C0475224
history of coronary arteiy disease,C0683519;C0730226;C0850708;C0944983
cgfrby ckd epi ml min $nmbr$ $nmbr$ m $nmbr$ median iqr,C0162734;C0439445;C4281721;C0549183;C0876920;C2347635;C2348144;C2939193
mineralcorticoid receptor antagonist,C4543207
km rate,C0871208;C1521828
cardiovascular death hospitalization for heart failure,C3898876
hfref,
nothfref,
hf without known reduced ef,C0018488;C1313497;C1538440;C3273279
without hx of hf,C0262926;C3814444
age in years median iqr,C1510829;C0549183;C0876920;C2347635;C2348144;C2939193
blaek,
duration of diabetes in years median iqr,C0449238;C2926735;C0439234;C0549183;C0876920;C2347635;C2348144;C2939193
hbalc in median iqr,C0549183;C0876920;C2347635;C2348144;C2939193
egfr in ml min $nmbr$ $nmbr$ m^ median iqr,C1739039;C3811844;C3812682;C0549183;C0876920;C2347635;C2348144;C2939193
prior cad,C1504769;C2239547;C3813548;C4284121
prior pad,C0182158;C0332568;C3540603;C3669270;C3814046;C4319657
insulin at baseline,C0021641;C1533581;C1579433;C3714501
betablocker,C0001645
cv death or hhf,C0011065;C1306577;C4082313;C4552775
patients with prior ml hr $nmbr$ cl,C0030705;C0332152;C2826257
patients with ascvd but no prior ml hr $nmbr$ cl,C0030705;C3665365;C0332152;C0596019;C2826257
patients with only mrf hr $nmbr$ cl,C0030705;C0312443;C0596019;C1412879
absolute risk reductions,C3179139
ascvd no prior ml,C3665365;C0439526;C1705224;C3887665
cv death ml or ischemic stroke,C0439526;C1705224;C3887665;C0948008
tanezumab all doses combined,C2346819;C0178602;C0205195
tanezumab $nmbr$ $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
tanezumab $nmbr$ mg,C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
tanezumab all doses combined nsaida,C2346819;C0178602;C0205195
tanezumab $nmbr$ $nmbr$ mg nsaid,C0003211;C3536840
tanezumab $nmbr$ mg nsaid,C0003211;C3536840
active comparatorb,C0205177;C3853793;C3888249
diabetesc,
severe oa symptoms at baselined,C0436345;C0029408;C3887876
less severe oa symptoms at baseline,C0436345;C0029408;C3887876
aged $nmbr$ years,C0001779;C0439234;C0001792;C1999167
figure $nmbr$ least squares mean change in womac pain from baseline to week $nmbr$ for the subgroup analyses notes p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ vs placebo ^p $nmbr$ $nmbr$ ^^p $nmbr$ $nmbr$ ^^^p $nmbr$ $nmbr$ vs naproxen abbreviations bid twice daily ls least squares oa osteoarthritis sem standard error of the mean womac western ontario and mcmaster universities osteoarthritis index,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488;C2986480;C1317574;C0032042;C1696465;C1706408;C0023189;C1710181;C3472647
figure $nmbr$ least squares mean change in womac physical function from baseline to week $nmbr$ for the subgroup analyses notes p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ vs placebo ^p $nmbr$ $nmbr$ ^^p $nmbr$ $nmbr$ ^^^p $nmbr$ $nmbr$ vs naproxen abbreviations bid twice daily ls least squares oa osteoarthritis sem standard error of the mean womac western ontario and mcmaster universities osteoarthritis index,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488;C2986480;C1317574;C0032042;C1696465;C1706408;C0023189;C1710181;C3472647
figure $nmbr$ least squares mean change in pga from baseline to week $nmbr$ for the subgroup analyses notes p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ vs placebo ^p $nmbr$ $nmbr$ ^^p $nmbr$ $nmbr$ ^^^p $nmbr$ $nmbr$ vs naproxen abbreviations bid twice daily ls least squares oa osteoarthritis pga patient s global assessment sem standard error of the mean womac western ontario and mcmaster universities osteoarthritis index,C0392747;C0443172;C1705241;C4319952;C0168634;C1442488;C2986480;C1317574;C0032042;C1696465;C1706408;C0023189;C0030705;C1710181;C3472647
figure $nmbr$ percentage of patients with $nmbr$ $nmbr$ $nmbr$ and $nmbr$ improvement on the womac pain subscale at week $nmbr$ in the subgroups notes p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ vs placebo ^p $nmbr$ $nmbr$ ^^p $nmbr$ $nmbr$ ^^^p $nmbr$ $nmbr$ vs naproxen abbreviations bid twice daily oa osteoarthritis womac western ontario and mcmaster universities osteoarthritis index,C0439165;C1549488;C1561533;C2986411;C0030193;C0518090;C1962977;C2984058;C4085210;C4085211;C4085212;C4553004;C4554132;C0332174;C0439230;C1079230;C1317574;C0032042;C1696465;C1706408;C3472647
ethnicity not hispanic latino n,C0015031;C0243103;C1518424;C0086528
background lipid therapy per acc aha definition n a,C0039798;C0087111;C1363945
moderate intensity statin,C4081855;C0360714
coronary artery stenosis $nmbr$,C0242231
coronary artery bypass,C0010055
copd n,C0024117;C1412502;C3714496
diabetes related medication use n,C0011847;C0240320;C0011849
insulin use n,C0240016
lipid values mean sd,C0023779;C2699239
non hdl c mmol l mean sd,C1532563;C2699239
apob g l mean sd,C0439294;C2699239;C0456615
lp a nmol l mean sd,C0065058;C2699239;C1439335;C4553379
triacylglycerol mmol l mean sd,C1532563;C2699239
hba $nmbr$ c mmol mol median q $nmbr$ q $nmbr$,C0019016;C3829066;C1825777;C3538758
fasting serum glucose mmol l median q $nmbr$ q $nmbr$,C0202041;C1532563;C3534430
percent change from baseline to week $nmbr$ in auc mean sem,C3272907;C0332174;C0439230;C0376690;C0444504;C2347634;C2348143
baseline tg $nmbr$ $nmbr$ mmol l,C0168634;C1532563;C1442488
chylomicron triglycerides,C0008731;C0041004;C1325761
chylomicron cholesterol,C0008731;C0008377;C1325761
apob $nmbr$,C0003593;C3252643
age s $nmbr$ yr,C0001779;C0439234
major coronary event,C0205082;C0741923;C0205164;C4318856;C4521762
age $nmbr$ $nmbr$ yr,C0001779;C0439234
c $nmbr$ e $nmbr$ fab bolus n $nmbr$,C1186706;C1511237;C1705509;C3812160
c $nmbr$ e $nmbr$ fab bolus and infusion n $nmbr$,C1186706;C1511237;C1705509;C3812160;C0574032;C1827465
risk factors of group,C0035648;C1553898
elevated cholesterol,C0020443
history of smoking,C1519384
vascular disease of group,C0042373
cerebral,
previous infarction of group,C0205156;C0021308;C1552607
previous coronary procedure of group,C0018821;C1279986
angioplasty,C0162577;C1548817
no of diseased vessels of group,C0005847;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
coronary procedure of group,C0018821;C1279986
atherectomy,C0162513
duration of procedure,C2346509
contrast used ml,C0439526;C1705224;C3887665
thrombolytic agents,C0016018
of group,C0441833;C0687744;C1257890;C1519504;C1705428;C1705429
lowest activated clotting,C1708760;C1879547;C0005778;C1328723
time sec,C0040223;C0565930;C3541383
subgroup $nmbr$,C1079230;C1515021
c $nmbr$ e $nmbr$ fab bolus,C1186706;C1511237;C1705509;C3812160
and infusion,C0574032;C1827465
harzard ratio $nmbr$ ci,C0008107;C3259781
harzar ratio $nmbr$ ci,C0008107;C3259781
$nmbr$ $nmbr$ $nmbr$ $nmbr$ l l,C3539687
entry category,C0683312;C3889287
unstable,C0443343;C1883468
angina or acute mi,C0002962;C0155626
anatomy,C0002808;C0700276;C1384516
dalteparin n $nmbr$,C0206461
ulcer,C0041582;C3887532
inclusion findings,C2607943;C2926606;C3539655
unstable but no rest angina,C0002965
rest angina but not past $nmbr$ h,C0002965;C0152172;C1414318;C4284302
rest angina past $nmbr$ h,C0002965;C0152172
non q wave myocardial infarction,C0542269;C3537181
ecg changes t,C0855329
t wave inversion only,C0520888
st depression only,C0520887
st depression and t wave inversion,C0520887;C0520888
medication at entry,C0013227;C3244316;C4284232
oral fi blockers,C0442027;C4050619;C4521986
annanginal drugs $nmbr$ l s $nmbr$ ^,C0013227;C3687832
glyceryl trinitrate infusion,C0574032;C1827465
median delay h,C0033727;C0369286;C0441932;C0564385;C4528284
age distribution,C0001782
mean sd age in years,C0444504;C1510829;C2347634;C2348143
mean sd bmd in g cm $nmbr$,C0444504;C0439267;C2347634;C2348143
post erior anterior spine,C0037949;C2752558
vertebral fractures at baseline,C0080179;C0168634;C1442488
history of postmenopausal fracture,C1272071;C0232970
self rated health status,C0036588;C0018759;C1551994
very g ood ex cellent,C0439267;C4267693
fair poor,C0032854;C0542537;C2700379
mean sd anthropometry,C0444504;C0003188;C2347634;C2348143
baseline height cm,C0168634;C0489786;C1442488
body mass index kg cm $nmbr$,C0005893;C4054689;C0578022;C1305855
mean sd calcium intake in mg daily,C0489458;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761
ever,
digoxin n $nmbr$,C0012265
$nmbr$ $nmbr$ $nmbr$ s,
$nmbr$ s $nmbr$ s $nmbr$,C0565930;C2603362
median duration of chf mo,C0449238;C2926735
of patients $nmbr$ $nmbr$ $nmbr$ $nmbr$,C0030705
method of assessing ejection fraction,C0025663;C0449851;C0871511;C1516048;C0489482;C2700378
radionuclide ventriculography,C0017200;C0034610
two dimensional echocardiography,C0013524
contrast angiography,C0009924;C0002978;C1979874
cardiothoracic ratio $nmbr$ $nmbr$,C0456603;C1547037
no of signs or symptoms of chff,C0220912;C0220913;C0311392;C0683368;C1457887
primary cause of chf,C0205225;C0015127;C1524003;C0439612;C0439631
other vasodilators,C0042402
daily dose of study medication prescribed,C2348070;C0278329
anthropometry mean sd,C0003188;C2699239
w eight k g,C0205454;C0439267
number of patients with,C2360800
a ngina $nmbr$ day s previously,C0332173;C0439228;C0439505
infarct ion w ithin previous $nmbr$ day s,C0022023;C1700702
$nmbr$ l $nmbr$ $nmbr$,C0439394;C1706495;C3642217
infarction $nmbr$ $nmbr$ days,C0021308;C0439228
infarction $nmbr$ days previously,C0021308;C0439228
infarction date not reported,C0011008;C2348077;C0684224;C0700287;C4319718
medication within $nmbr$ days before enrolment,C0013227;C3244316;C4284232;C1516879;C1696073;C3888021
intravenous heparin,C0354566
medication after enrolment,C0013227;C3244316;C4284232
ticlopidin,
tertile of total cholesterol at baseline mean sd mmol l,C0201950;C0543421;C0168634;C1532563;C1442488
cwt mean se mm,C4330985;C4554674
difference $nmbr$ years baseline,C0168634;C1442488
tertile $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$,
p for heterogeneity of treatment effect between tertiles $nmbr$ $nmbr$,C0369773;C2603361
$nmbr$ $nmbr$ yr no,C0439234
$nmbr$ $nmbr$ vr no,C3476815
median vr,C0549183;C3476815;C0876920;C2347635;C2348144;C2939193
time from qualifying event to randomization,C0040223;C3541383;C1514624;C0441471;C4019010
coronary risk factors no,C2024776
history of systemic hypertension,C0455527
obesityj,
other vascular disease no,C0042373
claudication,C0021775;C0311395;C1456822
ptca only,C2936173
cabg only,C0010055
both ptca and cabg,C2936173;C0010055
oral hypoglycemic drug,C0359086
lipid levels mg dlj total cholesterol,C0201950;C0543421
totalhdl cholesterol ratio,C0456603;C1547037
unstable angina age,C0002965;C0001779
subgroups were defined on the basis of variables assessed before randomization the lipid levels represent the averages of the values measured four weeks before randomization and those measured at randomization to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ ci denotes confidence interval ldl low density lipoprotein and hdl high density lipoprotein tests for heterogeneity of treatment effect were undertaken across each of the subgroups in addition we performed tests for interaction between treatment and the following continuous base line variables age total ldl and hdl cholesterol and triglyceride levels there was no evidence of significant heterogeneity of treat ment effect in any prespecified subgroup p $nmbr$ $nmbr$ data were missing for three patients two in the placebo group and one in the pravastatin group,C1079230;C1704788;C3539106;C1516048;C0034656;C0428460;C1882932;C1510992;C2825518;C0444706;C3541902;C0042295;C0008377;C1532563;C1719797;C2911648;C0041004;C0008107;C3259781;C0009667;C0023823;C0023821;C0237455;C0332287;C0022885;C0392366;C1883712;C1704675;C0039798;C0087111;C1522326;C1533734;C1705169;C3538994;C3887704;C0168634;C1442488;C0023822;C0392885;C0428475;C3887511;C0019409;C0242960;C1511726;C3245479;C3714741;C1551393;C1705492;C3272743;C0032042;C0441833;C0687744;C1257890;C1519504;C1705428;C1705429;C1696465;C1706408;C0205447;C0085542
baseline abi affected limb,C0168634;C0015385;C1442488
baseline pfd m,C0016065;C1839454;C2827389;C3889643
baseline mwd m,C0168634;C1442488
plasma creatine mg dl,C0010286;C0439269
concurrent illness,C0205420;C0221423
concurrent medications,C0013227;C0802604;C2598133;C4284232
plasma lipoproteins mmol l,C0023820;C1532563
hdl $nmbr$,C3715113
lpa mg dl,C1096202;C0439269;C1439335;C3539666;C4049711;C4553379
week $nmbr$ mean sem,C0332174;C0439230
weeko mean sem,C0444504;C2347634;C2348143
pretreatment hdl c,C1550147;C3715113;C2709094;C3539075;C3539076
pretreatment triglycerides,C1550147;C0041004;C2709094;C3539075;C3539076
no of patients with stroke,C0030705;C0038454;C4554100
ldl hdl ratio,C0428621
table $nmbr$ relationship of baseline serum lipids to stroke or tia reduction,C0439849;C1705630;C1706279;C3540605;C0038454;C4554100;C0301630;C0392756;C1293152;C4551656
